scientific report 2019

IMIBIC
MAIMONIDES BIOMEDICAL RESEARCH INSTITUTE OF CORDOBA

Junta de Andalucía

UNIVERSIDAD DE CÓRDOBA

INDEX

1. Director's foreword for 2019 scientific report P. 4

2. GOVERNANCE AND STRUCTURE P. 8 // 2.1. ORGANIZATION CHART P. 9 // 2.2. SCIENTIFIC STRUCTURE P. 15

3. GOALS & HIGHLIGHTS 2019 P. 19 // 3.1. GOALS ACHIEVED IN 2019 P. 20 // 3.2. GOALS NOT REACHED P. 21 // 3.3. MAIN ACTIVITIES P. 21 // 3.4. HIGHLIGHTS P. 22

4. STAFF P. 24

5. MANAGEMENT STAFF P. 28 // 5.1 RESEARCH MANAGEMENT P. 29 // 5.2. INNOVATION MANAGEMENT P.29 // 5.3. FINANCIAL AND HUMAN RESOURCES MANAGEMENT P. 30 // 5.4. CORPORATE DEVELOPMENT P. 30

6. FUNDING P. 32 // 6.1. PROFIT & LOSS ACCOUNT: FIBICO P. 33// 6.2. Overheads and research promotion plan (RPP) P. 33 // 6.3. BALANCE SHEET FIBICO P. 33 // 6.4. FUNDING P. 34

7. FACTS & FIGURES P. 36 // 7.1 STAFF P. 37 // 7.2. PUBLICATIONS P. 38 // 7.3. NUMBER OF Clinical guidelines, CONSENSUS AND PROTOCOL DOCUMENTS P. 43 // 7.4. RESEARCH PROJECTS AND NETWORKS P. 43 // 7.5. CLINICAL TRIALS P. 46

8. SCIENTIFIC PRODUCTION P. 49 // 8.1. SCIENTIFIC PROGRAMS P. 50 // 8.2. RESEARCH GROUPS P. 66 // 8.3. OTHER SCIENTIFIC CONTRIBUTIONS BY THE HOSPITAL P. 172

9. PLATFORMS AND NETWORKS P. 174

10. TRAINING P. 178 // 10.1. TRAINING PROGRAMS P. 179 // 10.2. TRAINING ACTIVITIES P. 183 // 10.3. INSTITUTIONAL EVENTS P. 183 // 10.4. RESULTS OF THE TRAINING ACTIVITIES P. 186

11. INNOVATION AND TECHNOLOGY TRANSFER. P. 188

12. BIOMEDICAL RESEARCH SUPPORT UNITS. P. 193 // 12.1. ISOTOPE UNIT P. 194 // 12.2. ANIMAL EXPERIMENTATION UNIT P. 196 // 12.3. FLOW CYTOMETRY AND ADVANCED OPTICAL MICROSCOPY UNIT P. 198 // 12.4. PROTEOMICS UNIT P. 201 // 12.5. BIOINFORMATICS AND TECHNOLOGICAL INNOVATION UNIT P. 204 // 12.6. GENOMICS UNIT P. 207 // 12.7. CLINICAL RESEARCH UNIT P. 212 // 12.8. BIOBANK UNIT P. 214 // 12.9. METHODOLOGY AND BIOSTATISTICS UNIT P. 216

13. COMMUNICATIONS AND RRI. P. 220

14. GOALS FOR 2020. P. 224.

15. ANNEXES. P. 226 //. 15.1. PUBLICATIONS P. 227 // 15.2.CLINICAL TRIALS P. 290 // 15.3. ONGOING PROJECTS, NETWORKS & FELLOWSHIPS P. 317 // 15.4. FINANCED PROJECTS, NETWORKS & FELLOWSHIPS P. 334 // 15.5. AGREEMENTS WITH COMPANIES P. 336 // 15.6. SEMINARS P. 348 // 15.7. THESIS P.352

1 director's foreword for 2019 scientific report

The present scientific report provides a summary of the activity of the Maimonides Biomedical Research Institute of Cordoba, IMIBIC, during 2019.

In July 2019 IMIBIC's scientific direction changed. Thus, we'd like to start by expressing our utmost gratitude to Dr. Justo Castaño, Dr. Manuel Tena Sempere, and Dr. José López Miranda, for their magnificent work in directing the Institute during the past years. The results of their dedication are clearly shown in this scientific report. We would also like to thank the members of the different Committees that have contributed to the growth of the institute with their efforts and generosity.

The progressive development of the research activity at IMIBIC has enabled the recruitment of novel, competitive and young groups, which in 2019 accounted for a total of 27 Consolidated Groups, 8 Emerging Groups, and 9 Associated Groups. This structure ensures a solid basis for our activity while promoting generational renewal and collaboration and cross-talk between different disciplines, which nurtures the development of productive research programs, oriented towards solving health problems

of the society through translational research. The basic index of the research production of this community, the number and quality of scientific publications, has continued its steady growth, with a total of 517 articles published in 2019, 57% of them in the first quartile of their area, reflecting the efforts of our researchers to reach higher quality objectives each year. Along these lines, it should be recognized and praised that the results of all areas of activity of the Institute, from Innovation and Transfer of Technology to Core Support Services, from Research Training to Communication and Science Dissemination, have also continued their progress and consolidation. Advances in registered patents and innovation grants, incorporation of new equipment and methodologies, organisation of Seminars, the 10th Young Investigators Meeting, and our active participation in a number of events aimed at science communication illustrate the plethora of areas currently covered by the IMIBIC community. Furthermore, we were honoured to enjoy the outstanding keynote speech by Prof. Valentin Fuster at the 9th Maimonides Commemorative Lecture.

Meanwhile, our budget raised to reach 10,9 M€, confirming the economical robustness of the Institute amidst the uncertain situation of research funding in our environment. Maintaining a balanced budget over time is only possible through an active and joint work to obtain research funding from public and private institutions, by promoting high-quality Clinical Research and by linking the institute closely to its society milieu, this latter having been a very active area in 2019.

Nevertheless, the fertile grounds ensuring the future of IMIBIC are not just economic or based solely on scientific production or social recognition, but largely rely on a pivotal change in the way biomedical research is nowadays conceptually and practically appreciated by our young and senior researchers alike. These last years have provided a novel view, a new perspective over the future of biomedical research based on a profound self-confidence in the capacity of our research community to attain more difficult and superior goals. Not only the number and quality of publications but also the projects obtained by our researchers have continued growing in an environment of scarce research funding and decreasing resources, within a highly competitive and demanding environment. Most importantly, the research community encompassing scientists of clinical, translational and basic backgrounds, nurses, managers, technicians, support personnel, and, remarkably, volunteering personnel, patients and their families, have together achieved to build an overarching research environment capable to reach for goals that were unattainable an even unthinkable just a few years ago. The feeling of sincere gratitude and recognition for all those persons and institutions that made this advancement possible is as immense as their generosity.

Our proposal for the future is to support the growth of the Institute, always within the highest standards of quality, by generating results that can be translated into the health care settings.

This requires that we focus on the promotion of young talented researchers and encourage creativity, to keep evolving, and to attract excellent researchers to IMIBIC, who will help us consolidate as a research institute with recognition on the international level.

We must also keep increasing our capacity to obtain international funding, prioritising the funding by the European Commission, and boosting innovation and technology transfer as a tool to reduce the gap between biomedical research and health industries.

This goal is within our reach thanks to the good standing of the institute. Finally, to better align with the new standards set by the National Institute of Health Carlos III, we will pay special attention to incorporating the six principles of Responsible Research and Innovation (RRI) in all our activities: ethics, gender, governance, open access, scientific education, and public engagement.

Over the next pages, you will have the opportunity to view the results of this continued growth and the consolidation of our efforts to progress in the field of biomedical research, but most of all, you will witness the robust willingness to continue rising altogether in this common and enduring pathway.

Pablo Pérez Martínez
Scientific Director

María del Mar Malagón Poyato
Deputy Scientific Director

2. Governance and structure

2.1 Organization chart

IMIBIC's governing and representative bodies are detailed below:



A. COLLEGIATE BODIES

The collegiate bodies composing IMIBIC are the Governing Council, the Executive Committee, the Scientific Council, the External Scientific Board and the Internal Scientific Board. Each body has its competencies and is composed of several specialists.

GOVERNING COUNCIL

The Governing Council is the main governing body of IMIBIC. The Governing Council is composed of the following members:

• Two representatives from the Regional Ministry of Health and Families of the Andalusian Regional Government

Ms. Teresa Molina López
Director-General for Research and Knowledge Management of the Regional Ministry of Health (till February 2019).

Dr. Isaac Túnez Fiñana
Managing Director of Research, Development and innovation, Ministry of Health and Families (from February 2019).

Dr. Valle Garcia Sánchez
Managing Director of the Reina Sofia University Hospital and President of FIBICO.

• Two representatives from the Regional Ministry of Economy, Knowledge, Business and University

Mr. Manuel Carmona Jiménez
Territorial Delegate of Economy, Innovation, Science and Employment of Córdoba (till February 2019).

Mr. Ángel Herrador Leiva
Delegate for Employment, Training, Self-employment, Economics, Knowledge, Business and University (from February 2019).

Mr. Manuel García León
General Manager of Research and Knowledge Transfer of the Regional Ministry of Economy and Knowledge (till February 2019).

Ms. Rosa Mª Ríos Sánchez
General Manager of Research and Knowledge Transfer (from February 2019 to July 2019).

Mr. Pablo Cortés Achedad
General Manager of Research and Knowledge Transfer (from July 2019).

• Two representatives from the University of Córdoba
Mr. Antonio J. Cubero Atienza
Vice-rector of Coordination, Infrastructures and Sustainability.
Ms. Luisa M. Rancaño Martín
Managing Director.

• Scientific Director, IMIBIC
Dr. Justo P. Castaño Fuentes
(till July 2019).
Dr. Pablo Pérez Martínez
(from July 2019).

• One representative from the Progress and Health Andalusian Public Foundation (FPS).
Ms. Ana Madera Molano
Managing Director (till June 2019).
Mr. Gonzalo Balbontín Casillas
Managing Director (from September 2019).

• General Manager, IMIBIC
Mr. Álvaro Granados del Río

EXECUTIVE COMMITTEE

To facilitate agile decision making, on July 27, 2015, the Governing Council adopted an agreement to create an Executive Committee. The Executive Committee is composed of one member from each of the institutions that constitute the Governing Council, as set out in the collaboration agreement between the Regional Ministry of Health and Family, the Regional Ministry of Economy, Knowledge, Business and University, and the University of Córdoba. The Scientific Director and the General Manager will participate with voice but without vote.

SCIENTIFIC COUNCIL

The Scientific Council acts as an advisory body to the Scientific Director. It is composed of the Scientific Director, the Deputy Scientific Director of IMIBIC, the Principal Investigators (PI), Emerging Researchers (ER), Associated Researchers (AR), one representative from the Reina Sofia University Hospital (RSUH) Board of Directors, General Manager of IMIBIC and representatives of the technical and management staff. It was established on July 9, 2009.

INTERNAL SCIENTIFIC ADVISORY BOARD

The Internal Scientific Advisory Board is an advisory body to the Scientific Director. It is composed of the Scientific Director, Researchers, including Researchers in training, representing all of the Institute's priority scientific areas. It includes those responsible for Quality, Innovation and Training. It was established on November 25, 2019 (previously called Permanent Committee of the Scientific Council).

EXTERNAL SCIENTIFIC ADVISORY BOARD

The External Scientific Advisory Board is a body appointed by the Governing Board whose mission is to assist the Scientific Director in the performance of his/her duties. It acts as an advisory body to the Scientific Management, although its decisions are not legally binding. It was established on July 9, 2009 under the name of External Advisory Board and ratified by the Governing Council on December 21, 2009. The External Scientific Committee is made up of a minimum of three and a maximum of ten highly qualified professionals with recognized experience in the field of research, who should carry out their professional activity outside the Autonomous Community of Andalusia. The members of the board are:

• **Dr. Lina Badimón Maestro**
Director of the Cardiovascular Research Center (CSIC-ICCC) (Barcelona) and President of IMIBIC's External Scientific Advisory Board.
• **Dr. Carlos Diéguez González**
Director of the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (Santiago de Compostela).
• **Dr. José María Ordovás Muñoz**
Senior Scientist and Director for the Nutrition and Genomics Laboratory and Chair of the Functional Genomics Core of the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USA). Scientific Director of IMDEA Food (Madrid).
• **Dr. Francisco Sánchez Madrid.**
Professor of Immunology at the Autonomous University of Madrid and Chief Scientific Officer at the IIS-La Princesa.
• **Dr. Carlos López-Otín**
Professor of Biochemistry and Molecular Biology at the University of Oviedo (Oviedo). (till July 2019).
• **Dr. Pura Muñoz Cánoves**
ICREA Research Professor, Full Professor of Cell Biology and Principal Investigator at Pompeu Fabra University (UPF), Barcelona (from October 2019).

B. INDIVIDUAL BODIES

The Management Team is responsible for ensuring effective performance in order to increase the quality and impact of IMIBIC's research activity.

SCIENTIFIC DIRECTOR

Dr. Justo P. Castaño Fuentes
(Till July 2019). Full Professor of Cell Biology at the University of Cordoba.
Dr. Pablo Pérez Martínez
Full Professor of Medicine at the University of Córdoba and Internal Medicine specialist at the Reina Sofia University Hospital in Córdoba. He was appointed Scientific Director of IMIBIC by the Governing Council at a meeting held on July 5, 2019.

DEPUTY SCIENTIFIC DIRECTOR OF BASIC RESEARCH

Dr. Manuel Tena Sempere
(Till October 2019) Full Professor of Physiology in the Faculty of Medicine at the University of Córdoba. He was re-appointed Deputy Scientific Director of Basic Research of IMIBIC by the Governing Council at a meeting held on April 8, 2015.
Dr. María del Mar Malagón Poyato
Full Professor of Cell Biology at the University of Córdoba and Principal Investigator of the GC11 group. She was appointed Deputy Scientific Director of Basic Research by the Governing Council at a meeting held on October 1, 2019.

DEPUTY SCIENTIFIC DIRECTOR OF CLINICAL RESEARCH

Dr. José López Miranda
(till October 2019). Full Professor at the University of Córdoba and Head of the Internal Medicine Unit at Reina Sofia University Hospital. He was appointed Deputy Scientific Director of Clinical Research at IMIBIC by the Governing Council at a meeting held on April 8, 2015.

CLINICAL RESEARCH PROGRAM COORDINATION

Dr. Juan de la Haba Rodríguez
Specialist in Medical Oncology at Reina Sofia University Hospital and Associate Professor at the University of Córdoba. He is also a researcher in the GC06 group. He was appointed Coordinator of the Clinical Research of IMIBIC by the Governing Council at a meeting held on October 1, 2019.

GENERAL MANAGER

Mr. Álvaro Granados del Río
BSc in Business Administration and Management. Advanced Program for Management of Health

C. INTERNAL COMMITTEES

1. QUALITY COMMITTEE

This Committee will ensure that quality and ethical codes are maintained in all research activities and between researchers in accordance with the guidelines of the Quality Plan.

Dr. Mª del Mar Malagón Poyato	Deputy Scientific Director
Ms. Marisa Escabias Parejo	Quality specialist
Dr. Pablo Pérez Martínez	Scientific Director
Mr. Álvaro Granados del Río	General Manager
Dr. Mª Antonia Álvarez de Lara Sánchez	Head of quality and clinical documentation of RSUH
Dr. José Manuel Aranda Lara	Technical Advisor of the Territorial Delegate of the Andalusian Regional Ministry of Health and Families
Dr. Mª Teresa Roldán Arjona	Principal Investigator GC22
Dr. Luís Martínez Martínez	Principal Investigator GC24
Dr. Rafael Solana Lara	Principal Investigator GC01
Dr. Juan Ruano Ruiz	Principal Investigator GE03
Dr. Ana León Acuña	Postdoctoral Researcher GC09

2. TRAINING COMMITTEE

This committee will execute the Training Plan, particularly the Master's and Doctorate Programs in Biomedical Research.

Dr. Raúl Luque Huertas	Principal Investigator GC27
Ms. Inmaculada Varo Urbano	Training Officer
Dr. Juan Manuel Castellano Rodríguez	Postdoctoral Researcher GC10
Dr. Antonio Pablo Arenas de Larriva	Predoctoral Researcher GC09
Dr. Elisa Roldán Romero	Director of Studies, RSUH
Dr. Luis A. Pérula de Torres	Principal Investigator GC12
Dr. Joaquín Toro Santiago	Head of the Integrated Training Unit RSUH
Dr. Juan Manuel Jiménez Vacas	Predoctoral Researcher GC27
Dr. Nuria Barbarroja Puerto	Emerging Researcher GC05
Dr. Juan Solivera Vela	Head of Neurosurgery Service RSUH
Dr. Sebastián Ventura Soto	Principal Investigator GC25
Dr. Antonio Rivero Juárez	Emerging Researcher GC26
Ms. Maria Saarela	International Project Manager
Dr. Ipek Guler	Technician of Research Support Service: Methodology and Biostatistics

3. EQUALITY COMMITTEE

As responsible for the Equality Plan, this committee will promote equal opportunities and treatment between women and men, in accordance with the principles of corporate social responsibility and in compliance with the current legislation.

Dr. Mª del Mar Malagón Poyato	Deputy Scientific Director
Ms. Marisa Escabias Parejo	Quality Specialist
Mr. Álvaro Granados del Río	General Manager
Ms. Miriam Cruzado Caballero	Head of the Research Management Unit
Dr. Antonio Romero Ruiz	Post-Doctoral Researcher GC18
Dr. Alejandra Pera Rojas	Researcher GC01
Dr. Álvaro Jiménez Arranz	Senior Technical Specialist of Research Support Service: Genomics

4. INFRASTRUCTURES COMMITTEE AND RESEARCH SUPPORT SERVICES

This Committee will oversee existing IMIBIC Infrastructures and the execution of the Infrastructures Plan.

Dr. Mª del Mar Malagón Poyato	Deputy Scientific Director
Mr. Francisco Javier López Ruiz	Head of Financiiall and Human Resources Management
Mr. Álvaro Granados del Río	General Manager
Dr. Eduardo Chicano Gálvez	Senior Technical Specialist of Research Support Service: Proteomics
Dr. Esther Peralbo Santaella	Senior Technical Specialist of Research Support Services: Cytometry and Microscopy
Ms. Anabel Pozo Salas	Technician of Research Support Services: Animal Experimentation
Dr. Antonio Rodríguez Ariza	Co-Principal Investigator GC06
Dr. Rosario López Pedrera	Principal Investigator GC05
Dr. Victoria Guiote Moreno	Pre-Doctoral Researchers GA10
Dr. Sara Cantisán Bohórquez	Researcher GC03
Dr. Juan A. Moreno Gutiérrez	Principal Investigator GE06
Dr. Juan Roa Rivas	Researcher CG10
Dr. Feliciano Priego Capote	Principal Investigator GC21

5. CLINICAL RESEARCH COMMITTEE

The Clinical Research Committee will execute the IMIBIC Clinical Research Plan.

Dr. Juan de la Haba Rodríguez	Coordinator of Clinical Research
Ms. Esther Pacheco Rodríguez	Clinical Pharmacologist
Mr. Antonio Luque Pineda	Clinical Trial Manager
Mr. Álvaro Granados del Río	General Manager
Dr. Julián de la Torre Cisneros	Principal Investigator GC03
Dr. Concepción Herrera Arroyo	Principal Investigator GC14
Dr. Pilar Font Ugalde	Researcher GC05
Dr. Juan Ruano Ruiz	ResearcherGE03
Dr. Álvaro Arjona Sánchez	Researcher GC18
Dr. Enrique Gómez Gómez	Researcher GE05
Dr. Cristina Aguado Taberné	Researcher GC12
Dr. Juan Carlos Castillo Domínguez	Researcher GC15
Dr. Antonio Rivero Román	Principal Investigator GC26
Dr. Eduardo Agüera Morales	Emerging Researcher GE01
Dr. Mª José Méndez Vidal	Clinical Researcher GC06
Dr. Daniel López Ruiz	Principal Investigator GA08
Dr. Mª Dolores Mesa Rubio	Researcher GC15

6. INNOVATION COMMITTEE

The Clinical Research Committee will execute the IMIBIC Innovation Plan.

Dr. Pablo Pérez Martínez	Scientific Director
D. Luis Fernández Formoso	Project Manager
Dr. Mª del Mar Malagón Poyato	Deputy Scientific Director
Mr. Álvaro Granados del Río	General Manager
Dr. Marina Álvarez Benito	Researcher GA08
Dr. Eduardo Muñoz Blanco	Principal Investigator GC04
Dr. Francisco Javier Delgado Lista	Co-Principal Investigator GC09
Dr. Rafaela Ortega Castro	Post-Doctoral Researcher GC05
Dr. Juan Rafael Muñoz Castañeda	Emerging Researcher GC13
Dr. Juan Solivera Vela	Head of Neurosurgery Service RSUH
Dr. Manuel David Gahete Ortíz	Co-Principal Investigator GC27
Dr. Miguel González Andrades	Principal Investigator GE07
Dr. Antonio Rivero Juárez	Emerging Researcher GC26

7. SCIENTIFIC PROGRAMS

All IMIBIC Research groups must be integrated into the Scientific Programs in accordance with the Thematic Areas that IMIBIC is working in at any given time:

ACTIVE AGEING AND FRAILTY	Dr. Fernando Sarramea Crespo Dr. Rafael Solana Lara
NUTRITION, ENDOCRINE AND METABOLIC DISEASES	Dr. Manuel Tena Sempere Dr. Elena Yubero Serrano
INFECTIOUS AND IMMUNOLOGICAL DISEASES AND ORGAN TRANSPLANTATION	Dr. Antonio Rivero Román Dr. Sara Cantisán Bohórquez
CANCER (ONCOLOGY AND ONCOHEMATOLOGY)	Dr. Juan de la Haba Rodríguez Dr. Marco A. Calzado Canale
CHRONIC AND INFLAMMATORY DISEASES	Dr. Rosario López Pedrera Dr. Marina Álvarez Benito

INTERNAL COMMITTEES MEMBERS BY GENDER

INTERNAL BODIES AND COMMITTEES BY GENDER



2.2 SCIENTIFIC STRUCTURE

The research activities of IMIBIC are organized into five scientific programs, each comprising different research groups. The scientific programs target health problems that are both important and widespread, identifying areas in which the researchers of the institute can combine their efforts in transversal collaborative projects that aim to tackle and provide answers to the main health challenges faced by European society today, in line with the priorities set by the European Union's Horizon 2020 program. The structure of the programs guides researchers towards the improvement of patient and community health through excellent translational and clinical research and innovation. It encourages interaction and cooperation among the different groups, as well as aims to attract talent and continually improve the career development opportunities of young researchers. Our Scientific Programs reflect the strengths of our research teams and show the unique specialization of IMIBIC. The programs are as follows:

A. ACTIVE AGEING AND FRAILTY

This program is oriented towards understanding the molecular pathogenic basis of the ageing process, its relationship to quality of life and the search for new strategies of patient care. It includes the following lines of research:

- Immunology and senescence
- Attention and care of the chronically ill
- Frailty and quality of life in the elderly

B. NUTRITION, ENDOCRINE AND METABOLIC DISEASES

This program is oriented towards studying metabolic disorders and the endocrine system, with particular interest in the role of nutrition in the prevention and management of these processes at different stages of life. It also focuses on studies of reproductive health and neuroendocrine tumors. It includes the following lines of research:

- Metabolic syndrome
- Reproductive health
- Pediatric and perinatal diseases
- Neuroendocrine tumors

C. INFECTIOUS AND IMMUNOLOGICAL DISEASES AND ORGAN TRANSPLANTATION

This program focuses on the study of diseases caused by different infectious agents, with a special emphasis on infections in immunocompromised patients. It includes the following lines of research:

- HIV + Hepatitis C virus
- Transplants
- Multidrug resistance

D. CANCER (ONCOLOGY AND ONCOHEMATOLOGY)

This program focuses on the study of neoplastic diseases, including both solid tumors and hematologic neoplasms. It includes the following lines of research:

- Lung cancer
- Breast cancer
- Hepatocellular carcinoma
- Leukemia and lymphomas
- Digestive tumors
- Other tumors

E. CHRONIC AND INFLAMMATORY DISEASES

This program focuses on the study of a number of chronic diseases of modern society, with special emphasis on those of an inflammatory nature. This program includes both basic research and clinical studies, with the ultimate aim of promoting a better understanding of the basis of chronic/inflammatory diseases and improving their therapies. It includes the following lines of research:

- Cardiovascular diseases
- Diseases of the locomotor system and connective tissue
- Neurological diseases
- Mental health
- Kidney and urologic diseases
- Liver and digestive diseases
- Chronic inflammation and signalling

RESEARCH GROUPS

GC- CONSOLIDATED GROUP • GE - EMERGING GROUP • GA - ASSOCIATED GROUP

*Note: The programs to which each group is assigned to is highlighted in bold.

CODE	IMIBIC GROUPS and PROGRAMS	PRINCIPAL INVESTIGATOR(s)
GC1	**IMMUNOLOGY AND ALLERGY** PROGRAMS **1**, 3, 4, 5	Dr. Rafael Solana Lara (PI) Dr. Alejandra Pera Rojas (ER)
GC2	**OXIDATIVE AND NITROSATIVE STRESS IN ACUTE AND CHRONIC LIVER DISEASE** PROGRAMS 3, 4, **5**	Dr. Manuel De La Mata García (PI) Dr. José Antonio Bárcena Ruiz (CO-PI)
GC3	**INFECTIOUS DISEASES** PROGRAM **3**	Dr. Julián De La Torre Cisneros (PI) Dr. Sara Cantisán Bohórquez (ER)
GC4	**INFLAMMATION AND CANCER** PROGRAMS 2, **4**, 5	Dr. Eduardo Muñoz Blanco (PI) Dr. Marco A. Calzado Canale (CO-PI)
GC5	**SYSTEMIC AND CHRONIC INFLAMMATORY AUTOIMMUNE DISEASES OF THE LOCOMOTOR SYSTEM AND CONNECTIVE TISSUE.** PROGRAM **5**	Dr. Rosario López Pedrera (PI) Dr. Eduardo Collantes Estévez (CO-PI) Dr. Nuria Barbarroja Puerto (ER)
GC6	**NEW THERAPIES IN CANCER** PROGRAM **4**	Dr. Enrique Aranda Aguilar (PI) Dr. Antonio Rodríguez Ariza (CO-PI) Dr. Juan de la Haba Rodríguez (ER)
GC7	**NEPHROLOGY: CELL DAMAGE IN CHRONIC INFLAMMATION** PROGRAMS 1, 3, **5**	Dr. Alejandro Martín Malo (PI) Dr. Pedro Aljama García (CO-PI)
GC8	**HORMONES AND CANCER** PROGRAMS 2, **4**, 5	Dr. Justo P. Castaño Fuentes (PI)
GC9	**NUTRIGENOMICS: METABOLIC SYNDROME** PROGRAMS 1, **2**, 5	Dr. José López Miranda (PI) Dr. Francisco Pérez Jiménez (CO-PI) Dr. Yolanda Almadén Peña (CO-PI) Dr. Javier Delgado Lista (CO-PI) Dr. Pablo Pérez Martínez (CO-PI) Dr. Antonio Camargo García (ER) Dr. Antonio García Ríos (ER)
GC10	**HORMONAL REGULATION OF ENERGY BALANCE, PUBERTY AND REPRODUCTION** PROGRAM **2**	Dr. Manuel Tena Sempere (PI)
GC11	**METABOLISM AND ADIPOCYTE DIFFERENTIATION. METABOLIC SYNDROME** PROGRAM **2**	Dr. María del Mar Malagón Poyato (PI)
GC12	**EPIDEMIOLOGICAL RESEARCH IN PRIMARY CARE** PROGRAMS **1**, 3, 4, 5	Dr. Luis Ángel Pérula de Torres (PI)
GC13	**CALCIUM METABOLISM. VASCULAR CALCIFICATION** PROGRAMS 2, **5**	Dr. Mariano Rodríguez Portillo (PI) Dr. Juan Rafael Muñoz Castañeda (ER)
GC14	**CELL THERAPY** PROGRAMS **4**, 5	Dr. I. Concepción Herrera Arroyo (PI)
GC15	**INVASIVE CARDIOLOGY AND CELL THERAPY** PROGRAM **5**	Dr. Manuel Pan Álvarez-Ossorio (PI)
GC16	**CELL BIOLOGY IN HEMATOLOGY. HYPERCOAGULABILITY** PROGRAMS 3, **4**	Dr. Joaquín Sánchez García (PI) Dr. Francisco Velasco Gimena (CO- PI)
GC17	**PATHOPHYSIOLOGY OF THE ENDOCRINE SYSTEM OF VITAMIN D. BIOTECHNOLOGY AND AGING** PROGRAMS **1**	Dr. José Manuel Quesada Gómez (PI)
GC18	**TRANSLATIONAL RESEARCH IN SURGERY OF SOLID ORGAN TRANSPLANTS** PROGRAMS 3, 4, **5**	Dr. Javier Briceño Delgado (PI)
GC19	**ARTIFICIAL VISION APPLICATIONS (A.V.A.)** PROGRAMS **1**, 4, 5	Dr. Rafael Medina Carnicer (PI)
GC20	**GENETICS AND BEHAVIORAL DISEASES** PROGRAMS **4**, 5	Dr. Manuel Ruiz Rubio (PI) Dr. Juan A. Moriana Elvira (CO-PI)
GC21	**METABOLOMICS: IDENTIFICATION OF BIOACTIVE COMPONENTS** PROGRAMS **1**, 2, 4, 5	Dr. Feliciano Priego Capote (PI) Dr. Mª Dolores Luque de Castro (CO-PI)
GC22	**EPIGENETICS** PROGRAM **4**	Dr. Teresa Roldán Arjona (PI)
GC23	**METABOLISM IN CHILDHOOD** PROGRAMS **2**, 5	Dr. Mercedes Gil Campos (PI)
GC24	**CLINICAL AND MOLECULAR MICROBIOLOGY** PROGRAMS **3**	Dr. Luis Martínez Martínez (PI)
GC25	**KNOWLEDGE DISCOVERY AND INTELLIGENT SYSTEMS** PROGRAMS 1, 2, 3, **4**	Dr. Sebastián Ventura Soto (PI)
GC26	**CLINICAL VIROLOGY AND ZOONOSIS** PROGRAM **3**	Dr. Antonio Rivero Román (PI) Dr. Antonio Rivero Juárez (ER)
GC27	**ONCOBESITY AND METABOLISM** PROGRAM **4**	Dr. Raúl M. Luque Huertas (PI) Dr. Manuel David Gahete Ortiz (ER)

GE01	**OXIDATIVE STRESS AND NUTRITION** PROGRAMS 1, 2, **5**	Dr. Isaac Túnez Fiñana (PI) Dr. Eduardo Agüera Morales (ER)
GE02	**PREVENTIVE MEDICINE AND PUBLIC HEALTH** PROGRAM **3**	Dr. Bernardo R. Guzmán Herrador (PI)
GE03	**SKIN IMMUNE MEDIATED INFLAMMATORY DISEASES (SIMID)** PROGRAMS 4, **5**	Dr. Juan A. Ruano Ruiz (PI)
GE04	**APPLIED PSYCHOLOGY** PROGRAMS 1, **2**	Dr. Bárbara Luque Salas (PI)
GE05	**DISEASES OF THE GENITOURINARY SYSTEM** PROGRAMS 2, **4**	Dr. María José Requena Tapia (PI)
GE06	**PATHOPHYSIOLOGY OF RENAL AND VASCULAR DAMAGE** PROGRAM **5**	Dr. Juan A. Moreno Gutiérrez (PI)
GE07	**VISUAL QUALITY** PROGRAM **3**	Dr. Miguel González Andrades (PI)
GE08	**COMPREHENSIVE NURSING CARE: A MULTIDISCIPLINARY PERSPECTIVE** PROGRAMS **1**, 2, 4, 5	Dr. Mª Aurora Rodríguez Borrego (PI) (TILL 2019) Dr. Pablo López Soto (ER)
GA01	**LUNG TRANSPLANTATION. THORACIC MALIGNANCIES** PROGRAM **3**, 4	Dr. Ángel Salvatierra Velázquez (PI) Dr. Paula Moreno Casado (ER)
GA03	**PNEUMOLOGY** PROGRAMS 2, 4, **5**	Dr. Bernabé Jurado Gámez (PI)
GA04	**ENDOCRINOLOGY AND NUTRITION. INSULIN RESISTANCE, DIABETES AND METABOLISM** PROGRAM **2**	Dr. Mª Ángeles Gálvez Moreno (PI)
GA05	**STUDY OF GROWTH: ENDOCRINOLOGY AND CHILD NUTRITION** PROGRAM **2**	Dr. Ramón Cañete Estrada (PI)
GA08	**RADIOLOGY** PROGRAMS 4, **5**	Dr. Daniel López Ruiz (PI)
GA09	**CARDIOVASCULAR PATHOLOGY** PROGRAMS 3, **5**	Dr. Ignacio Muñoz Carvajal (PI)
GA10	**NUCLEAR MEDICINE** PROGRAMS **2**, 4	Dr. Juan A. Vallejo Casas (PI)
GA11	**LEARNING AND ARTIFICIAL NEURAL NETWORKS-AYRNA** PROGRAM **3**	Dr. César Hervás Martínez (PI)
GA12	**SEVERE MENTAL ILLNESS-HEALTH ALERTS** PROGRAMS **1**, 5	Dr. Fernando Sarramea Crespo (PI)

3. GOALS & HIGHLIGHTS 2019

3.1 Goals for 2019

	GLOBAL GOALS	INDICATORS / TARGETS	RESULTS 2019
1.	To promote and consolidate human resource integration in the institution	No. of coordinated actions between institutions	The H2020 co-funded P2Med Fellowships programme, to promote attraction of international talent, was signed with the EC and the project launched. An Agreement with UCO was reached to enable researchers who are not employed directly by UCO to teach at the University
2.	To develop strategies to increase the quality and number of scientific publications and the leadership of IMIBIC researchers in this area	≥ 50 articles in the top decile	102 articles were published in the top decile journals
3.	To promote and improve clinical research at the IMIBIC by increasing the development, quality and efficiency of independent clinical research projects	To implement a New Clinical Research Plan	The new Clinical Research Plan is being implemented
4.	To promote and improve the self-sustainability of the IMIBIC via optimization of internal resource management, attraction of more European and competitive public funding and by fostering partnerships with the business world	Core funding ≥ 2.2 million euros Income from private/public activity ≥ 53.5%	Core funding: 2,368,570 € Income from private/public activity: ≥ 53.5%
5.	Development of a strategy for the incorporation of new university and clinical groups, and to promote those that already exist	Creation of 2 new research groups (at least one emerging group) Promotion of 1 group	The strategy has focused on active search for researchers with independent research lines and excellent level of scientific activity, to be promoted to the category of Emerging Researcher, paving the way for the generational replacement of researchers. Furthermore, the strategy also focused on promoting existing groups to the category of Emerging Group. Two groups were promoted to emerging groups
6.	To increase recruitment of talented researchers and promote their professional development.	> 50 active employment contracts funded by competitive grants	59 active employment contracts are funded through competitive calls
7.	To foster, define and consolidate international alliances and partnerships	Application for funding for 30 international projects	25 applications for projects were submitted in competitive calls, although 31 were under preparation but finally not submitted
8.	To promote and increase the protection of intellectual property generated and the transfer of technology to the business community	>20% of patents exploited	0% of patents were exploited
9.	To guarantee the quality of service provided by the central biomedical research support unit (UCAIB) and management units of the Institute and to stimulate innovation through transversal collaboration	User satisfaction ≥ 85%	User satisfaction was 89.80%
10.	To develop and implement an action plan to promote research in primary care and nursing	No. of active projects in the area of primary care and nursing > 6	Active primary care / nursing projects: 9

3.2 Goals not reached

GLOBAL GOALS	INDICATORS / TARGETS	RESULTS 2019
To promote and increase the protection of intellectual property generated and technology transfer to the business community	>20% of patents exploited	0% of patents exploited

The "patents exploited" indicator refers to the percentage of patents that have been licensed during the current financial year in relation to the number of patents registered. Although various contacts have been made with companies, no licensing contracts haves been successfully signed. A number of strategies are being developed as part of the plan for future improvement. The Innovation Unit is being restructured by strengthening the activities of technological innovation to detect the most mature projects with potential transfer to the market and health care settings. Furthermore, the institute will abandon the policy of patenting exclusively for curricular or academic interest.

3.3 Main activities

1. BOOST TRANSLATIONAL RESEARCH IN PREDICTIVE MEDICINE.

In 2019, the following precision medicine projects continue to be active:

a. Ghrelin-O-acil-Transferase (GOAT) A New Biomarker for the Screening of Prostate Cancer: DTS18/00131.
Dr. Raúl Luque Huertas, Justo P. Castaño Fuentes (PI)
b. MERLIN - hoMEcare aRm rehabiLItatioN
Dr. Fernando Jesús Mayordomo Riera (PI)
c. 3TR - Identification of the Molecular Mechanisms of Non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions.
Dr. Eduardo Collantes (PI), (*proceeds to Phase Two)
d. POWER2DM – Predictive model-based decision support for diabetes patient empowerment
Dr. Francisco Javier Delgado Lista (PI)

In addition, Dr. Antonio Camargo (GC09) was awarded a technological development project by the National Institute of Health Carlos III DTS call, titled: "Microbial Composition of the Intestine as a Tool for Early Diagnosis of the Development of Type 2 Diabetes"

2. DEVELOP HIGH-QUALITY COLLABORATIVE RESEARCH PROJECTS IN THE IMIBIC GROUPS.

The IMIBIC Fellowship Programme for Personalised and Precision Medicine (IMIBIC-P2Med) co-funded by the EC's H2020 MSCA COFUND was launched.

3. BOOST COLLABORATIVE TRANSLATIONAL RESEARCH WITH RESULTS CLOSE TO THE MARKET.

23 patents were applied for and 13 clinical practice guidelines were published by IMIBIC groups.

4. CONSOLIDATE COLLABORATION BETWEEN RESEARCH GROUPS.

Main goal: To promote joint projects and publications involving IMIBIC groups, as stated in the Cooperative Scientific Plan.

MEASURABLE INDICATORS

- No. of projects involving collaboration between IMIBIC groups: **68**
- No. of joint publications between IMIBIC groups: **72**
- Patents involving the collaboration of more than one IMIBIC groups: **14**
- No. of intramural seminars: **11**

3.4 HIGHLIGHTS

P2MED

IMIBIC-P2Med is a new Postdoctoral Fellowship programme, co-funded by the EC H2020 Marie Skłodowska-Curie COFUND Programme (GA No 847468).

A call for proposals was opened in October 2019 (until Jan 2020) to grant a minimum of 6 Fellowships of up to 36 months to experienced researchers.

Awarded Fellows will be incorporated into IMIBIC during 2020. The programme will run from 2019 till 2024.

P2Med IMIBIC
FELLOWSHIP PROGRAMME FOR PERSONALISED AND PRECISION MEDICINE

"TRÉBOL" PROGRAMME

With respect to quality and environmental management, IMIBIC is committed to protecting and respecting the environment, acting to prevent the potentially negative impacts that research activity may generate on the environment. In December 2019 IMIBIC presented the final agreement of the Trébol Programme with the Environmental Protection Service of the University of Cordoba.

EQUALITY COMMITTEE

IMIBIC has approved its 2019-2022 Equality Plan, which states its commitment to establishing and developing policies that integrate equal treatment and opportunities for the IMIBIC community, without discrimination based on sex and incorporating diversity perspective, as well as promoting and encouraging measures to achieve genuine equality within our institution. Equal opportunities between women and men is established as a strategic principle of our Strategic Plan.

The management of the Equality Plan will be the responsibility of the Equality Committee, created in the Foundation and dependent on the Management of the Foundation. The Equality Committee will comprise:

a. The Scientific Council of IMIBIC, which will preside over the Committee.
b. The Management of FIBICO-IMIBIC
c. One person from the Management Unit designated by the Board/Management.
d. One person from the Biomedical Research Support Units designated by the Board/Management.
E. Two members representing established researchers, designated by the Board/Management.

The Equality Committee will be coordinated by the person responsible for Quality, including tasks of organisation of meetings and management of documentation. He/she will also provide the appropriate means to enable the Committee to work efficiently.

IMIBIC MAIMONIDES BIOMEDICAL RESEARCH INSTITUTE OF CORDOBA
Junta de Andalucía
UNIVERSIDAD DE CÓRDOBA

4.STAFF

2019

882(*)

(*) This data includes all IMIBIC staff (researchers, support and administrative staff)





R4 LEADING RESEARCHERS
R3 ESTABLISHED RESEARCHERS
R2 RECOGNISED RESEARCHERS
R1 FIRST STAGE RESEARCHERS

R1-R4 levels were defined following an internal evaluation of researchers, who were subclassified into sublevels (R2A-R2C, R3A-R3C) in 2018 according to internal standards (see 2018 IMIBIC Scientific Report). This classification has been revised in 2019, and researchers have been assigned to single stages (R1-R4) according to the Research profile descriptors provided by EURAXESS.

GENDER PERSPECTIVE

IMIBIC, through its Equality Plan, is committed to implement actions aimed at promoting gender parity in all personnel groups. The high number of female R3 researchers anticipates obtaining gender balance in R4 researchers in the next future.

RESEARCH STAFF 2019



ALL PERSONNEL IN 2019



N NURSES
R4 LEADING RESEARCHERS
R3 ESTABLISHED RESEARCHERS
R2 RECOGNISED RESEARCHERS
R1 FIRST STAGE RESEARCHERS
T TECHNICIANS

MANAGEMENT STAFF 2019



IMIBIC RESEARCH SUPPORT SERVICES 2019

5 management staff

5.1 research management

The mission of the IMIBIC Research Management Unit is to offer a complete service to research personnel through project managers who are assigned to researchers on an individual basis. The project managers' objective is to provide the researchers with the support necessary for the proper management and development of their scientific projects, as well as the corresponding justification and closure with funding agencies, and to provide advice on the different professional career paths in IMIBIC and related calls.

The team is made up of managers who are assigned specific groups to offer continuous individualized guidance and advice. The area also has specialist managers in international projects and staff providing technical support in project implementation/justification and administrative issues.

TEAM MEMBERS:

Miriam Cruzado Caballero
Head of Unit
Luis María Fernández Formoso
Project Manager
Mª Carmen Tejeda Agredano
Project Manager
José Carlos Prieto Baena
International Project Manager
Maria Saarela
International Project Manager
Raquel Berdud Arias
Grants & Projects Administrator
Marcos Notario Ríos
Grants & Projects Administrator
Carlos Lázaro Guevara
Grants & Project Assistant

5.2 innovation

THE OBJECTIVES OF THE INNOVATION UNIT ARE:

A. To identify the intangible assets derived from research carried out within its competences.
B. To provide comprehensive advice on the proper protection and transfer of research results.
C. To develop permanent strategic contacts with the business sector in order to seek agreements and synergies in terms of attracting resources for the development of projects and exploiting the knowledge generated.
D. To offer legal assistance for the correct formalization of collaboration agreements, development agreements, and so on.
E. To support and promote the creation of spinoffs.

TEAM MEMBERS:

Begoña Roibás da Torre
Head of Unit
David Requena Polonio
Innovation Project Manager

5.3 FINANCIAL AND HUMAN RESOURCES

MANAGEMENT

The Unit of Financial Management and Human Resources, which comprises Accounting, Invoicing, Financial and HR services, provides general support and administration to Research, Development and Innovation (R+D+i), making optimal use of the resources available.

The activity of the Unit is aligned with the mission of the Institute, and so maintains a strong commitment to the management of Research and Innovation in the province of Cordoba.

SERVICES OFFERED BY THIS UNIT INCLUDE:

- **Financial support to R+D+i projects**
- **Maximization of economic resources**
- **Management of agreements, contracts and private donations**
- **Human Resource Management**
- **Invoicing/billing and maintenance services associated with Clinical Trials and Observational Studies**
- **Budgetary control of activities**
- **Design and setting up of information flows and activities.**

TEAM MEMBERS:

Francisco Javier López Ruiz
Head of Unit
Marisa Escabias Parejo
Quality Specialist
Marta Manganaro
Legal and Contracts Specialist
Florencio Muñoz Encinas
Accountant and HR specialist
Silvia Miranda Castellano
HR Specialist
Maria del Carmen García Serrano
Clinical Research Assistant
Inmaculada Varo Urbano
Training officer
Enrique Muñoz Baena
IT Systems Coordinator
Manuel Jesús Carmona Hidalgo
IT Systems Assistant
Soledad María Cruz Moleón
IT Systems Assistant
Blanca Estévez Moreno
Clinical Research Administrator

5.4 CORPORATE DEVELOPMENT

The Corporate Development Unit comprises Communication, Fundraising and Management Control services and provides support and assistance to the research groups, as well as the Executive Board of the Institute.

THE MAIN SERVICES OFFERED BY THIS UNIT INCLUDE:

- **Increasing the visibility of the Institute within the province and elsewhere**
- **Managing fundraising through sponsorship and patronage**
- **Promotion and dissemination of research results**
- **Providing support to researchers in the preparation and coordination of events.**
- **Managing of the Institute's website and social media accounts**
- **Producing promotional material**
- **Collecting and validating information relevant to the Institute for further analysis**

TEAM MEMBERS:

Isabel De Castro Burón
Communications Officer
José Mª Rubio García-Sotoca
Communications (voluntary staff)
Estefanía Azcona Corrales
Controller
Ángela Ruiz Gallego
Controller
Marta Granados Aguirre
Administrative Assistant
Laura Bocero Fernández
Assistant to Scientific Director

MANAGEMENT STAFF 2019



6.FUNDING

FIBICO is the accounting and legal entity that hosts IMIBIC. The following tables present the audited Financial Statements of FIBICO and therefore of IMIBIC. There may be small differences between the financial figures of FIBICO and IMIBIC.

6.1 PROFIT & LOSS ACCOUNT: FIBICO

	2019	2018
REVENUES	10.545.024 €	9.746.090 €
COSTS OF GOODS	1.322.190 €	1.174.780 €
PERSONNEL	4.919.253 €	4.809.681 €
OTHER EXPENSES	3.481.520 €	2.918.429 €
DEPRECIATION	821.084 €	842.703 €
NET INCOME	**975 €**	**495 €**

6.2 OVERHEADS AND RESEARCH PROMOTION PLAN (RPP)

The financial structure of FIBICO, the foundation that manages IMIBIC, is based on various sources of funding, including notably, overhead costs, which in 2019 were broken down as follows:

OVERHEADS 2019	
COMPETITIVE FUNDING	299.332 €
PRIVATE FUNDING	128.916 €
OTHER	6.023 €
TOTAL	**434.272 €**

As stated in the accreditation guide for research institutes, "at least 20% of the indirect costs received annually should be allocated to actions aimed at supporting IIS researchers, such as capacity building, training, co-financing of contracts, IIS own projects for emerging groups, etc."
In view of this, 20% of the above amount should be allocated to the 'IMIBIC Research Promotion Plan'. In 2019, this included the following measures:

a. Assumption of the co-financing required for competitive calls for research talent (Miguel Servet, Sara Borrell, private entities, etc). In 2019, up to 238,700€ was allocated to expenses of this kind.
B.IMIBIC's RPP includes training stays at research centers of excellence abroad. In the last quarter of 2019, IMIBIC launched an Internal Research Promotion Plan to increase mobility and collaboration with other centers with a total endowment of 24,000€.

In addition, as part of its own programme to promote clinical research, the Institute also provides funding for contracting personnel required in the Institute's clinical research areas. In this sense, staff associated with clinical research (nurses, coordinators, administrative staff, etc.) increased to 232,000 €.

6.3 BALANCE SHEET FIBICO

ASSETS	2019	2018
NON-CURRENT ASSETS	5.461.727 €	5.128.488 €
ACCOUNTS RECEIVABLE	7.744.101 €	7.365.543 €
CASH AND EQUIVALENT	9.996.096 €	7.696.083 €
CURRENT ASSETS	17.740.198 €	15.061.626 €
TOTAL ASSETS	**23.201.925 €**	**20.190.115 €**

LIABILITIES	2019	2018
NON-CURRENT LIABILITIES	8.302.971 €	6.360.371 €
CURRENT LIABILITIES	10.856.772 €	9.481.679 €
EQUITY	4.042.181 €	4.348.065€
TOTAL LIABILITIES	**23.201.925 €**	**20.190.115 €**

6.4 FUNDING

2019 was a year of consolidation for the economic structure of IMIBIC. After the period 2013 to 2015 when the budget of the Institute was strongly marked by the obtaining of extraordinary funding for the development of 3 pre-commercial public procurement projects, 9 million euros in all, total funds raised for 2019 have managed to reach a similar level. It is also worth mentioning that funding from private sources has increased.

The evolution of funds raised since 2015:

TOTAL FUNDS RAISED (€)

2015	2016	2017	2018	2019
11.325.478	10.351.059	9.628.230	9.873.721	11.039.402

TOTAL FUNDS RAISED



Taking into account that the above figures also include funds raised for the acquisition of infrastructure (i.e. scientific equipment), we also present the same figures without the budgeted infrastructures item, which allows us to evaluate the growth and capacity to attract specific financing for the development of R & D projects. Total funds raised, excluding funds for infrastructures, was as follows:

TOTAL FUNDS RAISED WITHOUT INFRASTRUCTURE (€)

2015	2016	2017	2018	2019
11.175.450	9.616.514	9.628.230	9.873.721	10.739.402

TOTAL FUNDS RAISED WITHOUT INFRASTRUCTURE



THE BREAKDOWN OF FUNDS IS AS FOLLOWS:

PUBLIC	**5.978.407 €**
REGIONAL	1.645.711 €
NATIONAL	3.320.446 €
INTERNATIONAL	1.012.250 €
PRIVATE	**5.060.994 €**
CLINICAL RESEARCH	3.248.021 €
CONTRACTS WITH COMPANIES AND DONATIONS	1.812.973 €

As in previous years, the balance between private and public funding has been higher for public funding than private, although an increase in the percentage of private funds can be observed in recent years:

FUNDING SOURCES

	2015	2016	2017	2018	2019
PUBLIC	76%	70%	65%	54%	54%
PRIVATE	24%	30%	35%	46%	46%

2019

With respect to private funding from industry for clinical trials development, it is apparent from the figures presented in the table below and the results reflecting the development of the Institutional Plan for Clinical Research, setting a very positive trend compared with Contracts with Companies and Donations, that there have experienced growth in the amount of funds raised in the last few years. IMIBIC is taking appropriate measures to re-stimulate the attraction of funding from private sector and industry for the coming years:

	2015	2016	2017	2018	2019
CLINICAL RESEARCH	1.786.513	1.689.229	1.789.050	2.471.922	3.248.021
CONTRACTS WITH COMPANIES AND DONATIONS	870.238	985.203	1.607.453	2.071.610	1.812.973

PRIVATE FUNDS



7. Facts & Figures

7.1 Staff

IMIBIC was awarded the "HR Excellence in Research" quality seal by the European Commission in 2017. Since then, the Institute has developed a Human Resources Strategy for Researchers (HRS4R), based on the recommendations and the principles set out in the Charter & Code to guarantee transparency, accessibility, equity, and the pursuit of excellence in the recruitment of researchers. IMIBIC researchers are classified according to the Research profile descriptors provided by EURAXESS, as indicated in the Figures below.
The new HRS4R Action Plan will be implemented for the period 2020-2022.

HR EXCELLENCE IN RESEARCH

RESEARCHERS R1-R4



The above graph represents the classification of the IMIBIC researchers according to their Career Stage as defined by the Research Profiles Descriptors established by EURAXESS. The distribution of the R1-R4 researchers in 2019 between consolidated, emerging, and associated groups was as follows:

RESEARCHERS OF IMIBIC GROUPS



In 2019, IMIBIC obtained funding from competitive calls for 79 new staff, including 47 researchers, 18 clinicians and 14 technical and management staff. A total of 53 positions were funded by competitive calls from national agencies.

COMPETITIVE HUMAN RESOURCES GRANTS



FUNDING AGENCY	CALL	GRANTED IN 2019	ACTIVE IN 2019
ISCIII	Sara Borrell	3	4
ISCIII	Rio Hortega	2	4
ISCIII	Miguel Servet	3	3
ISCIII	Miguel Servet II	1	
ISCIII	Juan Rodés	2	
ISCIII	PFIS	3	3
ISCIII	IPFIS		3
ISCIII	GIS		1
ISCIII	Bioinformático	1	
ISCIII	Intensificationes	2	2
MICINN	Juan de la Cierva-Incorporación		2
MICINN	Juan de la Cierva-Formación	1	3
MICINN	Técnicos de apoyo	2	2
MICINN	Promoción Empleo Joven	5	5
MICINN	FPI		4
MEC	FPU	6	11
UCO	Ramón y Cajal		3
SAS	Nicolás Monardes	2	4
SAS	Intensificationes	6	10
SAS	Intensificationes de la unidad– Acción B		6
EC	Marie Sklodowska-Curie IF	1	
OTHERS		2	2
TOTAL		**42**	**77**

7.2 PUBLICATIONS

In 2019, our researchers contributed with 591 scientific documents, of which 557 were published in journals indexed in the article database Web Of Science and ranked within quartiles according to the journals' Impact Factor.



PUBLICATIONS PER YEAR AND TYPE



PUBLICATION RESULTS AND INDICATORS IN 2019

	TOTAL	Q1 *(INCLUDING D1)*	D1	Q2	Q3-Q4
ARTICLES	464	268	102	96	100
REVIEWS	53	29	5	13	11
TOTAL ARTICLES & REVIEWS	**517**	**297**	**107**	**109**	**111**
LETTERS	19	16	8	2	1
EDITORIAL MATERIAL	21	9	3	5	7
TOTAL PUBLICATIONS	**557**	**322**	**118**	**116**	**119**

Note: Publications have been ranked by quartiles according to the journals' impact factor.
Q1: Nº of publications published in journals ranked in the first quartile (top 25%) of their category according to the 2018 Journal Citation Report.
D1: Nº of publications published in journals ranked in the first decile (top 10%) of their category according to the 2018 Journal Citation Report.

DISTRIBUTION OF PUBLICATIONS IN NATIONAL AND INTERNATIONAL JOURNALS

INTERNATIONAL JOURNALS	NO. OF PUBLICATIONS
ORIGINAL ARTICLES	406
REVIEWS	47
EDITORIALS	13
LETTERS	14
NATIONAL JOURNALS	
ORIGINAL ARTICLES	58
REVIEWS	6
EDITORIALS	8
LETTERS IN NATIONAL JOURNALS	5
TOTAL	**557**

EVOLUTION OF PUBLICATIONS IN QUARTILE 1 & DECILE 1 JOURNALS



%Q1 and %D1: % of publications (original articles and reviews) published in journals ranked in the first quartile (top 25%) and decile (top 10%), respectively of their category as orders by the 2018 Journal Citation Reports. The red bar indicates the total number of all types of publications per year.

PUBLICATIONS IN 2019 (INCLUDING ORIGINAL ARTICLES + REVIEWS)



PUBLICATIONS LED BY IMIBIC



COLLABORATIONS

DISTRIBUTION OF PUBLICATIONS IN COLLABORATION WITH NATIONAL AND INTERNATIONAL GROUPS

AFFILIATION



Nearly 70% of the original articles and reviews published in 2019 included the IMIBIC affiliation.

NUMBER OF CITATIONS PER ESI CATEGORY



Citation per articles and/ or reviews, calculated by Clarivate Analytics' Essential Science Indicators (ESI) database

BIBLIOGRAPHIC INDICATORS

The following data corresponds to original articles and reviews published by IMIBIC researchers in 2019

	2017	2018	2019
FIRST, LAST OR CORRESPONDING AUTHOR (PUBLICATIONS LED BY IMIBIC INDICATOR)	46%	53%	39%
PUBLICATIONS LED BY IMIBIC INDICATOR	19	35	47
CATEGORY NORMALIZED CITATION IMPACT (CROWN INDICATOR)	1,28	1,66	2,14
HIGHLY CITED PAPERS (HCP INDICATOR)	18,21%	20,64%	25,34%

*Data calculated in June 2020.

7.3 Number of clinical guidelines, consensus and protocol documents

IMIBIC researchers have participated in the elaboration of several international Clinical Guidelines. These guidelines have a remarkable impact on patients' care and medical practice.

	TOTAL	%D1	%Q1
CLINICAL GUIDELINES AND CONSENSUS DOCUMENTS	13	8%	23%

Total number of Clinical Guidelines and Consensus Documents published in 2019 in journals indexed in the ISI Web of Science. Journals were ranked by their quartiles according to their Impact Factor.

7.4 Research projects and networks

Our researchers have developed a high number of competitive projects, specifically, 175 were active in 2019.
The European Regional Development Fund (ERDF) co-funded many of these activities.

RESEARCH PROJECTS BY GENDER OF THE PRINCIPAL INVESTIGATOR

Figures represent the number of ongoing projects financed by national and international funding agencies, either public or private, in 2019.

NATIONAL



INTERNATIONAL



Along with national and international grants, our researchers have been awarded research grants funded by regional agencies, through public competitive calls:

REGIONAL



These charts summarize our active and new competitive projects/networks/human resources obtained in 2019, classified by type of calls.

NATIONAL PROJECTS BY GENDER OF THE PRINCIPAL INVESTIGATOR

INTERNATIONAL PROJECTS BY GENDER OF THE PRINCIPAL INVESTIGATOR



ONGOING PROJECTS IN 2019

NACIONAL	No. OF ONGOING PROJECTS
Public	
Institute of Health Carlos III (ISCIII)	50
Ministry of Economy and Competitiveness (MINECO)	15
Spanish Ministry for Science, Innovation and Universities (MICINN)	1
Private	
Private Funding	16
REGIONAL	
Public	
Regional Ministry of Health and Families (CSyF)	37
Regional Ministry of Economy, Innovation, Science and Employment (CECEU)	2
University of Córdoba (UCO)	4
FIBICO	7
Private	
Private Funding	4
INTERNATIONAL	
Public	
European Commission	17
Other public agencies	1
Private	
Private Funding	4

PROJECTS GRANTED IN 2019

NATIONAL	No. OF GRANTED PROJECTS
Public	
Institute of Health Carlos III (ISCIII)	11
Ministry of Economy and Competitiveness (MINECO)	1
University of Córdoba (UCO)	1
Private	
Private Funding	8
REGIONAL	
Public	
Regional Ministry of Health and Families (CSyF)	12
Private	
Private Funding	1
INTERNATIONAL	
Public	
European Commission	3
Private	
Private Funding	1

7.5 Clinical Trials

The following graphs summarize the number of active clinical trials in 2019. 134 new clinical trials were initiated and a total of 624 studies were active in 2019. Among them, 359 clinical trials are active within their 3 first years of activity (239 clinical trials with drugs, 105 observational studies and 15 medical devices studies).

ONGOING CLINICAL TRIALS IN 2019



OS: Observational Studies / MD: Medical Devices
Most of the clinical trials are sponsored by Spanish industry and are developed within the areas of oncology, gastroenterology, hematology and neurology.

CLINICAL TRIALS BY GENDER OF THE PRINCIPAL INVESTIGATOR

Clinical Trials Classified according to the Promoter in 2019

	CLINICAL TRIALS WITH DRUGS	OBSERVATIONAL STUDIES	MEDICAL DEVICES
PHARMACEUTICAL INDUSTRY	289	100	11
OTHER ENTITIES	98	101	9
SELF PROMOTED (FIBICO)	8	5	3
TOTAL	**395**	**206**	**23**



8. Scientific Production

SCIENTIFIC PROGRAM 1: ACTIVE AGEING AND FRAILTY

GENERAL GOALS

The objectives of the scientific activity of Program 1: "Ageing and Fragility" in 2019 continued to be to advance knowledge of the molecular and cellular bases of senescence and to develop initiatives offering opportunities for healthy ageing that prevent frailty and loss of function.

5 HIGHLIGHTED PUBLICATIONS:

Examples that are particularly noteworthy for their scientific importance and also for collaboration with external groups and other programs in the Institute include:

1. Low Intake of Vitamin E Accelerates Cellular Aging in Patients with Established Cardiovascular Disease: The CORDIOPREV Study. Corina A, Rangel-Zúñiga OA, Jiménez-Lucena R, Alcalá-Díaz JF, Quintana-Navarro G, Yubero-Serrano EM, López-Moreno J, Delgado-Lista J, Tinahones F, Ordovás JM, López-Miranda J, Pérez-Martínez P. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 2019. 74 (6). 770-777. DOI: 10.1080/10408398.2018.1442316. IF: 4,711. Q1. D1.

2. Coenzyme Q(10): From bench to clinic in aging diseases, a translational review. Gutiérrez-Mariscal FM, Yubero-Serrano EM, Villalba JM, López-Miranda J. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION. 2019. 59 (14). 2240-2257. DOI: 10.3390/toxins11030175. IF: 6,704. Q1. D1.

3. IgA Nephropathy in Elderly Patients. Sevillano AM, Díaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J, Calviño J, Castillo L, Cobelo C, Delgado-Mallén P, Espinosa M, Fernández-Juárez G, Fernández-Reyes MJ, García-Osuna R, García P, Goicoechea M, González-Cabrera F, Guzmán DA, Heras M. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2019. 14 (8). 1183-1192. DOI: 10.2215/CJN.13251118. IF: 6,243. Q1. D1.

4. FGF23, Biomarker or Target? Rodelo-Haad C, Santamaría R, Muñoz-Castañeda JR, de Mier MVPR, Martín-Malo A, Rodríguez M. TOXINS. 2019. 11 (3). DOI: 10.1093/gerona/gly195. IF: 3,895. Q1.

5. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. Ellis KL, de Isla LP, Alonso R, Fuentes F, Watts GF, Mata P. 2019. 73 (9). 1029-1039. DOI: 10.1016/j.jacc.2018.12.037. IF: 18,639. Q1

SUB-PROGRAMS

- **Immunology and senescence**
- **Care of the chronically ill**
- **Frailty and quality of life of the elderly**

Nº OF PUBLICATIONS: 74
- Own: 68%
- In collaboration: 8
- IF: 268,662
- Q1 (including D1): 58%
- D1: 13%

NO. OF ONGOING PROJECTS: 32
- Collaborative projects: 17

NO. OF ONGOING CLINICAL TRIALS: 28

PROGRAM 1

COLLABORATIVE PROJECTS PROGRAM 1



PUBLICATIONS IN COLLABORATION PROGRAM 1



SCIENTIFIC PROGRAM 2: nutrition, endocrine and metabolic diseases

GENERAL GOALS

The general objective of the "Nutrition, Endocrine and Metabolic Diseases" Program is to generate new knowledge in the field of nutrition, metabolic diseases and neuroendocrinology that will help prevent health problems in these areas and also improve management of them. Modern societies face an epidemic of diseases associated with inappropriate diet, with metabolic disease being particularly important. Metabolic diseases are often associated with obesity and are the subject of active research. Despite considerable advances in knowledge, the exact causes of these diseases, the mechanisms involved in their development, the nature of all their comorbidities and how to tackle prevention and treatment effectively are still not known. These processes are very closely linked to life expectancy and quality of life, the wellbeing of society and the sustainability of public health services, which is why addressing them is a priority. There is also considerable variability in individual susceptibility to these diseases or for them to be more or less severe. Some of the factors that contribute to differences in individual susceptibility are already known or suspected, such as the genetic substrate, epigenetic components, neuroendocrine mechanisms in appetite regulation or molecular mechanisms in biology, such as oxidative stress, inflammation or the response to hypoxia. A key objective of our program therefore is to maintain a multidisciplinary approach based on precision medicine techniques. Important objectives of our program are to integrate clinical and molecular information in order to identify the characteristics that make us unique and so pave the way for personalized medicine in the future, particularly in the areas of cardiovascular disease, diabetes, reproductive alterations associated with metabolic disorders and neuroendocrine tumors. It is considered a priority of our scientific activity that our efforts be constantly imbued with the desire to foster synergies, promote talent and employability in the National Health System and to accelerate the transfer and translationality of our advances, thus contributing to wealth creation in our environment.

In 2019, Scientific Program 2 implemented a wide range of research studies—both basic, clinical, and translational—related to the specific objectives of its various sub-programs. These studies have led to a large number of publications and other scientific contributions, which confirms the growth trend of previous years with a 25% increase in the total number of scientific articles with respect to the years 2015-2016. Likewise, the continuity and achievement of a significant number of competitive projects financed by national and international agencies, as well as other successes, such as invitations as guest speakers and awards received by the teams that make up the Program, help define a profile of excellence that lays the foundations for the development of personalized and precision medicine in the management of a wide range of highly prevalent diseases, ranging from diabetes and obesity to various reproductive disorders

5 HIGHLIGHTED PUBLICATIONS:

1. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, Serra-Majem L, Wärnberg J, Romaguera D, Estruch R, Vidal J, Martínez JA, Arós F, Vázquez C, Ros E, Vioque J, López-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martín V, Lapetra J, Pintó X, Daimiel L, Delgado-Rodríguez M, Matía P, Gómez-Gracia E, Díez-Espino J, Babio N, Castañer O, Sorlí JV, Fiol M, Zulet MÁ, Bulló M, Goday A, Martínez-González MÁ; PREDIMED-Plus investigators. Diabetes Care. 2019 May. 42(5):777-788. DOI: 10.2337/dc18-0836. IF: 15.270. Q1. D1.

2. Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: From the CORDIOPREV study. Camargo A, Jimenez-Lucena R, Alcala-Diaz JF, Rangel-Zuñiga OA, Garcia-Carpintero S, López-Moreno J, Blanco-Rojo R, Delgado-Lista J, Perez-Martinez P, van Ommen B, Malagón MM, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J. Clin Nutr. 2019 Apr. 38 (2):529-538. DOI: 10.1016/j.clnu.2018.03.016. IF: 6.402. Q1. D1.

3. Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications. Romero-Ruiz A, Avendaño MS, Dominguez F, Lozoya T, Molina-Abril H, Sangiao-Alvarellos S, Gurrea M, Lara-Chica M, Fernandez-Sanchez M, Torres-Jimenez E, Perdices-Lopez C, Abbara A, Steffani L, Calzado MA, Dhillo WS, Pellicer A, Tena-Sempere M. Am J Obstet Gynecol. 2019 May. 220 (5):480.e1-480.e17. DOI: 10.1016/j.ajog.2019.01.228. IF: 6.120. Q1. D1.

4. Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3. Heras V, Sangiao-Alvarellos S, Manfredi-Lozano M, Sanchez-Tapia MJ, Ruiz-Pino F, Roa J, Lara-Chica M, Morrugares-Carmona R, Jouy N, Abreu AP, Prevot V, Belsham D, Vazquez MJ, Calzado MA, Pinilla L, Gaytan F, Latronico AC, Kaiser UB, Castellano JM, Tena-Sempere M. PLoS Biol. 2019 Nov 7. 17 (11):e3000532. DOI: 10.1371/journal.pbio.3000532. IF: 8.386. Q1. D1.

5. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. J Clin Med. 2019 Nov 22. 8 (12). pii: E2056. DOI: 10.3390/jcm8122056. IF: 5.583; Q1.

SUB-PROGRAMS

- **Metabolic syndrome**
- **Reproductive health**
- **Pediatric and perinatal diseases**
- **Neuroendocrine tumors**

METABOLIC SYNDROME SUB-PROGRAM IN 2019

The objectives of this sub-program were successfully completed in the course of 2019. In general, the scientific output of this sub-program increased compared to previous years. The original publications contribute to providing answers to most of the specific objectives of this sub-program: establishing possible mechanisms involved in the development of type 2 diabetes, such as endotoxemia; defining the molecular bases for improved intervention strategies, such as eating a Mediterranean diet and exercise, which could be an optimal strategy for reducing cardiovascular risk factors. Also in 2019, research projects financed in previous years continued to be developed, and four research projects with national and international funding were launched: to evaluate the role of the alpha cell in the development of type 2 diabetes in order to identify new biomarkers for management of the disease, or to analyze the influence of obesity on the development of diabetic nephropathy, and the role of heart-healthy diets as dietary therapy in the development of this disease. The results of this sub-program have been presented at different national and international conferences.

REPRODUCTIVE HEALTH SUB-PROGRAM IN 2019

Development of this sub-program has enabled substantial progress to be made in the achievement of its specific objectives, which are associated on the one hand with obtaining better knowledge of the physiopathology of widespread reproductive disorders frequently associated with metabolic and/or neuroendocrine alterations, and on the other, with defining new diagnostic and therapeutic strategies for those disorders. In this connection, 2019 saw relevant articles published in first-decile journals characterizing the physiopathological role of kisspeptins, both in reproductive disorders caused by environmental factors and in the therapeutic management of such common reproductive conditions as polycystic ovary syndrome. Similarly, studies have been completed on the possible usefulness of certain circulating miRNAs and kisspeptins as biomarkers of gestational alterations, such as ectopic pregnancy; this aspect has also been protected by a patent. Novel data have been published on the possible contribution of kisspeptins to body weight control and glycemic homeostasis. These activities were carried out in the framework of up to six competitive projects financed by international, national and regional agencies, one of which started in 2019. As further indicators of excellence, the results of this sub-program were presented in the form of guest lectures at various international scientific conferences, and a contract for the recruitment of highly qualified human resources to this subprogram was awarded by the Marie S. Curie action.

PEDIATRIC AND PERINATAL DISEASES SUB-PROGRAM IN 2019

The activities of this sub-program have made significant progress towards meeting the specific objectives of the program. On the one hand, there has been a very large number of publications aimed at characterizing the molecular and hormonal bases of childhood obesity, as well as analyzing the influence of certain nutritional interventions in childhood on health promotion. These studies are complemented by others aimed at defining possible associations between metabolic factors and certain pediatric diseases, such as autism, as well as new methods for estimating physical condition in pre-adolescents. At the same time, the sub-program has also made significant preclinical contributions to the characterization of new pubertal control mechanisms linked, on the one hand, to the identification of a new control system based on miRNA regulators for Mkrn3 (whose mutation produces early puberty in children), and on the other, to the definition of new neuroendocrine mechanisms controlling puberty due to environmental factors with endocrine-disrupting activity. These activities were developed within the framework of up to four national competitive projects, including a coordinated multicenter project aimed at studying molecular markers of metabolic risk in puberty, a clinical study focused on an analysis of Mediterranean lifestyle dietary habits in the prevention of childhood obesity, and a translational research project aimed at identifying new neuroendocrine mechanisms for controlling puberty and its alterations in conditions of obesity.

NEUROENDOCRINE TUMORS SUB-PROGRAM IN 2019

The progress of this sub-program has led to the achievement of the specific objectives proposed, related to the characterization of the molecular and hormonal profile of neuroendocrine tumors, which are strongly associated with alterations of metabolic state, and to the establishment of new tools for the early detection and treatment of this type of tumor. Significant contributions were made during 2019, with articles published in journals in the first quartile and decile of their category, which show that deregulated splicing machinery is associated with the development of pituitary neuroendocrine tumors or prostate cancer, the key role of type 2 diabetes as a risk factor for the development of different types of tumor, or how different components of the spliceosome or enzyme ghrelin-O-acyltransferase (GOAT) could be used as prognostic biomarkers for prostate cancer. These activities were developed in the framework of different competitive projects financed by international, national and regional agencies, many of them initiated in the same year. As additional indicators of excellence, the results produced in this sub-program have been presented in the form of guest lectures at various national and international scientific conferences.

HIGHLIGHTS IN 2019

- **NO. OF PUBLICATIONS:** 96
  - Own: 41%
  - In collaboration: 30
  - IF: 431,02
  - Q1 (including D1): 63%
  - D1: 20%
- **NO. OF ONGOING PROJECTS:** 58
  - Collaborative projects: 20
- **NO. OF ONGOING CLINICAL TRIALS:** 62

PROGRAM 2

COLLABORATIVE PROJECTS PROGRAM 2

PUBLICATIONS IN COLLABORATION PROGRAM 2

SCIENTIFIC PROGRAM 3: INFECTIOUS AND IMMUNOLOGICAL DISEASES AND ORGAN TRANSPLANTATION

GENERAL GOALS

To develop a common line of quality research addressing health problems related to host-foreign agent interactions, specifically in the study of organ transplants, autoimmune and infectious diseases. This line is designed to achieve deliverable results with an impact on the clinical practice of bio-health professionals that lead to increased quality of life for the patient and the wellbeing of society. It is of the utmost importance to strengthen the alliances of the program's groups at regional, national and international level and/or with public or private companies, in order to: improve the chances of success when applying for research projects, enhance the creation of new spinoffs by group members, and lay down firm foundations to support the training and job stability of researchers through specific effective actions that ensure that the milestones are achieved, and with a translational focus that has an impact on improving the quality of patient care, either through the technological transfer of results to industry or through their application in clinical practice guidelines.

Consistent with the research needs of IMIBIC Program 3, the original research objectives have changed. In 2019, a total of 7 research groups (3 consolidated groups, 2 emerging groups and 2 associated groups) participated in IMIBIC Program 3.

5 HIGHLIGHTED PUBLICATIONS:

1. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Pérez AB, Chueca N, García-Deltoro M, Martínez-Sapiña AM, Lara-Pérez MM, García-Bujalance S, Aldámiz-Echevarría T, Vera-Méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-Arboledas JC, Poyato A, Téllez F, Rivero-Juárez A, Merino D, Vivancos-G. JOURNAL OF HEPATOLOGY. 2019. 71 (5). 876-888. DOI: 10.1016/j.jhep.2019.06.022. IF: 18,946. Q1. D1.

2. Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain. Caballero-Gómez J, Jiménez-Ruiz S, López-López P, Vicente J, Risalde MA, Cano-Terriza D, Frias M, Barasona JA, Rivero A, García-Bocanegra I, Rivero-Juárez A. TRANSBOUNDARY AND EMERGING DISEASES. 2019. 66 (5). 1803-1808. DOI: 10.1111/tbed.13251. IF: 3,554. Q1. D1.

3. Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. Pérez AB, Vrancken B, Chueca N, Aguilera A, Reina G, Toro MG, Vera F, von Wichman MA, Arenas JI, Téllez F, Pineda JA, Omar M, Bernal E, Rivero-Juárez A, Fernández-Fuertes E, de la Iglesia A, Pascasio JM, Lemey P, García F, Cuypers L. EUROSURVEILLANCE. 2019. 24 (9). 25-34. DOI: 10.2807/1560-7917.ES.2019.24.9.1800227. IF: 7,421. Q1. D1.

4. Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts. Islam MM, Sharifi R, Mamodaly S, Islam R, Nahra D, Abusamra DB, Hui PC, Adibnia Y, Goulamaly M, Paschalis EI, Cruzat A, Kong J, Nilsson PH, Argileso P, Mollnes TE, Chodosh J, Dohlman CH, González-Andrades M. ACTA BIOMATERIALIA. 2019. 96. 330-344. DOI: 10.1016/j.actbio.2019.07.002. IF: 6,638. Q1. D1.

5. Hepatitis E virus infection in equines in Spain. García-Bocanegra I, Rivero A, Caballero-Gómez J, López-López P, Cano-Terriza D, Frías M, Jiménez-Ruiz S, Risalde MA, Gómez-Villamandos JC, Rivero-Juárez A. TRANSBOUNDARY AND EMERGING DISEASES. 2019. 66 (1). 66-71. DOI: 10.1111/tbed.12962. IF: 3,554. Q1. D1.

SUB-PROGRAMS

- **HIV + Hepatitis C**
- **Transplantation**
- **Multiresistance**

SUB-PROGRAM: HIV AND/OR HCV INFECTION IN 2019

The articles generated in this sub-program include "High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world", published in the Journal of Hepatology (D1), which describes the high cure rates obtained with a strategy based on characterizing resistance mutations in order to select a rescue treatment for HCV infection. In the same area of research, also worthy of note is the article "Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain", published in Eurosurveillance (D1). This article analyzes the national transmission of the hepatitis C virus in order to develop interventions to prevent transmission. These publications have been selected as 2 of the 5 outstanding publications of Program 3. In the same area, a project on HIV infection financed by the ISCIII also started in 2019.

SUB-PROGRAM: TRANSPLANTS IN 2019

In this sub-program, a clinical trial started with ISCIII funding and an innovation project with regional funding. The activity of the Emerging GE-7 group "Visual Quality", which has generated 3 articles in first quartile journals should be underlined. Among them, the article "Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts", published in Acta Biomaterialia (D1), which evaluates the effect of gamma radiation as a method of sterilization on the ultrastructure and biological properties of porcine corneas. This publication has been selected as one of the 5 outstanding publications of Program 3.

SUB-PROGRAM: HIV AND/OR HCV INFECTION IN 2019

Among the groups that were formed in 2019 and joined Program 3 is the consolidated group, GC-26: "Clinical Virology and Zoonoses". The objectives of this new group include the immunology, pathogenesis, treatment and prevention of emerging zoonotic diseases. A good example of the activity of this new objective of the Program is the article "Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain", published in Transboundary and Emerging Diseases (D1). Another highlighted article in the same thematic area is "Hepatitis E virus infection in equines in Spain", also published in Transboundary and Emerging Diseases (D1). Both articles have been selected as among the 5 most outstanding publications of Program 3.

HIGHLIGHTS IN 2019

- **NO. OF PUBLICATIONS:** 89
  - Own: 36%
  - In collaboration: 9
  - IF: 386,33
  - Q1 (including D1): 62%
  - D1: 28%
- **NO. OF ONGOING PROJECTS:** 35
  - Collaborative projects: 11
- **NO. OF ONGOING CLINICAL TRIALS:** 42

PROGRAM 3

COLLABORATIVE PROJECTS PROGRAM 3

PUBLICATIONS IN COLLABORATION PROGRAM 3

SCIENTIFIC PROGRAM 4: cancer (oncology and oncohematology)

GENERAL GOALS

Despite the increase in the number of patients diagnosed with cancer, mortality is decreasing in both sexes and for most tumors. This is due to advances in treatment, but also to prevention and early diagnosis measures. IMIBIC's transversal cancer research program should therefore be aimed at making progress in all areas: prevention, diagnosis and treatment of cancer, focusing efforts particularly on contributing to the development of precision and personalized medicine (PPM) in cancer.

During 2019, this scientific program continued to focus on the main areas of cancer research: prevention, diagnosis and treatment. Its various sub-programs (lung cancer, breast cancer, hepatocarcinoma, leukemias and lymphomas, digestive tumors and other tumors) have developed multidisciplinary research with a high level of collaboration between basic and clinical groups, with the help of the research support units (UCAIB). Furthermore, research activity is largely concentrated in or around the Reina Sofia University Hospital and the University of Cordoba, which offer an ideal setting for healthcare, scientific, technological and teaching innovation.

5 HIGHLIGHTED PUBLICATIONS:

1. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Santos C, Azuara D, Viéitez JM, Páez D, Falco E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Buges C, Durán G, Salud A, Navarro V, Capella G, Aranda E, Salazar R, de Mena IR, Rodríguez S. ANNALS OF ONCOLOGY. 2019. 30 (5). 796-803. DOI: 10.1093/annonc/mdz082. IF: 14,196. Q1. D1.

2. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2. Morrugares, R., Correa-Sáez, A., Moreno, R., Garrido-Rodríguez, M., Muñoz, E., de la Vega, L., and Calzado, M.A. CELLULAR AND MOLECULAR LIFE SCIENCES. 2019. DOI: 10.1007/s00018-019-03309-9. IF: 7,014. Q1. D2.

3. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernández JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP, Luque R. CANCERS. 2019. 11 (10; 1439). DOI: 10.3390/cancers11101439. IF: 6,162. Q1. D2.

4. Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. Gómez-Gómez, E; Jiménez-Vacas, JM; Pedraza-Arévalo, S; López-López, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibáñez-Costa, A; León-González, AJ; Sánchez-Sánchez, R; González-Serrano, T; Requena-Tapia, MJ; Castaño, JP; Carrasco-Valiente. JOURNAL OF CLINICAL MEDICINE. 2019. 8 (9; 1400). DOI: 10.3390/jcm8091400. IF: 5,688. Q1. D1.

5. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. Arjona-Sánchez A, Rodríguez-Ortiz L, Baratti D, Schneider MA, Gutiérrez-Calvo A, García-Fadrique A, Tuynman JB, Cascales-Campos PA, Martin VC, Morales R, Salti GI, Arteaga X, Pacheco D, Alonso-Gómez J, Yalkin O, Villarejo-Campos P, Sánchez-Hidalgo JM, et al. ANNALS OF SURGICAL ONCOLOGY. 2019. 26 (8). 2595-2604. DOI: 10.1245/s10434-019-07378-9. IF: 3,857. Q1. D1.

- **Lung cancer**
- **Breast cancer**
- **Hepatocellular carcinoma**
- **Leukemias and lymphomas**
- **Digestive tumors**
- **Other tumors**

Following various preferential lines of research, the different groups have focused their efforts on such important objectives as early detection, development of new therapies, improvements in imaging and surgical techniques, the application of advanced data analysis methods, association studies with other diseases, as well as the application of new therapeutic approaches by conducting clinical drug response studies. Specific objectives include identification of new therapeutic targets and biomarkers (circulating cells and DNA), improvement of immunotherapy programs, robotic laparoscopic tool applications, as well as the use of Big Data. This has led to a large number of publications in high-impact journals, and to quality projects in highly competitive calls.

The following studies, which are markedly translational in nature and directed by both basic and clinical researchers, may be highlighted as examples of the effort made.

• The study coordinated by Dr. Calzado, which is fundamentally basic research with a clinical perspective, focuses on the NOTCH family of proteins and presents a new regulation mechanism mediated by the DYRK2 kinase. This finding identifies a new therapeutic target linked to situations of resistance to chemotherapy treatment.

• Another important study this year that reinforces the value of splicing studies as a source of prognostic information was carried out by Dr Luque's group. They demonstrated severe dysregulation in the splicing components involved in pituitary neuroendocrine tumors.

• We highlight two studies on prostate cancer by Dr. Gómez. Using the capillary electrophoresis-mass spectrometry technique, he identified a profile of 19 biomarkers in urine in just over 800 patients with low PSA levels (<15 ng/ml). In validation, this biomarker profile resulted in sensitivity of 90% and specificity of 59%. In the search for new prognostic factors predictive of response to prostate cancer treatment, the published results showed the value and potential role of EN2 protein in prostate cancer biology.

• Another study with significant clinical potential is the one by Dr. Arjona, who analyzed the value of RAS mutational status in colon cancer as a predictor of evolution after resection in peritoneal carcinomatosis. The study led to a new international prospective study of which he is the coordinator.

• The last two studies coordinated by Dr. Aranda on colorectal carcinoma show the methodological importance of integrating molecular studies into prospective clinical trials as a source of information that can be quickly applied in clinical practice.

HIGHLIGHTS IN 2019

- **NO. OF PUBLICATIONS:** 73
  - Own: 52%
  - In collaboration: 29
  - IF: 369,05
  - Q1 (including D1): 62%
  - D1: 25%
- **NO. OF ONGOING PROJECTS:** 60
  - Collaborative projects: 34
- **NO. OF ONGOING CLINICAL TRIALS:** 194

PROGRAM 4

COLLABORATIVE PROJECTS PROGRAM 4



PUBLICATIONS IN COLLABORATION PROGRAM 4

SCIENTIFIC PROGRAM 5:
CHRONIC AND INFLAMMATORY DISEASES

GENERAL GOALS

There is a direct relationship between life expectancy increases in the population and a higher incidence and prevalence of chronic and inflammatory diseases. These diseases impair quality of life and have a significant effect on the role this type of patient can play in society. Furthermore, since they are chronic conditions requiring long-term treatment, they consume a considerable amount of health budget resources. For these reasons, the main objective of this program is focused on tackling chronic disease from three fundamental standpoints:

- **To expand knowledge and identify the molecular bases underlying this type of disease.**
- **To use this new knowledge as the basis for developing new therapeutic strategies that can improve prognosis and development of the disease.**
- **To develop new preventive strategies to stop or delay the onset or evolution of this type of disease.**

Achievement of the objectives set out in this program is framed within the development of numerous research projects, both international and national/regional, obtained through competitive calls by the research groups belonging to the program. These include an international project initiated within the framework of one of the key objectives of this program: 'To develop new therapeutic strategies that can improve the prognosis and evolution of chronic inflammatory pathologies', which is funded by the European Union (IMI2 - grant agreement no. 831434) and will last 7 years (2019-2026). The main objective of this project is to identify the molecular mechanisms of non-response to treatment, relapses and remissions in autoimmune (lupus and rheumatoid arthritis), inflammatory (inflammatory bowel disease, multiple sclerosis) and allergic (asthma) diseases.
It is important to highlight the collaborations established between 2 or more research groups belonging to the various sub-programs for the publication of articles. In addition, while most of the publications this year were contributed by the consolidated groups in this program, the clear contribution made by the emerging and associated groups, some of which joined in the last 2 years, is also worth noting.

5 HIGHLIGHTED PUBLICATIONS:

1. Identification of a 3 '-Untranslated Genetic Variant of RARB Associated with Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. López-Mejías R, Carmona FD, Genre F, Remuzgo-Martínez S, González-Juanatey C, Corrales A, Vicente EF, Pulito-Cueto V, Miranda-Filloy JA, Huaranga MAR, Blanco R, Robustillo-Villarino M, Rodríguez-Carrio J, Alperi-López M, Alegre-Sancho JJ, Mijares V, et al. ARTHRITIS & RHEUMATOLOGY. 2019. 71 (3). 351-360. DOI: 10.1002/art.40734. IF: 9. Q1. D1.

2. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Sanmartí R, Veale DJ, Martín-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE, Alcañiz C, Álvaro-Gracia JM, Balsa A, de Pablos JL, Miguel CD, Rodríguez JM, Alves J, Aurrecoechea E, Calvo J, Belzunegui J, Blanco F, Cáliz R, Calvo J. ARTHRITIS & RHEUMATOLOGY. 2019. 71 (10).1616-1625. DOI: 10.1002/art.40905. IF: 7,873. Q1. D1.

3. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, Pineda C, Martínez-Moreno JM, Herencia C, Vergara N, de Mier MVPR, Santamaría R, Rodelo-Haad C, Casado-Díaz A, Lorenzo V, Carvalho C, Frazão JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodríguez M, et al. KIDNEY INTERNATIONAL. 2019. 95 (5). 1064-1078. DOI: 10.1016/j.kint.2018.12.015. IF: 8,306. Q1. D1.

4. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons with Inflammatory Bowel Disease and a History of Extracolonic Cancers. Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez JM, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert JP, Domènech E. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2019. 114(5). 771-776. DOI: 10.14309/ajg.0000000000000210. IF: 10,231. Q1. D1.

5. LUBAC determines chemotherapy resistance in squamous cell lung cancer. Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. JOURNAL OF EXPERIMENTAL MEDICINE. 2019. 216 (2). 450-465. DOI: 10.1084/jem.20180742. IF: 10,892. Q1. D1.

The articles published during 2019 that have been selected as reference studies identify the significant progress made in achieving the main objective of program 5, which is focused on the characterization of clinical-molecular profiles underlying the development of chronic diseases and the development of new therapeutic strategies for their management and follow-up. These studies show substantial advances in our knowledge of disease mechanisms in cardiovascular, autoimmune, kidney, digestive and tumor pathologies, and in the cellular and molecular processes that explain efficacy and/or non-response to new pharmacological therapies.
It is also necessary to emphasize that the quality of these publications derives from the development of robust studies that include large cohorts of patients, the implementation of new clinical trials and/or the generation of animal models as a basis for the study of disease and response to therapy.
Finally, it should be noted that these studies are included in national or international projects that are currently underway and/or were initiated in 2019, which means that new quality knowledge will shortly be generated in these lines of research.

SUB-PROGRAMS

- **Cardiovascular diseases**
- **Diseases of the musculoskeletal system and connective tissue**
- **Neurological diseases and mental health**
- **Kidney and urological diseases**
- **Liver and digestive diseases**
- **Chronic inflammation and signalling**

SUB-PROGRAM CARDIOVASCULAR DISEASES IN 2019

Among the action plans implemented in this sub-program, the following should be highlighted: 1. The development of studies to evaluate the contribute of diet to the molecular mechanisms involved in endothelial dysfunction in patients with CVD. 2. The evaluation and characterization of subclinical coronary atherosclerosis in familial hypercholesterolemia. 3. Characterization of complex coronary lesions and/or with stents. 4. Studies evaluating the use of percutaneous transluminal treatment to treat heart disease. 5. Development of studies related to the care of patients with CV disease.

It is important to underline the significant contribution of associated and emerging groups to the achievement of the objectives set out.

SUB-PROGRAM DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE IN 2019

Among the action plans implemented in this sub-program, the following should be highlighted: 1. Analysis of mechanisms underlying the development of thrombosis and cardiovascular disease in systemic autoimmune conditions -antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis - and studies of the effect of new therapies. 2. Development of molecular, clinical and epidemiological research to define the physiopathology of disease and therapeutic response in patients with spondyloarthritis. 3. Development of new treatments for food allergies, and approaching the complex patient with anaphylaxis to Hymenoptera venom. 4. Molecular-based allergy diagnostics using allergenic molecules, phenotyping of olive pollen allergy. Identification and differential treatment.
As in the case of sub-program 1, the role of emerging and associated groups in the implementation of the proposed objectives should be underlined. These made a significant contribution to the impact of the area with 5 quality publications (Group GE-

03, 'Immune-mediated inflammatory skin diseases' contributed to a high IF journal in D1; group GA03: 'Pneumology' published 2 articles in journals in D1 and 2 in Q1).

SUB-PROGRAM NEUROLOGICAL DISEASES AND MENTAL HEALTH IN 2019

Among the action plans implemented in this sub-program, the following should be highlighted: 1. Development of studies on the role of oxidative status in neurodegenerative processes and other chronic pathologies 2. Development of new endovascular recanalization techniques in stroke patients.
The emerging groups (GE1, 'Neuroplasticity and oxidative stress': 2 publications in Q1-journals) and associated groups (GA8, 'Radiodiagnosis': 2 publications in D1 and one in Q1) made significant contributions to the achievement of the objectives of this sub-program.

SUB-PROGRAM KIDNEY AND UROLOGICAL DISEASES IN 2019

Among the action plans implemented in this sub-program, the following should be highlighted: 1. Study of the underlying basis of vascular calcification in chronic kidney disease. 2. Evaluation of inflammation and calcifying vascular disease in uremia. 3. Identification of biomarkers of kidney damage and vascular calcification. 4. Epidemiological analysis of bone alterations and molecular mechanisms of progression of kidney disease. It should be noted that a new emerging group (GE06 'Physiopathology of renal and vascular damage') has been integrated into this sub-program this year, which is expected to contribute to the expansion of the scientific and strategic objectives of this sub-program, as well as enhance their quality.

SUB-PROGRAM LIVER AND DIGESTIVE DISEASES 2019

Among the action plans implemented, the following should be highlighted: 1. Identification of markers predictive of response to anti-TNF drugs in patients with inflammatory bowel disease, with functional validation of genetic polymorphism (SNP rs6105269) in Crohn's disease. 2. Characterization of the relationship between the molecular composition (the somatostatin/cortisatin/ghrelin system and their receptors in particular) of biological samples obtained from patients with liver diseases (steatosis, cirrhosis and cancer; blood and liver samples), their clinical characteristics and patient response to treatment with drugs commonly used for the treatment of these pathologies.

SUB-PROGRAM CHRONIC INFLAMMATION AND SIGNALING IN 2019

Among the action plans implemented in this sub-program, the following should be highlighted: 1. Evaluation of the effects of natural compounds and their derivatives on the modulation of inflammatory response in various tissues and their impact on the course of prevalent inflammation-based diseases. 2. Determination of associations between different types of cancer and diseases of an inflammatory nature. 3. Development of translational projects aimed at validating new therapies (with patent protection) in the management of chronic inflammatory-based diseases, including neurological, dermatological and metabolic alterations.

HIGHLIGHTS IN 2019

- **NO. OF PUBLICATIONS:** 134
  - Own: 28%
  - In collaboration: 26
  - IF: 573,59
  - Q1 (including D1): 49%
  - D1: 19%
- **NO. OF ONGOING PROJECTS:** 63
  - Collaborative projects: 32
- **NO. OF ONGOING CLINICAL TRIALS:** 213

PROGRAM 5

COLLABORATIVE PROJECTS PROGRAM 5



COLLABORATIVE PUBLICATIONS PROGRAM 5



GC01: IMMUNOLOGY AND ALLERGY

TEAM

Last name	First name	
Solana Lara	Rafael	R4
Alonso Diaz	Corona	R3
Espinazo Romeu	Mª Luisa	R3
Jurado Roger	Aurora	R3
Moreno Aguilar	Carmen	R3
Pera Rojas	Alejandra	R3
Ruiz León	Berta	R3
Serrano Delgado	María Del Pilar	R3
Barasona Villarejo	Mª Jose	R2
González Fernández	Rafael	R2
Manzanares Martin	Bárbara	R2
Molina Alcaide	Juan Eduardo	R2
Navas Romo	Ana Maria	R2
Saiz Sánchez	Vanessa	R2
Cañones Barceló	Estrella	R1
García Gallego	Azahara	R1
Yarce Bustamante	Oscar Albeiro	R1
Trujillo Aguilera	Antonio	R1
Gutiérrez González	Carmen María	T
Guerra González	Mercedes	N
Velarde Martínez	Mª Luisa	ADM

SCIENTIFIC PRODUCTION

12	58%	8%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. REIPI - Spanish Network for Research in Infectious Diseases (Collaborator)
ii. ARADyAL - Spanish Network for asthma, adverse and allergic reactions (Asma, Reacciones ADversas y ALérgicas) (PI: Carmen Moreno Aguilar)
iii. PAIDI CTS-208 Molecular immunology

Competitive funding obtained for contracts:

i. Intensificación (SAS) - Carmen Moreno Aguilar

5 Agreements with companies

KEYWORDS

- **IMMUNOSENESCENCE**
- **AGING**
- **MELANOMA**
- **NK CELLS**
- **NKT CELLS**
- **NK RECEPTORS**
- **CMV**
- **CYTOTOXIC T LYMPHOCYTES (CTL**
- **AORTIC STENOSIS**
- **PROINFLAMMATORY CELLS**
- **ALLERGY**
- **ANAPHYLAXIS**
- **POLLEN**
- **HYMENOPTERA**
- **FOOD**
- **MITE**
- **DRUGS**

HIGHLIGHTED PUBLICATIONS

1. Gastaminza G, Ruiz-Canela M, Andres-Lopez B, Villarejo MJB, Cabanas R, Garcia-Nunez I, Goikoetxea MJ, Laguna JJ, Lobera T, Lopez-San Martin M, Martin-Lazaro J, Mielgo-Ballesteros R, Moreno E, Moya-Quesada MD, Ortega-Rodriguez N, Rojas-Perez-Ezquerra P, Rosado A, Salas M, Sanchez-Morillas L, Vila-Albelda C, Corominas M. Quality of Life in Patients with Allergic Reactions to Medications: Influence of a Drug Allergy Evaluation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 2019; 7(8):2714-2721.
IF: 7,550 Q1 D1

2. Eguiluz-Graci, I, Testera-Montes A, Gonzalez M, Perez-Sanchez N, Ariza A; Salas M, Moreno-Aguilar C, Campo P, Jose Torres M, Rondon C. Safety and reproducibility of nasal allergen challenge. ALLERGY. 2019 Jun;74(6):1125-1134.
IF: 6,771 Q1

3. Sanchez-Solares J, Delgado-Dolset MI, Mera-Berriatua L, Hormias-Martin G, Cumplido JA; Saiz V, Carrillo T, Moreno-Aguilar C, Escribese MM, Gomez-Casado C, Barber D. Respiratory allergies with no associated food allergy disrupt oral mucosa integrity. ALLERGY. 2019 Nov;74(11):2261-2265.
IF: 6,771 Q1

4. Oeo-Santos, C; Navas, A; Benede, S; Ruiz-Leon, B; Diaz-Perales, A; Vogel, L; Moreno Aguilar, C; Jurado, A; Villalba, M; Barderas, R. New insights into the sensitization to nonrelated nsLTPs from pollen and food: New role of allergen Ole e 7. Allery Wiley 06/11/2019. 75 (4). 798-807.
IF: 6,77 Q1

5. Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, Alonso C, Solana R*, Tarazona R. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. Cancers (Basel). 2019 Jun 23;11(6). pii: E877
IF 6,162 Q1

ACTIVITY

Nº ONGOING PROJECTS: 7
Nº PROJECTS STARTING IN 2020: 3
Nº CLINICAL TRIALS: 3
Nº PHD THESES: 1

MAIN RESULTS

Clinical Guidelines:

i. Tabar, A., Acevedo, I., Nunez, B., Beitia azuecos, JM., Moreno, C. and Vidal, C. Quality Standar for Allergen Immunotherapy Clinics in Spain: Consensus Document. Journal of Investigational Allergology and Clinical Immunology. 29(4). 272-279. DOI: 10.18176/jiaci.0318. PMID: 30222115

GC02: OXIDATIVE AND NITROSATIVE STRESS IN ACUTE AND CHRONIC LIVER DISEASE

TEAM

Last name	First name	
Bárcena Ruiz	José Antonio	R4
De La Mata García	Manuel	R4
Aguilar Melero	Patricia	R3
Barrera Baena	Pilar	R3
Costán Rodero	Guadalupe	R3
Ferrín Sánchez	Gustavo	R3
Iglesias Flores	Eva	R1
Montero Álvarez	José Luis	R3
Padilla Peña	Alicia	R3
Peinado Peinado	José	R3
Poyato González	Antonio	R3
Rodríguez Perálvarez	Manuel Luis	R3
González Rubio	Sandra	R2
Linares Luna	Clara Isabel	R2
Requejo Aguilar	Raquel	R3
Vida Pérez	Luis	R2
Benítez Cantero	José Manuel	R1
Fernández González	Rocío	R1
Guerrero Misas	Marta	R1
Medina Medina	Rosario	R1
Díaz Sillero	Encarna	T
Gómez Núñez	Mª Isabel	T
Salgueiro Rodríguez	Mª Isabel	T

SCIENTIFIC PRODUCTION

31	29%	48%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBER on Liver and Digestive Diseases (CIBERehd)
ii. Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
iii.The research team is part of the scientific groups CTS-273 in Study of acute affections of the digestive system, and BIO-216 on Molecular mechanisms of antioxidant and proteomic defense, both pertaining to the Andalusian Plan for Research, Development and Innovation (PAIDI)

Competitive funding obtained for contracts:

i. Post-MIR Researcher: Sop Fuga de Cerebros ROCHE – Marta Guerrero Misas (SFC17/04)
ii. Intensificación (SAS) - Manuel De la Mata García
ii .Intensificación Unidad "Acción B" (SAS) – Manuel Rodríguez Perálvarez

10 agreements with companies

KEYWORDS

- **LIVER TRANSPLANT**
- **HEPATOCELLULAR CARCINOMA**
- **CROHN'S DISEASE**
- **ULCERATIVE COLITIS**
- **CHOLESTASIS**
- **LIQUID BIOPSY**
- **PROTEOMICS**
- **REDOX HOMEOSTASIS**
- **ANTI-TNF**

HIGHLIGHTED PUBLICATIONS

1. López-Grueso MJ, Gonzalez-Ojeda R, Requejo-Aguilar R, McDonagh B, Fuentes-Almagro CA, Muntane J, Barcena JA, Padilla CA. Thioredoxin and glutaredoxin regulate metabolism through different multiplex thiol switches. REDOX BIOLOGY. 2019. 21. DOI:10.1016/j.redox.2018.11.007.
IF: 7,793 Q1 D1

2. López-Grueso MJ, González R, Muntané J, Bárcena JA, Padilla CA. Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells. Antioxidants. 2019. 8 (10): 501.
IF: 4,520 Q1

3. López-Grueso MJ, Tarradas Valero RM, Carmona-Hidalgo B, Lagal DJ, Perina- do J, McDonagh B, Requejo-Aguilar R, Bárcena JA, Padilla CA. Peroxiredoxin 6 Down-Regulation Induces Metabolic Remodeling and Cell Cycle Arrest in HepG2 Cells. Antioxidants (Basel). 2019 Oct 23;8(11). pii: E505.
IF: 4,520 Q1

4. Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2019. 20. 2. DOI:10.3390/ijms20020336.
IF: 4,183 Q2

5. Padilla CA, Bárcena JA, López-Grueso MJ, Requejo-Aguilar R. The Regulation of TORC1 Pathway by the Yeast Chaperones Hsp31 Is Mediated by SFP1 and Affects Pro- teasomal Activity. Biochimica et Biophysica Acta - General Subjects. 2019. 1863 (3).
IF: 3,681 Q2

ACTIVITY

Nº ONGOING PROJECTS: 5
Nº PROJECTS STARTING IN 2020: 1
Nº CLINICAL TRIALS: 46
Nº PHD THESES: 1

GC03: INFECTIOUS DISEASES

TEAM

Last name	First name	
De La Torre Cisneros	Julián Carlos	R4
Cantisán Bohórquez	Sara	R3
Castón Osorio	Juan José	R3
Pérez Nadales	Elena	R3
Natera Kindelan	Clara	R2
Rumbao Aguirre	José Manuel	R2
Vidal Verdu	Elisa	R2
Cano Yuste	Ángela	R1
Méndez Natera	Alejandra	R1
Páez Vega	Aurora	R1
Recio Rufián	Manuel	R1
Valle Arroyo	Jorge	R1
Añón Gámez	Mª Teresa	ADM
Cantueso Méndez	Inmaculada	ADM
De la Torre Giménez	Julián	T
Frutos Adame	Azahara	T
Salinas Gavilán	Ana	T

SCIENTIFIC PRODUCTION

20	20%	45%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION:

Networks:

i. Spanish Network for Research on Infectious Diseases (Red Española de Investigación en patología Infecciosa; REIPI, http://reipi.org).
ii. COMBACTE-NET (combatting bacterial resistance in Europe – networks), Project ID: 115523.
iii. COMBACTE-CARE (combatting bacterial resistance in Europe – carbapenem-resistence), Project ID: 115620.
iv. INCREMENT-SOT, an international consortium for the clinical study of blood stream infections caused by multi-drug resistant Enterobacterales in solid organ transplantation (SOT). We promote and coordinate this international network, which includes 40 centers specialised in SOT from 16 countries worldwide.
v. PROACTIVE group: Optimization in the use of antibiotics and treatment of complex bacterial infections caused by resistant strains, Ministry of Health, Junta de Andalucía. File: AC-0044-2013. Principal Investigator: Jesús Rodríguez Baño (Hospital Virgen Macarena). PI at Reina Sofía University Hospital: Julián de la Torre Cisneros.
vi.PAIDI CTS-647. Coordinator of the Group "Translational Research in Infectious Diseases" that belongs to the Andalusian Research Plan (PAI CTS647), since July 2009.

International projects:

i. COMBACTE-NET
ii. COMBACTE-CARE
iii. CAVICOR

Competitive funding obtained for contracts:

i. Intensificación Unidad "Acción B" (SAS) – Sara Cantisán Bohórquez
ii.Intensificación (SAS) – Antonio Rivero / Julián de la Torre Cisneros
iii. RIO HORTEGA (ISCIII) – Jorge Rodríguez Gómez
iv. FPU (MEC) – Alejandra Méndez Natera

4 contracts with companies

AWARD - Julián de la Torre Cisneros- Fundación Senefro

KEYWORDS

- **CYTOMEGALOVIRUS**
- **MULTIDRUG-RESISTANT**
- **MICROORGANISMS**
- **IMMUNOPATHOLOGY**
- **TRANSPLANTATION**
- **SPECIFIC IMMUNE RESPONSE**

HIGHLIGHTED PUBLICATIONS

1. Palacios-Baena ZR, Delgado-Valverde M, Mendez AV, Almirante B, Gomez-Zorrilla S, Borrell N, Corzo JE, Gurgui M, de la Calle C, Garcia-Alvarez L, Ramos L, Gozalo M, Morosini MI, Molina J, Causse M, Pascual A, Rodriguez-Bano J, de Cueto M, Reig AMP, QuintanOo Quintano, FT ; Pena, C ; Otalora, MEG; de Alegria, CR ; Canton, R ; Lepe, JA ; Cisneros, JM ; Torre-Cisneros, J ; Lara, R. REIPI GEIRAS-SEIMC Bacterae. Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. Clinical Infectious Diseases. 2019 Sept; 69 (6): 956 – 962.

IF: 9,055 Q1 D1

2. Fernández-Ruiz M, Giménez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisán S, Torre-Cisneros J, Fortún J, Andrés A, San Juan R, López-Medrano F, Navarro D, Aguado JM, Gonzalez, E; Polanco, N ; Rodriguez, R; Aranzamendi, M; Carmona, O; Escudero, R; Martin-Davila, P; Fernandez, A; Aguado, R; Vidal, E; Aguera, ML; Rodriguez-Benot, A; Rodelo-Haad, C; Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Regular monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 2019 Mar; 25(3): 381.e1-381.e10.

IF: 6,425 Q1 D1

3. Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Castón JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Baño J, Torre-Cisneros J. Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 2019. 79. 3. 245-252.

IF: 5,099 Q1

4. Machuca I, Gutiérrez-Gutiérrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Pérez E, Pérez-Nadales E, Castón JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual Á, Martínez-Martínez L, Rodríguez-Baño J, Torre-Cisneros J; REIPI/ESGBIS/INCREMENT group. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteremia cohort: The prognostic significance of colistin resistance. Int J Antimicrob Agents. 2019 Oct; 54(4):442-448.

IF: 4,615 Q1

5. Ramos-Vivas J, Chapartegui-González I, Fernández-Martínez M, González-Rico C, Fortún J, Escudero R, Marco F, Linares L, Montejo M, Aranzamendi M, Muñoz P, Valerio M, Aguado JM, Resino E, Ahufinger IG, Vega AP, Martínez L, Fariñas MC, San Millan JCR, Rodrigo, E, Morencos, FC , Fabrega, E , Cuadrado, A , Farinas-Alvarez, C , Gozalo, M , Revillas, FA, Davila, PM , Martinez, A , Garbajosa, PR , Moreno, A , Bodro, M, Solano, MF , Blanco, MJ , Nieto, J , Machado, M, Olmedo, M , Fernandez, SR , Sanz, CR , Rangel, TV , Bento, CA , Recalde, AG , Eworo, A , Fernandez-Lomana, FA , Rodriguez-Ferrero, ML , Camara, LAS , Chaves, F , Cisneros, JD; ENTHERE Study Group, the Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Biofilm formation by multidrug resistant Enterobacteriaceae strains isolated from solid organ transplant recipients. Sci Rep. 2019 Jun 20; 9(1):8928.

IF: 4,011 Q1

ACTIVITY

Nº ONGOING PROJECTS: 12

Nº PROJECTS STARTING IN 2020: 1

Nº CLINICAL TRIALS: 18

Nº PHD THESES: 1

MAIN RESULTS

Clinical Guidelines:

i.Tacconelli E, Mazzaferri F, Marie de Smet A, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J ESCMID-EUCIC clinical guidelines on decolonisation of multidrug-resistant Gram-negative bacteria carriers. Clinical Microbioly and Infection. 25(7). 807-817. DOI: 10.1016/j.cmi.2019.01.005. PMID: 30708122

GC04: INFLAMMATION AND CANCER

TEAM

Last name	First name	
Muñoz Blanco	Eduardo	R4
Calzado Canale	Marco Antonio	R4
García Martín	Adela	R2
Navarrete Rueda	Carmen	R2
Correa Sáez	Alejandro	R1
Garrido Rodríguez	Martín	R1
Jiménez Izquierdo	Rafael	R1
Morrugares Carmona	Rosario	R1
Palomares Cañero	Belén	R1
Millán Ortega	Estrella	R1
Prados González	María Eugenia	R1
Collado Rojas	Juan Antonio	T

SCIENTIFIC PRODUCTION

16	38%	88%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. AIDS Research Network (RIS)
ii. PAIDI BIO-304 scientific group

Competitive funding obtained for contracts:

i. I-PFIS contract - Belén Palomares Cañero
ii. FPU (MEC) – Alejandro Correa Sáez

4 agreements with companies

KEYWORDS

- **INFLAMMATION**
- **CANCER**
- **TISSUE REGENERATION**
- **HIV-1 LATENCY**
- **PHARMACOLOGY AND NURACEUTICALS**

HIGHLIGHTED PUBLICATIONS

1. Morrugares R, Correa-Sáez A, Moreno R, Garrido-Rodríguez M, Muñoz E, de la Vega L, Calzado MA. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2. Cell Mol Life Sci. 2019 Oct 11.
IF: 7,014 Q: 1 D: 1

2. García-Martín A, Garrido-Rodríguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, Rolland A, Appendino G, Muñoz E. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis. Biochem Pharmacol. 2019 May; 163:321-334.
IF: 4,825 Q1 D: 1

3. Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. LUBAC determines chemotherapy resistance in squamous cell lung cancer. J Exp Med. 2019 Feb 4; 216(2):450-465.
IF: 10,892 Q1 D: 1

4. Garrido-Rodríguez M, Ortea I, Calzado MA, Muñoz E, García V. SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. J Proteomics. 2019 Feb 20; 193:217-229.
IF: 3, 537 Q: 1

5. Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E, Galve-Roperh I. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-inducedneurodegeneration. Transl Neurodegener. 2019 Mar 8; 8:9.
IF: 5,534 Q: 1

ACTIVITY

Nº ONGOING PROJECTS: 3
Nº ACTIVE PATENTS: 1

GC05: SYSTEMIC AND CHRONIC INFLAMMATORY AUTOIMMUNE DISEASES OF THE LOCOMOTOR SYSTEM AND CONNECTIVE TISSUE

TEAM

Last name	First name	
López Pedrera	Rosario	R4
Collantes Estévez	Eduardo	R4
Escudero Contreras	Alejandro	R4
Barbarroja Puerto	Nuria	R3
Aguirre Zamorano	Mª Ángeles	R3
Alburquerque Sendin	Francisco	R3
Font Ugalde	Pilar	R3
Castro Villegas	Mª Carmen	R3
Caracuel Ruiz	Miguel Ángel	R2
Pérez Guijo	Verónica	R2
Gómez Gracia	Inmaculada	R2
López Montilla	Mª Dolores	R2
Calvo Gutierrez	Jerusalem	R2
Ibáñez Costa	Alejandro	R2
López Medina	Clementina	R2
Ortega Castro	Rafaela	R2
Pérez Sánchez	Carlos	R2
Arias De La Rosa	Iván	R1
Aranda Valera	Concepción	R1
Jurado Ruiz	Luis Pedro	R1
Ladehesa Pineda	María Lourdes	R1
Luque Tévar	María	R1
Segura Ruíz	Rocío	R1
Patiño Trives	Alejandra Mª	R1
Ruiz Vílchez	Desiree	N
Armenteros Ortiz	Pedro José	N
Ábalos Aguilera	Mª Carmen	T

SCIENTIFIC PRODUCTION

27	19%	52%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i.Research network in inflammation and rheumatic diseases (RIER) –National Institute of Health Carlos III

ii.Chronic inflammatory diseases of musculoskeletal system and connective tissue CTS1004, Andalusian Plan for Research, Development and Innovation (PAIDI).

International projects:

i. Collantes Estevez, E. Title: Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases Mechanisms for the Improvement of Drug Development and Therapy. PRECISESADS (http://www.precisesads.eu/). General coordinator: Marta Alarcón-Riquelme, FPS. Funding entity: Innovative Medicine Initiative (IMI) – EU + EFPIA. GA: 115565-3.

ii. Collantes Estevez, E. Can Inertial Movement Sensors (IMUs) provide a valid and reliable way of measuring Spinal Mobility in Axial Spondyloarthritis (axSpa): a Clinimetric Evaluation. Funding Agency: Foundation for Research in Rheumatology. Reference: FOREUM-2015-001.

iii. Collantes Estevez, E. 3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions; Funding Agency: Innovative Medicines Initiative (IMI) – EU + EFPIA; Reference: IMI2-2018-14- 01-F2.

Competitive funding obtained for contracts:

i. Juan de la Cierva Formación (MICINN)- Alejandro Ibáñez Costa
ii. Nicolás Monardes (SAS) – Rosario López Pedrera
iii. Intensificación (SAS) – Eduardo Collantes Estévez
iv. Intensificación Unidad "Acción B" (SAS) – Jerusalem Calvo Gutiérrez
i.Ramón y Cajal (MICINN) – Nuria Barbarroja Puerto

7 Contracts with companies

Strengthening of research activity Programme - Alejandro Escudero

AWARD: "PREMIO NACIONAL DE INVESTIGACIÓN 2019 COLEGIO OFICIAL DE MÉDICOS DE LA PROVINCIA DE CORDOBA - Defective glucose and lipid metabolism in rheumatoid arthritis is determinded by chronic inflammation in metabolic tissues."

KEYWORDS

- **AUTOIMMUNE DISEASES**
- **SPONDILOARTHROPATHIES**
- **INLAMATION**
- **ATHEROTHROMBOSIS**
- **METABOLIC SYNDROME**
- **ORGANDAMAGE**
- **BIOMARKERS**
- **NEW THERAPIES**

HIGHLIGHTED PUBLICATIONS

1. Lopez-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeon CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B. European Scleroderma Grp; ASIG: Rios, R; Callejas, JL; Vargas-Hitos, JA; Garcia-Portales, R; Camps, MT; Fernandez-Nebro, A; Gonzalez-Escribano, MF; Garcia-Hernandez, FJ; Castillo, MJ; Aguirre, MA; Gomez-Gracia, I; Fernandez-Gutierrez, B; Rodriguez-Rodriguez, L; de la Pena, PG; Vicente, E; Andreu, JL; de Castro, MF; Lopez-Longo, FJ; Martinez, L; Fonollosa, V; Guillen, A; Espinosa, G; Tolosa, C; Pros, A; Rodriguez-Carballeira, M; Narvaez, FJ; Rubio-Rivas, M; Ortiz-Santamaria, V; Madronero, AB; Gonzalez-Gay, MA; Diaz, B; Trapiella, L; Sousa, A; Egurbide, MV; Fanlo-Mateo, P; Saez-Comet, L; Diaz, F; Hernandez, V; Beltran, E; Roman-Ivorra, JA; Grau, E; Alegre-Sancho, JJ; Freire, M; Blanco-Garcia, FJ; Oreiro, N; Witte, T; Kreuter, A; Riemekasten, G; Airo, P; Magro, C; Voskuyl, AE; Vonk, MC; Hesselstrand, R; Proudman, S; Stevens, W; Nikpour, M; Zochling, J; Sahhar, J; Roddy, J; Nash, P; Tymms, K; Rischmueller, M; Lester, S; Vyse, T; Herrick, AL; Worthington, J; Denton, CP; Allanore, Y; Brown, MA; Radstake, TRDJ; Fonseca, C; Chang, HY; Mayes, MD; Martin, JGWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications. 2019 Oct 31.
IF: 11,878 Q1 D1

2. Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE; ToSpace Study Group. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatology. 2019 Oct.
IF: 9,002 Q1 D1

3. Perez-Sanchez C, Cecchi I, Barbarroja N, Patino-Trives AM, Luque-Tevar M, Perez-Sanchez L, Ibanez-Costa A, de la Rosa IA, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MA, Collantes E, Lopez-Pedrera C. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2019. 23. 9. 6308-6318.
IF: 4,658 Q1

4. Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patino-Trives AM, Luque-Tevar M, Ibanez-Costa A, Perez-Sanchez L, de la Rosa IA, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme M. Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. Front Immunol. 2019 May 21;10:1111.
IF: 4,716 Q2

5. Lopez-Pedrera C, Barbarroja N, Patino-Trives AM, Collantes E, Aguirre MA, Perez-Sanchez C. New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. FRONTIERS IN IMMUNOLOGY. 2019. 10. DOI:10.3389/fimmu.2019.00764.
IF: 4,716 Q2

ACTIVITY

Nº ONGOING PROJECTS: 10

Nº PROJECTS STARTING IN 2020: 2

Nº CLINICAL TRIALS: 35

MAIN RESULTS

Clinical Guidelines:

i. Flórez García MT, Carmona L, Almodóvar R, Fernández de Las Peñas C, García Pérez F, Pérez Manzanero MÁ, García García JM6, Soriano Segarra L, Jiménez Díaz JF, Mendoza Laiz N6, de Miguel Mendieta E, Torre Alonso JC, Linares Ferrando LF, Collantes Estévez E, Sanz Sanz J, Zarco Montejo P. Recommendations for the prescription of physical exercise for patients with spondyloarthritis. Reumatología Clínica. 15(2). 77-83. DOI: 10.1016/j.reuma.2017.06.014. PMID: 28807651

ii. Almodovar, R; Bueno, A; Batlle, E; Beltran-Catalan, E; Bernabeu, D; Copete, CC; Cepero, A; Crespo, C; Diez, F; Fernandez-Carballido, C; Lorente, FG; De Miguel, AG; Juanola, X; Linares, L; Perez-Barquero, RM; Castro, C; Ramos, MJM; Moreno, M; Navarro-Compan, V; Pack, C; Quiles, C; Veintemillas, M; Zarco, P. Magnetic resonance imaging assessment in patients with axial spondyloarthritis: development of checklists for use in clinical practice. RHEUMATOLOGY INTERNATIONAL. 39. 2119-2127. DOI: 10.1007/s00296-019-04441-2. PMID: 31535169

GC06: NEW THERAPIES IN CANCER

TEAM

Last name	First name	
Aranda Aguilar	Enrique	R4
Rodríguez Ariza	Antonio	R4
De La Haba Rodríguez	Juan Rafael	R3
Barneto Aranda	Isidoro C.	R2
Gómez España	Maria Auxiliadora	R2
Martínez Peinado	Antonio	R2
Villar Pastor	Carlos	R2
Guil Luna	Silvia	R2
López Sánchez	Laura Maria	R2
Morales Estévez	Cristina	R2
Valladares Ayerbes	Manuel Jesús	R2
Peñarando Sáez	Jon	R2
Méndez Vidal	Maria Jose	R2
Serrano Blanch	Raquel	R2
Mena Osuna	Rafael	R1
Ortíz Morales	María Jose	R1
Toledano Fonseca	Marta del Pilar	R1
Jiménez Izquierdo	Rafael Manuel	R1
Cano Osuna	Maria Teresa	R1
Fuentes Vaamonde	Elena	R1
Moreno Vega	Alberto Luis	R1
Porras Quintela	Ignacio	R1
Rodríguez Alonso	Beatriz	R1
Rodríguez Alonso	Rosa Mª	R1
Sánchez Mauriño	Pedro	R1
Aranda Aguilar	Asunción	T
Campón Montilla	Daniel José	T
Díaz Díaz	Mª Ángeles	T
Jaraba Mezquida	Isabel	T
Leña Barranco	Amalia	T
Marin Serrano	Jacinta	T
Marin Serrano	Maria Jose	T
Mesa Blanco	Mª Pilar	T
Miranda García	Rosario	T
Molina Alcaide	Juan Eduardo	T
Pavón Gómez	Rebeca	T
Rodríguez Rodríguez De Julián	Sonia	ADM

SCIENTIFIC PRODUCTION

26	42%	69%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBER on cancer (CIBERONC)
ii. PAIDI CTS-234

Competitive funding obtained for contracts:

i. Nicolas Monardes (SAS) - Antonio Rodríguez Ariza
ii. Juan de la Cierva Incorporación (MICINN) - Silvia Guil Luna
iii. Asociación Española Contra en Cáncer – Ana Mantrana Soldado (AECC19/8959)
iv. Intensificación (SAS) – Enrique Aranda Aguilar

15 agreements with companies

KEYWORDS

- **COLORECTAL CANCER**
- **BREAST CANCER**
- **NITRIC OXIDE**
- **PROTEOMICS**
- **BIOMARKERS**
- **PROGNOSIS**
- **PREDICTION OF RESPONSE**
- **LIQUID BIOPSY**
- **TARGETED THERAPY**
- **PRECISION ONCOLOGY**

HIGHLIGHTED PUBLICATIONS

1. Jimenez-Vacas JM, Gomez-Gomez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-Lopez F, Sanchez-Sanchez R, Guler I, Blanca A, Mendez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 2019. 8. 12.
IF: 5,688 Q1 D1

2. Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S. Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 2019. 63. 9.
IF: 5,151 Q1 D1

3. Penarando J, Aranda E, Rodriguez-Ariza A. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says “NO” to antitumor immune response. TRANSLATIONAL RESEARCH. 2019. 210. 99-108.
IF: 4,915 Q1 D1

4. Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. BRITISH JOURNAL OF CANCER. 2019. 121. 5. 378-383.
IF: 5,416 Q1

5. Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECU- LAR MEDICINE.
IF: 4,658 Q1

ACTIVITY

Nº ONGOING PROJECTS: 9

Nº CLINICAL TRIALS: 118

MAIN RESULTS

Clinical Guidelines

i. Gomez-Espana, MA; Gallego, J; Gonzalez-Flores, E; Maurel, J; Paez, D; Sastre, J; Aparicio, J; Benavides, M; Feliu, J; Vera, R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 21. 46-54. DOI: 10.1007/s12094-018-02002-w. PMID: 30565083

GC07: NEPHROLOGY. CELL DAMAGE IN CHRONIC INFLAMMATION

TEAM

Last name	First name	
Aljama García	Pedro	R4
Martin Malo	Alejandro	R4
Agüera Morales	Maria Luisa	R3
Espinosa Hernández	Mario	R3
Navarro Cabello	Maria Dolores	R3
Rodríguez Benot	Alberto	R3
Santamaría Olmo	Rafael	R3
Soriano Cabrera	Sagrario	R3
Guerrero Pavón	Fátima	R3
Ariza Fuentes	Francisco Javier	R2
Crespo Montero	Rodolfo	R1
Esquivias De Motta	Elvira	R1
García Montemayor	Victoria Eugenia	R1
Rabasco Ruiz	Cristina	R1
Sánchez-Agesta Martínez	Marina	R1
Amaral Neiva	Francisco	R1
Ansio Vázquez	Inmaculada	R1
López López	Isabel	R1
López Andreu	Maria	R1
Moyano Peregrin	Cayetana	R1
Ojeda López	Raquel	R1
Rosa Guerrero	Pedro	R1
Torres de Rueda	Álvaro	R1
Jiménez Moral	Maria José	T
Obrero Sojo	Teresa	T
Carmona Muñoz	Andrés	R1

SCIENTIFIC PRODUCTION

19	26%	42%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Spanish Renal Research Network (REDinREN)
ii. Optimizing Dialysis Results ORD group
iii. The Right Therapy Contest
iv. Hyperphosphatemia and CKD

Competitive funding obtained for contracts:

i. Ampliación Contratación Andrés Carmona Muñoz PI Excelencia Convocatoria 2011
ii. Intensificación (SAS) – Alejandro Martín Malo

5 agreements with companies

KEYWORDS

- **CELL ACTIVATION**
- **CHRONIC RENAL FAILURE**
- **MICROINFLAMMATION**
- **CELL THERAPY**
- **HEMODIALYSIS**
- **RENAL TRANSPLANTATION**
- **INFLAMMATION**
- **CELLULAR STRESS**
- **GENOMIC DAMAGE**
- **ENDOTHELIUM**

HIGHLIGHTED PUBLICATIONS

1. Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M. Severe and malignant hypertension are common in primary atypical hemolytic uremic síndrome. Kidney Int. 2019 Oct;96(4):995-1004. PMID: 31420192
IF: 8,306 Q1 D1

2. Sevillano AM, Diaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J6, Calviño J, Castillo L, Cobelo C, Delgado-Mallén P, Espinosa M, Fernandez-Juarez G, Fernandez-Reyes MJ, Garcia-Osuna R, Garcia P, Goicoechea M, Gonzalez-Cabrera F, Guzmán DA, Heras M, Martín-Reyes G, Martinez A, Olea T, Peña JK, Quintana LF, Rabasco C, López Revuelta K, Rodas L, Rodriguez-Mendiola N, Rodriguez E, San Miguel L, Sanchez de la Nieta MD22, Shabaka A, Sierra M, Valera A, Velo M, Verde E, Ballarin J, Noboa O, Moreno JA, Gutiérrez E, Praga M. IgA Nephropathy in Elderly Patients. Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1183-1192 PMID: 31311818
IF: 6.243 Q1 D1

3. Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, Pineda C, Martínez-Moreno JM, Herencia C, Vergara N, Pendón-Ruiz de Mier MV, Santamaría R, Rodelo-Haad C, Casado-Díaz A, Lorenzo V, Carvalho C, Frazão JM, Felsenfeld AJ, Richards WG1, Aguilera-Tejero E, Rodríguez M, López I, Muñoz-Castañeda JR. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int. 2019 Mar 12. pii: S0085-2538(19)30043-2. PMID 30878213.
IF: 8,306 Q1 D1

4. Rodelo-Haad C, Santamaria R, Muñoz-Castañeda J, Pendón-RuizdeMier MV, Martin-Malo A, Rodriguez M. FGF23, Biomarker or Target? Toxins (Basel). 2019 Mar 22;11(3). pii: E175. PMID 30909513.
IF: 3,895 Q1

5. Fernández-Ruiz M, Giménez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez- Vega A, Cantisán S, Torre-Cisneros J, Fortún J, Andrés A, San Juan R, López-Medrano F, Navarro D, Aguado JM, Gonzalez, E; Polanco, N ; Rodriguez, R; Aranzamendi, M; Carmona, O; Escudero, R; Martin-Davila, P; Fernandez, A; Aguado, R; Vidal, E; Aguera, ML; Rodriguez-Benot, A; Rodelo-Haad, C; Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 2019 Mar;25(3):381. PMID 29803844.
IF: 5,394 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 5

Nº CLINICAL TRIALS: 16

Nº PHD THESES: 1

MAIN RESULTS

Clinical Guidelines

i.Sandubete, EJC; de la Blanca, EBP; del Rio, CAO; Olmo, RS; Mendoza, ML; Martinez, MB; Infante, CM; Marin-Leon, I; de la Paz, MP; Castellano, PG; Blanes, JRG; Navarro, EG; Rodriguez, ML; Arduan, AO; Guzman, JD; Martinez, PL; Villalba, JC; Perez, JMC.Spanish multidisciplinary clinical practice guidelines for Anderson-Fabry Disease in Adults. I. Method and recommendations. REVISTA CLINICA ESPANOLA. 219. 200-207. DOI: 10.1016/j.rce.2018.09.017. PMID: 30691688

GC08: HORMONES AND CANCER

TEAM

Last name	First name	
Castaño Fuentes	Justo Pastor	R4
Gracia Navarro	Francisco	R4
Martínez Fuentes	Antonio Jesús	R4
Pedraza Arévalo	Sergio	R2
Blanco Acevedo	Cristóbal José	R1
Blázquez Encinas-Rey	Ricardo	R1
Caro Cuenca	Mª Teresa	R1
Fuentes Fayos	Antonio Carlos	R1
Moreno Moreno	Paloma	R1
Jiménez Puyer	Manuel	R1
Sánchez Frías	Marina Esther	R1
del Teso Rodríguez	Javier	R1
Rivero Cortes	Esther	T

SCIENTIFIC PRODUCTION

17	29%	76%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. CIBER Physiopathology of Obesity and Nutrition – CIBERobn
ii. Spanish Group on Endocrine and Neuroendocrine Tumors (GETNE)
iii. TransBioNet – Spanish Translational Bioinformatics Network
iv. Rare Cancer Genomics
v. Sociedad Española de Endocrinología y Nutrición - Área de Conocimiento de Neuroendocrinología.
vi. Sociedad Andaluza de Endocrinología, Diabetes y Nutrición - Grupo de Trabajo de Neuroendocrinología.
vii. Registro Español Molecular de Adenomas Hipofisarios (REMAH)
viii. BIO-139 "Cellular and Molecular Endocrinology" Research Group of the Andalusian Plan for Research, Development and Innovation (PAIDI)
ix. Agrifood Campus of International Excellence (ceiA3)

International projects:

i. IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med). H2020 MSCA COFUND FP 2018. Coordinator: Justo Pastor Castaño Fuentes. Funding agency: European Commission. Reference: GA nr: 847468. MSCA-CO-FUND-2018

Competitive funding obtained for contracts:

i. Ayuda del programa de Formación de Profesorado Universitario (MEC) - Sergio Pedraza Arévalo
ii. Ayuda del programa de Formación de Profesorado Universitario (MEC) – Antonio Carlos Fuentes Fayos.
iii. Ayuda del programa de Formación de Profesorado Universitario (MEC) – Ricardo Bálzquez Encinas Rey.

Agreement with companies

KEYWORDS

- **CELLULAR AND MOLECULAR ENDOCRINE ONCOLOGY**
- **PANCREATIC CANCER**
- **NEUROENDOCRINE TUMORS**
- **PITUITARY TUMORS**
- **ALTERNATIVE SPLICING**
- **SPLICE-VARIANTS**
- **SPLICEOSOME**
- **SOMATOSTATIN**
- **SOMATOSTATIN-RECEPTORS**
- **CORTISTATIN**
- **GHRELIN**
- **SIGNALING**

HIGHLIGHTED PUBLICATIONS

1. Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, López-Fernandez JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP*, Luque R. Splicing machinery is dysregulated in pituitary neuroendocrine tumors and is associated with aggressiveness features. CANCERS. 2019. 11.10.1439. *Co-senior author
IF: 6,162 Q1

2. Herrera-Martínez AD, Pedraza-Arévalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP, Luque RM. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2019. 104. 1. 57-73.
IF: 5,605 Q1

3. Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, L-López F, Ibáñez-Costa A, Moreno-Moreno P, Alhambra-Expósito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castaño JP, Luque RM; Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms. 2019. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513).
IF: 5,605 Q1

4. Del Río-Moreno M, Alors-Pérez E, De Souza PB, Prados-González ME, Castaño JP*, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. 2019. TRANSLATIONAL RESEARCH. 211. (147-160). *Co-senior author
IF: 4,915 Q1 D1

5. Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted systemic treatment of neuroendocrine tumors: Current options and future perspectives. 2019. DRUGS. 79. 1. 21-42.
IF: 4,993 Q1

ACTIVITY

Nº ONGOING PROJECTS: 4

Nº PROJECTS STARTING IN 2020: 1

Nº CLINICAL TRIALS: 1

Nº PHD THESES: 4

Nº ACTIVE PATENTS: 4

GC09: NUTRIGENOMICS. METABOLIC SYNDROME

TEAM

Last name	First name	
Almadén Peña	Yolanda	R4
Delgado Lista	Javier	R4
López Miranda	José	R4
Pérez Jiménez	Francisco	R4
Pérez Martínez	Pablo	R4
Camargo García	Antonio	R3
García Ríos	Antonio	R3
Blanco Molina	Mª Ángeles	R3
Fernández De La Puebla	Rafael Ángel	R3
Fuentes Jiménez	Francisco	R3
López Jiménez	Luciano	R3
Montero Pérez-Barquero	Manuel	R3
Pérez Caballero	Anabel	R3
Rangel Zuñiga	Oriol Alberto	R3
Yubero Serrano	Elena M	R3
Alcalá Díaz	Juan Francisco	R2
Criado García	Juan	R2
Corina Baba	Andreea	R2
de la Cruz Ares	Silvia	R2
Gómez Delgado	Francisco	R2
Gómez Luna	Purificación	R2
Gutiérrez Mariscal	Francisco Manuel	R2
Jiménez Morales	Anabel	R2
León Acuña	Ana	R2
Roncero Ramos	Irene	R2
Torres Peña	José David	R2
Arenas de Larriva	Antonio Pablo	R1
Fernández Gándara	Carolina	R1
López Moreno	Javier	R1
Pérez Cardelo	Mª Magdalena	R1
Vals Delgado	Cristina	R1
Vega Rojas	Ana María	R1
Villasanta González	Alejandro	R1
Carreras Calero	Rosario	T
Díaz Marin	Begoña	T
Morales Martínez	José Andrés	T
Peña Orihuela	Patricia Judith	T
Perez Corral	Isabel	T
Quintana Navarro	Gracia	T
Redondo Garrido	Ana	T

SCIENTIFIC PRODUCTION

52	19%	62%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBER Physiopathology of Obesity and Nutrition (CIBERobn)
ii. PAIDI CTS-525: INTERACTION GENES AND ENVIRONMENT
iii. PAIDI CTS-212: NUTRITION AND DISEASE
iv. NUTRIEPIGEN (NutriEpiGen is a working group of Spanish researchers specialized in the arena of lifestyle and epigenetics; Funded by the Ministry of Science, Innovation and Universities of Spain. Reference: AGL 2017-90623-RED)

Competitive funding obtained for contracts:

i. Sara Borrell (ISCIII) - Irene Roncero Ramos
ii. FPI (MICINN) - Cristina Vals Delgado
iii. Miguel Servet I (ISCIII) - Antonio Camargo García
iv. Intensificación Unidad "Acción B" (SAS) – Antonio García Ríos
v. Intensificación Unidad "Acción B" (SAS) – Pablo Pérez Martínez (25%), José Lopez Miranda (25%)
vi. RIO HORTEGA (ISCIII) - Ana León Acuña
vii. Nicolás Monardes (SAS)- Yolanda Almadén Peña
viii. PFIS (ISCIII) - Magdalena Pérez Cardelo
ix. Juan de la Cierva Formación (MICINN) - Silvia de la Cruz Ares

7 Agreements with companies

KEYWORDS

- **ATHEROSCLEROSIS**
- **ENDOTHELIUM**
- **METABOLIC SYNDROME**
- **TYPE 2 DIABETES MELLITUS**
- **MEDITERRANEAN DIET**
- **OLIVE OIL**
- **POLYPHENOLS**
- **ANTIOXIDANTS**
- **INFLAMMATION**
- **OXIDATIVE STRESS**
- **CHOLESTEROL**
- **POLYPHENOLS**
- **GENE EXPRESSION**
- **PROTEOMICS**
- **NUTRIGENETICS**
- **NUTRIGENOMICS**

HIGHLIGHTED PUBLICATIONS

1. Gutierrez-Mariscal FM, Yubero-Serrano EM, Villalba JM, Lopez-Miranda J. Coenzyme Q(10): From bench to clinic in aging diseases, a translational review. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION. 2019. 59. 14. 2240-2257.
IF: 6,704 Q1 D1

2. Corina A, Rangel-Zuniga OA, Jimenez-Lucena R, Alcala-Diaz JF, Quintana-Navarro G, Yubero-Serrano EM, Lopez-Moreno J, Delgado-Lista J, Tinahones F, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Low Intake of Vitamin E Accelerates Cellular Aging in Patients With Established Cardiovascular Disease: The CORDIOPREV Study. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 2019. 74. 6. 770-777.
IF: 4,711 Q1 D1

3. Camargo A, Jimenez-Lucena R, Alcala-Diaz JF, Rangel-Zuniga OA, Garcia-Carpintero S, Lopez-Moreno J, Blanco-Rojo R, Delgado-Lista J, Perez-Martinez P, van Ommen B, Malagon MM, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J. Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: From the CORDIOPREV study. CLINICAL NUTRITION. 2019. 38. 2. 529-538.
IF: 6,402 Q1 D1

4. Santos-Marcos JA, Haro C, Vega-Rojas A, Alcala-Diaz JF, Molina-Abril H, Leon-Acuna A, Lopez-Moreno J, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A. Sex Differences in the Gut Microbiota as Potential Determinants of Gender Predisposition to Disease. MOLECULAR NUTRITION & FOOD RESEARCH. 2019. 63. 7.
IF: 4,653 Q1 D1

5. Gomez-Delgado F, Alcala-Diaz JF, Leon-Acuna A, Lopez-Moreno J, Delgado-Lista J, Gomez-Marin B, Roncero-Ramos I, Yubero-Serrano EM, Rangel-Zuniga OA, Vals-Delgado C, Luque RM, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Apolipoprotein E genetic variants interact with Mediterranean diet to modulate postprandial hypertriglyceridemia in coronary heart disease patients: CORDIOPREV study. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2019. 49. 8.
IF: 2,784 Q1

ACTIVITY

Nº ONGOING PROJECTS: 14

Nº PROJECTS STARTING IN 2020: 2

Nº CLINICAL TRIALS: 21

Nº PHD THESES: 2

Nº ACTIVE PATENTS: 2



GC10: HORMONAL REGULATION OF ENERGY BALANCE, PUBERTY AND REPRODUCTION

TEAM

Last name	First name	
Tena Sempere	Manuel	R4
Gaytán Luna	Francisco	R3
Pinilla Jurado	Leonor	R3
Vázquez Villar	María Jesús	R3
Roa Rivas	Juan	R3
Romero Ruiz	Antonio	R3
Avendaño Herrador	María Soledad	R3
Castellano Rodríguez	Juan Manuel	R2
Pineda Reyes	Rafael	R2
León Téllez	Silvia	R2
García Galiano	David	R2
Sobrino Cabello	Verónica	R2
Sánchez-Garrido Nogueras	Miguel	R2
Velasco Aguayo	Inmaculada	R2
Barroso Romero	Alexia	R2
Ruiz Pino	Francisco	R2
Perdices López	Cecilia María	R1
Ruiz Cruz	Miguel	R1
Torres Jiménez	Encarnación	R1
Rodríguez Vázquez	Elvira	R1
Onieva Jiménez	Rocío	T
Rodríguez Sánchez	Ana Belén	T
Sánchez Tapia	Mª Jesús	T
Franssen	Delphine	C
Heras Domínguez	Violeta	C
Ruohonen	Suvi	C
Fernandois Vicencio	Daniela	C

*C: Collaborators.

SCIENTIFIC PRODUCTION

12	50%	92%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBEROBN (CIBER Fisiopatología de la Obesidad y Nutrición)
ii. Theme Area: Reproductive Endocrinology (Basic Lead; European Society of Endocrinology)
iii. FiDiPro Program – Finnish Academy

International Projects

i. Tena-Sempere, M. New Frontiers in Reproductive medicine: Exploring novel mechanisms for the control of puberty and fertility, and their interplay with metabolic homeostasis and disease. Funding agency: FiDiPro Program (Finnish Distinguished Professorship Program) 2015-2019, Academy of Finland.
ii. PINEDA REYES, R. Society for Endocrinology Early Career Grant for Rafael Pineda Reyes. Funding Agency: SOCIETY FOR ENDOCRINOLOGY. Reference:SfE-ECG-2017-001.

Competitive funding obtained for contracts:

i. Sara Borrell (ISCIII) - María Soledad Avendaño Herrador
ii. Miguel Servet I (ISCIII) - Juan Roa Rivas
iii. Juan de la Cierva Incorporación (MICINN) – Miguel A. Sánchez-Garrido Nogueras
iv. FPU (MEC) – Miguel Ruiz Cruz
v. FPI (MICINN) – Elvira Rodíguez Vázquez

11 Agreements with companies

KEYWORDS

- **PUBERTY**
- **FERTILITY**
- **OBESITY**
- **METABOLISM**
- **ENERGY SENSORS**
- **KISSPEPTINS**
- **NEUROPEPTIDES**
- **GONADOTROPINS**
- **GONADS**
- **POLYCYSTIC OVARY SYNDROME**
- **ENDOMETRIOSIS**
- **HYPOGONADISM**
- **MICRORNAS**
- **EPIGENETICS**

HIGHLIGHTED PUBLICATIONS

1. Heras V, Sangiao-Alvarellos S, Manfredi-Lozano M, Sanchez-Tapia MJ, Ruiz-Pino F, Roa J, Lara-Chica M, Morrugares-Carmona R, Jouy N, Abreu AP, Prevot V, Belsham D, Vazquez MJ, Calzado MA, Pinilla L, Gaytan F, Latronico AC, Kaiser UB, Castellano JM, Tena-Sempere M. Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3. PLOS BIOLOGY 2019. 17(11):e3000532.
IF: 8,38 Q1 D: 1

2. Ruiz-Pino F, Miceli D, Franssen D, Vazquez MJ, Farinetti A, Castellano JM, Panzica G, Tena-Sempere M. Environmentally Relevant Perinatal Exposures to Bisphenol A Disrupt Postnatal Kiss1/NKB Neuronal Maturation and Puberty Onset in Female Mice. ENVIRONMENTAL HEALTH PERSPECTIVES. 2019. 127. 10. 107011.
IF: 7,736 Q1 D: 1

3. Romero-Ruiz A, Avendano MS, Dominguez F, Lozoya T, Molina-Abril H, Sangiao-Alvarellos S, Gurrea M, Lara-Chica M, Fernandez-Sanchez M, Torres-Jimenez E, Perdices-Lopez C, Abbara A, Steffani L, Calzado MA, Dhillo WS, Pellicer A, Tena-Sempere M. Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2019. 220. 5. 480. e1-480.e17. DOI:10.1016/j.ajog.2019.01.228.
IF: 6,12 Q1 D: 1

4. Romero-Ruiz A, Skorupskaite K, Gaytan F, Torres E, Perdices-Lopez C, Mannaerts BM, Qi S, Leon S, Manfredi-Lozano M, Lopez-Rodriguez C, Avendaño MS, Sanchez-Garrido MA, Vazquez MJ, Pinilla L, van Duin M, Kohout TA, Anderson RA, Tena-Sempere M. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome. HUMAN REPRODUCTION 2019. 34 (12):2495-2512.
IF: 5,506 Q1: D:1

5. Velasco I, León S, Barroso A, Ruiz-Pino F, Heras V, Torres E, León M, Ruohonen ST, García-Galiano D, Romero-Ruiz A, Sánchez-Garrido MA, Olhsson C, Castellano JM, Roa J, Poutanen M, Pinilla L, Vázquez MJ, Tena-Sempere M. Gonadal hormone-dependent vs. -independent effects of kisspeptin signaling in the control of body weight and metabolic homeostasis. METABOLISM 2019. 98:84-94
IF: 6,513 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 7
Nº PROJECTS STARTING IN 2020: 1
Nº PHD THESES: 3

GC11: METABOLISM AND ADIPOCYTE DIFFERENTIATION-METABOLIC SYNDROME

TEAM

Last name	First name	
Malagón Poyato	Maria Del Mar	R4
Guzmán Ruiz	Rocío	R3
Gordon Bermúdez-Coronel	Ana	R3
Clemente Postigo	María Mercedes	R2
Fernández Vega	Alejandro	R1
López Alcalá	Jaime	R1
Ruiz Navarro	Maria Del Carmen	R1
Sánchez Ceínos	Julia	R1
Tercero Alcázar	Carmen	R1
Molero Murillo	Laura	T

SCIENTIFIC PRODUCTION

3	67%	100%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. CIBER Physiopathology of Obesity and Nutrition (CIBERobn), National Institute of Health Carlos III. [http://www.ciberobn.es/en]
ii. FLEXIMET. Integrated Projects of Excellence Call 2014. National Institute of Health Carlos III.
iii. Research Network on Adipose Plasticity and Related Pathologies. Adipoplast. Ministry of Economy and Competitiveness, Spain.
iv. ADIPOSEQ. CIBERobn, National Institute of Health Carlos III.
v. COST Action "Delivery of Antisense RNA Therapeutics" (CA17103).

Competitive funding obtained for contracts:

i. FPI (MICINN) – Jaime David López Alcalá
ii. Juan de la Cierva Formación (MICINN) – María Mercedes Clemente Postigo

KEYWORDS

- **ADIPOSE TISSUE**
- **ADIPOCYTES**
- **ADIPOGENESIS**
- **BARIATRIC SURGERY**
- **CELLULAR STRESS**
- **EXTRACELLULAR MATRIX**
- **FIBROSIS**
- **CELL IMAGING**
- **INSULIN SIGNALING**
- **INSULIN RESISTANCE**
- **INTRACELLULAR TRAFFIC**
- **LIPID DROPLETS**
- **LIPIDS**
- **MICROSCOPY**
- **OBESITY**
- **PROTEOMICS**
- **PROTEIN NETWORKS**

HIGHLIGHTED PUBLICATIONS

1. Ortega FJ, Moreno-Navarrete JM, Mercader JM, Gómez-Serrano M, García-Santos E, Latorre J, Lluch A, Sabater M, Caballano-Infantes E, Guzmán R, Macías-González M, Buxo M, Gironés J, Vilallonga R, Naon D, Botas P, Delgado E, Corella D, Burcelin R, Frühbeck G, Ricart W, Simó R, Castrillon-Rodríguez I, Tinahones FJ, Bosch F, Vidal-Puig A, Malagón MM, Peral B, Zorzano A, Fernández-Real JM. Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function. FASEB J. 2019 Aug; 33(8):9656-9671.
IF: 5,391 Q1 D1

2. Camargo A, Jimenez-Lucena R, Alcala-Diaz JF, Rangel-Zuniga OA, Garcia-Carpintero S, Lopez-Moreno J, Blanco-Rojo R, Delgado-Lista J, Perez-Martinez P, van Ommen B, Malagon MM, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J. Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: From the CORDIOPREV study. APR 2019. 38 (2). 529 – 538.
IF: 6,402 Q1 D1

3. Ezquerro S, Mocha F, Fruhbeck G, Guzman-Ruiz R, Valenti V, Mugueta C, Becerril S, Catalan V, Gomez-Ambrosi J, Silva C, Salvador J, Colina I, Malagon MM, Rodriguez A. Ghrelin Reduces TNF-alpha-Induced Human Hepatocyte Apoptosis, Autophagy, and Pyroptosis: Role in Obesity-Associated NAFLD. JAN 2019. 104 (1). 21-37.
IF: 5,605 Q1

Other Publications

1. Gousset K, Gordon A, Kumar Kannan S, Tovar J. A novel Microproteomic Approach Using Laser Capture Microdissection to Study Cellular Protrusions. Int J Mol Sci. 2019 Mar 7;20(5). pii: E1172.
IF: 4,183 Q1

2. Clemente-Postigo M, Oliva-Olivera W, Coin-Aragüez L, Ramos-Molina B, Giraldez-Perez RM, Lhamyani S, Alcaide-Torres J, Perez-Martinez P, El Bekay R, Cardona F, Tinahones FJ. Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. Am J Physiol Endocrinol Metab. 2019;316(2): E319-E332
IF: 4,125 Q1

ACTIVITY

Nº ONGOING PROJECTS: 3

Nº PHD THESES: 1

GC12: CLINICAL AND EPIDEMIOLOGICAL RESEARCH IN PRIMARY CARE (GICEAP)

TEAM

Last name	First name	
Pérula De Torres	Luis Ángel	R4
Blanco Hungría	Antonio	R3
González Lama	Jesús	R3
Rich Ruiz	Manuel	R3
Serrano Merino	Jesús	R3
Vaquero Abellán	Manuel	R3
Aguado Taberné	Cristina	R2
Arias Blanco	María Del Carmen	R2
Arias Vega	Mª Raquel	R2
Carrera González	María Del Pilar	R2
Fernández García	José Ángel	R2
Fonseca Del Pozo	Francisco Javier	R2
Apacicio Martinez	Pilar	R2
González Carretero	Juan Ignacio	R2
Hidalgo Requena	Antonio	R2
Jiménez García	Celia	R2
Martin Rioboó	Enrique	R2
Montero Monterroso	José Luis	R2
Muñoz Del Castillo	Francisco	R2
Olaya Caro	Inmaculada	R2
Parras Rejano	Juan Manuel	R2
Pérula De Torres	Carlos	R2
Ranchal Sánchez	Antonio	R2
Redondo Sánchez	Juana	R2
Roldán Villalobos	Ana	R2
Ruiz Moral	Roger	R2
Ruiz Moruno	Francisco Javier	R2
Criado Larumbe	Margarita	R2
Ramírez Baena	Miguel	R2
Silva Aycaguer	Luis Carlos	R2
Varas Fabra	Francisco José	R2
Villegas Becerril	Enrique	R2
Leiva Cepas	Fernando	R2
Valero Martín	Antonio José	R2
Marín González	Beatriz	R1
Muñoz Alcaraz	María Nieves	R1
Muñoz Gómez	Rafaela	R1
Romero Rodríguez	Esperanza María	R1
Navarrete Martínez	Esther	R1
Sánchez Cañete	Eva María	R1
López Ruiz	Victoria	R1

SCIENTIFIC PRODUCTION

18	6%	28%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. PC Health Research Network (Rediapp), ISCIII
ii. PAIDI CTS452 (Family and Community Medicine), Universidad de Córdoba

3 agreements with companies

KEYWORDS

- **PRIMARY CARE**
- **EPIDEMIOLOGY**
- **PREVENTIVE MEDICINE**
- **APPLIED PESEARCH**
- **FAMILY AND COMMUNITY EDICINE**
- **COMMUNICATION AND HEALTH**
- **COMMUNITY HEALTH**
- **PUBLIC HEALTH**
- **ENVIRONMENT**

HIGHLIGHTED PUBLICATIONS

1. Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A, Fitzmaurice DA, Gomez-Doblas JJ, Harbison J, Healey JS, Hobbs FDR, Kaasenbrood F, Keen W, Lee VW, Lindholt JS, Lip GYH, Mairesse GH, Mant J, Martin JW, Martin-Rioboo E, McManus DD, Muniz J, Munzel, T ; Nakamya, J; Neubeck, L; Orchard, JJ ; de Torres, LAP; Proietti, M ; Quinn, FR ; Roalfe, AK ; Sandhu, RK ; Schnabel, RB ; Smyth, B ; Soni, A ; Tieleman, R ; Wang, JG ; Wild, PS ; Yan, BP ; Freedman, B. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLOS MEDICINE. 2019. 16. 9. (e1002903).
IF: 11,048 Q: 1 D1

2. Aguera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Pena J. Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE. 2019. 8. 1.
IF: 3,644 Q: 1

3. Romero-Rodriguez E, Pérula de Torres LA, Fernández Garcia JA, Roldán Villalobos R, Ruiz Moral R, Parras Rejano JM. Impact of a primary care training program on the prevention and management of unhealthy alcohol use: A quasi-experimental study. PATIENT EDUCATION AND COUNSELING. 2019. 102. 11. 2060-2067.
IF: 2,821 Q: 1

4. Aparicio-Martinez P, Perea-Moreno AJ, Martinez-Jimenez MP, Redel-Macias MD, Pagliari C, Vaquero-Abellan M. Social Media, Thin-Ideal, Body Dissatisfaction and Disordered Eating Attitudes: An Exploratory Analysis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2019. 16. 21. (4177).
IF: 2,468 Q: 1

5. Hernandez-Ascanio J, Perula-de Torres LA, Roldan-Villalobos A, Perula-de Torres JC, Rich-Ruiz M. Effectiveness of a multicomponent intervention to reduce social isolation and loneliness in community-dwelling elders: A randomized clinical trial. Study protocol. Collaborative Grp Asys Proyect. JOURNAL OF ADVANCED NURSING. 2019. 76. 1. 337-346.
IF: 2,376 Q: 1

ACTIVITY

Nº ONGOING PROJECTS: 8
Nº PROJECTS STARTING IN 2020: 1
Nº CLINICAL TRIALS: 4
Nº ACTIVE PATENTS: 2

GC13: CALCIUM METABOLISM. VASCULAR CALCIFICATION

TEAM

Last name	First name	
Rodríguez Portillo	Mariano	R4
Aguilera Tejero	Escolástico	R4
Muñoz Castañeda	Juan Rafael	R4
Canalejo Raya	Antonio L.	R3
López Villalba	Ignacio	R3
Díaz Tocados	Juan Miguel	R2
Pendón Ruiz De Mier	Mª Victoria	R2
Pineda Martos	Carmen María	R2
Raya Bermúdez	Ana Isabel	R2
Rodelo Haad	Cristian	R2
Rodríguez Ortiz	Mª Encarnación	R2
López Baltanás	Rodrigo	R1
Ríos Varo	Rafael	R1
Vergara Segura	Noemí	R1
García Valdivia	Sandra	ADM
Membrives González	Cristina	T

SCIENTIFIC PRODUCTION

9	11%	33%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Spanish Renal Research Network (REDinREN)
ii. PAIDI CTS-179 Scientific group
iii. European Uremic Toxic (EUTOX)
iv. CKD-MBD GROUP (ERA-EDTA)

Competitive funding obtained for contracts:

i. Nicolás Monardes (SAS) - Juan Muñoz Castañeda
ii. Intensificación (ISCIII) – Mariano Rodríguez Portillo
iii. RIO HORTEGA – Mª Victoria Pendón Ruiz de Mier

6 agreements with companies

KEYWORDS

- **CALCIUM**
- **PHOSPHORUS**
- **MINERAL METABOLISM**
- **PARATHYROID GLANDS**
- **PTH**
- **CALCIFICATION**
- **UREMIA**
- **HPTH2º**
- **VASCULAR CALCIFICATION**
- **RENAL FAILURE**
- **BONE MINERAL DISEASE**
- **VDR**
- **CASR**
- **MESENCHYMAL STEM CELLS**
- **WNT / BETA-CATENIN**

HIGHLIGHTED PUBLICATIONS

1. Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM, Herencia C, Vergara N, de Mier MVPR, Santamaria R, Rodelo-Haad C, Casado-Diaz A, Lorenzo V, Carvalho C, Frazao JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodriguez M, Lo. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. KIDNEY INTERNATIONAL. 2019. 95. 5. 1064-1078.
IF: 8,306 Q1 D1

2. Rodriguez-Ortiz ME, Gomez-Delgado F, de Larriva APA, Canalejo A, Gomez-Luna P, Herencia C, Lopez-Moreno J, Rodriguez M, Lopez-Miranda J, Almaden Y. Serum Magnesium is associated with Carotid Atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study). SCIENTIFIC REPORTS. 2019. 9.
IF: 4,011 Q1

3. Rodelo-Haad C, Santamaria R, Munoz-Castaneda JR, de Mier MVPR, Martin-Malo A, Rodriguez M. FGF23, Biomarker or Target?. TOXINS. 2019. 11. 3.
IF: 3,895 Q1

4. Rodelo-Haad C, Aguera ML, Carmona A, Navarro MD, Carracedo J, Rodriguez-Benot A, Aljama P. Pancreatic autoantibodies and CD14(+)CD16(+) monocytes subset are associated with the impairment of beta-cell function after simultaneous pancreas-kidney transplantation. PLOS ONE. 2019. 14. 2.
IF: 2,776 Q2

5. Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A. Parathyroidectomy in dialysis patients: Indications, methods, and consequences. SEMINARS IN DIALYSIS. 2019.32. 5. 444-451.
IF: 2,056 Q3

ACTIVITY

Nº ONGOING PROJECTS: 7

Nº CLINICAL TRIALS: 5

Nº PHD THESES: 2

BRUKER
PET/MR 3T
BRUKER
BRUKER

GC14: CELLULAR THERAPY

TEAM

Last name	First name	
Herrera Arroyo	Inmaculada Concepción	R4
Ortega Salas	Rosa	R3
Centeno Haro	Macarena	R2
Martin Palanco	Vanesa	R2
Nogueras Martin	Sonia	R2
Carmona Luque	Maria Dolores	R2
Jimenez Moreno	Rosario	R2
Pavlovic Pavlovic	Kristina	R1
Ortiz Espejo	Lourdes	R1
Gutiérrez Fernández	Rosario	T

SCIENTIFIC PRODUCTION

3

PUBLICATIONS

ADDITIONAL INFORMATION

Networks:

i. RADITA (Andalusian Network for the desing and translation of Advanced Therapies)

ii. EATRIS ATMP platform (European Infrastructure for Translational Medicine)

Competitive funding obtained for contracts:

i. Intensificación (SAS) – Inmaculada Concepción Herrera Arroyo

20 agreements with companies

KEYWORDS

- **STEM CELLS**
- **CELL THERAPY**
- **REGENERATIVE MEDICINE**
- **MYOCARDIAL REGENERATION**
- **THERAPEUTIC ANGIOGENESIS**
- **CELL-GENE THERAPY**
- **CAR-T CELLS**

HIGHLIGHTED PUBLICATIONS

1. Romero M, Suarez-de-Lezo J, Herrera C, Pan M, Lopez-Aguilera J, Suarez-de-Lezo J, Baeza-Garzon F, Hidalgo-Lesmes FJ, Fernandez-Lopez O, Martinez-Atienza J, Cebrian E, Martin-Palanco V, Jimenez-Moreno R, Gutierrez-Fernandez R, Nogueras S, Carmona MD, Ojeda S, Cuende N, Mata R. Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopath. BMC CARDIOVASCULAR DISORDERS. 2019; 19(1). Núm. art.:203.
IF: 1,497 Q3

2. Ruiz-Ortiz M, Rodriguez-Diego S, Delgado M, Kim J, Weinsaft JW, Ortega R, Carnero L, Sanchez JJ, Carrasco F, Lopez-Aguilera J, Lopez-Granados A, Arizon JM, Paredes N, Oneto-Fernandez J, Pan M, Mesa D. Myocardial deformation and acute cellular rejection after heart transplantation: Impact of inter-vendor variability in diagnostic effectiveness. ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES. 2019; 36(12): 2185-2194.
IF: 1,287 Q4

3. Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Robles-Arista JC, Rodriguez-Peralvarez M, Garcia MD, Lopez-Cillero P, Briceno J. Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 2019; 51(1):20-24.
IF: 0,959 Q4

Other Publications

1. Bento L, Bastida JM, Garcia-Cadenas I, Garcia-Torres E, Rivera D, Bosch-Vilaseca A, De Miguel C, Martinez-Munoz ME, Fernandez-Aviles F, Roldan E, Chinea A, Yanez L, Zudaire T, Vaz CP, Espigado I, Lopez J, Valcarcel D, Duarte R, Cabrera R, Herrera C, Gonzalez-Porras JR, Gutierrez A, Solano C, Sampol A. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2019; 25(9):1825-1831.
IF: 3,796 Q2

ACTIVITY

Nº ONGOING PROJECTS: 4

Nº CLINICAL TRIALS: 1

Nº PHD THESES: 1

GC15: INVASIVE CARDIOLOGY AND CELL THERAPY

TEAM

Last name	First name	
Pan Álvarez-Ossorio	Manuel	R4
Anguita Sánchez	Manuel P.	R3
Arizón Arizón Del Prado	José Mª	R3
Castillo Domínguez	Juan Carlos	R3
Delgado Ortega	Mónica Maria	R3
López Granados	Amador	R3
Mazuelos Bellido	Francisco	R3
Mesa Rubio	Maria Dolores	R3
Ojeda Pineda	Soledad	R3
Pavlovic Djurovic	Djordje	R3
Romero Moreno	Miguel Ángel	R3
Ruiz Ortiz	Martín	R3
Segura Saint-Gerons	Jose Mª	R3
Suárez de Lezo Herreros de Tejada	Javier	R3
López Aguilera	José	R2
Hidalgo Lesmes	Francisco José	R2
Luque Moreno	Aurora	R1
González Manzanares	Rafael	R1
Cebrián Salgado	Eva	ADM

SCIENTIFIC PRODUCTION

21	5%	57%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Dr Manuel Pan Álvarez-Ossorio is member of the work group European Bifurcation Club and leader of the organization of many of the meetings and courses organized by the group on an international level.
ii. One of our researchers, Dr Miguel A Romero Moreno is member of the Working Group on Grown Up Congenital Heart Disease European Society of Cardiology and Dr. Anguita the president of the Spanish Society of Cardiology (Sociedad Española de Cardiología).
iii. Dr Anguita and Dr Pan are both active members of the group that develops the guidelines for clinical practice of the Spanish Society of Cardiology (Sociedad Española de Cardiología).3 contratos con empresas.

International projects:

i. Atlantis, Reshape-HF, Secure
The SECURE Project has received the award for the best European cooperative R&D project. The group has received a total of 55 awards for its publications in high impact journals of in the field.

4 agreements with companies.

KEYWORDS

- **CARDIAC INTERVENTIONS**
- **CELLULAR THERAPY**
- **STENTS**
- **PERCUTANEOUS AORTIC VALVES**
- **CLOSING BIRTH DEFECTS**

HIGHLIGHTED PUBLICATIONS

1. Vlastra W, Chandrasekhar J, Vendrik J, Gutierrez-Ibanes E, Tchetche D, de Brito FS, Barbanti M, Kornowski R, Latib A, D'Onofrio A, Ribichini F, Baan J, Tijssen JGP, Pan M, Dumonteil N, Mangione JA, Sartori S, D'Errigo P, Tarantini G, Lunardi M, Orvin K, Pagnesi M , Gila JS, Modine T, Dangas G, Mehran R, Piek JJ, Delewi, R. Transfemoral TAVR in Nonagenarians From the CENTER Collaboration. JACC-CARDIOVASCULAR INTERVENTIONS. MAY 27 2019; 12 (10). 911-920.
IF: 9,544 Q1 D1

2. Fernandez JJS, Ortiz MR, Luque CO, Galvez JMC, Penas ER, Rubio DM, Ortega MD, Dominguez JCC, Sanchez MA, Aguilera JL, Avalos FC, Alvarez-Ossorio MP. Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR Registry. REVISTA ESPAÑOLA DE CARDIOLOGIA. OCT 2019; 72 (10). 827-834.
IF: 5,126 Q1

3. Lekuona I, Anguita M, Zamorano JL, Rodriguez JM, de Soroa PB, Perez-Alcantara F. Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?. REVISTA ESPANOLA DE CARDIOLOGIA. 2019. 72. 5. 398 – 406.
IF: 5,126 Q1

4. Cequier A, de Prado AP, Moreno R, Cosin-Sales J, de Sa EL, Evangelista A, Bueno H, Anguita M. Percutaneous cardiological intervention and cardiac surgery: patient-centered care. Position statement of the Spanish Society of Cardiology. REVISTA ESPANOLA DE CARDIOLOGIA. 2019. 72. 8. 658-663.
IF: 5,126 Q1

5. Poletti Murga-Eizagaetxebarria N, Rodriguez-Padial L, Muniz J, Sambola A, Gomez-Doblas JJ, Pedreira M, Alonso-Martin JJ, Beltran P, Rodriguez-Roca G, Anguita M, Roig E. The Gender Perspective Within the OFRECE Study: Differences in Health Care Among Patients Consulting for Chest Pain and/or Palpitations. REVISTA ESPANOLA DE CARDIOLOGIA. 2019. 72. 10. 813-819.
IF: 5,078 Q1

ACTIVITY

Nº ONGOING PROJECTS: 3

Nº CLINICAL TRIALS: 17

GC16: CELLULAR BIOLOGY IN HEMATOLOGY. HYPERCOAGULABILITY

TEAM

Last name	First name	
Sánchez García	Joaquín	R4
Velasco Gimena	Francisco	R4
Arqueros Martínez	Víctor	R3
Martin Calvo	Carmen	R3
Molina Hurtado	Jose Ramón	R3
Rojas Contreras	Rafael	R3
Serrano López	Josefina	R3
Álvarez Rivas	Miguel A.	R3
Casaño Sánchez	Javier	R3
Fernández de la Mata	Margarita	R3
García Torres	Estefanía	R3
Rodríguez Villa	Antonia	R3
Tabares Carrasco	Salvador	R3
Martínez Losada	Mª del Carmen	R2
Janusz	Kamila	R2
Dorado Pardo	Javier	T

SCIENTIFIC PRODUCTION

13
PUBLICATIONS

15%
PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. PETHEMA (Programa Español de Tratamientos en Hematología)
ii. GESMD (Grupo Español de Síndromes Mielodisplásicos)
iii. European Society for Blood and Marrow Transplantation –EBMT
iv. Observational Immune Tolerance Induction research programme - IbsITI.

8 agreements with companies

AWARD: "XIV PREMIO NACIONAL DE INVESTIGACION - COLEGIO OFICIAL DE MÉDICOS DE LA PROVINCIA DE CORDOBA"

KEYWORDS

- **ACUTE LEUKEMIA**
- **LYMPHOMA**
- **ALLOGENIC STEM CELL TRANSPLANTATION**
- **HYPERCOAGULABILITY**

HIGHLIGHTED PUBLICATIONS

1. Ribera JM, García O, Moreno MJ, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M,Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genescà E, Bravo P, García-Belmonte D, García-Guiñón A, Hernández-Rivas JM, Feliu E; PETHEMA Group of the Spanish Society of Hematology. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer. 2019 Cancer. 2019 Aug 15;125(16):2810-2817.
IF: 6,102 Q1

2. Martos L, Fernández-Pardo Á, López-Fernández MF, Ibáñez F, Herrero S, Tàssies D, González-Porras JR, Solmoirago MJ, Costa MJ, Reverter JC, Marco P, Roldán V, Lecumberri R, Velasco F, Oto J, Iruin G, Alonso MN, Vayá A, Bonanad S, Ferrando F, Martí E, Cid AR, Plana E, Oña F, Cuesta I, González-López TJ, España F, Medina P, Navarro S; Working Group of the Spanish Society of Thrombosis Haemostasis. (SETH). Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. Thromb Haemost. 2019 Sep;119(9):1409-1418.
IF: 4,733 Q1

3. Rodríguez-Veiga R, Montesinos P, García E, Boluda B, Rojas R, Serrano J, Martínez-Cuadrón D, Martín C, Sanz J, Tabares S, Piñana JL, Lorenzo I, Montoro J, Salavert M, Pemán J, Jarque I, Solves P, Sanz GF, Torres A, Sanz MA. Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. Mycoses. 2019 Jan 11.
IF: 3,065 Q2

4. Revilla N, Corral J, Miñano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I, Gonzalez-Lopez TJ, de la Morena-Barrio ME, Gonzalez-Porras JR, Vicente V, Lozano ML. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets. 2019;30(6):743-751.
IF: 3,106 Q2

5. Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res. 2019 Jan;76:1-10.
IF: 2,066 Q3

ACTIVITY

Nº ONGOING PROJECTS: 3

Nº CLINICAL TRIALS: 35

GC17: PHYSIOPATHOLOGY OF ENDOCRINE VITAMIN D SYSTEM BIOTECHNOLOGY AND AGING

TEAM

Last name	First name	
Quesada Gómez	José Manuel	R4
Casado Díaz	Antonio	R4
Cuenca Acevedo	Rafael	R2
Romero Sánchez	Mª Concepción	R2
Rodríguez Ramos	Ángel	R1
Torrecillas Baena	Bárbara	R1

SCIENTIFIC PRODUCTION

3	33%	33%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES)
ii. PAIDI CTS-413 scientific group

Competitive funding obtained for contracts:

i. Intensificación (SAS) – Jose Manuel Quesada Gómez

1 agreement with companies

KEYWORDS

- **OSTEOPOROSIS**
- **VITAMIN D**
- **CAROTENOIDS**
- **FATTY ACIDS**
- **HUMAN MESENCHYMAL STEM CELLS (MSCH) OF ADULT ADIPOCYTES**
- **OSTEOBLASTS**
- **POLYPHENOLS**
- **GENE EXPRESSION**
- **PROTEOMICS**
- **NUTRIGENETICS**
- **NUTRIGENOMICS**
- **ENDOTHELIAL PROGENITOR CELLS**
- **EXOSOMES**
- **AGING**
- **REGENERATIVE MEDICINE**

HIGHLIGHTED PUBLICATIONS

1. Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, Pineda C, Martínez-Moreno JM, Herencia C, Vergara N, Pendón-Ruiz de Mier MV, Santamaría R, Rodelo-Haad C, Casado-Díaz A, Lorenzo V, Carvalho C, Frazão JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodríguez M, López I, Muñoz-Castañeda JR. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. KIDNEY INT. 2019 May;95(5):1064-1078.
IF: 8,306 Q1 D1

2. Casado-Díaz A, Dorado G, Quesada-Gómez JM. Influence of olive oil and its components on mesenchymal stem cell biology. WORLD J STEM CELLS. 2019 Dec 26;11(12):1045-1064.
IF: 3,534 Q2

3. Casado-Diaz A, Dorado G, Giner M, Montoya MJ, Navarro-Valverde C, Diez-Perez A, Quesada-Gomez JM. Proof of Concept on Functionality Improvement of Mesenchymal Stem-Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures. CALCIFIED TISSUE INTERNATIONAL. 2019. 104. 6. 631-640.
IF: 3,265 Q2

Other publications

1. Bouillon R, Quesada-Gomez JM. Calcifediol or vitamin D to optimize vitamin D status: Reply to letter of M Sosas. OSTEOPOROSIS INTERNATIONAL. 2019. 30. 12. 2521-2522.
IF: 3,83 Q2

2. Gomez Q, Henriquez S. Vitamin D and muscle function. REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL. 2019. 11. 1. 3-5.

ACTIVITY

Nº ONGOING PROJECTS: 4

Nº CLINICAL TRIALS: 2

GC18: TRANSLATIONAL RESEARCH IN SURGERY OF SOLID ORGAN TRANSPLANTATION

TEAM

Last name	First name	
Briceño Delgado	Francisco Javier	R4
Ciria Bru	Rubén	R3
López Cillero	Pedro	R3
Medina Fernández	Francisco Javier	R3
Robles Ariza	Juan Carlos	R3
Rufián Peña	Sebastián	R3
Arjona Sánchez	Álvaro	R3
Leva Vallejo	Manuel	R2
Pozo Laderas	Juan Carlos	R3
Sánchez Hidalgo	Juan Manuel	R3
Jiménez Gómez	Jesús	R2
Leva Vallejo	Manuel	R2
Padial Aguado	Ana Cristina	R2
Regueiro López	Juan Carlos	R2
Pleguezuelo Navarro	María	R2
Navarro Rodríguez	Elena	R1
Gómez Gómez	Irene	R1

SCIENTIFIC PRODUCTION

20	15%	35%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. CIBER on Liver and Digestive Diseases (CIBERehd).

International Projects:

i. Arjona Sánchez, A. EuroPMP - European Network on Pseudomyxoma Peritonei. Funding Agency: COMISIÓN EUROPEA. Reference: OC-2017-1-17101

1 agreements with companies

KEYWORDS

- **LIVER TRANSPLANT**
- **PANCREAS TRANSPLANT**
- **KIDNEY TRANSPLANT**
- **LUNG TRANSPLANT**
- **HEART TRANSPLANT**
- **LIVING DONOR TRANSPLANTATION**
- **PEDIATRIC TRANSPLANTATION**
- **SPLIT TRANSPLANTATION**
- **EXPANDED CRITERIA DONORS**

HIGHLIGHTED PUBLICATIONS

1. Arjona-Sancheza A, Rodriguez-Ortiz L, Baratti D, Schneider MA, Gutierrez-Calvo A, Garcia-Fadrique A, Tuynman JB, Cascales-Campos PA, Martin VC, Morales R, Salti GI, Arteaga X, Pacheco D, Alonso-Gomez J, Yalkin O, Villarejo-Campos P, Sanchez-Hidalgo JM, Cas. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. ANNALS OF SURGICAL ONCOLOGY. 2019. 26. 8. 2595-2604.
IF: 3,857 Q1 D1

2. Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J. Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 2019. 43. 5. 261-269.
IF:5,099 Q1

3. Ciria R, Gomez-Luque I, Ocana S, Cipriani F, Halls M, Briceno J, Okuda Y, Troisi R, Rotellar F, Soubrane O, Abu Hilal M. A Systematic Review and Meta-Analysis Comparing the Short- and Long-Term Outcomes for Laparoscopic and Open Liver Resections for Hepatocellular Carcinoma: Updated Results from the European Guidelines Meeting on Laparoscopic Liver Surgery, Southampton, UK,. ANNALS OF SURGICAL ONCOLOGY. 2019. 26. 1. 252-263.
IF: 3,681 Q1 D2

4. Arjona-Sanchez A, Esquivel J, Glehen O, Passot G, Turaga KK, Labow D, Rufian-Pena S, Morales R, van der Speeten K. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 2019. 33. 3. 854-860.
IF: 3,209 Q1

5. Arjona-Sanchez A, Duran M, Sanchez-Hidalgo JM, Rufian-Pena S. Peritoneal carcinomatosis from ovarian carcinoma treated by interval laparoscopic complete cytoreduction and HIPEC with extraction through natural orifice. SURGICAL ONCOLOGY-OXFORD. 2019. 31. 14-15.
IF: 3 Q1

ACTIVITY

Nº ONGOING PROJECTS: 4

Nº PROJECTS STARTING IN 2020: 1

MAIN RESULTS

Clinical Guidelines:

i. Hessheimer, AJ; Coll, E; Ruiz, P; Gastaca, M; Rivas, JI; Gamez, M; Sanchez, B; Santoyo, J; Ramirez, P; Parrilla, P; Marin, LM; Gomez-Bravo, MA; Garcia-Valdecasas, JC; Lopez-Monclus, J; Bosca, A; Lopez-Andujar, R; Fundora-Suarez, J; Villar, J; Garcia-Sesma, A; Jimenez, C; Rodriguez-Laiz, G; Llado, L; Rodriguez, JC; Barrera, M; Charco, R; Lopez-Baena, JA; Briceno, J; Pardo, F; Blanco, G; Pacheco, D; Dominguez-Gil, B; Turrion, VS; Fondevila, C. The UK DCD Risk Score: Still no consensus on futility in DCD liver transplantation. JOURNAL OF HEPATOLOGY. 70. 1034-1035. DOI: 10.1016/j.jhep.2019.01.004. PMID: 30782424

ii. Ciria, R; Gomez-Luque, I; Ocana, S; Cipriani, F; Halls, M; Briceno, J; Okuda, Y; Troisi, R; Rotellar, F; Soubrane, O; Abu Hilal, M. A Systematic Review and Meta-Analysis Comparing the Short- and Long-Term Outcomes for Laparoscopic and Open Liver Resections for Hepatocellular Carcinoma: Updated Results from the European Guidelines Meeting on Laparoscopic Liver Surgery, Southampton, UK, 2017. ANNALS OF SURGICAL ONCOLOGY. 26. 252-263. DOI: 10.1245/s10434-018-6926-3. PMID: 30390167

GC19: ARTIFICIAL VISION APPLICATIONS

TEAM

Last name	First name	
Medina Carnicer	Rafael	R4
Muñoz Salinas	Rafael	R4
Carmona Poyato	Ángel	R3
Fernández Garcia	Nicolás Luis	R3
Garrido Castro	Juan Luis	R3
Madrid Cuevas	Francisco José	R3
Marín Jiménez	Manuel Jesús	R3
Yeguas Bolívar	Enrique	R3
Sarmadi Nasser	Hamid	R1
Romero Ramírez	Francisco José	R1
Jurado Rodríguez	David	R1

SCIENTIFIC PRODUCTION

2	100%
PUBLICATIONS	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Competitive funding obtained for contracts:
i. I-PFIS (ISCIII) - Sarmadi Nasser, Hamid

FOREUM Abstract Award 2019 - Juan Luis Garrido Castro; Funding Agency: FOUNDATION FOR RESEARCH IN RHEUMATOLOGY; Reference: FOREUM_AWARD19/01

KEYWORDS

- **COMPUTER VISION**
- **IMAGE SEGMENTATION**
- **PATTERN RECOGNITION**
- **3D RECONSTRUCTION**
- **AUGMENTED REALITY**
- **HUMAN RECOGNITION**
- **HUMAN POSE ESTIMATION**

HIGHLIGHTED PUBLICATIONS

1. Munoz-Salinas R, Sarmadi H, Cazzato D, Medina-Carnicer R. Flexible body scanning without template models. SIGNAL PROCESSING. 2019. 154. 350-362.
IF: 4,086 Q1

2. Sarmadi H, Munoz-Salinas R, Berbis MA, Luna A, Medina-Carnicer R. 3D Reconstruction and alignment by consumer RGB-D sensors and fiducial planar markers for patient positioning in radiation therapy. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE. 2019. 180.
IF: 3,424 Q1

3. Munoz-Salinas R, Marin-Jimenez MJ, Medina-Carnicer R. SPM-SLAM: Simultaneous localization and mapping with squared planar markers. PATTERN RECOGNITION. 2019. 86. 156-171.
IF: 5,898 Q1 D1

Other Publications

1. Sarmadi H, Munoz-Salinas R, Berbis MA, Medina-Carnicer R. Simultaneous Multi-View Camera Pose Estimation and Object Tracking With Squared Planar Markers. IEEE ACCESS. 2019. 7. 22927-22940.
IF: 4,098 Q1

2. Duran-Rosal AM, Gutierrez PA, Carmona-Poyato A, Heryas-Martinez C; A hybrid dynamic exploitation barebones particle swarm optimisation algorithm for time series segmentation. NEUROCOMPUTING. 353. (45-55). 2019.
IF: 4,072 Q1

ACTIVITY

Nº ONGOING PROJECTS: 3

GC20: GENETICS AND BEHAVIOURAL DISEASES

TEAM

Last name	First name	
Ruiz Rubio	Manuel	R4
Moriana Elvira	Juan Antonio	R4
Alós Cívico	Francisco José	R3
Antolí Cabrera	Adoración	R3
Burgos Marín	Rafael	R3
Gámez Granados	Juan Carlos	R3
García Torres	Francisco Mariano	R3
Guijarro Granados	Teresa	R3
Martín Borreguero	Pilar	R3
Moreno Osella	Eliana	R3
Pérez Dueñas	Carolina	R3
Romero Balsera	Maria Auxiliadora	R3
Sánchez Raya	Mª Araceli	R3
Soto Hidalgo	José Manuel	R3
Gálvez Lara	Mario	R3
Cuadrado Hidalgo	Fátima	R3
Velasco Rodríguez	Judith	R1
Jurado González	Francisco Javier	R1
Maldonado Herves	Miguel Ángel	R1
Corpas López	Jorge	R1
Vacas Ruiz	Julia	R1
Venceslá Martínez	José Fernando	R1
Espejo Durán	Carmen	R1

SCIENTIFIC PRODUCTION

8	50%
PUBLICATIONS	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. Excellence research and interdisciplinary Network for the diagnosis and promotion of youth issues, emotions and psychological well-being (MINEICO PSI2015-70943-REDT).

1 agreement with companies

Technology Transfer:

Some of the members of the research team participate in the creation and management for the Centro de Atención Infantil Temprana de la Universidad de Córdoba (CAIT-UCO) [Centre for early child attention of the University of Cordoba], institution under the Corporación Empresarial [Business Corporation] of the University of Córdoba. This centre has an agreement with the Andalusian Ministry of Health providing 70 vacancies for children with developmental disorders (or at risk for) referred by paediatric services. The centre has a private line of attention, conducts research under the IMIBIC group, and provides formal training and education. Web: http://www.uco.es/cait/index.html

KEYWORDS

- **BEHAVIOUR GENETICS**
- **AUTISM SPECTRUM DISORDER**
- **C. ELEGANS**
- **ONCOLOGY**
- **CLINICAL PSYCHOLOGY**
- **PSYCHO-ONCOLOGY**
- **PSYCHOLOGICAL TREATMENT**
- **PRIMARY CARE**
- **DEPRESSION**
- **ANXIETY**
- **BASED-EVIDENCE PSYCHOLOGY**
- **EARLY ATTENTION**
- **DEVELOPMENTAL DISORDERS**
- **NEUROPSYCHOLOGICAL ALTERATIONS**
- **RARE DISEASES**
- **DEVELOPMENTAL DISABILITY**
- **VERBAL BEHAVIOUR**
- **COGNOSCITIVE BEHAVIOUR**

HIGHLIGHTED PUBLICATIONS

1. Moreno, E., Muñoz, R., Medrano, L., González, C., Ruiz, P., Limonero, J., Moretti, L., Cano, A., Moriana, J.A. Factorial invariance of a computerized version of the GAD-7 across various demographic groups and over time in primary care patients. Journal of Affective Disorders 2019 Jun 1; 252:114-121.
IF: 4,084 Q1

2. Rodríguez-Ramos, A., García-Torres F, Moriana, J.A., & Ruiz-Rubio, M. (2019). Emotional stability is associated with the MAOA promoter uVNTR polymorphism in women. Brain Behavior. 2019 Sep;9(9):e01376.
IF: 2,072 Q3

3 Gálvez Lara, M., Corpas, J. &, Moriana, J.A. Evidence-based brief psychological treatment for emotional disorders in primary and specialized care: study protocol of a randomized controlled trial. Frontiers in Psychology. 2019 Jan 8;9: 2674.
IF: 2,129 Q2

4. Gálvez Lara, M., Corpas, J., Velasco, J.,& Moriana, J.A. El conocimiento y el uso en la práctica clínica de los tratamientos psicológicos basados en la evidencia. Clínica y Salud, 2019. 30 (3), 115-122.
IF: 0,632 Q4

5. Molero, A., Martin, R., Moriana, J.A., Nitsche, M.A., & Rivera, G.N. (2019). Bilateral Prefrontal Cortex Anodal tDCS Effects on Self-reported Aggressiveness in Imprisoned Violent Offenders. Neuroscience, 397, 31-40.
IF= 3,244 Q2

ACTIVITY

Nº ONGOING PROJECTS: 2

GC21: METABOLOMICS AND IDENTIFICATION OF BIOACTIVE COMPOUNDS

TEAM

Last name	First name	
Priego Capote	Feliciano	R4
Luque De Castro	Maria Dolores	R4
Calderón Santiago	Mónica	R2
Ledesma Escobar	Carlos Augusto	R2
Delgado Povedano	Mª Del Mar	R2
López Bascón	María Asunción	R2
Díaz Lozano	Azahara	R1
Castillo Peinado	Laura De Los Santos	R1
Luque Córdoba	Diego	R1
Mena Bravo	Antonio	R1
Criado Navarro	Inmaculada	R1
Tomé Rodríguez	Sonia	R1

SCIENTIFIC PRODUCTION

10	20%	90%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. CIBERFES - Cooperative Research Thematic Network on Aging and Frailty [link: http://www.ciberfes.es/en] (Collaborator)
ii. Dr Priego Capote is the coordinator of the FQM-227 - Analytical Chemistry Research Group, of the Andalusian Plan for Research, Development and Innovation (PAIDI).
iii. Metabored – Red Española de Metabolómica (Collaborator)

International projects:

i. Interreg-Med Program. ARISTOIL-Enforcement of Mediterranean olive oil sector competitiveness through development and application of innovative production and quality control methodologies related to olive oil health protecting properties. INTERREG-MED-1033.

4 agreements with companies

KEYWORDS

- **METABOLOMICS**

- **MASS SPECTROMETRY**
- **TARGETED ANALYSIS**
- **UNTARGETED ANALYSIS**
- **SAMPLE PREPARATION**
- **CLINICAL ANALYSIS**
- **AGROFOOD**
- **BIOACTIVE COMPOUNDS**

HIGHLIGHTED PUBLICATIONS

1. Criado-Navarro I, Mena-Bravo A, Calderon-Santiago M, Priego-Capote F; Determination of glycerophospholipids in vegetable edible oils: Proof of concept to discriminate olive oil categories. FOOD CHEMISTRY. 299.
IF: 5,399 Q1 D1

2. Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, Luque de Castro MD, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S; Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 9.
IF: 5,151 Q1 D1

3. Lopez-Bascon MA, Calderon-Santiago M, Arguello H, Morera L, Garrido JJ, Priego-Capote F; Comprehensive analysis of pig feces metabolome by chromatographic techniques coupled to mass spectrometry in high resolution mode: Influence of sample preparation on the identification coverage. TALANTA. 199. 303-309.
IF: 4,916 Q1

4. Castillo-Peinado LS, Lopez-Bascon MA, Mena-Bravo A, Luque de Castro MD, Priego-Capote F; Determination of primary fatty acid amides in different biological fluids by LC-MS/MS in MRM mode with synthetic deuterated standards: Influence of biofluid matrix on sample preparation. TALANTA. 193. 29-36.
IF: 4,916 Q1

5. Mena-Bravo A, Calderon-Santiago M, Luque de Castro MD, Priego-Capote F; Evaluation of short-term storage prior to analysis of vitamin D-3 and metabolites in human serum by liquid chromatography coupled to tandem mass spectrometry. TALANTA. 198. 344-349.
IF: 4,916 Q1

ACTIVITY

Nº ONGOING PROJECTS: 2
Nº PHD THESES: 2

IMIBIC

GC22: EPIGENETICS

TEAM

Last name	First name	
Roldán Arjona	Mª Teresa	R4
Rodríguez Ariza	Rafael	R3
Córdoba Cañero	Mª Dolores	R2
Martínez Macías	Mª Isabel	R2
Dorado León	Macarena	R1

SCIENTIFIC PRODUCTION

3	33%	33%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Our group participates in the COST Action (CM1406) Epigenetic Chemical Biology (EPICHEMBIO).
ii. CA18111-Genome editing in plants - a technology with transformative potential (PlantEd).

Competitive funding obtained for contracts:

i. FPI (MICINN) – Macarena Dorado León
ii. First Prize to the best oral presentation at the III Congress of Young Researchers in Biomedicine to Macarena Dorado León (2019)

3 agreements with companies

KEYWORDS

- **EPIGENETICS**
- **DNA REPAIR**
- **CANCER**
- **DNA METHYLATION**
- **DNA DEMETHYLATION**
- **DNA GLYCOSYLASES**
- **BASE EXCISION REPAIR**

HIGHLIGHTED PUBLICATIONS

1. Roldán-Arjona T, Ariza RR, Córdoba-Cañero D. DNA Base Excision Repair in Plants: An Unfolding Story With Familiar and Novel Characters (2019) Front Plant Sci. 10:1055.
IF: 4,106 Q1 D1

2. Parrilla-Doblas JT, Roldán-Arjona T, Ariza RR, Córdoba-Cañero D. Active DNA Demethylation in Plants. (2019) Int J Mol Sci. 21;20(19). pii: E4683.
IF: 4,813 Q2

3. Cabral Medeiros NM, Córdoba-Cañero D, García-Gil CB, Ariza RR, Roldán-Arjona T, Scortecci K. Characterization of an AP endonuclease from sugarcane - ScARP1. Biochem Biophys Res Commun. (2019) Jun 30;514(3):926-932.
IF: 2,705 Q2

ACTIVITY

Nº ONGOING PROJECTS: 2

Nº PHD THESES: 1

GC23: METABOLISM IN CHILDHOOD

TEAM

Last name	First name	
Gil Campos	María Mercedes	R4
Antón Gamero	Montserrat	R3
De la Torre Aguilar	Mª Jose	R3
Flores Rojas	Katherine	R3
Ibarra Ibarra De La Rosa	Ignacio	R3
López Laso	Eduardo	R3
Mateos González	Maria Elena	R3
Pérez Navero	Juan Luis	R3
Velasco Jabalquinto	María José	R3
Llorente Cantarero	Francisco Jesús	R3
Ariza Jiménez	Ana Belén	R2
Gómez Fernández	Antonio Rafael	R1
Jurado Castro	José Manuel	R1
Ordoñez Díaz	María Dolores	R1
Rodríguez Benítez	María Victoria	R1

SCIENTIFIC PRODUCTION

17	23%	71%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBEROBN
ii. CIBERER
iii. PAIDI CTS-639 Scientific group
iv. Spanish Pediatric Clinical Trials Network RECLIP

International projects:

i. Mateos Gonzalez, ME. ChiLTERN - Children's Liver Tumour European Research Network. Funding Agency: European Commission. Reference: PHC-18-2015-001.

1 agreement with companies

KEYWORDS

- **AUTISM**
- **CHILDREN**
- **CHILDHOOD**
- **METABOLIC SYNDROME**
- **OBESITY**
- **ONCOLOGY**
- **PHYSICAL ACTIVITY**
- **PRE-PROBIOTICS**
- **RENAL DISEASE**

HIGHLIGHTED PUBLICATIONS

1. de Lamas C, de Castro MJ, Gil-Campos M, Gil A, Couce ML, Leis R; Effects of Dairy Product Consumption on Height and BoneMineral Content in Children: A Systematic Review of Controlled Trials. ADVANCES IN NUTRITION. 2019 May 1;10(suppl_2):S88-S96.
IF: 7,24 Q1 D1

2. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A; Mechanisms of Action of Probiotics. ADVANCES IN NUTRITION. 2019 Jan 1;10(suppl_1):S49-S66
IF: 7,24 Q1 D1

3. Anguita-Ruiz A, Plaza-Diaz J, Ruiz-Ojeda FJ, Ruperez AI, Leis R, Bueno G, Gil-Campos M, Vazquez-Cobela R, Canete R, Moreno LA, Gil A, Aguilera CM; X chromosome genetic data in a Spanish children cohort, dataset description and analysis pipeline. SCIENTIFIC DATA. 2019 Jul 22;6(1):130.
IF: 5,929 Q1

4. Plaza-Diaz J, Gomez-Fernandez A, Chueca N, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K, Martin-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F, Gil-Campos M; Autism Spectrum Disorder (ASD) with and without Mental Regression Is Associated with Changes in the Fecal Microbiota. NUTRIENTS. 11. 2.
IF: 4,171 Q1

5. Rodriguez-Herrera A, Mulder K, Bouritius H, Rubio R, Munoz A, Agosti M, Lista G, Corvaglia L, Ludwig T, Abrahamse-Berkeveld M, Perez-Navero JL; Gastrointestinal Tolerance, Growth and Safety of a Partly Fermented Formula with Specific Prebiotics in Healthy Infants: A Double-Blind, Randomized, Controlled Trial. NUTRIENTS. 11. 7.
IF: 4,171 Q1

ACTIVITY

Nº ONGOING PROJECTS: 5

Nº CLINICAL TRIALS: 10

GC24: CLINICAL AND MOLECULAR MICROBIOLOGY

TEAM

Last name	First name	
Martínez Martínez	Luis	R4
Causse Del Rio	Manuel	R3
Egea Miranda	Maria Del Pilar	R3
Gracia Ahufinger	Irene	R3
Tejero García	Rocío	R3
Pérez Jiménez	Ana Belén	R3
Rodríguez López	Fernando Carlos	R3
Ruiz Martínez	Pilar	R3
Linares Sicilia	María José	R3
Fernández García	Mª Dolores	R2
Guzmán Puche	Julia	R1
Marfil Pérez	Eduardo	R1
Muñoz De La Rosa	Montserrat	R1
Sánchez León	Irene	R1
Blanco Martín	Tania	R1
Pedraza Merino	Rosa	R1
Espinar García	Mónica	R1
Elías López	Cristina	T

SCIENTIFIC PRODUCTION

23	30%	61%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Spanish Network for Research on Infectious Diseases (Red Española de Investigación en patología Infecciosa; REIPI, http://reipi.org).
ii. Andalusian Network For Clinical Research In Infectious Diseases (Red Andaluza Para La Realización De Ensayos Clínicos En Enfermedades Infecciosas).

Competitive funding obtained for contracts:

i. Miguel Servet I (ISCIII) - Mª Dolores Fernández García

3 agreements with companies

KEYWORDS

- **ANTIMICROBIAL-RESISTANCE**
- **BETA-LACTAMASES**
- **AMINOGLYCOSIDE-MODIFYING-ENZYMES**
- **METHYL-TRANSFERASES**
- **QNR**
- **QUINOLONES**
- **POLYMYXINS**
- **CARBAPENEMS**
- **CEPHALOSPORINS**
- **HETERORESISTANCE**
- **ANTIBIOGRAM**
- **SUSCEPTIBILITY-TESTING**
- **MOLECULAR-TYPING**
- **ENTEROBACTERIA**
- **PSEUDOMONAS**
- **ACINETOBACTER**

HIGHLIGHTED PUBLICATIONS

1. Ruiz P, Causse M, Vaquero M, Casal M. In Vitro Activity of Tedizolid against ycobacterium tuberculosis. Antimicrob Agents Chemother. 2019, 63. pii:e01939-18.
IF: 4,715 Q1

2. Haeili M, Kafshdouz M, Pishnian Z, Feizabadi MM, Martínez-Martínez L. Comparison of susceptibility testing methods for determining the activity of colistin against Gram-negative bacilli of clinical origin. J Med Microbiol 2019, 68:60-66.
IF: 1,926 Q4

3. Puig CRD, Torres MF, Marfil-Perez E, Ferandez MIR, Del Rio MC, Balbin JA, Martinez-Martinez L. Comparison between Vitek MS, Bruker Biotyper,Vitek2, and API20E for differentiation of species of the genus Raoultella. Eur J Clin Microbiol Infect Dis. 2019 , 38:467-470.
IF: 2,591 Q3

4. Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One. 2019 Aug 30;14(8):e0221231.
IF: 3,776 Q2

5. Del Barrio-Tofiño E, Sánchez-Diener I, Zamorano L, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI. Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. J Antimicrob Chemother 2019, 74: 3217–3220.
IF: 5,113 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 5

Nº PROJECTS STARTING IN 2020: 1

Nº CLINICAL TRIALS: 3

GC25: KNOWLEDGE DISCOVERY AND INTELLIGENT SYSTEMS IN BIOMEDICINE

TEAM

Last name	First name	
Ventura Soto	Sebastián	R4
Cano Rojas	Alberto	R3
García Martínez	Carlos	R3
Gibaja Galindo	Eva Lucrecia	R3
Luque Rodríguez	María	R3
Romero Morales	Cristóbal	R3
Romero Salguero	José Raúl	R3
Zafra Gómez	Amelia	R3
Luna Ariza	Jose Maria	R3
Moyano Murillo	José María	R2
Ramírez Quesada	Aurora	R2
Delgado Osuna	José Antonio	R1
Luque Guzmán	Carmen	R1
Pérez Perdomo	Eduardo	R1
Robles Berumen	Hermes	R1
Moyano Martin-Castaño	Antonio	R1
Esteban Toscano	Aurora	R1
Barbudo Lunar	Rafael	R1
Trassierras Fresco	Antonio	R1
Marín Sanz	Juan Antonio	R1

SCIENTIFIC PRODUCTION

2
PUBLICATIONS

100%
PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:
i. Red de Excelencia en Big Data y Análisis de Datos Escalable.
ii. Red de Excelencia en Ingeniería del Software basada en Búsqueda (SEBASENet)

Competitive funding obtained for contracts:
i. iPFIS. (ISCIII) - Eduardo Pérez Perdomo

2 agreements with companies

KEYWORDS

- **BIOMEDICAL DATA ANALYSIS**
- **BIG DATA**
- **DATA SCIENCE**
- **DATA MINING**
- **MACHINE LEARNING**
- **PREDICTIVE MODELS**
- **CLASSIFICATION**
- **REGRESSION**
- **DESCRIPTIVE MODELS**
- **ASSOCIATION**
- **CLUSTERS**

HIGHLIGHTED PUBLICATIONS

1. del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. AUG 2019. 8. 3389-3402.
IF: 5,605 Q1

2. Luque C, Luna JM, Luque M, Ventura S; An advanced review on text mining in medicine. WILEY INTERDISCIPLINARY REVIEWS-DATA MINING AND KNOWLEDGE DISCOVERY.2019. 9. **3. IF: 2,541 Q1**

Other Publications

1. Moyano JM, Gibaja EL, Cios KJ, Ventura S; An evolutionary approach to build ensembles of multi-label classifiers. INFORMATION FUSION. 50. 168-180.
IF: 10,716 Q1 D1

2. Saeed-Ul Hassan, Waheed H, Aljohani NR, Ali M, Ventura S, Herrera F; Virtual learning environment to predict withdrawal by leveraging deep learning. INTERNATIONAL JOURNAL OF INTELLIGENT SYSTEMS. 34. 8. 1935-1952.
IF: 7,229 Q1 D1

3. Reyes O, Ventura S; Performing Multi-Target Regression via a Parameter Sharing-Based Deep Network. INTERNATIONAL JOURNAL OF NEURAL SYSTEMS. 29. 9. 1950014.
IF: 6,411 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 2

GC26: CLINICAL VIROLOGY AND ZOONOSIS

TEAM

Last name	First name	
Rivero Román	Antonio	R4
Rivero Juárez	Antonio	R3
Frías Casas	Mario	R2
Camacho Espejo	Angela	R2
Caballero Gómez	Javier	R1
Ruiz Cáceres	Inmaculada	R1
López López	Pedro	R1
Machuca Sánchez	Isabel	R1
Ruiz Torres	Laura	T
Zafra Soto	Ismael	T

SCIENTIFIC PRODUCTION

36	30%	80%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. AIDS Research Network (RIS, RD16/0025/0034)
ii. HEVnet (ECDC: NP/2016/OCS/7892/01)

Competitive funding obtained for contracts:

i. Sara Borrell (ISCIII) - Mario Frias Casas
ii. Miguel Servet I (ISCIII) - Antonio Rivero Juárez
iii. Intensificación Unidad "Acción B" (SAS) – Ángela Camacho Espejo

18 agreements with companies

KEYWORDS

- **HIV**
- **HCV**
- **HEV**
- **INFECTION**
- **AIDS**
- **ART**
- **CD4**
- **HEPATITIS**
- **PATHOGENS**
- **FIBROSIS**
- **CIRRHOSIS**
- **INNATE IMMUNITY**
- **PHARMACOGENOMICS**
- **VIRAL RESERVOIR**
- **ZOONOSES**

HIGHLIGHTED PUBLICATIONS

1. Rivero-Juarez A, Lopez-Lopez P, Frias M, Rivero A; Hepatitis E Infection in HIV-Infected Patients. FRONTIERS IN MICROBIOLOGY. 10.
IF: 4,259 Q1

2. Rivero-Juarez A, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, Lopez-Lopez P, Andujar-Troncoso G, Machuca I, Camacho A, Munoz-Valbuena P, Rivero A; Hepatitis E virus in Spanish donors and the necessity for screening. JOURNAL OF VIRAL HEPATITIS. 26. 5. 603-608.
IF: 4,016 Q1

3. Frias M, Rivero-Juarez A, Tellez F, Palacios R, Jimenez-Arranz A, Pineda JA, Merino D, Gomez-Vidal MA, Perez-Camacho I, Camacho A, Rivero A; Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. SCIENTIFIC REPORTS. 9.
IF: 4,011 Q1

4. Caballero-Gomez J, Jimenez-Ruiz S, Lopez-Lopez P, Vicente J, Risalde MA, Cano-Terriza D, Frias M, Barasona JA, Rivero A, Garcia-Bocanegra I, Rivero-Juarez A; Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 66. 5. 1803-1808.
IF: 3,554 Q1 D1

5. Garcia-Bocanegra I, Rivero A, Caballero-Gomez J, Lopez-Lopez P, Cano-Terriza D, Frias M, Jimenez-Ruiz S, Risalde MA, Gomez-Villamandos JC, Rivero-Juarez A; Hepatitis E virus infection in equines in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 66. 1. 66-71.
IF: 3,554 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 5
Nº PROJECTS STARTING IN 2020: 3
Nº CLINICAL TRIALS: 12

MAIN RESULTS

Clinical Guidelines:

i. Perez-Molina, JA; Polo, R; Lopez-Aldeguer, J; Lozano, F; Aguirrebengoa, K; Arribas, JR; Boix, V; Berenguer, J; Blanco, JR; Domingo, P; Estrada, V; Galindo, MJ; Garcia, F; Gatell, JM; Gonzalez-Garcia, J; Gutierrez, F; Iribarren, JA; Knobel, H; Llibre, JM; de Quiros, JCLB; Lopez-Cortes, LF; Losa, JE; Marino, A; Miro, JM; Montes, M; Moreno, S; Negredo, E; Perez-Elias, MJ; Podzamczer, D; Portilla, J; Poveda, E; Pulido, F; Ribera, E; Rivero, A ; Rubio, R; Santos, J; Sanz-Moreno, J; Sanz-Sanz, J; Serrano, S; de la Torre, J; Tuset, M; von Wichman, MA; Martinez, E . Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 195-202. DOI: 10.1016/j.eimc.2018.02.010. PMID: 29759422
ii. Crespo, M; Lozano, F; Buzon, MJ; Curran, A; Estrada, V; Garcia, F; Imaz, A; Cortes, LL; Losa, JE; Masia, M; Merchante, N; Marino, A; Ocampo, A ; Perez-Molina, JA; Poveda, E; Riera, M; Santin, M; Santos, J; Valencia, E; Arazo, P; de la Torre, J; Aldeguer, JL; Palacios, R; Rivero, A; Rubio, R; Sanz, J; Tellez, MJ . Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 467-475. DOI: 10.1016/j.eimc.2018.03.011. PMID: 29793873
iii. Garcia, LM; Iniesta, C; Garrido, J; Fuster, MJ; Pujol, F; Meulbroek, M; Poveda, T; Riera, M; Antela, A; Moreno, S; Dalmau, D; River, A; Garcia, D; Espacio, R; del Amo, J. HIV Pre-Exposure Prophylaxis (PrEP) in Spain: Political and Administrative Situation. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 656-660. DOI: 10.1016/j.eimc.2018.05.012. PMID: 29910148

GC27: ONCOBESITY AND METABOLISM

TEAM

Last name	First name	
Luque Huertas	Raúl Miguel	R4
Gahete Ortiz	Manuel David	R3
González Serrano	Mª Teresa	R2
Moreno Rodríguez	Mª del Mar	R2
León González	Antonio José	R2
Del Río Moreno	Mercedes	R2
Vázquez Borrego	Mª Carmen	R2
Gómez Gómez	Enrique	R2
Alors Pérez	Emilia Mª	R1
Herrero Aguayo	Vicente	R1
Jiménez Vacas	Juan Manuel	R1
Sáez Martínez	Prudencio	R1
López Cánovas	Juan Luis	R1
Sánchez Sánchez	Rafael	R1
Sánchez Medianero	Mª Teresa	R1
Toledano Delgado	Álvaro	R1
Montero Hidalgo	Antonio Jesús	R1
Pérez Gómez	Jesús Miguel	R1
López López	Fernando	R1
Lara López	Araceli	R1
Delgado Luque	Jesús	R1
Moreno Montilla	María Trinidad	R1
García Fernández	Helena	R1

SCIENTIFIC PRODUCTION

28	32%	75%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. CIBERobn Physiopathology of Obesity and Nutrition.
ii. Spanish Society of Endocrinology and Nutrition (SEEN). Area of Knowledge of Neuroendocrinology
iii. REMAH - Spanish Molecular Registry of Hypophyseal Adenomas
iv. Andalusian Society of Endocrinology, Diabetes and Nutrition (SAEDYN). Area of Knowledge of Neuroendocrinology
v. ceiA3 - Agrifood Campus of International Excellence
vi. PAIDI BIO-139 Cellular and Molecular Endocrinology (Andalusian Plan for Research, Development and Innovation – PAIDI
vii. TransBioNet – Spanish Translational Bioinformatics Network
viii. Global Engagement Advisory Group of the Endocrine Society (USA)
ix. European Society of Endocrinology (ESE). Pituitary and Neuroendocrinology Focus Area.
x. European Neuroendocrine Association. ENEA Young Researchers Committee (EYRC).
xi. Red de Investigación Nacional of the Ministry of Science, Innovation and Universities.

Competitive funding obtained for contracts:

i. PFIS (ISCIII)- Emilia Alors Pérez
ii. Sara Borrell (ISCIII) - Antonio José León González
iii. ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER – Elena M. Yubero Serrano
iv. FPU (MEC) – Vicente Herrero Aguayo
v. FPU (MEC) – Prudencio Saez Martínez
vi. FPU (MEC) – Antonio Jesús Montero Hidalgo
vii. FPU (MEC) – Jesús Miguel Pérez Gómez

5 agreements with companies

KEYWORDS

- **OBESITY**
- **CANCER**
- **TUMOR PATHOLOGIES**
- **PROSTATE CANCER**
- **BRAIN TUMORS**
- **HEPATOCELLULAR CARCINOMA**
- **PITUITARY TUMORS**
- **DIABETES**
- **METABOLIC DYSREGULATIONS**
- **ADIPOSE TISSUE**
- **INFLAMMASOME**
- **MIRNAS**
- **SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP)**
- **EXTRACELLULAR VESICLES**
- **SPLICING/SPLICEOSOME**
- **NON-SENSE MEDIATED MRNA DECAY**
- **HETEROGENEITY**
- **DIAGNOSTIC BIOMARKERS**
- **PROGNOSTIC BIOMARKERS**

HIGHLIGHTED PUBLICATIONS

1. Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 22. 8. (12).
IF: 5,583 Q1 D1

2. Del Rio-Moreno M, Alors-Perez E, De Souza PB, Prados-Gonzalez ME, Castano JP, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. TRANSLATIONAL RESEARCH. 211. (147-160).
IF: 4,915 Q1 D1

3. Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103).
IF: 4,915 Q1 D1

4. Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque RM; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS.11.10.1439.
IF: 6,162 Q1

5. Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente, Gahete MD, Luque RM; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE.8.9.1400.
IF: 5,688 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 6

Nº PROJECTS STARTING IN 2020: 2

Nº PHD THESES: 4

Nº ACTIVE PATENTS: 3

GE01: NEUROPLASTICITY AND OXIDATIVE STRESS

TEAM

Last name	First name	
Túnez Fiñana	Isaac	R4
Agüera Morales	Eduardo	R3
Caballero Villarraso	Javier	R3
Escribano Durán	Begoña María	R3
Jimena Medina	Ignacio	R3
Lillo Roldán	Rafael	R3
Luque Carabot	Evelio	R3
Peña Amaro	José	R3
Espejo Portero	Isabel	R2
Feijoo López	Montserrat	R2
Galván Carmona	Alejandro	R2
Gascón Luna	Félix	R2
Gómez Chaparro	Jose Luis	R2
Cruz Guerrero	Antonio	R2
Ochoa Sepúlveda	Juan José	R2
Peña Toledo	Mª Ángeles	R2
Rodríguez Cantalejo	Fernando	R2
Ruiz Villén	Mª Concepción	R2
Barcos Martínez	Montserrat	R2
Ramírez Rivera	Alberto	R2
Conde Gavilán	Cristina	R1
Galván Jurado	Alberto	R1
Moyano Gallego	Mª José	R1
Peña García	Victoria	R1
Romero Baldonado	Cristina	R1
Valverde Moyano	Roberto	R1
Giraldo Polo	Ana Isabel	T
Latorre Luque	Manuel	T

SCIENTIFIC PRODUCTION

16	12%	37%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Spanish Brain Stimulation Network (Red Española de Estimulación Cerebral)
ii. PAIDI CTS-624 Neuroplasticity and oxidative stress

International projects:

i. Agüera Morales, E. DIATOMIC-2019-02-001 dreaMS - A telehealth tool for monitoring and treatment of Multiple Sclerosis patients. COMISIÓN EUROPEA.

13 agreements with companies

KEYWORDS

- **ANTIOXIDANT SYSTEMS**
- **HUNTINGTON'S DISEASE**
- **MULTIPLE SCLEROSIS**
- **NEURODEGENERATIVE DISEASES**
- **NEUROPLASTICITY**
- **OXIDATIVE STRESS**
- **CELL DEATH**
- **TRANSCRANIAL MAGNETIC STIMULATION**

HIGHLIGHTED PUBLICATIONS

1. Anguita-Ruiz A, Pastor-Villaescusa B, Leis R, Bueno G, Hoyos R, Vazquez-Cobela R, Latorre-Millan M, Canete MD, Caballero-Villarraso J, Gil A, Canete R, Aguilera CM; Common Variants in 22 Genes Regulate Response to Metformin Intervention in Children with Obesity: A Pharmacogenetic Study of a Randomized Controlled Trial. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1471.
IF: 5,688 Q1 D1

2. Aguera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Pena J; Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE. 8. 1. (23-31).
IF: 3,644 Q1

3. de Lima ME, Colpo AZC, Maya-Lopez M, Rangel-Lopez E, Becerril-Chavez H, Galvan-Arzate S, Villeda-Hernandez J, Sanchez-Chapul L, Tunez I, Folmer V, Santamaria A; Comparing the Effects of Chlorogenic Acid and Ilex paraguariensis Extracts on Different Markers of Brain Alterations in Rats Subjected to Chronic Restraint Stress. NEUROTOXICITY RESEARCH. 35. 2. (373-386).
IF: 3,311 Q1 D1

4. Kotlar I, Rangel-Lopez E, Colonnello A, Aguilera-Portillo G, Serratos IN, Galvan-Arzate S, Pedraza-Chaverri J, Tunez I, Wajner M, Santamaria A; Anandamide Reduces the Toxic Synergism Exerted by Quinolinic Acid and Glutaric Acid in Rat Brain Neuronal Cells. NEUROSCIENCE. 401. (84-95).
IF: 3,244 Q2

5. Caballero-Villarraso J, Jimenez-Jimenez MJ, Escribano BM, Aguera E, Santamaria A, Tunez I; Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 18. 6. (478-490).
IF: 2,761 Q2

ACTIVITY

Nº ONGOING PROJECTS: 3

Nº CLINICAL TRIALS: 31

GE02: PREVENTIVE MEDICINE AND PUBLIC HEALTH

TEAM

Last name	First name	
Guzmán Herrador	Bernardo R.	R4
Barranco Quintana	José Luis	R3
Díaz Molina	Carmen	R3
Salcedo Leal	Mª Inmaculada	R3
Torcello Gaspar	Ricardo	R3
Narbona Rodríguez	Francisco Javier	R3
Rodríguez Torronteras	Alejandro	R3
Ayora Torres	Mª del Pilar	R2
Coca Baena	Mª Teresa	R2
Díaz Gavira	Concepción	R2
González Nebauer	Valeria	R2
Herrera Tierno	Jesús	R2
Fernández Martínez	Nicolás Francisco	R1
Gavilán León	Francisco José	R1
Ortíz González-Serna	Rocío	R1
Ruíz Montero	Rafael	R1
Romero Muñoz	Mª Jesús	T

SCIENTIFIC PRODUCTION

1	100%
publications	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Sociedad Andaluza de Medicina Preventiva y Salud Pública (SAMPSP).
ii. Sociedad Española de Medicina Preventiva y Salud Pública e higiene (SEMPSPH).

KEYWORDS

- **PUBLIC HEALTH**
- **HEALTHCARE ASSOCIATED INFECTIONS**
- **VACCINATION**
- **VACCINE UPTAKE**
- **ADHERENCE**

HIGHLIGHTED PUBLICATIONS

1. Ferrara P, Shantikumar S, Verissimo VC, Ruiz-Montero R, Masuet-Aumatell C, Ramon-Torrell JM, Buckley K, Verissimo VHC, Costa D, Del Prete V, Ferrara P, Ivankovic D, Peixoto VRFD, Peremiquel-Trillas P, Duque MP, Ruiz-Montero R, Shantikumar S, Thomas R, Voc; Knowledge about E-Cigarettes and Tobacco Harm Reduction among Public Health Residents in Europe. International journal of environmental research and public health. 16. 12.
IF: 2,468 Q1

Other publications

1. Kuhn KG, Nygård KM, Löfdahl M, Trönnberg L, Rimhanen-Finne R, Sunde LS, Guzman-Herrador B, Ethelberg S. Campylobacteriosis in the Nordic countries from 2000 to 2015: Trends in time and space. Scand J Public Health. 2019 Nov 25:1403494819875020.
IF: 1,761 Q2

2. González-Rubio, R., Zamalloa, P. L., Llorente, A. H. A., Peremiquel-Trillas, P., Ruiz-Montero, R., Gullón, P.,García Díez M, Reques Sastre L y Grupo de Competencias de ARS-MPSP. (2019). Competencias para Medicina Preventiva y Salud Pública: propuestas tras un proceso comparativo y participativo. Educación Médica. (2019 Nov). https://doi.org/10.1016/j.edumed.2019.09.004

ACTIVITY:

Nº CLINICAL TRIALS: 1

GE03: INFLAMMATORY IMMUNE-MEDIATED CUTANEOUS DISEASES

TEAM

Last name	First name	
Ruano Ruiz	Juan	R4
Gómez García	Francisco	R3
Isla Tejera	Beatriz	R3
Vélez García-Nieto	Antonio	R3
Franco García	Francisco	R1
Hernández Romero	José Luis	R1
Aguilar Luque	Macarena	R1
Carmona Fernández	Pedro Jesús	R1
Gay Mimbrera	Jesús	R1
Gómez Arias	Pedro Jesús	R1
Sanz Cabanillas	Juan Luis	R1
Viguera Guerra	Isabel	R1
Allalou Ruiz	Yasmín	T
Clemente Milla	María del Carmen	T
López García	María	T
López González	Carmen	T

SCIENTIFIC PRODUCTION

5	20%	40%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Cochrane Skin group
ii. Cochrane Bias Method group
iii. PAIDI CTS-1041 Scientific Group. Coordinator (PI) of the Group "New diagnostic and therapeutic methods in immunomediated inflammatory skin diseases"" that belongs to the Andalusian Research Plan since March 2018
iv. Laboratory for Investigative Dermatology, Rockefeller University, NY, USA
v. Ezcema center and the Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine Center at Mount Sinai New York (EEUU)
vi. Dept. of Population Health Science and Policy and Icahn Institute for Genomics and Multiscale Biology at Icahn School of Medicine Center at Mount Sinai New York (EEUU)Cochrane Skin group

Competitive funding obtained for contracts:

i. Intensificación (SAS) – Juan A. Ruano Ruiz

8 agreements with companies

KEYWORDS

- **IMMUNE-MEDIATED SKIN DISEASES**
- **PSORIASIS**
- **ATOPIC DERMATITIS**
- **VITILIGO**
- **ALOPECIA AREATA**
- **GENETIC POLYMORPHISMS**
- **BIOLOGICAL THERAPIES**
- **CELL CULTURE**
- **COLD ATMOSPHERIC PLASMA**
- **COST-EFFICIENCY ANALYSES**
- **SYSTEMATIC REVIEWS**
- **META-ANALYSES**
- **META-EPIDEMIOLOGY**

HIGHLIGHTED PUBLICATIONS

1. Zhou LS, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, Estrada YD, Peng XY, del Duca E, Sanz-Cabanillas J, Ruano J, Xu H, Zhang N, Wen HC, Gonzalez J, Garcet S, Krueger JG, Guttman-Yassky E; Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2019 Jul;144(1):144-156.
IF: 14,11 Q1 D1

2. Montilla AM, Gomez-Garcia F, Gomez-Arias PJ, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B, Ruano J; Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. DERMATOLOGY AND THERAPY. 2019 Dec;9(4):655-683.
IF: 3,615 Q1

3. Viguera-Guerra I, Ruano J, Aguilar-Luque M, Gay-Mimbrera J, Montilla A, Fernandez-Rueda JL, Fernandez-Chaichio J, Sanz-Cabanillas JL, Gomez-Arias PJ, Garcia-Nieto AV, Gomez-Garcia F, Isla-Tejera B; Evolution of international collaborative research efforts to develop non-Cochrane systematic reviews. PLOS ONE. 2019 Feb 27;14(2):e0211919.
IF: 2,776 Q2

4. Gomez-Garcia F, Gomez-Arias PJ, Hernandez J, Montilla AM, Gay-Mimbrera J, Aguilar-Luque M, Viguera-Guerra I, Garcia-Nieto AV, Isla-Tejera B, Ruano J; Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ OPEN. 2019 May 22;9(5):e028303.
IF: 2,413 Q2

5. Gonzalez M, Fernandez-Pugnaire MA, Grimalt R, Hermosa-Gelbard A, Bernardez C, Molina-Ruiz AM, Ormaechea-Perez N, Fernandez-Crehuet P, Vano-Galvan S; Risk factors associated with frontal fibrosing alopecia: a multicentre case-control study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2019 Jun;44(4):404-410. doi: 10.1111/ced.13785.
IF: 1,771 Q3

ACTIVITY

Nº ONGOING PROJECTS: 4

Nº CLINICAL TRIALS: 18

GE04: APPLIED PSYCHOLOGY

TEAM

Last name	First name	
Luque Salas	Bárbara	R4
Tabernero Urbieta	Carmen	R4
Arenas Moreno	Alicia	R3
Castillo Mayén	Rosario	R3
Cuadrado	Esther	R3
Moyano Pacheco	Manuel	R3
Rubio García	Sebastián	R3
Gutiérrez Domingo	Tamara	R2
Farhane Medina	Naima Z.	R1
Villaécija Rodríguez	Joaquín	R1

SCIENTIFIC PRODUCTION

4	75%
PUBLICATIONS	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. PAIDI HUM-414
ii. PAIDI HUM-928
iii. Unidad de Investigación Consolidada de Castilla y León
iv. Instituto de Neurociencias de Castilla Y León.

Competitive funding obtained for contracts:

i. FPU (MEC) - Joaquín Villaécija Rodríguez

KEYWORDS

- **MOTIVATION**
- **SELF-EFFICACY**
- **AGING**
- **WOMEN**
- **POSITIVITY**
- **EMOTIONS**
- **DIET**
- **CARDIOVASCULAR DISEASE**
- **COPE WITH STRESS**
- **EMOTIONAL SELF-REGULATION**
- **MANAGEMENT TRAINING PROGRAMS**
- **E-HEALTH**

HIGHLIGHTED PUBLICATIONS

1. Tabernero, C., Luque, B. & Cuadrado, E. A Multilevel Study of Alcohol Consumption in Young Adults: Self-E cacy, Peers' Motivations and Protective Strategies. International journal of environmental research and public health. 2019. 16, 2827.
IF: 2.468 Q:1

2. Tabernero, C., Gutiérrez-Domingo, T., Luque, B., García-Vázquez, O., & Cuadrado, E. Protective Behavioral Strategies and Alcohol Consumption: The Moderating Role of Drinking-Group Gender Composition. International journal of environmental research and public health. (2019). 16(5), 900.
IF: 2.468 Q1

3. García-Torres, F., & Castillo-Mayén, R. Differences in Eysenck's Personality Dimensions between a Group of Breast Cancer Survivors and the General Population. International journal of environmental research and public health, (2019). 16(7), 1240.
IF: 2,468 Q1

4. Checa, P., Abundis-Gutierrez, A., Pérez-Dueñas, C., & Fernández-Parra, A. Influence of maternal and paternal parenting style and behaviour problems on academic outcomes in primary school. Brief report. Frontiers in psychology. (2019). 10, 378.
IF: 2.129 Q2

Other publications

1. Bélanger, J.J., Schumpe, B. M., Nociti, N., Moyano, M., Dandeneau, S., Chamberland, P. E., & Vallerand, R. J. (2019). Passion and moral disengagement: Different pathways to political activism. Journal of Personality, 87, 1234-1249.
IF: 3,084 Q1 D1

ACTIVITY

Nº ONGOING PROJECTS: 5

Nº PHD THESES: 1

GE05: GENITOURINARY DISEASES

TEAM

Last name	First name	
Requena Tapia	María José	R3
Blanca Pedregosa	Ana María	R2
Campos Hernández	Juan Pablo	R2
Carrasco Valiente	Julia	R2
Rubio Galisteo	Juan Manuel	R1
Sánchez González	Álvaro	R1
Anglada Curado	Francisco	R1
Márquez López	Javier	R1
Prieto Castro	Rafael	R1
Ruíz García	Jesús	R1
Valero Rosa	José	R1

SCIENTIFIC PRODUCTION

11	27%	45%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Life Length – a biotechnology-based company whose activity focuses on the commercialization of the TAT telomere measurement technique.
ii. CTS-172 –Group of Urological Pathology, pertaining to the Andalusian Plan for Research, Development and Innovation (PAIDI)

International projects:

i. ONCOCHECK. A simple blood test for prognosis and monitoring of patients undergoing cancer therapy. Funding agency: European Commission. Reference: SMEInst-2017-01

12 agreements with companies

KEYWORDS

- **BLADDER CANCER**
- **PROSTATE CANCER**
- **KIDNEY TRANSPLANTATION**
- **BIOMARKERS**
- **DIAGNOSIS**
- **PROGNOSIS**
- **PREDICTIVE**
- **ROBOTIC LAPAROSCOPIC SURGERY**

HIGHLIGHTED PUBLICATIONS:

1. Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1400.
IF: 5,688 Q1 D1

2. Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena- Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. J Clin Med. 2019 Nov 22;8(12). pii: E2056.
IF: 5,688 Q1 D1

3. Frantzi M, Gomez EG, Pedregosa AB, Rosa JV, Latosinska A, Culig Z, Merseburger AS, Luque RM, Tapia MJR, Mischak H, Valiente JC; CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. BRITISH JOURNAL OF CANCER. 120. 12. (1120-1128). DOI: 10.1038/s41416-019-0472-z.
IF: 5,416 Q1

4. Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103).
IF: 4,915 Q1 D1

5. Gomez-Gomez E, Carrasco-Valiente J, Campos-Hernandez JP, Blanca-Pedregosa AM, Jimenez- Vacas JM, Ruiz-Garcia J, Valero-Rosa J, Luque RM, Requena-Tapia MJ; Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 2. (934-942).
IF: 4,658 Q1

ACTIVITY

Nº ONGOING PROJECTS: 3
Nº CLINICAL TRIALS: 5
Nº PHD THESES: 1
Nº ACTIVE PATENTS: 3
Nº CLINICAL GUIDELINES: 3

GE06: PATHOPHYSIOLOGY OF RENAL AND VASCULAR DAMAGE

TEAM

Last name	First name	
Moreno Gutiérrez	Juan Antonio	R3
Durán Torralba	Mª del Carmen	R2
López Aguilera	José	R2
Rodríguez Almodóvar	Ana María	R2
Rayego Mateos	Sandra	R2
García Caballero	Cristina	R1
Guerrero Hue	Melania	R1
Sanz Zorrilla	Alicia	R1

SCIENTIFIC PRODUCTION

4	50%	75%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. CIBERCV Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares
ii. ERA-EDTA Immunonephrology Working Group. European Renal Association – European Dialysis and Transplant Association
iii. GLOSEN (Spanish group for glomerulonephritis)
iv. COST Action CA18216 - Network for Research in Vascular Ageing. European Cooperation in Science and Technology. Horizon 2020 Framework Programme of the European Union. 2019-2023.L

Competitive funding obtained for contracts:

i. PFIS (ISCIII) - Melania Guerrero Hue
ii. Ramón y Cajal (MICINN) – Juan Antonio Moreno Gutiérrez

KEYWORDS

- **KIDNEY**
- **HEMOGLOBIN**
- **MYOGLOBIN**
- **CELL DEATH**
- **MACROPHAGES**
- **OXIDATIVE STRESS**
- **PODOCYTES**
- **ACUTE KIDNEY INJURY**
- **IGA NEPHROPATHY**
- **INTRAVASCULAR HEMOLYSIS**
- **RHABDOMYOLYSIS**
- **NRF2**

HIGHLIGHTED PUBLICATIONS

1. Guerrero-Hue M, Garcia-Caballero C, Palomino-Antolin A, Rubio-Navarro A, Vazquez-Carballo C, Herencia C, Martin-Sanchez D, Farre-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA; Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. FASEB JOURNAL. 33. 8. (8961-8975).
IF: 5,595 D1

2. Rubio-Navarro A, Vazquez-Carballo C, Guerrero-Hue M, Garcia-Caballero C, Herencia C, Gutierrez E, Yuste C, Sevillano A, Praga M, Egea J, Cannata P, Cortegano I, de Andres B, Gaspar ML, Cadenas S, Michalska P, Leon R, Ortiz A, Egido J, Moreno JA; Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. FRONTIERS IN PHARMACOLOGY. 10.
IF: 3,845 Q1

3. Moreno JA, Sevillano A, Gutierrez E, Guerrero-Hue M, Vazquez-Carballo C, Yuste C, Herencia C, Garcia-Caballero C, Praga M, Egido J; Glomerular Hematuria: Cause or Consequence of Renal Inflammation?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 9.
IF: 3,687 Q2

4. Sevillano AM, Diaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J, Calviño J, Castillo L, Cobelo C, Delgado-Mallén P, Espinosa M, Fernandez-Juarez G, Fernandez-Reyes MJ, Garcia-Osuna R, Garcia P, Goicoechea M, Gonzalez-Cabrera F, Guzmán DA, Heras M, Martín-Reyes G, Martinez A, Olea T, Peña JK, Quintana LF, Rabasco C, López Revuelta K, Rodas L, Rodriguez-Mendiola N, Rodriguez E, San Miguel L, Sanchez de la Nieta MD, Shabaka A, Sierra M, Valera A, Velo M, Verde E, Ballarin J, Noboa O, Moreno JA, Gutiérrez E, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). 2019. IgA Nephropathy in Elderly Patients. Clinical journal of the American Society of Nephrology: CJASN. 14-8, pp.1183-1192
IF: 6,243 Q1 D1

Other Publications

1. Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). 2019. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney international. 96-4, pp.995-1004.
IF: 8,306 Q1

ACTIVITY

Nº ONGOING PROJECTS: 1

Nº CLINICAL TRIALS: 1

GE07: VISUAL QUALITY

TEAM

Last name	First name	
González Andrades	Miguel	R3
Gallardo Galera	José María	R3
Giménez Gómez	Rafael	R3
Martín Suárez	Eva María	R3
García Martín	Manuel	R2
Caballos Castilla	Rafael	R2
Contieri Lambiese	Fabio	R2
Ibarra de la Rosa	Encarnación	R2
Herrador Montuel	Ángeles	R2
Avilés Mora	Carmen	R2
Hens Gutierrez	Jose Manuel	R1
Arias	Manuel	R1
Pugliese Rojas	Francisco Antonio	R1
Pérez Cordobés	María José	R1
Fernández Choquet de Isla	Jose Ignacio	R1
Giménez-Almenara Amo	Francisco Javier	R1
Fernández Molina	Francisco José	R1
Mohedano Rincón	José María	R1

SCIENTIFIC PRODUCTION

4	50%	75%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. OFTARED ISCIII (Enfermedades Oculares: Prevención, detección precoz y tratamiento de la patología ocular prevalente, degenerativa y crónica)
ii. Spanish Society of Ophthalmology
iii. European Society of Ophthalmology
iv. Andalusian Initiative for Advanced Therapies

3 agreements with companies

AWARD - COLEGIO OFICIAL DE MÉDICOS DE GRANADA - Controling the 3D architecture of self-lifting auto-generated tissue equivalents (SLATEs) for optimized corneal graft composition and stability.

KEYWORDS

- **OPHTHALMOLOGY**
- **BIOMEDICAL ENGINEERING**
- **CORNEA**
- **RECONSTRUCTIVE SURGERY**
- **RETINA**
- **DRUG DELIVERY**
- **GLAUCOMA**
- **NNOMEDICINE**
- **TISSUE ENGINEERING**
- **NANOPARTICLES**
- **REGENERATIVE MEDICINE**
- **BIOMATERIALS**

HIGHLIGHTED PUBLICATIONS

1. Chitnis GD, Verma MKS, Lamazouade J, Gonzalez-Andrades M, Yang K, Dergham A, Jones PA, Mead BE, Cruzat A, Tong Z, Martyn K, Solanki A, Landon-Brace N, Karp JM. A resistance-sensing mechanical injector for the precise delivery of liquids to target tissue. Nat Biomed Eng. 2019;3(8):621-631.
IF: 17,135 Q1 D1

2. Islam MM, Sharifi R, Mamodaly S, Islam R, Nahra D, Abusamra DB, Hui PC, Adibnia Y, Goulamaly M, Paschalis EI, Cruzat A, Kong J, Nilsson PH, Argüeso P, Mollnes TE, Chodosh J, Dohlman CH, Gonzalez-Andrades M. Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts. Acta Biomater. 2019; 96:330- 344.
IF: 6,638 Q1 D1

3. Sharifi R, Yang Y, Adibnia Y, Dohlman CH, Chodosh J, Gonzalez-Andrades M. Finding an Optimal Corneal Xenograft: Comparative Analysis of Corneal Matrix Proteins Across Species. Sci Rep. 2019; 9; 1: 1876.
IF: 4,011 Q1

4. Rico-Sánchez L, Garzón I, González-Andrades M, Ruíz-García A, Punzano M, Lizana-Moreno A, Muñoz-Ávila JI, Sánchez-Quevedo MDC, Martínez-Atienza J, Lopez-Navas L, Sanchez-Pernaute R, Oruezabal RI, Medialdea S, Gonzalez-Gallardo MDC, Carmona G, Sanbonmatsu-Gámez S, Perez M, Jimenez P, Cuende N, Campos A, Alaminos M. Successful development and clinical translation of a novel anterior lamellar artificial cornea. J Tissue Eng Regen Med. 2019;13(12):2142-2154.
IF: 3,319 Q2

ACTIVITY

Nº ONGOING PROJECTS: 1
Nº PROJECTS STARTING IN 2020: 2
Nº CLINICAL TRIALS: 3

GE08: COMPREHESIVE NURSING CARE. MULTIDISCIPLINARY PERSPECTIVE

TEAM

Last name	First name		
Rodríguez Borrego	María Aurora*	R4	*(until June 4th, 2019)*
López Soto	Pablo Jesús*	R3	*(since June 4th, 2019)*
Alanis López	Joaquín	R3	
Carmona Torres	Juan Manuel	R3	
Cobo Cuenca	Ana Isabel	R3	
Dios Guerra	Caridad	R3	
Gonçalves Nitschke	Rosane	R3	
Guerra Martín	María Dolores	R3	
Hidalgo Lopezosa	Pedro	R3	
Laredo Aguilera	José Alberto	R3	
Morales Cané	Ignacio	R3	
Cuevas Pareja	Francisca	R2	
Fernández Rodríguez	Vicente	R2	
Medina Valverde	María José	R2	
Miñarro Del Moral	Rosa	R2	
Muñoz Alonso	Adoración	R2	
Redondo Pedraza	Rosa	R2	
Rodríguez Muñoz	Pedro Manuel	R2	
Aramburu Imazt	Alejandra	R1	
Arévalo Buitrago	Pedro	R1	
Clapés Roldán	Cristina	R1	
González Gancedo	Jacob	R1	
Herrera Torres	María Macarena	R1	
Jiménez Ruz	Andrea	R1	
López Cerdá	Elena	R1	
Bretones	José Miguel	R1	
Debbia	Fabio	R1	
Moral Arroyo	Juan Antonio	R1	

SCIENTIFIC PRODUCTION

18	11%	67%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. PAIDI CTS-666 scientific group

International Project:

i. Gonçalves Nitschke, Rosane. A tecnossocialidade no quotidiano da promoção da saúde das famílias contemporâneas: imagens, potências e límites. CNPq (Brasil); Reference N: 438814/2018-5.

KEYWORDS

- **INTEGRAL NURSING CARE**
- **INTEGRAL HUMAN BEING**
- **NURSING CARE PHILOSOPHY**
- **FEMALE NURSES**
- **PROFESSIONAL DEVELOPMENT OF NURS ING PROFESSIONALS**
- **HEALTHCARE IN OLDER PEOPLE**
- **ASSESSMENT OF TRAINING METHODS IN HIGHER EDUCATION**
- **AGING-LIFE QUALITY**
- **NURSING SERVICE MANAGEMENT**
- **FRAGILITY**
- **EVIDENCE-BASED NURSING CARE**
- **HEALTH AND GENDER**
- **HEALTH AND DISEASE**
- **HABITS OF LIFE: DRUG ADDICTION**
- **DISEASE EXPERIENCE**
- **ERGO-DYNAMIC**
- **HEALTH COMMUNICATION**

HIGHLIGHTED PUBLICATIONS

1. Manfredini F, Lamberti N, Guerzoni F, Napoli N, Gasbarro V, Zamboni P, Mascoli F, Manfredini R, Basaglia N, Rodriguez-Borrego MA, Lopez-Soto PJ; Rehabilitative Exercise Reduced the Impact of Peripheral Artery Disease on Vascular Outcomes in Elderly Patients with Claudication: A Three-Year Single Center Retrospective Study. JOURNAL OF CLINICAL MEDICINE. 8. 2.
IF: 5,688 Q1 D: 1

2. Lamberti N, Lopez-Soto PJ, Rodriguez-Borrego MA, Straudi S, Basaglia N, Zamboni P, Manfredini R, Manfredini F; Restless Leg Syndrome in Peripheral Artery Disease: Prevalence among Patients with Claudication and Benefits from Low-Intensity Exercise. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1403.
IF: 5,688 Q1 D: 1

3. Rodríguez Morales-Cane I, Lopez-Soto PJ, Rodriguez-Borrego MA; Tranexamic acid in trauma patients in the emergency department: systematic review and meta-analysis. EMERGENCIAS. 31. 4. (261-269).
IF: 3,35 Q1

4. Rodríguez-Muñoz PM, Carmona-Torres JM, Hidalgo-Lopezosa P, Cobo-Cuenca AI, Rodríguez- Borrego MA; Evolution of alcohol and tobacco consumption in young people in Spain, after the law 42/2010 against smoking: 2011-2014. ADICCIONES. 31. 4. (274-283)
IF: 3,167 Q1

5. Hidalgo-Cobo-Cuenca AI, Martin-Espinosa NM, Rodriguez-Borrego MA, Carmona-Torres JM; Determinants of satisfaction with life and self-esteem in women with breast cancer. QUALITY OF LIFE RESEARCH. 28. 2. (379-387). DOI: 10.1007/s11136-018-2017-y.
IF: 2,488 Q1

ACTIVITY

Nº ONGOING PROJECTS: 4

Nº PROJECTS STARTING IN 2020: 2

Nº CLINICAL TRIALS: 1

Nº PHD THESES: 5

globalpet
24°C 24C 22C
46% 49% 46%
349

GA01: LUNG TRANSPLANTS. THORACIC NEOPLASMS

TEAM

Last name	First name	
Salvatierra Velázquez	Ángel	R4
Algar Algar	Francisco Javier	R3
Álvarez Kindelán	Antonio	R3
Ayala Montoro	José	R3
Baamonde Laborda	Carlos	R3
Espinosa Jiménez	Dionisio	R3
Cerezo Madueño	Francisco	R3
González García	Francisco Javier	R3
Herrera Merchán	Antonio	R3
Moreno Casado	Paula	R3
Muñoz Foss	Anna	R3
Robles Arista	Juan Carlos	R3
Carrasco Fuentes	Guadalupe	R1
Guaman Arcos	Hugo Darío	R1
Murillo Brito	Diego Alejandro	R1
Mendoza Porcuna	Manuela	T

SCIENTIFIC PRODUCTION

3	67%	100%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. Sociedad española de neumología y cirugía torácica – SEPAR
ii. Asociación de neumología y cirugía torácica del sur - NEUMOSUR
iii. Sociedad española de cirugía torácica – SECT

1 agreement with companies

KEYWORDS

- **LUNG PRESERVATION**
- **CHRONIC REJECTION**
- **BRONCHIOLITIS OBLITERANS. ENDOTHELIUM**
- **INFLAMMATION**
- **OXIDATIVE STRESS**
- **PROTEOMICS**
- **GENOMICS**
- **LUNG CANCER**
- **BIOMARKERS**
- **ECMO**
- **EX-VIVO LUNG PERFUSIÓN**

HIGHLIGHTED PUBLICATIONS

1. Filosso PL, Guerrera F, Falco NR, Thomas P, Yuste MG, Rocco G, Welter S, Casado PM, Rendina EA, Venuta F, Ampollini L, Nosotti M, Raveglia F, Rena O, Stella F, Larocca V, Ardissone F, Brunelli A, Margaritora S, Travis WD, Sagan D, Sarkaria I, Evangelista, Lim, Eric, Papagiannopoulos, Konstantinos, Asamura, Hisao. Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY. FEB 2019. 55 (2). 273-279.
IF: 3.847 Q1

2. Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. LUBAC determines chemotherapy resistance in squamous cell lung cáncer. JOURNAL OF EXPERIMENTAL MEDICINE. FEB 2019. 216 (2). 450-465.
IF: 10.892 Q1 D1

3. Mazo C, Pont T, Ballesteros MA, Lopez E, Rellan L, Robles JC, Rello J. Pneumonia versus graft dysfunction as the cause of acute respiratory failure after lung transplant: a 4-year multicentre prospective study in 153 adults requiring intensive care admission. EUROPEAN RESPIRATORY JOURNAL. SEP 1 2019. 54 (3).
IF: 11.807 Q1 D1

Other publications

1 Alvarez A, Moreno P. Demographic ageing and its influence on current lung transplant practice. JOURNAL OF THORACIC DISEASE. SEP 2019 .11(15). S1992-S1994.
IF: 2.027 Q3

2. Broncano J, Alvarado-Benavides AM, Bhalla S, Alvarez-Kindelan A, Raptis CA, Luna A. Role of advanced magnetic resonance imaging in the assessment of malignancies of the mediastinum. WORLD JOURNAL OF RADIOLOGY. MAR 28 2019. 11 (3). 27-45.

ACTIVITY

Nº ONGOING PROJECTS: 1

GA03: PNEUMOLOGY

TEAM

Last name	First name	
Jurado Gámez	Bernabé	R3
Arenas De Larriva	Marisol	R3
Arenas Vacas	Antonio Pablo	R2
Entrenas Costa	Luis M	R2
Cobos Ceballos	María Jesús	R1
Feu Collado	Nuria	R1
García Gíl	Francisco Luis	R1
Lama Martínez	Rafael	R1
Pascual Martínez	Natalia	R1
Redel Montero	Javier	R1
Santos Luna	Francisco	R1
Vaquero Barrios	José Manuel	R1

SCIENTIFIC PRODUCTION

6	33%	67%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

Networks:

i. SOCIEDAD ESPAÑOLA DE NEUMOLOGÍA Y CIRUGÍA TORÁCICA – SEPAR
ii. ASOCIACIÓN DE NEUMOLOGÍA y CIRUGÍA TORÁCICA DEL SUR - NEUMOSUR
iii. EUROPEAN RESPIRATORY SOCIETY

4 agreements with companies

KEYWORDS

- **CANCER**
- **HYPOXEMIA**
- **CELL DAMAGE**
- **CHRONIC RESPIRATORY DISEASE**
- **METABOLOMICS**
- **PROTEOMICS**
- **TELECARE**
- **TELEMEDICINE**
- **RESPIRATORY THERAPIES**

HIGHLIGHTED PUBLICATIONS:

1. Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, et al. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. Pharmacoecon Open. 2019;3(3):333–342.
IF: 6,966 Q1 D1

2. Pérez de Llano LA, Cosío BG, Domingo C, Urrutia I, Bobolea I, Valero A, Entrenas Costa LM, Quirce S, Barranco P, Marina Malanda N, Andrés LP, Alvarez-Gutiérrez FJ. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019 Sep- Oct;7(7):2277-2283.e2.
IF: 7,55 Q1 D1

3. Campos-Rodriguez F, Asensio-Cruz MI, Cordero-Guevara J, Jurado-Gamez B, Carmona-Bernal C, Gonzalez-Martinez M, Troncoso MF, Sanchez-Lopez V, Arellano-Orden E, Garcia-Sanchez MI, Martinez-Garcia MA; Spanish Sleep Network . Effect of continuous positive airway pressure on inflammatory, antioxidant, and depression biomarkers in women with obstructive sleep apnea: a randomized controlled trial. Sleep. 2019 Oct 9;42(10):zsz145.
IF: 4,571 Q1

4. Sarramea F, Jaén-Moreno MJ, Feu N, et al. Prepare the smoking cessation in severe mental illness: Early diagnosis and prevention opportunities. Preparar la cesación tabáquica en el trastorno mental grave: diagnóstico precoz y oportunidades de prevención. Rev Psiquiatr Salud Ment. 2019;12(2):133–134.
IF: 2,927 Q2

5. Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Montiel FJ, Gomez C, del Pozo GI, Alcala JA, Gutierrez-Rojas L, Balanza-Martinez V, Chauca GM, Carrion L, Osuna MI, Sanchez MD, Caro I, Ayora M, Valdivia F, Lopez MS, Poyato JM, Sarramea F. Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk - TIMER-): study protocol for a randomized controlled trial. Trials. 2019;20(1):47.

ACTIVITY

Nº ONGOING PROJECTS: 1
Nº CLINICAL TRIALS : 4

GA04: ENDOCRINOLOGY AND NUTRITION. INSULIN RESISTANCE, DIABETES AND METABOLISM

TEAM

Last name	First name	
Gálvez Moreno	Mª Ángeles	R3
Calañas Continente	Alfonso	R3
Molina Puerta	Mª José	R3
Palomares Ortega	Rafael	R3
Paniagua González	Juan Antonio	R3
Herrera Martínez	Aura Dulcinea	R3
Alhambra Expósito	Rosa María	R1
Muñoz Jiménez	Concepción	R1
Rebollo Román	Ángel	R1
Padillo Cuenca	José Carlos	R1

SCIENTIFIC PRODUCTION

14	7%	57%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Competitive funding obtained for contracts:

i. Rio Hortega (ISCIII) – Aura Dulcinea Herrera Martínez

2 agreements with companies

AWARD - FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA - Beca SANCYD-VEGENAT de investigación al mejor proyecto en obesidad 2016: Uso de las TIC para control del peso en pacientes con sobrepeso y obesidad.

KEYWORDS

- **INSULIN RESISTANCE**
- **SS-PANCREATIC DYSFUNCTION**
- **PREDIABETES**
- **METABOLIC SYNDROME**
- **ADIPOTOXICITY**
- **ADIPOSE TISSUE**
- **INFLAMMATION**
- **OXIDATIVE STRESS**
- **GENE EXPRESSION**
- **METABOLOMICS**
- **PITUITARY ADENOMA**
- **SOMATOSTATIN RECEPTORS**
- **VITAMIN D**
- **METABOLIC SYNDROME**
- **NEUROENDOCRINE TUMORS**
- **BARIATRIC SURGERY**
- **ADIPOSE TISSUE**
- **HORMONES**
- **DIABETES MELLITUS**
- **FERTILITY**
- **PREGNANCY**

HIGHLIGHTED PUBLICATIONS

1. Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS. 11. 10. 1439.
IF: 6,162 Q: 1 D: 2

2. Herrera-Martinez AD, Pedraza-Arevalo S, L-Lopez F, Gahete MD, Galvez-Moreno MA, Castano JP, Luque RM; Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 1. (57-73).
IF: 5,605 Q: 1

3. Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, L-Lopez F, Ibanez-Costa A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, ; Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513).
IF: 5,605 Q: 1

4. Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castano JP, de Herder WW, Feelders RA; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. DRUGS. 79. 1. (21-42).
IF: 4,993 Q: 1

5. Herrera-Martinez AD, Pedraza-Arevalo S, L-Lopez F, Gahete MD, Galvez-Moreno MA, Castano JP, Luque RM; Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 1. (57-73).
IF: 4,774 Q: 1

ACTIVITY

Nº ONGOING PROJECTS: 2

Nº PROJECTS STARTING IN 2020: 2

Nº CLINICAL TRIALS: 9

MAIN RESULTS

Clinical Guidelines:

Chico, A., Aguilera, E., Ampudia-Blasco, F. J., Bellido, V., Cardona-Hernández, R., Escalada, F. J., Palomares R., González-Blanco, C. Clinical Approach to Flash Glucose Monitoring: An Expert Recommendation. Journal of Diabetes Science and Technology. 14(1). 155-164. DOI: 10.1177/1932296819841911. PMID: 31081362

GA05: STUDY OF GROWTH. ENDOCRINOLOGY AND CHILD NUTRITION

TEAM

Last name	First name	
Cañete Estrada	Ramón	R4
Jiménez Reina	Luis	R4
García Martínez	Elena	R3
Martos Estepa	Rosario	R3
Párraga Quiles	Mª José	R3
Tofé Valera	Inés	R3
Torres Borrego	Javier	R3
Valle Jiménez	Miguel	R3
Vázquez Rueda	Fernando	R3
Ruiz González	Mª Dolores	R3
Cañete Vázquez	Mª Dolores	R3
Gómez Guzmán	Elena	R1

SCIENTIFIC PRODUCTION

10	20%	60%
PUBLICATIONS	PUBLICATIONS IN FIRST DECILE	PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBERobn
ii. PAIDI CTS-329

International projects:

i. Tofé Valera, IM. ALBINO - Effect of allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome. Funding Agency: COMISIÓN EUROPEA. Reference: PHC18-2015-001

KEYWORDS

- **CHILD OBESITY**
- **METABOLIC SYNDROME**
- **DIET**
- **ENDOTHELIUM**
- **INFLAMMATION**
- **CARDIOVASCULAR BIOMARKERS**
- **GENE EXPRESSION**
- **PROTEOMICS**
- **INTRAUTERINE-GROWTH-RETARDATION (IUGR)**
- **GROWTH HORMONE (GH)**
- **FOOD ALLERGY**

HIGHLIGHTED PUBLICATIONS

1. Anguita-Ruiz A, Pastor-Villaescusa B, Leis R, Bueno G, Hoyos R, Vázquez-Cobela R, Latorre-Millán M, Cañete MD, Caballero-Villarraso J, Gil Á, Cañete R, Aguilera CM. Common Variants in 22 Genes Regulate Response to Metformin Intervention in Children with Obesity: A Pharmacogenetic Study of a Randomized Controlled Trial. J Clin Med. 2019 Sep 16;8(9). pii: E1471.
IF: 5,688 D1

2. Moreno-Galdo A, Perez-Yarza EG, Ramilo O, Rubi T, Escribano A, Torres A, Sardon O, Oliva C, Perez G, Cortell I, Rovira-Amigo S, Pastor-Vivero MD, Perez-Frias J, Velasco V, Torres J, Figuerola J, Barrio MI, Garcia-Hernandez G, Mejias A. SAREPREM 3235 Investigators. Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants. 2019.
IF: 4,654 D1 Q1

3. Nuñez-Ramiro A, Benavente-Fernández I, Valverde E, Cordeiro M, Blanco D, Boix H, Cabañas F, Chaffanel M, Fernández-Colomer B, Fernández-Lorenzo JR, Kuligowski J, Loureiro B, Moral-Pumarega MT, Pavón A, Sánchez-Illana A, Tofé I, Hervás D, García-Robles A, Parra-Llorca A, Cernada M, Martinez-Rodilla J, Lorente-Pozo S, Llorens R, Marqués R, Vento M; on behalf of the Hypotop Study Group. Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded Trial. Neonatology. 2019;116(1):76-84.
IF: 2,688 Q1

4. Moreno M, Castillo-Corullón S, Pérez-Ruiz E, Luna MC, Antón-Pacheco JL, Mondejar-Lopez P, De-la-Serna O, Villa JR, Osona B, Torres-Borrego J, Santiago-Burruchaga M, Asensio O, Andres-Martin A, Delgado-Pecellin I, González Y, Palmero A, Escribano A. Spanish multicentre study on morbidity and pathogenicity of tracheal bronchus in children. Pediatr Pulmonol. 2019 Oct;54(10):1610-1616.
IF: 2,801 Q1

5. Ruiz-Ojeda FJ, Anguita-Ruiz A, Rupérez AI, Gomez-Llorente C, Olza J, Vázquez-Cobela R, Gil-Campos M, Bueno G, Leis R, Cañete R, Moreno LA, Gil A, Aguilera CM. Effects of X-chromosome Tenomodulin Genetic Variants on Obesity in a Children's Cohort and Implications of the Gene in Adipocyte Metabolism. Sci Rep. 2019 Mar 8;9(1):3979.
IF: 4,011 Q1

ACTIVITY

Nº ONGOING PROJECTS: 2

Nº CLINICAL TRIALS: 7

Nº PHD THESES: 1

GA08: RADIOLOGY

TEAM

Last name	First name	
Álvarez Benito	Marina	R4
Blanco Negrero	Marta	R3
Bravo Rey	Isabel Mª	R3
Bravo Rodríguez	Francisco de Asís	R3
Cara García	María	R3
Contreras De Miguel	Elvira	R3
Cortés García	José Ignacio	R3
Delgado Acosta	Fernando	R3
Elias Cabot	Esperanza	R3
Escribano Fernández	José	R3
Espejo Herrero	Juan José	R3
Fernández López	Isabel Mª	R3
Fernández Valverde	Francisco	R3
García Jurado	Pedro Blas	R3
García Ortega	Mª José	R3
García-Revillo García	José	R3
Izquierdo Palomares	Lucía Nuria	R3
Jiménez Gómez	Elvira	R3
Lombardo Galera	Mª Sagrario	R3
Martín Rodríguez	Cristina	R3
Mesa Quesada	Juan	R3
Muñoz Carrasco	Rafaela	R3
Muñoz Sánchez	Raquel	R3
Oteros Fernández	Rafael	R3
Pedrosa Garriguet	Margarita	R3
Pérez Montilla	Mª Eugenia	R3
Pulido Carmona	Cristina	R3
Roldán Romero	Elisa	R3
Romero Martín	Sara	R3
Vicente Rueda	Josefa	R3
Sanabria Gay	Ana Belén	R3
Benito Ysamat	Alberto	R2
Espejo Pérez	Simona	R2
López Ruiz	Daniel	R2
Gordillo Arnau	José Enrique	R2
Ramos Gómez	Manuel	R2
Raya Povedano	José	R2
Rudski Ricondo	Luciana	R2
Segui Azpilicueta	Pedro	R2
Amate Rivas	Cristina	T
Cerro Luna	Ana Isabel	T

SCIENTIFIC PRODUCTION

6	33%	50%
publications	publications in first decile	publications in first quartile

ADDITIONAL INFORMATION

3 agreements with companies

AWARD - Garrido Castro, Juan Luis. FOREUM Abstract Award 2019 Funding Agency Foundation for Research in Rheumatology (FOREUM) Reference: FOREUM_AWARD19/01.

KEYWORDS

- **CLINICAL TRIALS**
- **RHEUMATIC DISEASES**
- **STEM CELLS**
- **PATHOCHRONY**
- **ARTERIAL ISCHEMIA OF THE LOWER LIMBS**
- **RADIOLOGICAL ASSESSMENT OF RESPONSE**
- **TO DRUGS**
- **THERAPEUTIC ANGIOGÉNESIS**
- **DIAGNOSTIC RADIOLOGICAL SCANS**
- **NEOPLASMS**
- **THERAPEUTIC RADIOLOGICAL SCANS**
- **DEMYELINATING DISEASES**

HIGHLIGHTED PUBLICATIONS

1. Garcia AG, Moniche F, Escudero-Martinez I, Mancha F, Tomasello A, Ribo M, Delgado-Acosta F, Ochoa JJ, de las Heras JA, Lopez-Mesonero L, Gonzalez-Delgado M, Murias E, Gil J, Gil R, Zamarro J, Parrilla G, Mosteiro S, Fernandez-Couto MD, de Alarcon LF, Rami; Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting Results From a National Prospective Multicenter Study. JACC-CARDIOVASCULAR INTERVENTIONS. 12. 9. (873-882).
IF: 9,544 Q1 D1

2. Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103).
IF: 4,915 Q1 D1

3. Delgado F, Oteros R, Jimenez-Gomez E, Rey IB, Bautista MD, Moyano RV; Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment. JOURNAL OF NEUROINTERVENTIONAL SURGERY. 11. 2. (147-152).
IF: 3,526 Q1

4. Moreno-Sanchez T, Moreno-Ramirez M, Machancoses FH, Pardo-Moreno P, Navarro-Vergara PF, Garcia-Revillo J; Efficacy of Paclitaxel Balloon for Hemodialysis Stenosis Fistulae After One Year Compared to High-Pressure Balloons: A Controlled, Multicenter, Randomized Trial. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY.
IF: 1,928 Q3

5. Gomez EJ, Rey IB, Fernandez RO, Acosta FD; Endovascular treatment of stroke in children under 2 years with heart failure and ventricular assist device. INTERVENTIONAL NEURORADIOLOGY. 25. 5. (516-520).
IF: 1,45 Q4

ACTIVITY

Nº ONGOING PROJECTS: 1

Nº CLINICAL TRIALS: 1

Nº PHD THESES: 1

GA09: CARDIOVASCULAR PATHOLOGY

TEAM

Last name	First name	
Muñoz Carvajal	Ignacio	R4
Blázquez Ruiz	María Del Valle	R3
Casares Mediavilla	Jaime Guillermo	R3
Chacón Quevedo	Antonio	R3
Elías Fuentes	Agustín	R3
Hervás Sotomayor	Daniela	R3
Jiménez Castilla	Agustina	R3
Moya González	Javier	R3
Narváez De Vera	Miguel Ángel	R3
Pernía Oreña	Isabel	R3
Sartor	Lucio	R3
Alados Arboledas	Pedro José	R2
Merino Cejas	Carlos Manuel	R2
Zurita Martínez	Federico	R2
Conejero Jurado	María Teresa	R1
Bilbao Carrasco	Lucía	R1
Domínguez del Castillo	José Joaquín	R1
Fernández Carbonell	Azahara	R1
González Caldevilla	Alejandro	R1
Inga Távara	Laura Isabel	R1
Turegano Cisneros	José María	R1
Cabrera Arenas	Inmaculada	N
Caliz Fuentes	Javier	N
Jurado Morata	Aurea	N
López Romero	Rosalía	N
Riballo Cortes	Raquel	N
Romero Morales	María del Carmen	ADM
Ferres Serrano	Juan José	T

SCIENTIFIC PRODUCTION

5
PUBLICATIONS

60%
PUBLICATIONS IN FIRST QUARTILE

ACTIVITY

Nº ONGOING PROJECTS: 1

Nº CLINICAL TRIALS: 4

ADDITIONAL INFORMATION

International projects:

i. Muñoz Carvajal, I. STARS - Empowering Patients by Professional Stress Avoidance and Recovery Services. Funding agency: European Commission H2020. Reference: PM-12-2016-002

1 agreement with companies

KEYWORDS

- **CARDIOVASCULAR**
- **CARDIAC SURGERY**

HIGHLIGHTED PUBLICATIONS

1. Couto-Mallon D, Gonzalez-Vilchez F, Almenar-Bonet L, Diaz-Molina B, Segovia-Cubero J, Gonzalez-Costello J, Delgado-Jimenez J, Castel-Lavilla MA, Crespo-Leiro MG, Rangel-Sousa D, Martinez-Selles M, Rabago-Juan-Aracil G, De-la-Fuente-Galan L, Blasco-Peiro T, Hervás-Sotomayor D; Prognostic Value of Serum Lactate Levels in Patients Undergoing Urgent Heart Transplant: A Subanalysis of the ASIS-TC Spanish Multicenter Study. REVISTA ESPAÑOLA DE CARDIOLOGIA. 2019 Mar;72(3):208-214.
IF: 5,126 Q1

2. Barge-Caballero E, Gonzalez-Vilchez F, Delgado JF, Mirabet-Perez S, Gonzalez-Costello J, Perez-Villa F, Martinez-Selles M, Segovia-Cubero J, Hervás-Sotomayor D, Blasco-Peiro T, De la Fuente-Galan L, Lambert-Rodriguez JL, Rangel-Sousa D, Almenar-Bonet L, G; Use of Intra-aortic Balloon Pump as a Bridge to Heart Transplant in Spain: Results From the ASIS-TC Study. REVISTA ESPAÑOLA DE CARDIOLOGIA. 2019 Oct;72(10):835-843.
IF: 5,126 Q1 D2

3. Rodriguez-Caulo EA, Macias D, Adsuar A, Ferreiro A, Arias-Dachary J, Parody G, Fernandez F, Daroca T, Rodriguez-Mora F, Garrido JM, Munoz-Carvajal I, Barquero JM, Valderrama JF, Melero JM; Biological or mechanical prostheses for isolated aortic valve replacement in patients aged 50-65 years: the ANDALVALVE study. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY. 2019 Jun 1;55(6):1160-1167.
IF: 3,847 Q1

4. Barge-Caballero G, Castel-Lavilla MA, Almenar-Bonet L, Garrido-Bravo IP, Delgado JF, Rangel-Sousa D, Gonzalez-Costello J, Segovia-Cubero J, Farrero-Torres M, Lambert-Rodriguez JL, Crespo-Leiro MG, Hervas-Sotomayor D, Portoles-Ocampo A, Martinez-Selles M, ; Venoarterial extracorporeal membrane oxygenation with or without simultaneous intra-aortic balloon pump support as a direct bridge to heart transplantation: results from a nationwide Spanish registry. INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY. 2019 Nov 1;29(5):670-677.
IF: 1,931 Q2

5. Perez-Navero JL, Merino-Cejas C, de la Rosa II, Jaraba-Caballero S, Frias-Perez M, Gomez-Guzman E, Gil-Campos M, de la Torre-Aguilar MJ; Evaluation of the vasoactive-inotropic score, mid-regional pro-adrenomedullin and cardiac troponin I as predictors of low cardiac output syndrome in children after congenital heart disease surgery. MEDICINA INTENSIVA. 2019 Aug - Sep;43(6):329-336.
IF: 1,982 Q3

GA10: NUCLEAR MEDICINE

TEAM

Last name	First name	
Vallejo Casas	Juan Antonio	R3
Moreno Ortega	Estefanía	R3
Mena Bares	Luisa María	R2
Pacheco Capote	Carmen	R2
Albalá González	María Dolores	R1
Benítez Velasco	Ana	R1
Carmona Asenjo	Elvira	R1
Maza Muret	Fº Roberto	R1
Guiote Moreno	María Victoria	R1
Márquez Fernández	Juan	R1
Prieto Prieto	Juan Carlos	R1
Rodríguez Cáceres	Esther	R1
Santos Bueno	Antonio María	R1
Zurera Pareja	Rocío	R1
Martín Ruiz	Antonio	T
Moriana Porras	María del Carmen	T
Rojas Arroyo	Anahí	T

SCIENTIFIC PRODUCTION

1

PUBLICATIONS

ADDITIONAL INFORMATION

2 agreements with companies

KEYWORDS

- **NUCLEAR MEDICINE**

HIGHLIGHTED PUBLICATIONS

1. Mena-Bares LM, Benitez-Cantero JM, Iglesias-Flores E, Gros-Alcalde B, Moreno-Ortega E, Maza-Muret FR, Carmona-Asenjo E, Garcia-Sanchez MV, Vallejo-Casas JA. Bile acid malabsorption in patients with chronic diarrhea and Crohn's disease. REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS. 111 (1). 40-44.
IF: 1,858 Q4

Other publications

1. Garcia-Figueiras, Roberto; Baleato-Gonzalez, Sandra; Padhani, Anwar R.; Luna-Alcala, Antonio; Antonio Vallejo-Casas, Juan; Sala, Evis; Vilanova, Joan C.; Koh, Dow-Mu; Herranz-Carnero, Michel; Alberto Vargas, Herbert. How clinical imaging can assess cancer biology. INSIGHTS INTO IMAGING. MAR 4 2019. 10 (1) UNSP 28

GA11: LEARNING AND ARTIFICIAL NEURAL NETWORKS

TEAM

Last name	First name	
Hervás Martínez	César	R4
Gutiérrez Peña	Pedro A.	R3
Becerra Alonso	David	R3
Carbonero Ruz	Mariano	R3
De La Paz Marín	Mónica	R3
Fernández Caballero	Juan Carlos	R3
Fernández Navarro	Francisco	R3
García Alonso	Carlos	R3
Martínez Estudillo	Alfonso Carlos	R3
Martínez Estudillo	Francisco José	R3
Pérez Ortiz	María	R3
Rodero Cosano	Mª Luisa	R3
Salcedo Sanz	Sancho	R3
Salinas Pérez	José A.	R3
Sánchez Monedero	Javier	R3
Torres Jiménez	Mercedes	R3
Dorado Moreno	Manuel	R2
Durán Rosal	Antonio M	R2
Barbero Gómez	Javier	R1
Guijo Rubio	David	R1
Vargas Yún	Víctor	R1

SCIENTIFIC PRODUCTION

4
PUBLICATIONS

75%
PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:
i. DAMA Network
ii. MAPAS Network

KEYWORDS

- **ORDINAL CLASSIFICATION**
- **ARTIFICIAL NEURAL NETWORKS**
- **PROCESSING OF BIOMEDICAL IMAGES**
- **TIME SERIES SEGMENTATION**
- **REGRESSION MODELS**
- **ORDINAL REGRESSION**
- **EVOLUTIONARY COMPUTATION**

HIGHLIGHTED PUBLICATIONS

Other publications

1. Duran-Rosal AM, Gutierrez PA, Carmona-Poyato A, Hervas-Martinez C; A hybrid dynamic exploitation barebones particle swarm optimisation algorithm for time series segmentation. NEUROCOMPUTING. 353. (45-55).
IF: 4,072 Q1

2. Sanchez-Monedero J, Gutierrez PA, Perez-Ortiz M; ORCA: A Matlab/Octave Toolbox for Ordinal Regression. JOURNAL OF MACHINE LEARNING RESEARCH. 20 (1-5).
IF: 4,091 Q1

3. Comino F, Guijo-Rubio D, de Adana MR, Hervas-Martinez C; Validation of multitask artificial neural networks to model desiccant wheels activated at low temperature. INTERNATIONAL JOURNAL OF REFRIGERATION-REVUE INTERNATIONALE DU FROID. 100. (434-442).
IF: 3,177 Q1

4. Fernandez JC, Carbonero M, Gutierrez PA, Hervas-Martinez C; Multi-objective evolutionary optimization using the relationship between F-1 and accuracy metrics in classification tasks. APPLIED INTELLIGENCE. 49. 9. (3447-3463).
IF: 2,882 Q2

5. Duran-Rosal AM, Gutierrez PA, Salcedo-Sanz S, Hervas-Martinez C; Dynamical memetization in coral reef optimization algorithms for optimal time series approximation. PROGRESS IN ARTIFICIAL INTELLIGENCE. 8. 2. (253-262).

ACTIVITY

Nº ONGOING PROJECTS: 2
Nº PHD THESES: 2

GA12: SEVERE MENTAL ILLNESS-HEALTH ALERTS

TEAM

Last name	First name	
Sarramea Crespo	Fernando	R3
Gutiérrez Rojas	Luis	R3
Luque Luque	Rogelio	R3
Alcalá Partera	Jose Ángel	R2
Jaén Moreno	María José	R2
Feu	Nuria	R2
Carrión Exposito	Laura	R1
Chauca Chauca	Geli Marie	R1
Del Pozo Seseña	Gloria Isabel	R1
Gómez Moreno	Cristina	R1
López Carnerero	Mª Soledad	R1
Montiel López	Francisco Javier	R1
Osuna Carmona	María Isabel	R1
Padilla Obrero	Leonor	R1
Prada Carrasco	Carmen	R1
Prados Ojeda	Juan Luis	R1
Redondo Écija	Justa	R1
Sánchez Martínez	Mª Dolores	R1
Valdivia Romero	Francisca	R1
Zurita Gotor	Pilar	R1
Ruiz Rull	Cristina Esther	R1

SCIENTIFIC PRODUCTION

5
PUBLICATIONS

40%
PUBLICATIONS IN FIRST QUARTILE

ADDITIONAL INFORMATION

Networks:

i. CIBERSAM (Grupo 05)
ii. Grupo PAIDI (CTS 550)
iii. GETBA (Grupo para el Estudio del Trastorno bipolar en Andalucía)

KEYWORDS

- **SEVERE MENTAL DISORDER**
- **SCHIZOPHRENIA**
- **BIPOLAR DISORDER**
- **TOBACCO CESSATION**
- **MORTALITY**
- **READINESS TO CHANGE**
- **CHRONIC OBSTRUCTIVE PULMONARY DISEASE**
- **SCREENING**

HIGHLIGHTED PUBLICATIONS

1. Carbone EA, Pugliese V, Bruni A, Aloi M, Calabro G, Jaen-Moreno MJ, Segura-Garcia C, De Fazio P; Adverse childhood experiences and clinical severity in bipolar disorder and schizophrenia: A transdiagnostic two-step cluster analysis. JOURNAL OF AFFECTIVE DISORDERS. 259. (104-111).
IF: 4,084 Q1 D2

2. Sarramea F, Jaen-Moreno MJ, Balanza-Martinez V, Osuna MI, Alcala JA, Montiel FJ, Gomez C, Sanchez MD, Rico AB, Redondo-Ecija J, Gil S, Valdivia F, Caballero-Villarraso J, Gutierrez-Rojas L; Setting the stage to quit smoking in Bipolar Disorder patients: brief advice in clinical practice. ADICCIONES. 31. 2. (136-145).
IF: 3,167 Q1

3. Tamayo-Agudelo W, Jaen-Moreno MJ, Leon-Campos MO, Holguin-Lew J, Luque-Luque R, Bell V; Validation of the Spanish-language Cardiff Anomalous Perception Scale. PLOS ONE. 14. 3.
IF: 2,776 Q2

4. Crespo FS, Jaen-Moreno MJ, Gutierrez-Rojas L, Balanza-Martinez V, Garcia-Alvarez L, Martinez PAS, Garcia-Portilla MP, Guler I, Bobes J; Readiness to Change Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. EUROPEAN ADDICTION RESEARCH. 25. 5. (256-262).
IF: 2,653 Q2

5. Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Montiel FJ, Gomez C, del Pozo GI, Alcala JA, Gutierrez-Rojas L, Balanza-Martinez V, Chauca GM, Carrion L, Osuna MI, Sanchez MD, Caro I, Ayora M, Valdivia F, Lopez MS, Poyato JM, Sarramea F; Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk TIMER): study protocol for a randomized controlled trial. TRIALS. 20.
IF: 1,975 Q3

ACTIVITY

Nº ONGOING PROJECTS: 1

8.3 Other scientific contributions by the hospital

MEDICAL SERVICES	Nº PUBLICATIONS	Q1	D1
CLINICAL ANALYSES UNIT	8	50%	13%
DIGESTIVE SYSTEM UNIT	27	41%	22%
CARDIOLOGY UNIT	30	67%	10%
CARDIOVASCULAR SURGERY UNIT	5	60%	-
GENERAL SURGERY UNIT	29	52%	21%
ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT	1	-	-
PAEDIATRIC SURGERY UNIT	1	-	-
THORACIC SURGERY AND LUNG TRANSPLANTATION UNIT	3	67%	33%
INTENSIVE CARE UNIT	9	44%	11%
ENDOCRINOLOGY AND NUTRITION UNIT	18	44%	11%
INFECTIOUS DISEASES UNIT	48	71%	31%
PHARMACY UNIT	5	20%	-
GYNECOLOGY & OBSTRETRICS UNIT	3	-	-
HEMATOLOGY UNIT	15	13%	-
IMMUNOLOGY AND ALLERGOLOGY UNIT	13	62%	8%
PATHOLOGICAL ANATOMY UNIT	10	60%	40%
DERMATOLOGY UNIT	12	58%	33%
MAXILOGACIAL SURGERY UNIT	1	-	-
INTERNAL LEVELS OF PREVENTION, PROMOTION AND HEALTH SURVEILLANCE UNIT	1	100%	-
RADIOLOGY AND BREAST CANCER UNIT	8	38%	25%
INTERNAL MEDICINE UNIT	51	63%	20%
NUCLEAR MEDICINE UNIT	1	-	-
MICROBIOLOGY UNIT	23	61%	26%
NEPHROLOGY UNIT	24	38%	21%
PNEUMOLOGY UNIT	8	63%	25%
NEUROSURGERY AND NEUROPHYSIOLOGY UNIT	3	67%	-
NEUROLOGY UNIT	9	56%	22%
OPTHALMOLOGY UNIT	4	75%	50%
MEDICAL ONCOLOGY UNIT	31	65%	39%
PEDIATRICS UNIT	28	54%	14%
RHEUMATOLOGY UNIT	22	55%	14%
MENTAL HEALTH UNIT	8	25%	-
EMERGENCIES UNIT	6	83%	33%
UROLOGY UNIT	11	55%	27%

9. Platforms and networks

IMIBIC researchers are involved in a wide range of strategic initiatives coordinated by the National Institute of Health Carlos III (ISCIII). These include the Networks for Cooperative Research in Health (RETICs in Spanish) and in the Biomedical Research Networking Centers (CIBERs in Spanish). In addition, IMIBIC is a member of two European infrastructure and several other national and international networks.

Among the 44 groups integrated into the IMIBIC, 23 participate in partnership programs related to different strategic initiatives of the ISCIII. 12 groups are involved in 8 different RETICs. Additionally, 11 groups are involved in 6 CIBERs and there are 35 groups involved in the Andalusian Plan for Research, Development & Innovation (PAIDI Program).



CIBER PROGRAM

Our researchers lead or participate in the following CIBER nodes:

Principal Investigator (PI) / Collaborators
CIBER on Obesity and Nutrition (CIBERobn)
Dr. José López Miranda (PI)
Dr. Manuel Tena-Sempere (PI)
Dr. Mercedes Gil Campos (PI)
Dr. Mª Mar Malagón Poyato
Dr. Justo P. Castaño Fuentes
CIBER on Liver and Digestive Diseases (CIBERehd)
Dr. Manuel de la Mata García (PI)
CIBER on Rare Diseases (CIBERER)
Dr. Eduardo López Laso
Dr. Rafael Camino León
CIBER on Fragility and Healthy Aging (CIBERFES)
Dr. José Manuel Quesada Gómez (PI) (retired in August 2019)
Dr. Feliciano Priego Capote
Dr. Manuel Rich Ruiz
CIBER on Cancer (CIBERONC)
Dr. Enrique Aranda Aguilar (PI)
CIBER on Mental Health (CIBERSAM)
Dr. Fernando Sarramena Crespo

RETICS

ISCIII Networks for Cooperative Research in Health that IMIBIC is involved in:

Principal Investigator (PI)/ Collaborators
AIDS Research Network (RIS)
Dr. Antonio Rivero Román (PI)
The Spanish Renal Research Network (REDinREN)
Dr. Pedro Aljama García (PI)
Dr. Mariano Rodríguez Portillo
Spanish Network for Research in Infectious Diseases (REIPI)
Dr. Julián de la Torre Cisneros (PI)
Dr. Rafael Solana Lara
Dr. Luis Martínez Martínez
The Spanish Biobank Network
Dr. Manuel Medina Pérez
Primary Care Prevention and Health Promotion Network (RedIAPP)
Dr. Luis A. Pérula de Torres
Spanish Network for asthma, adverse and allergic reactions (ARADYAL)
Dra. Carmen Moreno Aguilar (PI)
The Research Network for Inflammation and Rheumatic Diseases (RIER)
Dr. Eduardo Collantes Estévez (PI)
The Spanish Network of Multiple Sclerosis (REEM)
Dr. Eduardo Agüera Morales (PI)
Dr. Isaac Túnez Fiñana
Healthcare Research Unit (Investén-ISCIII)
Dr. Manuel Rich Ruiz
Eye Diseases: Prevention, early detection and treatment of prevalent, degenerative and chronic ocular pathology OFTARED ISCIII
Dr. José María Gallardo Galera (PI)

OTHER

IMIBIC is a member of the following national and international networks, platforms and infrastructures:

- Medical Technology Innovation Platform (ITEMAS)
- Clinical Research and Clinical Trials Units Platform (SCReN)
- European Infrastructure for Translational Medicine (EATRIS)
- Spanish Translational Network (TransBioNet)
- European Network on Pseudomyxoma Peritonei (EuroPMP)
- Epigenetic Chemical Biology (epichembio)
- Network for Research in Vascular Ageing (VascAgeNet)
- European Clinical Research Infraestructure Network (ECRIN)

THE ANDALUSIAN PLAN FOR RESEARCH, DEVELOPMENT AND INNOVATION (PAIDI)

Many IMIBIC researchers belong to or lead groups formed under the Andalusian Plan for Research, Development and Innovation (PAIDI, in Spanish).

BIO-139. Principal investigator: Justo P. Castaño Fuentes
BIO-139. Collaborator: María Del Mar Malagón Poyato
BIO-139. Collaborator: Raúl Miguel Luque Huertas
BIO-216. Principal investigator: José Antonio Bárcena Ruiz
BIO-272. Principal investigator: Manuel Ruiz Rubio
BIO-301. Principal investigator: Rafael Rodríguez Ariza
BIO-310. Principal investigator: Manuel Tena Sempere
BIO-304. Collaborator: Ángel Salvatierra Velázquez
CTS-208. Collaborator: Rafael Solana Lara
CTS-179. Principal investigator: Escolástico Aguilera Tejero
CTS-212. Principal investigator: Pablo Pérez Martínez
CTS-273. Principal investigator: Manuel de la Mata García
CTS-234. Principal investigator: Enrique Aranda Aguilar
CTS-260. Principal investigator: Pedro Aljama García
CTS-273. Collaborator. Francisco Javier Briceño Delgado
CTS-329. Principal investigator: Ramón Cañete
CTS-413. Principal investigator: José Manuel Quesada Gómez
CTS-452. Principal investigator: Luis A. Pérula de Torres
CTS-525. Principal investigator: José López Miranda
CTS 550. Principal investigator: Fernando Sarramea
CTS-639. Principal investigator: María Mercedes Gil Campos
CTS-620. Principal investigator: Francisco Velasco Gimena
CTS-624. Principal investigator: Isaac Túnez Fiñana
CTS-647. Principal investigator: Julián Carlos de la Torre Cisneros
CTS-651. Principal investigator: Juan Antonio Paniagua González
CTS-666. Principal investigator: Aurora Rodríguez Borrego
CTS-985. Principal investigator: José Peña Amaro
CTS-992. Principal investigator: Bernabé Jurado Gámez
CTS-1004. Principal investigator: Eduardo Collantes Estevez
CTS-1041. Principal investigator: Juan Alberto Ruano Ruiz
FQM-227. Principal investigator: María Dolores Luque de Castro
HUM-414. Principal investigator: Carmen Tabernero Urbieta
HUM-924. Principal investigator: Juan Antonio Moriana
TIC-122. Principal investigator: Sebastián Ventura Soto
TIC-148. Principal investigator: César Hervás Martínez
TIC-161. Principal investigator: Rafael Medina Carnicer

10. Training

The Institute conceives training as a fundamental institutional tool to fulfil and improve its scientific goals. Thus, a multifaceted program is designed on an annual basis to foster and provide high-quality scientific training to our researchers, which is adapted to the different stages of their scientific career. It includes the organization of an annual program of seminars by known national and international leaders in trending scientific topics, and courses that cover concepts related to our current lines of research as well as practical applications on the latest technologies. Along with these activities, the Institute maintains two key training activities: the annual Young Investigators Meeting, aimed at fostering the interaction and exchange of knowledge among our youngest researchers, and the "Maimonides Commemorative Lecture" which includes lectures by leading experts in Biomedicine, and is intended to recognize and award our top scientists. Finally, IMIBIC is responsible for the PhD Program in Biomedicine and also participates in two additional PhD programs of the University of Cordoba, that, in all, are aimed to train highly qualified researchers, promote teaching and favour professional qualification in the field of biomedical sciences.
Training Program Director: Prof. Raúl M. Luque Huertas, PhD.

10.1 Training Programs

PHD IN BIOMEDICINE

IMIBIC leads a unique PhD Program in Biomedicine. This program, coordinated by Prof. Dr. Luis Martínez Martínez, aims to train qualified professionals and to promote the development of professional skills in the field of biomedical sciences.

Website: https://www.uco.es/estudios/idep/doctorado-programas-biomedicina

MASTER'S DEGREES

The Master's Degree Program associated to IMIBIC encompasses three degrees, one of them led by a member of the IMIBIC, as follows
- Translational Biomedical Research
Academic Director: Prof. Raúl M Luque Huertas, PhD. (IMIBIC)

Website: https://www.uco.es/estudios/idep/investigacion-biomedica-traslacional

TRAINING ACTIVITIES IN 2019



COURSES AND WORKSHOPS

Specific courses, seminars and other training activities in different research areas were held during 2019 at the IMIBIC.

TITLE	DURATION	ORGANISER
Análisis Estadístico con SPSS	4 hours	IMIBIC
¿Cómo calcular el tamaño muestral? Estimación puntual y contrastes de hipótesis	2,5 hours	IMIBIC
32nd IEEE CBMS International Symposium on Computer-Based Medical Systems	23 hours	IMIBIC-CBMS
4th Edition Systematic Reviews & Meta-analyses	7,9 ECTS	IMIBIC-HURS
Análisis de imagen con FIJI para imágenes de fluorescencia e histología.	2 hours	IMIBIC
Análisis Estadístico con SPSS	4 hours	IMIBIC
Comunicar y difundir. Buenas prácticas en el uso y manejo de la información en Ciencias de la Salud.	5 hours	IMIBIC-BVSSPA
Contexto de la Investigación Biomédica y carrera profesional	3 hours	IMIBIC
Cronoprevención caídas intrahospitalarias	1 hour	IMIBIC
Radiodiagnóstico en cáncer de próstata	4,5 hour	IMIBIC
Developing Skills in Scientific Writing	16 hours	IMIBIC- Fundación Esteve
Enfermería basada en la evidencia	8 hours	IMIBIC
Funcionamiento, reglamento y composición del Comité para la Integridad de la Investigación	2 hours	IMIBIC-UCO
Gestión de Innovación. Identificación de Ideas, valorización y comercialización	1 hours	IMIBIC
H2020 Proyectos de Investigación	1 hour	IMIBIC
Herramientas clave para la protección de los resultados de investigación y su transferencia	1 hour	IMIBIC
Impulso de la Investigación e Innovación en el Sistema Sanitario Público de Andalucía	4 hours	IMIBIC-Consejería la Salud y Familias
Incorporación de la perspectiva de género en la investigación	5 hours	IMIBIC
Iniciación al software estadístico R con aplicaciones en la investigación biomédica	8 hours	IMIBIC
Introducción a la propiedad industrial e intelectual en el sector biomédico	2,5 hours	IMIBIC-Consejería la Salud y Familias
Jornada de Drug Discovery "Programas de investigación para descubrimiento de fármacos"	5 hours	IMIBIC, CIBERER y ASEBIO
Jornada sobre los aspectos regulatorios claves para la llegada a fases clínicas de los resultados de investigación	5,5 hours	IMIBIC
MIRA (Mutatios Identification for RNA Alternations)	1 hour	IMIBIC
Non alcoholic fatty liver disease and the metabolic disease	45 minutes	IMIBIC
Patologías asociadas a alteraciones de la regulación del FGF23	5 hours	IMIBIC-HURS
Propiedad Industrial e Intelectual en el Sistema Sanitario Público Andaluz (Patenta Salud)	2,5 hours	IMIBIC
Realización de mamografías en cribado de cáncer de mama	10 hours	IMIBIC
Reunión del comité del pulmón "Tratando juntos al paciente EGFRm+ desde el Comité Multidisciplinar de CP"	2,5 hours	IMIBIC-Consejería comité Salud y Familias
XXII Reunión de actualización en tratamiento oncológico: Cáncer de mama	5 hours	IMIBIC-Consejería de Salud y Familias
Buenas prácticas de documentación en investigación clínica	1 hour	IMIBIC
XIII Curso de Actualización "Escenarios clínicos de la práctica diaria en Diabetes Tipo 2"	4,5 hours	IMIBIC-HURS-Colegio de Médicos

EVENTS AND CONFERENCES

TITLE	DURATION	ORGANISER
I Jornada sobre Comunicación Sanitaria en Andalucía "Llegar al entorno online desde el offline"	7 hours	IMIBIC-HURS
Detección de oportunidades y valorización	1,5	IMIBIC
Electrocardiografía Clinica	10 hours	Servicio Cardiologia HURS, Sociedad Andaluza de Cardiología
Nanomateriales	9,5 hours	IMIBIC
Foro Único del Consejo Social de la UCO	2 hours	IMIBIC
Jornada de Actualización en Inmunoterapia	5 hours	Fufosa y HURS
Premios IMIBIC-Roche	11,5 hours	IMIBIC-Roche
Campaña OEPM-ITEMAS: LAS PATENTES, HERRAMIENTA CLAVE PARA LA INVESTIGACIÓN	1 hour	IMIBIC
EuroPMP Workshop: Pseudomixoma Peritoneal	10 hours	IMIBIC: Dr. Arjona y Dr. Romero
Tumores de Baja Prevalencia	3,5 hours	Kentours Producciones y Eventos, S.L.
I Jornada uso optimización opioides	11,5 hours	UGC Anestesiología
I Reunión de manejo de los efectos secundarios inmunomediados	5,5 hours	Dra. Cristina Morales
II Certamen casos quirúrgicos en Glaucoma	3 hours	Allergan
Jornada Enfermedades raras	10 hours	IMIBIC
Jornada anual SVEA (Sistema de Vigilancia Epidemiológica de Andalucía)	10 hours	Escuela Andaluza de salud pública
Dificultades en la atención Sanitaria hacia la violencia de género en el SSPA	4,5 hours	IMIBIC - Escuela Andaluza de salud pública
I Jornada IMIBIC "Investigando en Familia" y I Premio IMIBIC "Imaginación para la Investigación"	6 hours	IMIBIC
V Jornada de Investigación Traslacional en Enfermedades Raras: últimos avances en enfermedades metabólicas hereditarias	9 hours	IMIBIC-Consejería de Salud y Familias

Vª EDICIÓN ESTIMULACIÓN MAGNÉTICA TRANSCRANEAL Y NEUROMODULACIÓN	8,5 hours	IMIBIC-Consejería ESTIMULACIÓN Salud y Familias
XIX Jornadas científicas de Medicina Familiar y Comunitaria de Córdoba	17 hours	IMIBIC-Consejería científicas Salud y Familias
IX Lección Conmemorativa Maimónides	3,5 hours	IMIBIC
Jornadas Jóvenes Investigadores 2019	11,5 hours	IMIBIC
I Jornada de Mejora de la Investigación en Atención Primaria	6 hours	IMIBIC-Consejería de Salud y Familias

OTHER ACTIVITIES

TYPE OF ACTIVITY	TITLE	DURATION	ORGANIZER
CLINICAL SESSION	Reunión Inmunoterapia	4,5 hours	Otros
INFO SESSION	IMIBIC-P2Med Postdoctoral programme	2 hours	IMIBIC
TECHNICAL SEMINAR	MERCK DAY	3 hours	MERCK
CLINICAL SESSION	Reinheart	8 hours	
CLINICAL SESSION	Simposio cardiometabólio	6 hours	IMIBIC
BOOK RELEASE	"Patologías asociadas a alteraciones de la regulación del FGF23"	5 hours	kYOWAKIRIN
WORKSHOP	Taller Pfizer	5 hours	Gerente HURS
CLINICAL SESSION	ACTUALIZACIÓN EN EL TRATAMIENTO DE LA LLC Y EL LLP	1 hour	Janssen
CLINICAL SESSION	Reunión del comité de pulmón	2,5 hours	DR. Isidoro Barneto
CLINICAL SESSION	Reunión del comité del pulmón "Tratando juntos al paciente EGFRm+ desde el Comité Multidisciplinar de CP"	2,5 hours	Tagrisso
INFO SESSION	Assembly de un proyecto europeo de Cirugía Cardiovascular (Proyecto STARS)	18,5 hours	IMIBIC
INFO SESSION	Convocatorias de Recursos Humanos de la Comisión Europea H2020: Marie Sklodowska Curie Actions - Individual Fellowships (MSCA-IF) e ERC Starting, Consolidator y Advanced Grants	1 hour	IMIBIC

10.2 Training activities

IMIBIC RESEARCH SEMINARS

Regular seminars and research events offer the opportunity to meet recognized national and international speakers covering a diverse range of topics in biomedicine. IMIBIC research seminars promote networking and contribute to strengthening the knowledge of the research community of the Institute. The Institute launches a yearly cycle of seminars aimed at promoting interactions, sharing ideas, and strengthening the bonds among IMIBIC scientists and recognised scientist from other research institutions. In 2019, a total of 19 external seminars were presented.
In addition, young researchers (preferentially post-doctoral researchers) of our Institute have the opportunity to present their ongoing studies in a fortnight-scheduled cycle of intramural seminars, which was launched for the first time in 2015. In 2019, a total of 11 intramural seminars were held.

10.3 Institutional events

10TH IMIBIC YOUNG INVESTIGATORS MEETING

The IMIBIC Young Investigators Meetings is intended to provide the ideal environment to strengthen the skills and knowledge of young scientists, fostering translational research by facilitating the interface between experimental basic science and clinical medicine to improve health and the quality of life. By sharing the results obtained by young researchers at the IMIBIC and related centers, including other groups of the University of Cordoba, we intend to encourage inter-disciplinary research and, especially, quality training.
The objectives of the Meetings are:

- To provide a platform to discuss the latest knowledge and methods in translational medical research.
- To promote interactions and the exchange of ideas between pre- and post-doctoral scientists and strengthen the bonds among research groups.
- To facilitate interdisciplinary actions and communication to bring together basic and clinical research.
- To foster and provide high-quality scientific training to young researchers.
- To consolidate the annual IMIBIC Meetings as a youthful and fresh reference forum for the research community and, in particular, for our young researchers.

The 10th Meeting took place at the IMIBIC Building on 16-17 May 2019. The Meeting program included different sessions encompassing the IMIBIC Scientific Programs, as follows:

9TH MAIMONIDES COMMEMORATIVE LECTURE AND IMIBIC AWARDS 2019

This initiative aims to recognize the biomedical research carried out by IMIBIC staff and to emphasize the importance of the results obtained at the Institute. In 2019 the "Enrique Aguilar Benítez de Lugo" Prize was awarded to the most relevant scientific publication in collaboration with international groups, together with an Award for the best work in clinical research.

In each edition, an outstanding biomedical scientist is invited to give the "Maimónides Lecture", a conference focusing on the latest knowledge on basic, applied, and/or translational biomedical science of excellence. In 2019, the guest was Dr. Valentín Fuster.

Prof. Valentín Fuster combines roles as General Director of the Spanish National Center for Cardiovascular Research (CNIC) in Madrid and Director of the Cardiovascular Institute and Physician-in-Chief at the Mount Sinai Medical Center, New York. He is also Editor in Chief of the Journal of the American College of Cardiology (JACC), the main source of clinical news and analysis in cardiovascular medicine, published by the American College of Cardiology.

The innumerable positions Dr. Fuster has held during his career include President of the American Heart Association, President of the World Heart Federation, member of the Institute of Medicine of the US National Academy of Sciences (where he chairs the committee for the prevention of the global epidemic in heart disease), member of the US National Heart, Lung and Blood Institute Advisory Council, and President of the American College of Cardiology Training Program. After qualifying in medicine at the University of Barcelona, Valentín Fuster continued his studies in the USA. He was professor of Medicine and Cardiovascular Diseases at the Mayo Medical School, Minnesota and at the Medical School of Mount Sinai Hospital, New York, and from 1991 to 1994 was full professor of Medicine at Harvard Medical School in Boston. In 1994 he was named director of the Cardiovascular Institute at Mount Sinai, a post he has combined since 2012 with that of Physician-in-Chief.

Dr. Fuster has been named Doctor Honoris Causa by thirty-four universities and has received three of the most important awards from the US National Institutes of Health. He is an author on more than 1000 scientific articles in international medical journals, and has published two leading books on clinical cardiology and research: The Heart and Atherothrombosis and Coronary Artery Disease.

He is the most highly cited Spanish research scientist, according to the Cybermetrics Lab ranking, which is based on an analysis of Google Scholar. At the time of writing his work has been cited 238,436 times in the scientific literature. He also has a higher h index than any other Spanish researcher, indicating that he tops rankings for both the quantity and the quality of research. His h index is currently 187, indicating that he 187 of his publications have been cited at least 187 times in other publications.

His contributions to cardiovascular medicine have had an enormous impact on the treatment of patients with heart disease. His research into the origin of cardiovascular events, which has contributed to improved treatment of heart attack patients, was recognized in 1996 by the award of the Prince of Asturias Award for Technical and Scientific Research.

In 2012, Dr. Fuster was named by the American College of Cardiology as one of the Living Legends in Cardiovascular Medicine, and was awarded the Research Achievement Award, the highest award given by the American Heart Association.

Dr. Fuster was also recently awarded the Ron Haddock International Impact Award by the American Heart Association and the American Stroke Association in recognition of his global leadership. Further recognition in Spain came in the form of the Severo Ochoa Prize for Biomedical Research and the Mapfre Foundation Lifetime Achievement Award in recognition of his work on the prevention and treatment of cardiovascular disease. According to the evaluation committee, Dr. Fuster's career stands as a model of the kind of research and innovation in which Spain needs to excel in order to compete in the global economy.

Among his many achievements, Dr. Fuster is the only cardiologist to have received the highest research awards from the four leading international cardiology organizations: the American Heart Association, the American College of Cardiology, theEuropean Society of Cardiology, and the Interamerican Society of Cardiology. In 2019, the Spanish Ministry of Science, Innovation and Universities awarded Dr Fuster the National Research Prize, and he was named "Physician of the Year" in the ABC Salud awards for his contribution to cardiovascular medicine and his recent research into the links between heart and brain health.

In addition to his dedication to research, Dr. Fuster is strongly committed to his responsibility to communicate to the public. In recent years, this commitment has produced six books aimed at a general audience, which have been very positively received. This vocation and the clear need to promote healthy lifestyle habits led Dr. Fuster to set up the Science, Health and Education Foundation (SHE), with the goal of improving public health, especially among young people.

IMIBIC
INSTITUTO MAIMÓNIDES DE INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA

Junta de Andalucía

UNIVERSIDAD DE CÓRDOBA

10.4 RESULTS OF THE TRAINING ACTIVITIES

DOCTORAL THESES

The Institute holds the PhD Program on Biomedicine, which helps prepare young scientists in biomedical and clinical research. Experienced mentors in the IMIBIC supervise the research training in health and health-related areas of a considerable number of pre-doctoral students. A list is provided below of the 27 Doctoral Theses supervised by researchers from the Institute that were presented in 2019.

THESIS DEFENCES - COURSE 2018/2019

THESIS WITH INTERNATIONAL MENTION

THESIS WITHOUT INTERNATIONAL MENTION

RESEARCH STAYS

IMIBIC is committed to foster the training of our PhD students in national and international centers of reference in biomedical research to allow the opportunity to experience research in a foreign environment, facilitate the integration of graduates into the scientific community and create networks.

Twenty-seven researchers from the IMIBIC completed a research stay in a national or international center in 2019, 4 of them were financed by public competitive grants, 4 by private competitive grants, 14 stays of doctoral students to obtain the international mention and 15 by the institutions own research visit grants.

Likewise, external visitors are invited to carry out their research at our Institute. Altogether 15 visiting scientists stayed at IMIBIC during 2019.

TRAINING ATTENDANCE IN 2019

The total number of participants in all the training activities celebrated at IMIBIC in 2019 amounts to 3,245.

PARTICIPATION IN TRAINING ACTIVITIES IN 2019

NO. OF MALE PARTICIPANTS

NO. OF FEMALE PARTICIPANTS

TRAINING ATTENDANCE IN 2019



11. INNOVATION AND TECHNOLOGY TRANSFER

IMIBIC's strategic plan includes a specific transversal plan to promote innovations produced by the HURS. In the process of transfer to clinical practice, support is provided from the conception of the idea to design, development and implementation. The constant focus of the whole process is to improve the health of patients.

In April 2019, the ISCIII launched a new guide to become an IIS. This guide set out the indicators that need to be identified and implemented by the innovation and transfer unit of IMIBIC. These indicators are related to:

- Increase in patent registration and licensing.
- Knowledge transfer towards the productive sector.
- Development of new healthcare products.
- Implementation of new clinical processes.
- Creation of spinoffs and startups
- Academic clinical research or clinical trials
- Clinical Practice Guidelines

IMIBIC currently has an Innovation Plan that is part of the Strategic Plan for 2016-2020. The above indicators go beyond what was set out in that Plan and seek to reflect a mission and specific activity geared towards giving clear and direct responses to health problems, as well as the creation of a productive framework.

Hence, as part of a deep internal reflection on processes of innovation, multiple meetings were held involving different IMIBIC stakeholders and it was decided to change the mission of the Innovation and Transfer Unit in favor of a model that was more in line with these indicators. One of the conclusions applied at the beginning of the current Strategic Plan was that, while it was necessary to pay attention to any innovation that might emerge from HURS/IMIBIC, it was first necessary to create a culture of innovation. To achieve these new milestones set by the ISCIII, several conclusions were drawn. The most important included injecting fresh energy into the Technological Innovation Unit so that it could respond to development initiatives with a shorter route to the market/patient, as well as make a detailed study of patents prioritizing their quality and real possibilities of development rather than their number. By so doing, we are sure that we shall reach interest groups closer to the Institute with greater potential in this regard: we are referring here mainly to researchers working in the areas of Surgery, Radiodiagnosis, Ophthalmology, Pneumology, Nursing, Rehabilitation, etc.

In developing the ideas of healthcare personnel, it was laid down as a requirement that innovation development should be aimed at transfer to clinical practice. To achieve this, it is not enough to protect inventions. We are now moving towards clinical validation of technology. IMIBIC has set up a technological innovation unit with sufficient funding (obtained through a call from the Regional Ministry of Economy, Knowledge, Business and Universities, approximately 129.000 €) to induce a higher level of project development, as well as the equipment necessary to do so properly and to ensure that their quality and level of development are such that they are eligible for different competitive calls, for setting up tech-based enterprises, a 3D printing and creation service in the HURS, and public-private partnerships promoting R&D&i in Spain.

At the end of 2019, another application was submitted to the Regional Ministry of Economy, Knowledge, Business and Universities to provide more and better equipment for the new Technological Innovation Unit (approximately 440.000 €). If granted, this new funding will be targeted at boosting tissue engineering, regenerative medicine, development of molecular strategies, nanosystems and medical devices.

The focus of the innovation and transfer unit continues to be personalized medicine, with innovations in place to improve patient care and diagnosis, and professionals with a clear innovative spirit and desire for continuous improvement.

In order to promote an innovative culture in IMIBIC, the Innovation and Transfer Unit held 160 meetings in 2019 with different agents (researchers, companies, public institutions, and so on) with 15 formative actions (courses, forums and workshops) with a view to updating its portfolio of innovations with as many insights, innovative ideas and research results as possible that could potentially be protected in terms of IP Other key activities carried out by the Innovation Unit in 2019 were:

- IMIBIC is a member of the ITEMAS platform (Innovation Platform in Medical and Health Technologies) funded by the National Institute of Health Carlos III (ISCIII) which promotes innovation in health technologies as a key tool to provide sustainability to the National Health System. Since 2013, the Innovation Unit has been an active member of the ITEMAS ISO 166.002:2014 Certification Work Group. The Innovation Unit also collaborated with ITEMAS in organizing courses targeted at the IMIBIC research community.

- The Innovation Unit successfully passed the reaccreditation audit of its quality management system compliance with ISO standard 166.002:2014.

- 28 ideas were studied in 2019, 15 of which were considered captured (not closed as of 31/12/2019) and 13 are being developed in the current financial year, having obtained financing for them. The result of the activity carried out by IMIBIC's innovation unit is the granting of 20 industrial patents/intellectual property rights. Nine innovation projects are currently being financed for an amount of 1,071,376.50 euros (following the criteria of ITEMAS) and monitored according to the regulations of the different financing agents. Particular mention can be made of the following:

- One project was selected for funding in the "Desarrollo Tecnológico en Salud (DTS)" 2019 call of the ISCIII.
- The Innovation unit has submitted applications to other calls for project proposals and 3 were selected for funding: a project on EITHealth-2018-01, one autonomous community call on primary care and one international competitive project in the private sector (Pfizer-ISR-2019-01). The total amount of the projects funded was 172.001€.

As a result of all the activities described above, the following results were obtained:

EVOLUTION OF RESULTS	2015	2016	2017	2018	2019
PATENTS (INCLUDING UTILITY MODELS AND IPR)	14	9	16	13	14
PCTS	7	6	6	3	9
LICENSES	3	1	1	2	0

Industrial and intellectual property patents

During 2019, a total of 23 applications were made for industrial/intellectual property registration:

TITLE	Nº REGISTRY	REGISTRY TYPE	OWNER ENTITY	RESEARCH GROUPS
TTPHARMACY	RPI201899905559866	INTELLECTUAL PROPERTY REGISTRY	SAS/ UCO	PHARMACY
Method for diagnosing or predicting the development of brain tumors in individuals	P201931147	Patent	SAS/ UCO	GC27 (OncObesity and Metabolism)/ Endocrinology and Nutrition / Neurosurgery
Composition for the prevention, improvement, relief and/or treatment of disease caused by inflammation and oxidative stress in vascular and smooth muscle cells.	P201930979	Patent	SAS	Internal Medicine / Nephrology
Proteomic markers of response to anti-TNF drugs in patients with Crohn's disease	P201930901	Patent	SAS	Digestive/ pediatrícs
Identification of new proteins in thrombi from patients with ischemic stroke as biomarkers for stratification and prediction of clinical development	P201930850	Patent	SAS	Rheumatology / Hematology/ Neuroradiology
Compounds capable of modulating expression of snRNP200 for the treatment of prostate cancer	P201930722	Patent	UCO-SAS	Oncology/Urology
Compounds capable of modulating expression of SRSF3 for the treatment of prostate cancer	P201930721	Patent	UCO-SAS	Oncology/Urology
Compounds capable of modulating expression of SRRM11 for the treatment of prostate cancer	P201930720	Patent	UCO-SAS	Oncology/Urology
Method for diagnosing or predicting the development of prostate cancer in individuals	P201930104	Patent	UCO-SAS	GC27 (OncObesity and Metabolism)/ Urology
Method of obtaining useful data for the diagnosis, stratification and/or follow-up of patients with rheumatoid arthritis	P201930123	Patent	SAS-UCO	GC5 -Chronic inflammatory and systemic autoimmune diseases / Rheumatology
Method of predicting response to cancer treatment with anti-angiogenic agents	P201930122	Patent	UCO-SAS	Grupo GC-06 New therapies in cancer/ Oncology
Compounds capable of modulating expression of SRSF3 for the treatment of prostate cancer	P201930721	Patent	UCO-SAS	Urology
Method of diagnosis of HEV	PCT/ES2019/070764	PCT	SAS	Infectious Diseases/ GC-26

Multilayer cranial support	PCT/ES2019/070708	PCT	SAS/Andrés de la Riva	Neurosurgery and Neurophysiology/ Family Medicine / Intensive Care
Circulating mRNA as a predictive tool for the development of Type 2 diabetes mellitus	PCT/ES2019/070374	PCT	SAS/ UCO/CIBEROBN	Internal Medicine
Method of obtaining useful data for the diagnosis, stratification and/or follow-up of patients with rheumatoid arthritis	PCT/ES2019/070608	PCT	SAS/ UCO	Rheumatology
In vitro method for the diagnosis of ectopic pregnancy	PCT/EP2019/066529	PCT	UCO/FIVI	UCO/FIVI
Tool Coupling	PCT/EP2017/065597 CN109843515A	PCT	SAS/ UCO/ UMA/ Tecnalia	Urology/ Cardiovascular Surgery/Thoracic Surgery / General Surgery
Peptides derived from the truncated somatostatin receptor sst5TMD4 as biomarkers and therapeutic targets in tumor pathologies	PCT/ES2018/070361	PCT	SAS/ UCO	Endocrinology and Nutrition
Use of in1-ghrelin for the diagnosis of prostate cancer	PCT/ES2017/070797 EP 3 498 337 A1	PCT	SAS/ UCO	Urology
Use of in1-ghrelin for the diagnosis of prostate cancer	PCT/ES2017/070797 US-2019-0331684-A1	PCT	SAS/ UCO	Urology
Direct hemostasis device	U201931950	Utility Model	SAS	Nursing / Resuscitation
Volume limiting device for resuscitation balloon	U201931681	Utility Model	SAS	Nursing / Resuscitation

12. Biomedical research support units

12.1 ISOTOPE UNIT

STAFF

Eduardo Muñoz Blanco, PhD
Supervisor
Miguel Rodríguez
Operator

BRIEF DESCRIPTION

The Preclinical Imaging Service (SIP) is a highly advanced facility which provides non-invasive, in vivo imaging of the structure and function of body organs and tissues in preclinical animal models.

The equipment is located within the IMIBIC animal facility, which has modern facilities of approximately 800 m2 and capacity for housing and experimental management of >3,500 rodents, being in an ideal location to provide interdisciplinary work in cardiovascular biology, oncology, neuroscience and physiology, among others.

The main purposes of this department are to supply high-quality imaging support to the rest of the research groups in IMIBIC.

EQUIPMENT AND FACILITIES

• PET / MR 3T is the only combined magnetic resonance and PET equipment available nationwide. The PET equipment is based on highly sensitive continuous LYSO crystal technology with 2 rings of 8 detectors that can provide 80 mm (transaxial) X 148 mm (axial) fields of view, up to 285 mm (axial) by moving the bed, with MRI-compatible silicon photomultipliers, sensitivity of 5%, up to 9% (NEMA norm) and sub-millimeter resolution (≤ 0.7 mm); The MRI equipment is 3 Tesla and 18 cm magnet with cryogen free technology, without the need for a cooling line, with magnet homogeneity of ± 0.1 ppm (DSV 5 cm) and ± 0.05 ppm (DSV 3.5 cm), necessary to work with diffusion sequences and localized spectroscopy with a system of gradients capable of providing 450 mT / m.

The PET / MR displays an automatic positioning system for the animal for both the PET and MRI modalities and a touch screen with an integrated camera to facilitate positioning and monitoring.
This equipment was installed in June 2018 and will be available for use as soon as possible after a suitable set-up procedure which will be done in the near future.

• µCT (SkyScan 1176 model) is an X-ray tomography system (90 kV source) allowing a 3D spatial resolution of less than 10 µm and a respiratory gating system for prospective or retrospective extraction of respiratory movements during emission of the image. The system features a 12 bit, distortion-corrected 11-megapixel refrigerated X-ray chamber (4000x2670) with fiber-optic coupled scintillator.

Whole body rat and mouse scanning capability: 68mm or 35mm scanning diameter, up to 200mm scanning length by multiple automatic connected scanners. This µCT equipment can carry out longitudinal tests with less than 10mG radiation exposure, as well as with the PET or MRI image co-registration.

MAIN SERVICES

- To advise on experimental design, selection of equipment and supervision of procedures.
- To advise during acquisition and imaging procedures using MRI, microCT and PET.
- Specific applications:

• MRI Applications:
  » Structural analysis of soft tissue and body composition (compartmentalization).
  » Analysis of structures by diffusion (diffusion weighted imaging).
  » Analysis of metabolic composition by spectroscopy.
  » Analysis of brain activity using fMRI.

• MicroCT Applications:
  » Structural analysis.

• PET Applications:
  » Analysis of metabolic activity (normal and tumor tissue).

12.2 animal experimentation unit

STAFF

Ana Mª Molina López
Director of SAEX
Anabel Pozo Salas
(Clinical diagnostic laboratory technician) - MINECO
Estefanía Escudero Jabonero
(Technician in pathological anatomy and cytology) - MINECO

BRIEF DESCRIPTION

The fundamental objective of the animalarium service is to guarantee the maintenance and well-being of the animals, and also to offer various techniques for the study of these animals, given the variety of equipment that our unit has.

EQUIPMENT AND FACILITIES

The unit comprises:

- Treatment room: is equipped with body composition measurement equipment, a respirometry chamber (with capacity for 10 animals) and equipment for optogenetics.
- Laboratory 1: has micro-CT/PET/MRN for rodents, as well as a gamma library, a ventilated cabinet for 6 animals and an anesthesia machine.
- Operating room: Consists of 6 surgery workstations for pigs (operating table and gas system), 3 anaesthesia machines, 3 laparoscopic towers, 1 surgical magnifying glass, 1 arc light and 1 ultrasound scanner.

- It also has 3 laminar flow hoods, 2 gas extraction hoods, 2 hot plates for rodents, 1 microscope, 3 magnifying glasses, 4 scales.
- The rederivation technique has now been implemented and the micro-CT/PET/MRN is expected to be launched shortly.

HIGHLIGHTS

NUMBER OF IMIBIC USERS: **25**
NUMBER OF EXTERNAL USERS: **0**
NUMBER OF PROJECTS: **17**

INSTITUTIONAL PROJECTS

- 26/06/2018/106. (GC04). Estudio de la eficacia de derivados cannabinoides en un modelo de artritis inducida por colágeno (CIA).
- 23/04/2019/068. (GC04). Estudio de la eficacia de derivados cannabinoides en un modelo de daño hepático por la administración del tetracloruro de carbono.
- 13/03/15/207. (GC04). Proyecto de enfermedad inflamatoria intestinal.
- 2014PI/017. (GC04). Efectos de los Cannabinoides en la enfermedad de Huntington.
- 23/03/2018/034. (GC04). Estudio de modelo escleroderma inducido por Angiotensina II.
- 2014PI/016. (GC04). Efectos de los Cannabinoides en la Esclerodermia.
- P17/01785. (GC07). Mecanismos moleculares implicados en los procesos de adhesión y migración celular: Efecto del tratamiento de enfermedad renal crónica sobre la disfunción endothelial.
- PI-0268-2018. (GC07). Bioingeniería Regenerativa: Modelo in vitro de recelularización de un scaffold renal con células mesenquimales.
- BFU2017-83934-P. (GC10). “KISSPEPTINAS Y PUBERTAD - Nuevos aspectos fisiologicos e implicaciones fisiopatologicas en alteraciones puberales asociadas a obesidad.
- PI-0370-2016. (GC10). Papel fisiopatológico, pronóstico y diagnóstico de los miRNAs circulantes en el hipogonadismo asociado a la obesidad.
- PI-0358-2018-FIB. (GC10). Efectos Del Tratamiento Con Glp-1 Sobre La Función Gonadal Masculina En Condiciones De Diabesidad: Análisis Mecanísticos E Implicaciones Terapéuticas Para El Hipogonadismo Asociado A Enfermedad Metabólica.
- FIS PI17/01010. (GC13). Caracterización de los cambios en Wnt inducidos por Mg y esclerotina y su repercusión en el trastorno mineral, óseo y vascular asociado a la enfermedad renal crónica.
- PSS.0251. (GC13). Research Program Agreement Amgen-GC13.
- PSS.0247. (GC13). PRECLINICAL RESEARCH PROGRAM AGREEMENT AMGEN.
- PI16/00264. (GC27). Nuevos mecanismos moleculares en la interacción patológica entre obesidad y cáncer de próstata: splicing alternativo y miRNAs como potenciales biomarcadores y dianas terapéuticas.
- PI17/02287. (GC27). Implicación de nuevos factores moleculares y endocrino-metabólicos en la interacción patológica entre la obesidad y el desarrollo de hepatocarcinoma.
- DTS18/00131. (GC27). Ghrelina-O-acil-Transferasa (GOAT): Nuevo biomarcador para el Screening del Cáncer de Próstata.



12.3 Flow cytometry and advanced optical microscopy unit

STAFF

Esther Peralbo Santaella, PhD
Senior technician - Linking Technicians to Common Research Support Structures Program; Funding Agency: ANDALUSIAN HEALTH SERVICE; Reference: F2-0009-2018
Gema García Jurado, PhD
Microscopy technician – Contract, Technical Support Staff Program; Funding Agency: MINISTRY OF ECONOMY AND COMPETITIVENESS; Reference: PTA2015-11242-I

BRIEF DESCRIPTION

The Unit comprises two technological areas that are of great importance in the field of biomedical research: Flow cytometry and confocal fluorescence microscopy.

Its mission is to offer access to equipment with a broad spectrum of applications in these areas to IMIBIC researchers, to public and private institutions, and to provide technical expertise and training. The Unit also provides scientific and technical advice and support on experimental design, sample preparation, flow cytometry data analysis, image processing analysis and data interpretation.

EQUIPMENT AND FACILITIES

- Flow Cytometry Laboratory
  Equipped with:
  - » BD LSRFortessa SORP analyser: 4 lasers (405, 488, 561 and 640 nm) and 20 detectors (18 fluorescence parameters + FSC/SSC).
  - » BC Cytomics FC500 MCL analyser: 2 lasers (488 and 633 nm) and 7 detectors (5 fluorescence parameters + FSC/SSC). Multi Carousel Loader (up to 32 tubes).
  - » BD FACSCalibur analyser: 1 laser (488 nm) and 5 detectors (3 fluorescence parameters + FSC/SSC).
  - » BD FACSAria III Cell Sorter: 3 lasers (407, 488 and 633 nm) and 13 fluorescent detectors (11 fluorescent parameters + FSC/SSC). Four-way and single-cell sorting capabilities. Sorted cells collection: into tubes, onto plates or slides. Temperature Control. Aerosol Management Option (AMO).

- Confocal Fluorescence Microscopy Laboratory
  Equipped with:
  - » Zeiss LSM 710 Spectral Confocal Laser Scanning Microscope: inverted motorized stand. 7 laser lines: 405, 458, 488, 514, 543, 594 and 633 nm. Scanning module with 3 spectral R/FL detection channels (PMTs) and 1 transmitted-light channel (PMT). Integrated large incubation chamber.
  - » Zeiss LSM 5 Exciter Confocal Laser Scanning Microscope: inverted motorized stand. 6 laser lines: 405, 458, 488, 514, 543 and 633 nm. Scanning module with 2 R/FL detection channels (PMTs). Stage top incubator.
  - » Zeiss Axio Vert.A1 inverted fluorescence microscope.

MAIN SERVICES

- Self-use (non-operator-assisted) of flow cytometry analysers and microscopy equipment (only for internal users properly trained in use of the equipment).
- Operator-assisted use of instruments.
- Cell sorting: only provided as an operator-assisted service.
- Image processing and analysis. Flow cytometry data analysis.
- Advice and support on experimental design, sample preparation methods, interpretation and presentation of data.
- Developing/implementing flow cytometry and microscopy assays/applications, and image analysis tools in accordance with user needs.

HIGHLIGHTS

NUMBER OF IMIBIC USERS: **35**
NUMBER OF EXTERNAL USERS: **5**
NUMBER OF MEETINGS WITH IMIBIC GROUPS: **3**
NUMBER OF MEETINGS WITH EXTERNAL GROUPS: **2**
SCI ARTICLES PUBLISHED: **7**
COURSES AND WORKSHOPS: **2**
TECHNIQUES IMPLEMENTED DURING THE YEAR:
Ex vivo imaging of fresh tissue with fluorescence confocal mosaicing microscopy, using acridine orange (nuclear specific dye).

FEATURES ARTICLES

- **Pancreatic autoantibodies and CD14+CD16+ monocytes subset are associated with the impairment of ß-cell function after simultaneous pancreas-kidney transplantation.** Rodelo-Haad C, Agüera ML, Carmona A, Navarro MD, Carracedo J, Rodriguez-Benot A, Aljama P. PLoS One. 2019 Feb 22; 14(2):e0212547.
- **Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.** Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, Pineda C, Martínez-Moreno JM, Herencia C, Vergara N, Pendón-Ruiz de Mier MV, Santamaría R, Rodelo-Haad C, Casado-Díaz A, Lorenzo V, Carvalho C, Frazão JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodríguez M, López I, Muñoz-Castañeda JR. Kidney Int. 2019 May; 95(5):1064-1078.
- **Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis.** García-Martín A, Garrido-Rodríguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, Rollland A, Appendino G, Muñoz E. Biochem Pharmacol. 2019 May; 163:321-334.
- **Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated with Cardiovascular Disease in Rheumatoid Arthritis.** Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patiño-Trives AM, Luque-Tevar M, Ibáñez-Costa A, Perez-Sanchez L, de la Rosa I, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme ME, Collantes-Estevez E, López-Pedrera C; PRECISESADS Clinical Consortium and Flow Cytometry Study Group. Front Immunol. 2019 May 21; 10:1111.
- **Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.** Pérez-Sánchez C, Cecchi I, Barbarroja N, Patiño-Trives AM, Luque-Tévar M, Pérez-Sánchez L, Ibáñez-Costa A, Arias de la Rosa I, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MÁ, Collantes E, López-Pedrera C; BIOSAR Study Group. J Cell Mol Med. 2019 Sep; 23(9):6308-6318.
- **Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.** Morrugares R, Correa-Sáez, Moreno R, Garrido-Rodríguez M, Muñoz E, de la Vega L, Calzado MA. Cell Mol Life Sci. 2019 Oct 11.
- **Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3.** Heras V, Sangiao-Alvarellos S, Manfredi-Lozano M, Sanchez-Tapia MJ, Ruiz-Pino F, Roa J, Lara-Chica M, Morrugares-Carmona R, Jouy N, Abreu AP, Prevot V, Belsham D, Vazquez MJ, Calzado MA, Pinilla L, Gaytan F, Latronico AC, Kaiser UB, Castellano JM, Tena-Sempere M. PLoS Biol. 2019 Nov 7; 17(11):e3000532.

COURSES AND WORKSHOPS

- Practical course: "Procesamiento y análisis de imágenes de microscopía con ImageJ/Fiji", delivered by Gema García Jurado. 9 October, 2019.
- In 2019, Unit staff also delivered 14 training sessions to researchers in the use of instruments and software analysis.



12.4 Proteomics unit

STAFF

Ignacio Ortea, PhD
Core Facility Coordinator. LCMS quantitative proteomics expert - Contracts for the Incorporation of Specialized Technicians into Common Research Support Structures. Ministry of Health and Families, 2013.

Eduardo Chicano, PhD
Specialized Technician. MS-Imaging expert and bioinformatician - Contracts for the Incorporation of Specialized Technicians into Common Research Support Structures. Ministry of Health and Families, 2012.

Rocío Pérez Espejo.
Support technician. Wet laboratory, sample preparation and lab maintenance support.

Ismael Luna Álvarez.
Support technician. Bioinformatics support – Aid Programme for the Promotion of Youth Employment and Implementation of the Youth Guarantee Plan in R+D+i . MICINN 2019.

Cristina Morilla Murga.
Support technician. Wet laboratory, sample preparation and lab maintenance support - Aid Programme for the Promotion of Youth Employment and Implementation of the Youth Guarantee Plan in R+D+i . MICINN 2019.

BRIEF DESCRIPTION

The Proteomics Unit provides researchers with state-of-the-art technologies in the field. Currently, the Proteomics Unit is a specialized platform in LCMS quantitative proteomics and MALDI Imaging. Skilled staff provide individualized, fit-for-purpose support, including project planning, sample preparation, mass spectrometry analysis and data analysis.

EQUIPMENT

- Q-TOF mass spectrometer, Triple TOF 5600+ (Sciex)
- Q-TOF mass spectrometer
- Triple TOF 5600+ (Sciex)
- Triple quadrupole mass spectrometer Xevo TQS (Waters)
- MALDI-TOF/TOF mass spectrometer, 5800 (Sciex)
- nano-HPLC, Eksigent LC415 (Sciex)
- nano-UPLC, nanoAcquity M-Class (Waters)
- Sprayer, Sunchrom Suncollect (Sunchrom)

MAIN SERVICES

- Identification and characterization of proteins by MALDI-TOF/TOF
- Identification and characterization of proteins by LC-MS/MS
- Quantitative Proteomics:
  - » SWATH
  - » SRM (Selected Reaction Monitoring)
  - » pseudoSRM (Parallel Reaction Monitoring, PRM)
- MALDI Imaging mass spectrometry
- Project supervision and collaboration
- Training in software used for data analysis

HIGHLIGHTS

NUMBER OF IMIBIC USERS: **27**
NUMBER OF EXTERNAL USERS: **17**
PRIZES OR GRANTS RECEIVED: **2**
SCI ARTICLES PUBLISHED: **6**
GRANT-AIDED PROJECTS: **1**
COURSES AND TALKS: **5**

PhD Thesis "Variaciones en la expresión proteica de niños prepuberales con déficit de GH y tras tratamiento con hormona del crecimiento" by Isabel Ruiz; PhD Supervisor: Ignacio Ortea. February 2019.

FEATURES ARTICLES

- **Redox and global interconnected proteome changes in mice exposed to complex environmental hazards surrounding Doñana National Park.** Michán C, Chicano-Gálvez E, Fuentes-Almagro CA, Alhama J. Environ Pollut. 2019 Sep;252(Pt A):427-439. doi: 10.1016/j.envpol.2019.05.085. Epub 2019 May 27. PMID: 31158671
- **SWATH Differential Abundance Proteomics and Cellular Assays Show In Vitro Anticancer Activity of Arachidonic Acid- and Docosahexaenoic Acid-Based Monoacylglycerols in HT-29 Colorectal Cancer Cells.** González-Fernández MJ, Fabrikov D, Ramos-Bueno RP, Guil-Guerrero JL, Ortea I. Nutrients. 2019 Dec 6;11(12):2984. doi: 10.3390/nu11122984. PMID: 31817645
- **SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours.** López-Sánchez LM, Jiménez-Izquierdo R, Peñarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Díaz C, Ortea I, De la Haba-Rodríguez JR, Aranda E, Rodríguez-Ariza A. J Cell Mol Med. 2019 Dec;23(12):8219-8232. doi: 10.1111/jcmm.14693. Epub 2019 Sep 27. PMID: 31560832
- **Review of Recent DNA-Based Methods for Main Food-Authentication Topics.** Böhme K, Calo-Mata P, Barros-Velázquez J, Ortea I. J Agric Food Chem. 2019 Apr 10;67(14):3854-3864. doi: 10.1021/acs.jafc.8b07016. Epub 2019 Apr 1. PMID: 30901215
- **SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone.** Garrido-Rodríguez M, Ortea I, Calzado MA, Muñoz E, García V. J Proteomics. 2019 Feb 20; 193:217-229. doi: 10.1016/j.jprot.2018.10.012. PMID: 30626528
- **Recent applications of omics-based technologies to main topics in food authentication.** Böhme K, Calo-Mata P, Barros-Velázquez J, Ortea I. TrAC Trends in Analytical Chemistry 2019, 110:221-232.

INSTITUTIONAL PROJECTS

- MICINN Institutional GRANTED Project: New MS-Imaging Platform for Precision Medicine.

COURSES AND WORKSHOPS

- Master's Degree in Translational Biomedical Research at University of Cordoba (MIBT-UCO). Proteomics.
- Master's Degree in Biotechnology at University of Cordoba (MB-UCO). Proteomics (MS-Imaging).
- SCAI/Bruker MALDI Day at University of Cordoba. MS-Imaging Applications.
- Proteomics Workshop at the Instituto de Investigación Sanitaria del Principado de Asturias (Health Research Institute of the Principality of Asturias).
- III Clinical Genomics and Proteomics workshops at the IBIMA.



12.5 Bioinformatics and Technological Innovation Unit

STAFF

Sebastián Ventura Soto, PhD
Head of Unit and Team Leader of the Knowledge Discovery and Intelligent Systems" (KDIS) research group - Professor of Computer Sciences and Artificial Intelligence at the University of Córdoba.
Jesús Fernández Chaichio
Technician FIBICO contract, pending resolution of the MINECO PTA/2019 call.
Fernando Abollo Jiménez, PhD
Technician - Contract from the National Institute of Health Carlos III - 2019 Strategic Action in Health (AES-2019) call.
Juan Antonio Marín Sanz, PhD
Technician - FIBICO contract, through MINECO's Youth Guarantee Plan.

BRIEF DESCRIPTION

The mission of the Bioinformatics and Technological Innovation Unit is to provide engineering and computing services that satisfy both the bioinformatics analysis requirements and the different technological needs that arise in research and clinical practice, with an emphasis on the promotion and implementation of state-of-the-art technologies. The Unit can be divided into two working areas.

Technological Innovation. The basic goal of the area is to take the use of the new Information and Communication Technologies closer to the different research groups, so that they can be applied in their projects as required, without the need for the research team to devote additional time to learning. Likewise, advisory and consultancy services are available to provide the most appropriate technological responses.

Bioinformatics. The overall objective of this area is to provide bioinformatic analyses to research groups that demand them. More specifically, the unit focuses on implementing platforms that include different types of analysis sequentially. In this way, the unit can provide a service in this field while implementing new analyses and updating those already provided. The decision of which platforms are implemented and the order in which they are to be developed is mainly determined by the needs of the center.

EQUIPMENT AND FACILITIES

- Computing resources: BullX R428-E3 node. 4x Intel Xeon E5-4610v2 8c, 32 cores. 256 GB RAM
- 3D Printer: BCN3D+ Fused Deposition Material Printer.
- Development resources: Apple Mac Mini for iOS app development.

MAIN SERVICES

The unit's services can be divided in two main categories:

- Bioinformatic services
  - » Biocomputing tools to support groups conducting relevant research projects
  - » Direct analysis of relevant research projects and the technical data needed for support
  - » Bioinformatics covers various fields and diverse applications such as:
  - » Nucleic acid analysis (DNA / RNA)
  - » Analysis of peptide sequences, structures, functions, metabolic pathways and interactions with genes
  - » Generation of knowledge relative to the study of new drugs
- Technological Innovation services
  - » Software development
  - » Algorithm design and implementation
  - » Database construction and Electronic Data Capture tools
  - » 3D modeling and printing
  - » Engineering & consulting

HIGHLIGHTS

The Bioinformatics and Technological Innovation Unit has continued its activity of promoting the use of computer technologies among the different research groups. As part of these activities, the Unit initiated a cycle of seminars, which began with one centered on the use of Electronic Data Capture tools and databases in clinical research. This cycle will be continued in the following years with more advanced topics. As a result, the Unit has increased its activity and the number of collaborations and funded projects in which it participates.

NUMBER OF IMIBIC USERS: **26**
NUMBER OF EXTERNAL USERS: **60**
NUMBER OF MEETINGS WITH IMIBIC GROUPS: **30**
NUMBER OF MEETINGS WITH EXTERNAL GROUPS: **6**
NUMBER OF ACTIVE PROJECTS: **5**

INSTITUTIONAL PROJECTS

- PIN 0385/Consejería de Salud 2016. REPIR Project. Development of a clinical decision support system for the management of non-terminal chronic kidney disease in children based on the application of Data Mining on the REPIR II database (Registro Español Pediátrico de Insuficiencia Renal Crónica - Spanish Paediatric Registry of Chronic Kidney Disease).
- PI 0447/Consejería de Salud 2017. EDCNO project. Effectiveness of cognitive behavioural therapy for chronic pain from a gender perspective through Information Technology in the Southern Health Area of Córdoba.
- PIN 0316/Consejería de Salud 2017. ÉACO project. Development and validation of a networked technological instrument supporting decision making in clinical practice.
- PIN 0483/Consejería de Salud 2017. TIS project. Improvement of patient safety based on the introduction of this perspective in Healthcare Information Technology through methodologies for its evaluation.
- PI-PIN/CIBERer. MAPER Development and improvement of CIBERER's MAPER platform.

12.6 Genomics unit

STAFF

Álvaro Jiménez Arranz
Coordinator. Senior Technical Specialist - Recipient of a competitive contract from the 2015 Call for "Ayudas para la Vinculación de Técnicos de Apoyo a ECAIs" (SSPA).
Natalia Cervantes Gómez
Technical Specialist - Recipient of a competitive contract from the 2018 Call for Aid for the promotion of youth employment and implementation of the Youth Guarantee in R+D+i (MICINN).
Pilar Rubín González de Canales
Laboratory Technician

BRIEF DESCRIPTION

The aim of the Genomics Service is to provide researchers with cutting-edge equipment, as well as scientific and technical advice for the development of various analytical techniques used in the comprehensive study of DNA and RNA (genotyping / expression / regulation). This allows researchers to obtain high-quality results for the development of outstanding translational biomedical research. The Unit offers its services to IMIBIC researchers as well as those at other public and private institutions. The Genomics Unit collaborates closely with other Research Support Services, such as Bioinformatics, Proteomics and Cytometry.

EQUIPMENT AND FACILITIES

The resources currently available in the Genomics Unit are:

- Illumina MiSeq
  - » MiSeq is an Illumina platform sequencing technology based on SBS (sequencing by synthesis), which is currently the most widely adopted NGS (next-generation sequencing) technology in the world on account of its speed, accuracy and quality. This sequencer can generate up to 15 Gb/run and perform 2x300bp paired-end reads, leading to greater accuracy, especially in problematic areas, such as those involving homopolymers. The MiSeq system allows researchers to perform DNA-Seq, RNA-Seq, Methyl-Seq and ChIP-Seq analysis, which have a wide range of applications.
  - » nCounter DX / NanoString technology
  - » The NanoString nCounter system uses a novel technique of molecular barcodes linked to specific probes that can detect and count hundreds of targets in a single reaction without amplification, so that users can study a large number of mRNAs, miRNAs and DNA molecules simultaneously with sensitivity and 'gold standard' reproducibility. Its applications include gene expression analysis, gene fusion, copy number variation (CNV) and simultaneous analysis of mRNAs and RNA regulators such as miRNAs and lncRNAs.
  - » The nCounter Dx is CE and IVD certified for conducting analyses that ensure care quality, which, along with these various applications, makes the nCounter a tool with high potential for clinical use. There is a CE-marked test for in vitro diagnostics (CE-IVD) currently on the market, which was approved by the FDA for breast cancer (Prosigna-PAM50) based on a molecular gene expression analysis of 50 genes. This allows it to classify the tumor into one of four intrinsic subtypes related to disease prognosis and choice of treatment. In addition, the launch of another validated kit for in-vitro diagnostics (CE-IVD / FDA) is currently underway, based on 20 differential gene expression patterns, aimed at determining DLBCL (Diffuse Large B-Cell Lymphoma) subtypes and related disease treatment.
- Digital PCR (dPCR): QX200 Droplet Digital PCR System
  - » Digital PCR offers a more precise and sensitive alternative to conventional qPCR for absolute quantification and detection of rare alleles without the need for standards or endogenous controls due to droplet partitioning.
- Quantitative PCR (qPCR)
  - » The Unit has 3 platforms aimed at genotyping PCR and gene expression studies:
  - » Light Cycler 480 (96-well platform)
  - » Light Cycler 96 (96-well platform)
  - » 7900 HT Fast (384-well platform)

  With regard to IMIBIC research staff, the Unit offers the possibility of using the qPCR platforms on a "self-service" basis (without a technical operator).
- Others
  - » The Unit has additional appliances designed for quantification, quality analysis and determining the size of nucleic acid fragments:
  - » Nanodrop ND1000 (Spectrophotometer)
  - » DeNovix DS-11 (Spectrophotometer)
  - » Quantus (Fluorometer)
  - » 2200 TapeStation (Microelectrophoresis)

  A grant was recently awarded to finance new equipment (Fluidigm Juno and Biomark HD systems) for the Unit. This will, among other things, enable high throughput genotyping analyses to be performed.

MAIN SERVICES

- Technical support and scientific and methodological advice on the choice and optimization of genomic techniques
- Design support for targeted NGS or NCounter panels
- Technical and scientific support in the use of qPCR platforms and probe design
- Nucleic acid quality controls (spectrophotometry, fluorometry and microelectrophoresis)
- Analysis of targeted gene expression panels (up to 800 genes) using NCounter System
- PAM50 signature analysis (ProsignaTM) for breast cancer prognosis
- Screening of up to 800 miRNAs in tissue, peripheral blood cells and serum/plasma by NanoString Technologies (NCounter System)
- Gene expression and genotyping studies using real-time PCR
- Absolute quantification by Droplet Digital PCR System (viral load analysis…)
- Liquid biopsy: Rare mutation detection in cfDNA by ddPCR
- NGS library preparation
- Characterization of microbiome by sequencing of 16S rRNA gene using NGS
- NGS analysis of SNVs, indels and CNVs related to Acute Myeloid Leukemia (AML)
- NGS (next generation sequencing) by Illumina Miseq
- Training and support in the use of data analysis software related to the Unit's technology
- Project supervision and partnerships

HIGHLIGHTS

In 2019, the Genomics Unit continued the progressive increase in the number of projects and users since its inception in 2015, analyzing 2388 samples from research and clinical diagnosis during the past year and providing support for 80 users. The users include 20 of the 35 groups belonging to the IMIBIC, 2 Departments from the University of Cordoba (Genetics Department of the Faculty of Sciences and the Department of Pathological Anatomy of the Faculty of Veterinary Sciences) and 2 departments of the Reina Sofia University Hospital (Pathological Anatomy and Oncology). Furthermore, since 2018, several external centers have been requesting our services (ULL-University of La Laguna, Tenerife; CIMA-Center for Applied Medical Research, Navarra; CUN/UNAV-Navarra University Clinic.).

Protocols and services implemented previously have been improved following GLP (Good Laboratory Practices) principles, in order to guarantee the quality, reproducibility and reliability of the results, and new services introduced, such as NGS analysis of SNVs, indels and CNVs related to Acute Myeloid Leukemia.

Integration of the Genomics Unit into a multidisciplinary team with the Reina Sofia University Hospital to implement protocols for genetic/genomic diagnosis, such as the PAM50 signature (ProsignaTM) for breast cancer prognosis, has been consolidated. In addition, the Unit continues to participate in Nanostring's Translational Research Program as a testing lab of the Lymphoma Subtyping Test (LST) for determining cell-of-origin subtypes of diffuse large B-cell lymphomas, and remains a member of the Pharmacogenetics Work Group of SCReN - The Spanish Clinical Research Network of the National Institute of Health Carlos III – in the Cordoba group. The Unit has also been included this year in a Fundación Pethema program, which aims to implement NGS as a diagnostic tool for myeloid leukemia.

During 2019, the Genomics Unit obtained funding for the incorporation of a new technical specialist, Natalia Cervantes, who is the grant beneficiary of a competitive contract supported by the 2018 Call for "Ayudas para la promoción de empleo joven e implantación de la Garantía Juvenil en I+D+i" (MICINN: Ministerio de Ciencia, Innovación y Universidades / Ministry of Science, Innovation and Universities). Furthermore, the Unit Coordinator, Álvaro Jiménez, has been granted renewed funding until 2023, supported by the 2015 Call for "Ayudas para la Vinculación de Técnicos de Apoyo a ECAIs" (SSPA: Sistema Sanitario Público de Andalucía / Andalusian Public Health System).

As mentioned previously, the Unit has recently been subsidized and will be able to incorporate two new pieces of equipment for high-throughput genomic analysis by microfluidics aimed at the study of gene expression, genotyping and NGS library preparation (Fluidigm Juno and Biomark HD), from the 2018 Call of the "Programa Estatal de Investigación y Equipamiento Científico-Técnico / State Program for Scientific and Technical Research and Equipment" (MICINN: Ministerio de Ciencia, Innovación y Universidades). This equipment is scheduled to be incorporated in mid 2020.

NUMBER OF IMIBIC USERS: **73**
NUMBER OF EXTERNAL USERS: **7**
SCI ARTICLES PUBLISHED: **6**
COURSES AND TRAINING SESSIONS: **4**

FEATURES ARTICLES

- A total of six scientific articles were published during 2019 in which Genomics Unit equipment was mentioned. The following co-authorships stand out:

- A coauthored publication with group GC26 (Clinical Virology and Zoonoses) from IMIBIC:
  - » Mario Frías, Antonio Rivero-Juárez, Francisco Téllez, Rosario Palacios, Álvaro Jiménez-Arranz, Juan Antonio Pineda, Dolores Merino, María Amparo Gómez-Vidal, Inés Pérez-Camacho, Ángela Camacho, Antonio Rivero. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. Sci Rep. 2019 Aug 29;9(1):12507. doi: 10.1038/s41598-019-48966-9. PMID: 31467339.

- A conference communication as coauthors with group GC16 (Cell Biology in Hematology: Hypercoagulability) from IMIBIC, which received the award for the best communication from a Hematology Laboratory at the XXXVIII Reunión Anual de la Asociación Andaluza de Hematología y Hemoterapia (38th Annual Meeting of the Andalusian Association of Hematology and Hemotherapy) (AAHH). Abril 2019.
  - » J. Sánchez-García, Javier Dorado, Antonio Martínez Peinado, A. Jiménez-Arranz, J Serrano-López, J. Serrano. Detección de duplicaciones internas en tándem y mutaciones del gen FLT-3 mediante Next-Generation Sequencing (Detection of internal tandem duplications and mutations of the FLT-3 gene by Next-Generation Sequencing). SEHH 2019 LXI Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia (61st National Conference of the Spanish Society of Hematology and Hemotherapy).

- Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. Mario Frías, Antonio Rivero-Juárez, Francisco Téllez, Rosario Palacios, Álvaro Jiménez-Arranz, Juan Antonio Pineda, Dolores Merino, María Amparo Gómez-Vidal, Inés Pérez-Camacho, Ángela Camacho, Antonio Rivero. Sci Rep. 2019 Aug 29;9(1):12507. doi: 10.1038/s41598-019-48966-9. PMID: 31467339 (GC26)
  - » Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated with Cardiovascular Disease in Rheumatoid Arthritis. Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patiño-Trives AM, Luque-Tevar M, Ibáñez-Costa A, Perez-Sanchez L, de la Rosa IA, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme ME, Collantes-Estevez E, López-Pedrera C; PRECISESADS Clinical Consortium and Flow Cytometry Study Group. Front Immunol. 2019 May 21;10:1111. doi: 10.3389/fimmu.2019.01111. eCollection 2019. PMID: 31169830 (GC05)

- Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. Rheumatology (Oxford). Arias de la Rosa I, Radin M, Cecchi I, Rubini E, Pérez-Sánchez C, Aguirre MÁ, Menegatti E, Barbarroja N, Collantes E, Sciascia S, Roccatello D, López Pedrera C. 2019 Oct 1;58(10):1870-1872. doi: 10.1093/rheumatology/kez166. No abstract available. PMID: 31034051 (GC05)

- Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. Pérez-Sánchez C, Arias-de la Rosa I, Aguirre MÁ, Luque-Tévar M, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, Ábalos-Aguilera MC, Collantes-Estévez E, Segui P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martínez C, González-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, López-Pedrera C. Haematologica. 2018 May;103(5):908-918. doi: 10.3324/haematol.2017.184416. Epub 2018 Mar 15. PMID: 29545345 (GC05)

- Low Intake of Vitamin E Accelerates Cellular Aging in Patients with Established Cardiovascular Disease: The CORDIOPREV Study. Corina A, Rangel-Zúñiga OA, Jiménez-Lucena R, Alcalá-Díaz JF, Quintana-Navarro G, Yubero-Serrano EM, López-Moreno J, Delgado-Lista J, Tinahones F, Ordovás JM, López-Miranda J, Pérez-Martínez P. J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):770-777. doi: 10.1093/gerona/gly195. PMID: 30165472 (GC09)

- Proof of Concept on Functionality Improvement of Mesenchymal Stem Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures. Casado-Díaz A, Dorado G, Giner M, Montoya MJ, Navarro-Valverde C, Díez-Pérez A, Quesada-Gómez JM. Calcif Tissue Int. 2019 Jun;104(6):631-640. doi: 10.1007/s00223-019-00533-0. Epub 2019 Feb 6. PMID: 30725167 (GC17)

COURSES AND TRAINING SESSIONS

- Specific training sessions for research groups in experimental design, technical applications and data analysis related to the Unit's equipment:
  - » Training in data analysis using R-based software, NSolver: Groups GC05, GC08 and GE05
  - » Training in the analysis of metagenomic data using Gaia 2.0 analysis software: Group GC13
  - » Training in the tool aimed at designing custom panels of Nanostring nDesign: Group GC01
  - » Training in qPCR data analysis using LC96 and 7900HT analysis software: Groups GC16 and GE06
- Support for the UCAIB of Methodology and Biostatistics in the design of the program to be taught in the course "Statistical tools for omics data analysis"

12.7 Clinical research unit

STAFF

Juan de la Haba Rodríguez, PhD
Clinical Research Coordinator
María Esther Pacheco Rodríguez, PhD
Clinical Pharmacologist
Antonio Miguel Luque Pineda
José Carlos Garrido Gracia
Macarena Guijo Molero
Clinical Trial Managers
Inés Carmen Rodríguez García
Nurse Coordinator
Manuel Rejano Castañeda,
Araceli Chicano Gálvez
Juan María Fernández Marín
Eva María Castell Cano
María Dolores Díaz Ruano
Miguel Puentes Aguado
Fernando Román Arenas
Nurses
Rubén Sánchez Nieves
Inmaculada Gálvez Membrives
Nursing Assistants

BRIEF DESCRIPTION

The IMIBIC Clinical Research Unit promotes clinical research at the IMIBIC and Reina Sofia University Hospital and also aims to establish collaborations with other research centers. IMIBIC is currently a member of the Spanish Clinical Research Network (SCReN).
The Unit focuses on the development of clinical trials including design, feasibility, regulatory affairs, launch, management, monitoring, pharmacovigilance, data management, statistics and delivery of clinical assistance. All operations are GCP compliant.
The IMIBIC Clinical Research Unit consists of two facilities: The Provincial Hospital Clinical Research Unit and the General Hospital Clinical Research Unit. Both are adapted to perform phase I-IV clinical trials in patients.

EQUIPMENT AND FACILITIES

- 10 doctors' consultation rooms and a storeroom
- 2 hospital wards each containing: crash trolley with semi-automatic defibrillator and emergency medication, intravenous fluids, an insulin pump, healing trolleys, oxygen outlets in all positions and audiovisual system
- 14 armchairs and rooms with 3 single beds, all with ongoing monitoring
- Pediatric area
- 12-lead ECGs
- Measuring boards and scales
- Blood pressure meter in each office
- Customized bathrooms
- Individual lockers for patients
- 2 living rooms for patients
- 2 waiting rooms for patients and family
- 1 multi-purpose room
- 2 laboratories for sample processing and centrifuges
- Freezers (-80ºC and -20ºC)
- 2 storerooms for materials
- High definition ultrasound scanner
- 2 offices for study coordinators
- 2 CRA offices
- 2 archives

MAIN SERVICES

- Methodological support
- Launch and regulatory affairs
- Study development
- Monitoring
- Pharmacovigilance
- Delivery of clinical assistance

HIGHLIGHTS

During 2019, the Unit provided assistance and support in the start-up, coordination, data management or monitoring of 34 independent clinical research projects in the following Units, among others: Cardiology, Hematology, Internal Medicine, Pediatrics, General Surgery, Nephrology, Rheumatology, Pulmonology and Infectious Diseases. Concerning research activity, 5,643 patients were treated in the facilities of the Clinical Research Unit. 177 clinical research projects were carried out. The main areas that developed their activity in the unit were: Oncology, Rehabilitation Medicine, Internal Medicine, Nephrology, Infectious Diseases, Dermatology, Urology, Rheumatology, Cardiology, Pediatrics, Psychiatry, Endocrinology, Ophthalmology, Digestive System, Allergy and Immunology.
As a member of the Spanish Clinical Research Network (SCReN), the Unit has coordinated 2 multicenter clinical trials as sponsor and actively participated in 9 other clinical trials interacting with different groups in Spain. The Unit also collaborates with several working groups in the network.
To promote clinical research, the Unit has organized working meetings with health professionals in different areas: Urology, Pediatrics, Immunology, General Surgery, Palliative Care, Cardiac Surgery, Diagnostic Radiology, etc. The research lines of the main pharmaceutical companies and the capacity of participation of these units have been evaluated. Meetings have been organized with the medical departments of the pharmaceutical companies.

NUMBER OF IMIBIC USERS: **40**
NUMBER OF EXTERNAL USERS: **5**



12.8 BIOBANK UNIT

STAFF

Rosa Mª Ortega Salas, PhD
Scientific Manager
Alba Aguilera García
Fernando López López
Technicians

BRIEF DESCRIPTION

The Biobank Unit is one of the research support platforms whose mission is to liaise between doctors, researchers and patients donating biological samples for biomedical research purposes to ensure that all currently applicable legal and ethical safeguards are upheld.
The IMIBIC Biobank is part of the Andalusian Public Health System Biobank (SSPA), an initiative of the Department of Equality, Health and Social Policy of the Regional Government. It is part of the thematic network of Hospital Biobanks belonging to the National Institute of Health Carlos III (ISCIII), and a subprogram of the Thematic Networks for Cooperative Research in Health (RETICS)

EQUIPMENT AND FACILITIES

The Unit has its own laboratory resources for sample transformation (safety booths, PCR cabinet, microtome, cryostat, floating bath, centrifuge, histobath, automated tissue processor for inclusion in paraffin, paraffin wax dispenser, etc.) and other equipment such as:

- Tissue Safe: fully automated preparation of tissue samples in a vacuum.
- Tissue Arrayer: assembles different tissue samples in a single 3D matrix for subsequent histological analysis.
- Quiacube: Automatic, compact system for analysis of DNA, RNA, plasmids and proteins from varying samples.

For sample storage, there are currently three types of freezers: one for temperatures of 4ºC, two for temperatures of -20ºC, and seven for -80ºC. There is also a room to store paraffin blocks at room temperature.

MAIN SERVICES

The service portfolio is divided into four main areas:

- Custodial: storing samples at different temperatures.
- Processing: transforming multiple types of biological sample in accordance with the procedures and technical criteria commonly used by researchers in their projects.
- Provision of human samples and data on human health and disease research, selected according to the specific clinical and diagnostic criteria of researchers.
- Technical, scientific and ethical consultancy concerning the collection, storage, and management of human samples in biomedical research.

12.9 METHODOLOGY AND BIOSTATISTICS UNIT

STAFF

Ipek Guler Caamano Fajardo
Specialized biostatistician

BRIEF DESCRIPTION

The Unit offers methodological consulting and statistical support to IMIBIC researchers and healthcare professionals belonging to the Andalusian Public Health System in the Province of Cordoba, ensuring a high-quality response to the needs of researchers and robust statistical results on research projects.

EQUIPMENT AND FACILITIES

The main statistical programs used for data analysis are:

- IBM SPSS 24 (Copyright 2010 by SPSS Inc.)
- R (versión 3.6.2)
- GranMo versión 7.12 (abril 2012)

MAIN SERVICES

The services offered by the Methodology and Biostatistics Unit in personalized consultations (face to face, telematic or virtual meetings) include:

- Revision of the research methodology and protocols: presentation of hypotheses, formulation of objectives, selection of epidemiological design, definition of variables, selection of statistical analysis etc.
- Guidance for literature search concerning statistical techniques and methodologies
- Sample size calculation.
- Validation of questionnaires and other measuring instruments.
- Exploratory and descriptive analysis of data.
- Inferential analysis (univariate and multivariate).
- Evaluation of diagnostic tests: sensitivity, specificity, predictive values, ROC curves, decision curves, optimal cut-point analysis.
- Survival analysis
- Longitudinal data analysis
- Joint modeling of longitudinal and survival data in observational studies.
- Functional data analysis.
- Basic statistical analysis for omics data (gene expression, enrichment analysis).
- Other statistical techniques (Bayesian analysis, meta-analysis, etc.).
- Interpretation of results
- Guidance in presenting and disseminating research results
- Revision of scientific publications in terms of quality criteria set by the journal and in accordance with the type of study.

HIGHLIGHTS

NUMBER OF IMIBIC USERS: **35**
NUMBER OF EXTERNAL USERS: **2**
EXTERNAL PROJECT: **1**

FEATURES ARTICLES

- **"Readiness to Change" Predicts Efficacy of Reduction among Smokers with Severe Mental Illness.** Sarramea Crespo F, Jaén-Moreno M, J, Gutiérrez-Rojas L, Balanzá-Martínez V, García-Alvarez L, Saiz Martínez P, A, Garcia-Portilla M, P, Guler I, Bobes J. Eur Addict Res. 2019; 2 5:256-262. doi: 10.1159/000500450. (Grupo GA12)
- **Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays.** Navas, A., Molina, J., Agüera, M., Guler, I., Jurado, A., Rodríguez-Benot, A., Alonso, C., & Solana, R.S. 2019 Front. Immunol. (Grupo GC01)
- **Biology of telomeres in prostate cancer: Development of new risk models.** Galisteo, J.M., Gómez, E.G., Castiñeira, R.C., Fernández, L., Pedregosa, A.M., Esteban, L.M., Pedro, N.D., González, S.G., Guler, I., Valiente, J.C., Tapia, M.J., & Najarro, P. 2019. (GC27 – external collaboration with company)
- **Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer.** Jiménez-Vacas, J. M., Gómez-Gómez, E., Montero-Hidalgo, A. J., Herrero-Aguayo, V., L-López, F., Sánchez-Sánchez, R., Luque, R. M. 2019. Journal of clinical medicine, 8(12), 2056. doi:10.3390/jcm8122056. (GC27)
- **Telomere-based risk models for the early 4 diagnosis of prostate cancer 5 6 Running title:** Telomeres in prostate cancer diagnosis. Juan Manuel Rubio Galiste , Luis Fernández, Enrique Gómez Gómez , Nuria de Pedro, Roque

Cano Castiñeira, Ana Blanca Pedregosa, Ipek Guler , Julia Carrasco Valiente, Laura Esteban, Sheila González Nila Castelló, Lissette Otero, Jorge Garcia, Enrique Segovia, Maria José Requena Tapia, Pilar Najarro (Accepted by Prostate Cancer and Prostatic Diseases) (GC27)

- **Impact of noise on psychophysiological state of patients admitted to a cardiovascular intensive care unit.** Prospective study Ignacio MORALES-CANÉ, Juan Antonio MORAL-ARROYO, Fabio DEBBIA, Ipek GULER, Francisca LLAMASRECIO, Darío ACUÑA-CASTROVIEJO, María Aurora RODRÍGUEZ-BORREGO, Pablo Jesús LÓPEZ-SOTO (Submitted to Australian Critical Care)

COURSES AND WORKSHOPS

- "Iniciación al software estadístico R con aplicaciones biomédicas" (Introduction to statistical software R with biomedical applications)
  - » 22, 25, 29 April, and 2 May, 2019
- "Análisis estadístico con SPSS" (Statistical analysis with SPSS)
  - » 6 and 18 December 2019
- External Seminar "Statistical tools for omics data analysis".
  - » 27 June, Dr. Natalia Vilor-Tejedor, Researcher at the Center for Genomic Regulation (CRG) in Barcelona

13. communication and RRI

125	51	377	182
NUMBER OF EVENTS	PRESS RELEASES	NUMBER OF NEWS IN PRESS	NEWS IN OTHER AUDIO-VISUAL MEDIA

75.020	38 INSTITUTIONAL / 17 EDUCATIONAL	1.055	>1.000.000
NUMBER OF WEBSITE VISITS	NUMBER OF VISITS TO IMIBIC	NUMBER OF PEOPLE WHO VISITED IMIBIC	SOCIAL MEDIA DATA INTERACTIONS

- **Scientific dissemination and outreach activities targeted to educational institutions:** within these activies, which represent the majority of the scientific outreach activities the following types of activity can be distinguished, based on the level of studies of the participating students, characteristics of the school and type of activity:

  » IMIBIC 2019 school visit programme for high school students. 16 visits in all were made, involving a total of 292 students and 28 teachers.

  » IMIBIC 2019 school visit programme for CFGS [Higher Level Training Cycle] students in the health care specialty, specifically the Clinical and Biomedical Laboratory Training Courses, 4 groups, and Pathological Anatomy and Cytology, 2 groups, with 107 students and 10 teachers taking part.

  » Students participating in "A very practical visit". This activity was part of the "Promoting STEM vocations from Biomedicine" project, with funding from the FECYT (Spanish Foundation for Science and Technology) and was planned for implementation in the 2019/2020 academic year. 125 students and 9 teachers took part in 6 visits during the first term of the 2019/2020 school year.

  » Presentation by IMIBIC in the School Visits Programme of the HURS (Reina Sofia University Hospital). We have collaborated in this activity for the past 8 years in succession. The Institute participated in 11 visits, and 293 high school students and 16 teachers from various schools in Cordoba and the province took part.

  » Participation in external activities for Bachillerato students:

    ◊ IES Science Project (PIIISA)(Project for the Initiation of Research and Innovation in Secondary Schools in Andalusia): 6 students (1º Bachillerato) from a school in Cordoba and another in Ronda (Malaga), accompanied by a teacher carried out 3 work sessions over 12 hours under the direction of a pre-doctoral researcher at IMIBIC. During this time, they carried out a research project that gave them a first taste of the techniques and methodology of basic research.

    ◊ UCO (University of Cordoba) Research Campus for high school students: 8 students (2º Bachillerato) spent three mornings in an IMIBIC research group, where they had the opportunity to take a closer look at basic research.

  » Finally, we would like to mention two advisory activities carried out with a group of 8 students (elementary school) and teacher from the Colegio Salesianos in Córdoba, who participated in the First Lego League programme, and with the pupil who obtained the best mark in the province of Córdoba in the EBAU (High school Assessment for Access to University) test held in June 2019.

- **Scientific outreach activities for other social groups:** In this section, based on the characteristics, age and interests of the participating social groups, the following activities can be highlighted:

  » Collaboration with the Health Promotion Unit of the Cordoba City Council, in which members of the Municipal Centres for the Elderly and the Adult Lifelong Learning Centres made a total of 9 visits to the IMIBIC. Led by IMIBIC specialists in the areas of nutrition, emotional well-being and healthy exercise, 166 citizens took part in activities to promote healthy lifestyles.

  » In collaboration with the HURS, we conducted two activities:

    ◊ Open day at the Reina Sofía University Hospital (HURS), with the participation of 235 future Specialist Residents, pending the choice of hospital where they will carry out their training.

    ◊ IMIBIC Open Day for HURS Specialist Residents who had just joined to do their training.

  » A Stroll through Science: A complete day, morning and afternoon, is devoted to this activity, organized by the Cordoba Teachers' Association for Scientific Culture in collaboration with Cordoba City Council, which takes place outdoors in the streets and is open to the general public. 37 IMIBIC researchers participated in it.

  » During 2019, two collaborative activities were carried out with the Spanish Red Cross and the Cordoba Association of Lupus Patients.

- **Science communication activities for children:** In this section, two visits were made by pupils aged 10-11 years from the British School in Cordoba, with 37 children and 4 teachers taking part. Likewise, during the first days of the school Christmas holidays, the first edition of the "Researching as a Family" event was held, aimed at the children and families of IMIBIC workers. A total of 85 children and 55 researchers participated in activities for 4-9- and 10-14-year olds, and prizes were awarded for the best work presented.

14. GOALS FOR 2020

	GOALS FOR 2020	INDICATORS/TARGETS
1.	Promote and consolidate institutional integration in its relationship with human resources.	To sign the New Collaboration Agreement for the Development of the IMIBIC. Affiliation (>70% IMIBIC).
2.	Develop strategies to increase the quality and number of scientific publications and the leadership of IMIBIC researchers in these publications.	To have ≥ 20% publications in the first decile or a Normalized Score Index>1 (2017 and 2018).
3.	Strengthen and improve IMIBIC's self-sustainability and optimize management of its own resources by attracting more European and competitive public funds, and promoting collaboration with the business community.	To increase fundraising for commercial clinical studies. Obtain funds ≥ 2.8 million euros.
4.	Develop a strategy to incorporate new clinical and basic research groups, as well as to promote existing groups from one category.	Approval of the new group evaluation criteria.
5.	Increase recruitment of talented researchers and promote their professional development.	To have > 55 competitively funded employment contracts active.
6.	Promote, define and consolidate international alliances and collaborations.	Increase the number of project proposals submitted to European and other international calls.
7.	Promote and increase protection of knowledge generated and technology transfer to the business world.	Implementation of a strategy to transfer ideas generated within the Institute or already patented to the patient care by activities such as: - Innovation Ideas Fair - Specific Innovation Awards. - Collaboration with the School of Engineering for joint projects, final study projects, etc.
8.	Guarantee the quality of the service provided by the research support and management units of the Institute and to promote transversal innovation through them.	Result of the satisfaction survey ≥ 85%.
9.	Develop and implement an action plan for the promotion of research in primary care and nursing.	Find a suitable space for primary care research installations.
10.	Develop a Succession Plan for the Next Generation of researchers	Plan implemented 100%.

15 annexes

PUBLICATIONS

PUBLICATIONS	IMIBIC GROUP
Navas A, Molina J, Aguera ML, Guler I, Jurado A, Rodriguez-Benoto A, Alonso C, Solana R; Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays. FRONTIERS IN IMMUNOLOGY. 10. DOI: 10.3389/fimmu.2019.01712. IF: 4,716. Q2. Article. IMIBIC GROUPS: GC01 GC07	GC01
San Segundo-Acosta P, Oeo-Santos C, Benede S, de los Rios V, Navas A, Ruiz-Leon B, Moreno C, Pastor-Vargas C, Jurado A, Villalba M, Barderas R; Delineation of the Olive Pollen Proteome and Its Allergenome Unmasks Cyclophilin as a Relevant Cross-Reactive Allergen. JOURNAL OF PROTEOME RESEARCH. 18. 8. (3052-3066). DOI: 10.1021/acs.jproteome.9b00167. IF: 3,78. Q1. Article. IMIBIC GROUPS: GC01	GC01
Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Banas H, Casas-Aviles I, Duran E, Alonso C, Solana R, Tarazona R; DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. CANCERS. 11. 6. DOI: 10.3390/cancers11060877. IF: 6,162. Q1. Review. IMIBIC GROUPS: GC01	GC01
Montero-Martin G, Mallempati KC, Gangavarapu S, Sanchez-Gordo F, Herrero-Mata MJ, Balas A, Vicario JL, Sanchez-Garcia F, Gonzalez-Escribano MF, Muro M, Moya-Quiles MR, Gonzalez-Fernandez R, Ocejo-Vinyals JG, Marin L, Creary LE, Osoegawa K, Vayntrub T, Car; High-resolution characterization of allelic and haplotypic HLA frequency distribution in a Spanish population using high-throughput next-generation sequencing. HUMAN IMMUNOLOGY. 80. 7. (429-436). DOI: 10.1016/j.humimm.2019.02.005. IF: 2,202. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC01	GC01
Sanchez-Correa B, Lopez-Sejas N, Duran E, Labella F, Alonso C, Solana R, Tarazona R; Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. CANCER IMMUNOLOGY IMMUNOTHERAPY. 68. 5. (861-870). DOI: 10.1007/s00262-019-02336-6. IF: 4,9. Q1. Review. IMIBIC GROUPS: GC01	GC01
Tabar AI, Acevedo N, Mazuecos JMB, Ibanez F, Garde G, de Rojas HF, Pinana D, Fernandez O, Martos R, Fernandez R, Reig R, Martinez A, Aguilar M, Vidal C; Quality Standards for Allergen Immunotherapy Clinics in Spain: Consensus Document. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 29. 4. (272-279). DOI: 10.18176/jiaci.0318. IF: 3,802. Q2. Article. IMIBIC GROUPS: GC01	GC01
Sanchez-Solares J, Delgado-Dolset MI, Mera-Berriatua L, Hormias-Martin G, Cumplido JA, Saiz V, Carrillo T, Moreno-Aguilar C, Escribese MM, Gomez-Casado C, Barber D; Respiratory allergies with no associated food allergy disrupt oral mucosa integrity. ALLERGY. 0. DOI: 10.1111/all.13860. IF: 6,048. Q1. Letter; Early Access. IMIBIC GROUPS: GC01	GC01
Eguiluz-Gracia I, Testera-Montes A, Gonzalez M, Perez-Sanchez N, Ariza A, Salas M, Moreno-Aguilar C, Campo P, Torres MJ, Rondon C; Safety and reproducibility of nasal allergen challenge. ALLERGY. 74. 6. (1125-1134). DOI: 10.1111/all.13728. IF: 6,771. Q1. Article. IMIBIC GROUPS: GC01	GC01
San Segundo-Acosta P, Oeo-Santos C, Navas A, Jurado A, Villalba M, Barderas R; Ole e 15 and its human counterpart -PPIA- chimeras reveal an heterogeneous IgE response in olive pollen allergic patients. SCIENTIFIC REPORTS. 9. 15027. DOI: 10.1038/s41598-019-51005-2. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC01	GC01
Oeo-Santos C, Navas A, Benede S, Ruiz-Leon B, Diaz-Perales A, Vogel L, Moreno-Aguilar C, Jurado A, Villalba M, Barderas R; New insights into the sensitization to nonrelated nsLTPs from pollen and food: New role of the allergen Ole e 7. ALLERGY. DOI: 10.1111/all.14086. IF: 6,771. D2 Q1. Article; Early Access. IMIBIC GROUPS: GC01	GC01
Almeida JS, Couceiro P, Lopez-Sejas N, Alves V, Ruzickova L, Tarazona R, Solana R, Freitas-Tavares P, Santos-Rosa M, Rodrigues-Santos P; NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. FRONTIERS IN IMMUNOLOGY. 10. 2493. DOI: 10.3389/fimmu.2019.02493. IF: 4,716. Q2. Article. IMIBIC GROUPS: GC01	GC01
Gastaminza G, Ruiz-Canela M, Andres-Lopez B, Villarejo MJB, Cabanas R, Garcia-Nunez I, Goikoetxea MJ, Laguna JJ, Lobera T, Lopez-San Martin M, Martin-Lazaro J, Mielgo-Ballesteros R, Moreno E, Moya-Quesada MD, Ortega-Rodriguez N, Rojas-Perez-Ezquerra P, Ro; Quality of Life in Patients with Allergic Reactions to Medications: Influence of a Drug Allergy Evaluation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 7. 8. (2714-2721). DOI: 10.1016/j.jaip.2019.05.017. IF: 7,55. D1 Q1. Article. IMIBIC GROUPS: GC01	GC01

PUBLICATIONS	IMIBIC GROUP
Ariza A, Torres MJ, Moreno-Aguilar C, Fernandez-Santamaria R, Fernandez TD; Early Biomarkers for Severe Drug Hypersensitivity Reactions. CURRENT PHARMACEUTICAL DESIGN. 25. 36. (3829-3839). DOI: 10.2174/1381612825666191107105440. IF: 2,412. Q3. Review. IMIBIC GROUPS: GC01	GC01
Chaparro M, Donday MG, Barreiro-de Acosta M, Domenech E, Esteve M, Garcia-Sanchez V, Nos P, Panes J, Martinez C, Gisbert JP; Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. 12. . DOI: 10.1177/1756284819874202. IF: 3,961. Q2. Article. IMIBIC GROUPS: GC02	GC02
Mena-Bares LM, Benitez-Cantero JM, Iglesias-Flores E, Gros-Alcalde B, Moreno-Ortega E, Maza-Muret FR, Carmona-Asenjo E, Garcia-Sanchez MV, Vallejo-Casas JA; Bile acid malabsorption in patients with chronic diarrhea and Crohn's disease. REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS. 111. 1. (40-44). DOI: 10.17235/reed.2018.5376/2017. IF: 1,858. Q4. Article. IMIBIC GROUPS: GA10 GC02 Medicina Ap Digestivo	GC02
De Luca L, Kalafateli M, Bianchi S, Alasaker N, Buzzetti E, Rodriguez-Peralvarez M, Thorburn D, O'Beirne J, Patch D, Leandro G, Westbrook R, Tsochatzis EA; Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors. LIVER INTERNATIONAL. 39. 8. (1557-1565). DOI: 10.1111/liv.14185. IF: 5,542. Q1. Article. IMIBIC GROUPS: GC02	GC02
Cabre E, Manosa M, Marin I, Martin-Mateos R, Iglesias-Flores E, Barreiro-de-Acosta M, Nos P, Busquets D, Menchen LA, Lopez-Sanroman A, Domenech E; Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study. DIGESTIVE AND LIVER DISEASE. 51. 5. (669-674). DOI: 10.1016/j.dld.2018.12.004. IF: 3,037. Q2. Article. IMIBIC GROUPS: GC02	GC02
Chaparro M, Garre A, Ricart E, Iglesias-Flores E, Taxonera C, Domenech E, Gisbert JP, Manosa M, Mendoza IV, Minguez M, Arguelles F, Parga LD, Arroyo M, Lopez-Sanroman A, Tirado MR, Guardiola J, Arranz MDM, Beltran B, Barrio J, Riestra S, Garcia-Planella E; Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 49. 4. (419-428). DOI: 10.1111/apt.15114. IF: 7,731. D1. Article. IMIBIC GROUPS: GC02	GC02
del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC25 GC02 GC09 Anatomía Patológica	GC02
Barreiro-De Acosta M, Domenech E, Arranz MDM, Sanchez VG, Casbas AG, Chaparro M, Alcain G, Iborra M, Taxonera C, Rodriguez-Lago I, Menchen L, Khorrami S, Romero C, Cea-Calvo L, Julia B; Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. 13. 8. (807-813). DOI: 10.1080/17474124.2019.1626717. IF: 2,991. Q3. Article. IMIBIC GROUPS: GC02	GC02
Chaparro M, Barreiro-de Acosta M, Benitez JM, Cabriada JL, Casanova MJ, Ceballos D, Esteve M, Fernandez H, Ginard D, Gomollon F, Lorente R, Nos P, Riestra S, Rivero M, Robledo P, Rodriguez C, Sicilia B, Torrella E, Garre A, Garcia-Esquinas E, Rodriguez-Ar; EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. 12. DOI: 10.1177/1756284819847034. IF: 3,961. Q2. Article. IMIBIC GROUPS: GC02	GC02
Chaparro M, Aterido A, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, Garcia-Sanchez V, Marin-Jimenez I, Barreiro-de Acosta M, Vera I, Martin-Arranz MD, Hernandez-Breijo B, Mesonero F, Sempere L, Gomollon F, Hinojosa J, Bermejo F, Beltran B, Rodr; Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. 12. DOI: 10.1177/1756284819867848. IF: 3,961. Q2. Article. IMIBIC GROUPS: GC02	GC02
Manosa M, Chaparro M, Juan A, Arajol C, Alfaro I, Minguez M, Velayos B, Benitez JM, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert JP, Domenech E; Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. AMERICAN JOURNAL OF GASTROENTEROLOGY. 114. 5. (771-776). DOI: 10.14309/ajg.0000000000000210. IF: 10,231. D1. Article. IMIBIC GROUPS: GC02	GC02

PUBLICATIONS	IMIBIC GROUP
Calafat M, Manosa M, Canete F, Ricart E, Iglesias E, Calvo M, Rodriguez-Moranta F, Taxonera C, Nos P, Mesonero F, Martin-Arranz MD, Minguez M, Gisbert JP, Garcia-Lopez S, de Francisco R, Gomollon F, Calvet X, Garcia-Planella E, Rivero M, Martinez-Cadilla; Increased risk of thiopurine-related adverse events in elderly patients with IBD. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 0. . DOI: 10.1111/apt.15458. IF: 7,731. D1. Article; Early Access. IMIBIC GROUPS: GC02	GC02
Rodriguez-Peralvarez M, Amado V, de la Mata M; Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 50. 4. (478-479). DOI: 10.1111/apt.15300. IF: 7,731. D1. Letter. IMIBIC GROUPS: GC02 Medicina Ap Digestivo	GC02
Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang ZY, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J; Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. GUT. 68. 6. (1065-1075). DOI: 10.1136/gutjnl-2018-316408. IF: 17,943. D1. Article. IMIBIC GROUPS: GC02	GC02
Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M; mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 2. . DOI: 10.3390/ijms20020336. IF: 4,183. Q2. Article. IMIBIC GROUPS: GC02 Medicina Ap Digestivo GC18 Cirugía General y Digestiva GC18 Anatomía Patológica	GC02
Pozo-Laderas JC, Rodriguez-Peralvarez M, Munoz-Villanueva MC, Rivera-Espinar F, Durban-Garcia I, Munoz-Trujillo J, Robles-Arista JC, Briceno-Delgado J; Pretransplant predictors of early mortality in adult recipients of liver transplantation in the MELD-Na Era. MEDICINA INTENSIVA. 43. 5. (261-269). DOI: 10.1016/j.medin.2018.03.008. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC18 Medicina Intensiva GC02 GC18 Unidad Metdología y Estadistica Imibic	GC02
Chavarria C, Casanova MJ, Chaparro M, Barreiro-de Acosta M, Ezquiaga E, Bujanda L, Rivero M, Arguelles-Arias F, Martin-Arranz MD, Martinez-Montiel MP, Valls M, Ferreiro-Iglesias R, Llao J, Moraleja-Yudego I, Casellas F, Antolin-Melero B, Cortes X, Plaza R; Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. JOURNAL OF CROHNS & COLITIS. 13. 8. (996-1002). DOI: 10.1093/ecco-jcc/jjz024. IF: 6,637. Q1. Article. IMIBIC GROUPS: GC02	GC02
Taxonera C, Lopez-Sanroman A, Vera-Mendoza I, Domenech E, Ruiz VV, Marin-Jimenez I, Guardiola J, Castro L, Esteve M, Iglesias E, Ceballos D, Martinez-Montiel P, Gisbert JP, Minguez M, Echarri A, Calvet X, Barrio J, Hinojosa J, Martin-Arranz MD, Marquez-Mo; Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. DIGESTIVE AND LIVER DISEASE. 51. 4. (529-535). DOI: 10.1016/j.dld.2019.01.002. IF: 3,037. Q2. Article. IMIBIC GROUPS: GC02	GC02
Picazo C, McDonagh B, Peinado J, Barcena JA, Matallana E, Aranda A; Saccharomyces cerevisiae Cytosolic Thioredoxins Control Glycolysis, Lipid Metabolism, and Protein Biosynthesis under Wine-Making Conditions. APPLIED AND ENVIRONMENTAL MICROBIOLOGY. 85. 7. . DOI: 10.1128/AEM.02953-18. IF: 4,077. Q1. Article. IMIBIC GROUPS: GC02	GC02
Rodriguez-Lago I, Benitez JM, Sempere L, Saez-Gonzalez E, Barreiro-de Acosta M, de Zarate JO, Cabriada JL; The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? JOURNAL OF CLINICAL APHERESIS. 0. . DOI: 10.1002/jca.21746. IF: 3,088. Q2. Article; Early Access. IMIBIC GROUPS: GC02	GC02
Padilla CA, Barcena JA, Lopez-Grueso MJ, Requejo-Aguilar R; The regulation of TORC1 pathway by the yeast chaperones Hsp31 is mediated by SFP1 and affects proteasomal activity. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS. 1863. 3. (534-546). DOI: 10.1016/j.bbagen.2018.12.011. IF: 3,681. Q2. Article. IMIBIC GROUPS: GC02	GC02
Lopez-Grueso MJ, Gonzalez-Ojeda R, Requejo-Aguilar R, McDonagh B, Fuentes-Almagro CA, Muntane J, Barcena JA, Padilla CA; Thioredoxin and glutaredoxin regulate metabolism through different multiplex thiol switches. REDOX BIOLOGY. 21. . DOI: 10.1016/j.redox.2018.11.007. IF: 7,793. D1. Article. IMIBIC GROUPS: GC02	GC02
Ayllon MD, Ciria R, Gomez-Luque I, Rodriguez-Peralvarez M, Padial A, Luque A, Lopez-Cillero P, de la Mata M, Briceno J; Use of Peritoneovenous Shunt for the Management of Refractory Ascites. TRANSPLANTATION PROCEEDINGS. 51. 1. (41-43). DOI: 10.1016/j.transproceed.2018.04.089. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GC02	GC02

PUBLICATIONS	IMIBIC GROUP
Perez AB, Chueca N, Garcia-Deltoro M, Martinez-Sapina AM, Lara-Perez MM, Garcia-Bujalance S, Aldamiz-Echevarria T, Vera-Mendez FJ, Pineda JA, Casado M, Pascasio JM, Salmeron J, Alados-Arboledas JC, Poyato A, Tellez F, Rivero-Juarez A, Merino D, Vivancos-G; High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. JOURNAL OF HEPATOLOGY. 71. 5. (876-888). DOI: 10.1016/j.jhep.2019.06.022. IF: 18,946. D1. Article. IMIBIC GROUPS: GC24 GC02 GC26	GC02
Canete F, Manosa M, Casanova MJ, Gonzalez-Sueyro RC, Barrio J, Bermejo F, Nos P, Iglesias-Flores E, Garcia-Planella E, Perez-Calle JL, Vicente R, Vera M, Ramos L, Rivero M, De Francisco R, Montserrat A, Benitez O, Navarro P, Taxonera C, Hinojosa E, Marque; Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. INFLAMMATORY BOWEL DISEASES. 25. 11. (1862-1870). DOI: 10.1093/ibd/izz084. IF: 4,005. Q2. Article. IMIBIC GROUPS: GC02	GC02
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J; Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 19. 11. (1388-1398). DOI: 10.2174/1871520619666190417162409. IF: 2,18. Q3. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GE01 GC02	GC02
Chaparro M, Garre A, Veloz MFG, Moron JMV, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jimenez I, Calvet X, Bujanda L, Rivero M, Gomollon F, Benitez JM, Bermejo F, Alcaide N, Gutierrez A, Manosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro; Effectiveness and Safety of the Switch from Remicade (R) to CT-P13 in Patients with Inflammatory Bowel Disease. JOURNAL OF CROHNS & COLITIS. 13. 11. (1380-1386). DOI: 10.1093/ecco-jcc/jjz070. IF: 7,827. D2 Q1. Article. IMIBIC GROUPS: GC02	GC02
Aterido A, Palau N, Domenech E, Mateu PN, Gutierrez A, Gomollon F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Munoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Panes J, Garcia-Sanchez V, Lopez-Lasanta M, Pluma A, Codo L, Garcia-Montero A,; Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. PHARMACOGENOMICS JOURNAL. 19. 6. (547-555). DOI: 10.1038/s41397-019-0090-4. IF: 3,503. Q2. Article. IMIBIC GROUPS: GC02	GC02
Gutierrez A, Rivero M, Martin-Arranz MD, Sanchez VG, Castro M, Barrio J, de Francisco R, Barreiro-de Acosta M, Julia B, Cea-Calvo L, Romero C, Sainz NB, Domenech E; Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN study. GASTROENTEROLOGY REPORT. 7. 3. (168-175). DOI: 10.1093/gastro/goz010. IF: 2,194. Q3. Article. IMIBIC GROUPS: GC02	GC02
Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutierrez A, Abalos JG, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodriguez-Lago I, Mesonero F, de Francisco R, Gomez-Gomez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Arranz EM, Canete F, Vicente R, Sicilia B, Antolin B, Prieto V, Marquez L, Benitez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Calle JLP, Van Domselaar M, Rodriguez C, Calvet X, Munoz-Villafranca C, Garcia-Sepulcre MF, Munoz-Garrido P, Fernandez-Clotet A, Irwin LG, Hernandez S, Guardiola J, Sempere L, Munoza CG, Hernandez V, Beltran B, Barrio J, Alba C, Moraleja I, Lopez-Sanroman A, Riestra S, Montiel PM, Garre A, Arranz L, Garcia MJ, Arranz MDM, Corsino P, Arias L, Fernandez-Salazar L, Fernandez-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Villarino MTA, Mora M, Ruiz L, Lopez-Serrano P, Blazquez I, Villoria A, Fernandez M, Bermejo F, Banales JM, Domenech E, Gisbert JP; Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. JOURNAL OF CROHNS & COLITIS. 13. 12. (1492-1500). DOI: 10.1093/ecco-jcc/jjz094. IF: 7,827. D2 Q1. Article. IMIBIC GROUPS: GC02	GC02
Grueso MJL, Valero RMT, Carmona-Hidalgo B, Ruiz DJL, Peinado J, McDonagh B, Aguilar RR, Ruiz JAB, Pena CAP; Peroxiredoxin 6 Down-Regulation Induces Metabolic Remodeling and Cell Cycle Arrest in HepG2 Cells. ANTIOXIDANTS. 8. 11. . DOI: 10.3390/antiox8110505. IF: 4,52. D1 Q1. Article. IMIBIC GROUPS: GC02	GC02
Lopez-Grueso MJ, Gonzalez R, Muntane J, Barcena JA, Padilla CA; Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells. ANTIOXIDANTS. 8. 10. . DOI: 10.3390/antiox8100501. IF: 4,52. D1 Q1. Article. IMIBIC GROUPS: GC02	GC02

PUBLICATIONS	IMIBIC GROUP
Montecatine-Alonso E, Gil-Navarro MV, Fernandez-Llamazares CM, Fernandez-Polo A, Soler-Palacin P, Llorente-Gutierrez J, Calvo MTGT, Esquivel-Mora MD, Perez-Rodrigo I, Cisneros JM, Goycochea-Valdiviai WA, Neth O, Benito CAV, Chavarri-Gil E, Gallego-Fernand; Antimicrobial defined daily dose adjusted by weight: a proposal for antibiotic consumption measurement in children. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 5. (301-306). DOI: 10.1016/j.eimc.2018.07.011. IF: 1,685. Q4. Article. IMIBIC GROUPS: Farmacia GC03	GC03
Ramos-Vivas J, Chapartegui-Gonzalez I, Fernandez-Martinez M, Gonzalez-Rico C, Fortun J, Escudero R, Marco F, Linares L, Montejo M, Aranzamendi M, Munoz P, Valerio M, Aguado JM, Resino E, Ahufinger IG, Vega AP, Martinez L, Farinas MC, San Millan JCR, Rodri; Biofilm formation by multidrug resistant Enterobacteriaceae strains isolated from solid organ transplant recipients. SCIENTIFIC REPORTS. 9. . DOI: 10.1038/s41598-019-45060-y. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC24 GC03	GC03
Jimenez-Ruiz S, Paniagua J, Isla J, Martinez-Padilla AB, Risalde MD, Caballero-Gomez J, Cano-Terriza D, Pujols J, Arenas A, Garcia-Bocanegra I; Description of the first Schmallenberg disease outbreak in Spain and subsequent virus spreading in domestic ruminants. COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES. 65. . (189-193). DOI: 10.1016/j.cimid.2019.06.002. IF: 1,871. Q1. Article. IMIBIC GROUPS: GC03	GC03
Fernandez-Cooke E, Tascon AB, Sanchez-Manubens J, Anton J, Lozano CDG, Santos JA, Pinto EV, Garulo DC, Rodriguez BM, Alonso MB, Cuadros EN, Gomez MLN, Dominguez-Rodriguez S, Calvo C, Perez DM, Cantero MM, Gallego BC, Campos LIM, Garcia FS, Lovillo MC, Mar; Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group. PLOS ONE. 14. 5. . DOI: 10.1371/journal.pone.0215665. IF: 2,776. Q2. Article. IMIBIC GROUPS: GC03	GC03
Tacconelli E, Mazzaferri F, De Smet AM, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodriguez-Bano J; ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. CLINICAL MICROBIOLOGY AND INFECTION. 25. 7. (807-817). DOI: 10.1016/j.cmi.2019.01.005. IF: 6,425. D1. Article. IMIBIC GROUPS: GC03	GC03
Machuca I, Gutierrez-Gutierrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Perez E, Perez-Nadales E, Caston JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual A, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J, Salamanca E, ; External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 54. 4. (442-448). DOI: 10.1016/j.ijantimicag.2019.07.017. IF: 4,615. Q1. Article. IMIBIC GROUPS: GC26 GC03 Medicina Intensiva GC24	GC03
Caballero-Villarraso J, Aguado R, Canete MD, Roldan L, Canete R, Santamaria M; Hormone replacement therapy in children with growth hormone deficiency: impact on immune profile. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY. 19. . (1-5). DOI: 10.1080/13813455.2019.1628070. IF: 2,11. Q3. Article; Early Access. IMIBIC GROUPS: GE01 GA05 GC03	GC03
Shepshelovich D, Tau N, Green H, Rozen-Zvi B, Issaschar A, Falcone M, Coussement J, Zusman O, Manuel O, Mor E, Torre-Cisneros J, Yahav D; Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: A multinational survey. TRANSPLANT INFECTIOUS DISEASE. 0. . DOI: 10.1111/tid.13134. IF: 2,112. Q3. Article; Early Access. IMIBIC GROUPS: GC03	GC03
Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, Garcia E, Hemmati P, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, de la Calle GM, Manzur A, Marin JI, Marquez-Gomez I, Martin-Davila P, Mikulska M, Mon; Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ OPEN. 9. 5. . DOI: 10.1136/bmjopen-2018-025744. IF: 2,413. Q2. Article. IMIBIC GROUPS: GC16 GC03 Hematología	GC03
Palacios-Baena ZR, Delgado-Valverde M, Mendez AV, Almirante B, Gomez-Zorrilla S, Borrell N, Corzo JE, Gurgui M, de la Calle C, Garcia-Alvarez L, Ramos L, Gozalo M, Morosini MI, Molina J, Causse M, Pascual A, Rodriguez-Bano J, de Cueto M, Reig AMP, Quintan; Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. CLINICAL INFECTIOUS DISEASES. 69. 6. (956-962). DOI: 10.1093/cid/ciy1032. IF: 9,055. D1. Article. IMIBIC GROUPS: Enfermedades Infecciosas GC03 GC24	GC03

PUBLICATIONS	IMIBIC GROUP
Lopez-Alad R, Guiu A, Mosquera MM, Lopez-Medrano F, Cofan F, Linares L, Torre-Cisneros J, Vidal E, Moreno A, Aguado JM, Cordero E, Martin-Gandul C, Carratala J, Sabe N, Niubo J, Cervera C, Capon A, Cervilla A, Santos M, Bodro M, Munoz P, Farinas MC, Anton; Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing. PLOS ONE. 14. 7. . DOI: 10.1371/journal.pone.0219701. IF: 2,776. Q2. Article. IMIBIC GROUPS: GC03	GC03
Sanchez-Fabra D, Dyar OJ, del Pozo JL, Amiguet JA, Colmenero JD, Farinas MD, Lopez-Medrano F, Portilla J, Praena J, Torre-Cisneros J, Rodriguez-Bano J, Pulcini C, Pano-Pardo JR; Perspective of Spanish medical students regarding undergraduate education in infectious diseases, bacterial resistance and antibiotic use. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 1. (25-30). DOI: 10.1016/j.eimc.2017.12.003. IF: 1,685. Q4. Article. IMIBIC GROUPS: GC03	GC03
Fortun J, Gioia F, Cardozo C, Gudiol C, Diago E, Caston JJ, Munoz P, Lopez J, Puerta-Alcalde P, Enzenhofer M, Ramos A, Frutos A, Machado M, Garcia-Vidal C, Parody R, Martin-Davila P; Posaconazole salvage therapy: The Posifi study. MYCOSES. 62. 6. (526-533). DOI: 10.1111/myc.12911. IF: 3,065. Q2. Article. IMIBIC GROUPS: GC03	GC03
Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J; Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 79. 3. (245-252). DOI: 10.1016/j.jinf.2019.06.014. IF: 5,099. Q1. Article. IMIBIC GROUPS: GC03 GC26 GC24 Medicina Intensiva GC18	GC03
Fernandez-Ruiz M, Gimenez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisan S, Torre-Cisneros J, Fortun J, Andres A, San Juan R, Lopez-Medrano F, Navarro D, Aguado JM, Gonzalez E, Polanco N, Rodriguez R, Aranzamendi M, Carmona ; Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. CLINICAL MICROBIOLOGY AND INFECTION. 25. 3. . DOI: 10.1016/j.cmi.2018.05.010. IF: 6,425. D1. Article. IMIBIC GROUPS: GC03 GC07	GC03
Mitsuwan W, Jimenez-Munguia I, Visutthi M, Sianglum W, Jover A, Barcenilla F, Garcia M, Pujol M, Gasch O, Dominguez MA, Camoez M, Duenas C, Ojeda E, Martinez JA, Marco F, Chaves F, Lagarde M, Lopez-Medrano F, Montejo JM, Bereciertua E, Hernandez JL, von W; Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles. MICROBIAL PATHOGENESIS. 128. . (112-118). DOI: 10.1016/j.micpath.2018.12.019. IF: 2,581. Q3. Article. IMIBIC GROUPS: GC03	GC03
Giannella M, Pascale R, Gutierrez-Gutierrez B, Cano A, Viale P; The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. 17. 4. (265-273). DOI: 10.1080/14787210.2019.1595590. IF: 3,09. Q2. Review. IMIBIC GROUPS: GC03	GC03
Lopez-Medrano F, Silva JT, Fernandez-Ruiz M, Vidal E, Origuen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernandez D, Jironda-Gallegos C, Escudero R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sanchez-Sobrino B, Montero MM, Redondo D, Candel FJ, Pere; Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort. AMERICAN JOURNAL OF TRANSPLANTATION. 20. 2. (451-462). DOI: 10.1111/ajt.15614. IF: 7,163. D1 Q1. Article; Early Access. IMIBIC GROUPS: GC03	GC03
Montilla AM, Gomez-Garcia F, Gomez-Arias PJ, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B, Ruano J; Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. DERMATOLOGY AND THERAPY. 9. 4. (655-683). DOI: 10.1007/s13555-019-00329-y. IF: 3,615. D2 Q1. Review; Early Access. IMIBIC GROUPS: GE03 Farmacia GC03	GC03
Paez-Vega A, Cantisan S, Vaquero JM, Vidal E, Luque-Pineda A, Lobo-Acosta MA, Perez AB, Alonso-Moralejo R, Iturbe D, Monforte V, Otero-Gonzalez I, Pastor A, Ussetti P, Torre-Cisneros J; Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial. BMJ OPEN. 9. 8. . DOI: 10.1136/bmjopen-2019-030648. IF: 2,376. Q2. Article. IMIBIC GROUPS: GC03 GA03 GC24	GC03
Chianese G, Golin-Pacheco SD, Taglialatela-Scafati O, Collado JA, Munoz E, Appendino G, Pollastro F; Bioactive triterpenoids from the caffeine-rich plants guayusa and mate. FOOD RESEARCH INTERNATIONAL. 115. (504-510). DOI: 10.1016/j.foodres.2018.10.005. IF: 3,579. Q1. Article; Proceedings Paper. IMIBIC GROUPS: GC04	GC04

PUBLICATIONS	IMIBIC GROUP
Garcia-Martin A, Garrido-Rodriguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, Rollland A, Appendino G, Munoz E; Cannabinoid derivatives acting as dual PPAR gamma/CB2 agonists as therapeutic agents for systemic sclerosis. BIOCHEMICAL PHARMACOLOGY. 163. (321-334). DOI: 10.1016/j.bcp.2019.02.029. IF: 4,825. D1. Article. IMIBIC GROUPS: GC04	GC04
Romero-Ruiz A, Avendano MS, Dominguez F, Lozoya T, Molina-Abril H, Sangiao-Alvarellos S, Gurrea M, Lara-Chica M, Fernandez-Sanchez M, Torres-Jimenez E, Perdices-Lopez C, Abbara A, Steffani L, Calzado MA, Dhillo WS, Pellicer A, Tena-Sempere M; Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 220. 5. (480.e1-480.e17). DOI: 10.1016/j.ajog.2019.01.228. IF: 6,12. D1. Article. IMIBIC GROUPS: GC10 GC04	GC04
Burgaz S, Garcia C, Gomez-Canas M, Munoz E, Fernandez-Ruiz J; Development of An Oral Treatment with the PPAR-gamma-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease. MOLECULES. 24. 15. DOI: 10.3390/molecules24152702. IF: 3,06. Q2. Article. IMIBIC GROUPS: GC04	GC04
Cena-Diez R, Martin-Moreno A, de la Mata FJ, Gomez-Ramirez R, Munoz E, Ardoys M, Munoz-Fernandez MA; G1-S4 or G2-S16 carbosilane dendrimer in combination with Platycodin D as a promising vaginal microbicide candidate with contraceptive activity. INTERNATIONAL JOURNAL OF NANOMEDICINE. 14. (2371-2380). DOI: 10.2147/IJN.S188495. IF: 4,471. Q1. Article. IMIBIC GROUPS: GC04	GC04
Rogati F, Milan E, Appendino G, Correa A, Caprioglio D, Minassi A, Munoz E; Identification of a Strigoterpenoid with Dual Nrf2 and Nf-kappa B Modulatory Activity. ACS MEDICINAL CHEMISTRY LETTERS. 10. 4. (606-610). DOI: 10.1021/acsmedchemlett.8b00604. IF: 3,737. Q2. Article. IMIBIC GROUPS: GC04	GC04
Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A; LUBAC determines chemotherapy resistance in squamous cell lung cancer. JOURNAL OF EXPERIMENTAL MEDICINE. 216. 2. (450-465). DOI: 10.1084/jem.20180742. IF: 10,892. D1. Article. IMIBIC GROUPS: GA01 GC04	GC04
Caprioglio D, Allegrone G, Pollastro F, Valera S, Lopatriello A, Collado JA, Munoz E, Appendino G, Taglialatela-Scafati O; O -Methyl Phytocannabinoids: Semi-synthesis, Analysis in Cannabis Flowerheads, and Biological Activity *. PLANTA MÉDICA. 85. 43810. (981-986). DOI: 10.1055/a-0883-5383. IF: 2,494. Q1. Article. IMIBIC GROUPS: GC04	GC04
Caprioglio D, Mattoteia D, Minassi A, Pollastro F, Lopatriello A, Munoz E, Taglialatela-Scafati O, Appendino G; One-Pot Total Synthesis of Cannabinol via Iodine-Mediated Deconstructive Annulation. ORGANIC LETTERS. 21. 15. (6122-6125). DOI: 10.1021/acs.orglett.9b02258. IF: 6,555. D1. Article. IMIBIC GROUPS: GC04	GC04
Aguareles J, Paraiso-Luna J, Palomares B, Bajo-Graneras R, Navarrete C, Ruiz-Calvo A, Garcia-Rinon D, Garcia-Taboada E, Guzman M, Munoz E, Galve-Roperh I; Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. TRANSLATIONAL NEURODEGENERATION. 8. DOI: 10.1186/s40035-019-0148-x. IF: 5,534. Q1. Article. IMIBIC GROUPS: GC04	GC04
Relano-Rodriguez I, Juarez-Sanchez R, Pavicic C, Munoz E, Munoz-Fernandez MA; Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment. JOURNAL OF NANOBIOTECHNOLOGY. 17. DOI: 10.1186/s12951-019-0500-4. IF: 5,345. Q1. Article. IMIBIC GROUPS: GC04	GC04
Garrido-Rodriguez M, Ortea I, Calzado MA, Munoz E, Garcia V; SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. JOURNAL OF PROTEOMICS. 193. (217-229). DOI: 10.1016/j.jprot.2018.10.012. IF: 3,537. Q1. Article. IMIBIC GROUPS: GC04 Unidad Proteómica Imibic	GC04
Cuadari A, Pollastro F, Unciti-Broceta JD, Caprioglio D, Minassi A, Lopatriello A, Munoz E, Taglialatela-Scafati O, Appendino G; The dimerization of Delta (9)-tetrahydrocannabinolic acid A (THCA-A). ACTA PHARMACEUTICA SINICA B. 9. 5. (1078-1083). DOI: 10.1016/j.apsb.2019.06.007. IF: 5,808. D1. Article. IMIBIC GROUPS: GC04	GC04
Morrugares R, Correa-Saez A, Moreno R, Garrido-Rodriguez M, Munoz E, de la Vega L, Calzado MA; Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2. CELLULAR AND MOLECULAR LIFE SCIENCES. . DOI: 10.1007/s00018-019-03309-9. IF: 7,014. D2 Q1. Article; Early Access. IMIBIC GROUPS: GC04	GC04

PUBLICATIONS	IMIBIC GROUP
Heras V, Sangiao-Alvarellos S, Manfredi-Lozano M, Sanchez-Tapia MJ, Ruiz-Pino F, Roa J, Lara-Chica M, Morrugares-Carmona R, Jouy N, Abreu AP, Prevot V, Belsham D, Vazquez MJ, Calzado MA, Pinilla L, Gaytan F, Latronico AC, Kaiser UB, Castellano JM, Tena-Sempere M; Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3. PLOS BIOLOGY. 17. 11. DOI: 10.1371/journal.pbio.3000532. IF: 8,386. D1 Q1. Article. IMIBIC GROUPS: GC10 GC04	GC04
Gotz MR, Collado JA, Fernandez-Ruiz J, Fiebich BL, Garcia-Toscano L, Gomez-Canas M, Koch O, Leha A, Munoz E, Navarrete C, Pazos MR, Holzgrabe U; Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives. FRONTIERS IN PHARMACOLOGY. 10. DOI: 10.3389/fphar.2019.01284. IF: 3,845. Q1. Article. IMIBIC GROUPS: GC04	GC04
Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, L-Lopez F, Ibanez-Costa A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, ; Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513). DOI: 10.1210/jc.2019-00056. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC05 GA04 Endocrinología	GC05
Kishimoto M, Yoshida K, Ichikawa N, Inoue H, Kaneko Y, Kawasaki T, Matsui K, Morita M, Suda M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Haji Y, Rokutanda R, Yanaoka H, Cheung PP, Gu JR, Kim TH, Luo SF, Okada M, Medina CL, Molto A,; Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. JOURNAL OF RHEUMATOLOGY. 46. 8. (896-903). DOI: 10.3899/jrheum.180412. IF: 3,634. Q2. Article. IMIBIC GROUPS: GC05	GC05
Perez-Sanchez C, Cecchi I, Barbarroja N, Patino-Trives AM, Luque-Tevar M, Perez-Sanchez L, Ibanez-Costa A, de la Rosa IA, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MA, Collantes E, Lopez-Pedrera C; Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 9. (6308-6318). DOI: 10.1111/jcmm.14517. IF: 4,658. Q1. Article; Early Access. IMIBIC GROUPS: GC05	GC05
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L, Gomez-Reino JJ; Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. RHEUMATOLOGY INTERNATIONAL. 39. 3. (509-515). DOI: 10.1007/s00296-018-4177-z. IF: 2,2. Q3. Article. IMIBIC GROUPS: GC05	GC05
Lopez-Mejias R, Carmona FD, Genre F, Remuzgo-Martinez S, Gonzalez-Juanatey C, Corrales A, Vicente EF, Pulito-Cueto V, Miranda-Filloy JA, Huaranga MAR, Blanco R, Robustillo-Villarino M, Rodriguez-Carrio J, Alperi-Lopez M, Alegre-Sancho JJ, Mijares V, Lera-; Identification of a 3 '-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. ARTHRITIS & RHEUMATOLOGY. 71. 3. (351-360). DOI: 10.1002/art.40734. IF: 9,002. D1. Article. IMIBIC GROUPS: GC05	GC05
Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patino-Trives AM, Luque-Tevar M, Ibanez-Costa A, Perez-Sanchez L, de la Rosa IA, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme M; Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. FRONTIERS IN IMMUNOLOGY. 10. DOI: 10.3389/fimmu.2019.01111. IF: 4,716. Q2. Article. IMIBIC GROUPS: GC05	GC05
Lopez-Pedrera C, Barbarroja N, Patino-Trives AM, Collantes E, Aguirre MA, Perez-Sanchez C; New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. FRONTIERS IN IMMUNOLOGY. 10. DOI: 10.3389/fimmu.2019.00764. IF: 4,716. Q2. Review. IMIBIC GROUPS: GC05	GC05
Gratacos J, Pontes C, Juanola X, Sanz J, Torres F, Avendano C, Vallano A, Calvo G, de Miguel E, Sanmarti R, Almirall M, Aparicio M, Sellas A, Vives R, Albinana N, Moreno M, Clavaguera T, Torre-Alonso JC, Veroz R, Rodriguez-Lozano C, Linares LF, Urruticoec; Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. ARTHRITIS RESEARCH & THERAPY. 21. DOI: 10.1186/s13075-018-1772-z. IF: 4,148. Q2. Article. IMIBIC GROUPS: GC05	GC05

PUBLICATIONS	IMIBIC GROUP
Canet LM, Sanchez-Maldonado JM, Caliz R, Ramos AR, Lupianez CB, Canhao H, Martinez-Bueno M, Escudero A, Segura-Catena J, Sorensen SB, Hetland ML, Soto-Pino MJ, Ferrer MA, Garcia A, Glintborg B, Filipescu I, Perez-Pampin E, Gonzalez-Utrilla A, Nevot MAL, C; Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. PHARMACOGENOMICS JOURNAL. 19. 1. (83-96). DOI: 10.1038/s41397-018-0057-x. IF: 3,503. Q2. Article. IMIBIC GROUPS: GC05	GC05
Dantas LO, Moreira RDC, Norde FM, Serrao PRMS, Alburquerque-Sendin F, Salvini TF; The effects of cryotherapy on pain and function in individuals with knee osteoarthritis: a systematic review of randomized controlled trials. CLINICAL REHABILITATION. 33. 8. (1310-1319). DOI: 10.1177/0269215519840406. IF: 2,738. Q1. Review. IMIBIC GROUPS: GC05	GC05
Ribeiro IL, Camargo PR, Alburquerque-Sendin F, Ferrari AV, Arrais CL, Salvini TF; Three-dimensional scapular kinematics, shoulder outcome measures and quality of life following treatment for breast cancer - A case control study. MUSCULOSKELETAL SCIENCE AND PRACTICE. 40. (72-79). DOI: 10.1016/j.msksp.2019.01.012. IF: 1,725. Q2. Article. IMIBIC GROUPS: GC05	GC05
Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, Demetrio-Pablo R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, Hernandez MV, Hernandez-Garfella M, Valls-Pascual E, Martinez-Costa L, Sellas-Fernandez A, Cordero-Coma M, Diaz-Llopis M, Gallego R, Garci; Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet's Disease: National Multicenter Study of 177 Cases. ARTHRITIS & RHEUMATOLOGY. 71. 12. (2081-2089). DOI: 10.1002/art.41026. IF: 9,002. D1. Article; Early Access. IMIBIC GROUPS: GC05	GC05
Castellvi I, Eguiluz S, Escudero-Contreras A, Rios JJ, Calvo-Alen J, Callejas-Rubio JL, De la Puente C, Simeon CP, Narvaez FJ, Espinosa G, Carreira PE, Rubio-Rivas M, Alegre JJ, Guillen-Del-Castillo A, Roman-Ivorra JA, Fonollosa V. (LAUDES Study Group: de; LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. RHEUMATOLOGY INTERNATIONAL. 39. 11. (1875-1882). DOI: 10.1007/s00296-019-04436-z. IF: 2,2. Q3. Article. IMIBIC GROUPS: GC05	GC05
Sanchez-Maldonado JM, Caliz R, Cana L, ter Horst R, Bakker O, den Broeder AA, Martinez-Bueno M, Canhao H, Rodriguez-Ramos A, Lupianez CB, Soto-Pino MJ, Garcia A, Perez-Pampin E, Gonzalez-Utrilla A, Escudero LA, Segura-Catena J, Netea-Maier RT, Ferrer MA, ; Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. SCIENTIFIC REPORTS. 9. 4812. DOI: 10.1038/s41598-019-51255-0. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC05	GC05
de la Rosa IA, Radin M, Cecchi I, Rubini E, Perez-Sanchez C, Aguirre MA, Menegatti E, Barbarroja N, Collantes E, Sciascia S, Roccatello D, Pedrera CL; Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. RHEUMATOLOGY. 58. 10. (1870-1872). DOI: 10.1093/rheumatology/kez166. IF: 5,245. Q1. Letter. IMIBIC GROUPS: GC05	GC05
Barbarroja N, Arias-de la Rosa I, Lopez-Medina C, Camacho-Sanchez MD, Gomez-Garcia I, Velez-Garcia AJ, Escudero-Contreras A, Lopez-Pedrera C, Lopez-Montilla MD, Collantes-Estevez E; Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 11. DOI: 10.1177/1759720X19880742. IF: 5,045. D2 Q1. Letter. IMIBIC GROUPS: GC05 GE03	GC05
Ribeiro IL, Moreira RFC, Ferrari AV, Alburquerque-Sendin F, Camargo PR, Salvini TF; Effectiveness of early rehabilitation on range of motion, muscle strength and arm function after breast cancer surgery: a systematic review of randomized controlled trials. CLINICAL REHABILITATION. 33. 12. (1876-1886). DOI: 10.1177/0269215519873026. IF: 2,738. D2 Q1. Review; Early Access. IMIBIC GROUPS: GC05	GC05
Radin M, Schreiber K, Cuadrado MJ, Cecchi I, Andreoli L, Franceschini F, Caleiro T, Andrade D, Gibbone E, Khamashta M, Buyon J, Izmirly P, Aguirre MA, Benedetto C, Roccatello D, Marozio L, Sciascia S; Pregnancy outcomes in mixed connective tissue disease: a multicentre study. RHEUMATOLOGY. 58. 11. (2000-2008). DOI: 10.1093/rheumatology/kez141. IF: 5,149. D2 Q1. Article. IMIBIC GROUPS: GC05	GC05
Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, Gonzalez C, Ercole L, Alonso R, Fonseca JE, Alcaniz C, Alvaro-Gracia JM, Balsa A, de Pablos JL, Miguel CD, Rodriguez JM, Alves J, Aurrecoechea E, Calvo J, Belzunegui J, Blanco F, Caliz R, Calvo J,; Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. ARTHRITIS & RHEUMATOLOGY. 71. 10. (1616-1625). DOI: 10.1002/art.40905. IF: 7,873. D1 Q1. Article. IMIBIC GROUPS: GC05	GC05

PUBLICATIONS	IMIBIC GROUP
Dantas LO, Breda CC, Serrao PRMD, Aburquerque-Sendin F, Jorge AES, Cunha JE, Barbosa GM, Durigan JLQ, Salvini TD; Short-term cryotherapy did not substantially reduce pain and had unclear effects on physical function and quality of life in people with knee osteoarthritis: a randomised trial. JOURNAL OF PHYSIOTHERAPY. 65. 4. (215-221). DOI: 10.1016/j.jphys.2019.08.004. IF: 5,551. D1 Q1. Article. IMIBIC GROUPS: GC05	GC05
Lopez-Medina C, Molto A, Gerald F, Dubremetz M, Grange L, Thibaud G, Charles B, Lafarge D, Beauvais C, Gossec L, Dougados M; Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients. JOINT BONE SPINE. 86. 5. (610-614). DOI: 10.1016/j.jbspin.2019.01.023. IF: 3,278. Q2. Article. IMIBIC GROUPS: GC05	GC05
Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Vendramini MBG, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji LL, Branch DW, de Jesus G, Fortin PR, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Sevim E, Bertolaccini ML, Pengo V, Cohen H; Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 17. 12. (2069-2080). DOI: 10.1111/jth.14596. IF: 4,662. D2 Q1. Article. IMIBIC GROUPS: GC05	GC05
Lopez-Medina C, Dougados M, Ruyssen-Witrand A, Molto A; Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort. ARTHRITIS RESEARCH & THERAPY. 21. DOI: 10.1186/s13075-019-1927-6. IF: 4,148. Q2. Article. IMIBIC GROUPS: GC05	GC05
Radin M, Schreiber K, Sciascia S, Roccatello D, Cecchi I, Zamorano MAA, Cuadrado MJ; Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. THROMBOSIS AND HAEMOSTASIS. 119. 12. (1920-1926). DOI: 10.1055/s-0039-1696687. IF: 4,733. D2 Q1. Article. IMIBIC GROUPS: GC05	GC05
Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji LL, Belmont HM, Cohen H, de Jesus GR, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Gandara APR, Vendramini MBG, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D. APS ACTION: Pons-Estel, G; Giannakopoulos, B; Krilis, S; de Jesus, G; Levy, R; Ugolini-Lopes, M; Rosa, R; Andrade, D; Fortin, PF; Zhang, ZL; Zuily, S; Wahl, D; Tektonidou, M; Nalli, C; Andreoli, L; Tincani, A; Chighizola, CB; Gerosa, M; Meroni, P; Banzato, A; Pengo, V; Sciascia, S; De Ceulaer, K; Davis, S; Amengual, O; Atsumi, T; Uthman, I; Limper, M; Derksen, R; de Groot, P; Ugarte, A; Irastorza, GR; Rodriguez-Pinto, I; Cervera, R; Rodriguez, E; Cuadrado, M; Zamorano, MAA; Lopez-Pedrera, R; Artim-Esen, B; Inanc, M; Mackie, I; Efthymiou, M; Cohen, H; Bertolaccini, ML; Khamashta, M; Sanna, G; Knight, JS; Petri, M; Roubey, R; Ortel, T; Gonzalez, E; Willis, R; Levine, S; Rand, J; Belmont, HM; Barbhaiya, M; Erkan, D; Salmon, J; Lockshin, M; Branch, W; The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. SEMINARS IN ARTHRITIS AND RHEUMATISM. 49. 3. (464-468). DOI: 10.1016/j.semarthrit.2019.04.009. IF: 5,072. D2 Q1. Article. IMIBIC GROUPS: GC05	GC05
Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E; A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. BRITISH JOURNAL OF CANCER. 121. 5. (378-383). DOI: 10.1038/s41416-019-0537-z. IF: 5,416. Q1. Article. IMIBIC GROUPS: GC06	GC06
Herrero CC, Zoilo JJR, Martin DM, Martinez FC, Porta VG, Aguilar EA, Mena AC, Garcia EDR, Lopez JGF, Saus MF, Lopez RL; Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). CLINICAL & TRANSLATIONAL ONCOLOGY. 21. 3. (380-390). DOI: 10.1007/s12094-018-1925-1. IF: 2,441. Q3. Article. IMIBIC GROUPS: GC06	GC06
Borrero-Palacios A, Cebrian A, del Pulgar MTG, Garcia-Carbonero R, Garcia P, Aranda E, Elez E, Lopez-Lopez R, Cervantes A, Valladares M, Nadal C, Vieitez JM, Guillen-Ponce C, Rodriguez J, Hernandez I, Garcia JL, Vega-Bravo R, Puime-Otin A, Martinez-Useros; Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-39291-2. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC06	GC06

PUBLICATIONS	IMIBIC GROUP
Vivancos A, Aranda E, Benavides M, Elez E, Gomez-Espana MA, Toledano M, Alvarez M, Parrado MRC, Garcia-Barberan V, Diaz-Rubio E; Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-45616-y. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC06	GC06
Puente J, Gonzalez-del-Alba A, Sala-Gonzalez N, Mendez-Vidal MJ, Pinto A, Rodriguez A, Sanz JM, del Toro JRM, Rodriguez EU, Garcia-Porrero A, Vazquez S; Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC CANCER. 19. 1. DOI: 10.1186/s12885-019-5974-9. IF: 2,933. Q3. Article. IMIBIC GROUPS: GC06	GC06
Martin M, Loibl S, Hyslop T, De la Haba-Rodriguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Janez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, C; Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. EUROPEAN JOURNAL OF CANCER. 117. (91-98). DOI: 10.1016/j.ejca.2019.06.002. IF: 6,68. Q1. Article. IMIBIC GROUPS: GC06	GC06
Maniscalco L, Guil-Luna S, Iussich S, Gattino F, Trupia C, Millan Y, de Las Mulas JM, Cespedez RS, Saeki K, Accornero P, De Maria R; Expression of the Short Form of RON/STK in Feline Mammary Carcinoma. VETERINARY PATHOLOGY. 56. 2. (220-229). DOI: 10.1177/0300985818806967. IF: 2,116. D1. Article. IMIBIC GROUPS: GC06	GC06
Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E; First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC CANCER. 19. DOI: 10.1186/s12885-019-5753-7. IF: 2,933. Q3. Article. IMIBIC GROUPS: GC06 Oncología Médica	GC06
Penarando J, Aranda E, Rodriguez-Ariza A; Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response. TRANSLATIONAL RESEARCH. 210. (99-108). DOI: 10.1016/j.trs1.2019.03.003. IF: 4,915. D1. Review. IMIBIC GROUPS: GC06	GC06
Ciruelos E, Perez-Garcia JM, Gavila J, Rodriguez A, de la Haba-Rodriguez J; Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. CLINICAL DRUG INVESTIGATION. 39. 7. (595-606). DOI: 10.1007/s40261-019-00790-9. IF: 1,918. Q3. Review. IMIBIC GROUPS: GC06	GC06
Romero I, Mallol P, Santaballa A, Del Campo JM, Mori M, Gonzalez-Santiago S, Casado A, Vicente D, Ortega E, Herrero A, Guerra E, Barretina-Ginesta P, Rubio MJ, Martinez A, Bover I, Vidal L, Arcusa A, Martin L, Garcia Y, Gonzalez-Martin A; Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. ANTI-CANCER DRUGS. 30. 6. (628-635). DOI: 10.1097/CAD.0000000000000794. IF: 1,801. Q3. Article. IMIBIC GROUPS: GC06	GC06
Ciruelos EM, Diaz MN, Isla MD, Lopez R, Bernabe R, Gonzalez E, Cirauqui B, Coves J, Morales S, Arcediano A, Barneto I, Cerezuela P, Illarramendi JJ, Morales C, Ponce S; Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. EUROPEAN JOURNAL OF CANCER CARE. 0. DOI: 10.1111/ecc.13164. IF: 2,421. D1. Article; Early Access. IMIBIC GROUPS: GC06	GC06
Carles J, Gallardo E, Domenech M, Font A, Bellmunt J, Figols M, Mellado B, Saez MI, Suarez C, Mendez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, Garcia J, Macia S, Maldonado X, Foro P; Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 103. 2. (344-352). DOI: 10.1016/j.ijrobp.2018.10.005. IF: 6,203. D1. Article. IMIBIC GROUPS: GC06	GC06
Santos C, Azuara D, Vieitez JM, Paez D, Falco E, Elez E, Lopez-Lopez C, Valladares M, Robles-Diaz L, Garcia-Alfonso P, Buges C, Duran G, Salud A, Navarro V, Capella G, Aranda E, Salazar R, de Mena IR, Rodriguez S; Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. ANNALS OF ONCOLOGY. 30. 5. (796-803). DOI: 10.1093/annonc/mdz082. IF: 14,196. D1. Article. IMIBIC GROUPS: GC06	GC06

PUBLICATIONS	IMIBIC GROUP
Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzman JC, Hernando ; Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. EUROPEAN UROLOGY. 75. 3. (368-373). DOI: 10.1016/j.eururo.2018.09.049. IF: 17,298. D1. Article. IMIBIC GROUPS: GC06	GC06
Castro E, Romero-Laorden N, del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendon Y, Garcia-Carbonero I, Borrega P, Vidal MJM, Montesa A, Nombela P, Fernandez-Parra E, del Alba AG, Vi; PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. JOURNAL OF CLINICAL ONCOLOGY. 37. 6. (490-503). DOI: 10.1200/JCO.18.00358. IF: 28,245. D1. Article. IMIBIC GROUPS: GC06	GC06
Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S; Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 9. DOI: 10.1002/mnfr.201800864. IF: 5,151. D1. Article. IMIBIC GROUPS: Anatomía Patológica GC21 GC06	GC06
Sartor O, Heinrich D, Mariados N, Vidal MJM, Keizman D, Karlsson CT, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, Trandafir L, Wagner V, Li R, Nordquist LT; Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. PROSTATE. 79. 14. (1683-1691). DOI: 10.1002/pros.23893. IF: 2,876. Q2. Article; Early Access. IMIBIC GROUPS: GC06	GC06
Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R; SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 21. 1. (46-54). DOI: 10.1007/s12094-018-02002-w. IF: 2,441. Q3. Article. IMIBIC GROUPS: GC06	GC06
Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A; SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 0. DOI: 10.1111/jcmm.14693. IF: 4,658. Q1. Article; Early Access. IMIBIC GROUPS: GC06 Cirugía General y Digestiva GC06 U Proteómica Imibic	GC06
Vidal J, Bellosillo B, Vivas CS, Garcia-Alfonso P, Carrato A, Cano MT, Garcia-Carbonero R, Elez E, Losa F, Massuti B, Valladares-Ayerbes M, Vieitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capella G, Salazar R, Tabernero J, Aranda E, Montagut C; Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. ANNALS OF ONCOLOGY. 30. 3. (439-446). DOI: 10.1093/annonc/mdz005. IF: 14,196. D1. Article. IMIBIC GROUPS: GC06	GC06
Diaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Galvez F, Falcon A, Alamo MD, Morales C, Amerigo M, Pascual J, Sanchez-Munoz A, Gonzalez-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Pr; Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. FRONTIERS IN ONCOLOGY. 9. 1178. DOI: 10.3389/fonc.2019.01178. IF: 4,137. Q2. Article. IMIBIC GROUPS: GC06	GC06
Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M, Custodio A, Hernandez R, Lacalle A, Cano JM, Aguado G, de Castro EM, Mancenido FA, Macias I, Visa L, Richard MM, Mangas M, Canovas MS, Longo F, Rey LI, Lago NM, Carnicero AM, Sanchez A, Azkarate A, Limon ML; Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. THROMBOSIS AND HAEMOSTASIS. 119. 11. (1849-1859). DOI: 10.1055/s-0039-1694012. IF: 4,733. D2 Q1. Article. IMIBIC GROUPS: GC06	GC06
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D; Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. NATURE MEDICINE. 25. 11. (1706-1714). DOI: 10.1038/s41591-019-0628-7. IF: 30,641. D1 Q1. Article. IMIBIC GROUPS: GC06	GC06

PUBLICATIONS	IMIBIC GROUP
Jimenez-Vacas JM, Gomez-Gomez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-Lopez F, Sanchez-Sanchez R, Guler I, Blanca A, Mendez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM; Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 12. DOI: 10.3390/jcm8122056. IF: 5,688. D1 Q1. Article. IMIBIC GROUPS: GC27 GC08 GE05 GC06	GC06
Puig-Gay N, Jacobs-Cacha C, Sellares J, Guirado L, Roncero FG, Jimenez C, Zarraga S, Paul J, Lauzurica R, Alonso A, Fernandez A, Beneyto I, Mazuecos A, Hernandez D, Rodriguez-Benot A, Franco A, Jimeno L, Crespo M, Meseguer A, Moreso F, Seron D, Lopez-Hell; Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. TRANSPLANT INTERNATIONAL. 32. 3. (313-322). DOI: 10.1111/tri.13372. IF: 3,526. Q1. Article. IMIBIC GROUPS: GC07	GC07
Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM, Herencia C, Vergara N, de Mier MVPR, Santamaria R, Rodelo-Haad C, Casado-Diaz A, Lorenzo V, Carvalho C, Frazao JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodriguez M, Lo; Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. KIDNEY INTERNATIONAL. 95. 5. (1064-1078). DOI: 10.1016/j.kint.2018.12.015. IF: 8,306. D1. Article. IMIBIC GROUPS: GC13 GC07 GC09 GC17	GC07
Navas A, Molina J, Aguera ML, Guler I, Jurado A, Rodriguez-Benoto A, Alonso C, Solana R; Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays. FRONTIERS IN IMMUNOLOGY. 10. DOI: 10.3389/fimmu.2019.01712. IF: 4,716. Q2. Article. IMIBIC GROUPS: GC01 GC07	GC07
Martin-Malo A, Borchard G, Fluhmann B, Mori C, Silverberg D, Jankowska EA; Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients. ESC HEART FAILURE. 6. 2. (241-253). DOI: 10.1002/ehf2.12400. IF: 3,047. Q2. Review. IMIBIC GROUPS: GC07	GC07
Perez-Saez MJ, Covarrubias OL, Hernandez D, Moreso F, Melilli E, Juega J, de Sousa E, Lopez-Sanchez P, Rodriguez-Ferrero ML, Maruri-Kareaga N, Navarro MD, Valero R, Mazuecos MA, Llamas F, Martin-Moreno P, Fernandez-Garcia A, Espi J, Jimenez C, Ramos A, Ga; Early outcomes of kidney transplantation from elderly donors after circulatory death (GEODAS study). BMC NEPHROLOGY. 20. DOI: 10.1186/s12882-019-1412-0. IF: 2,088. Q3. Article. IMIBIC GROUPS: GC07	GC07
Rodelo-Haad C, Santamaria R, Munoz-Castaneda JR, de Mier MVPR, Martin-Malo A, Rodriguez M; FGF23, Biomarker or Target? TOXINS. 11. 3. DOI: 10.3390/toxins11030175. IF: 3,895. Q1. Review. IMIBIC GROUPS: GC07 GC13	GC07
Sevillano AM, Diaz M, Caravaca-Fontan F, Barrios C, Bernis C, Cabrera J, Calvino J, Castillo L, Cobelo C, Delgado-Mallen P, Espinosa M, Fernandez-Juarez G, Fernandez-Reyes MJ, Garcia-Osuna R, Garcia P, Goicoechea M, Gonzalez-Cabrera F, Guzman DA, Heras M,; IgA Nephropathy in Elderly Patients. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 14. 8. (1183-1192). DOI: 10.2215/CJN.13251118. IF: 6,243. D1. Article. IMIBIC GROUPS: GC07	GC07
Garcia-Montemayor V, Sanchez-Agesta M, Aguera ML, Calle O, Navarro MD, Rodriguez A, Aljama P; Influence of Pre-renal Transplant Secondary Hyperparathyroidism on Later Evolution After Transplantation. TRANSPLANTATION PROCEEDINGS. 51. 2. (344-349). DOI: 10.1016/j.transproceed.2018.12.012. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC07	GC07
Stel VS, Awadhpersad R, Pippias M, Ferrer-Alamar M, Finne P, Fraser SD, Heaf JG, Hemmelder MH, Martinez-Castelao A, de Meester J, Palsson R, Prischl FC, Segelmark M, Traynor JP, Santamaria R, Reisaeter AV, Massy ZA, Jager KJ; International comparison of trends in patients commencing renal replacement therapy by primary renal disease. NEPHROLOGY. 24. 10. (1064-1076). DOI: 10.1111/nep.13531. IF: 1,913. Q3. Article. IMIBIC GROUPS: GC07	GC07
Portoles JM, Perez-Saez MJ, Lopez-Sanchez P, Lafuente-Covarrubias O, Juega J, Hernandez D, Espi J, Navarro MD, Mazuecos MA, Rodriguez-Ferrero ML, Maruri-Kareaga N, Moreso F, Melilli E, de Souza E, Ruiz JC, Llamas F, Gutierrez-Dalmau A, Guirado L, Martin-M; Kidney transplant from controlled donors following circulatory death: Results from the GEODAS-3 multicentre study. NEFROLOGIA. 39. 2. (151-159). DOI: 10.1016/j.nefro.2018.07.013. IF: 1,439. Q4. Article. IMIBIC GROUPS: GC07	GC07
de Cordoba SR, Hernandez ME; Kidney, hypertension and complement activation. In search of new therapeutic targets. NEFROLOGIA. 39. 2. (111-114). DOI: 10.1016/j.nefro.2018.10.002. IF: 1,439. Q4. Editorial Material. IMIBIC GROUPS: GC07	GC07

PUBLICATIONS	IMIBIC GROUP
Rodelo-Haad C, Aguera ML, Carmona A, Navarro MD, Carracedo J, Rodriguez-Benot A, Aljama P; Pancreatic autoantibodies and CD14(+)CD16(+) monocytes subset are associated with the impairment of beta-cell function after simultaneous pancreas-kidney transplantation. PLOS ONE. 14. 2. DOI: 10.1371/journal.pone.0212547. IF: 2,776. Q2. Article. IMIBIC GROUPS: GC07	GC07
Fernandez-Ruiz M, Gimenez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisan S, Torre-Cisneros J, Fortun J, Andres A, San Juan R, Lopez-Medrano F, Navarro D, Aguado JM, Gonzalez E, Polanco N, Rodriguez R, Aranzamendi M, Carmona ; Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. CLINICAL MICROBIOLOGY AND INFECTION. 25. 3. DOI: 10.1016/j.cmi.2018.05.010. IF: 6,425. D1. Article. IMIBIC GROUPS: GC03 GC07	GC07
Varas J, Perez-Saez MJ, Ramos R, Merello JI, de Francisco ALM, Luno J, Praga M, Aljama P, Pascual J, Canaud B, Gauly A, Maduell F, Martin-Malo A, Stuard S, Zawada A; Returning to haemodialysis after kidney allograft failure: a survival study with propensity score matching. NEPHROLOGY DIALYSIS TRANSPLANTATION. 34. 4. (667-672). DOI: 10.1093/ndt/gfy215. IF: 4,198. Q1. Article. IMIBIC GROUPS: GC07	GC07
Rodelo-Haad C, Esquivias-Motta E, Amaral-Neiva F, Martin-Malo A, Aljama P, Rodriguez M; Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy. BREAST JOURNAL. 25. 5. (998-999). DOI: 10.1111/tbj.13389. IF: 2,433. Q2. Editorial Material. IMIBIC GROUPS: GC13 GC07	GC07
Cavero T, Arjona E, Soto K, Caravaca-Fontan F, Rabasco C, Bravo L, de la Cerda F, Martin N, Blasco M, Avila A, Huerta A, Cabello V, Jarque A, Alcazar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martinez-Gallardo R, Perez L; Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. KIDNEY INTERNATIONAL. 96. 4. (995-1004). DOI: 10.1016/j.kint.2019.05.014. IF: 8,306. D1. Article. IMIBIC GROUPS: GC07	GC07
Sandubete EJC, de la Blanca EBP, del Rio CAO, Olmo RS, Mendoza ML, Martinez MB, Infante CM, Marin-Leon I, de la Paz MP, Castellano PG, Blanes JRG, Navarro EG, Rodriguez ML, Arduan AO, Guzman JD, Martinez PL, Villalba JC, Perez JMC; Spanish multidisciplinary clinical practice guidelines for Anderson-Fabry Disease in Adults. I. Method and recommendations. REVISTA CLINICA ESPAÑOLA. 219. 4. (200-207). DOI: 10.1016/j.rce.2018.09.017. IF: 1,043. Q3. Article. IMIBIC GROUPS: GC07 Análisis Clínicos	GC07
Garcia-Menendez E, Vidas MM, Alique M, Carracedo J, de Sequera P, Corchete E, Garcia R, Chamond RR, Perez JMP; Statins and antiplatelet agents are associated with changes in the circulatory markers of endothelial dysfunction in chronic kidney disease. NEFROLOGIA. 39. 3. (287-293). DOI: 10.1016/j.nefro.2018.11.001. IF: 1,439. Q4. Article. IMIBIC GROUPS: GC07	GC07
Ortiz A, Sanchez-Nino MD, Crespo-Barrio M, De-Sequera-Ortiz P, Fernandez-Giraldez E, Garcia-Maset R, Macia-Heras M, Perez-Fontan M, Rodriguez-Portillo M, Salgueira-Lazo M, Sanchez-Alvarez E, Santamaria-Olmo R, Simal-Blanco F, Pino-Pino MD; The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. NEFROLOGIA. 39. 1. (29-34). DOI: 10.1016/j.nefro.2018.09.002. IF: 1,439. Q4. Review. IMIBIC GROUPS: GC07 GC13	GC07
Garcia MIP, Pino MDDY, Rodriguez RA, Rodelo-Haad C, Carreno TP; The value of ABPM and subclinical target organ damage parameters in diagnosis of resistant hypertension. NEFROLOGIA. 39. 1. (67-72). DOI: 10.1016/j.nefro.2018.03.007. IF: 1,439. Q4. Article. IMIBIC GROUPS: GC07	GC07
Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M; Complement Activation and Thrombotic Microangiopathies. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 14. 12. (1719-1732). DOI: 10.2215/CJN.05830519. IF: 6,243. D1 Q1. Article. IMIBIC GROUPS: GC07	GC07
Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, L-Lopez F, Ibanez-Costa A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, ; Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513). DOI: 10.1210/jc.2019-00056. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC05 GA04 Endocrinología	GC08

PUBLICATIONS	IMIBIC GROUP
del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC25 GC02 GC09 Anatomía Patológica	GC08
Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibanez-Costa A, Madrazo-Atutxa A, Japon MA, Castano JP, Luque RM, Cano DA, Soto-Moreno A; E-cadherin expression is associated with somatostatin analogue response in acromegaly. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 5. (3088-3096). DOI: 10.1111/jcmm.13851. IF: 4,658. Q1. Article. IMIBIC GROUPS: GC27 GC08	GC08
Herrera-Martinez AD, Feelders RA, de Herder WW, Castano JP, Moreno MAG, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ; Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. HORMONES & CANCER. 10. 43526. (107-119). DOI: 10.1007/s12672-019-00361-6. IF: 2,581. Q3. Article. IMIBIC GROUPS: GA04 GC08	GC08
Fuentes-Fayos AC, Garcia-Martinez A, Herrera-Martinez AD, Jimenez-Vacas JM, Vazquez-Borrego MC, Castano JP, Pico A, Gahete MD, Luque RM; Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. MINERVA ENDOCRINOLOGICA. 44. 2. (109-128). DOI: 10.23736/S0391-1977.19.02970-5. IF: 1,817. Q4. Review. IMIBIC GROUPS: GC27 GC08 GA04	GC08
Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castano JP, Luque RM; Mouse models of endocrine tumors. JOURNAL OF ENDOCRINOLOGY. 240. 3. (R73-R96). DOI: 10.1530/JOE-18-0571. IF: 4,381. Q1. Review. IMIBIC GROUPS: GC27 GC08	GC08
Del Rio-Moreno M, Alors-Perez E, De Souza PB, Prados-Gonzalez ME, Castano JP, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. TRANSLATIONAL RESEARCH. 211. (147-160). DOI: 10.1016/j.trsl.2019.02.013. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08	GC08
Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08 GA08 GE05 Anatomía Patológica	GC08
Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castano JP, de Herder WW, Feelders RA; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. DRUGS. 79. 1. (21-42). DOI: 10.1007/s40265-018-1033-0. IF: 4,993. Q1. Review. IMIBIC GROUPS: GA04 GC08 GC27	GC08
Herrera-Martinez AD, Pedraza-Arevalo S, L-Lopez F, Gahete MD, Galvez-Moreno MA, Castano JP, Luque RM; Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 1. (57-73). DOI: 10.1210/jc.2018-01455. IF: 5,605. Q1. Article. IMIBIC GROUPS: GA04 GC08 GC27	GC08
Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1400. DOI: 10.3390/jcm8091400. IF: 5,688. D1. Article. IMIBIC GROUPS: GC27 GC08 GE05 Anatomía Patológica	GC08
Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schatzlein M, Mesa J, Castano JP, Luque RM, Simo R; Metabolic Fingerprint of Acromegaly and Its Potential Usefulness in Clinical Practice. JOURNAL OF CLINICAL MEDICINE. 8. 10. 1549. DOI: 10.3390/jcm8101549. IF: 5,688. D1 Q1. Article. IMIBIC GROUPS: GC08 GC27	GC08
Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS. 11. 10. 1439. DOI: 10.3390/cancers11101439. IF: 6,162. D2 Q1. Article. IMIBIC GROUPS: GC27 GC08 Neurocirugía GA04	GC08

PUBLICATIONS	IMIBIC GROUP
Jimenez-Vacas JM, Gomez-Gomez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-Lopez F, Sanchez-Sanchez R, Guler I, Blanca A, Mendez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM; Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 12. DOI: 10.3390/jcm8122056. IF: 5,688. D1 Q1. Article. IMIBIC GROUPS: GC27 GC08 GE05 GC06	GC08
Arroyo-Olivares R, Alonso R, Quintana-Navarro G, Fuentes-Jimenez F, Mata N, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, Arrieta F, Garcia-Cruces J, Garrido-Sanjuan JA, Banegas JR, Mata P; Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: the SAFEHEART study. PUBLIC HEALTH NUTRITION. 22. 8. (1433-1443). DOI: 10.1017/S1368980018003853. IF: 2,526. Q2. Article. IMIBIC GROUPS: GC09	GC09
Ruiz-Ruiz F, Medrano FJ, Santos-Lozano JM, Rodriguez-Torres P, Navarro-Puerto A, Calderon EJ, del Rio CAO, Marin-Leon I, Romero-Alonso A, Varela-Aguilar JM, Martinez MNB, Molina MAB, Vales EC, Montoro AE, Dalmau FGB, Hernandez AL, Rodriguez JAN, Santos JT; Anticoagulant treatment of medical patients with complex clinical conditions. REVISTA CLINICA ESPAÑOLA. 219. 1. (34-43). DOI: 10.1016/j.rce.2018.04.007. IF: 1,043. Q3. Review. IMIBIC GROUPS: GC09	GC09
Gomez-Delgado F, Alcala-Diaz JF, Leon-Acuna A, Lopez-Moreno J, Delgado-Lista J, Gomez-Marin B, Roncero-Ramos I, Yubero-Serrano EM, Rangel-Zuniga OA, Vals-Delgado C, Luque RM, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Apolipoprotein E genetic variants interact with Mediterranean diet to modulate postprandial hypertriglyceridemia in coronary heart disease patients: CORDIOPREV study. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 49. 8. DOI: 10.1111/eci.13146. IF: 2,784. Q1. Article. IMIBIC GROUPS: GC09 GC27 Medicina Interna	GC09
Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM, Herencia C, Vergara N, de Mier MVPR, Santamaria R, Rodelo-Haad C, Casado-Diaz A, Lorenzo V, Carvalho C, Frazao JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodriguez M, Lo; Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. KIDNEY INTERNATIONAL. 95. 5. (1064-1078). DOI: 10.1016/j.kint.2018.12.015. IF: 8,306. D1. Article. IMIBIC GROUPS: GC13 GC07 GC09 GC17	GC09
De Larriva APA, Alonso A, Norby FL, Roetker NS, Folsom AR; Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 17. 5. (818-826). DOI: 10.1111/jth.14420. IF: 4,662. Q1. Article. IMIBIC GROUPS: GC09	GC09
Gutierrez-Mariscal FM, Yubero-Serrano EM, Villalba JM, Lopez-Miranda J; Coenzyme Q(10): From bench to clinic in aging diseases, a translational review. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION. 59. 14. (2240-2257). DOI: 10.1080/10408398.2018.1442316. IF: 6,704. D1. Review. IMIBIC GROUPS: GC09	GC09
Franco J, Formiga F, Corbella X, Conde-Martel A, Llacer P, Rocha PA, Gorricho GO, Satue J, Rangel LS, Manzano L, Montero-Perez-Barquero M. (Grp Invest RICA: Anarte L, Aramburu O, Arevalo-Lorido JC, Carrascosa S, Carrera M, Cepeda JM, Cerqueiro JM, Davila; De novo acute heart failure: Clinical features and one-year mortality in the Spanish nationwide Registry of Acute Heart Failure. MEDICINA CLINICA. 152. 4. (127-134). DOI: 10.1016/j.medcli.2018.05.012. IF: 1,277. Q3. Article. IMIBIC GROUPS: GC09	GC09
Cano-Ibanez N, Gea A, Martinez-Gonzalez MA, Salas-Salvado J, Corella D, Zomeno MD, Romaguera D, Vioque J, Aros F, Warnberg J, Martinez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pinto X, Tur JA, Garcia-Rios A, Riquelme-Gallego B, Delgado-Rodri; Dietary Diversity and Nutritional Adequacy among an Older Spanish Population with Metabolic Syndrome in the PREDIMED-Plus Study: A Cross-Sectional Analysis. NUTRIENTS. 11. 5. DOI: 10.3390/nu11050958. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC09	GC09
Llacer P, Nunez J, Bayes-Genis A, Martel AC, Hernandez YC, Manglano JD, Rocha PA, Rangel LS, Del Olmo VG, Manzano L, Perez-Barquero MM; Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 60. (18-23). DOI: 10.1016/j.ejim.2018.10.010. IF: 3,66. Q1. Article. IMIBIC GROUPS: GC09	GC09

PUBLICATIONS	IMIBIC GROUP
del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC25 GC02 GC09 Anatomía Patológica	GC09
Salas-Salvado J, Diaz-Lopez A, Ruiz-Canela M, Basora J, Fito M, Corella D, Serra-Majem L, Warnberg J, Romaguera D, Estruch R, Vidal J, Martinez JA, Aros F, Vazquez C, Ros E, Vioque J, Lopez-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martin V, La; Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. DIABETES CARE. 42. 5. (777-788). DOI: 10.2337/dc18-0836. IF: 15,27. D1. Article. IMIBIC GROUPS: GC09	GC09
Perez-Calahorra S, Laclaustra M, Marco-Benedi V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez-Tembra M, Civeira F; Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. ATHEROSCLEROSIS. 284. (245-252). DOI: 10.1016/j.atherosclerosis.2019.02.003. IF: 4,255. Q1. Article. IMIBIC GROUPS: GC09	GC09
Davila LA, Bermudez V, Aparicio D, Cespedes V, Escobar MC, Duran-Aguero S, Cisternas S, Costa JD, Rojas-Gomez D, Reyna N, Lopez-Miranda J; Effect of Oral Nutritional Supplements with Sucromalt and Isomaltulose versus Standard Formula on Glycaemic Index, Entero-Insular Axis Peptides and Subjective Appetite in Patients with Type 2 Diabetes: A Randomised Cross-Over Study. NUTRIENTS. 11. 7. DOI: 10.3390/nu11071477. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC09	GC09
Gulseth HL, Gjelstad IMF, Tiereny AC, McCarthy D, Lovegrove JA, Defoort C, Blaak EE, Lopez-Miranda J, Dembinska-Kiec A, Riserus U, Roche HM, Drevon CA, Birkeland KI; Effects of dietary fat on insulin secretion in subjects with the metabolic syndrome. EUROPEAN JOURNAL OF ENDOCRINOLOGY. 180. 5. (321-328). DOI: 10.1530/EJE-19-0022. IF: 5,107. Q1. Article. IMIBIC GROUPS: GC09	GC09
Quiros-Lopez R, Manzano-Espinosa L, Bilbao A, Perez-Barquero M, Cepeda-Rodrigo JM, Escobar-Martinez A; External validation of the CACE-HF risk score for mortality in patients with heart failure. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 66. (35-40). DOI: 10.1016/j.ejim.2019.05.010. IF: 3,66. Q1. Article. IMIBIC GROUPS: GC09	GC09
Yubero-Serrano EM, Lopez-Moreno J, Gomez-Delgado F, Lopez-Miranda J; Extra virgin olive oil: More than a healthy fat. EUROPEAN JOURNAL OF CLINICAL NUTRITION. 72. S. (8-17). DOI: 10.1038/s41430-018-0304-x. IF: 3,114. Q2. Article; Proceedings Paper. IMIBIC GROUPS: GC09	GC09
Catoi AF, Vodnar DC, Corina A, Nikolic D, Citarrella R, Perez-Martinez P, Rizzo M; Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives. CURRENT PHARMACEUTICAL DESIGN. 25. 18. (2038-2050). DOI: 10.2174/1381612825666190708190437. IF: 2,412. Q3. Review. IMIBIC GROUPS: GC09	GC09
Amoros JG, Formiga F, Bodas OA, Arxe AA, Martel AC, Simon MAQ, Juanes RO, Bartolome JAS, Ramos MFD, Perez-Barquero MM; Hemoconcentration as a prognostic factor after hospital discharge in acute heart failure in the RICA registry. REVISTA CLINICA ESPAÑOLA. 219. 1. (1-9). DOI: 10.1016/j.rce.2018.07.003. IF: 1,043. Q3. Article. IMIBIC GROUPS: GC09	GC09
Formiga F, Chivite D, Corbella X, Conde-Martel A, Arevalo-Lorido JC, Trullas JC, Silvestre JP, Garcia SC, Manzano L, Montero-Perez-Barquero M (Rica Investigators Grp: Alvarez-Rocha P, Anarte L, Aramburu-Bodas O, Carrascosa S, Casado J, Cerqueiro JM, Diez-; Influence of potassium levels on one-year outcomes in elderly patients with acute heart failure. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 60. (24-30). DOI: 10.1016/j.ejim.2018.10.016. IF: 3,66. Q1. Article. IMIBIC GROUPS: GC09	GC09
Papandreou C, Diaz-Lopez A, Babio N, Martinez-Gonzalez MA, Bullo M, Corella D, Fito M, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez AJ, Serra-Majem L, Estruch R, Fernandez-Garcia JC, Lapetra J, Pinto X, Tur JA, Garcia-Rios A, Bueno-Cavanil; Long Daytime Napping Is Associated with Increased Adiposity and Type 2 Diabetes in an Elderly Population with Metabolic Syndrome. JOURNAL OF CLINICAL MEDICINE. 8. 7. DOI: 10.3390/jcm8071053. IF: 5,688. D1. Article. IMIBIC GROUPS: GC09	GC09

PUBLICATIONS	IMIBIC GROUP
Corina A, Rangel-Zuniga OA, Jimenez-Lucena R, Alcala-Diaz JF, Quintana-Navarro G, Yubero-Serrano EM, Lopez-Moreno J, Delgado-Lista J, Tinahones F, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Low Intake of Vitamin E Accelerates Cellular Aging in Patients With Established Cardiovascular Disease: The CORDIOPREV Study. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 74. 6. (770-777). DOI: 10.1093/gerona/gly195. IF: 4,711. D1. Article. IMIBIC GROUPS: GC09	GC09
Clemente-Postigo M, Oliva-Olivera W, Coin-Araguez L, Ramos-Molina B, Giraldez-Perez RM, Lhamyani S, Alcaide-Torres J, Perez-Martinez P, El Bekay R, Cardona F, Tinahones FJ; Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 316. 2. (E319-E332). DOI: 10.1152/ajpendo.00277.2018. IF: 4,125. Q1. Article. IMIBIC GROUPS: GC09	GC09
Bibiloni MD, Julibert A, Bouzas C, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Zomeno MD, Vioque J, Romaguera D, Martinez JA, Warnberg J, Lopez-Miranda J, Estruch R, Bueno-Cavanillas A, Aros F, Tinahones F, Serra-Majem L, Martin V, Lapetra J, Vazque; Nut Consumptions as a Marker of Higher Diet Quality in a Mediterranean Population at High Cardiovascular Risk. NUTRIENTS. 11. 4. DOI: 10.3390/nu11040754. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC09	GC09
Camargo A, Jimenez-Lucena R, Alcala-Diaz JF, Rangel-Zuniga OA, Garcia-Carpintero S, Lopez-Moreno J, Blanco-Rojo R, Delgado-Lista J, Perez-Martinez P, van Ommen B, Malagon MM, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J; Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: From the CORDIOPREV study. CLINICAL NUTRITION. 38. 2. (529-538). DOI: 10.1016/j.clnu.2018.03.016. IF: 6,402. D1. Article. IMIBIC GROUPS: GC09 GC11	GC09
Kolovou GD, Watts GF, Mikhailidis DP, Perez-Martinez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjaerg-Hansen A, Tentolouris N, Nordestgaard BG; Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. CURRENT VASCULAR PHARMACOLOGY. 17. 5. (498-514). DOI: 10.2174/1570161117666190507110519. IF: 2,583. Q2. Review. IMIBIC GROUPS: GC09	GC09
Kolovou GD, Watts GF, Mikhailidis DP, Perez-Martinez P, Mora S, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjaerg-Hansen A, Tentolouris N, Nordestgaard BG; Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. CURRENT VASCULAR PHARMACOLOGY. 17. 5. (515-537). DOI: 10.2174/1570161117666190503123911. IF: 2,583. Q2. Review. IMIBIC GROUPS: GC09	GC09
Kolovou GD, Watts GF, Mikhailidis DP, Perez-Martinez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjaerg-Hansen A, Tentolouris N, Nordestgaard BG; Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. CURRENT VASCULAR PHARMACOLOGY. 17. 5. (538-540). DOI: 10.2174/1570161117999190517115432. IF: 2,087. Q3. Article. IMIBIC GROUPS: GC09	GC09
Trullas JC, Casado J, Morales-Rull JL, Formiga F, Conde-Martel A, Quiros R, Epelde F, Gonzalez-Franco A, Manzano L, Montero-Perez-Barquero M; Prevalence and outcome of diuretic resistance in heart failure. INTERNAL AND EMERGENCY MEDICINE. 14. 4. (529-537). DOI: 10.1007/s11739-018-02019-7. IF: 2,335. Q2. Article. IMIBIC GROUPS: GC09	GC09
Garcia-Hernandez FJ, Castillo-Palma MJ, Tolosa-Vilella C, Guillen-del Castillo A, Rubio-Rivas M, Freire M, Vargas-Hitos JA, Todoli-Parra JA, Rodriguez-Carballeira M, Espinosa-Garriga G, Colunga-Arguelles D, Ortego-Centeno N, Trapiella-Martinez L, Rodero-R; Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. CLINICAL RHEUMATOLOGY. 38. 4. (1117-1124). DOI: 10.1007/s10067-018-4390-x. IF: 2,293. Q3. Article. IMIBIC GROUPS: GC09	GC09
Montero-Perez-Barquero M, Manzano L; Quality of life, compliance and satisfaction of patients with atrial fibrillation who are undergoing anticoagulant treatment. REVISTA CLINICA ESPAÑOLA. 219. 6. (320-321). DOI: 10.1016/j.rce.2019.03.002. IF: 1,184. Q3. Editorial Material. IMIBIC GROUPS: GC09	GC09
Rodriguez-Ortiz ME, Gomez-Delgado F, de Larriva APA, Canalejo A, Gomez-Luna P, Herencia C, Lopez-Moreno J, Rodriguez M, Lopez-Miranda J, Almaden Y; Serum Magnesium is associated with Carotid Atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study). SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-44322-z. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC13 GC09	GC09

PUBLICATIONS	IMIBIC GROUP
Santos-Marcos JA, Haro C, Vega-Rojas A, Alcala-Diaz JF, Molina-Abril H, Leon-Acuna A, Lopez-Moreno J, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A; Sex Differences in the Gut Microbiota as Potential Determinants of Gender Predisposition to Disease. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 7. DOI: 10.1002/mnfr.201800870. IF: 4,653. D1. Article. IMIBIC GROUPS: Medicina Interna GC09 GC10	GC09
Papandreou C, Babio N, Diaz-Lopez A, Martinez-Gonzalez MA, Becerra-Tomas N, Corella D, Schroder H, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez AJ, Serra-Majem L, Estruch R, Munoz-Garach A, Lapetra J, Pinto X, Tur JA, Garcia-Rios A, Bueno-; Sleep Duration is Inversely Associated with Serum Uric Acid Concentrations and Uric Acid to Creatinine Ratio in an Elderly Mediterranean Population at High Cardiovascular Risk. NUTRIENTS. 11. 4. DOI: 10.3390/nu11040761. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC09	GC09
Santos-Marcos JA, Perez-Jimenez F, Camargo A; The role of diet and intestinal microbiota in the development of metabolic syndrome. JOURNAL OF NUTRITIONAL BIOCHEMISTRY. 70. (1-27). DOI: 10.1016/j.jnutbio.2019.03.017. IF: 4,414. Q1. Review. IMIBIC GROUPS: GC09	GC09
Chivite D, Franco J, Formiga F, Salamanca-Bautista P, Manzano L, Conde-Martel A, Arevalo-Lorido JC, Suarez-Pedreira I, Casado-Cerrada J, Montero-Perez-Barquero M; The short-term prognostic value of C-reactive protein in elderly patients with acute heart failure. REVISTA CLINICA ESPAÑOLA. 219. 1. (10-17). DOI: 10.1016/j.rce.2018.04.019. IF: 1,043. Q3. Article. IMIBIC GROUPS: GC09	GC09
Julibert A, Bibiloni MD, Bouzas C, Martinez-Gonzalez MA, Salas-Salvado J, Corella D, Zomeno MD, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pinto X, Lopez-Miranda J, Garcia-Molina L, ; Total and Subtypes of Dietary Fat Intake and Its Association with Components of the Metabolic Syndrome in a Mediterranean Population at High Cardiovascular Risk. NUTRIENTS. 11. 7. DOI: 10.3390/nu11071493. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC09	GC09
Masana L, Ibarretxe D, Rodriguez-Borjabad C, Plana N, Valdivielso P, Pedro-Botet J, Civeira F, Lopez-Miranda J, Guijarro C, Mostaza J, Pinto X; Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. ATHEROSCLEROSIS. 287. (89-92). DOI: 10.1016/j.atherosclerosis.2019.06.905. IF: 4,255. Q1. Review. IMIBIC GROUPS: GC09	GC09
Ellis KL, de Isla LP, Alonso R, Fuentes F, Watts GF, Mata P; Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 73. 9. (1029-1039). DOI: 10.1016/j.jacc.2018.12.037. IF: 18,639. D1. Article. IMIBIC GROUPS: GC09	GC09
Miramontes-Gonzalez JP, Usategui-Martin R, de Isla LP, Alonso R, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, Jimenez FF, Martin-Vallejo J, Gude AER, Jimenez DL, Padro T, Gonzalez-Sarmiento R, Mata P; VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. ATHEROSCLEROSIS. 285. (17-22). DOI: 10.1016/j.atherosclerosis.2019.03.019. IF: 4,255. Q1. Article. IMIBIC GROUPS: GC09	GC09
Huerta-Preciado J, Franco J, Formiga F, Iborra PL, Epelde F, Franco AG, Ormaechea G, Manzano L, Cepeda-Rodrigo JM, Montero-Perez-Barquero M. With the Aid of RICA Investigators Group: Rocha, PA; Anarte, L; Arevalo-Lorido, JC; Cabanes, Y; Carrascosa, S; Izq; Differential characteristics of acute heart failure in very elderly patients: the prospective RICA study. AGING CLINICAL AND EXPERIMENTAL RESEARCH. . DOI: 10.1007/s40520-019-01363-8. IF: 2,331. Q3. Article; Early Access. IMIBIC GROUPS: GC09	GC09
Alvarez-Alvarez I, Martinez-Gonzalez MA, Sanchez-Tainta A, Corella D, Diaz-Lopez A, Fito M, Vioque J, Romaguera D, Martinez JA, Warnberg J, Lopez-Miranda J, Estruch R, Bueno-Cavanillas A, Aros F, Tur JA, Tinahones FJ, Serra-Majem L, Martin V, Lapetra J, F; Adherence to an Energy-restricted Mediterranean Diet Score and Prevalence of Cardiovascular Risk Factors in the PREDIMED-Plus: A Cross-sectional Study. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 11. (925-934). DOI: 10.1016/j.rec.2018.08.010. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC09	GC09
Lopez-Bascon MA, Calderon-Santiago M, Diaz-Lozano A, Camargo A, Lopez-Miranda J, Priego-Capote F; Development of a qualitative/quantitative strategy for comprehensive determination of polar lipids by LC-MS/MS in human plasma. ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 412. 2. SI. (489-498). DOI: 10.1007/s00216-019-02261-8. IF: 3,286. D3 Q1. Article; Early Access. IMIBIC GROUPS: GC21 GC09	GC09

PUBLICATIONS	IMIBIC GROUP
Leon-Acuna A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, Roncero-Ramos I, Yubero-Serrano E, Tinahones FJ, Castro-Clerico M, Delgado-Lista J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study. ATHEROSCLEROSIS. 290. (118-124). DOI: 10.1016/j.atherosclerosis.2019.09.025. IF: 4,255. D2 Q1. Article. IMIBIC GROUPS: GC09 Análisis Clínicos GC27	GC09
Pedro-Botet J, Lopez-Miranda J, Badimon L, Civeira F, Guijarro C, Millan J, Mostaza JM, Pinto X, Valdivielso P, Masana L; Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. DOI: 10.1007/s40256-019-00376-y. IF: 2,578. Q2. Review; Early Access. IMIBIC GROUPS: GC09	GC09
Arevalo-Lorido JC, Carretero-Gomez J, Robles NR, Llacer P, Carrera M, Suarez-Pedreira I, Alvarez-Rocha P, Manzano-Espinosa L, Cepeda-Rodrigo JM, Montero-Perez-Barquero M. (on behalf of the RICA Investigators Group. Rocha, PA; Anarte, L; Arevalo-Lorido, JC; Prognostic Role of Hyponatremia in Heart Failure Patients Depending on Renal Disease: Clinical Evidence. CARDIOLOGY. 144. 1-2. (1-8). DOI: 10.1159/000502566. IF: 1,561. Q4. Article. IMIBIC GROUPS: GC09	GC09
Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, Tada MT, Lima I, Jannes CE, Krieger JE, Pereira AC, Quintana-Navarro G, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, Mata P, Santos RD; Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia from different countries. EUROPEAN JOURNAL OF CLINICAL NUTRITION. 73. 12. (1622-1625). DOI: 10.1038/s41430-019-0529-3. IF: 3,114. Q2. Article. IMIBIC GROUPS: GC09	GC09
Tresserra-Rimbau A, Castro-Barquero S, Vitelli-Storelli F, Becerra-Tomas N, Vazquez-Ruiz Z, Diaz-Lopez A, Corella D, Castaner O, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pinto X, Tur JA, Lopez-Miranda J, Garcia-Molina L, Delgado-Rodriguez M, Matia-Martin P, Daimiel L, Rubin-Garcia M, Vidal J, Galdon A, Ros E, Basterra-Gortari FJ, Babio N, Sorli JV, Hernaez A, Konieczna J, Notario-Barandiaran L, Tojal-Sierra L, Perez-Lopez J, Abete I, Alvarez-Perez J, Fernandez-Garcia JC, Santos-Lozano JM, Galera-Cusi A, Julibert A, Ruiz-Canela M, Martinez-Lacruz R, Perez-Vega KA, Galmes-Panades AM, Pastor-Polo C, Moreno-Rodriguez A, Gea A, Fito M, Lamuela-Raventos RM, Salas-Salvado J; Associations between Dietary Polyphenols and Type 2 Diabetes in a Cross-Sectional Analysis of the PREDIMED-Plus Trial: Role of Body Mass Index and Sex. ANTIOXIDANTS. 8. 11. DOI: 10.3390/antiox8110537. IF: 4,52. D1 Q1. Article. IMIBIC GROUPS: GC09	GC09
Corina A, Abrudan MB, Nikolic D, Catoi AF, Chianetta R, Castellino G, Citarrella R, Stoian AP, Perez-Martinez P, Rizzo, M; Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers. CURRENT PHARMACEUTICAL DESIGN. 25. 35. (3704-3714). DOI: 10.2174/1381612825666191105111232. IF: 2,412. Q3. Review. IMIBIC GROUPS: GC09	GC09
de Isla LP, Arroyo-Olivares R, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, Fuentes F, Munoz-Torrero JFS, Mediavilla JD, Gonzalez-Estrada A, Miramontes-Gonzalez JP, de Andres R, Mauri M, Mosquera D, Cepeda JM, Suarez L, Barba-Romero MA, Argueso R, Alvarez-Banos P, Michan A, Romero-Jimenez MJ, Garcia-Cruces J, Padro T, Alonso R, Mata P; Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. JOURNAL OF CLINICAL LIPIDOLOGY. 13. 6. (989-996). DOI: 10.1016/j.jacl.2019.10.005. IF: 3,581. Q2. Article. IMIBIC GROUPS: GC09	GC09
Ditano-Vazquez P, Torres-Pena JD, Galeano-Valle F, Perez-Caballero AI, Demelo-Rodriguez P, Lopez-Miranda J, Katsiki N, Delgado-Lista J, Alvarez-Sala-Walther LA; The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. NUTRIENTS. 11. 11. DOI: 10.3390/nu11112833. IF: 4,171. D2 Q1. Review. IMIBIC GROUPS: GC09	GC09
Blasco V, Pinto FM, Fernandez-Atucha A, Prados N, Tena-Sempere M, Fernandez-Sanchez M, Candenas L; Altered expression of the kisspeptin/KISS1R and neurokinin B/NK3R systems in mural granulosa and cumulus cells of patients with polycystic ovarian syndrome. JOURNAL OF ASSISTED REPRODUCTION AND GENETICS. 36. 1. (113-120). DOI: 10.1007/s10815-018-1338-7. IF: 2,82. Q1. Article. IMIBIC GROUPS: GC10	GC10
Sliwowska JH, Ziarniak K, Dudek M, Matuszewska J, Tena-Sempere M; Dangerous liaisons for pubertal maturation: the impact of alcohol consumption and obesity on the timing of puberty. BIOLOGY OF REPRODUCTION. 100. 1. (25-40). DOI: 10.1093/biolre/ioy168. IF: 3,184. Q1. Review. IMIBIC GROUPS: GC10	GC10

PUBLICATIONS	IMIBIC GROUP
Romero-Ruiz A, Avendano MS, Dominguez F, Lozoya T, Molina-Abril H, Sangiao-Alvarellos S, Gurrea M, Lara-Chica M, Fernandez-Sanchez M, Torres-Jimenez E, Perdices-Lopez C, Abbara A, Steffani L, Calzado MA, Dhillo WS, Pellicer A, Tena-Sempere M; Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 220. 5. (480.e1-480.e17). DOI: 10.1016/j.ajog.2019.01.228. IF: 6,12. D1. Article. IMIBIC GROUPS: GC10 GC04	GC10
Vazquez MJ, Velasco I, Tena-Sempere M; Novel mechanisms for the metabolic control of puberty: implications for pubertal alterations in early-onset obesity and malnutrition. JOURNAL OF ENDOCRINOLOGY. 242. 2. (R51-R65). DOI: 10.1530/JOE-19-0223. IF: 4,381. Q1. Review. IMIBIC GROUPS: GC10	GC10
Santos-Marcos JA, Haro C, Vega-Rojas A, Alcala-Diaz JF, Molina-Abril H, Leon-Acuna A, Lopez-Moreno J, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A; Sex Differences in the Gut Microbiota as Potential Determinants of Gender Predisposition to Disease. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 7. DOI: 10.1002/mnfr.201800870. IF: 4,653. D1. Article. IMIBIC GROUPS: Medicina Interna GC09 GC10	GC10
Ruiz-Pino F, Miceli D, Franssen D, Vazquez MJ, Farinetti A, Castellano JM, Panzica G, Tena-Sempere M; Environmentally Relevant Perinatal Exposures to Bisphenol A Disrupt Postnatal Kiss1/NKB Neuronal Maturation and Puberty Onset in Female Mice. ENVIRONMENTAL HEALTH PERSPECTIVES. 127. 10. 107011. DOI: 10.1289/EHP5570. IF: 7,736. D1 Q1. Article. IMIBIC GROUPS: GC10	GC10
Velasco I, Leon S, Barroso A, Ruiz-Pino F, Heras V, Torres E, Leon M, Ruohonen ST, Garcia-Galiano D, Romero-Ruiz A, Sanchez-Garrido MA, Olhsson C, Castellano JM, Roa J, Poutanen M, Pinilla L, Vazquez MJ, Tena-Sempere M; Gonadal hormone-dependent vs. -independent effects of kisspeptin signaling in the control of body weight and metabolic homeostasis. METABOLISM-CLINICAL AND EXPERIMENTAL. 98. (84-94). DOI: 10.1016/j.metabol.2019.06.007. IF: 6,513. D1 Q1. Article. IMIBIC GROUPS: GC10	GC10
Boto L, Pineda M, Pineda R; Potential impacts of horizontal gene transfer on human health and physiology and how anthropogenic activity can affect it. FEBS JOURNAL. 286. 20. (3959-3967). DOI: 10.1111/febs.15054. IF: 4,739. D2 Q1. Review. IMIBIC GROUPS: GC10	GC10
Heras V, Sangiao-Alvarellos S, Manfredi-Lozano M, Sanchez-Tapia MJ, Ruiz-Pino F, Roa J, Lara-Chica M, Morrugares-Carmona R, Jouy N, Abreu AP, Prevot V, Belsham D, Vazquez MJ, Calzado MA, Pinilla L, Gaytan F, Latronico AC, Kaiser UB, Castellano JM, Tena-Sempere M; Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3. PLOS BIOLOGY. 17. 11. DOI: 10.1371/journal.pbio.3000532. IF: 8,386. D1 Q1. Article. IMIBIC GROUPS: GC10 GC04	GC10
Braxton TM, Sarpong DEA, Dovey JL, Guillou A, Evans BAJ, Castellano JM, Keenan BE, Baraghithy S, Evans SL, Tena-Sempere M, Mollard P, Tam J, Wells T; Thermoneutrality improves skeletal impairment in adult Prader-Willi syndrome mice. JOURNAL OF ENDOCRINOLOGY. 243. 3. (175-186). DOI: 10.1530/JOE-19-0279. IF: 4,381. Q1. Article. IMIBIC GROUPS: GC10	GC10
Ortega FJ, Moreno-Navarrete JM, Mercader JM, Gomez-Serrano M, Garcia-Santos E, Latorre J, Lluch A, Sabater M, Caballano-Infantes E, Guzman R, Macias-Gonzalez M, Buxo M, Girones J, Vilallonga R, Naon D, Botas P, Delgado E, Corella D, Burcelin R, Fruhbeck G; Cytoskeletal transgelin 2 contributes to gender-dependent adipose tissue expandability and immune function. FASEB JOURNAL. 33. 8. (9656-9671). DOI: 10.1096/fj.201900479R. IF: 5,391. D1. Article. IMIBIC GROUPS: GC11	GC11
Ezquerro S, Mocha F, Fruhbeck G, Guzman-Ruiz R, Valenti V, Mugueta C, Becerril S, Catalan V, Gomez-Ambrosi J, Silva C, Salvador J, Colina I, Malagon MM, Rodriguez A; Ghrelin Reduces TNF-alpha-Induced Human Hepatocyte Apoptosis, Autophagy, and Pyroptosis: Role in Obesity-Associated NAFLD. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 1. (21-37). DOI: 10.1210/jc.2018-01171. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC11	GC11
Camargo A, Jimenez-Lucena R, Alcala-Diaz JF, Rangel-Zuniga OA, Garcia-Carpintero S, Lopez-Moreno J, Blanco-Rojo R, Delgado-Lista J, Perez-Martinez P, van Ommen B, Malagon MM, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J; Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: From the CORDIOPREV study. CLINICAL NUTRITION. 38. 2. (529-538). DOI: 10.1016/j.clnu.2018.03.016. IF: 6,402. D1. Article. IMIBIC GROUPS: GC09 GC11	GC11
Romero-Rodriguez E, de Torres LAP, Garcia JAF, Rejano JMP, Villalobos AR, Guillen FC, Lopez SF, Marquez RF, Moral RR, Larumbe MC; Alcohol consumption in Spanish primary health care providers: a national, cross-sectional study. BMJ OPEN. 9. 2. DOI: 10.1136/bmjopen-2018-024211. IF: 2,376. Q2. Article. IMIBIC GROUPS: GC12	GC12

PUBLICATIONS	IMIBIC GROUP
Perula-de Torres LA, Atalaya JCVM, Garcia-Campayo J, Roldan-Villalobos A, Magallon-Botaya R, Bartolome-Moreno C, Moreno-Martos H, Melus-Palazon E, Lietor-Villajos N, Valverde-Bolivar FJ, Hachem-Salas N, Rodriguez LA, Navarro-Gil M, Epstein R, Cabezon-Cres; Controlled clinical trial comparing the effectiveness of a mindfulness and self-compassion 4-session programme versus an 8-session programme to reduce work stress and burnout in family and community medicine physicians and nurses: MINDUUDD study protocol. BMC FAMILY PRACTICE. 20. DOI: 10.1186/s12875-019-0913-z. IF: 2,431. Q2. Article. IMIBIC GROUPS: GC12 Atención Primaria Distrito Sur Lucena	GC12
Angus C, Li JS, Romero-Rodriguez E, Anderson P, Parrott S, Brennan A; Cost-effectiveness of strategies to improve delivery of brief interventions for heavy drinking in primary care: results from the ODHIN trial. EUROPEAN JOURNAL OF PUBLIC HEALTH. 29. 2. (219-225). DOI: 10.1093/eurpub/cky181. IF: 2,234. Q2. Article. IMIBIC GROUPS: GC12	GC12
Aguera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Pena J; Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE. 8. 1. (23-31). DOI: 10.1016/j.jshs.2017.05.007. IF: 3,644. Q1. Article. IMIBIC GROUPS: GE01 Urgencias GC12	GC12
Granados NM, Abellan MV, Estepa MT, Diaz MMP, Pedraza RR; Frequent attendance in a Primary Health Care District. GACETA SANITARIA. 33. 1. (38-44). DOI: 10.1016/j.gaceta.2017.07.011. IF: 1,656. Q2. Article. IMIBIC GROUPS: Atención Primaria GC12 GE08	GC12
Romero-Rodriguez E, de Torres LAP, Garcia JAF, Villalobos AR, Moral RR, Rejano JMP; Impact of a primary care training program on the prevention and management of unhealthy alcohol use: A quasi-experimental study. PATIENT EDUCATION AND COUNSELING. 102. 11. (2060-2067). DOI: 10.1016/j.pec.2019.05.019. IF: 2,821. Q1. Article. IMIBIC GROUPS: GC12	GC12
Romero-Rodriguez E, de Torres LAP, Leiva-Cepas F, Garcia JAF, Lopez SF, Muro MMR, Guillem FC, Villalobos AR, Moral RR, Rejano JMP, Marquez RSF, Dominguez PMC, Moreno CB, de Torres CP; Knowledge, attitudes and preventive practices of primary health care professionals towards alcohol use: A national, cross-sectional study. PLOS ONE. 14. 5. DOI: 10.1371/journal.pone.0216199. IF: 2,776. Q2. Article. IMIBIC GROUPS: GC12 Distrito Sanitario Cordoba Centro Distrito Sanitario Cordoba Norte	GC12
Romero-Rodriguez E, de Torres LAP, Rejano JMP, Leiva-Cepas F, Guillem FC, Marquez RF, Garcia JAF, Moral RR, Villalobos AR, Lopez SF, Dominguez PMC, Moreno CB, de Torres CP; Prevalence of hazardous alcohol use among Spanish primary care providers. BMC FAMILY PRACTICE. 20. DOI: 10.1186/s12875-019-0999-3. IF: 2,431. Q2. Article. IMIBIC GROUPS: GC12 Distrito Sanitario Cordoba Centro Distrito Sanitario Cordoba Norte	GC12
Moral RR, Martin DM, de Leonardo CG, de Torres LAP, Martinez FC; Promoting Health Promotion: Medical students perceptions about an educational program on behavioral change in primary care. ATENCION PRIMARIA. 51. 7. (435-441). DOI: 10.1016/j.aprim.2018.02.013. IF: 1,346. Q3. Article. IMIBIC GROUPS: GC12	GC12
Vaquero-Alvarez M, Romero-Saldana M, Valle-Alonso J, Cantarero FJL, Blancas-Sanchez IM, del Pozo FJF; Study of obesity in a rural children population and its relationship with anthropometric variables. ATENCION PRIMARIA. 51. 6. (341-349). DOI: 10.1016/j.aprim.2018.03.007. IF: 1,346. Q3. Article. IMIBIC GROUPS: GC12	GC12
Romero-Rodriguez E, Cuevas L, Simon L, Bermejo-Sanchez E, Galan I; Changes in Alcohol Intake During Pregnancy in Spain, 1980 to 2014. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH. 43. 11. (2367-2373). DOI: 10.1111/acer.14193. IF: 3,235. Q2. Article; Early Access. IMIBIC GROUPS: GC12	GC12
Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A, Fitzmaurice DA, Gomez-Doblas JJ, Harbison J, Healey JS, Hobbs FDR, Kaasenbrood F, Keen W, Lee VW, Lindholt JS, Lip GYH, Mairesse GH, Mant J, Martin JW, Martin-Rioboo E, McManus DD, Muniz J, Mu; Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLOS MEDICINE. 16. 9. e1002903. DOI: 10.1371/journal.pmed.1002903. IF: 11,048. D1. Article. IMIBIC GROUPS: GC12	GC12
Aparicio-Martinez P, Perea-Moreno AJ, Martinez-Jimenez MP, Redel-Macias MD, Vaquero-Abellan M, Pagliari C; A Bibliometric Analysis of the Health Field Regarding Social Networks and Young People. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 20. 4024. DOI: 10.3390/ijerph16204024. IF: 2,468. Q2. Article. IMIBIC GROUPS: GC12	GC12

PUBLICATIONS	IMIBIC GROUP
Hernandez-Ascanio J, Perula-de Torres LA, Roldan-Villalobos A, Perula-de Torres JC, Rich-Ruiz M; Effectiveness of a multicomponent intervention to reduce social isolation and loneliness in community-dwelling elders: A randomized clinical trial. Study protocol. JOURNAL OF ADVANCED NURSING. 76. 1. (337-346). DOI: 10.1111/jan.14230. IF: 2,376. D2 Q1. Article; Early Access. IMIBIC GROUPS: GC12	GC12
Rodriguez EMR, de Torres LAP, Ruiz AL, Garcia JAF, Rejano JMP, Villalobos AR; Effectiveness of training programs on alcohol consumption in the Primary Care setting: Systematic review. ATENCION PRIMARIA. 51. 9. (536-547). DOI: 10.1016/j.aprim.2018.07.004. IF: 1,346. Q3. Review. IMIBIC GROUPS: GC12	GC12
Aparicio-Martinez P, Perea-Moreno AJ, Martinez-Jimenez MP, Redel-Macias MD, Pagliari C, Vaquero-Abellan M; Social Media, Thin-Ideal, Body Dissatisfaction and Disordered Eating Attitudes: An Exploratory Analysis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 21. 4177. DOI: 10.3390/ijerph16214177. IF: 2,468. D3 Q1. Article. IMIBIC GROUPS: GC12	GC12
Diaz BM, Molina-Recio G, Romero-Saldana M, Sanchez JR, Taberne CA, Blanco CA, Molina-Luque R, De La Iglesia JM; Validation (in Spanish) of the Mini Nutritional Assessment survey to assess the nutritional status of patients over 65 years of age. FAMILY PRACTICE. 36. 2. (172-178). DOI: 10.1093/fampra/cmy051. IF: 1,986. Q2. Article. IMIBIC GROUPS: GC12	GC12
Alvarez-Fernandez C, Vaquero-Abellan M, Romero-Saldana M, Alvarez-Lopez C; Workers especially sensitive to cardiovascular risk. REVISTA ESPAÑOLA DE SALUD PÚBLICA. 93. IF: 0,635. Q4. Article. IMIBIC GROUPS: GC12	GC12
Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM, Herencia C, Vergara N, de Mier MVPR, Santamaria R, Rodelo-Haad C, Casado-Diaz A, Lorenzo V, Carvalho C, Frazao JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodriguez M, Lo; Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. KIDNEY INTERNATIONAL. 95. 5. (1064-1078). DOI: 10.1016/j.kint.2018.12.015. IF: 8,306. D1. Article. IMIBIC GROUPS: GC13 GC07 GC09 GC17	GC13
Rodelo-Haad C, Santamaria R, Munoz-Castaneda JR, de Mier MVPR, Martin-Malo A, Rodriguez M; FGF23, Biomarker or Target? TOXINS. 11. 3. DOI: 10.3390/toxins11030175. IF: 3,895. Q1. Review. IMIBIC GROUPS: GC07 GC13	GC13
Perez-del Palacio J, Diaz-Navarro C, Martin-Blazquez A, Gonzalez-Olmedo C, Vergara-Segura N, Algieri F, Rodriguez-Nogales A, Gonzalez-Tejero MR, Casares-Porcel M, Molero-Mesa J, Rodriguez-Cabezas ME, Genilloud O, Galvez J, Vicente F; Metabolomic analysis of Lavandula dentata L. and Lavandula stoechas L. extracts by LC-QTOF/MS experiments and multivariate analysis techniques as a chemotaxonomical tool. PLANT BIOSYSTEMS. 0. DOI: 10.1080/11263504.2019.1591536. IF: 1,525. Q2. Article; Early Access. IMIBIC GROUPS: GC13	GC13
Rodriguez-Ortiz ME, de Mier MVPR, Rodriguez M; Parathyroidectomy in dialysis patients: Indications, methods, and consequences. SEMINARS IN DIALYSIS. 32. 5. (444-451). DOI: 10.1111/sdi.12772. IF: 2,056. Q3. Review. IMIBIC GROUPS: GC13	GC13
Rodelo-Haad C, Esquivias-Motta E, Amaral-Neiva F, Martin-Malo A, Aljama P, Rodriguez M; Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy. BREAST JOURNAL. 25. 5. (998-999). DOI: 10.1111/tbj.13389. IF: 2,433. Q2. Editorial Material. IMIBIC GROUPS: GC13 GC07	GC13
Rodriguez-Ortiz ME, Gomez-Delgado F, de Larriva APA, Canalejo A, Gomez-Luna P, Herencia C, Lopez-Moreno J, Rodriguez M, Lopez-Miranda J, Almaden Y; Serum Magnesium is associated with Carotid Atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study). SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-44322-z. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC13 GC09	GC13
Ortiz A, Sanchez-Nino MD, Crespo-Barrio M, De-Sequera-Ortiz P, Fernandez-Giraldez E, Garcia-Maset R, Macia-Heras M, Perez-Fontan M, Rodriguez-Portillo M, Salgueira-Lazo M, Sanchez-Alvarez E, Santamaria-Olmo R, Simal-Blanco F, Pino-Pino MD; The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. NEFROLOGIA. 39. 1. (29-34). DOI: 10.1016/j.nefro.2018.09.002. IF: 1,439. Q4. Review. IMIBIC GROUPS: GC07 GC13	GC13

PUBLICATIONS	IMIBIC GROUP
Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Rob; Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (20-24). DOI: 10.1016/j.transproceed.2018.04.092. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva Anatomía Patológica GC14 Medicina Intensiva	GC14
Ruiz-Ortiz M, Rodriguez-Diego S, Delgado M, Kim J, Weinsaft JW, Ortega R, Carnero L, Sanchez JJ, Carrasco F, Lopez-Aguilera J, Lopez-Granados A, Arizon JM, Paredes N, Oneto-Fernandez J, Pan M, Mesa D; Myocardial deformation and acute cellular rejection after heart transplantation: Impact of inter-vendor variability in diagnostic effectiveness. ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES. 36. 12. (2185-2194). DOI: 10.1111/echo.14544. IF: 1,287. Q4. Article; Early Access. IMIBIC GROUPS: GC15 Cardiología GC14	GC14
Romero M, Suarez-de-Lezo J, Herrera C, Pan M, Lopez-Aguilera J, Suarez-de-Lezo J, Baeza-Garzon F, Hidalgo-Lesmes FJ, Fernandez-Lopez O, Martinez-Atienza J, Cebrian E, Martin-Palanco V, Jimenez-Moreno R, Gutierrez-Fernandez R, Nogueras S, Carmona MD, Ojeda S, Cuende N, Mata R; Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol. BMC CARDIOVASCULAR DISORDERS. 19. 1. DOI: 10.1186/s12872-019-1182-4. IF: 1,947. Q3. Article. IMIBIC GROUPS: GC15 Cardiología GC14	GC14
Anguita P, Anguita M, Castillo JC, Gamez P, Bonilla V, Herrera M; Are Dentists in Our Environment Correctly Following the Recommended Guidelines for Prophylaxis of Infective Endocarditis?. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 1. (86-88). DOI: 10.1016/j.recesp.2018.04.015. IF: 5,126. Q1. Letter. IMIBIC GROUPS: GC15	GC15
Fernandez EC, Granados AL, Martinez MDZ, del Castillo-Medina R; Consensus in cardiology on non-vitamin-K oral anticoagulants for patients with atrial fibrillation. CURRENT MEDICAL RESEARCH AND OPINION. 35. 9. (1571-1582). DOI: 10.1080/03007995.2019.1605049. IF: 2,665. Q1. Review. IMIBIC GROUPS: GC15	GC15
Plaza-Martin M, Sanmartin-Fernandez M, Alvarez-Alvarez B, Andrea R, Seoane-Garcia T, Gonzalez-D'Gregorio J, Hernandez-Betancor I, Rozado J, Carrasco-Avalos F, Alameda-Ortiz MD, Gomez-Talavera S, Sanchis J, Sanchez MA, Peral-Disdier V, Ibanez B, Diaz SD, G; Contemporary differences between men and women with acute coronary syndromes: CIAM multicenter registry. JOURNAL OF CARDIOVASCULAR MEDICINE. 20. 8. (525-530). DOI: 10.2459/JCM.0000000000000812. IF: 1,427. Q4. Article. IMIBIC GROUPS: GC15	GC15
Poletti E, Azzalini L, Ayoub M, Ojeda S, Zivelonghi C, La Manna A, Bellini B, Lostalo A, Luque A, Venuti G, Montorfano M, Agostoni P, Pan M, Carlino M, Mashayekhi K; Conventional vascular access site approach versus fully trans-wrist approach for chronic total occlusion percutaneous coronary intervention: a multicenter registry. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. 0. DOI: 10.1002/ccd.28513. IF: 2,551. Q2. Article; Early Access. IMIBIC GROUPS: GC15	GC15
Gonzalez-Vilchez F, Delgado JF, Palomo J, Mirabet S, Diaz-Molina B, Almenar L, Arizon JM, Rangel-Sousa D, Perez-Villa F, Garrido IP, de la Fuente L, Gomez-Bueno M, Sanz ML, Crespo-Leiro MG; Conversion From Immediate-Release Tacrolimus to Prolonged-Release Tacrolimus in Stable Heart Transplant Patients: A Retrospective Study. TRANSPLANTATION PROCEEDINGS. 51. 6. (1994-2001). DOI: 10.1016/j.transproceed.2019.04.028. IF: 0,959. Q4. Article. IMIBIC GROUPS: GC15	GC15
Hidalgo F, Pan M, Ojeda S, de Lezo JS, Lostalo A, Luque A, Martin E, Segura J, Mazuelos F, Romero M; Feasibility and Efficacy of the Jailed Pressure Wire Technique for Coronary Bifurcation Lesions. JACC-CARDIOVASCULAR INTERVENTIONS. 12. 1. (109-111). DOI: 10.1016/j.jcin.2018.10.036. IF: 9,544. D1. Letter. IMIBIC GROUPS: GC15 Cardiología	GC15
Sambola A, Anguita M, Guzman G, Beltran P, Mila L, Gine M; Gender Differences in the Professional Lives of Cardiologists in 70 Spanish Hospitals. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 3. (272-274). DOI: 10.1016/j.recesp.2018.05.038. IF: 5,126. Q1. Letter. IMIBIC GROUPS: GC15	GC15
Sambola A, Anguita M, Gine M; Is There a Gender Gap in Spanish Cardiology? REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 3. (195-197). DOI: 10.1016/j.recesp.2018.07.016. IF: 5,126. Q1. Editorial Material. IMIBIC GROUPS: GC15	GC15

PUBLICATIONS	IMIBIC GROUP
Amat-Santos IJ, Martin-Yuste V, Fernandez-Diaz JA, Martin-Moreiras J, Caballero-Borrego J, Salinas P, Ojeda S, Rivero F, Villota JN, Mohandes M, Dubois D, Ojeda FB, Rumiz E, Hernandez JMD, Jimenez-Mazuecos J, Lacunza J, Tejedor P, Gomez I, Goncalves-Ramir; Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 5. (373-382). DOI: 10.1016/j.rec.2018.05.020. IF: 5,126. Q1. Article. IMIBIC GROUPS: GC15	GC15
Saldivar HG, Alaminos LV, Rodriguez-Pascual C, de la Morena G, Fernandez-Golfin C, Amoros C, Alonso MB, Dolz LM, Sole AA, Guzman-Martinez G, Gomez-Doblas JJ, Jimenez AA, Fuentes ME, Gay LG, Ortiz MR, Avanzas P, Abu-Assi E, Ripoll-Vera T, Diaz-Castro O, Os; Prognosis of Patients With Severe Aortic Stenosis After the Decision to Perform an Intervention. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 5. (392-397). DOI: 10.1016/j.rec.2018.03.023. IF: 5,126. Q1. Article. IMIBIC GROUPS: GC15	GC15
Anguita P, Castillo JC, Herrera M, Anguita M; Prophylaxis of Infective Endocarditis in Dentistry: Analysis of the Situation After Almost a Decade of Clinical Practice Guidelines. Response. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 1. (96-96). DOI: 10.1016/j.recesp.2018.07.012. IF: 5,126. Q1. Letter. IMIBIC GROUPS: GC15	GC15
del Pino MDL, Ortiz MR, Ortega MD, Fernandez JS, Quero CF, Jimenez ED, Moreno MR, Saint-Gerons JS, Pineda SO, Pan Alvarez-Ossorio M, Rubio DM; Prosthesis-patient mismatch after transcatheter aortic valve replacement: prevalence and medium term prognostic impact. INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING. 35. 5. (827-836). DOI: 10.1007/s10554-018-01519-z. IF: 1,86. Q3. Article. IMIBIC GROUPS: Cardiología GC15	GC15
Granero VCL, Santos SF, Fernandez-Golfin C, Gomez AG, Martin MP, Galarza JMD, Faletra FF, Swaans MJ, Lopez-Fernandez T, Mesa D, La Canna G, Garcia TE, Habib G, Monzonis AM, Gomez JLZ; Sustained Improvement of Left Ventricular Strain following Transcatheter Aortic Valve Replacement. CARDIOLOGY. 143. 43497. (52-61). DOI: 10.1159/000500633. IF: 1,561. Q4. Article. IMIBIC GROUPS: GC15	GC15
Vlastra W, Chandrasekhar J, Vendrik J, Gutierrez-Ibanes E, Tchetche D, de Brito FS, Barbanti M, Kornowski R, Latib A, D'Onofrio A, Ribichini F, Baan J, Tijssen JGP, Pan M, Dumonteil N, Mangione JA, Sartori S, D'Errigo P, Tarantini G, Lunardi M, Orvin K, P; Transfemoral TAVR in Nonagenarians From the CENTER Collaboration. JACC-CARDIOVASCULAR INTERVENTIONS. 12. 10. (911-920). DOI: 10.1016/j.jcin.2019.02.031. IF: 9,544. D1. Article. IMIBIC GROUPS: GC15	GC15
Lekuona I, Anguita M, Zamorano JL, Rodriguez JM, de Soroa PB, Perez-Alcantara F; Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain? REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 5. (398-406). DOI: 10.1016/j.rec.2018.03.024. IF: 5,126. Q1. Article. IMIBIC GROUPS: GC15	GC15
Azzalini L, Poletti E, Ayoub M, Ojeda S, Zivelonghi C, La Manna A, Bellini B, Lostalo A, Luque A, Venuti G, Montorfano M, Agostoni P, Pan M, Carlino M, Mashayekhi K; Coronary artery perforation during chronic total occlusion percutaneous coronary intervention: epidemiology, mechanisms, management, and outcomes. EUROINTERVENTION. 15. 9. (E804-+-). DOI: 10.4244/EIJ-D-19-00282. IF: 4,018. Q2. Article. IMIBIC GROUPS: GC15 Cardiología	GC15
Lopez-Fernandez T, Martin-Garcia A, Rabadan IR, Mitroi C, Ramos PM, Diez-Villanueva P, Cervantes CE, Martin CA, Salinas GLA, Arenas M, Esteban VIA, de la Pena FA, Fernandez AC, Pardo HG, Garcia-Sanz R, Porras JRG, de Sa EL, Lozano T, Vera PM, Marin VM, Ru; Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 9. (749-759). DOI: 10.1016/j.rec.2019.03.019. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC15	GC15
Sanchez MA, Martin JJA, Fillat AC, Doblas JJG, Rivera LP, Goya IL, Rodrigo FR, Romo AI, Miguel CM, Masip AE, Melchor LS, Bueno H, Molina BD, Ferreira-Gonzalez I, Somoza FJE; Cardiologists and the Cardiology of the Future. Vision and proposals of the Spanish Society of Cardiology for the Cardiology of the 21st Century. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 8. (659-657). DOI: 10.1016/j.rec.2019.02.025. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC15	GC15
Rius JB, Huelmos A, Sanchez MA; Health Care Simulation in Cardiology: Promises and Realities. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 8. (606-607). DOI: 10.1016/j.rec.2019.02.018. IF: 5,078. D2 Q1. Editorial Material. IMIBIC GROUPS: GC15	GC15

PUBLICATIONS	IMIBIC GROUP
Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, Husser O, Herrmann HC, Nombela-Franco L, Cheema A, Le Breton H, Stortecky S, Kapadia S, Bartorelli AL, Sinning JM, Amat-Santos I, Munoz-Garcia AJ, Lerakis S, Gutierrez-Ibanes E, Abdel-Wahab M, ; Infective Endocarditis Following Transcatheter Aortic Valve Replacement Comparison of Balloon- Versus Self-Expandable Valves. CIRCULATION-CARDIOVASCULAR INTERVENTIONS. 12. 11. e007938. DOI: 10.1161/CIRCINTERVENTIONS.119.007938. IF: 6,088. D2 Q1. Article. IMIBIC GROUPS: GC15	GC15
Fernandez JJS, Ortiz MR, Luque CO, Galvez JMC, Penas ER, Rubio DM, Ortega MD, Dominguez JCC, Sanchez MA, Aguilera JL, Avalos FC, Alvarez-Ossorio MP; Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR Registry. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 10. (827-834). DOI: 10.1016/j.rec.2018.08.019. IF: 5,126. D2 Q1. Article. IMIBIC GROUPS: GC15	GC15
Ruiz-Ortiz M, Rodriguez-Diego S, Delgado M, Kim J, Weinsaft JW, Ortega R, Carnero L, Sanchez JJ, Carrasco F, Lopez-Aguilera J, Lopez-Granados A, Arizon JM, Paredes N, Oneto-Fernandez J, Pan M, Mesa D; Myocardial deformation and acute cellular rejection after heart transplantation: Impact of inter-vendor variability in diagnostic effectiveness. ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES. 36. 12. (2185-2194). DOI: 10.1111/echo.14544. IF: 1,287. Q4. Article; Early Access. IMIBIC GROUPS: GC15 Cardiología GC14	GC15
Cequier A, de Prado AP, Moreno R, Cosin-Sales J, de Sa EL, Evangelista A, Bueno H, Anguita M; Percutaneous cardiological intervention and cardiac surgery: patient-centered care. Position statement of the Spanish Society of Cardiology. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 8. (658-663). DOI: 10.1016/j.rec.2019.02.024. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC15	GC15
Gonzalez-Vilchez F, Almenar-Bonet L, Crespo-Leiro MG, Segovia-Cubero J, Gonzalez-Costello J, del Prado JMA, Sousa-Casasnovas I, Sobrino-Marquez JM, Delgado-Jimenez J, Perez-Villa F, Gomez-Buena M, Hernandez-Perez F, Martinez-Penades S, Cebrian-Pinar M, Lo; Spanish Heart Transplant Registry. 30th Official Report of the Spanish Society of Cardiology Working Group on Heart Failure (1984-2018). REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 11. (954-962). DOI: 10.1016/j.rec.2019.09.005. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC15 Cardiología	GC15
Murga-Eizagaetxebarria N, Rodriguez-Padial L, Muniz J, Sambola A, Gomez-Doblas JJ, Pedreira M, Alonso-Martin JJ, Beltran P, Rodriguez-Roca G, Anguita M, Roig E; The Gender Perspective Within the OFRECE Study: Differences in Health Care Among Patients Consulting for Chest Pain and/or Palpitations. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 10. (813-819). DOI: 10.1016/j.rec.2018.11.021. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC15	GC15
Romero M, Suarez-de-Lezo J, Herrera C, Pan M, Lopez-Aguilera J, Suarez-de-Lezo J, Baeza-Garzon F, Hidalgo-Lesmes FJ, Fernandez-Lopez O, Martinez-Atienza J, Cebrian E, Martin-Palanco V, Jimenez-Moreno R, Gutierrez-Fernandez R, Nogueras S, Carmona MD, Ojeda S, Cuende N, Mata R; Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol. BMC CARDIOVASCULAR DISORDERS. 19. 1. DOI: 10.1186/s12872-019-1182-4. IF: 1,947. Q3. Article. IMIBIC GROUPS: GC15 Cardiología GC14	GC15
Martinez-Cuadron D, Gil C, Serrano J, Rodriguez G, Perez-Oteyza J, Garcia-Boyero R, Jimenez-Bravo S, Vives S, Vidriales MB, Lavilla E, Perez-Simon JA, Tormo M, Colorado M, Bergua J, Lopez JA, Herrera P, Hernandez-Campo P, Gorrochategui J, Primo D, Rojas J; A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. LEUKEMIA RESEARCH. 76. (1-10). DOI: 10.1016/j.leukres.2018.11.006. IF: 2,066. Q3. Article. IMIBIC GROUPS: GC16	GC16
Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, Gonzalez-Campos J, Chillon M, Holowiecka A, Esteve J, Bergua J, Gonzalez-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernandez I, de la Serna J, Moreno MJ, Perez-Encinas M, K; An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. LEUKEMIA & LYMPHOMA. 60. 4. (1030-1035). DOI: 10.1080/10428194.2018.1516875. IF: 2,674. Q3. Article. IMIBIC GROUPS: GC16	GC16
Megias-Vericat JE, Martinez-Cuadron D, Lopez JM, Bergua JM, Tormo M, Serrano J, Gonzalez A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martinez AL, de la Fuente A, Amador ML, Hernandez-Rivas JA, Fernandez MA, Cervero CJ, Morino D, Campo PH, G; Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. 11. DOI: 10.4084/MJHID.2019.016. IF: 1,586. Q4. Article. IMIBIC GROUPS: GC16	GC16

PUBLICATIONS	IMIBIC GROUP
Garcia-Cadenas I, Yanez L, Jarque I, Martino R, Perez-Simon JA, Valcarcel D, Sanz J, Bermudez A, Munoz C, Calderon-Cabrera C, Garcia E, Alonso L, Suarez-Lledo M, Gonzalez Vicent M, Heras I, Viguria MC, Batlle M, Vazquez L, Lopez J, Solano C; Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). EUROPEAN JOURNAL OF HAEMATOLOGY. 102. 6. (465-471). DOI: 10.1111/ejh.13226. IF: 2,217. Q3. Article. IMIBIC GROUPS: GC16	GC16
Alonso L, Gonzalez-Vicent M, Belendez C, Badell I, Sastre A, Rodriguez-Villa A, Bermudez-Cortes M, Hladun R, de Heredia CD; Hematopoietic stem cell transplantation in pediatric patients with thalassemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). MEDICINA CLINICA. 152. 4. (135-140). DOI: 10.1016/j.medcli.2018.05.013. IF: 1,277. Q3. Article. IMIBIC GROUPS: GC16	GC16
Martos L, Fernandez-Pardo A, Lopez-Fernandez MF, Ibanez F, Herrero S, Tassies D, Gonzalez-Porras JR, Solmoirago MJ, Costa MJ, Reverter JC, Marco P, Roldan V, Lecumberri R, Velasco F, Oto J, Iruin G, Alonso MN, Vaya A, Bonanad S, Ferrando F, Marti E, Cid A; Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. THROMBOSIS AND HAEMOSTASIS. 119. 9. (1409-1418). DOI: 10.1055/s-0039-1692440. IF: 4,733. Q1. Article. IMIBIC GROUPS: GC16	GC16
Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, Garcia E, Hemmati P, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, de la Calle GM, Manzur A, Marin JI, Marquez-Gomez I, Martin-Davila P, Mikulska M, Mon; Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ OPEN. 9. 5. DOI: 10.1136/bmjopen-2018-025744. IF: 2,413. Q2. Article. IMIBIC GROUPS: GC16 GC03 Hematología	GC16
Ribera JM, Garcia O, Moreno MJ, Barba P, Garcia-Cadenas I, Mercadal S, Montesinos P, Barrios M, Gonzalez-Campos J, Martinez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genesca E; Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. CANCER. 125. 16. (2810-2817). DOI: 10.1002/cncr.32156. IF: 6,102. Q1. Article; Proceedings Paper. IMIBIC GROUPS: GC16	GC16
Revilla N, Corral J, Minano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I, Gonzalez-Lopez TJ, de la Morena-Barrio ME, Gonzalez-Porras JR, Vicente V, Lozano ML; Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. PLATELETS. 30. 6. (743-751). DOI: 10.1080/09537104.2018.1513476. IF: 3,106. Q2. Article. IMIBIC GROUPS: GC16	GC16
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germin; Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. LEUKEMIA & LYMPHOMA. 60. 1. (246-249). DOI: 10.1080/10428194.2018.1468893. IF: 2,674. Q3. Letter. IMIBIC GROUPS: GC16	GC16
Rodriguez-Veiga R, Montesinos P, Garcia E, Boluda B, Rojas R, Serrano J, Martinez-Cuadron D, Martin C, Sanz J, Tabares S, Pinana JL, Lorenzo I, Montoro J, Salavert M, Peman J, Jarque I, Solves P, Sanz GF, Torres A, Sanz MA; Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. MYCOSES. 62. 5. (418-427). DOI: 10.1111/myc.12891. IF: 3,065. Q2. Article. IMIBIC GROUPS: GC16	GC16
Bento L, Bastida JM, Garcia-Cadenas I, Garcia-Torres E, Rivera D, Bosch-Vilaseca A, De Miguel C, Martinez-Munoz ME, Fernandez-Aviles F, Roldan E, Chinea A, Yanez L, Zudaire T, Vaz CP, Espigado I, Lopez J, Valcarcel D, Duarte R, Cabrera R, Herrera C, Gonza; Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25. 9. (1825-1831). DOI: 10.1016/j.bbmt.2019.05.023. IF: 3,599. Q2. Article. IMIBIC GROUPS: GC16	GC16

PUBLICATIONS	IMIBIC GROUP
Salamero O, Martinez-Cuadron D, Sobas M, Benavente C, Vives S, De la Serna J, Perez-Encinas M, Escoda L, Gil C, Brunet S, Ramos F, Esteve J, Amigo M, Krsnik I, Manso F, Arias J, Gonzalez-Campos J, Serrano J, Oleksiuk J, Barrios M, Garcia-Boyero R, Novo A, Sanz MA, Montesinos P. PETHEMA and PALG Groups: Helbig, G; Holowiecka, A; Armatys, A; Hawrylecka, D; Golos, A; Ejduk, A; Majcherek, M; Skret, A; Czyzewska, J; Grosicki, S; Zarzycka, E; Watek, M; Piatkowska-Jakubas, B; Holojda, J; Pluta, A; Podhorecka, M; Gromek, T; Guzicka, E; Charlinski, G; Paluszewska, M; de Heredia, JMB; Hernandez, JM; Arias, J; Ramos, F; Roman, A; de la Serna, J; Negri, S; Rayon, C; Esteve, J; Fernandez-Calvo, FJ; Diaz-Mediavilla, J; Gil, C; Perez-Encinas, M; Tormo, M; Olave, M; Amutio, E; Pedro, C; Gorosquieta, A; Viguria, M; Zudaire, M; Molero, T; Sayas, MJ; Guardia, R; Manso, F; Rivas, C; Esquembre, C; Garcia, R; Alcala, A; Lopez, JA; Rubio, V; Amigo, ML; Linares, M; Ribera, JM; San Miguel, JDG; Deben, G; Escoda, L; de la Camara, R; Molines, A; Loureiro, C; Allegue, MJ; Amador, L; Marti, JM; Madero, L; Lassaletta, A; Cabezudo, M; Garcia-Larana, J; Rojas, R; Ortega, F; Penarrubia, MJ; Puente, F; Lopez-Ibor, B; Brunet, S; Bergua, JM; Ibañez, J; Sanchez, P; Novo, A; Font, LL; Guinea, JM; Montero, A; Gonzalez, M; Sanz, MA; Martin, G; Martinez, J; Montesinos, P; Verdeguer, A; Garcia, P; Conde, E; Garcia, J; Capote, FJ; Krsnik, I; Bueno, J; Bastida, P; Rubio, A; Fuster, JL; Gonzalez, J; Perez, I; Molina, J; Mateos, MC; Ardaiz, MA; Rodriguez-Calvillo, M; Poderos, C; Arnan, M; Duarte, R; Hernandez, JA; Diaz-Morfa, M; Martin-Chacon, E; Calvo-Villas, JM; Garcia-Belmonte, D; Hernandez-Maraver, D; Miskiewicz, W; Real life outcomes of patients aged >= 75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. LEUKEMIA & LYMPHOMA. 60. 11. (2720-2732). DOI: 10.1080/10428194.2019.1607327. IF: 2,674. Q3. Article. IMIBIC GROUPS: GC16	GC16
Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM, Herencia C, Vergara N, de Mier MVPR, Santamaria R, Rodelo-Haad C, Casado-Diaz A, Lorenzo V, Carvalho C, Frazao JM, Felsenfeld AJ, Richards WG, Aguilera-Tejero E, Rodriguez M, Lo; Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. KIDNEY INTERNATIONAL. 95. 5. (1064-1078). DOI: 10.1016/j.kint.2018.12.015. IF: 8,306. D1. Article. IMIBIC GROUPS: GC13 GC07 GC09 GC17	GC17
Casado-Diaz A, Dorado G, Giner M, Montoya MJ, Navarro-Valverde C, Diez-Perez A, Quesada-Gomez JM; Proof of Concept on Functionality Improvement of Mesenchymal Stem-Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures. CALCIFIED TISSUE INTERNATIONAL. 104. 6. (631-640). DOI: 10.1007/s00223-019-00533-0. IF: 3,265. Q2. Article. IMIBIC GROUPS: GC17	GC17
Bouillon R, Quesada-Gomez JM; Calcifediol or vitamin D to optimize vitamin D status: Reply to letter of M Sosas. OSTEOPOROSIS INTERNATIONAL. 30. 12. (2521-2522). DOI: 10.1007/s00198-019-05164-7. IF: 3,83. Q2. Letter; Early Access. IMIBIC GROUPS: GC17	GC17
Gomez JMQ, Nogues X, Henriquez MS, Bouillon R; Vitamin D supplementation and musculoskeletal health. A controversial necessity. MEDICINA CLINICA. 53. 11. (432-436). DOI: 10.1016/j.medcli.2019.05.010. IF: 1,277. Q3. Editorial Material. IMIBIC GROUPS: GC17	GC17
Halls MC, Alseidi A, Berardi G, Cipriani F, Van der Poel M, Davila D, Ciria R, Besselink M, D'Hondt M, Dagher I, Alrdrighetti L, Troisi RI, Abu Hilal M; A Comparison of the Learning Curves of Laparoscopic Liver Surgeons in Differing Stages of the IDEAL Paradigm of Surgical Innovation Standing on the Shoulders of Pioneers. ANNALS OF SURGERY. 269. 2. (221-228). DOI: 10.1097/SLA.0000000000002996. IF: 9,476. D1. Article. IMIBIC GROUPS: GC18	GC18
Muller-Arteaga C, Batista-Miranda JE, Libano CZ, Moreno RE, Solchaga GM, Nebra JC, Vallejo ML, Garcia OG, Errando-Smet C, Arlandis-Guzman S; Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin. ACTAS UROLOGICAS ESPAÑOLAS. 43. 3. (143-150). DOI: 10.1016/j.acuro.2018.07.005. IF: 1,136. Q4. Article. IMIBIC GROUPS: GC18	GC18
Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Rufian-Pena S, Casado-Adam A, Cosano-Alvarez A, Briceno-Delgado J; Colorectal peritoneal metastases: Optimal management review. WORLD JOURNAL OF GASTROENTEROLOGY. 25. 27. (3484-3502). DOI: 10.3748/wjg.v25.i27.3484. IF: 3,411. Q2. Review. IMIBIC GROUPS: Cirugía General y Digestiva GC18	GC18
Morales JM, Ruiz-Rabelo JF, Diaz-Piedra C, Di Stasi LL; Detecting Mental Workload in Surgical Teams Using a Wearable Single-Channel Electroencephalographic Device. JOURNAL OF SURGICAL EDUCATION. 76. 4. (1107-1115). DOI: 10.1016/j.jsurg.2019.01.005. IF: 2,209. Q2. Article. IMIBIC GROUPS: GC18	GC18

PUBLICATIONS	IMIBIC GROUP
Ciria R, Ayllon MD, Briceno J; Difficulty scores in laparoscopic liver surgery-getting closer to a powerful and necessary tool. HEPATOBILIARY SURGERY AND NUTRITION. 8. 4. (428-430). DOI: 10.21037/hbsn.2019.02.11. IF: 3,911. Q1. Editorial Material. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	GC18
Duran M, Calleja R, Naranjo A, Briceno J; Gastric and intestinal pneumatosis. GASTROENTEROLOGIA Y HEPATOLOGIA. 42. 7. (447-448). DOI: 10.1016/j.gastrohep.2019.03.004. IF: 1,078. Q4. Editorial Material. IMIBIC GROUPS: GC18 Cirugía General y Digestiva Medicina Ap Digestivo	GC18
Briceno J, Ciria R, Lopez P, Luque A, Arjona-Sanchez A, Sanchez-Hidalgo JM, Ayllon MD, Gomez-Luque I, Gomez J; Laparoscopic Living Donor Hepatectomy for Pediatric Liver Transplantation: the First 7 Cases in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (56-57). DOI: 10.1016/j.transproceed.2018.03.140. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	GC18
Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M; mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 2. DOI: 10.3390/ijms20020336. IF: 4,183. Q2. Article. IMIBIC GROUPS: GC02 Medicina Ap Digestivo GC18 Cirugía General y Digestiva Anatomía Patológica	GC18
Ramia JM, Martin-Perez E, Poves I, Fabregat-Prous J, Olea JLY, Sanchez-Bueno F, Botello-Martinez F, Briceno J, Miyar-de Leon A, Serradilla M, Moya-Herraiz A, Secanella L, Bueno FS, Serrablo A, Fabrega JF, Cabus SS, Bravo MAG, Padillo J, Blanco L, Balcells; Multicentric study on total pancreatectomies. CIRUGIA ESPAÑOLA. 97. 7. (377-384). DOI: 10.1016/j.ciresp.2019.04.004. IF: 0,835. Q4. Article. IMIBIC GROUPS: GC18	GC18
Hessheimer AJ, Coll E, Torres F, Ruiz P, Gastaca M, Rivas JI, Gomez M, Sanchez B, Santoyo J, Ramirez P, Parrilla P, Marin LM, Gomez-Bravo MA, Garcia-Valdecasas JC, Lopez-Monclus J, Bosca A, Lopez-Andujar R, Fundora-Suarez J, Villar J, Garcia-Sesma A, Jime; Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation. JOURNAL OF HEPATOLOGY. 70. 4. (658-665). DOI: 10.1016/j.jhep.2018.12.013. IF: 18,946. D1. Article. IMIBIC GROUPS: GC18	GC18
Briceno J, Ciria R, Gomez-Luque I; Planning Generational Change in a Liver Transplant Team. TRANSPLANTATION PROCEEDINGS. 51. 1. (71-73). DOI: 10.1016/j.transproceed.2018.04.091. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	GC18
Pozo-Laderas JC, Rodriguez-Peralvarez M, Munoz-Villanueva MC, Rivera-Espinar F, Durban-Garcia I, Munoz-Trujillo J, Robles-Arista JC, Briceno-Delgado J; Pretransplant predictors of early mortality in adult recipients of liver transplantation in the MELD-Na Era. MEDICINA INTENSIVA. 43. 5. (261-269). DOI: 10.1016/j.medin.2018.03.008. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC18 Medicina Intensiva GC02 Unidad Metdología y Estadistica Imibic	GC18
Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J; Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 79. 3. (245-252). DOI: 10.1016/j.jinf.2019.06.014. IF: 5,099. Q1. Article. IMIBIC GROUPS: GC03 GC26 GC24 Medicina Intensiva GC18	GC18
Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, Schneider MA, Gutierrez-Calvo A, Garcia-Fadrique A, Tuynman JB, Cascales-Campos PA, Martin VC, Morales R, Salti GI, Arteaga X, Pacheco D, Alonso-Gomez J, Yalkin O, Villarejo-Campos P, Sanchez-Hidalgo JM, Cas; RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. ANNALS OF SURGICAL ONCOLOGY. 26. 8. (2595-2604). DOI: 10.1245/s10434-019-07378-9. IF: 3,857. D1. Article. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	GC18
Hessheimer AJ, Coll E, Ruiz P, Gastaca M, Rivas JI, Gomez M, Sanchez B, Santoyo J, Ramirez P, Parrilla P, Marin LM, Gomez-Bravo MA, Garcia-Valdecasas JC, Lopez-Monclus J, Bosca A, Lopez-Andujar R, Fundora-Suarez Y, Villar J, Garcia-Sesma A, Jimenez C, Rod; Reply to: "ormothermic regional perfusion - What is the benefit?''. JOURNAL OF HEPATOLOGY. 71. 2. (443-445). DOI: 10.1016/j.jhep.2019.04.005. IF: 15,04. D1. Letter. IMIBIC GROUPS: GC18	GC18

PUBLICATIONS	IMIBIC GROUP
Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Rob; Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (20-24). DOI: 10.1016/j.transproceed.2018.04.092. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva Anatomía Patológica GC14 Medicina Intensiva	GC18
Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Ayllon-Teran MD, Gomez-Luque I, Ciria-Bru R, Luque-Molina A, Lopez-Cillero P, Rufian-Pena S, Briceno-Delgado J; Super-rapid Technique in Donation After Circulatory Death Liver Donors: Advantages and Disadvantages. TRANSPLANTATION PROCEEDINGS. 51. 1. (25-27). DOI: 10.1016/j.transproceed.2018.05.034. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: Cirugía General y Digestiva GC18	GC18
Hessheimer AJ, Coll E, Ruiz P, Gastaca M, Rivas JI, Gamez M, Sanchez B, Santoyo J, Ramirez P, Parrilla P, Marin LM, Gomez-Bravo MA, Garcia-Valdecasas JC, Lopez-Monclus J, Bosca A, Lopez-Andujar R, Fundora-Suarez J, Villar J, Garcia-Sesma A, Jimenez C, Rod; The UK DCD Risk Score: Still no consensus on futility in DCD liver transplantation. JOURNAL OF HEPATOLOGY. 70. 5. (1034-1035). DOI: 10.1016/j.jhep.2019.01.004. IF: 18,946. D1. Letter. IMIBIC GROUPS: GC18	GC18
Ayllon MD, Ciria R, Gomez-Luque I, Rodriguez-Peralvarez M, Padial A, Luque A, Lopez-Cillero P, de la Mata M, Briceno J; Use of Peritoneovenous Shunt for the Management of Refractory Ascites. TRANSPLANTATION PROCEEDINGS. 51. 1. (41-43). DOI: 10.1016/j.transproceed.2018.04.089. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GC02	GC18
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J; Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 19. 11. (1388-1398). DOI: 10.2174/1871520619666190417162409. IF: 2,18. Q3. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GE01 GC02	GC18
Duran M, Naranjo A, Briceno J; Sigmoid Gallstone Ileus. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 17. 13. (E153-E153). DOI: 10.1016/j.cgh.2019.01.031. IF: 7,958. D1 Q1. Editorial Material. IMIBIC GROUPS: Cirugía General y Digestiva GC18	GC18
Fernandez GB, Bravo MAG, Delgado JB, Lopez AV, Lopez-Guerra D, Rodriguez-Laiz G, Villar-del-Moral J, Sanchez FP, Santoyo J, Andujar RL, Nuno J, Turrion VS, Pinto IG, Jimenez C, Baena JAL, Gutierrez MG, Prous JF, Sanchez DP, Barrera M, Garcia-Gil A, Ramirez P, Varo, E, Bilbao I, Fondevila C, Rodriguez-Sanjuan JC; A survey of Heads of Surgery and Residents on accessibility and employment in liver transplant teams in Spain. CIRUGIA ESPAÑOLA. 97. 10. (560-567). DOI: 10.1016/j.ciresp.2019.03.018. IF: 0,835. Q4. Article. IMIBIC GROUPS: GC18	GC18
Ciria R, Gomez-Luque I, Ocana S, Cipriani F, Halls M, Briceno J, Okuda Y, Troisi R, Rotellar F, Soubrane O, Abu Hilal M; A Systematic Review and Meta-Analysis Comparing the Short- and Long-Term Outcomes for Laparoscopic and Open Liver Resections for Hepatocellular Carcinoma: Updated Results from the European Guidelines Meeting on Laparoscopic Liver Surgery, Southampton, UK, 2017. ANNALS OF SURGICAL ONCOLOGY. 26. 1. (252-263). DOI: 10.1245/s10434-018-6926-3. IF: 3,681. D2 Q1. Review. IMIBIC GROUPS: GC18	GC18
Arjona-Sanchez A, Duran M, Sanchez-Hidalgo JM, Rufian-Pena S; Peritoneal carcinomatosis from ovarian carcinoma treated by interval laparoscopic complete cytoreduction and HIPEC with extraction through natural orifice. SURGICAL ONCOLOGY-OXFORD. 31. (14-15). DOI: 10.1016/j.suronc.2019.08.005. IF: 3. Q1. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18	GC18
Sarmadi H, Munoz-Salinas R, Berbis MA, Luna A, Medina-Carnicer R; 3D Reconstruction and alignment by consumer RGB-D sensors and fiducial planar markers for patient positioning in radiation therapy. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE. 180. DOI: 10.1016/j.cmpb.2019.105004. IF: 3,424. Q1. Article. IMIBIC GROUPS: GC19	GC19
Duran-Rosal AM, Gutierrez PA, Carmona-Poyato A, Heryas-Martinez C; A hybrid dynamic exploitation barebones particle swarm optimisation algorithm for time series segmentation. NEUROCOMPUTING. 353. (45-55). DOI: 10.1016/j.neucom.2018.05.129. IF: 4,072. Q1. Article. IMIBIC GROUPS: GA11 GC19	GC19
Munoz-Salinas R, Sarmadi H, Cazzato D, Medina-Carnicer R; Flexible body scanning without template models. SIGNAL PROCESSING. 154. (350-362). DOI: 10.1016/j.sigpro.2018.09.022. IF: 4,086. Q1. Article. IMIBIC GROUPS: GC19	GC19

PUBLICATIONS	IMIBIC GROUP
Sarmadi H, Munoz-Salinas R, Berbis MA, Medina-Carnicer R; Simultaneous Multi-View Camera Pose Estimation and Object Tracking With Squared Planar Markers. IEEE ACCESS. 7. (22927-22940). DOI: 10.1109/ACCESS.2019.2896648. IF: 4,098. Q1. Article. IMIBIC GROUPS: GC19	GC19
Munoz-Salinas R, Marin-Jimenez MJ, Medina-Carnicer R; SPM-SLAM: Simultaneous localization and mapping with squared planar markers. PATTERN RECOGNITION. 86. (156-171). DOI: 10.1016/j.patcog.2018.09.003. IF: 5,898. D1. Article. IMIBIC GROUPS: GC19	GC19
Plaza-Diaz J, Gomez-Fernandez A, Chueca N, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K, Martin-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F, Gil-Campos M; Autism Spectrum Disorder (ASD) with and without Mental Regression Is Associated with Changes in the Fecal Microbiota. NUTRIENTS. 11. 2. DOI: 10.3390/nu11020337. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC23 GC20	GC20
Garcia-Torres F, Castillo-Mayen R; Differences in Eysenck's Personality Dimensions between a Group of Breast Cancer Survivors and the General Population. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 7. DOI: 10.3390/ijerph16071240. IF: 2,468. Q1. Article. IMIBIC GROUPS: GC20 GE04	GC20
Rodriguez-Ramos A, Moriana JA, Garcia-Torres F, Ruiz-Rubio M; Emotional stability is associated with the MAOA promoter uVNTR polymorphism in women. BRAIN AND BEHAVIOR. 0. DOI: 10.1002/brb3.1376. IF: 2,072. Q3. Article; Early Access. IMIBIC GROUPS: GC20	GC20
Galvez-Lara M, Corpas J, Vencesla JF, Moriana JA; Evidence-Based Brief Psychological Treatment for Emotional Disorders in Primary and Specialized Care: Study Protocol of a Randomized Controlled Trial. FRONTIERS IN PSYCHOLOGY. 9. DOI: 10.3389/fpsyg.2018.02674. IF: 2,129. Q2. Article. IMIBIC GROUPS: GC20 Salud Mental	GC20
Moreno E, Munoz-Navarro R, Medrano LA, Gonzalez-Blanch C, Ruiz-Rodriguez P, Limonero JT, Moretti LS, Cano-Vindel A, Moriana JA; Factorial invariance of a computerized version of the GAD-7 across various demographic groups and over time in primary care patients. JOURNAL OF AFFECTIVE DISORDERS. 252. (114-121). DOI: 10.1016/j.jad.2019.04.032. IF: 4,084. Q1. Article. IMIBIC GROUPS: GC20	GC20
Rangel-Huerta OD, Gomez-Fernandez A, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K, Martin-Borreguero P, Gil-Campos M; Metabolic profiling in children with autism spectrum disorder with and without mental regression: preliminary results from a cross-sectional case-control study. METABOLOMICS. 15. 7. DOI: 10.1007/s11306-019-1562-x. IF: 3,167. Q2. Article. IMIBIC GROUPS: GC23 GC20	GC20
Abril-Requena A, Garcia-Torres F, Alos FJ; Sexual dysfunction and phobic anxiety in breast cancer survivors. PSYCHO-ONCOLOGY. 28. 1. (195-197). DOI: 10.1002/pon.4894. IF: 3,43. D1. Letter. IMIBIC GROUPS: GC20	GC20
Kuba K, Weissflog G, Gotze H, Garcia-Torres F, Mehnert A, Esser P; The relationship between acceptance, fatigue, and subjective cognitive impairment in hematologic cancer survivors. INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY. 19. 2. (97-106). DOI: 10.1016/j.ijchp.2018.12.001. IF: 3,317. Q1. Article. IMIBIC GROUPS: GC20	GC20
Galvez-Lara M, Corpas J, Velasco J, Moriana JA; Knowledge and use of evidence-based psychological treatments in clinical practice. CLINICA Y SALUD. 30. 3. (115-122). DOI: 10.5093/clysa2019a12. IF: 0,632. Q4. Article. IMIBIC GROUPS: GC20	GC20
Egea J, Gonzalez-Rodriguez A, Gomez-Guerrero C, Moreno JA; Editorial: Role of Nrf2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches. FRONTIERS IN PHARMACOLOGY. 10. 1149. DOI: 10.3389/fphar.2019.01149. IF: 3,845. D3 Q1. Editorial Material. IMIBIC GROUPS: GC20	GC20
Lopez-Bascon MA, Calderon-Santiago M, Arguello H, Morera L, Garrido JJ, Priego-Capote F; Comprehensive analysis of pig feces metabolome by chromatographic techniques coupled to mass spectrometry in high resolution mode: Influence of sample preparation on the identification coverage. TALANTA. 199. (303-309). DOI: 10.1016/j.talanta.2019.02.073. IF: 4,916. Q1. Article. IMIBIC GROUPS: GC21	GC21
Criado-Navarro I, Mena-Bravo A, Calderon-Santiago M, Priego-Capote F; Determination of glycerophospholipids in vegetable edible oils: Proof of concept to discriminate olive oil categories. FOOD CHEMISTRY. 299. DOI: 10.1016/j.foodchem.2019.125136. IF: 5,399. D1. Article. IMIBIC GROUPS: GC21	GC21

PUBLICATIONS	IMIBIC GROUP
Castillo-Peinado LS, Lopez-Bascon MA, Mena-Bravo A, de Castro MDL, Priego-Capote F; Determination of primary fatty acid amides in different biological fluids by LC-MS/MS in MRM mode with synthetic deuterated standards: Influence of biofluid matrix on sample preparation. TALANTA. 193. (29-36). DOI: 10.1016/j.talanta.2018.09.088. IF: 4,916. Q1. Article. IMIBIC GROUPS: GC21	GC21
Brito RE, Capote FP, Escobar CAL, Montoya MR, Mellado JMR; Electrochemical Oxidation Pathways of Hydroxycoumarins on Carbon Electrodes Examined by LSCV and LC-MS/MS. JOURNAL OF THE ELECTROCHEMICAL SOCIETY. 166. 8. (H331-H335). DOI: 10.1149/2.0781908jes. IF: 3,12. Q1. Article. IMIBIC GROUPS: GC21	GC21
Mena-Bravo A, Calderon-Santiago M, de Castro MDL, Priego-Capote F; Evaluation of short-term storage prior to analysis of vitamin D-3 and metabolites in human serum by liquid chromatography coupled to tandem mass spectrometry. TALANTA. 198. (344-349). DOI: 10.1016/j.talanta.2019.02.030. IF: 4,916. Q1. Article. IMIBIC GROUPS: GC21	GC21
Ledesma-Escobar CA, Priego-Capote F, Robles-Olvera VJ, Garcia-Torres R, De Corcuera JIR, de Castro MDL; GC-MS study of changes in polar/mid-polar and volatile compounds in Persian lime (Citrus latifolia) during fruit growth. JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE. 99. 3. (1020-1028). DOI: 10.1002/jsfa.9266. IF: 2,422. Q1. Article. IMIBIC GROUPS: GC21	GC21
Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S; Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 9. DOI: 10.1002/mnfr.201800864. IF: 5,151. D1. Article. IMIBIC GROUPS: Anatomía Patológica GC21 GC06	GC21
Lope V, Toribio MJ, Perez-Gomez B, Castello A, Mena-Bravo A, Sierra MA, Lucas P, Herran-Vidaurrazaga MD, Gonzalez-Vizcayno C, Pino MN, Cruz-Campos I, Roca-Navarro MJ, Aragones N, Romieu I, Martinez-Cortes M, de Castro MDL, Pollan M; Serum 25-hydroxyvitamin D and mammographic density in premenopausal Spanish women. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. 189. (101-107). DOI: 10.1016/j.jsbmb.2019.03.004. IF: 3,785. Q2. Article. IMIBIC GROUPS: GC21	GC21
de Castro MDL, Jurado-Lopez A; The role of analytical chemists in the research on the cultural heritage. TALANTA. 205. DOI: 10.1016/j.talanta.2019.07.001. IF: 4,916. Q1. Review. IMIBIC GROUPS: GC21	GC21
Lopez-Bascon MA, Calderon-Santiago M, Diaz-Lozano A, Camargo A, Lopez-Miranda J, Priego-Capote F; Development of a qualitative/quantitative strategy for comprehensive determination of polar lipids by LC-MS/MS in human plasma. ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 412. 2. SI. (489-498). DOI: 10.1007/s00216-019-02261-8. IF: 3,286. D3 Q1. Article; Early Access. IMIBIC GROUPS: GC21 GC09	GC21
Medeiros NMC, Cordoba-Canero D, Garcia-Gil CB, Ariza RR, Roldan-Arjona T, Scortecci KC; Characterization of an AP endonuclease from sugarcane-ScARP1. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 514. 3. (926-932). DOI: 10.1016/j.bbrc.2019.04.156. IF: 2,705. Q2. Article. IMIBIC GROUPS: GC22	GC22
Roldan-Arjona T, Ariza RR, Cordoba-Canero D; DNA Base Excision Repair in Plants: An Unfolding Story With Familiar and Novel Characters. FRONTIERS IN PLANT SCIENCE. 10. DOI: 10.3389/fpls.2019.01055. IF: 4,106. D1. Review. IMIBIC GROUPS: GC22	GC22
Parrilla-Doblas JT, Roldan-Arjona T, Ariza RR, Cordoba-Canero D; Active DNA Demethylation in Plants. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 19. 4683. DOI: 10.3390/ijms20194683. IF: 4,183. Q2. Review. IMIBIC GROUPS: GC22	GC22
Barja-Fernandez S, Folgueira C, Castelao C, Pena-Leon V, Gonzalez-Saenz P, Vazquez-Cobela R, Aguilera CM, Gil-Campos M, Bueno G, Gil A, Moreno LA, Ruiz-Pinon M, Garcia-Palacios M, Casanueva FF, Dieguez C, Nogueiras R, Leis R, Seoane LM; ANGPTL-4 is Associated with Obesity and Lipid Profile in Children and Adolescents. NUTRIENTS. 11. 6. DOI: 10.3390/nu11061340. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC23	GC23
Plaza-Diaz J, Gomez-Fernandez A, Chueca N, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K, Martin-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F, Gil-Campos M; Autism Spectrum Disorder (ASD) with and without Mental Regression Is Associated with Changes in the Fecal Microbiota. NUTRIENTS. 11. 2. DOI: 10.3390/nu11020337. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC23 GC20	GC23

PUBLICATIONS	IMIBIC GROUP
Ruiz-Ojeda FJ, Anguita-Ruiz A, Ruperez AI, Gomez-Llorente C, Olza J, Vazquez-Cobela R, Gil-Campos M, Bueno G, Leis R, Canete R, Moreno LA, Gil A, Aguilera CM; Effects of X-chromosome Tenomodulin Genetic Variants on Obesity in a Children's Cohort and Implications of the Gene in Adipocyte Metabolism. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-40482-0. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC23 GA05	GC23
Perez-Navero JL, Merino-Cejas C, de la Rosa II, Jaraba-Caballero S, Frias-Perez M, Gomez-Guzman E, Gil-Campos M, de la Torre-Aguilar MJ; Evaluation of the vasoactive-inotropic score, mid-regional pro-adrenomedullin and cardiac troponin I as predictors of low cardiac output syndrome in children after congenital heart disease surgery. MEDICINA INTENSIVA. 43. 6. (329-336). DOI: 10.1016/j.medin.2018.04.005. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC23 Pediatría GA09 GA05	GC23
Martinez-Monseny A, Cuadras D, Bolasell M, Muchart J, Arjona C, Borregan M, Algrabli A, Montero R, Artuch R, Velazquez-Fragua R, Macaya A, Perez-Cerda C, Perez-Duenas B, Perez B, Serrano M, Aguilera-Albesa S, Gutierrez-Solana LG, Lopez L, Felipe A, Mirand; From gestalt to gene: early predictive dysmorphic features of PMM2-CDG. JOURNAL OF MEDICAL GENETICS. 56. 4. (236-245). DOI: 10.1136/jmedgenet-2018-105588. IF: 5,899. Q1. Article. IMIBIC GROUPS: GC23	GC23
Rodriguez-Herrera A, Mulder K, Bouritius H, Rubio R, Munoz A, Agosti M, Lista G, Corvaglia L, Ludwig T, Abrahamse-Berkeveld M, Perez-Navero JL; Gastrointestinal Tolerance, Growth and Safety of a Partly Fermented Formula with Specific Prebiotics in Healthy Infants: A Double-Blind, Randomized, Controlled Trial. NUTRIENTS. 11. 7. DOI: 10.3390/nu11071530. IF: 4,171. Q1. Article. IMIBIC GROUPS: GC23	GC23
Tejada-Ortigosa EM, Flores-Rojas K, Moreno-Quintana L, Munoz-Villanueva MC, Perez-Navero JL, Gil-Campos M; Health and socio-educational needs of the families and children with rare metabolic diseases: Qualitative study in a tertiary hospital. ANALES DE PEDIATRIA. 90. 1. (42-50). DOI: 10.1016/j.anpedi.2018.03.003. IF: 1,166. Q3. Article. IMIBIC GROUPS: GC23 Pediatría	GC23
Gomis-Perez C, Urrutia J, Marce-Grau A, Malo C, Lopez-Laso E, Felipe-Rucian A, Raspall-Chaure M, Macaya A, Villarroel A; Homomeric Kv7.2 current suppression is a common feature in KCNQ2 epileptic encephalopathy. EPILEPSIA. 60. 1. (139-148). DOI: 10.1111/epi.14609. IF: 5,562. Q1. Article. IMIBIC GROUPS: GC23	GC23
Rangel-Huerta OD, Gomez-Fernandez A, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K, Martin-Borreguero P, Gil-Campos M; Metabolic profiling in children with autism spectrum disorder with and without mental regression: preliminary results from a cross-sectional case-control study. METABOLOMICS. 15. 7. DOI: 10.1007/s11306-019-1562-x. IF: 3,167. Q2. Article. IMIBIC GROUPS: GC23 GC20	GC23
Leppanen MH, Henriksson P, Henriksson H, Nystrom CD, Llorente-Cantarero FJ, Lof M; Physical Activity Level Using Doubly-Labeled Water in Relation to Body Composition and Physical Fitness in Preschoolers. MEDICINA-LITHUANIA. 55. 1. DOI: 10.3390/medicina55010002. IF: 1,467. Q3. Article. IMIBIC GROUPS: GC23	GC23
Guffon N, Tylki-Szymanska A, Borgwardt L, Lund AM, Gil-Campos M, Parini R, Hennermann JB; Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. MOLECULAR GENETICS AND METABOLISM. 126. 4. (470-474). DOI: 10.1016/j.ymgme.2019.01.024. IF: 3,61. Q2. Article. IMIBIC GROUPS: GC23	GC23
Gil-Campos M; Reflection on the evaluation of eating habits and physical activity in school children. NUTRICION HOSPITALARIA. 36. 2. (245-246). DOI: 10.20960/nh.02580. IF: 0,759. Q4. Editorial Material. IMIBIC GROUPS: GC23	GC23
Anguita-Ruiz A, Plaza-Diaz J, Ruiz-Ojeda FJ, Ruperez AI, Leis R, Bueno G, Gil-Campos M, Vazquez-Cobela R, Canete R, Moreno LA, Gil A, Aguilera CM; X chromosome genetic data in a Spanish children cohort, dataset description and analysis pipeline. SCIENTIFIC DATA. 6. DOI: 10.1038/s41597-019-0109-3. IF: 5,929. Q1. Article; Data Paper. IMIBIC GROUPS: GC23 GA05	GC23
de Lamas C, de Castro MJ, Gil-Campos M, Gil A, Couce ML, Leis R; Effects of Dairy Product Consumption on Height and BoneMineral Content in Children: A Systematic Review of Controlled Trials. ADVANCES IN NUTRITION. 10. 2. (S88-S96). DOI: 10.1093/advances/nmy096. IF: 7,24. D1. Review. IMIBIC GROUPS: Pediatría GC23	GC23

PUBLICATIONS	IMIBIC GROUP
Maldonado J, Gil-Campos M, Maldonado-Lobon JA, Benavides MR, Flores-Rojas K, Jaldo R, del Barco IJ, Bolivar V, Valero AD, Prados E, Penalver I, Olivares M; Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial. BMC PEDIATRICS. 19. 1. 361. DOI: 10.1186/s12887-019-1753-7. IF: 1,983. Q2. Article. IMIBIC GROUPS: GC23	GC23
Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A; Mechanisms of Action of Probiotics. ADVANCES IN NUTRITION. 10. 1. (S49-S66). DOI: 10.1093/advances/nmy063. IF: 7,24. D1. Article; Proceedings Paper. IMIBIC GROUPS: GC23	GC23
Castro C, Galan-Sanchez F, Linares MJ, Tejero R, Ruiz M, Serrano ML, Rodriguez-Iglesias M, Martin-Mazuelos E, Mediavilla C, Clavijo-Frutos E, Dominguez A, Fajardo M, Freyre C, Galan F, Garcia F, Linares MJ, Lopez-Prieto MD, Martin-Mazuelos E, Navarro JM, ; A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns. MEDICAL MYCOLOGY. 57. 4. (412-420). DOI: 10.1093/mmy/myy080. IF: 2,851. D1. Article. IMIBIC GROUPS: GC24	GC24
Camprubi-Font C, del Castillo BR, Barrabes S, Martinez-Martinez L, Martinez-Medina M; Amino Acid Substitutions and Differential Gene Expression of Outer Membrane Proteins in Adherent-Invasive Escherichia coli. FRONTIERS IN MICROBIOLOGY. 10. DOI: 10.3389/fmicb.2019.01707. IF: 4,259. Q1. Article. IMIBIC GROUPS: GC24	GC24
Cirit OS, Fernandez-Martinez M, Yayla B, Martinez-Martinez L; AMINOGLYCOSIDE RESISTANCE DETERMINANTS IN MULTIRESISTANT ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE CLINICAL ISOLATES FROM TURKISH AND SYRIAN PATIENTS. ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA. 66. 3. (327-335). DOI: 10.1556/030.66.2019.005. IF: 1,107. Q4. Article. IMIBIC GROUPS: GC24	GC24
Ramos-Vivas J, Chapartegui-Gonzalez I, Fernandez-Martinez M, Gonzalez-Rico C, Fortun J, Escudero R, Marco F, Linares L, Montejo M, Aranzamendi M, Munoz P, Valerio M, Aguado JM, Resino E, Ahufinger IG, Vega AP, Martinez L, Farinas MC, San Millan JCR, Rodri; Biofilm formation by multidrug resistant Enterobacteriaceae strains isolated from solid organ transplant recipients. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-45060-y. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC24 GC03	GC24
Martinez-Martinez L; Carbapenemases: The never-ending story. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 2. (73-75). DOI: 10.1016/j.eimc.2018.12.006. IF: 1,685. Q4. Editorial Material. IMIBIC GROUPS: GC24	GC24
Perez-Vazquez M, Oteo-Iglesias J, Sola-Campoy PJ, Carrizo-Manzoni H, Bautista V, Lara N, Aracil B, Alhambra A, Martinez-Martinez L, Campos J; Characterization of Carbapenemase-Producing Klebsiella oxytoca in Spain, 2016-2017. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 63. 6. DOI: 10.1128/AAC.02529-18. IF: 4,715. Q1. Article. IMIBIC GROUPS: GC24	GC24
Puig CRD, Torres MF, Marfil-Perez E, Ferandez MIR, Del Rio MC, Balbin JA, Martinez-Martinez L; Comparison between Vitek MS, Bruker Biotyper, Vitek2, and API20E for differentiation of species of the genus Raoultella. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 38. 3. (467-470). DOI: 10.1007/s10096-018-03444-4. IF: 2,591. Q3. Article. IMIBIC GROUPS: GC24	GC24
Haeili M, Kafshdouz M, Pishnian Z, Feizabadi MM, Martinez-Martinez L; Comparison of susceptibility testing methods for determining the activity of colistin against Gram-negative bacilli of clinical origin. JOURNAL OF MEDICAL MICROBIOLOGY. 68. 1. (60-66). DOI: 10.1099/jmm.0.000879. IF: 1,926. Q4. Article. IMIBIC GROUPS: GC24	GC24
Machuca I, Gutierrez-Gutierrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Perez E, Perez-Nadales E, Caston JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual A, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J, Salamanca E, ; External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 54. 4. (442-448). DOI: 10.1016/j.ijantimicag.2019.07.017. IF: 4,615. Q1. Article. IMIBIC GROUPS: GC26 GC03 Medicina Intensiva GC24	GC24

PUBLICATIONS	IMIBIC GROUP
Palacios-Baena ZR, Delgado-Valverde M, Mendez AV, Almirante B, Gomez-Zorrilla S, Borrell N, Corzo JE, Gurgui M, de la Calle C, Garcia-Alvarez L, Ramos L, Gozalo M, Morosini MI, Molina J, Causse M, Pascual A, Rodriguez-Bano J, de Cueto M, Reig AMP, Quintan; Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. CLINICAL INFECTIOUS DISEASES. 69. 6. (956-962). DOI: 10.1093/cid/ciy1032. IF: 9,055. D1. Article. IMIBIC GROUPS: Enfermedades Infecciosas GC03 GC24	GC24
Ruiz P, Causse M, Vaquero M, Casal M; In Vitro Activity of Tedizolid against Mycobacterium tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 63. 4. DOI: 10.1128/AAC.01939-18. IF: 4,715. Q1. Article. IMIBIC GROUPS: GC24 Microbiología	GC24
Perez AB, Vrancken B, Chueca N, Aguilera A, Reina G, Toro MG, Vera F, von Wichman MA, Arenas JI, Tellez F, Pineda JA, Omar M, Bernal E, Rivero-Juarez A, Fernandez-Fuertes E, de la Iglesia A, Pascasio JM, Lemey P, Garcia F, Cuypers L; Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. EUROSURVEILLANCE. 24. 9. (25-34). DOI: 10.2807/1560-7917.ES.2019.24.9.1800227. IF: 7,421. D1. Article. IMIBIC GROUPS: GC24	GC24
Ishikawa M, Garcia-Mateo N, Cusak A, Lopez-Hernandez I, Fernandez-Martinez M, Muller M, Ruttiger L, Singer W, Lowenheim H, Kosec G, Fujs S, Martinez-Martinez L, Schimmang T, Petkovic H, Knipper M, Duran-Alonso MB; Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-38634-3. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC24	GC24
Lopez-Camacho E, Pano-Pardo JR, Sotillo A, Elias-Lopez C, Martinez-Martinez L, Gomez-Gil R, Mingorance J; Meropenem heteroresistance in clinical isolates of OXA-48-producing Klebsiella pneumoniae. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 93. 2. (162-166). DOI: 10.1016/j.diagmicrobio.2018.09.008. IF: 2,314. Q3. Article. IMIBIC GROUPS: GC24	GC24
Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E, Castro C, Chen YC, Chen Y, Chryssanthou E, Dannaoui E, Garcia-Effron G, Gonzalez GM, Govender NP, Guinea J, Kidd S, Lackner M, Lass-Florl C, Linares-Sicilia MJ, Lopez-Soria L, Mag; Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 63. 1. DOI: 10.1128/AAC.01651-18. IF: 4,715. Q1. Article. IMIBIC GROUPS: GC24	GC24
Perez AB, Chueca N, Macias J, Pineda JA, Salmeron J, Rivero-Juarez A, Hidalgo-Tenorio C, Espinosa MD, Tellez F, Von-Wichmann MA, Omar M, Santos J, Hernandez-Quero J, Anton JJ, Collado A, Lozano AB, Garcia-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales; Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLOS ONE. 14. 8. DOI: 10.1371/journal.pone.0221231. IF: 3,776. Q2. Article. IMIBIC GROUPS: GC24 GC26	GC24
Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J; Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 79. 3. (245-252). DOI: 10.1016/j.jinf.2019.06.014. IF: 5,099. Q1. Article. IMIBIC GROUPS: GC03 GC26 GC24 Medicina Intensiva GC18	GC24
del Barrio-Tofino E, Zamorano L, Cortes-Lara S, Lopez-Causape C, Sanchez-Diener I, Cabot G, Bou G, Martinez-Martinez L, Oliver A, Galan F, Gracia I, Rodriguez MA, Martin L, Sanchez JM, Vinuela L, Garcia MV, Lepe JA, Aznar J, Lopez-Hernandez I, Seral C, Ca; Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 74. 7. (1825-1835). DOI: 10.1093/jac/dkz147. IF: 5,113. D1. Article. IMIBIC GROUPS: GC24	GC24
Guzman-Puche J, Gracia-Ahufinger I, Causse M, Tejero-Garcia R, Rodriguez-Lopez FC, Casal-Roman M; System, gram-stain and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for diagnosis of urinary tract infections directly from urine samples. JOURNAL OF CHEMOTHERAPY. 31. 2. (74-80). DOI: 10.1080/1120009X.2019.1573284. IF: 1,599. Q4. Article. IMIBIC GROUPS: GC24 Microbiología	GC24
Kieffer N, Guzman-Puche J, Poirel L, Kang HJ, Jeon CO, Nordmann P; ZHO-1, an intrinsic MBL from the environmental Gram-negative species Zhongshania aliphaticivorans. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 74. 6. (1568-1571). DOI: 10.1093/jac/dkz057. IF: 5,217. D1. Article. IMIBIC GROUPS: GC24	GC24

PUBLICATIONS	IMIBIC GROUP
Perez AB, Chueca N, Garcia-Deltoro M, Martinez-Sapina AM, Lara-Perez MM, Garcia-Bujalance S, Aldamiz-Echevarria T, Vera-Mendez FJ, Pineda JA, Casado M, Pascasio JM, Salmeron J, Alados-Arboledas JC, Poyato A, Tellez F, Rivero-Juarez A, Merino D, Vivancos-G; High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. JOURNAL OF HEPATOLOGY. 71. 5. (876-888). DOI: 10.1016/j.jhep.2019.06.022. IF: 18,946. D1. Article. IMIBIC GROUPS: GC24 GC02 GC26	GC24
del Barrio-Tofino E, Sanchez-Diener I, Zamorano L, Cortes-Lara S, Lopez-Causape C, Cabot G, Bou G, Martinez-Martinez L, Oliver A. GEMARA-SEIMC/REIPI: Galan, F; Gracia, I; Rodriguez, MA; Martin, L; Sanchez, JM; Vinuela, L; Garcia, MV; Lepe, JA; Aznar, J; L; Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 74. 11. (3217-3220). DOI: 10.1093/jac/dkz346. IF: 5,113. D1 Q1. Article. IMIBIC GROUPS: GC24	GC24
Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R, Ramos-Vivas J, Coenye T, Fernandez-Cuenca F, Vila J, Martinez-Martinez L, Rodriguez-Bano J, Pascual A, Cisneros JM, Pachon J, Bou G, Tomas M; Combined Use of the Ab105-2 phi Delta CI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. MICROORGANISMS. 7. 11. DOI: 10.3390/microorganisms7110556. IF: 4,167. Q2. Article. IMIBIC GROUPS: GC24	GC24
Paez-Vega A, Cantisan S, Vaquero JM, Vidal E, Luque-Pineda A, Lobo-Acosta MA, Perez AB, Alonso-Moralejo R, Iturbe D, Monforte V, Otero-Gonzalez I, Pastor A, Ussetti P, Torre-Cisneros J; Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial. BMJ OPEN. 9. 8. DOI: 10.1136/bmjopen-2019-030648. IF: 2,376. Q2. Article. IMIBIC GROUPS: GC03 GA03 GC24	GC24
Padillo F, Luna JM, Ventura S; A Grammar-Guided Genetic Programing Algorithm for Associative Classification in Big Data. COGNITIVE COMPUTATION. 11. 3. (331-346). DOI: 10.1007/s12559-018-9617-2. IF: 4,287. Q1. Article. IMIBIC GROUPS: GC25	GC25
Ramirez A, Romero JR, Ventura S; A survey of many-objective optimisation in search-based software engineering. JOURNAL OF SYSTEMS AND SOFTWARE. 149. (382-395). DOI: 10.1016/j.jss.2018.12.015. IF: 2,559. Q1. Article. IMIBIC GROUPS: GC25	GC25
Luque C, Luna JM, Luque M, Ventura S; An advanced review on text mining in medicine. WILEY INTERDISCIPLINARY REVIEWS-DATA MINING AND KNOWLEDGE DISCOVERY. 9. 3. DOI: 10.1002/widm.1302. IF: 2,541. Q1. Review. IMIBIC GROUPS: GC25	GC25
Moyano JM, Gibaja EL, Cios KJ, Ventura S; An evolutionary approach to build ensembles of multi-label classifiers. INFORMATION FUSION. 50. (168-180). DOI: 10.1016/j.inffus.2018.11.013. IF: 10,716. D1. Article. IMIBIC GROUPS: GC25	GC25
del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC02 GC09 Anatomía Patológica	GC25
Luna JM, Fournier-Viger P, Ventura S; Frequent itemset mining: A 25 years review. WILEY INTERDISCIPLINARY REVIEWS-DATA MINING AND KNOWLEDGE DISCOVERY. 0. DOI: 10.1002/widm.1329. IF: 2,541. Q1. Review; Early Access. IMIBIC GROUPS: GC25	GC25
Romero C, Ventura S; Guest Editorial: Special Issue on Early Prediction and Supporting of Learning Performance. IEEE TRANSACTIONS ON LEARNING TECHNOLOGIES. 12. 2. (145-147). DOI: 10.1109/TLT.2019.2908106. IF: 2,315. Q1. Editorial Material. IMIBIC GROUPS: GC25	GC25
Ramirez A, Romero JR, Garcia-Martinez C, Ventura S; JCLEC-MO: A Java suite for solving many-objective optimization engineering problems. ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE. 81. (14-28). DOI: 10.1016/j.engappai.2019.02.003. IF: 3,526. Q1. Article. IMIBIC GROUPS: GC25	GC25
Robles-Berumen H, Zafra A, Fardoun HM, Ventura S; LEAC: An efficient library for clustering with evolutionary algorithms. KNOWLEDGE-BASED SYSTEMS. 179. (117-119). DOI: 10.1016/j.knosys.2019.05.008. IF: 5,101. Q1. Article. IMIBIC GROUPS: GC25	GC25

PUBLICATIONS	IMIBIC GROUP
Abouzid H, Chakkor O, Reyes OG, Ventura S; Signal speech reconstruction and noise removal using convolutional denoising audioencoders with neural deep learning. ANALOG INTEGRATED CIRCUITS AND SIGNAL PROCESSING. 100. 3. (501-512). DOI: 10.1007/s10470-019-01446-6. IF: 0,823. Q4. Article. IMIBIC GROUPS: GC25	GC25
Saeed-Ul Hassan, Waheed H, Aljohani NR, Ali M, Ventura S, Herrera F; Virtual learning environment to predict withdrawal by leveraging deep learning. INTERNATIONAL JOURNAL OF INTELLIGENT SYSTEMS. 34. 8. (1935-1952). DOI: 10.1002/int.22129. IF: 7,229. D1. Article. IMIBIC GROUPS: GC25	GC25
Luna JM, Ondra M, Fardoun HM, Ventura S; Optimization of quality measures in association rule mining: an empirical study. INTERNATIONAL JOURNAL OF COMPUTATIONAL INTELLIGENCE SYSTEMS. 12. 1. (59-78). DOI: 10.2991/ijcis.2018.25905182. IF: 2,153. Q3. Article. IMIBIC GROUPS: GC25	GC25
Reyes O, Ventura S; Performing Multi-Target Regression via a Parameter Sharing-Based Deep Network. INTERNATIONAL JOURNAL OF NEURAL SYSTEMS. 29. 9. 1950014. DOI: 10.1142/S012906571950014X. IF: 6,411. D1 Q1. Article. IMIBIC GROUPS: GC25	GC25
Real LM, Fernandez-Fuertes M, Saez ME, Rivero-Juarez A, Frias M, Tellez F, Santos J, Merino D, Moreno-Grau S, Gomez-Salgado J, Gonzalez-Serna A, Corma-Gomez A, Ruiz A, Macias J, Pineda JA; A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). LIVER INTERNATIONAL. 39. 10. (1918-1926). DOI: 10.1111/liv.14177. IF: 4,5. Q1. Article. IMIBIC GROUPS: GC26	GC26
Jaimes-Bernal C, Rallon N, Benito JM, Omar M, Gomez-Vidal MA, Marquez FJ, Sanchez-Arcas B, Trujillo M, Royo JL, Saulle I, Biasin M, Rivero-Juarez A, Caruz A; A Knockout IFNL4 Variant Is Associated With Protection From Sexually Transmitted HIV-1 Infection. JOURNAL OF INFECTIOUS DISEASES. 219. 5. (772-776). DOI: 10.1093/infdis/jiy584. IF: 5,045. Q1. Article. IMIBIC GROUPS: GC26	GC26
Fresco-Taboada A, Risalde MA, Gortazar C, Tapia I, Gonzalez I, Venteo A, Sanz A, Rueda P; A lateral flow assay for the rapid diagnosis of Mycobacterium bovis infection in wild boar. TRANSBOUNDARY AND EMERGING DISEASES. 66. 5. (2175-2179). DOI: 10.1111/tbed.13260. IF: 3,554. D1. Article. IMIBIC GROUPS: GC26	GC26
Thomas J, Infantes-Lorenzo JA, Moreno I, Romero B, Garrido JM, Juste R, Dominguez M, Dominguez L, Gortazar C, Risalde MA; A new test to detect antibodies against Mycobacterium tuberculosis complex in red deer serum. VETERINARY JOURNAL. 244. (98-103). DOI: 10.1016/j.tvjl.2018.12.021. IF: 1,919. Q1. Article. IMIBIC GROUPS: GC26	GC26
Macias J, Tellez F, Rivero-Juarez A, Palacios R, Morano LE, Merino D, Collado A, Garcia-Fraile L, Omar M, Pineda JA, Merchante N, Mancebo M, Rivero A, Marquez M, Romero J, de los Santos I, Gomez-Vidal MA; Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients. JOURNAL OF VIRAL HEPATITIS. 26. 1. (48-54). DOI: 10.1111/jvh.13003. IF: 4,016. Q1. Article. IMIBIC GROUPS: GC26	GC26
Caballero-Gomez J, Jimenez-Ruiz S, Lopez-Lopez P, Vicente J, Risalde MA, Cano-Terriza D, Frias M, Barasona JA, Rivero A, Garcia-Bocanegra I, Rivero-Juarez A; Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 66. 5. (1803-1808). DOI: 10.1111/tbed.13251. IF: 3,554. D1. Article. IMIBIC GROUPS: GC26	GC26
Frias M, Rivero-Juarez A, Tellez F, Palacios R, Jimenez-Arranz A, Pineda JA, Merino D, Gomez-Vidal MA, Perez-Camacho I, Camacho A, Rivero A; Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-48966-9. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC26 Unidad Genómica Imibic	GC26
Perez-Molina JA, Polo R, Lopez-Aldeguer J, Lozano F, Aguirrebengoa K, Arribas JR, Boix V, Berenguer J, Blanco JR, Domingo P, Estrada V, Galindo MJ, Garcia F, Gatell JM, Gonzalez-Garcia J, Gutierrez F, Iribarren JA, Knobel H, Llibre JM, de Quiros JCLB, Lop; Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 3. (195-202). DOI: 10.1016/j.eimc.2018.02.010. IF: 1,685. Q4. Article. IMIBIC GROUPS: GC26	GC26

PUBLICATIONS	IMIBIC GROUP
Machuca I, Gutierrez-Gutierrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Perez E, Perez-Nadales E, Caston JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual A, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J, Salamanca E, ; External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 54. 4. (442-448). DOI: 10.1016/j.ijantimicag.2019.07.017. IF: 4,615. Q1. Article. IMIBIC GROUPS: GC26 GC03 Medicina Intensiva GC24	GC26
Garcia-Bocanegra I, Camacho-Sillero L, Risalde MA, Dalton KP, Caballero-Gomez J, Aguero M, Zorrilla I, Gomez-Guillamon F; First outbreak of myxomatosis in Iberian hares (Lepus granatensis). TRANSBOUNDARY AND EMERGING DISEASES. 0. DOI: 10.1111/tbed.13289. IF: 3,554. D1. Article; Early Access. IMIBIC GROUPS: GC26	GC26
Aguilar-Jimenez W, Zapata W, Rivero-Juarez A, Pineda JA, Laplana M, Taborda NA, Biasin M, Clerici M, Caruz A, Fibla J, Rugeles MT; Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability. INFECTION GENETICS AND EVOLUTION. 73. (276-286). DOI: 10.1016/j.meegid.2019.05.014. IF: 2,611. Q3. Article. IMIBIC GROUPS: GC26	GC26
Real LM, Macias J, Rivero-Juarez A, Tellez F, Merino D, Moreno-Grau S, Orellana A, Gomez-Salgado J, Saez ME, Frias M, Corma-Gomez A, Merchante N, Ruiz A, Caruz A, Pineda JA, Fernandez-Fuertes M, Iglesias M, Rincon P; Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-45389-4. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC26	GC26
Rivero-Juarez A, Lopez-Lopez P, Frias M, Rivero A; Hepatitis E Infection in HIV-Infected Patients. FRONTIERS IN MICROBIOLOGY. 10. DOI: 10.3389/fmicb.2019.01425. IF: 4,259. Q1. Review. IMIBIC GROUPS: GC26	GC26
Rivero-Juarez A, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, Lopez-Lopez P, Andujar-Troncoso G, Machuca I, Camacho A, Munoz-Valbuena P, Rivero A; Hepatitis E virus in Spanish donors and the necessity for screening. JOURNAL OF VIRAL HEPATITIS. 26. 5. (603-608). DOI: 10.1111/jvh.13064. IF: 4,016. Q1. Article. IMIBIC GROUPS: GC26	GC26
Garcia-Bocanegra I, Rivero A, Caballero-Gomez J, Lopez-Lopez P, Cano-Terriza D, Frias M, Jimenez-Ruiz S, Risalde MA, Gomez-Villamandos JC, Rivero-Juarez A; Hepatitis E virus infection in equines in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 66. 1. (66-71). DOI: 10.1111/tbed.12962. IF: 3,554. D1. Article. IMIBIC GROUPS: GC26	GC26
Corma-Gomez A, Morano L, Tellez F, Rivero-Juarez A, Real LM, Alados JC, Rios-Villegas MJ, Vera-Mendez FJ, Munoz RP, Geijo P, Macias J, Pineda JA; HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS. 33. 7. (1167-1174). DOI: 10.1097/QAD.0000000000002186. IF: 4,914. Q1. Article. IMIBIC GROUPS: GC26	GC26
Merchante N, Figueruela B, Rodriguez-Fernandez M, Rodriguez-Arrondo F, Revollo B, Ibarra S, Galindo MJ, Merino E, Montero M, Tellez F, Garcia-Deltoro M, Rivero-Juarez A, Delgado-Fernandez M, Rios-Villegas MJ, Aguirrebengoa K, Garcia MA, Portu J, Vera-Mend; Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS. 33. 2. (269-278). DOI: 10.1097/QAD.0000000000002065. IF: 4,499. Q1. Article. IMIBIC GROUPS: GC26	GC26
Rivero-Juarez A, Tellez F, Castano-Carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua-Garcia M, Zapata-Lopez A, Collado A, Gomez-Vidal MA, Perez-Stachowski J, Munoz-Medina L, Fernandez-Fuertes E, Rivero A; Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients. HIV MEDICINE. 20. 6. (359-367). DOI: 10.1111/hiv.12715. IF: 3,734. Q2. Article. IMIBIC GROUPS: GC26	GC26
Perez AB, Chueca N, Macias J, Pineda JA, Salmeron J, Rivero-Juarez A, Hidalgo-Tenorio C, Espinosa MD, Tellez F, Von-Wichmann MA, Omar M, Santos J, Hernandez-Quero J, Anton JJ, Collado A, Lozano AB, Garcia-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales; Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLOS ONE. 14. 8. DOI: 10.1371/journal.pone.0221231. IF: 3,776. Q2. Article. IMIBIC GROUPS: GC24 GC26	GC26

PUBLICATIONS	IMIBIC GROUP
Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J; Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 79. 3. (245-252). DOI: 10.1016/j.jinf.2019.06.014. IF: 5,099. Q1. Article. IMIBIC GROUPS: GC03 GC26 GC24 Medicina Intensiva GC18	GC26
Macias J, Morano LE, Tellez F, Granados R, Rivero-Juarez A, Palacios R, Rios MJ, Merino D, Perez-Perez M, Collado A, Figueruela B, Morano A, Freyre-Carrillo C, Martin JM, Rivero A, Garcia F, Pineda JA; Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. JOURNAL OF HEPATOLOGY. 71. 1. (45-51). DOI: 10.1016/j.jhep.2019.02.018. IF: 15,04. D1. Article. IMIBIC GROUPS: GC26	GC26
Neukam K, Fernandez MD, Quero JH, Rivero-Juarez A, Llaves-Flores S, Onate FJ, Gutierrez-Valencia A, Espinosa N, Viciana P, Lopez-Cortes LF; Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 81. 1. (E1-E5). DOI: 10.1097/QAI.0000000000001990. IF: 4,116. Q1. Article. IMIBIC GROUPS: GC26	GC26
Cano-Terriza D, Almeria S, Caballero-Gomez J, Diaz-Cao JM, Jimenez-Ruiz S, Dubey JP, Garcia-Bocanegra I; Serological survey of Toxoplasma gondii in captive nonhuman primates in zoos in Spain. COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES. 65. (54-57). DOI: 10.1016/j.cimid.2019.04.002. IF: 1,871. Q1. Article. IMIBIC GROUPS: GC26	GC26
Macias J, Granados R, Tellez F, Merino D, Perez M, Morano LE, Palacios R, Paniagua M, Frias M, Merchante N, Pineda JA, Merchante N, Mancebo M, Rivero A, Rivero-Juarez A, Marquez M, Ojeda G, Santos J, Romero J, de los Santos I, Omar M, Gomez-Vidal MA, Prad; Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. JOURNAL OF VIRAL HEPATITIS. 26. 1. (16-24). DOI: 10.1111/jvh.12990. IF: 4,016. Q1. Article. IMIBIC GROUPS: GC26	GC26
Caballero-Gomez J, Rivero-Juarez A, Cano-Terriza D, Risalde MA, Lopez-Lopez P, Frias M, Jimenez-Ruiz S, Rivero A, Garcia-Bocanegra I; Survey for Hepatitis E virus infection in non-human primates in zoos in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 66. 4. (1771-1775). DOI: 10.1111/tbed.13196. IF: 3,504. D1. Article. IMIBIC GROUPS: GC26	GC26
Thomas J, Infantes-Lorenzo JA, Moreno I, Cano-Terriza D, de Juan L, Garcia-Bocanegra I, Dominguez L, Dominguez M, Gortazar C, Risalde MA; Validation of a new serological assay for the identification of Mycobacterium tuberculosis complex-specific antibodies in pigs and wild boar. PREVENTIVE VETERINARY MEDICINE. 162. (11-17). DOI: 10.1016/j.prevetmed.2018.11.004. IF: 2,302. D1. Article. IMIBIC GROUPS: GC26	GC26
Jimenez-Sousa MA, Jimenez JL, Fernandez-Rodriguez A, Brochado-Kith O, Bellon JM, Gutierrez F, Diez C, Bernal-Morell E, Viciana P, Munoz-Fernandez MA, Resino S, Moreno S, del Amo J, Dalmau D, Navarro ML, Gonzalez MI, Blanco JL, Garcia F, Rubio R, Iribarren; VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naive HIV-Infected Patients. JOURNAL OF CLINICAL MEDICINE. 8. 3. DOI: 10.3390/jcm8030311. IF: 5,688. D1. Article. IMIBIC GROUPS: GC26	GC26
Roy A, Tome I, Romero B, Lorente-Leal V, Infantes-Lorenzo JA, Dominguez M, Martin C, Aguilo N, Puentes E, Rodriguez E, de Juan L, Risalde MA, Gortazar C, Dominguez L, Bezos J; Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis. VETERINARY RESEARCH. 50. 1. 82. DOI: 10.1186/s13567-019-0702-7. IF: 3,117. D1. Article. IMIBIC GROUPS: GC26	GC26
Perez AB, Chueca N, Garcia-Deltoro M, Martinez-Sapina AM, Lara-Perez MM, Garcia-Bujalance S, Aldamiz-Echevarria T, Vera-Mendez FJ, Pineda JA, Casado M, Pascasio JM, Salmeron J, Alados-Arboledas JC, Poyato A, Tellez F, Rivero-Juarez A, Merino D, Vivancos-G; High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. JOURNAL OF HEPATOLOGY. 71. 5. (876-888). DOI: 10.1016/j.jhep.2019.06.022. IF: 18,946. D1. Article. IMIBIC GROUPS: GC24 GC02 GC26	GC26
Camacho-Sillero L, Caballero-Gomez J, Gomez-Guillamon F, Martinez-Padilla A, Aguero M, San Miguel E, Zorrilla I, Rayas E, Talavera V, Garcia-Bocanegra I; Monitoring of the novel rabbit haemorrhagic disease virus type 2 (GI.2) epidemic in European wild rabbits (Oryctolagus cuniculus) in southern Spain, 2013-2017. VETERINARY MICROBIOLOGY. 237. 108361. DOI: 10.1016/j.vetmic.2019.07.013. IF: 2,791. D1. Article. IMIBIC GROUPS: GC26	GC26

PUBLICATIONS	IMIBIC GROUP
Vrancken B, Cuypers L, Perez AB, Chueca N, Anton-Basantas J, de la Iglesia A, Fuentes J, Pineda JA, Tellez F, Bernal E, Rincon P, Von Wichman MA, Fuentes A, Vera F, Rivero-Juarez A, Jimenez M, Vandamme AM, Garcia F; Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. JOURNAL OF HEPATOLOGY. 71. 6. (1270-1272). DOI: 10.1016/j.jhep.2019.08.010. IF: 18,946. D1 Q1. Letter. IMIBIC GROUPS: GC26	GC26
Crespo M, Lozano F, Buzon MJ, Curran A, Estrada V, Garcia F, Imaz A, Cortes LL, Losa JE, Masia M, Merchante N, Marino A, Ocampo A, Perez-Molina JA, Poveda E, Riera M, Santin M, Santos J, Valencia E, Arazo P, de la Torre J, Aldeguer JL, Palacios R, Rivero; Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 7. (467-475). DOI: 10.1016/j.eimc.2018.03.011. IF: 1,685. Q4. Article. IMIBIC GROUPS: GC26	GC26
Lopez-Lopez P, Rivero-Juarez A, Frias M, Machuca I, Caballero-Gomez J, Olivas I, Camacho A, Risalde MD, Garcia-Bocanegra I, Rivero A; Mutations in the Progesterone Receptor (PROGINS) May Reduce the Symptoms of Acute Hepatitis E and Protect Against Infection. FRONTIERS IN MICROBIOLOGY. 10. DOI: 10.3389/fmicb.2019.02617. IF: 4,259. D2 Q1. Article. IMIBIC GROUPS: GC26	GC26
Lopez-Lopez P, Frias M, Camacho A, Rivero A, Rivero-Juarez A; Human Immunodeficiency Virus Infected Patients are Not at Higher Risk for Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis. MICROORGANISMS. 7. 12. DOI: 10.3390/microorganisms7120618. IF: 4,167. Q2. Review. IMIBIC GROUPS: GC26	GC26
Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G, Gahete MD; Aggressive and Malignant Prolactinomas. NEUROENDOCRINOLOGY. 109. 1. (57-69). DOI: 10.1159/000497205. IF: 6,804. D1. Article; Proceedings Paper. IMIBIC GROUPS: GC27	GC27
Gomez-Delgado F, Alcala-Diaz JF, Leon-Acuna A, Lopez-Moreno J, Delgado-Lista J, Gomez-Marin B, Roncero-Ramos I, Yubero-Serrano EM, Rangel-Zuniga OA, Vals-Delgado C, Luque RM, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Apolipoprotein E genetic variants interact with Mediterranean diet to modulate postprandial hypertriglyceridemia in coronary heart disease patients: CORDIOPREV study. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 49. 8. DOI: 10.1111/eci.13146. IF: 2,784. Q1. Article. IMIBIC GROUPS: GC09 GC27 Medicina Interna	GC27
Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, L-Lopez F, Ibanez-Costa A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, ; Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513). DOI: 10.1210/jc.2019-00056. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC05 GA04 Endocrinología	GC27
Frantzi M, Gomez EG, Pedregosa AB, Rosa JV, Latosinska A, Culig Z, Merseburger AS, Luque RM, Tapia MJR, Mischak H, Valiente JC; CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. BRITISH JOURNAL OF CANCER. 120. 12. (1120-1128). DOI: 10.1038/s41416-019-0472-z. IF: 5,416. Q1. Article. IMIBIC GROUPS: GC27 GE05	GC27
Gomez-Gomez E, Carrasco-Valiente J, Campos-Hernandez JP, Blanca-Pedregosa AM, Jimenez-Vacas JM, Ruiz-Garcia J, Valero-Rosa J, Luque RM, Requena-Tapia MJ; Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 2. (934-942). DOI: 10.1111/jcmm.13994. IF: 4,658. Q1. Article. IMIBIC GROUPS: GC27 GE05	GC27
Coelho MCA, Vasquez ML, Wildemberg LE, Vazquez-Borrego MC, Bitana L, Camacho AHD, Silva D, Ogino LL, Ventura N, Sanchez-Sanchez R, Chimelli L, Kasuki L, Luque RM, Gadelha MR; Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-018-37692-3. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC27	GC27
Soriano S, Castellano-Munoz M, Rafacho A, Alonso-Magdalena P, Marroqui L, Ruiz-Pino A, Bru-Tari E, Merino B, Irles E, Bello-Perez M, Iborra P, Villar-Pazos S, Vettorazzi JF, Montanya E, Luque RM, Nadal A, Quesada I; Cortistatin regulates glucose-induced electrical activity and insulin secretion in mouse pancreatic beta-cells. MOLECULAR AND CELLULAR ENDOCRINOLOGY. 479. (123-132). DOI: 10.1016/j.mce.2018.09.09. IF: 3,693. Q2. Article. IMIBIC GROUPS: GC27	GC27

PUBLICATIONS	IMIBIC GROUP
del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC25 GC02 GC09 Anatomía Patológica	GC27
Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibanez-Costa A, Madrazo-Atutxa A, Japon MA, Castano JP, Luque RM, Cano DA, Soto-Moreno A; E-cadherin expression is associated with somatostatin analogue response in acromegaly. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 5. (3088-3096). DOI: 10.1111/jcmm.13851. IF: 4,658. Q1. Article. IMIBIC GROUPS: GC27 GC08	GC27
Herrera-Martinez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ; Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. ENDOCRINE-RELATED CANCER. 26. 6. (585-599). DOI: 10.1530/ERC-19-0086. IF: 4,774. Q1. Article. IMIBIC GROUPS: GA04 GC27	GC27
Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A; Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 127. 8. (545-553). DOI: 10.1111/apm.12973. IF: 2,225. Q2. Article. IMIBIC GROUPS: GE05 GC27	GC27
Fuentes-Fayos AC, Garcia-Martinez A, Herrera-Martinez AD, Jimenez-Vacas JM, Vazquez-Borrego MC, Castano JP, Pico A, Gahete MD, Luque RM; Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. MINERVA ENDOCRINOLOGICA. 44. 2. (109-128). DOI: 10.23736/S0391-1977.19.02970-5. IF: 1,817. Q4. Review. IMIBIC GROUPS: GC27 GC08 GA04	GC27
Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castano JP, Luque RM; Mouse models of endocrine tumors. JOURNAL OF ENDOCRINOLOGY. 240. 3. (R73-R96). DOI: 10.1530/JOE-18-0571. IF: 4,381. Q1. Review. IMIBIC GROUPS: GC27 GC08	GC27
Del Rio-Moreno M, Alors-Perez E, De Souza PB, Prados-Gonzalez ME, Castano JP, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. TRANSLATIONAL RESEARCH. 211. (147-160). DOI: 10.1016/j.trsl.2019.02.013. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08	GC27
Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Curras-Freixes M, Leton R, Torres-Perez R, Richter S, Pita G, Herraez B, Cianchetta G, Honrado E, Maestre L, Urioste M, Aller J, Garcia-Uriarte O, Galvez MA, Luque RM, Lahera M, Moreno-Rengel C, Eisenh; Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. AMERICAN JOURNAL OF HUMAN GENETICS. 104. 4. (651-664). DOI: 10.1016/j.ajhg.2019.02.017. IF: 9,924. D1. Article. IMIBIC GROUPS: GA04 GC27	GC27
Borque-Fernando A, Rubio-Briones J, Esteban LM, Dong Y, Calatrava A, Gomez-Ferrer A, Gomez-Gomez E, Fabra JMG, Rodriguez-Garcia N, Gonzalez PAL, Garcia-Rodriguez J, Rodrigo-Aliaga M, Herrera-Imbroda B, Soto-Villalba J, Martinez-Breijo S, Hernandez-Canas V; Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. PROSTATE CANCER AND PROSTATIC DISEASES. 22. 1. (84-90). DOI: 10.1038/s41391-018-0074-5. IF: 4,6. Q1. Article. IMIBIC GROUPS: GC27	GC27
Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08 GA08 GE05 Anatomía Patológica	GC27
Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castano JP, de Herder WW, Feelders RA; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. DRUGS. 79. 1. (21-42). DOI: 10.1007/s40265-018-1033-0. IF: 4,993. Q1. Review. IMIBIC GROUPS: GA04 GC08 GC27	GC27
Herrera-Martinez AD, Pedraza-Arevalo S, L-Lopez F, Gahete MD, Galvez-Moreno MA, Castano JP, Luque RM; Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 1. (57-73). DOI: 10.1210/jc.2018-01455. IF: 5,605. Q1. Article. IMIBIC GROUPS: GA04 GC08 GC27	GC27

PUBLICATIONS	IMIBIC GROUP
Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1400. DOI: 10.3390/jcm8091400. IF: 5,688. D1. Article. IMIBIC GROUPS: GC27 GC08 GE05 Anatomía Patológica	GC27
Leon-Acuna A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, Roncero-Ramos I, Yubero-Serrano E, Tinahones FJ, Castro-Clerico M, Delgado-Lista J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study. ATHEROSCLEROSIS. 290. (118-124). DOI: 10.1016/j.atherosclerosis.2019.09.025. IF: 4,255. D2 Q1. Article. IMIBIC GROUPS: GC09 Análisis Clínicos GC27	GC27
Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schatzlein M, Mesa J, Castano JP, Luque RM, Simo R; Metabolic Fingerprint of Acromegaly and Its Potential Usefulness in Clinical Practice. JOURNAL OF CLINICAL MEDICINE. 8. 10. 1549. DOI: 10.3390/jcm8101549. IF: 5,688. D1 Q1. Article. IMIBIC GROUPS: GC08 GC27	GC27
Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS. 11. 10. 1439. DOI: 10.3390/cancers11101439. IF: 6,162. D2 Q1. Article. IMIBIC GROUPS: GC27 GC08 Neurocirugía GA04	GC27
Jimenez-Vacas JM, Gomez-Gomez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-Lopez F, Sanchez-Sanchez R, Guler I, Blanca A, Mendez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM; Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 12. DOI: 10.3390/jcm8122056. IF: 5,688. D1 Q1. Article. IMIBIC GROUPS: GC27 GC08 GE05 GC06	GC27
Hoa O, Lafont C, Fontanaud P, Guillou A, Kemkem Y, Kineman RD, Luque RM, Coll TF, Le Tissier P, Mollard P; Imaging and Manipulating Pituitary Function in the Awake Mouse. ENDOCRINOLOGY. 160. 10. (2271-2281). DOI: 10.1210/en.2019-00297. IF: 3,8. Q2. Article. IMIBIC GROUPS: GC27	GC27
Thomas PB, Seim I, Jeffery PL, Gahete MD, Maugham M, Crisp GJ, Stacey A, Shah ET, Walpole C, Whiteside EJ, Nelson CC, Herington AC, Luque RM, Veedu RN, Chopin LK; The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth. INTERNATIONAL JOURNAL OF ONCOLOGY. 55. 6. (1223-1236). DOI: 10.3892/ijo.2019.4891. IF: 3,571. Q2. Article. IMIBIC GROUPS: GC27	GC27
Filosso PL, Guerrera F, Falco NR, Thomas P, Yuste MG, Rocco G, Welter S, Casado PM, Rendina EA, Venuta F, Ampollini L, Nosotti M, Raveglia F, Rena O, Stella F, Larocca V, Ardissone F, Brunelli A, Margaritora S, Travis WD, Sagan D, Sarkaria I, Evangelista; Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY. 55. 2. (273-279). DOI: 10.1093/ejcts/ezy250. IF: 3,847. Q1. Article; Proceedings Paper. IMIBIC GROUPS: GA01	GA01
Alvarez A, Moreno P; Demographic ageing and its influence on current lung transplant practice. JOURNAL OF THORACIC DISEASE. 11. 15. (S1992-S1994). DOI: 10.21037/jtd.2019.06.71. IF: 2,027. Q3. Editorial Material. IMIBIC GROUPS: GA01	GA01
Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A; LUBAC determines chemotherapy resistance in squamous cell lung cancer. JOURNAL OF EXPERIMENTAL MEDICINE. 216. 2. (450-465). DOI: 10.1084/jem.20180742. IF: 10,892. D1. Article. IMIBIC GROUPS: GA01 GC04	GA01
Mazo C, Pont T, Ballesteros MA, Lopez E, Rellan L, Robles JC, Rello J; Pneumonia versus graft dysfunction as the cause of acute respiratory failure after lung transplant: a 4-year multicentre prospective study in 153 adults requiring intensive care admission. EUROPEAN RESPIRATORY JOURNAL. 54. 3. 1801512. DOI: 10.1183/13993003.01512-2018. IF: 11,807. D1. Article. IMIBIC GROUPS: GA01	GA01

PUBLICATIONS	IMIBIC GROUP
Campos-Rodriguez F, Reyes-Nunez N, Queipo-Corona C, Sanchez-Armengol A, Jurado-Gamez B, Cordero-Guevara J, Troncoso MF, Abad-Fernandez A, Caballero-Rodriguez J, Martin-Romero M, Encabo-Motino A, Sacristan-Bou L, Navarro-Esteva J, Somoza-Gonzalez M, Masa J; Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women. ARCHIVOS DE BRONCONEUMOLOGIA. 55. 4. (201-207). DOI: 10.1016/j.arbres.2018.09.012. IF: 4,214. Q1. Article. IMIBIC GROUPS: GA03	GA03
Costa LME, Casas-Maldonado F, Campos JGS, Padilla-Galo A, Levy A, Gutierrez FJA, Fernandez APGB, Morales-Garcia C, Dominguez RG, Sanchez GV, Caballero LM, Pereira-Vega A, Polo CG, Chica GP, Villasclaras JJM; Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PHARMACOECONOMICS-OPEN. 3. 3. (333-342). DOI: 10.1007/s41669-019-0117-4. IF: 6,966. D1. Article. IMIBIC GROUPS: GA03	GA03
de Llano LAP, Cosio BG, Domingo C, Urrutia I, Bobolea I, Valero A, Costa LME, Quirce S, Barranco P, Malanda NM, Andres LP, Alvarez-Gutierrez FJ; Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 7. 7. (2277-2283.e2). DOI: 10.1016/j.jaip.2019.01.017. IF: 7,55. D1. Article. IMIBIC GROUPS: GA03	GA03
Sarramea F, Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Balanza-Martinez V, Gutierrez-Rojas L, Garcia-Portilla MP; Prepare the smoking cessation in severe mental illness: Early diagnosis and prevention opportunities. REVISTA DE PSIQUIATRIA Y SALUD MENTAL. 12. 2. (133-134). DOI: 10.1016/j.rpsm.2018.08.001. IF: 2,927. Q2. Letter. IMIBIC GROUPS: GA12 GA03	GA03
Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Montiel FJ, Gomez C, del Pozo GI, Alcala JA, Gutierrez-Rojas L, Balanza-Martinez V, Chauca GM, Carrion L, Osuna MI, Sanchez MD, Caro I, Ayora M, Valdivia F, Lopez MS, Poyato JM, Sarramea F; Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk TIMER): study protocol for a randomized controlled trial. TRIALS. 20. DOI: 10.1186/s13063-018-3139-9. IF: 1,975. Q3. Article. IMIBIC GROUPS: Salud Mental GA12 GA03 Distrito Sur. Salud Mental Hospital Infanta Margarita Cabra	GA03
Campos-Rodriguez F, Asensio-Cruz MI, Cordero-Guevara J, Jurado-Gamez B, Carmona-Bernal C, Gonzalez-Martinez M, Troncoso MF, Sanchez-Lopez V, Arellano-Orden E, Garcia-Sanchez MI, Martinez-Garcia MA, Reyes-Nunez N, Sanchez-Armengol A, Abad-Fernandez A, Alon; Effect of continuous positive airway pressure on inflammatory, antioxidant, and depression biomarkers in women with obstructive sleep apnea: a randomized controlled trial. SLEEP. 42. 10. UNSP zsz145. DOI: 0.1093/sleep/zsz145. IF: 4,571. D2 Q1. Article. IMIBIC GROUPS: GA03	GA03
Costa LME, Castillo ME; Discrepancies Between GEMA And GINA In The Classification Of Inhaled Corticosteroids. ARCHIVOS DE BRONCONEUMOLOGIA. 55. 12. (667-667). DOI: 10.1016/j.arbres.2019.06.018. IF: 4,214. Q1. Letter. IMIBIC GROUPS: GA03	GA03
Paez-Vega A, Cantisan S, Vaquero JM, Vidal E, Luque-Pineda A, Lobo-Acosta MA, Perez AB, Alonso-Moralejo R, Iturbe D, Monforte V, Otero-Gonzalez I, Pastor A, Ussetti P, Torre-Cisneros J; Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial. BMJ OPEN. 9. 8. DOI: 10.1136/bmjopen-2019-030648. IF: 2,376. Q2. Article. IMIBIC GROUPS: GC03 GA03 GC24	GA03
Alvarez-Escola C, Venegas-Moreno EM, Garcia-Arnes JA, Blanco-Carrera C, Marazuela-Azpiroz M, Galvez-Moreno MA, Menendez-Torre E, Aller-Pardo J, Salinas-Vert I, Resmini E, Torres-Vela EM, Gonzalo-Redondo MA, Vilchez-Joya R, de Miguel-Novoa MP, Halperin-Rab; ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. ENDOCRINOLOGIA DIABETES Y NUTRICION. 66. 5. (320-329). DOI: 10.1016/j.endinu.2018.12.004. IF: 0,934. Q4. Article. IMIBIC GROUPS: GA04	GA04
Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, L-Lopez F, Ibanez-Costa A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, ; Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513). DOI: 10.1210/jc.2019-00056. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC05 GA04 Endocrinología	GA04
Herrera-Martinez AD, Feelders RA, de Herder WW, Castano JP, Moreno MAG, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ; Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. HORMONES & CANCER. 10. 43526. (107-119). DOI: 10.1007/s12672-019-00361-6. IF: 2,581. Q3. Article. IMIBIC GROUPS: GA04 GC08	GA04

PUBLICATIONS	IMIBIC GROUP
Herrera-Martinez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ; Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. ENDOCRINE-RELATED CANCER. 26. 6. (585-599). DOI: 10.1530/ERC-19-0086. IF: 4,774. Q1. Article. IMIBIC GROUPS: GA04 GC27	GA04
Fuentes-Fayos AC, Garcia-Martinez A, Herrera-Martinez AD, Jimenez-Vacas JM, Vazquez-Borrego MC, Castano JP, Pico A, Gahete MD, Luque RM; Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. MINERVA ENDOCRINOLOGICA. 44. 2. (109-128). DOI: 10.23736/S0391-1977.19.02970-5. IF: 1,817. Q4. Review. IMIBIC GROUPS: GC27 GC08 GA04	GA04
Herrera-Martinez AD, Hofland LJ, Moreno MAG, Castano JP, de Herder WW, Feelders RA; Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. ENDOCRINE-RELATED CANCER. 26. 3. (R157-R179). DOI: 10.1530/ERC-18-0354. IF: 4,774. Q1. Review. IMIBIC GROUPS: GA04	GA04
Exposito MRA, Puerta MJM, Olveira G, Irigoyen CA, Soto MF, Almeida JMG, Luna PPG, Perez AMG, Rocamora JAI, Soria JBM, Cunill JLP, Restrepo JMR, Perez IR, Aguayo PS, Lopez FJV; Recommendations of the GARIN group for dietary managing of patient with chronic kidney disease. NUTRICION HOSPITALARIA. 36. 1. (183-217). DOI: 10.20960/nh.1823. IF: 0,759. Q4. Article. IMIBIC GROUPS: GC08 GA04	GA04
Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Curras-Freixes M, Leton R, Torres-Perez R, Richter S, Pita G, Herraez B, Cianchetta G, Honrado E, Maestre L, Urioste M, Aller J, Garcia-Uriarte O, Galvez MA, Luque RM, Lahera M, Moreno-Rengel C, Eisenh; Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. AMERICAN JOURNAL OF HUMAN GENETICS. 104. 4. (651-664). DOI: 10.1016/j.ajhg.2019.02.017. IF: 9,924. D1. Article. IMIBIC GROUPS: GA04 GC27	GA04
Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castano JP, de Herder WW, Feelders RA; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. DRUGS. 79. 1. (21-42). DOI: 10.1007/s40265-018-1033-0. IF: 4,993. Q1. Review. IMIBIC GROUPS: GA04 GC08 GC27	GA04
Morillas C, Escalada J, Palomares R, Bellido D, Gomez-Peralta F, Perez A; Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. DIABETES THERAPY. 10. 5. (1893-1907). DOI: 10.1007/s13300-019-0671-x. IF: 2,827. Q3. Article. IMIBIC GROUPS: GA04	GA04
Herrera-Martinez AD, Pedraza-Arevalo S, L-Lopez F, Gahete MD, Galvez-Moreno MA, Castano JP, Luque RM; Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 1. (57-73). DOI: 10.1210/jc.2018-01455. IF: 5,605. Q1. Article. IMIBIC GROUPS: GA04 GC08 GC27	GA04
Lecube A, Sanchez E, Andres A, Saldana C, Morales MJ, Calanas A, Minambres I, Pellitero S, Cordido F, Bueno M, Caixas A, Vilarrasa N; Assessing Motivational Stages and Processes of Change for Weight Management Around Bariatric Surgery: a Multicenter Study. OBESITY SURGERY. 29. 10. (3348-3356). DOI: 10.1007/s11695-019-04001-4. IF: 3,603. D2 Q1. Article. IMIBIC GROUPS: GA04	GA04
Rebollo-Roman A, de Damas-Medina M, Molina-Puerta MJ, Calanas-Continente A, Manzano-Garcia G; Nutritional approach in systemic sclerosis: report of a case. NUTRICION HOSPITALARIA. 36. 5. (1231-1234). DOI: 10.20960/nh.02732. IF: 0,754. Q4. Article. IMIBIC GROUPS: GC08 GA04	GA04
Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS. 11. 10. 1439. DOI: 10.3390/cancers11101439. IF: 6,162. D2 Q1. Article. IMIBIC GROUPS: GC27 GC08 Neurocirugía GA04	GA04
Hofland J, Herrera-Martinez AD, Zandee WT, de Herder WW; Management of carcinoid syndrome: a systematic review and meta-analysis. ENDOCRINE-RELATED CANCER. 26. 3. (R145-R156). DOI: 10.1530/ERC-18-0495. IF: 4,774. Q1. Review. IMIBIC GROUPS: GC08	GA04
Exposito MRA, Puerta MJM, Olveira G, Irigoyen CA, Soto MF, Almeida JMG, Luna PPG, Perez AMG, Rocamora JAI, Soria JBM, Cunill JLP, Restrepo JMR, Perez IR, Aguayo PS, Lopez FJV; Recommendations of the GARIN group for dietary managing of patient with chronic kidney disease. NUTRICION HOSPITALARIA. 36. 1. (183-217). DOI: 10.20960/nh.1823. IF: 0,759. Q4. Article. IMIBIC GROUPS: GC08 GA04	GA04

PUBLICATIONS	IMIBIC GROUP
Rebollo-Roman A, de Damas-Medina M, Molina-Puerta MJ, Calanas-Continente A, Manzano-Garcia G; Nutritional approach in systemic sclerosis: report of a case. NUTRICION HOSPITALARIA. 36. 5. (1231-1234). DOI: 10.20960/nh.02732. IF: 0,754. Q4. Article. IMIBIC GROUPS: GC08 GA04	GA04
Moral L, Vizmanos G, Torres-Borrego J, Praena-Crespo M, Tortajada-Girbes M, Pellegrini FJ, Asensio O; Asthma diagnosis in infants and preschool children: a systematic review of clinical guidelines. ALLERGOLOGIA ET IMMUNOPATHOLOGIA. 47. 2. (107-121). DOI: 10.1016/j.aller.2018.05.002. IF: 1,64. Q4. Review. IMIBIC GROUPS: GA05	GA05
Ruiz-Ojeda FJ, Anguita-Ruiz A, Ruperez AI, Gomez-Llorente C, Olza J, Vazquez-Cobela R, Gil-Campos M, Bueno G, Leis R, Canete R, Moreno LA, Gil A, Aguilera CM; Effects of X-chromosome Tenomodulin Genetic Variants on Obesity in a Children's Cohort and Implications of the Gene in Adipocyte Metabolism. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-40482-0. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC23 GA05	GA05
Perez-Navero JL, Merino-Cejas C, de la Rosa II, Jaraba-Caballero S, Frias-Perez M, Gomez-Guzman E, Gil-Campos M, de la Torre-Aguilar MJ; Evaluation of the vasoactive-inotropic score, mid-regional pro-adrenomedullin and cardiac troponin I as predictors of low cardiac output syndrome in children after congenital heart disease surgery. MEDICINA INTENSIVA. 43. 6. (329-336). DOI: 10.1016/j.medin.2018.04.005. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC23 Pediatría GA09 GA05	GA05
Caballero-Villarraso J, Aguado R, Canete MD, Roldan L, Canete R, Santamaria M; Hormone replacement therapy in children with growth hormone deficiency: impact on immune profile. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY. 19. (1-5). DOI: 10.1080/13813455.2019.1628070. IF: 2,11. Q3. Article; Early Access. IMIBIC GROUPS: GE01 GA05 GC03	GA05
Moreno M, Castillo-Corullon S, Perez-Ruiz E, Luna MC, Anton-Pacheco JL, Mondejar-Lopez P, De-la-Serna O, Villa JR, Osona B, Torres-Borrego J, Santiago-Burruchaga M, Asensio O, Andres-Martin A, Delgado-Pecellin I, Gonzalez Y, Palmero A, Escribano A; Spanish multicentre study on morbidity and pathogenicity of tracheal bronchus in children. PEDIATRIC PULMONOLOGY. 0. DOI: 10.1002/ppul.24435. IF: 2,801. Q1. Article; Early Access. IMIBIC GROUPS: GA05	GA05
Nunez-Ramiro A, Benavente-Fernandez I, Valverde E, Cordeiro M, Blanco D, Boix H, Cabanas F, Chaffanel M, Fernandez-Colomer B, Fernandez-Lorenzo JR, Kuligowski J, Loureiro B, Moral-Pumarega MT, Pavon A, Sanchez-Illana A, Tofe I, Hervas D, Garcia-Robles A, ; Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded Trial. NEONATOLOGY. 116. 1. (76-84). DOI: 10.1159/000499084. IF: 2,688. Q1. Article. IMIBIC GROUPS: GA05	GA05
Anguita-Ruiz A, Plaza-Diaz J, Ruiz-Ojeda FJ, Ruperez AI, Leis R, Bueno G, Gil-Campos M, Vazquez-Cobela R, Canete R, Moreno LA, Gil A, Aguilera CM; X chromosome genetic data in a Spanish children cohort, dataset description and analysis pipeline. SCIENTIFIC DATA. 6. DOI: 10.1038/s41597-019-0109-3. IF: 5,929. Q1. Article; Data Paper. IMIBIC GROUPS: GC23 GA05	GA05
Anguita-Ruiz A, Pastor-Villaescusa B, Leis R, Bueno G, Hoyos R, Vazquez-Cobela R, Latorre-Millan M, Canete MD, Caballero-Villarraso J, Gil A, Canete R, Aguilera CM; Common Variants in 22 Genes Regulate Response to Metformin Intervention in Children with Obesity: A Pharmacogenetic Study of a Randomized Controlled Trial. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1471. DOI: 10.3390/jcm8091471. IF: 5,688. D1. Article. IMIBIC GROUPS: GA05 GE01	GA05
Canete MD, Valle-Martos R, Martos R, Canete R, Valle M, Jimenez-Reina L; Effects of growth hormone therapy on metabolic parameters, adipokine and endothelial dysfunction in prepuberal children. ACTA PAEDIATRICA. 108. 11. (2027-2033). DOI: 10.1111/apa.14849. IF: 2,265. Q2. Article. IMIBIC GROUPS: GA05	GA05
Moreno-Galdo A, Perez-Yarza EG, Ramilo O, Rubi T, Escribano A, Torres A, Sardon O, Oliva C, Perez G, Cortell I, Rovira-Amigo S, Pastor-Vivero MD, Perez-Frias J, Velasco V, Torres J, Figuerola J, Barrio MI, Garcia-Hernandez G, Mejias A; Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants. PEDIATRIC ALLERGY AND IMMUNOLOGY. 31. 2. (124-132). DOI: 10.1111/pai.13134. IF: 4,654. D1 Q1. Article; Early Access. IMIBIC GROUPS: GA05	GA05
Garcia AG, Moniche F, Escudero-Martinez I, Mancha F, Tomasello A, Ribo M, Delgado-Acosta F, Ochoa JJ, de las Heras JA, Lopez-Mesonero L, Gonzalez-Delgado M, Murias E, Gil J, Gil R, Zamarro J, Parrilla G, Mosteiro S, Fernandez-Couto MD, de Alarcon LF, Rami; Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting Results From a National Prospective Multicenter Study. JACC-CARDIOVASCULAR INTERVENTIONS. 12. 9. (873-882). DOI: 10.1016/j.jcin.2019.01.247. IF: 9,544. D1. Article. IMIBIC GROUPS: GA08 GE01	GA08

PUBLICATIONS	IMIBIC GROUP
Gomez EJ, Rey IB, Fernandez RO, Acosta FD; Endovascular treatment of stroke in children under 2 years with heart failure and ventricular assist device. INTERVENTIONAL NEURORADIOLOGY. 25. 5. (516-520). DOI: 10.1177/1591019919844946. IF: 1,45. Q4. Article. IMIBIC GROUPS: Radiodiagnóstico GA08	GA08
Delgado F, Oteros R, Jimenez-Gomez E, Rey IB, Bautista MD, Moyano RV; Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment. JOURNAL OF NEUROINTERVENTIONAL SURGERY. 11. 2. (147-152). DOI: 10.1136/neurintsurg-2018-014163. IF: 3,526. Q1. Article. IMIBIC GROUPS: GA08 Radiodiagnóstico Medicina Intensiva Neurología	GA08
Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08 GA08 GE05 Anatomía Patológica	GA08
Acosta FD, Gomez EJ, Rey IB, Moyano RV, Bravo-Rodriguez FD, Fernandez RO; Contrast-induced nephropathy: A dilemma between loss of neurons or nephrons in the setting of endovascular treatment of acute ischemic stroke. INTERVENTIONAL NEURORADIOLOGY. 26. 1. (33-37). DOI: 10.1177/1591019919883755. IF: 1,45. Q4. Article; Early Access. IMIBIC GROUPS: GA08 Radiodiagnóstico GE01	GA08
Moreno-Sanchez T, Moreno-Ramirez M, Machancoses FH, Pardo-Moreno P, Navarro-Vergara PF, Garcia-Revillo J; Efficacy of Paclitaxel Balloon for Hemodialysis Stenosis Fistulae After One Year Compared to High-Pressure Balloons: A Controlled, Multicenter, Randomized Trial. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY. 43. 3. (382-390). DOI: 10.1007/s00270-019-02372-w. IF: 1,928. Q3. Article; Early Access. IMIBIC GROUPS: GA08	GA08
Rodriguez-Caulo EA, Macias D, Adsuar A, Ferreiro A, Arias-Dachary J, Parody G, Fernandez F, Daroca T, Rodriguez-Mora F, Garrido JM, Munoz-Carvajal I, Barquero JM, Valderrama JF, Melero JM; Biological or mechanical prostheses for isolated aortic valve replacement in patients aged 50-65 years: the ANDALVALVE study. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY. 55. 6. (1160-1167). DOI: 10.1093/ejcts/ezy459. IF: 3,847. Q1. Article; Proceedings Paper. IMIBIC GROUPS: GA09	GA09
Perez-Navero JL, Merino-Cejas C, de la Rosa II, Jaraba-Caballero S, Frias-Perez M, Gomez-Guzman E, Gil-Campos M, de la Torre-Aguilar MJ; Evaluation of the vasoactive-inotropic score, mid-regional pro-adrenomedullin and cardiac troponin I as predictors of low cardiac output syndrome in children after congenital heart disease surgery. MEDICINA INTENSIVA. 43. 6. (329-336). DOI: 10.1016/j.medin.2018.04.005. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC23 Pediatría GA09 GA05	GA09
Couto-Mallon D, Gonzalez-Vilchez F, Almenar-Bonet L, Diaz-Molina B, Segovia-Cubero J, Gonzalez-Costello J, Delgado-Jimenez J, Castel-Lavilla MA, Crespo-Leiro MG, Rangel-Sousa D, Martinez-Selles M, Rabago-Juan-Aracil G, De-la-Fuente-Galan L, Blasco-Peiro T; Prognostic Value of Serum Lactate Levels in Patients Undergoing Urgent Heart Transplant: A Subanalysis of the ASIS-TC Spanish Multicenter Study. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 3. (208-214). DOI: 10.1016/j.recesp.2018.02.010. IF: 5,126. Q1. Article. IMIBIC GROUPS: GA09	GA09
Barge-Caballero E, Gonzalez-Vilchez F, Delgado JF, Mirabet-Perez S, Gonzalez-Costello J, Perez-Villa F, Martinez-Selles M, Segovia-Cubero J, Hervas-Sotomayor D, Blasco-Peiro T, De la Fuente-Galan L, Lambert-Rodriguez JL, Rangel-Sousa D, Almenar-Bonet L, G; Use of Intra-aortic Balloon Pump as a Bridge to Heart Transplant in Spain: Results From the ASIS-TC Study. REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 10. (835-843). DOI: 10.1016/j.rec.2018.07.003. IF: 5,126. D2 Q1. Article. IMIBIC GROUPS: GA09	GA09
Barge-Caballero G, Castel-Lavilla MA, Almenar-Bonet L, Garrido-Bravo IP, Delgado JF, Rangel-Sousa D, Gonzalez-Costello J, Segovia-Cubero J, Farrero-Torres M, Lambert-Rodriguez JL, Crespo-Leiro MG, Hervas-Sotomayor D, Portoles-Ocampo A, Martinez-Selles M, ; Venoarterial extracorporeal membrane oxygenation with or without simultaneous intra-aortic balloon pump support as a direct bridge to heart transplantation: results from a nationwide Spanish registry. INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY. 29. 5. (670-677). DOI: 10.1093/icvts/ivz155. IF: 1,931. Q2. Article. IMIBIC GROUPS: GA09	GA09

PUBLICATIONS	IMIBIC GROUP
Mena-Bares LM, Benitez-Cantero JM, Iglesias-Flores E, Gros-Alcalde B, Moreno-Ortega E, Maza-Muret FR, Carmona-Asenjo E, Garcia-Sanchez MV, Vallejo-Casas JA; Bile acid malabsorption in patients with chronic diarrhea and Crohn's disease. REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS. 111. 1. (40-44). DOI: 10.17235/reed.2018.5376/2017. IF: 1,858. Q4. Article. IMIBIC GROUPS: GA10 GC02 Medicina Ap Digestivo	GA10
Duran-Rosal AM, Gutierrez PA, Carmona-Poyato A, Heryas-Martinez C; A hybrid dynamic exploitation barebones particle swarm optimisation algorithm for time series segmentation. NEUROCOMPUTING. 353. (45-55). DOI: 10.1016/j.neucom.2018.05.129. IF: 4,072. Q1. Article. IMIBIC GROUPS: GA11 GC19	GA11
Fernandez JC, Carbonero M, Gutierrez PA, Hervas-Martinez C; Multi-objective evolutionary optimization using the relationship between F-1 and accuracy metrics in classification tasks. APPLIED INTELLIGENCE. 49. 9. (3447-3463). DOI: 10.1007/s10489-019-01447-y. IF: 2,882. Q2. Article. IMIBIC GROUPS: GA11	GA11
Comino F, Guijo-Rubio D, de Adana MR, Hervas-Martinez C; Validation of multitask artificial neural networks to model desiccant wheels activated at low temperature. INTERNATIONAL JOURNAL OF REFRIGERATION-REVUE INTERNATIONALE DU FROID. 100. (434-442). DOI: 10.1016/j.ijrefrig.2019.02.002. IF: 3,177. Q1. Article. IMIBIC GROUPS: GA11	GA11
Sarramea F, Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Balanza-Martinez V, Gutierrez-Rojas L, Garcia-Portilla MP; Prepare the smoking cessation in severe mental illness: Early diagnosis and prevention opportunities. REVISTA DE PSIQUIATRIA Y SALUD MENTAL. 12. 2. (133-134). DOI: 10.1016/j.rpsm.2018.08.001. IF: 2,927. Q2. Letter. IMIBIC GROUPS: GA12 GA03	GA12
Crespo FS, Jaen-Moreno MJ, Gutierrez-Rojas L, Balanza-Martinez V, Garcia-Alvarez L, Martinez PAS, Garcia-Portilla MP, Guler I, Bobes J; Readiness to Change Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. EUROPEAN ADDICTION RESEARCH. 25. 5. (256-262). DOI: 10.1159/000500450. IF: 2,653. Q2. Article. IMIBIC GROUPS: GA12	GA12
Sarramea F, Jaen-Moreno MJ, Balanza-Martinez V, Osuna MI, Alcala JA, Montiel FJ, Gomez C, Sanchez MD, Rico AB, Redondo-Ecija J, Gil S, Valdivia F, Caballero-Villarraso J, Gutierrez-Rojas L; Setting the stage to quit smoking in Bipolar Disorder patients: brief advice in clinical practice. ADICCIONES. 31. 2. (136-145). DOI: 0. IF: 3,167. Q1. Article. IMIBIC GROUPS: GA12 GE01	GA12
Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Montiel FJ, Gomez C, del Pozo GI, Alcala JA, Gutierrez-Rojas L, Balanza-Martinez V, Chauca GM, Carrion L, Osuna MI, Sanchez MD, Caro I, Ayora M, Valdivia F, Lopez MS, Poyato JM, Sarramea F; Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk TIMER): study protocol for a randomized controlled trial. TRIALS. 20. DOI: 10.1186/s13063-018-3139-9. IF: 1,975. Q3. Article. IMIBIC GROUPS: Salud Mental GA12 GA03 Distrito Sur. Salud Mental Hospital Infanta Margarita Cabra	GA12
Tamayo-Agudelo W, Jaen-Moreno MJ, Leon-Campos MO, Holguin-Lew J, Luque-Luque R, Bell V; Validation of the Spanish-language Cardiff Anomalous Perception Scale. PLOS ONE. 14. 3. DOI: 10.1371/journal.pone.0213425. IF: 2,776. Q2. Article. IMIBIC GROUPS: GA12	GA12
Carbone EA, Pugliese V, Bruni A, Aloi M, Calabro G, Jaen-Moreno MJ, Segura-Garcia C, De Fazio P; Adverse childhood experiences and clinical severity in bipolar disorder and schizophrenia: A transdiagnostic two-step cluster analysis. JOURNAL OF AFFECTIVE DISORDERS. 259. (104-111). DOI: 10.1016/j.jad.2019.08.049. IF: 4,084. D2 Q1. Article. IMIBIC GROUPS: GA12	GA12
Kotlar I, Rangel-Lopez E, Colonnello A, Aguilera-Portillo G, Serratos IN, Galvan-Arzate S, Pedraza-Chaverri J, Tunez I, Wajner M, Santamaria A; Anandamide Reduces the Toxic Synergism Exerted by Quinolinic Acid and Glutaric Acid in Rat Brain Neuronal Cells. NEUROSCIENCE. 401. (84-95). DOI: 10.1016/j.neuroscience.2019.01.014. IF: 3,244. Q2. Article. IMIBIC GROUPS: GE01	GE01
Garcia AG, Moniche F, Escudero-Martinez I, Mancha F, Tomasello A, Ribo M, Delgado-Acosta F, Ochoa JJ, de las Heras JA, Lopez-Mesonero L, Gonzalez-Delgado M, Murias E, Gil J, Gil R, Zamarro J, Parrilla G, Mosteiro S, Fernandez-Couto MD, de Alarcon LF, Rami; Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting Results From a National Prospective Multicenter Study. JACC-CARDIOVASCULAR INTERVENTIONS. 12. 9. (873-882). DOI: 10.1016/j.jcin.2019.01.247. IF: 9,544. D1. Article. IMIBIC GROUPS: GA08 GE01	GE01
de Lima ME, Colpo AZC, Maya-Lopez M, Rangel-Lopez E, Becerril-Chavez H, Galvan-Arzate S, Villeda-Hernandez J, Sanchez-Chapul L, Tunez I, Folmer V, Santamaria A; Comparing the Effects of Chlorogenic Acid and Ilex paraguariensis Extracts on Different Markers of Brain Alterations in Rats Subjected to Chronic Restraint Stress. NEUROTOXICITY RESEARCH. 35. 2. (373-386). DOI: 10.1007/s12640-018-9963-6. IF: 3,311. Q2. Article. IMIBIC GROUPS: GE01	GE01

PUBLICATIONS	IMIBIC GROUP
Aguera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Pena J; Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE. 8. 1. (23-31). DOI: 10.1016/j.jshs.2017.05.007. IF: 3,644. Q1. Article. IMIBIC GROUPS: GE01 GE01 Urgencias GC12	GE01
Caballero-Villarraso J, Aguado R, Canete MD, Roldan L, Canete R, Santamaria M; Hormone replacement therapy in children with growth hormone deficiency: impact on immune profile. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY. 19. (1-5). DOI: 10.1080/13813455.2019.1628070. IF: 2,11. Q3. Article; Early Access. IMIBIC GROUPS: GE01 GA05 GC03	GE01
Sarramea F, Jaen-Moreno MJ, Balanza-Martinez V, Osuna MI, Alcala JA, Montiel FJ, Gomez C, Sanchez MD, Rico AB, Redondo-Ecija J, Gil S, Valdivia F, Caballero-Villarraso J, Gutierrez-Rojas L; Setting the stage to quit smoking in Bipolar Disorder patients: brief advice in clinical practice. ADICCIONES. 31. 2. (136-145). DOI: 0. IF: 3,167. Q1. Article. IMIBIC GROUPS: GA12 GE01	GE01
Aguilar-Agudo A, Herruzo-Cabrera J, Ochoa-Sepulveda JJ, Pino-Osuna MJ; Social return of investment (SROI) in evidence-based treatments. CLINICA Y SALUD. 30. 1. (13-20). DOI: 10.5093/clysa2019a4. IF: 0,632. Q4. Article. IMIBIC GROUPS: GE01	GE01
Aguilera-Portillo G, Rangel-Lopez E, Villeda-Hernandez J, Chavarria A, Castellanos P, Elmazoglu Z, Karasu C, Tunez I, Pedraza G, Konigsberg M, Santamaria A; The Pharmacological Inhibition of Fatty Acid Amide Hydrolase Prevents Excitotoxic Damage in the Rat Striatum: Possible Involvement of CB1 Receptors Regulation. MOLECULAR NEUROBIOLOGY. 56. 2. (844-856). DOI: 10.1007/s12035-018-1129-2. IF: 4,586. Q1. Article. IMIBIC GROUPS: GE01	GE01
Anguita-Ruiz A, Pastor-Villaescusa B, Leis R, Bueno G, Hoyos R, Vazquez-Cobela R, Latorre-Millan M, Canete MD, Caballero-Villarraso J, Gil A, Canete R, Aguilera CM; Common Variants in 22 Genes Regulate Response to Metformin Intervention in Children with Obesity: A Pharmacogenetic Study of a Randomized Controlled Trial. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1471. DOI: 10.3390/jcm8091471. IF: 5,688. D1. Article. IMIBIC GROUPS: GA05 GE01	GE01
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J; Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 19. 11. (1388-1398). DOI: 10.2174/1871520619666190417162409. IF: 2,18. Q3. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GE01 GC02	GE01
Acosta FD, Gomez EJ, Rey IB, Moyano RV, Bravo-Rodriguez FD, Fernandez RO; Contrast-induced nephropathy: A dilemma between loss of neurons or nephrons in the setting of endovascular treatment of acute ischemic stroke. INTERVENTIONAL NEURORADIOLOGY. 26. 1. (33-37). DOI: 10.1177/1591019919883755. IF: 1,45. Q4. Article; Early Access. IMIBIC GROUPS: GA08 Radiodiagnóstico GE01	GE01
Caballero-Villarraso J, Jimenez-Jimenez MJ, Escribano BM, Aguera E, Santamaria A, Tunez I; Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 18. 6. (478-490). DOI: 10.2174/1871527318666190703102330. IF: 2,761. Q2. Review. IMIBIC GROUPS: GE01 GE01 GE01	GE01
Fernandez-Del Olmo A, Cruz-Cortes M, Conde C, Ontanilla E, Rosa-Muela C, Martos C, Caceres D, de Leon JMRS; The role of the cognitive reserve in the cognitive recovery of patients who have suffered a severe addiction to substances. REVISTA DE NEUROLOGIA. 69. 8. (323-331). DOI: 10.33588/rn.6908.2019095. IF: 0,485. Q4. Article. IMIBIC GROUPS: GE01	GE01
Colonnello A, Aguilera-Portillo G, Rubio-Lopez LC, Robles-Banuelos B, Rangel-Lopez E, Cortez-Nunez S, Evaristo-Priego Y, Silva-Palacios A, Galvan-Arzate S, Garcia-Contreras R, Tunez I, Chen P, Aschner M, Santamaria A; Comparing the Neuroprotective Effects of Caffeic Acid in Rat Cortical Slices and Caenorhabditis elegans: Involvement of Nrf2 and SKN-1 Signaling Pathways. NEUROTOXICITY RESEARCH. . DOI: 10.1007/s12640-019-00133-8. IF: 3,311. Q2. Article; Early Access. IMIBIC GROUPS: GE01	GE01
Conde C, Escribano BM, Luque E, Feijoo M, Caballero-Villarraso J, Valdelvira ME, Ochoa-Sepulveda JJ, Lillo R, Paz E, Santamaria A, Aguera E, Tunez I; Extra-Virgin Olive Oil Modifies the Changes Induced in Non-Nervous Organs and Tissues by Experimental Autoimmune Encephalomyelitis Models. NUTRIENTS. 11. 10. DOI: 10.3390/nu11102448. IF: 4,171. D2 Q1. Article. IMIBIC GROUPS: GE01	GE01

PUBLICATIONS	IMIBIC GROUP
Ferrara P, Shantikumar S, Verissimo VC, Ruiz-Montero R, Masuet-Aumatell C, Ramon-Torrell JM, Buckley K, Verissimo VHC, Costa D, Del Prete V, Ferrara P, Ivankovic D, Peixoto VRFD, Peremiquel-Trillas P, Duque MP, Ruiz-Montero R, Shantikumar S, Thomas R, Voc; Knowledge about E-Cigarettes and Tobacco Harm Reduction among Public Health Residents in Europe. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 12. . . (-). DOI: 10.3390/ijerph16122071. IF: 2,468. Q1. Article. IMIBIC GROUPS: GE02	GE02
Zhou LS, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, Estrada YD, Peng XY, del Duca E, Sanz-Cabanillas J, Ruano J, Xu H, Zhang N, Wen HC, Gonzalez J, Garcet S, Krueger JG, Guttman-Yassky E; Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 144. 1. (144-156). DOI: 10.1016/j.jaci.2019.01.015. IF: 14,11. D1. Article. IMIBIC GROUPS: GE03	GE03
Alcantara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Garcia-Nieto AV; Dome-shaped nodules and scaly, verruciform plaques on the legs and feet. INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY. 85. 2. (226-228). DOI: 10.4103/ijdvl.IJDVL_255_17. IF: 3,03. Q2. Editorial Material. IMIBIC GROUPS: Dermatología GE03	GE03
Gomez-Garcia F, Gomez-Arias PJ, Hernandez J, Montilla AM, Gay-Mimbrera J, Aguilar-Luque M, Viguera-Guerra I, Garcia-Nieto AV, Isla-Tejera B, Ruano J; Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ OPEN. 9. 5. DOI: 10.1136/bmjopen-2018-028303. IF: 2,413. Q2. Review. IMIBIC GROUPS: GE03	GE03
Viguera-Guerra I, Ruano J, Aguilar-Luque M, Gay-Mimbrera J, Montilla A, Fernandez-Rueda JL, Fernandez-Chaichio J, Sanz-Cabanillas JL, Gomez-Arias PJ, Garcia-Nieto AV, Gomez-Garcia F, Isla-Tejera B; Evolution of international collaborative research efforts to develop non-Cochrane systematic reviews. PLOS ONE. 14. 2. DOI: 10.1371/journal.pone.0211919. IF: 2,776. Q2. Article. IMIBIC GROUPS: GE03	GE03
Moreno-Arrones OM, Saceda-Corralo D, Rodrigues-Barata AR, Castellanos-Gonzalez M, Fernandez-Pugnaire MA, Grimalt R, Hermosa-Gelbard A, Bernardez C, Molina-Ruiz AM, Ormaechea-Perez N, Fernandez-Crehuet P, Vano-Galvan S; Risk factors associated with frontal fibrosing alopecia: a multicentre case-control study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 44. 4. (404-410). DOI: 10.1111/ced.13785. IF: 1,771. Q3. Article. IMIBIC GROUPS: GE03	GE03
Barbarroja N, Arias-de la Rosa I, Lopez-Medina C, Camacho-Sanchez MD, Gomez-Garcia I, Velez-Garcia AJ, Escudero-Contreras A, Lopez-Pedrera C, Lopez-Montilla MD, Collantes-Estevez E; Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 11. DOI: 10.1177/1759720X19880742. IF: 5,045. D2 Q1. Letter. IMIBIC GROUPS: GC05 GE03	GE03
Montilla AM, Gomez-Garcia F, Gomez-Arias PJ, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B, Ruano J; Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. DERMATOLOGY AND THERAPY. 9. 4. (655-683). DOI: 10.1007/s13555-019-00329-y. IF: 3,615. D2 Q1. Review; Early Access. IMIBIC GROUPS: GE03 GE03 Farmacia GC03	GE03
Gonzalez-Cantero A, Carretero G, Rivera R, Ferrandiz C, Dauden E, de la Cueva P, Gomez-Garcia FJ, Belinchon I, Herrera-Ceballos E, Ruiz-Genao D, Ferran M, Alsina M, Sanchez-Carazo JL, Baniandres O, Sahuquillo-Torralba A, Rodriguez L, Vilar J, Garcia C, Carrascosa JM, Llamas-Velasco M, Herrera-Acosta E, Lopez-Estebaranz JL, Botella-Estrada R, Descalzo MA, Garcia-Doval I; Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. BRITISH JOURNAL OF DERMATOLOGY. 181. 5. (1085-1087). DOI: 10.1111/bjd.18164. IF: 6,714. D1 Q1. Letter. IMIBIC GROUPS: GE03	GE03
Tabernero C, Luque B, Cuadrado E; A Multilevel Study of Alcohol Consumption in Young Adults: Self-Efficacy, Peers' Motivations and Protective Strategies. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 16. DOI: 10.3390/ijerph16162827. IF: 2,468. Q1. Article. IMIBIC GROUPS: GE04	GE04
Garcia-Torres F, Castillo-Mayen R; Differences in Eysenck's Personality Dimensions between a Group of Breast Cancer Survivors and the General Population. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 7. DOI: 10.3390/ijerph16071240. IF: 2,468. Q1. Article. IMIBIC GROUPS: GC20 GE04	GE04

PUBLICATIONS	IMIBIC GROUP
Checa P, Abundis-Gutierrez A, Perez-Duenas C, Fernandez-Parra A; Influence of Maternal and Paternal Parenting Style and Behavior Problems on Academic Outcomes in Primary School. FRONTIERS IN PSYCHOLOGY. 10. DOI: 10.3389/fpsyg.2019.00378. IF: 2,129. Q2. Article. IMIBIC GROUPS: GE04	GE04
Tabernero C, Gutierrez-Domingo T, Luque B, Garcia-Vazquez O, Cuadrado E; Protective Behavioral Strategies and Alcohol Consumption: The Moderating Role of Drinking-Group Gender Composition. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 5. DOI: 10.3390/ijerph16050900. IF: 2,468. Q1. Article. IMIBIC GROUPS: GE04	GE04
Frantzi M, Gomez EG, Pedregosa AB, Rosa JV, Latosinska A, Culig Z, Merseburger AS, Luque RM, Tapia MJR, Mischak H, Valiente JC; CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. BRITISH JOURNAL OF CANCER. 120. 12. (1120-1128). DOI: 10.1038/s41416-019-0472-z. IF: 5,416. Q1. Article. IMIBIC GROUPS: GC27 GE05	GE05
Gomez-Gomez E, Carrasco-Valiente J, Campos-Hernandez JP, Blanca-Pedregosa AM, Jimenez-Vacas JM, Ruiz-Garcia J, Valero-Rosa J, Luque RM, Requena-Tapia MJ; Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 2. (934-942). DOI: 10.1111/jcmm.13994. IF: 4,658. Q1. Article. IMIBIC GROUPS: GC27 GE05	GE05
Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A; Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 127. 8. (545-553). DOI: 10.1111/apm.12973. IF: 2,225. Q2. Article. IMIBIC GROUPS: GE05 GC27	GE05
Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08 GA08 GE05 Anatomía Patológica	GE05
Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1400. DOI: 10.3390/jcm8091400. IF: 5,688. D1. Article. IMIBIC GROUPS: GC27 GC08 GE05 Anatomía Patológica	GE05
Volavsek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, Cimadamore A, Vau N, Pierconti F, Lopez-Beltran A; Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. VIRCHOWS ARCHIV. 475. 6. (735-744). DOI: 10.1007/s00428-019-02666-x. IF: 2,868. Q2. Article; Early Access. IMIBIC GROUPS: GE05	GE05
Jimenez-Vacas JM, Gomez-Gomez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-Lopez F, Sanchez-Sanchez R, Guler I, Blanca A, Mendez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM; Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 12. DOI: 10.3390/jcm8122056. IF: 5,688. D1 Q1. Article. IMIBIC GROUPS: GC27 GC08 GE05 GC06	GE05
Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R; Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS. 11. (1-13). DOI: 10.1080/14737159.2020.1699791. IF: 3,099. Q2. Review; Early Access. IMIBIC GROUPS: GE05	GE05
Guerrero-Hue M, Garcia-Caballero C, Palomino-Antolin A, Rubio-Navarro A, Vazquez-Carballo C, Herencia C, Martin-Sanchez D, Farre-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA; Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. FASEB JOURNAL. 33. 8. (8961-8975). DOI: 10.1096/fj.201900077R. IF: 5,595. D1. Article. IMIBIC GROUPS: GE06	GE06
Moreno JA, Sevillano A, Gutierrez E, Guerrero-Hue M, Vazquez-Carballo C, Yuste C, Herencia C, Garcia-Caballero C, Praga M, Egido J; Glomerular Hematuria: Cause or Consequence of Renal Inflammation?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 9. DOI: 10.3390/ijms20092205. IF: 3,687. Q2. Review. IMIBIC GROUPS: GE06	GE06

PUBLICATIONS	IMIBIC GROUP
Rubio-Navarro A, Vazquez-Carballo C, Guerrero-Hue M, Garcia-Caballero C, Herencia C, Gutierrez E, Yuste C, Sevillano A, Praga M, Egea J, Cannata P, Cortegano I, de Andres B, Gaspar ML, Cadenas S, Michalska P, Leon R, Ortiz A, Egido J, Moreno JA; Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. FRONTIERS IN PHARMACOLOGY. 10. DOI: 10.3389/fphar.2019.00740. IF: 3,845. Q1. Article. IMIBIC GROUPS: GE06	GE06
Chitnis GD, Verma MKS, Lamazouade J, Gonzalez-Andrades M, Yan K, Dergham A, Jones PA, Mead BE, Cruzat A, Tong ZX, Martyn K, Solanki A, Landon-Brace N, Karp JM; A resistance-sensing mechanical injector for the precise delivery of liquids to target tissue. NATURE BIOMEDICAL ENGINEERING. 3. 8. (621-631). DOI: 10.1038/s41551-019-0350-2. IF: 17,135. D1. Article. IMIBIC GROUPS: GE07	GE07
Islam MM, Sharifi R, Mamodaly S, Islam R, Nahra D, Abusamra DB, Hui PC, Adibnia Y, Goulamaly M, Paschalis EI, Cruzat A, Kong J, Nilsson PH, Argileso P, Mollnes TE, Chodosh J, Dohlman CH, Gonzalez-Andrades M; Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts. ACTA BIOMATERIALIA. 96. (330-344). DOI: 10.1016/j.actbio.2019.07.002. IF: 6,638. D1. Article. IMIBIC GROUPS: GE07	GE07
Sharifi R, Yang Y, Adibnia Y, Dohlman CH, Chodosh J, Gonzalez-Andrades M; Finding an Optimal Corneal Xenograft Using Comparative Analysis of Corneal Matrix Proteins Across Species. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-018-38342-4. IF: 4,011. Q1. Article. IMIBIC GROUPS: GE07	GE07
Rico-Sanchez L, Garzon I, Gonzalez-Andrades M, Ruiz-Garcia A, Punzano M, Lizana-Moreno A, Munoz-Avila JI, Sanchez-Quevedo MD, Martinez-Atienza J, Lopez-Navas L, Sanchez-Pernaute R, Oruezabal RI, Medialdea S, Gonzalez-Gallardo MD, Carmona G, Sanbonmatsu-Ga; Successful development and clinical translation of a novel anterior lamellar artificial cornea. JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. . DOI: 10.1002/term.2951. IF: 3,319. Q2. Article; Early Access. IMIBIC GROUPS: GE07	GE07
Lopez-Soto PJ, Fabbian F, Cappadona R, Zucchi B, Manfredini F, Garcia-Arcos A, Carmona-Torres JM, Manfredini R, Rodriguez-Borrego MA; Chronotype, nursing activity, and gender: A systematic review. JOURNAL OF ADVANCED NURSING. 75. 4. (734-748). DOI: 10.1111/jan.13876. IF: 2,376. Q1. Review. IMIBIC GROUPS: GE08	GE08
Cobo-Cuenca AI, Martin-Espinosa NM, Rodriguez-Borrego MA, Carmona-Torres JM; Determinants of satisfaction with life and self-esteem in women with breast cancer. QUALITY OF LIFE RESEARCH. 28. 2. (379-387). DOI: 10.1007/s11136-018-2017-y. IF: 2,488. Q1. Article. IMIBIC GROUPS: GE08	GE08
Carmona-Torres JM, Rodriguez-Borrego MA, Laredo-Aguilera JA, Lopez-Soto PJ, Santacruz-Salas E, Cobo-Cuenca AI; Disability for basic and instrumental activities of daily living in older individuals. PLOS ONE. 14. 7. DOI: 10.1371/journal.pone.0220157. IF: 2,776. Q2. Article. IMIBIC GROUPS: GE08	GE08
Granados NM, Abellan MV, Estepa MT, Diaz MMP, Pedraza RR; Frequent attendance in a Primary Health Care District. GACETA SANITARIA. 33. 1. (38-44). DOI: 10.1016/j.gaceta.2017.07.011. IF: 1,656. Q2. Article. IMIBIC GROUPS: Atención Primaria GC12 GE08	GE08
Lopez-Soto PJ, Morales-Cane I, Smolensky MH, Manfredini R, Dios-Guerra C, Rodriguez-Borrego MA, Carmona-Torres JM; Gender, socioeconomic, medical, and environmental factors related to domestic accidents of the elderly in Spain. Findings of a national survey. WOMEN & HEALTH. 59. 9. (985-996). DOI: 10.1080/03630242.2019.1587665. IF: 1,162. Q2. Article. IMIBIC GROUPS: GE08	GE08
Carmona-Torres JM, Cobo-Cuenca AI, Recio-Andrade B, Dios-Guerra C, Lopez-Soto PJ, Hidalgo-Lopezosa P, Rodriguez-Borrego MA; Health Professionals Who Suffer Intimate Partner Violence: A Descriptive, Multicenter, and Cross-Sectional Study. JOURNAL OF FORENSIC NURSING. 15. 1. (9-17). DOI: 10.1097/JFN.0000000000000231. IF: 0,642. Q4. Article. IMIBIC GROUPS: GE08	GE08
Manfredini F, Lamberti N, Guerzoni F, Napoli N, Gasbarro V, Zamboni P, Mascoli F, Manfredini R, Basaglia N, Rodriguez-Borrego MA, Lopez-Soto PJ; Rehabilitative Exercise Reduced the Impact of Peripheral Artery Disease on Vascular Outcomes in Elderly Patients with Claudication: A Three-Year Single Center Retrospective Study. JOURNAL OF CLINICAL MEDICINE. 8. 2. DOI: 10.3390/jcm8020210. IF: 5,688. D1. Article. IMIBIC GROUPS: GE08	GE08
Gonzalez-Gancedo J, Fernandez-Martinez E, Rodriguez-Borrego MA; Relationships among general health, job satisfaction, work engagement and job features in nurses working in a public hospital: A cross-sectional study. JOURNAL OF CLINICAL NURSING. 28. 43684. (1273-1288). DOI: 10.1111/jocn.14740. IF: 1,757. Q1. Article. IMIBIC GROUPS: GE08	GE08

PUBLICATIONS	IMIBIC GROUP
Lopez-Cerda E, Carmona-Torres JM, Rodriguez-Borrego MA; Social support for elderly people over 65 years in Spain. INTERNATIONAL NURSING REVIEW. 66. 1. (104-111). DOI: 10.1111/inr.12468. IF: 1,562. Q2. Article. IMIBIC GROUPS: GE08	GE08
Cobo-Cuenca AI, Laredo-Aguilera JA, Rodriguez-Borrego MA, Santacruz-Salas E, Carmona-Torres JM; Temporal Trends in Fecal Occult Blood Test: Associated Factors (2009-2017). INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 12. DOI: 10.3390/ijerph16122120. IF: 2,468. Q1. Article. IMIBIC GROUPS: GE08	GE08
Morales-Cane I, Lopez-Soto PJ, Rodriguez-Borrego MA; Tranexamic acid in trauma patients in the emergency department: systematic review and meta-analysis. EMERGENCIAS. 31. 4. (261-269). DOI: 0. IF: 3,35. Q1. Review. IMIBIC GROUPS: GE08	GE08
Lamberti N, Lopez-Soto PJ, Rodriguez-Borrego MA, Straudi S, Basaglia N, Zamboni P, Manfredini R, Manfredini F; Restless Leg Syndrome in Peripheral Artery Disease: Prevalence among Patients with Claudication and Benefits from Low-Intensity Exercise. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1403. DOI: 10.3390/jcm8091403. IF: 5,688. D1. Article. IMIBIC GROUPS: GE08	GE08
Munoz PMR, Torres JMC, Lopezosa PH, Cuenca AIC, Borrego MAR; Evolution of alcohol and tobacco consumption in young people in Spain, after the law 42/2010 against smoking: 2011-2014. ADICCIONES. 31. 4. (274-283). DOI: 10.20882/adicciones.1035. IF: 3,167. D2 Q1. Article. IMIBIC GROUPS: GE08	GE08
Manfredini R, Lamberti N, Manfredini F, Straudi S, Fabbian F, Borrego MAR, Basaglia N, Torres JMC, Soto PJL; Gender Differences in Outcomes Following a Pain-Free, Home-Based Exercise Program for Claudication. JOURNAL OF WOMENS HEALTH. DOI: 10.1089/jwh.2018.7113. IF: 2,09. D2 Q1. Article. IMIBIC GROUPS: GE08	GE08
Laredo-Aguilera JA, Cobo-Cuenca AI, Santacruz-Salas E, Martins MM, Rodriguez-Borrego MA, Lopez-Soto PJ, Carmona-Torres JM; Levels of Physical Activity, Obesity and Related Factors in Young Adults Aged 18-30 During 2009-2017. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 16. 20. 4033. DOI: 10.3390/ijerph16204033. IF: 2,468. D3 Q1. Article. IMIBIC GROUPS: GE08	GE08
Hidalgo-Lopezosa P, Jimenez-Ruz A, Carmona-Torres JM, Hidalgo-Maestre M, Rodriguez-Borrego MA, Lopez-Soto PJ; Sociodemographic factors associated with preterm birth and low birth weight: A cross-sectional study. WOMEN AND BIRTH. 32. 6. (E538-E543). DOI: 10.1016/j.wombi.2019.03.014. IF: 2,079. D2 Q1. Article. IMIBIC GROUPS: GE08	GE08
Fabbian F, Verzola A, Napoli N, De Giorgi A, Comai G, La Manna G, Gallerani M, Manfredini R, Rodriguez-Borrego MA, Lopez-Soto PJ; Impact of hospital admissions subsequent to renal transplantation on Italian regional resources: a retrospective study in the Italian region of Emilia-Romagna. MINERVA UROLOGICA E NEFROLOGICA. 71. 6. (612-618). DOI: 10.23736/S0393-2249.19.03280-6. IF: 2,477. Q2. Article. IMIBIC GROUPS: GE08	GE08
Helmy R, de Almeida SS, Denhaerynck K, Berben L, Dobbels F, Russell CL, Roza BD, De Geest S, Crespo-Leiro MG, Guppies S, De Simone P, Groenewoud A, Kugler C, Ohler L, Van Cleemput J, Poncelet AJ, Sebbag L, Michel M, Bernard A, Doesch A, Livi U, Potena L, ; Prevalence of Medication Nonadherence to Co-medication Compared to Immunosuppressants in Heart Transplant Recipients: Findings From the International Cross-sectional BRIGHT Study. CLINICAL THERAPEUTICS. 41. 1. (130-136). DOI: 10.1016/j.clinthera.2018.11.007. IF: 2,932. Q2. Article. IMIBIC GROUPS: GC09, Cardiología	Cardiology Unit
del Pino MDL, Ortiz MR, Ortega MD, Fernandez JS, Quero CF, Jimenez ED, Moreno MR, Saint-Gerons JS, Pineda SO, Pan Alvarez-Ossorio M, Rubio DM; Prosthesis-patient mismatch after transcatheter aortic valve replacement: prevalence and medium term prognostic impact. INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING. 35. 5. (827-836). DOI: 10.1007/s10554-018-01519-z. IF: 1,86. Q3. Article. IMIBIC GROUPS: Cardiología GC15	Cardiology Unit
Romero R, Gaytan JM, Aguirre A, Llorens P, Gil V, Herrero P, Jacob J, Martin-Sanchez FJ, Perez-Dura MJ, Alquezar A, Lopez ML, Roset A, Peacock WF, Hollander JE, Coll-Vinent B, Miro O, Fuentes M, Gil C, Alonso H, Garmila P, Martin-Sanchez FJ, Garcia GL, Ya; The role of atrial fibrillation in the short-term outcomes of patients with acute heart failure. CLINICAL RESEARCH IN CARDIOLOGY. 108. 6. (622-633). DOI: 10.1007/s00392-018-1389-x. IF: 4,907. Q1. Article. IMIBIC GROUPS: Cardiología	Cardiology Unit

PUBLICATIONS	IMIBIC GROUP
Nordmeyer J, Ewert P, Gewillig M, AlJufan M, Carminati M, Kretschmar O, Uebing A, Dahnert I, Rohle R, Schneider H, Witsenburg M, Benson L, Gitter R, Bokenkamp R, Mahadevan V, Berger F, Aggoun Y, Agnoletti G, Baumgartner H, de Lezo JS, Sofia R, Dessy H, De; Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation. EUROPEAN HEART JOURNAL. . DOI: 10.1093/eurheartj/ehz201. IF: 24,889. D1. Article. IMIBIC GROUPS: Cardiología	Cardiology Unit
Azzalini L, Poletti E, Ayoub M, Ojeda S, Zivelonghi C, La Manna A, Bellini B, Lostalo A, Luque A, Venuti G, Montorfano M, Agostoni P, Pan M, Carlino M, Mashayekhi K; Coronary artery perforation during chronic total occlusion percutaneous coronary intervention: epidemiology, mechanisms, management, and outcomes. EUROINTERVENTION. 15. 9. (E804-+-). DOI: 10.4244/EIJ-D-19-00282. IF: 4,018. Q2. Article. IMIBIC GROUPS: GC15 Cardiología	Cardiology Unit
Ruiz-Ortiz M, Rodriguez-Diego S, Delgado M, Kim J, Weinsaft JW, Ortega R, Carnero L, Sanchez JJ, Carrasco F, Lopez-Aguilera J, Lopez-Granados A, Arizon JM, Paredes N, Oneto-Fernandez J, Pan M, Mesa D; Myocardial deformation and acute cellular rejection after heart transplantation: Impact of inter-vendor variability in diagnostic effectiveness. ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES. 36. 12. (2185-2194). DOI: 10.1111/echo.14544. IF: 1,287. Q4. Article; Early Access. IMIBIC GROUPS: GC15 Cardiología GC14	Cardiology Unit
Gonzalez-Vilchez F, Almenar-Bonet L, Crespo-Leiro MG, Segovia-Cubero J, Gonzalez-Costello J, del Prado JMA, Sousa-Casasnovas I, Sobrino-Marquez JM, Delgado-Jimenez J, Perez-Villa F, Gomez-Buena M, Hernandez-Perez F, Martinez-Penades S, Cebrian-Pinar M, Lo; Spanish Heart Transplant Registry. 30th Official Report of the Spanish Society of Cardiology Working Group on Heart Failure (1984-2018). REVISTA ESPAÑOLA DE CARDIOLOGIA. 72. 11. (954-962). DOI: 10.1016/j.rec.2019.09.005. IF: 5,078. D2 Q1. Article. IMIBIC GROUPS: GC15 Cardiología	Cardiology Unit
Romero M, Suarez-de-Lezo J, Herrera C, Pan M, Lopez-Aguilera J, Suarez-de-Lezo J, Baeza-Garzon F, Hidalgo-Lesmes FJ, Fernandez-Lopez O, Martinez-Atienza J, Cebrian E, Martin-Palanco V, Jimenez-Moreno R, Gutierrez-Fernandez R, Nogueras S, Carmona MD, Ojeda S, Cuende N, Mata R; Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol. BMC CARDIOVASCULAR DISORDERS. 19. 1. DOI: 10.1186/s12872-019-1182-4. IF: 1,947. Q3. Article. IMIBIC GROUPS: GC15 Cardiología GC14	Cardiology Unit
Sandubete EJC, de la Blanca EBP, del Rio CAO, Olmo RS, Mendoza ML, Martinez MB, Infante CM, Marin-Leon I, de la Paz MP, Castellano PG, Blanes JRG, Navarro EG, Rodriguez ML, Arduan AO, Guzman JD, Martinez PL, Villalba JC, Perez JMC; Spanish multidisciplinary clinical practice guidelines for Anderson-Fabry Disease in Adults. I. Method and recommendations. REVISTA CLINICA ESPAÑOLA. 219. 4. (200-207). DOI: 10.1016/j.rce.2018.09.017. IF: 1,043. Q3. Article. IMIBIC GROUPS: GC07 Análisis Clínicos	Clinical Analysis Unit
Xiol C, Vidal S, Pascual-Alonso A, Blasco L, Brandi N, Pacheco P, Gerotina E, O'Callaghan M, Pineda M, Armstrong J. (Rett Working Group: Aguirre, FJ; Aleu, M; Alonso, X; Alsius, M; Amoros, M; Antinolo, G; Aquino, L; Arellano, C; Arriola, G; Arteaga, R; Ba; X chromosome inactivation does not necessarily determine the severity of the phenotype in Rett syndrome patients. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-48385-w. IF: 4,011. Q2. Article. IMIBIC GROUPS: GE01, análisis clínicos	Clinical Analysis Unit
Leon-Acuna A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, Roncero-Ramos I, Yubero-Serrano E, Tinahones FJ, Castro-Clerico M, Delgado-Lista J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study. ATHEROSCLEROSIS. 290. (118-124). DOI: 10.1016/j.atherosclerosis.2019.09.025. IF: 4,255. D2 Q1. Article. IMIBIC GROUPS: GC09 Análisis Clínicos GC27	Clinical Analysis Unit
Frias M, Rivero-Juarez A, Tellez F, Palacios R, Jimenez-Arranz A, Pineda JA, Merino D, Gomez-Vidal MA, Perez-Camacho I, Camacho A, Rivero A; Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. SCIENTIFIC REPORTS. 9. DOI: 10.1038/s41598-019-48966-9. IF: 4,011. Q1. Article. IMIBIC GROUPS: GC26 Unidad Genómica Imibic	Core Facilities Genomics
Pozo-Laderas JC, Rodriguez-Peralvarez M, Munoz-Villanueva MC, Rivera-Espinar F, Durban-Garcia I, Munoz-Trujillo J, Robles-Arista JC, Briceno-Delgado J; Pretransplant predictors of early mortality in adult recipients of liver transplantation in the MELD-Na Era. MEDICINA INTENSIVA. 43. 5. (261-269). DOI: 10.1016/j.medin.2018.03.008. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC18 Medicina Intensiva GC02 GC18 Unidad Metodología y Estadistica Imibic	Core Facilities Methodology and Statistics

PUBLICATIONS	IMIBIC GROUP
Michan C, Chicano-Galvez E, Fuentes-Almagro CA, Alhama J; Redox and global interconnected proteome changes in mice exposed to complex environmental hazards surrounding Donana National Park. ENVIRONMENTAL POLLUTION. 252. A. (427-439). DOI: 10.1016/j.envpol.2019.05.085. IF: 5,714. D1. Article. IMIBIC GROUPS: U Proteómica Imibic	Core Facilities Proteomics
Bohme K, Calo-Mata P, Barros-Velazquez J, Ortea I; Review of Recent DNA-Based Methods for Main Food-Authentication Topics. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY. 67. 14. (3854-3864). DOI: 10.1021/acs.jafc.8b07016. IF: 3,571. D1. Review. IMIBIC GROUPS: Unidad Proteómica Imibic	Core Facilities Proteomics
Garrido-Rodriguez M, Ortea I, Calzado MA, Munoz E, Garcia V; SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. JOURNAL OF PROTEOMICS. 193. (217-229). DOI: 10.1016/j.jprot.2018.10.012. IF: 3,537. Q1. Article. IMIBIC GROUPS: GC04 Unidad Proteómica Imibic	Core Facilities Proteomics
Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A; SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 0. DOI: 10.1111/jcmm.14693. IF: 4,658. Q1. Article; Early Access. IMIBIC GROUPS: GC06 Cirugía General y Digestiva U Proteómica Imibic	Core Facilities Proteomics
Gonzalez-Fernandez MJ, Fabrikov D, Ramos-Bueno RP, Guil-Guerrero JL, Ortea I; SWATH Differential Abundance Proteomics and Cellular Assays Show In Vitro Anticancer Activity of Arachidonic Acid- and Docosahexaenoic Acid-Based Monoacylglycerols in HT-29 Colorectal Cancer Cells. NUTRIENTS. 11. 12. DOI: 10.3390/nu11122984. IF: 4,171. D2 Q1. Article. IMIBIC GROUPS: Unidad Proteómica Imibic	Core Facilities Proteomics
Pereyra-Rodriguez JJ, Dominguez-Cruz JJ, Hernandez-Montoya C, Galan-Gutierrez M, Carrasco PM, Luna SA, Navarro-Trivino FJ, del Pozo J, Ruiz-Villaverde R; Entwicklung und Validierung eines Fragebogens zur Messung des Empowerments bei erwachsenen Patienten mit atopischer Dermatitis. Der DATEMP-Fragebogen. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 17. 9. (923-932). DOI: 10.1111/ddg.13934_g. IF: 3,924. Q1. Article. IMIBIC GROUPS: Dermatología	Dermatology Unit
Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellan M, Notario J, Soria C, Belinchon I, de la Cueva P, Ferran M, Carrascosa JM, Gomez FJ, Salgado L, Velasco M, Descalzo MA, Garcia-Doval I, Dauden E, Carretero G, Torrado R, Ferrandiz C, Llamas-Ve; Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. JOURNAL OF DERMATOLOGICAL TREATMENT. 30. 5. (461-465). DOI: 10.1080/09546634.2018.1535690. IF: 2,144. Q2. Article. IMIBIC GROUPS: Dermatología	Dermatology Unit
Mena-Bares LM, Benitez-Cantero JM, Iglesias-Flores E, Gros-Alcalde B, Moreno-Ortega E, Maza-Muret FR, Carmona-Asenjo E, Garcia-Sanchez MV, Vallejo-Casas JA; Bile acid malabsorption in patients with chronic diarrhea and Crohn's disease. REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS. 111. 1. (40-44). DOI: 10.17235/reed.2018.5376/2017. IF: 1,858. Q4. Article. IMIBIC GROUPS: GA10 GC02 Medicina Ap Digestivo	Digestive System Medicine Unit
Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M; mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 2. DOI: 10.3390/ijms20020336. IF: 4,183. Q2. Article. IMIBIC GROUPS: GC02 Medicina Ap Digestivo GC18 Cirugía General y Digestiva Anatomía Patológica GC08	Digestive System Medicine Unit
Jacob J, Llauger L, Herrero-Puente P, Martin-Sanchez FJ, Llorens P, Roset A, Gil V, Fuentes M, Lucas-Imbernon FJ, Miro O. (ICASEMES-Research Group: Gil, C; Alonso, H; Perez-Llantada, E; Llopis-Garcia, G; Santos-Matallana, MC; Barrenechea-Moxo, MLD; Salgad; Acute heart failure and adverse events associated with the presence of renal dysfunction and hyperkalaemia. EAHFE- renal dysfunction and hyperkalaemia. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 67. (89-96). DOI: 10.1016/j.ejim.2019.07.010. IF: 3,66. Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit

PUBLICATIONS	IMIBIC GROUP
Miro O, Rossello X, Gil V, Martin-Sanchez FJ, Llorens P, Herrero-Puente P, Jacob J, Pinera P, Mojarro EM, Lucas-Imbernon FJ, Llauger L, Aguera C, Lopez-Diez MP, Valero A, Bueno H, Pocock SJ, Gil MF, Salvo E, Escoda R, Aguilo S, Xipell C, Sanchez C, Gaytan; Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSI-AHF Scale. ANNALS OF EMERGENCY MEDICINE. 74. 2. (204-215). DOI: 10.1016/j.annemergmed.2019.03.010. IF: 5,209. D1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Yanez MC, Mota MS, Ferrer MF, Julian-Jimenez A, Pinera P, Llopis F, del Rio JG, de Zarate MMO, Estella A, Martin-Sanchez FJ, del Castillo JG, Puente PH, Diaz RR, Olmeda DM, Izquierdo RL, Nicolas JAS, Hurtado AAA, Vegas CD, Bautista JG, Candel FJ, Echebarr; Comparison of different strategies for short-term death prediction in the infected older patient. REVISTA ESPAÑOLA DE QUIMIOTERAPIA. 32. 2. (156-164). DOI: 0. IF: 0,76. Q4. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Aguera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Pena J; Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE. 8. 1. (23-31). DOI: 10.1016/j.jshs.2017.05.007. IF: 3,644. Q1. Article. IMIBIC GROUPS: GE01 GE01 Urgencias GC12	Emergencies Unit
Miro O, Sarasola AG, Fuenzalida C, Calderon S, Jacob J, Aguirre A, Wu D, Rizzi MA, Malchair P, Haro A, Herrera S, Gil V, Martin-Sanchez FJ, Llorens P, Puente PH, Bueno H, Rodriguez AD, Muller CE, Mebazaa A, Chioncel O, Alquezar-Arbe A. (ICA-SEMES Research; Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. EUROPEAN JOURNAL OF HEART FAILURE. 0. DOI: 10.1002/ejhf.1567. IF: 13,965. D1. Article; Early Access. IMIBIC GROUPS: Urgencias	Emergencies Unit
Rossello X, Gil V, Escoda R, Jacob J, Aguirre A, Martin-Sanchez FJ, Llorens P, Puente PH, Rizzi M, Raposeiras-Roubin S, Wussler D, Muller CE, Gayat E, Mebazaa A, Miro O. (ICA-SEMES Research Group: Fuentes, M; Gil, C; Alonso, H; Perez-Llantada, E; Martin-S; Impact of identifying precipitating factors on 30-day mortality in acute heart failure patients. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE. 0. DOI: 10.1177/2048872619869328. IF: 3,734. Q2. Article; Early Access. IMIBIC GROUPS: Urgencias	Emergencies Unit
Miro O, Gil V, Rossello X, Martin-Sanchez FJ, Llorens P, Jacob J, Herrero P, Mateo SH, Richard F, Escoda R, Fuentes M, Mojarro EM, Llauger L, Bueno H, Pocock S, Gil C, Garmila P, Adrada ER, Perdigones J, Escobar L, Xipell C, Sanchez C, Gaytan JM, Perez-Du; Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESSI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability. EMERGENCIAS. 31. 1. (5-14). DOI: 0. IF: 3,35. Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Llorens P, Javaloyes P, Masip J, Gil V, Herrero-Puente P, Martin-Sanchez FJ, Jacob J, Garrido JM, Herrera-Mateo S, Diez MPL, Concepcion-Aramendia L, Miro O, Fuentes M, Gil C, Alonso H, Perez-Llantada E, Garcia GL, Cadenas MS, Escoda R, Xipell C, Sanchez C; Prognostic value of chest radiographs in patients with acute heart failure: the Radiology in Acute Heart Failure (RAD-ICA) study. EMERGENCIAS. . DOI: 0. IF: 3,35. Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, Takagi K, Alquezar-Arbe A, Diez MPL, Martin E, Bibiano C, Escoda R, Gil C, Fuentes M, Garcia GL, Perez JMA, Jerez A, Tost J, Llauger L, Romero R, Garrido JM, Rodriguez-Adrada E, Sanchez C, Rossello X, Parissis J, Mebazaa A, Chioncel O, Llorens P. ICA-SEMES Research Group: Alonso, H; Perez-Llantada, E; Cadenas, MS; Xipell, C; Perez-Dura, MJ; Salvo, E; Pavon, J; Noval, A; Torres, JM; Lopez-Grima, ML; Valero, A; Juan, MA; Aguirre, A; Pedragosa, MA; Maso, SM; Alonso, MI; Ruiz, F; Franco, JM; Mecina, AB; Berenguer, M; Donea, R; Ramon, SS; Rodriguez, VC; Pinera, P; Nicolas, JAS; Garate, RT; Rizzi, MA; Herrera, S; Cabello, I; Haro, A; Richard, F; Diez, MPL; Alvarez, JV; Garcia, BP; Garcia, MG; Gonzalez, MS; Marquina, V; Jimenez, I; Hernandez, N; Brouzet, B; Espinosa, B; Andueza, JA; Ruiz, M; Calvache, R; Serralta, MTL; Jave, LEC; Arriaga, BA; Bergua, BS; Mojarro, EM; Jimenez, BSA; Becquer, LT; Burillo, G; Garcia, LL; LaSalle, GC; Urbano, CA; Soto, ABG; Padial, ED; Ferrer, ES; Lucas-Imbernon, FJ; Gaya, R; Mir, M; Rodriguez, B; Carballo, JL; Miranda, BR; Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. EUROPEAN JOURNAL OF HEART FAILURE. 21. 11. (1353-1365). DOI: 10.1002/ejhf.1502. IF: 12,129. D1 Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit

PUBLICATIONS	IMIBIC GROUP
Rossello X, Miro O, Llorens P, Jacob J, Herrero-Puente P, Gil V, Rizzi MA, Perez-Dura MJ, Espiga FR, Romero R, Sevillano JA, Vidan MT, Bueno H, Pocock SJ, Martin-Sanchez FJ, Fuentes M, Gil C, Alonso H, Garmila P, Adrada ER, Garcia GL, Yanez-Palma MC, Lopez SI, Escoda R, Xipell C, Sanchez C, Gaytan JM, Perez-Dura MJ, Salvo E, Pavon J, Noval A, Torres JM, Lopez-Grima ML, Valero A, Juan MA, Aguirre A, Morales JE, Mas SM, Alonso MI, Ruiz F, Franco JM, Diaz E, Mecina AB, Tost J, Sanchez S, Carbajosa V, Pinera P, Nicolas JAS, Garate RT, Alquezar A, Rizzi MA, Herrera S, Roset A, Cabello I, Richard F, Perez JMA, Diez MPL, Alvarez JV, Morilla AA, Irimia A, Javaloyes P, Marquina V, Jimenez I, Hernandez N, Brouzet B, Ramos S, Lopez A, Andueza JA, Sevillano JA, Calvache R, Lorca MT, Calderon L, Arriaga BA, Sierra B, Mojarro EM, Becquer LT, Burillo G, Garcia LL, LaSalle GC, Urbano CA, Garcia AB, Padial SED, Ferrer ES, Garrido M, Lucas FJ, Gaya R; Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. ANNALS OF EMERGENCY MEDICINE. 73. 6. (589-598). DOI: 10.1016/j.annemergmed.2018.12.009. IF: 5,209. D1 Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Miro O, Padrosa J, Takagi K, Gayat E, Gil V, Llorens P, Martin-Sanchez FJ, Herrero-Puente P, Jacob J, Montero MM, Tost J, Diez MPL, Traveria L, Torres-Garate R, Alonso MI, Aguera C, Valero A, Javaloyes P, Peacock WF, Bueno H, Mebazaa A. ICA-SEMES Research Group: Fuentes, M; Gil, C; Alonso, H; Garmila, P; Garcia, GL; Yanez-Palma, MC; Lopez, SI; Escoda, R; Xipell, C; Sanchez, C; Gaytan, JM; Perez-Dura, MJ; Salvo, E; Pavon, J; Noval, A; Torres, JM; Lopez-Grima, ML; Juan, MA; Aguirre, A; Morales, JE; Maso, SM; Ruiz, F; Franco, JM; Mecina, AB; Sanchez, S; Carbajosa, V; Pinera, P; Nicolas, JAS; Garate, RT; Alquezar, A; Rizzi, MA; Herrera, S; Roset, A; Cabello, I; Richard, F; Perez, JMA; Alvarez, JV; Garcia, BP; Gonzalez, MGGYS; Marquina, V; Jimenez, I; Hernandez, N; Brouzet, B; Ramos, S; Lopez, A; Andueza, JA; Romero, R; Ruiz, M; Calvache, R; Lorca, MT; Calderon, L; Arriaga, BA; Sierra, B; Mojarro, EM; Becquer, LT; Burillo, G; Garcia, LL; LaSalle, GC; Urbano, CA; Soto, ABG; Padial, ED; Ferrer, ES; Garrido, M; Lucas, FJ; Gaya, R; Bibiano, C; Mir, M; Rodriguez, B; Sanchez, N; Carballo, JL; Rodriguez-Adrada, E; Rodriguez, B; Influence of the length of hospitalisation in post-discharge outcomes in patients with acute heart failure: Results of the LOHRCA study. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 70. (24-32). DOI: 10.1016/j.ejim.2019.08.007. IF: 3,66. D2 Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Miro O, Martin-Sanchez FJ, Jacob J, Herrero-Puente P, Gil V, Llorens P. Grupo de Investigación ICA-SEMES: Fuentes, M; Gil, C; Alonso, H; Perez-Llantada, E; Garcia, GL; Cadenas, MS; Escoda, R; Xipell, C; Sanchez, C; Jerez, A; Perez-Dura, MJ; Salvo, E; Pavon, J; Noval, A; Torres, JM; Lopez-Grima, ML; Valero, A; Juan, MA; Aguirre, A; Pedragosa, MA; Maso, SM; Alonso, MI; Ruiz, F; Franco, JM; Mecina, AB; Tost, J; Berenguer, M; Donea, R; Ramon, SS; Rodriguez, VC; Pinera, P; Nicolas, JAS; Garate, RT; Alquezar-Arbe, A; Rizzi, MA; Herrera, S; Roset, A; Cabello, I; Haro, A; Richard, F; Perez, JMA; Diez, MPL; Puente, PH; Alvarez, JV; Garcia, BP; Garcia, MG; Gonzalez, MS; Javaloyes, P; Marquina, V; Jimenez, I; Hernandez, N; Brouzet, B; Espinosa, B; Gil, A; Andueza, JA; Romero, R; Ruiz, M; Calvache, R; Serralta, MTL; Jave, LEC; Arriaga, BA; Bergua, BS; Mojarro, EM; Jimenez, BSA; Becquer, LT; Burillo, G; Garcia, LL; La-Salle, GC; Urbano, CA; Soto, ABG; Padial, ED; Ferrer, ES; Garrido, JM; Lucas-Imbernon, FJ; Gaya, R; Bibiano, C; Mir, M; Rodriguez, B; Carballo, JL; Rodriguez-Adrada, E; Miranda, BR; Martin, MV; Casanova, PC; Alvaos, JE; Sacubitril/valsartan-treated patients with exacerbated acute heart failure: approaches to care in the emergency department and on the ward. EMERGENCIAS. 31. 6. (407-412). DOI: 0. IF: 3,35. D2 Q1. Article. IMIBIC GROUPS: Urgencias	Emergencies Unit
Wanden-Berghe C, Campos C, Burgos R, Alvarez J, Frias L, Matia P, Lobo G, Roman DD, Gonzalo M, Candela CG, Olmos MAM, Calleja BP, Luengo LM, Santacruz N, Rocamora JAI, Higuera I, Padin S, Leyes P, Sanchez R, Cardona D, Martin MA, Ballesta C, Suarez JP, Te; Spanish home enteral nutrition registry of the year 2016 and 2017 from the NADYA-SENPE Group. NUTRICION HOSPITALARIA. 36. 1. (233-237). DOI: 10.20960/nh.02365. IF: 0,759. Q4. Article. IMIBIC GROUPS: Endocrinología	Endocrinology Unit
Arjona-Sanchez A, Esquivel J, Glehen O, Passot G, Turaga KK, Labow D, Rufian-Pena S, Morales R, van der Speeten K; A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 33. 3. (854-860). DOI: 10.1007/s00464-018-6352-4. IF: 3,209. Q1. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18	General and Digestive Surgery Unit
Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Rufian-Pena S, Casado-Adam A, Cosano-Alvarez A, Briceno-Delgado J; Colorectal peritoneal metastases: Optimal management review. WORLD JOURNAL OF GASTROENTEROLOGY. 25. 27. (3484-3502). DOI: 10.3748/wjg.v25.i27.3484. IF: 3,411. Q2. Review. IMIBIC GROUPS: Cirugía General y Digestiva GC18	General and Digestive Surgery Unit

PUBLICATIONS	IMIBIC GROUP
Manzanedo I, Pereira F, Caro CR, Perez-Viejo E, Serrano A, Calvo AG, Regueira FM, Casado-Adam A, Cascales-Campos PA, Arteaga X, Garcia-Fadrique A, Sanz RG, Garcia AL, Zozaya G, Arjona A, Martinez JG; Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). ANNALS OF SURGICAL ONCOLOGY. 26. 8. (2615-2621). DOI: 10.1245/s10434-019-07450-4. IF: 3,681. Q1. Article. IMIBIC GROUPS: Cirugía General y Digestiva	General and Digestive Surgery Unit
Briceno J, Ciria R, Lopez P, Luque A, Arjona-Sanchez A, Sanchez-Hidalgo JM, Ayllon MD, Gomez-Luque I, Gomez J; Laparoscopic Living Donor Hepatectomy for Pediatric Liver Transplantation: the First 7 Cases in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (56-57). DOI: 10.1016/j.transproceed.2018.03.140. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	General and Digestive Surgery Unit
Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M; mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 2. DOI: 10.3390/ijms20020336. IF: 4,183. Q2. Article. IMIBIC GROUPS: GC02 Medicina Ap Digestivo GC18 Cirugía General y Digestiva GC18 Anatomía Patológica GC08	General and Digestive Surgery Unit
Briceno J, Ciria R, Gomez-Luque I; Planning Generational Change in a Liver Transplant Team. TRANSPLANTATION PROCEEDINGS. 51. 1. (71-73). DOI: 10.1016/j.transproceed.2018.04.091. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	General and Digestive Surgery Unit
Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, Schneider MA, Gutierrez-Calvo A, Garcia-Fadrique A, Tuynman JB, Cascales-Campos PA, Martin VC, Morales R, Salti GI, Arteaga X, Pacheco D, Alonso-Gomez J, Yalkin O, Villarejo-Campos P, Sanchez-Hidalgo JM, Cas; RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. ANNALS OF SURGICAL ONCOLOGY. 26. 8. (2595-2604). DOI: 10.1245/s10434-019-07378-9. IF: 3,857. D1. Article. IMIBIC GROUPS: GC18 Cirugía General y Digestiva	General and Digestive Surgery Unit
Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Rob; Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (20-24). DOI: 10.1016/j.transproceed.2018.04.092. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva Anatomía Patológica GC14 Medicina Intensiva GC18	General and Digestive Surgery Unit
Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Ayllon-Teran MD, Gomez-Luque I, Ciria-Bru R, Luque-Molina A, Lopez-Cillero P, Rufian-Pena S, Briceno-Delgado J; Super-rapid Technique in Donation After Circulatory Death Liver Donors: Advantages and Disadvantages. TRANSPLANTATION PROCEEDINGS. 51. 1. (25-27). DOI: 10.1016/j.transproceed.2018.05.034. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: Cirugía General y Digestiva GC18	General and Digestive Surgery Unit
Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A; SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 0. DOI: 10.1111/jcmm.14693. IF: 4,658. Q1. Article; Early Access. IMIBIC GROUPS: GC06 Cirugía General y Digestiva GC06 U Proteómica Imibic	General and Digestive Surgery Unit
Ayllon MD, Ciria R, Gomez-Luque I, Rodriguez-Peralvarez M, Padial A, Luque A, Lopez-Cillero P, de la Mata M, Briceno J; Use of Peritoneovenous Shunt for the Management of Refractory Ascites. TRANSPLANTATION PROCEEDINGS. 51. 1. (41-43). DOI: 10.1016/j.transproceed.2018.04.089. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GC02	General and Digestive Surgery Unit
del-Pino-Casado R, Serrano-Ortega N, Lopez-Martinez C, Orgeta V; Coping strategies and psychological distress in family carers of frail older people: A longitudinal study. JOURNAL OF AFFECTIVE DISORDERS. . DOI: 10.1016/j.jad.2019.06.038. IF: 4,084. Q1. Article. IMIBIC GROUPS: Cirugía General y Digestiva (enfermera)	General and Digestive Surgery Unit
Lopez-Martinez C, Serrano-Ortega N, Moreno-Camara S, del-Pino-Casado R; Association between Sense of Coherence and Mental Health in Caregivers of Older Adults. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. . DOI: 10.3390/ijerph16203800. IF: 2,468. D3 Q1. Article. IMIBIC GROUPS: Cirugía General y Digestiva (enfermería)	General and Digestive Surgery Unit

PUBLICATIONS	IMIBIC GROUP
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J; Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 19. 11. (1388-1398). DOI: 10.2174/1871520619666190417162409. IF: 2,18. Q3. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18 GE01 GC02	General and Digestive Surgery Unit
Arjona-Sanchez A, Duran M, Sanchez-Hidalgo JM, Rufian-Pena S; Peritoneal carcinomatosis from ovarian carcinoma treated by interval laparoscopic complete cytoreduction and HIPEC with extraction through natural orifice. SURGICAL ONCOLOGY-OXFORD. 31. (14-15). DOI: 10.1016/j.suronc.2019.08.005. IF: 3. Q1. Article. IMIBIC GROUPS: Cirugía General y Digestiva GC18	General and Digestive Surgery Unit
Mendoza N, Diaz-Ropero MP, Aragon M, Maldonado V, Llaneza P, Lorente J, Mendoza-Tesarik R, Maldonado-Lobon J, Olivares M, Fonolla J; Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. GYNECOLOGICAL ENDOCRINOLOGY. 35. 8. (695-700). DOI: 10.1080/09513590.2019.1576620. IF: 1,406. Q4. Article. IMIBIC GROUPS: Ginecología	Gynecology Unit
Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, Garcia E, Hemmati P, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, de la Calle GM, Manzur A, Marin JI, Marquez-Gomez I, Martin-Davila P, Mikulska M, Mon; Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ OPEN. 9. 5. DOI: 10.1136/bmjopen-2018-025744. IF: 2,413. Q2. Article. IMIBIC GROUPS: GC16 GC03 Hematología	Hematology Unit
Almazan MM, Perez JMD, Pozo JFM, Granados ALO, De Fuentes BM, Sanz PQ, Sanchez AIG, Gomez PR, Garcia JMJ, Rodriguez-Hermida FA, Bautista MJM, Ramos AR, Rodriguez BM, Diaz MCM, Guindo PN, Siles MG, Roldan RV, Morales JCR, Criado SMA, Roldan UB, Rueda AI, M; A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 41. 1. (272-279). DOI: 10.1007/s11096-018-0772-z. IF: 1,692. Q4. Article. IMIBIC GROUPS: Farmacia Hospitalaria	Hospital Pharmacy Unit
Palacios-Baena ZR, Delgado-Valverde M, Mendez AV, Almirante B, Gomez-Zorrilla S, Borrell N, Corzo JE, Gurgui M, de la Calle C, Garcia-Alvarez L, Ramos L, Gozalo M, Morosini MI, Molina J, Causse M, Pascual A, Rodriguez-Bano J, de Cueto M, Reig AMP, Quintan; Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. CLINICAL INFECTIOUS DISEASES. 69. 6. (956-962). DOI: 10.1093/cid/ciy1032. IF: 9,055. D1. Article. IMIBIC GROUPS: Enfermedades Infecciosas GC03 GC24	Infectious Diseases Unit
Kotfis K, Wittebole X, Jaschinski U, Sole-Violan J, Kashyap R, Leone M, Nanchal R, Fontes LE, Sakr Y, Vincent JL, Tomas E, Bibonge EA, Charra B, Faroudy M, Doedens L, Farina Z, Adler D, Balkema C, Kok A, Alaya S, Gharsallah H, Muzha D, Temelkov A, Georgie; A worldwide perspective of sepsis epidemiology and survival according to age: Observational data from the ICON audit. JOURNAL OF CRITICAL CARE. 51. (122-132). DOI: 10.1016/j.jcrc.2019.02.015. IF: 2,783. Q2. Article. IMIBIC GROUPS: Distrito Sur. Medicina Intensiva. Hosp Infanta Margarita Cabra	Intensive Medicine Unit
Ferron FR, Simon JMS; Conventional monitoring is not sufficient to assess respiratory effort during assisted ventilation. MEDICINA INTENSIVA. 43. 4. (197-206). DOI: 10.1016/j.medin.2018.02.015. IF: 1,982. Q3. Article. IMIBIC GROUPS: Medicina Intensiva	Intensive Medicine Unit
Machuca I, Gutierrez-Gutierrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Perez E, Perez-Nadales E, Caston JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual A, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J, Salamanca E, ; External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 54. 4. (442-448). DOI: 10.1016/j.ijantimicag.2019.07.017. IF: 4,615. Q1. Article. IMIBIC GROUPS: GC26 GC03 Medicina Intensiva GC24	Intensive Medicine Unit
Delgado F, Oteros R, Jimenez-Gomez E, Rey IB, Bautista MD, Moyano RV; Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment. JOURNAL OF NEUROINTERVENTIONAL SURGERY. 11. 2. (147-152). DOI: 10.1136/neurintsurg-2018-014163. IF: 3,526. Q1. Article. IMIBIC GROUPS: GA08 Radiodiagnóstico Medicina Intensiva Neurología	Intensive Medicine Unit

PUBLICATIONS	IMIBIC GROUP
Porcar MJB, Cubillo BR, Dominguez-Roldan JM, Rocha LA, Sanz B, Montes MC, Fernandez MC, Garcia JHD, Giraudo PE, Mateos AGDY, Lopez RG, Pavon RG, Sanchez FL, Llompart-Pou JA, Montenegro SL, Collado ZM, Galleymore PR, Vilaboa MR, Corral AS, Herrera-Gutierre; Practical document on the management of hyponatremia in critically ill patients. MEDICINA INTENSIVA. 43. 5. (302-316). DOI: 10.1016/j.medin.2018.12.002. IF: 1,982. Q3. Article. IMIBIC GROUPS: Medicina Intensiva	Intensive Medicine Unit
Pozo-Laderas JC, Rodriguez-Peralvarez M, Munoz-Villanueva MC, Rivera-Espinar F, Durban-Garcia I, Munoz-Trujillo J, Robles-Arista JC, Briceno-Delgado J; Pretransplant predictors of early mortality in adult recipients of liver transplantation in the MELD-Na Era. MEDICINA INTENSIVA. 43. 5. (261-269). DOI: 10.1016/j.medin.2018.03.008. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC18 Medicina Intensiva GC02 GC18 Unidad Metdología y Estadistica Imibic	Intensive Medicine Unit
Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J; Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 79. 3. (245-252). DOI: 10.1016/j.jinf.2019.06.014. IF: 5,099. Q1. Article. IMIBIC GROUPS: GC03 GC26 GC24 Medicina Intensiva GC18	Intensive Medicine Unit
Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Rob; Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (20-24). DOI: 10.1016/j.transproceed.2018.04.092. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva Anatomía Patológica GC14 Medicina Intensiva	Intensive Medicine Unit
Gomez-Delgado F, Alcala-Diaz JF, Leon-Acuna A, Lopez-Moreno J, Delgado-Lista J, Gomez-Marin B, Roncero-Ramos I, Yubero-Serrano EM, Rangel-Zuniga OA, Vals-Delgado C, Luque RM, Ordovas JM, Lopez-Miranda J, Perez-Martinez P; Apolipoprotein E genetic variants interact with Mediterranean diet to modulate postprandial hypertriglyceridemia in coronary heart disease patients: CORDIOPREV study. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 49. 8. DOI: 10.1111/eci.13146. IF: 2,784. Q1. Article. IMIBIC GROUPS: GC09 GC27 Medicina Interna	Internal Medicine Unit
Santos-Marcos JA, Haro C, Vega-Rojas A, Alcala-Diaz JF, Molina-Abril H, Leon-Acuna A, Lopez-Moreno J, Landa BB, Tena-Sempere M, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, Camargo A; Sex Differences in the Gut Microbiota as Potential Determinants of Gender Predisposition to Disease. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 7. DOI: 10.1002/mnfr.201800870. IF: 4,653. D1. Article. IMIBIC GROUPS: Medicina Interna GC09 GC10	Internal Medicine Unit
Perez-Alvarez R, Brito-Zeron P, Kostov B, Feijoo-Masso C, Fraile G, Gomez-de-la-Torre R, De-Escalante B, Lopez-Dupla M, Alguacil A, Chara-Cervantes J, Perez-Conesa M, Rascon J, Garcia-Morillo JS, Perez-Guerrero P, Fonseca-Aizpuru E, Akasbi M, Bonet M, Cal; Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients. EUROPEAN JOURNAL OF INTERNAL MEDICINE. . DOI: 10.1016/j.ejim.2019.08.025. IF: 3,66. D2 Q1. Article. IMIBIC GROUPS: Distrito Sanitario Cordoba Norte (Med Interna)	Internal Medicine Unit
Sanjuan-Sanjuan A, Heredero-Jung S, Ogledzki M, Arevalo-Arevalo R, Dean-Ferrer A; Flattening of the orbital lower eyelid fat as a long-term outcome after surgical treatment of orbital floor fractures. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY. . DOI: 10.1016/j.bjoms.2019.07.023. IF: 1,164. Q3. Article. IMIBIC GROUPS: Cirugía Maxilofacial	Maxillofacial Surgery Unit
Garcia YG, Ferre AD, Mendiola C, Barretina-Ginesta MP, Garcia LG, Bertran AS, Barcelo IB, Gil-Martin M, Manzano A, Perez MJR, Marin MR, Nunez CA, Garcia-Martinez E, Martin AG; Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 29. 6. (1050-1056). DOI: 10.1136/ijgc-2019-000256. IF: 1,746. Q3. Article. IMIBIC GROUPS: Oncología Médica	Medical Oncology Unit
Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E; First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC CANCER. 19. DOI: 10.1186/s12885-019-5753-7. IF: 2,933. Q3. Article. IMIBIC GROUPS: GC06 Oncología Médica	Medical Oncology Unit

PUBLICATIONS	IMIBIC GROUP
Roca-Lema D, Martinez-Iglesias O, Portela CFD, Rodriguez-Blanco A, Valladares-Ayerbes M, Diaz-Diaz A, Casas-Pais A, Prego C, Figueroa A; In Vitro Anti-proliferative and Anti-invasive Effect of Polysaccharide-rich Extracts from Trametes Versicolor and Grifola Frondosa in Colon Cancer Cells. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES. 16. 2. (231-240). DOI: 10.7150/ijms.28811. IF: 2,333. Q2. Article. IMIBIC GROUPS: Oncología Médica	Medical Oncology Unit
Gonzalez-Flores E, Serrano R, Sevilla I, Viudez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, Lopez C, Garcia-Carbonero R; SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 21. 1. (55-63). DOI: 10.1007/s12094-018-1980-7. IF: 2,441. Q3. Article. IMIBIC GROUPS: Oncología Médica	Medical Oncology Unit
Santiago-O'Farrill JM, Weroha SJ, Hou XN, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC; Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. CANCER. . DOI: 10.1002/cncr.32600. IF: 6,102. D2 Q1. Article; Early Access. IMIBIC GROUPS: Oncología Médica	Medical Oncology Unit
Gonzalez-Martin A, Pothuri B, Vergote I, Christensen RD, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Perez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ. ; Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 381. 25. (2391-2402). DOI: 10.1056/NEJMoa1910962. IF: 70,67. D1 Q1. Article. IMIBIC GROUPS: Oncología Médica	Medical Oncology Unit
Galvez-Lara M, Corpas J, Vencesla JF, Moriana JA; Evidence-Based Brief Psychological Treatment for Emotional Disorders in Primary and Specialized Care: Study Protocol of a Randomized Controlled Trial. FRONTIERS IN PSYCHOLOGY. 9. DOI: 10.3389/fpsyg.2018.02674. IF: 2,129. Q2. Article. IMIBIC GROUPS: GC20 Salud Mental	Mental Health Unit
Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Montiel FJ, Gomez C, del Pozo GI, Alcala JA, Gutierrez-Rojas L, Balanza-Martinez V, Chauca GM, Carrion L, Osuna MI, Sanchez MD, Caro I, Ayora M, Valdivia F, Lopez MS, Poyato JM, Sarramea F; Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk TIMER): study protocol for a randomized controlled trial. TRIALS. 20. DOI: 10.1186/s13063-018-3139-9. IF: 1,975. Q3. Article. IMIBIC GROUPS: Salud Mental GA12 GA03 Distrito Sur. Salud Mental Hospital Infanta Margarita Cabra	Mental Health Unit
Ruiz P, Causse M, Vaquero M, Casal M; In Vitro Activity of Tedizolid against Mycobacterium tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 63. 4. DOI: 10.1128/AAC.01939-18. IF: 4,715. Q1. Article. IMIBIC GROUPS: GC24 Microbiología	Microbiology Unit
Guzman-Puche J, Gracia-Ahufinger I, Causse M, Tejero-Garcia R, Rodriguez-Lopez FC, Casal-Roman M; System, gram-stain and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for diagnosis of urinary tract infections directly from urine samples. JOURNAL OF CHEMOTHERAPY. 31. 2. (74-80). DOI: 10.1080/1120009X.2019.1573284. IF: 1,599. Q4. Article. IMIBIC GROUPS: GC24 Microbiología	Microbiology Unit
Delgado F, Oteros R, Jimenez-Gomez E, Rey IB, Bautista MD, Moyano RV; Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment. JOURNAL OF NEUROINTERVENTIONAL SURGERY. 11. 2. (147-152). DOI: 10.1136/neurintsurg-2018-014163. IF: 3,526. Q1. Article. IMIBIC GROUPS: GA08 Radiodiagnóstico Medicina Intensiva Neurología	Neurology Unit
Alonso-Jimenez A, Kroon, RHMJM, Alejaldre-Monforte A, Nunez-Peralta C, Horlings CGC, Engelen BGM, Olive M, Gonzalez L, Verges-Gil E, Paradas C, Marquez C, Garibaldi M, Gallano P, Rodriguez MJ, Gonzalez-Quereda L, Gonzalez CD, Vissing J, Fornander F, Eisum; Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 90. 5. (576-585). DOI: 10.1136/jnnp-2018-319578. IF: 8,272. D1. Article. IMIBIC GROUPS: Neurología	Neurology Unit
Carrasco-Rozas A, Fernandez-Simon E, Lleixa MC, Belmonte I, Pedrosa-Hernandez I, Montiel-Morillo E, Nunez-Peralta C, Rossello JL, Segovia S, De Luna N, Suarez-Calvet X, Illa I. (Pompe Spanish Study group, Díaz-Manera J, Gallardo E: Diaz-Manera, J; Gallard; Identification of serum microRNAs as potential biomarkers in Pompe disease. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. . DOI: 10.1002/acn3.50800. IF: 4,656. D2 Q1. Article. IMIBIC GROUPS: Neurología	Neurology Unit

PUBLICATIONS	IMIBIC GROUP
Fernandez-Simon E, Carrasco-Rozas A, Gallardo E, Figueroa-Bonaparte S, Belmonte I, Pedrosa I, Montiel E, Suarez-Calvet X, Alonso-Perez J, Segovia S, Nunez-Peralta C, Llauger J, Mayos M, Illa I. (Spanish Pompe Study Group, Díaz-Manera J: Barba-Romero, MA; ; PDGF-BB serum levels are decreased in adult onset Pompe patients. SCIENTIFIC REPORTS. . DOI: 10.1038/s41598-018-38025-0. IF: 4,011. D3 Q1. Article. IMIBIC GROUPS: Neurología	Neurology Unit
Gandia-Gonzalez ML, Cerdan S, Barrios L, Lopez-Larrubia P, Feijoo PG, Palpan A, Roda JM, Solivera J; Assessment of Overall Survival in Glioma Patients as Predicted by Metabolomic Criteria. FRONTIERS IN ONCOLOGY. 9. DOI: 10.3389/fonc.2019.00328. IF: 4,137. Q2. Article. IMIBIC GROUPS: Neurocirugía	Neurosurgery Unit
Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, Lopez-Fernandez JM, Gadelha MR, Galvez-Moreno MA, Soto-Moreno A, Gahete MD, Castano JP, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS. 11. 10. 1439. DOI: 10.3390/cancers11101439. IF: 6,162. D2 Q1. Article. IMIBIC GROUPS: GC27 GC08 Neurocirugía GA04	Neurosurgery Unit
Hellings PW, Seys SF, Marien G, Agache I, Canonica W, Gevaert P, Haahtela T, Klimek L, Mullol J, Pfaar O, Scadding G, Scadding G, Valiulis A, Bousquet J, Pugin B. ARIA Masterclass Discussants: Al-Muhandis, N; Allatt, S; Almeyda, R; Armand, P; Markovic, MA; ARIA masterclass 2018: From guidelines to real-life implementation. RHINOLOGY. . DOI: 10.4193/Rhin19.011. IF: 3,354. D1 Q1. Article. IMIBIC GROUPS: Otorrinolaringología	Otorhinolaryngology Unit
Juarez-Soto A, Garin-Ferreira JM, Rodriguez-Fernandez A, Tirado-Hospital JL, Gonzalez-Serrano MT, Moreno-Jimenez J, Medina-Lopez R, Baena-Gonzalez V; Diagnosis of metastasis in castration-resistant prostate cancer patients: decision algorithm in imaging tests. ACTAS UROLOGICAS ESPAÑOLAS. 43. 2. (55-61). DOI: 10.1016/j.acuro.2018.05.011. IF: 1,136. Q4. Review. IMIBIC GROUPS: Anatomía Patológica	Pathological Anatomy Unit
del Rio-Moreno M, Alors-Perez E, Gonzalez-Rubio S, Ferrin G, Reyes O, Rodriguez-Peralvarez M, Sanchez-Frias ME, Sanchez-Sanchez R, Ventura S, Lopez-Miranda J, Kineman RD, de la Mata M, Castano JP, Gahete MD, Luque RM; Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021. IF: 5,605. Q1. Article. IMIBIC GROUPS: GC27 GC08 GC25 GC02 GC09 Anatomía Patológica	Pathological Anatomy Unit
Guerrero M, Ferrin G, Rodriguez-Peralvarez M, Gonzalez-Rubio S, Sanchez-Frias M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllon MD, Barrera P, Montero JL, de la Mata M; mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 20. 2. DOI: 10.3390/ijms20020336. IF: 4,183. Q2. Article. IMIBIC GROUPS: GC02 Medicina Ap Digestivo GC18 Cirugía General y Digestiva Anatomía Patológica GC08	Pathological Anatomy Unit
Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S; Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 63. 9. DOI: 10.1002/mnfr.201800864. IF: 5,151. D1. Article. IMIBIC GROUPS: Anatomía Patológica GC21 GC06 GC08	Pathological Anatomy Unit
Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Rob; Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 51. 1. (20-24). DOI: 10.1016/j.transproceed.2018.04.092. IF: 0,959. Q4. Article; Proceedings Paper. IMIBIC GROUPS: GC18 Cirugía General y Digestiva Anatomía Patológica GC14 Medicina Intensiva	Pathological Anatomy Unit
Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001. IF: 4,915. D1. Article. IMIBIC GROUPS: GC27 GC08 GA08 GE05 Anatomía Patológica	Pathological Anatomy Unit

PUBLICATIONS	IMIBIC GROUP
Gomez-Gomez, E; Jimenez-Vacas, JM; Pedraza-Arevalo, S; Lopez-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibanez-Costa, A; Leon-Gonzalez, AJ; Sanchez-Sanchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castano, JP; Carrasco-Valiente,; Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 8. 9. 1400. DOI: 10.3390/jcm8091400. IF: 5,688. D1. Article. IMIBIC GROUPS: GC27 GC08 GE05 Anatomía Patológica	Pathological Anatomy Unit
Couce ML, de Castro MJ, de Lamas C, Leis R; Effects of LC-PUFA Supplementation in Patients with Phenylketonuria: A Systematic Review of Controlled Trials. NUTRIENTS. 11. 7. DOI: 10.3390/nu11071537. IF: 4,171. Q1. Review. IMIBIC GROUPS: Pediatría	Pediatrics Unit
Perez-Navero JL, Merino-Cejas C, de la Rosa II, Jaraba-Caballero S, Frias-Perez M, Gomez-Guzman E, Gil-Campos M, de la Torre-Aguilar MJ; Evaluation of the vasoactive-inotropic score, mid-regional pro-adrenomedullin and cardiac troponin I as predictors of low cardiac output syndrome in children after congenital heart disease surgery. MEDICINA INTENSIVA. 43. 6. (329-336). DOI: 10.1016/j.medin.2018.04.005. IF: 1,982. Q3. Article. IMIBIC GROUPS: GC23 Pediatría GA09 GA05	Pediatrics Unit
Tejada-Ortigosa EM, Flores-Rojas K, Moreno-Quintana L, Munoz-Villanueva MC, Perez-Navero JL, Gil-Campos M; Health and socio-educational needs of the families and children with rare metabolic diseases: Qualitative study in a tertiary hospital. ANALES DE PEDIATRIA. 90. 1. (42-50). DOI: 10.1016/j.anpedi.2018.03.003. IF: 1,166. Q3. Article. IMIBIC GROUPS: GC23 Pediatría	Pediatrics Unit
Tagarro A, Cruz-Canete M, Otheo E, Launes C, Couceiro JA, Perez C, Alfayatei S, Calvo C, de Liria CRG; Oseltamivir for the treatment of influenza in children and adolescents. ANALES DE PEDIATRIA. 90. 5. (317.e1-317.e8). DOI: 10.1016/j.anpedi.2019.01.009. IF: 1,166. Q3. Article. IMIBIC GROUPS: Distrito Sur. Pediatría. Hosp Alto Guadalquivir Montilla	Pediatrics Unit
Darling A, Aguilera-Albesa S, Tello CA, Serrano M, Tomas M, Camino-Leon R, Fernandez-Ramos J, Jimenez-Escrig A, Poo P, O'Callaghan M, Ortez C, Nascimento A, Mesaque RCF, Madruga M, Arrabal L, Roldan S, Gomez-Martin H, Garrido C, Temudo T, Jou-Munoz C, Muc; PLA2G6-associated neurodegeneration: New insights into brain abnormalities and disease progression. PARKINSONISM & RELATED DISORDERS. 61. (179-186). DOI: 10.1016/j.parkreldis.2018.10.013. IF: 4,36. Q1. Article. IMIBIC GROUPS: Pediatría	Pediatrics Unit
de Lamas C, de Castro MJ, Gil-Campos M, Gil A, Couce ML, Leis R; Effects of Dairy Product Consumption on Height and BoneMineral Content in Children: A Systematic Review of Controlled Trials. ADVANCES IN NUTRITION. 10. 2. (S88-S96). DOI: 10.1093/advances/nmy096. IF: 7,24. D1. Review. IMIBIC GROUPS: Pediatría GC23	Pediatrics Unit
Lui K, Lee SK, Kusuda S, Adams M, Vento M, Reichman B, Darlow BA, Lehtonen L, Modi N, Norman M, Hakansson S, Bassler D, Rusconi F, Lodha A, Yang JM, Shah PS. (International Network for Evaluation of Outcomes (iNeo) of neonates Investigators: Marshall, P; ; Trends in Outcomes for Neonates Born Very Preterm and Very Low Birth Weight in 11 High-Income Countries. JOURNAL OF PEDIATRICS. . DOI: 10.1016/j.jpeds.2019.08.020. IF: 3,739. D1 Q1. Article. IMIBIC GROUPS: GC23 Pediatría	Pediatrics Unit
Montecatine-Alonso E, Gil-Navarro MV, Fernandez-Llamazares CM, Fernandez-Polo A, Soler-Palacin P, Llorente-Gutierrez J, Calvo MTGT, Esquivel-Mora MD, Perez-Rodrigo I, Cisneros JM, Goycochea-Valdiviai WA, Neth O, Benito CAV, Chavarri-Gil E, Gallego-Fernand; Antimicrobial defined daily dose adjusted by weight: a proposal for antibiotic consumption measurement in children. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37. 5. (301-306). DOI: 10.1016/j.eimc.2018.07.011. IF: 1,685. Q4. Article. IMIBIC GROUPS: Farmacia GC03	Pharmacy Unit
Valls J, Cambray S, Perez-Guallar C, Bozic M, Bermudez-Lopez M, Fernandez E, Betriu A, Rodriguez I, Valdivielso JM, Castro E, Maria V, Moli T, Vidal T, Soria M, Regidor MJA, Almirall J, Ponz E, Coloma JA, Rubio MAB, Diaz RR, Rodriguez MB, Gascon A, Sanjua; Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort. FRONTIERS IN GENETICS. 10. DOI: 10.3389/fgene.2019.00118. IF: 3,517. Q2. Article. IMIBIC GROUPS: Atención Primaria	Primary Care
Perula-de Torres LA, Atalaya JCVM, Garcia-Campayo J, Roldan-Villalobos A, Magallon-Botaya R, Bartolome-Moreno C, Moreno-Martos H, Melus-Palazon E, Lietor-Villajos N, Valverde-Bolivar FJ, Hachem-Salas N, Rodriguez LA, Navarro-Gil M, Epstein R, Cabezon-Cres; Controlled clinical trial comparing the effectiveness of a mindfulness and self-compassion 4-session programme versus an 8-session programme to reduce work stress and burnout in family and community medicine physicians and nurses: MINDUUDD study protocol. BMC FAMILY PRACTICE. 20. DOI: 10.1186/s12875-019-0913-z. IF: 2,431. Q2. Article. IMIBIC GROUPS: GC12 Atención Primaria Distrito Sur Lucena	Primary Care

PUBLICATIONS	IMIBIC GROUP
Granados NM, Abellan MV, Estepa MT, Diaz MMP, Pedraza RR; Frequent attendance in a Primary Health Care District. GACETA SANITARIA. 33. 1. (38-44). DOI: 10.1016/j.gaceta.2017.07.011. IF: 1,656. Q2. Article. IMIBIC GROUPS: Atención Primaria GC12	Primary Care
O'Ferrall-Gonzalez C, Almenara-Barrios J, Garcia-Carretero MA, Salazar-Couso A, Almenara-Abellan JL, Lagares-Franco C; Factors associated with the evolution of attitudes towards mental illness in a cohort of nursing students. JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING. . DOI: 10.1111/jpm.12572. IF: 2,009. D2 Q1. Article; Early Access. IMIBIC GROUPS: Atención Primaria	Primary Care
Rodriguez A, Arenas M, Lara PC, Lopez-Torrecilla J, Algara M, Conde A, Perez-Montero H, Munoz JL, Peleteiro P, Perez-Calatayud MJ, Contreras J, Ferrer C. Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group: Ortiz, MJ; Exposito, J; Palacios,; Are there enough radiation oncologists to lead the new Spanish radiotherapy?. CLINICAL & TRANSLATIONAL ONCOLOGY. . DOI: 10.1007/s12094-019-02095-x. IF: 2,441. Q3. Article. IMIBIC GROUPS: Oncología Radioterápica	Radiation Oncology Unit
Garcia BA, Guirado FN, Raya FN, Denis MV, Rodriguez FB, Montenegro PG; ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma. ACTA RADIOLOGICA. 0. DOI: 10.1177/0284185119864842. IF: 1,583. Q3. Article; Early Access. IMIBIC GROUPS: Radiodiagnóstico	Radiodiagnosis Unit
Gomez EJ, Rey IB, Fernandez RO, Acosta FD; Endovascular treatment of stroke in children under 2 years with heart failure and ventricular assist device. INTERVENTIONAL NEURORADIOLOGY. 25. 5. (516-520). DOI: 10.1177/1591019919844946. IF: 1,45. Q4. Article. IMIBIC GROUPS: Radiodiagnóstico GA08	Radiodiagnosis Unit
Delgado F, Oteros R, Jimenez-Gomez E, Rey IB, Bautista MD, Moyano RV; Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment. JOURNAL OF NEUROINTERVENTIONAL SURGERY. 11. 2. (147-152). DOI: 10.1136/neurintsurg-2018-014163. IF: 3,526. Q1. Article. IMIBIC GROUPS: GA08 Radiodiagnóstico Medicina Intensiva Neurología	Radiodiagnosis Unit
Acosta FD, Gomez EJ, Rey IB, Moyano RV, Bravo-Rodriguez FD, Fernandez RO; Contrast-induced nephropathy: A dilemma between loss of neurons or nephrons in the setting of endovascular treatment of acute ischemic stroke. INTERVENTIONAL NEURORADIOLOGY. 26. 1. (33-37). DOI: 10.1177/1591019919883755. IF: 1,45. Q4. Article; Early Access. IMIBIC GROUPS: GA08 Radiodiagnóstico GE01	Radiodiagnosis Unit
Gonzalez-Alvaro I, Castrejon I, Carmona L, on behalf of ACT-RAY, PROAR and EMECAR study groups Dougados M, Huizinga T, Abu Shakra M, Alberts A, Lopez MA, Amital H, Aringer M, Aslanidis S, Berenbaum F, Bijlsma H, Garcia FJB, Bliddal H, Borofsky M, Brocq O,; The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity. PLOS ONE. 14. 4. DOI: 10.1371/journal.pone.0214717. IF: 2,776. Q2. Article. IMIBIC GROUPS: Reumatología	Rheumatology Unit
Prieto-Alhambra D, Moral-Cuesta D, Palmer A, Aguado-Maestro I, Bardaji MFB, Branas F, Bueno GA, Caeiro-Rey JR, Cano IA, Barres-Carsi M, Delgado LG, Salomo-Domenech M, Etxebarria-Foronda I, Ferrer BL, Mills S, Herrando LE, Mifsut D, Evangelista LDR, Nogues; The impact of hip fracture on health-related quality of life and activities of daily living: the SPARE-HIP prospective cohort study. ARCHIVES OF OSTEOPOROSIS. 14. 1. DOI: 10.1007/s11657-019-0607-0. IF: 2,469. Q2. Article. IMIBIC GROUPS: Traumatología	Traumatology Unit
Hurtado-Pardo L, Cienfuegos JA, Antonanzas J, Benito A, Panadero P, Salguero J, Marti-Cruchaga P, Zozaya G, Valenti V, Pardo F, Rotellar F, Hernandez-Lizoain JL; Cystic tumors of the pancreas. An update of the surgical experience in a single institution. REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS. 111. 2. (87-93). DOI: 10.17235/reed.2018.5798/2018. IF: 1,858. Q4. Article. IMIBIC GROUPS: Urología	Urology Unit
Subiela JD, Mercade A, Balana J, Galisteo JMR, Gallioli A, Breda A, Rosales A, Palou J, Faba OR; Ultrasound-guided cryotherapy of small renal masses: Systematic review. ARCHIVOS ESPANOLES DE UROLOGIA. . DOI: 0. IF: 0,335. Q4. Article. IMIBIC GROUPS: Urología	Urology Unit

CLINICAL TRIALS

CLINICAL TRIALS	IMIBIC GROUP
Barason Villarejo, María José; Estudio Observacional sobre el control de la rinitis alergica moderada/grave en españa. Reference: 2769	GC01
Moreno Aguilar, Carmen; ANÁLISIS DE LOS PERFILES DE SENSIBILIZACIÓN MEDIANTE PRUEBA CUTÁNEA, DETERMINACIÓN DE IgE FRENTE A EXTRACTO COMPLETO Y DIAGNÓSTICO MOLECULAR EN PACIENTES CON ENFERMEDAD ALÉRGICA RESPIRATORIA POR SENSIBILIZACIÓN A PÓLENES. IMPLICACIONES DIAGNÓSTICAS Y TERAPÉUTICAS. Reference: 3070	GC01
Serrano Delgado, Pilar; Estudio observacional retrospectivo multicentrico para describir los fenotipos clinicos mas frecuentes del paciente con asma grave persistente en tratamiento con omalizumab en practica clinica habitual fenoma. Reference: 2733/2	GC01
Barrera Baena, Pilar; Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico de fase III con regorafenib en pacientes con carcinoma hepatocelular (CHC) después de Sorafenib. Reference: 0039/13	GC02
Benítez Cantero, José Manuel; A post-authorization safety of golimumab in UC using spanish ENEIDA registry. Reference: 3531	GC02
Benítez Cantero, José Manuel; Entyvio (vedolizumab) long-term safety study: an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease. Reference: 3355	GC02
Benítez Cantero, José Manuel; Estudio de ampliación de fase 3, multicéntrico, sin enmascaramiento en el que se evalúa ozanimod por vía oral para la enfermedad de Crohn activa de moderada a grave. Reference: /3874	GC02
Benítez Cantero, José Manuel; Estudio de estrategias de mantenimiento comparando práctica clínica habitual frente a treat to target en pacientes con enfermedad de Crohn tratados con Ustekinumab. Reference: /3414	GC02
Benítez Cantero, José Manuel; Estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento doble y comparativo con placebo, en el que se evalúa ozanimod por vía oral como tratamiento de mantenimiento para la enfermedad de Crohn activa de moderada a grave. Reference: /3867	GC02
Benítez Cantero, José Manuel; Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de CT-P13 en inyección subcutánea (CT-P13 SC) como tratamiento de mantenimiento en pacientes con enfermedad activa de Crohn de moderada a grave. Reference: /4402	GC02
Benítez Cantero, José Manuel; Estudio de inducción multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de Upadacitinib (ABT 494) en pacientes con colitis ulcerosa de moderada a grave. Reference: /4069	GC02
Benítez Cantero, José Manuel; Estudio de inducción n.º 2: estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento doble y comparativo con placebo, en el que se evalúa ozanimod por vía oral como tratamiento de inducción para la enfermedad de Crohn activa de moderada a grave. Reference: /3866	GC02
Benítez Cantero, José Manuel; Estudio en fase 2a, multicéntrico, aleatorizado, comparativo con placebo, con enmascaramiento doble y grupos paralelos, para evaluar la seguridad y la eficacia de la administración oral de PRV-6527 (JNJ-40346527), un inhibidor del receptor del factor 1 estimulante de colonias, en pacientes con enfermedad de Crohn activa moderada o intensa. Reference: /3751	GC02
Benítez Cantero, José Manuel; Estudio fase 3 multicéntrico, de extensión abierta, para evaluar la seguridad y eficacia a largo plazo de ABT-494 en pacientes con colitis ulcerosa. Reference: /3589	GC02
Benítez Cantero, José Manuel; Estudio multicéntrico, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de ABT 494 para el tratamiento de inducción y mantenimiento en pacientes con Colitis Ulcerosa de Moderada a Grave. Reference: /3588	GC02
De la Mata García, Manuel; Estudio abierto de fase Ib para evaluar la farmacocinética, la tolerabilidad y la seguridad de la trimetazidina oral en sujetos con insuficiencia hepática aguda sobre crónica. Reference: /4375	GC02
Iglesias Flores, Eva; A retrospective chart review study evaluating the longer-term effectiveness of darvadstrocel in patients who completed ADMIRE-CD. Reference: 4327	GC02

CLINICAL TRIALS	IMIBIC GROUP
Iglesias Flores, Eva; An Observational prospective long-term exposure registry of adult patients with moderate to severe ulcerative colitis. Reference: 3594	GC02
Iglesias Flores, Eva; Efectivida y tolerabilidad de ustekinumab en la práctica clíica en pacientes con enfermedad de Crohn activa. Reference: 4172	GC02
Iglesias Flores, Eva; Ensayo abierto y a largo plazo de la seguridad del tratamiento con BI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado ensayos anteriores de BI 655130. Reference: /3973	GC02
Iglesias Flores, Eva; Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de múltiples dosis y de inducción para evaluar la seguridad, la tolerabilidad y la dosis óptima de ABX464 en comparación con el placebo en pacientes con colitis ulcerosa de moderada a grave que hayan tenido una respuesta inadecuada, una pérdida de respuesta o intolerancia a al menos uno de los siguientes agentes: tratamiento inmunodepresor (es decir, azatioprina, 6-mercaptopurina, metotrexato), inhibidores del factor de necrosis tumoral alfa [FNT-α], vedolizumab, inhibidores de JAK y/o tratamiento con corticoesteroides. Reference: /4437	GC02
Iglesias Flores, Eva; Estudio de inducción en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo sobre mirikizumab en pacientes con fracaso convencional y biológico con colitis ulcerosa activa de moderada a grave. LUCENT 1. Reference: /3938	GC02
Iglesias Flores, Eva; Estudio de induccion multicentrico, aleatorizado, doble ciego y controaldo con placebo para evaluar la eficacia y la seguridad de risakzumab en pacientes con colitis ulcerosa activa moderada o grave sin respuesta de tratamiento biologico previo. Reference: /3905	GC02
Iglesias Flores, Eva; Estudio de mantenimiento en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo sobre mirikizumab en pacientes con colitis ulcerosa activa de moderada a grave. LUCENT 2. Reference: /3939	GC02
Iglesias Flores, Eva; Estudio multicentirco aleatorizado, doble ciego y controlado con placevo con tratamiento de mantenimiento durante 2 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con colitis ulcerosa que responda a la inducción de los estudios M16-067 Y M16-065. Reference: /3940	GC02
Iglesias Flores, Eva; Estudio multicéntrico de fase II/III, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia del tratamiento de inducción con BI 655130 en pacientes con colitis ulcerosa activa de moderada a grave que no han respondido al tratamiento previo con fármacos biológicos. Reference: /3776	GC02
Iglesias Flores, Eva; Estudio preliminar de eficacia de BI 655130 como tratamiento adicional en pacientes con colitis ulcerosa activa de leve a moderada durante el tratamiento con inhibidores de TNF. Reference: /3718	GC02
Iglesias Flores, Eva; Registro no intervencionista a largo plazo para evaluar la seguridad y la eficacia de HUMIRA (adalilumab) en pacientes con colitis ulcerosa moderamente activa y muy activa (LEGACY). Reference: 2315	GC02
Montero Álvarez, José Luis; Efectividad de Envarsus en la prevención del rechazo del trasplante de hígado: Estudio Post-autorización observacional prospectivo en condicones de práctica clínica habitual. Reference: 3391	GC02
Montero Álvarez, José Luis; Ensayo fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la combinación de quimioembolización transarterial (TACE) con durvalumab en monoterapia o con durvalumab más bevacizumab en pacientes con carcinoma hepatocelular que requieran tratamiento locorregional. Reference: /4222	GC02
Montero Álvarez, José Luis; Estudio abierto y de un solo grupo para evaluar la eficacia y la seguridad de glecaprevir (GLE)/pibrentasvir (PIB) en pacientes con infección crónica por el virus de la hepatitis C (VHC) de genotipo 1, 2, 4, 5 o 6 y cirrosis compensada no tratados previamente. Reference: /3561	GC02
Montero Álvarez, José Luis; Estudio clínico multicéntrico de fase II para evaluar la seguridad y la eficacia preliminar de dos regímenes posológicos de HepaStem en pacientes con insuficiencia hepática crónica agudizada. Reference: /3862	GC02
Montero Álvarez, José Luis; Estudio en fase III, aleatorizado y doble ciego de nivolumab adyuvante frente a placebo para participantes con carcinoma hepatocelular que presentan un riesgo alto de recaída después de la resección o la ablación hepática con intención curativa [Evaluación en ensayo clínico de la vía de punto de control y el nivolumab 9DX]. Reference: /3749	GC02

CLINICAL TRIALS	IMIBIC GROUP
Montero Álvarez, José Luis; REFINE: Estudio observacional de regorafenib en carcinoma hepatocelular. Reference: 3943	GC02
Poyato González, Antonio; Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma. Reference: 4000	GC02
Rodríguez Perálvarez, Manuel Luis; Ensayo doble ciego, aleatorizado, controlado con placebo, fase IIb sobre la eficacia y seguridad de comprimidos de ácido norursodesoxicólico en pacientes con esteatohepatitis no alcohólica (EHNA). Reference: /4220	GC02
Rodríguez Perálvarez, Manuel Luis; Estudio en fase II, multicéntrico y abierto, para investigar la eficacia, la seguridad y la farmacocinética del anticuerpo monoclonal anti-PD-1, BGB-A317, en pacientes con carcinoma hepatocelular irresecable tratado anteriormente. Reference: /3826	GC02
Cano Yuste, Ángela Mª; Estudio comparativo, aleatorizado, doble ciego, multicéntrico, de la seguridad, tolerabilidad, eficacia y farmacocinética de CF-301 frente a placebo agregado al tratamiento antibacteriano de referencia para el tratamiento de pacientes adultos que padecen sepsis por Staphylococcus aureus (bacteriemia) con endocarditis que afecta al lado derecho. Reference: /3585	GC03
Cano Yuste, Ángela Mª; Estudio de fase IIb, comparativo, multicéntrico, aleatorizado, doble ciego, para evaluar la eficacia y seguridad de VIS410 por vía intravenosa administrado junto con oseltamivir (Tamiflu®) en comparación con oseltamivir en monoterapia en adultos hospitalizados con infección por el virus de la gripe A que requieren soporte con oxígeno. Reference: /3521	GC03
Cano Yuste, Ángela Mª; Un estudio aleatorizado, doble ciego, con control de dosis controlado por placebo evaluando la seguridad, la farmacocinética y el beneficio clínico de la FLU-IGIV en pacientes hospitalizados con infección grave por influenza A. Reference: /4024	GC03
Castón Osorio, Juan José; Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con fármaco de comparación activo para evaluar la seguridad, la tolerabilidad y la eficacia de imipenem/cilastatina/relebactam (MK-7655A) en comparación con piperacilina/tazobactam en sujetos con neumonía bacteriana intrahospitalaria o neumonía bacteriana asociada a la ventilación mecánica. Reference: /3581	GC03
De la Torre Cisneros, Julian Carlos; A retrospective study to evaluate the epidemology, standar of care, outcomes and resource use associatedwith patiens who have, or rare at risk of, infection with carbapenem non-susceptible (CarbNS) gram-negative organisms of interest (Enterobacteriaceae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter spp) (CARVAR). Reference: 4112	GC03
De la Torre Cisneros, Julian Carlos; ESTUDIO COMPARATIVO EN FASE III, PROSPECTIVO, ALEATORIZADO, MULTICÉNTRICO, ABIERTO PERO ENMASCARADO PARA EL EVALUADOR PRINCIPAL Y DE GRUPOS PARALELOS PARA DETERMINAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE AZTREONAM-AVIBACTAM (ATM-AVI) +/- METRONIDAZOL (MTZ) EN COMPARACIÓN CON MEROPENEM +/- COLISTINA (MER +/- COL) EN EL TRATAMIENTO DE INFECCIONES GRAVES POR BACTERIAS GRAMNEGATIVAS, INCLUIDOS LOS PATÓGENOS MULTIRRESISTENTES QUE PRODUCEN METALO-β-LACTAMASA (MBL), PARA LAS QUE HAY POCAS O NINGUNA OPCIÓN DE TRATAMIENTO. Reference: /3829	GC03
De la Torre Cisneros, Julian Carlos; Estudio de fase III, aleatorizado, con doble enmascaramiento y comparador activo de comparación de la eficacia y la seguridad entre ridinilazol (200 mg, 2 veces/día) durante 10 días y vancomicina (125 mg, 4 veces/día) durante 10 días para el tratamiento de la infección por Clostridium difficile (ICD). Reference: /4379	GC03
De la Torre Cisneros, Julian Carlos; A MULTICENTER, RANDOMIZED, OPEN-LABEL CLINICAL STUDY OF S-649266 OR BEST AVAILABLE THERAPY FOR THE TREATMENT OF SEVERE INFECTIONS CAUSED BY CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS. Reference: /3406	GC03
Caracuel Ruiz, Miguel Ángel; Estudio prospectivo, multicéntrico para evaluar la eficacia y la seguridad de una inyección única de hialuronato sódico en pacientes con artrosis de rodilla. Reference: 4025	GC05
Castro Villegas, María Del Carmen; A multicenter, prospctive, observational cohort study to evaluate the real-world safety and effectiveness of Erelzi, an etanercept biosimilar (COMPACT). Reference: 4002	GC05
Castro Villegas, María Del Carmen; ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO Y CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE BIMEKIZUMAB EN SUJETOS CON ESPONDILITIS ANQUILOSANTE ACTIVA. Reference: /4217	GC05

CLINICAL TRIALS	IMIBIC GROUP
Castro Villegas, María Del Carmen; ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO Y CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE BIMEKIZUMAB EN SUJETOS CON ESPONDILOARTRITIS AXIAL ACTIVA NO RADIOGRÁFICA. Reference: /4216	GC05
Castro Villegas, María Del Carmen; Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de secukinumab en pacientes con espondiloartritis axial no radiográfica activa durante un periodo de 2 años. Reference: /3550	GC05
Castro Villegas, María Del Carmen; Estudio multicéntrico, observacional no intervencionista, transversal y retrospctivo, para evaluar el control de la actividad de la enfermedad en condiciones de práctica clínica habitual en pacientes con Espondilitis Anquilosante y Artritis Psoriásica tratados en consultas de reumatología de España (Estudio MiDAS). Reference: 4111	GC05
Collantes Estevez, Eduardo; Ensayo de fase IV, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de golimumab (MK-8259 [SCH 900259]) tras la retirada del tratamiento, en comparación con su continuación (pauta completa o reducida), en sujetos con espondiloartritis axial no radiológica. Reference: /3525	GC05
Collantes Estevez, Eduardo; Estudio de Extensión, Abierto, Multicéntrico, para Evaluar la Seguridad y Eficacia a Largo Plazo de Bimekizumab en Pacientes con Espondilitis Anquilosante. Reference: /3650	GC05
Collantes Estevez, Eduardo; Estudio de fase IIB multicéntrico, aleatorizado, doble ciego, controlado con placebo, de intervalos de dosis y grupos paralelos, para evaluar la eficacia y la seguridad de bimekizumab en pacientes con espondilitis anquilosante activa. Reference: /3342	GC05
Collantes Estevez, Eduardo; Estudio fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de Apremilast (CC-10004) en el tratamiento de espondilitis anquilosante activa. Reference: 0125/12	GC05
Collantes Estevez, Eduardo; Estudio multicéntrico abierto para evaluar los efectos del certolizumab pegol en la reducción de las crisis de uveítis anterior en pacientes con espondiloartritis axial con antecedentes de uveítis anterior. Reference: /3244	GC05
Collantes Estevez, Eduardo; Estudio multicéntrico, con una Parte A, abierta, seguida por una Parte B, aleatorizada, en doble ciego, de grupos paralelos y controlada con placebo, para evaluar el mantenimiento de la remisión en sujetos con espondiloartritis axial activa (EpAxa) en tratamiento con certolizumab pegol 200 mg/c2s o 200 mg/c4s, en comparación con placebo. Reference: /2894	GC05
Collantes Estevez, Eduardo; Estudio observacional de reproducibilidad de UCOTRACK, una determinacion automatizada de la movibildad, en pacientes con espondiloartritis axial. Reference: 3160	GC05
Collantes Estevez, Eduardo; Registro multinacional de características clínicas, incluida la progresión radiológica y carga de la enfermedad durante 5 años en contextos de la vida real (Patients with axial spondyloarthritis: Multi-Country Registry of clinical characteristics, including radiographic progression, and burden of disease over 5 years in real-life setting) PROOF. Reference: 2457	GC05
Collantes Estevez, Eduardo; Sensibilkidad al cambio del índice UCOASMI en pacientes con espondiloartritis axial y enfermedad activa según el índice BASDAI (estudio UCOTRACK-II). Reference: 4278	GC05
Escudero Contreras, Alejandro; Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de sarilumab en pacientes con arteritis de células gigantes. Reference: /3994	GC05
Escudero Contreras, Alejandro; Estudio ASCORE sobre la experiencia a largo plazo con abatacept s.c. en la práctica clinica habitual. Reference: 2686	GC05
Escudero Contreras, Alejandro; Estudio de fase 3, aleatorizado, con comparador activo, doble ciego para comparar ABT-494 con abatacept en sujetos con artritis reumatoide de actividad moderada a grave con respuesta insuficiente o intolerancia a los FARME biológicos (FARMEb) en tratamiento estable con fármacos antirreumáticos modificadores de la enfermedad sintéticos convencionales (FARMEsc). Reference: /3331	GC05
Escudero Contreras, Alejandro; ESTUDIO EN FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE RO7123520 COMO TRATAMIENTO COMPLEMENTARIO EN PACIENTES CON ARTRITIS REUMATOIDE ACTIVA MODERADA O GRAVE Y CON RESPUESTA INADECUADA A LOS INHIBIDORES DE TNF-α. Reference: /3556	GC05

CLINICAL TRIALS	IMIBIC GROUP
Escudero Contreras, Alejandro; Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de 24 semanas de duración, para comparar la eficacia y la seguridad de GSK3196165 con placebo y con sarilumab, en combinación con FARME sintéticos convencionales, en participantes con artritis reumatoide con actividad de moderada a intensa que han obtenido una respuesta inadecuada a los FARME biológicos y/o los inhibidores de la quinasa de Janus. Reference: /4377	GC05
Escudero Contreras, Alejandro; Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de 52 semanas de duración, para comparar la eficacia y la seguridad de GSK3196165 con placebo y con tofacitinib, en combinación con metotrexato, en participantes con artritis reumatoide con actividad de moderada a intensa que han obtenido una respuesta inadecuada al metotrexato. Reference: /4378	GC05
Escudero Contreras, Alejandro; Estudio multicéntrico, aleatorizado, controlado con placebo, con doble enmascaramiento, para evaluar la eficacia y la seguridad de dosis múltiples de BMS-986165 en sujetos con artritis psoriásica (AP) activa. Reference: /4317	GC05
López Montilla, Mª Dolores; Ensayo clínico multicéntrico en fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de guselkumab administrado por vía subcutánea en pacientes con artritis psoriásica activa. Reference: /3552	GC05
López Montilla, Mª Dolores; ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO, CONTROLADO CON PLACEBO Y CON FÁRMACO ACTIVO DE REFERENCIA (ADALIMUMAB), PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE BIMEKIZUMAB EN EL TRATAMIENTO DE SUJETOS CON ARTRITIS PSORIÁSICA ACTIVA. Reference: /4272	GC05
López Montilla, Mª Dolores; Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de fase III de secukinumab ubcutáneo (150 mg y 300 mg) en jeringas precargadas para demostrar la eficacia (incluida la inhibición de daño estructural), seguridad, y tolerabilidad hasta 2 años en pacientes con artritis psoriásica activa (FUTURE 5) A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of structural damage), safety, and tolerability up to 2 years in subjects with active psoriatic arthritis (FUTURE 5). Reference: 0107/15	GC05
López Montilla, Mª Dolores; Estudio fase 3, aleatorizado, doble ciego, que compara ABT-494 con Placebo en pacientes con artritis psoriásica activa, con una historia previa de respuesta inadecuada a al menos un fármaco modificador de la enfermedad (FAME) biológico, en artritis psoriásica - SELECT- PsA 2. Reference: /3631	GC05
López Montilla, Mª Dolores; Estudio multicéntrico, aleatorizado, doble ciego, con control activo para evaluar la eficacia en la semana 52 de secukinumab en monoterapia por vía subcutánea en comparación con adalimumab en monoterapia por vía subcutánea en pacientes con artritis psorásica activa. Reference: /3345	GC05
Requena Tapia, María José; Elaboración de un modelo predictivo de cistoscopia, basado en el test BTA-stat, para el seguimiento de pacientes con carcinoma vesical no músculo-invasivo de bajo grado (Estudio PreCis BTA). Reference: 2446	GC05
Requena Tapia, María José; Estudio aleatorizado, doble ciego y comparativo de ZYTIGA (acetato de abiraterona), más dosis bajas de prednisona, más terapia de privación de andrógenos (TPA), frente a TPA sola en sujetos con cáncer de próstata metastásico sin tratamiento hormonal previo (CPmSTHP), de nuevo diagnóstico y alto riesgo. Reference: 0280/12	GC05
Requena Tapia, María José; Estudio de fase III, aleatorizado, controlado con placebo y doble ciego de JNJ-56021927 en combinación con acetato de abiraterona y prednisona en comparación con acetato de abiraterona y prednisona en sujetos con cáncer de próstata metastásico resistente a la castración (CPRCm) que no han recibido nunca quimioterapia A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC). Reference: 0344/14	GC05
Requena Tapia, María José; Estudio fase 3 aleatorizado, doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de baja carga tumoral.. Reference: 0215/15	GC05
Ruiz García, Jesús Manuel; Estudio sobre la práctica clínica habitual en pacientes con Síndrome de Dolor Vesical (SDV) en unidades de Urología Funcional y Urodinámica. Reference: 2363	GC05

CLINICAL TRIALS	IMIBIC GROUP
Aranda Aguilar, Enrique; Ensayo clínico de fase III, aleatorizado, controlado con tratamiento activo, con enmascaramiento parcial y con detección de biomarcadores, de pembrolizumab en monoterapia y en combinación con cisplatino + 5-fluorouracilo frente a placebo + cisplatino + 5-fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) avanzado A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5- Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Reference: 0144/15	GC06
Aranda Aguilar, Enrique; Ensayo clínico multicéntrico fase III, randomizado para la comparación de epirubicina. Reference: 0012/04	GC06
Aranda Aguilar, Enrique; ENSAYO CLÍNICO MULTICÉNTRICO RANDOMIZADO, DE TRATAMIENTO DE MANTENIMIENTO BASADO EN BIOMARCADORES PARA PRIMERA LÍNEA DE CÁNCER COLORRECTAL METASTÁSICO (MODUL). Reference: 0295/15	GC06
Aranda Aguilar, Enrique; Estudio abierto, aleatorizado, fase 2 que compara S95005 con bevacizumab frente a capecitabina con bevacizumab en pacientes con cancer colorrectal metastático no tratado previamente que no son candidatos a terapia intensiva. Reference: 0015/16	GC06
Aranda Aguilar, Enrique; Estudio fase III multicéntrico, abierto, randomizado, con tres grupos de tratamiento para investigar la eficacia y seguridad de cobimetinib en combinación con atezolizumab y de atezolizumab en monoterapia, comparado con regorafenib, en pacientes con adenocarcinoma colorrectal localmente avanzada o metástasico no resecable tratado previamente. Reference: /3267	GC06
Aranda Aguilar, Enrique; Estudio fase III, aleatorizado, multicéntrico, doble ciego de nivolumab adyuvante o placebo en sujetos con cáncer resecado de esófago o de la unión gastroesofágica. Reference: /3123	GC06
Aranda Aguilar, Enrique; Estudio observacional retrospectivo sobre el tratamiento del cáncer colorrectal metastásico (CCRm) en España. Reference: 3252	GC06
Aranda Aguilar, Enrique; Estudio restrospectivo del manejo de pacientes con cáncer colorrectal metastásico resistentes a una primera línea basada en oxaliplatino. Reference: 2107	GC06
Aranda Aguilar, Enrique; Evaluación clínica de OncoBEAM mediante el panel extendido de 34 mutaciones de RAS: Comparación de la determinación de la mutación RAS en ADN tumoral circulante y en muestra de tejido en pacientes con cáncer colorrectal metastático. Reference: 3074	GC06
Aranda Aguilar, Enrique; Evaluación de un tratamiento de mantenimiento inmunomodulador en pacientes con cáncer colorrectal metastasico con reducción del tumor durante el tratamiento de inducción. Ensayo en Fase lll. Reference: 0151/14	GC06
Barneto Aranda, Isidoro; A randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin in 1st line treatment for patients with Advanced/Recurrent Non-Squamous non-small cell lung cancer in combination of paclitaxel and carboplatin. Reference: /3240	GC06
Barneto Aranda, Isidoro; Deteccion de la mutacion T790M mediante tecnologia BEAMing en pacientes con CPCNP y EGFR mutado en estadio IV. Estudio LUNGBEAM. Reference: 2930	GC06
Barneto Aranda, Isidoro; Ensayo clínico de fase III aleatorizado de lurbinectedina (PM01183)/ doxorubicina (DOX) en comparación con ciclofosfamida (CTX), doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmon (CMP) en quienes han fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS). Reference: /3217	GC06
Barneto Aranda, Isidoro; Ensayo de fase III, aleatorizado, con el anticuerpo monoclonal anti-PD-1 pembrolizumab (MK-3475) en comparación con placebo en pacientes con CPNM en estadios iniciales tras la resección y la finalización del tratamiento adyuvante de referencia (PEARLS). Reference: 0195/15	GC06
Barneto Aranda, Isidoro; ESTUDIO ABIERTO DE AFATINIB EN PACIENTES NO TRATADOS (PRIMERA LINEA) O TRATADOS PREVIAMENTE CON QUIMIOTERAPIA CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) LOCALMENTE AVANZADO O METASTÁSICO PORTADORES DE MUTACIÓN DE EGFR. Reference: 82/13	GC06
Barneto Aranda, Isidoro; Estudio de fase 2, abierto, de encorafenib + binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E. Reference: /4345	GC06

CLINICAL TRIALS	IMIBIC GROUP
Barneto Aranda, Isidoro; Estudio de Fase II/III, aleatorizado, abierto y de dos partes, de dinutuximab e irinotecán versus irinotecán como tratamiento de segunda línea en sujetos con cáncer de pulmón microcítico en recidiva o resistente. Reference: /3560	GC06
Barneto Aranda, Isidoro; ESTUDIO DE FASE III, ABIERTO Y ALEATORIZADO PARA COMPARAR ATEZOLIZUMAB (ANTICUERPO ANTI-PD-L1) CON UN DERIVADO DEL PLATINO (CISPLATINO O CARBOPLATINO) EN COMBINACIÓN CON PEMETREXED O GEMCITABINA EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO Y NO EPIDERMOIDE O EPIDERMOIDE EN ESTADIO IV SELECCIONADOS POR PD-L1 QUE NO HAN RECIBIDO QUIMIOTERAPIA PREVIA. Reference: /3554	GC06
Barneto Aranda, Isidoro; ESTUDIO DE FASE III/IV MULTICÉNTRICO, CON UN SOLO GRUPO DE TRATAMIENTO, PARA INVESTIGAR LA SEGURIDAD A LARGO PLAZO Y LA EFICACIA DE ATEZOLIZUMAB (TECENTRIQ) EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO LOCALMENTE AVANZADO O METASTÁSICO, TRATADOS PREVIAMENTE (TAIL). Reference: /3590	GC06
Barneto Aranda, Isidoro; Estudio en fase III, abierto y aleatorizado para investigar la eficacia y seguridad de Atelizumab (anticuerpo anti-PD-L1) en comparacion con el tratamiento de soporte optimo despues de quimioterapia adyuvante basada en cisplatino en pacientes seleccionados por PD-L1 con cancer de pulmon no microcitico en estadio IB-IIIA totalmente resecado. Reference: 0192/15	GC06
Barneto Aranda, Isidoro; ESTUDIO FASE III, ABIERTO, ALEATORIZADO, DE MPDL3280A (ANTICUERPO ANTI-PD-L1) EN COMBINACIÓN CON CARBOPLATINO + PACLITAXEL CON O SIN BEVACIZUMAB COMPARADO CON CARBOPLATINO + PACLITAXEL + BEVACIZUMAB EN PACIENTES CON CÁNCER DE PULMÓN NO EPIDERMOIDE NO MICROCÍTICO EN ESTADIO IV QUE NO HAN RECIBIDO QUIMIOTERAPIA PREVIA A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PDL1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN - PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN -PACLITAXEL - BEVACIZUMAB IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER. Reference: 0055/15	GC06
Barneto Aranda, Isidoro; ESTUDIO FASE III, ABIERTO, MULTICÉNTRICO, ALEATORIZADO QUE EVALÚA LA EFICACIA Y SEGURIDAD DE MPDL3280A (ANTICUERPO ANTI PD L1) EN COMBINACIÓN CON CARBOPLATINO + PACLITAXEL O MPDL3280A EN COMBINACIÓN CON CARBOPLATINO + NAB PACLITAXEL COMPARADO CON CARBOPLATINO + NAB PACLITAXEL EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO ESCAMOSO ESTADIO IV QUE NO HAN RECIBIDO QUIMIOTERAPIA PREVIA A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN - PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN- NAB PACLITAXEL VERSUS CARBOPLATIN - NAB-PACLITAXEL IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER. Reference: 0060/15	GC06
Barneto Aranda, Isidoro; Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, que evalúa la eficacia y seguridad de canakinumab frente a placebo como terapia adyuvante en pacientes adultos con cáncer de pulmón no microcítico (NSCLC) completamente resecado (R0), en estadío II-IIIA y IIIB (T>5 cm N2) según el AJCC/UICC v.8. Reference: /3783	GC06
Barneto Aranda, Isidoro; Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared with Avastin, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer. Reference: /3238	GC06
Cano Osuna, Mª Teresa; Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo, de Pembrolizumab (MK-3475) en combinación con Cisplatino y 5-Fluorouracilo en comparación con Placebo en combinación con Cisplatino y 5-Fluorouracilo como tratamiento de primera línea en sujetos con carcinoma de esófago avanzado o metastásico (KEYNOTE-590). Reference: /3689	GC06
Cano Osuna, Mª Teresa; Estudio de fase III aleatorizado de AM0010 combinado con FOLFOX en comparación con FOLFOX en monoterapia para el tratamiento de segunda línea en pacientes con cáncer de páncreas metastásico que ha progresado durante o después de un tratamiento de primera línea con gemcitabina. Reference: /3415	GC06

CLINICAL TRIALS	IMIBIC GROUP
De la Haba Rodríguez, Juan Rafael; COMPLEEMENT-1: ESTUDIO DE FASE IIIB, ABIERTO, MULTICÉNTRICO, PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE RIBOCICLIB (LEE011) EN COMBINACIÓN CON LETROZOL EN EL TRATAMIENTO DE HOMBRES Y MUJERES PRE/POSTMENOPÁUSICAS CON CÁNCER DE MAMA AVANZADO (CMA) CON RECEPTOR HORMONAL POSITIVO (HR+) Y HER2 NEGATIVO (HER2-) QUE NO HAYAN RECIBIDO TRATAMIENTO HORMONAL PARA LA ENFERMEDAD AVANZADA. Reference: /3441	GC06
De la Haba Rodríguez, Juan Rafael; Eficacia de olaparib en combinación con trastuzumab en pacientes con cáncer de mama avanzado HER2-positivo, y con mutación en BRCA o Deficiencia en la Recombinación Homóloga (DRH) - Estudio OPHELIA. Reference: /4065	GC06
De la Haba Rodríguez, Juan Rafael; Ensayo aleatorizado, en doble ciego y controlado con placebo, de neratinib (HKI-272) después de trastuzumab en mujeres con cáncer de mama en estadío inicial con sobreexposición/amplificación de HER-2/neu. Reference: 0181/09	GC06
De la Haba Rodríguez, Juan Rafael; Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib - [LEE011]: NATALEE). Reference: /4221	GC06
De la Haba Rodríguez, Juan Rafael; Ensayo de fase II, multicéntrico, internacional, no controlado para identificar los mecanismos moleculares de resistencia y sensibilidad a la reexposición a palbociclib tras la progresión a una combinación de palbociclib en pacientes con cáncer de mama metastásico ER positivo (BioPER). Código: MedOPP089. Reference: /3443	GC06
De la Haba Rodríguez, Juan Rafael; Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante. Estudio OLYMPIA. Reference: 0124/14	GC06
De la Haba Rodríguez, Juan Rafael; Estudio clínico de fase II, multicéntrico, abierto, randomizado, con dos grupos de tratamiento, para evaluar la eficacia y la seguridad de pertuzumab administrado en combinación con trastuzumab y un inhibidor de la aromatasa para tratamiento de primera línea de pacientes con cácner de mama avanzado (metastásico o localmente avanzado) HER2-positivo y receptor hormonal positivo. Reference: 0231/11	GC06
De la Haba Rodríguez, Juan Rafael; ESTUDIO DE FASE II MULTICÉNTRICO, MULTINACIONAL, DE EVALUACIÓN DE PERTUZUMAB EN COMBINACIÓN CON TRASTUZUMAB Y QUIMIOTERAPIA NEOADYUVANTE BASADA EN ANTRACICLINAS EN PACIENTES CON CÁNCER DE MAMA HER2 POSITIVO LOCALMENTE AVANZADO, INFLAMATORIO O PRECOZ. Reference: 0105/14	GC06
De la Haba Rodríguez, Juan Rafael; Estudio de fase II randomizado, multicéntrico, abierto para evaluar la eficacia y seguridad de palbociclib en combinación con fulvestrant o letrozol en pacientes con cáncer de mama metastasico HER2 negativo, ER+ (PARSIFAL 1). Reference: 0026/15	GC06
De la Haba Rodríguez, Juan Rafael; Estudio de Fase II, multicentrico, doble ciego, randomizado, controlado con placebo para evaluar la eficacia y seguridad de atezolizumab o placebo en combinacion con trastuzumab emtansina en pacientes con cancer de mama localmente avanzado o metastasico HER2-positivo que han recibido previamente terapia basada en taxanos, bien sola o en combinacion. Reference: /3189	GC06
De la Haba Rodríguez, Juan Rafael; Estudio de fase III, aleatorizado y doble ciego para evaluar pembrolizumab más quimioterapia frente a un placebo más quimioterapia como tratamiento neoadyuvante y pembrolizumab frente a un placebo como tratamiento adyuvante para el cáncer de mama triple negativo (CMTN). Reference: /3439	GC06
De la Haba Rodríguez, Juan Rafael; ESTUDIO DE FASE III, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE IPATASERTIB EN COMBINACIÓN CON PACLITAXEL PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER DE MAMA TRIPLE NEGATIVO O CÁNCER DE MAMA POSITIVO PARA RECEPTORES HORMONALES Y NEGATIVO PARA HER2, EN AMBOS CASOS LOCALMENTE AVANZADO O METASTÁSICO Y CON ALTERACIÓN DE PIK3CA/AKT1/PTEN. Reference: /4036	GC06
De la Haba Rodríguez, Juan Rafael; Estudio en fase 2/3, abierto y aleatorizado de olaparib más pembrolizumab en comparación con quimioterapia más pembrolizumab después de inducción del beneficio clínico con quimioterapia de primera línea más pembrolizumab en participantes con cáncer de mama triple negativo (CMTN) localmente recurrente inoperable o metastásico (KEYLYNK-009). Reference: /4413	GC06

CLINICAL TRIALS	IMIBIC GROUP
De la Haba Rodríguez, Juan Rafael; Estudio en fase 3 aleatorizado, abierto, de abemaciclib en combinación con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar, en pacientes con cáncer de mama en estadios iniciales, de alto riesgo, con afectación ganglionar, receptores hormonales positivos, HER2 negativo. Reference: /3529	GC06
De la Haba Rodríguez, Juan Rafael; Estudio en fase III, multicéntrico, aleatorizado y controlado con placebo de Atezolizumab (Anticuerpo Anti-PD-L1) combinado con Nab-Paclitaxel en comparación con placebo con Nab-Paclitaxel en pacientes con cáncer de mama triple negativo metastásico no tratado previamente. Reference: 0018/16	GC06
De la Haba Rodríguez, Juan Rafael; Estudio epidemiológico sobre la historia natural y manejo clínico de cáncer de mama localmente avanzado o metastásico: Estudio CASCADE. Reference: 2456	GC06
De la Haba Rodríguez, Juan Rafael; Estudio fase II, aleatorizado, que compara, en primera linea de quimioterapia, vinorelbina oral, como agente unico, en dos pautas de administracion diferentes en pacientes con cancer de mama avanzado. TempoBreast 1. Reference: 0233/15	GC06
De la Haba Rodríguez, Juan Rafael; Estudio fase III aleatorizado, doble ciego, controlado con placebo de BKM120 en combinación con fulvestrant en mujeres postmenopáusicas con cáncer de mama localmente avanzado o metastásico con receptores hormonales positivos HER2 negativo que han progresado durante o después del tratamiento con un inhibidor de la aromatasa. Reference: 0171/12	GC06
De la Haba Rodríguez, Juan Rafael; Estudio fase III aleatorizado, multicéntrico, abierto de lapatinib, trastuzumab, la administración secuencial de ambos y la administración combinada de ambos como tratamiento adyuvante en paciente con cáncer de mama HER2/ERbB2 positivo. Reference: 0090/07	GC06
De la Haba Rodríguez, Juan Rafael; Estudio fase III que evalúa palbociclib (PD-0332991), un inhibidor de quinasa dependiente de las ciclinas (CDK) 4/6, en pacientes con cáncer de mama primario con receptores hormonales positivos y HER2 normal y alto riesgo de recidiva tras quimioterapia neoadyuvante. Estudio PENELOPEB. Reference: 0059/14	GC06
De la Haba Rodríguez, Juan Rafael; ESTUDIO MULTICENTRICO, ABIERTO DE UN SOLO BRAZO DE ESTUDIO DE SEGURIDAD DE HERCEPTIN S.C. EN COMBINACION CON PERJETA Y DOCETAXEL, EN EL TRATAMIENTO DE PACIENTES CON CANCER DE MAMA AVANZADO HER2 POSITIVO (METASTASICO O LOCALMENTE RECURRENTE). Reference: 0005/15	GC06
De la Haba Rodríguez, Juan Rafael; Estudio multicéntrico, doble ciego, randomizado, controlado con placebo, para comparar quimioterapia más trastuzumab y placebo con quimioterapia más trastruzumab y pertuzumab, como tratamiento adyuvante en pacientes con cáncer de mama primario HER-2 positivo operable. Reference: 0198/11	GC06
De la Haba Rodríguez, Juan Rafael; Neoadyuvancia con Letrozol y Palbociclib en pacientes con cáncer de mama estadíos II-IIIb, Fenotipo RH (+) / HER2 (-) y Recurrence Score (Oncotype-Dx) Intermedio (18-25) o Alto (>25) con análisis de cambios en el RS a la cirugía. Reference: /4066	GC06
De la Haba Rodríguez, Juan Rafael; trastuzumab y pertuzumab sin quimioterapia en cancer de mama HER+: estrategia adaptada en funcion de la respuesta evaluada por FDG-PET. Estudio PHERGain. Reference: /3479	GC06
Maria Rodriguez, Rosa; A phase 3, open label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 Rearrangement (FIGHT-302). Reference: /4412	GC06
Méndez Vidal, María José; A multinational randomised, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer. Reference: 0194/14	GC06
Méndez Vidal, María José; A RANDOMIZED DOUBLE-BLIND CONTROLLED PHASE 3 STUDY OF CABOZANTINIB IN COMBINATION WITH NOVOLUMAB AND IPLIMUMAB VERSUS NIVOLUMBAB AND IPLIMUMAB IN SUBJECTS WITH PREVIOSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK. Reference: /4440	GC06
Méndez Vidal, María José; Análisis retrospectivo de factores clínicos asociados a un mayor beneficio con Axitinib en Cáncer Renal metastásico (Estudio AXILONG). Reference: 3789	GC06

CLINICAL TRIALS	IMIBIC GROUP
Méndez Vidal, María José; Ensayo clínico de fase II de la actividad de radio 223 en pacientes con cnáncer de próstata mestásico resistente a la castración (CPRCm) con progresión asintomática durante el tratamiento con acetato de abiraterona o enzalutamida y en función del estado mutacional del gen ARV7. Reference: /3271	GC06
Méndez Vidal, María José; Ensayo clinico de fase II de prembrolizumab (MK-3475) en sujetos con cancer urotelial avanzado/irresecable o metastasico Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer. Reference: 0362/14	GC06
Méndez Vidal, María José; Ensayo clínico en fase III, aleatorizado, abierto y multicéntrico para comparar la eficacia y la seguridad de lenvatinib en combinación con everolimus o pembrolizumab frente a sunitinib en monoterapia en el tratamiento de primera línea de sujetos con carcinoma de células renales en estadio avanzado (CLEAR). Reference: /3347	GC06
Méndez Vidal, María José; Ensayo de eficacia aleatorizado de doble ciego y fase 3 de PROSTVAC-V/F ± FEC-GM en hombres que tienen cáncer de próstata asintomático o mínimamente sintomático mestastásico resistente a la castración. Reference: 0235/12	GC06
Méndez Vidal, María José; Ensayo de fase 2, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de lenvatinib en dos dosis iniciales diferentes (18 mg y 14 mg una vez al día) en combinación con everolimus (5 mg una vez al día) en carcinoma de células renales después de un tratamiento previo dirigido contra el VEGF. Reference: /3586	GC06
Méndez Vidal, María José; Ensayo fase III, aleatorizado, abierto, multicéntrico e internacional para determinar la eficacia y la seguridad de durvalumab en combinación con gemcitabina + cisplatino como tratamiento neoadyuvante seguido de durvalumab en monoterapia como tratamiento adyuvante en pacientes con cáncer de vejiga músculo invasivo (NIAGARA). Reference: /4148	GC06
Méndez Vidal, María José; ESTUDIO DE EXTENSIÓN Y OBSERVACIONAL A LARGO PLAZO MULTICÉNTRICO, ABIERTO EN PACIENTES INCLUIDOS PREVIAMENTE EN UN ESTUDIO CLÍNICO DE ATEZOLIZUMAB PROMOCIONADO POR GENENTECH Y/O F. HOFFMANN-LA ROCHE LTD. Reference: /3868	GC06
Méndez Vidal, María José; Estudio de fase 2/3 aleatorizado, abierto, multicéntrico para evaluar la eficacia y seguridad de Rogaratinib (BAY 1163877) comparado con quimioterapia en pacientes FGFR positivos con carcinoma urotelial metastásico o localmente avanzado que hayan recibido previamente quimioterapia con platino. Reference: /3780	GC06
Méndez Vidal, María José; Estudio de fase 3, abierto y aleatorizado, para evaluar enfortumab vedotina en comparación con quimioterapia, en sujetos con cáncer urotelial localmente avanzado o metastásico ya tratado previamente (EV-301). Reference: /3906	GC06
Méndez Vidal, María José; Estudio de Fase 3, aleatorizado, controlado, multicéntrico y abierto, para comparar el tivozanib clorhidrato frente al sorafenib en sujetos con carcinoma de células renales avanzado resistente al tratamiento. Reference: /3001	GC06
Méndez Vidal, María José; Estudio de fase III aleatorizado, doble ciego, controlado con placebo de ODM-201 comparado con placebo, en combinación con el tratamiento estándar de privación androgénica y docetaxel en pacientes con cáncer de próstata metastásico sensible a hormonas. Reference: /3339	GC06
Méndez Vidal, María José; Estudio de Fase III multicéntrico, randomizado, controlado con placebo de atezolizumab (anticuerpo anti-pd-l1) en monoterapia y en combinación con quimioterapia basada en platino en pacientes con carcinoma urotelial localmente avanzado o metastásico no tratado previamente. Reference: /3417	GC06
Méndez Vidal, María José; ESTUDIO DE FASE III, MULTICÉNTRICO, MULTINACIONAL, ALEATORIZADO, ABIERTO, CON GRUPOS PARALELOS SOBRE AVELUMAB* (MSB0010718C) MÁS LOS MEJORES CUIDADOS PALIATIVOS FRENTE A LOS MEJORES CUIDADOS PALIATIVOS SOLOS COMO TRATAMIENTO DE MANTENIMIENTO EN PACIENTES CON CÁNCER UROTELIAL LOCALMENTE AVANZADO O MESTASTÁSICO SIN PROGRESIÓN DE LA ENFERMEDAD TRAS COMPLETAR LA QUIMIOTERAPIA DE PRIMERA LÍNEA BASADA EN PLATINO. Reference: /3714	GC06
Méndez Vidal, María José; Estudio en fase III sobre erdafitinib en comparación con vinflunina, docetaxel o pembrolizumab en sujetos con carcinoma urotelial avanzado y anomalías genéticas seleccionadas en FGFR. Reference: /3781	GC06

CLINICAL TRIALS	IMIBIC GROUP
Méndez Vidal, María José; ESTUDIO EN FASE III, MULTICÉNTRICO, RANDOMIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA INVESTIGAR IPATASERTIB EN COMBINACIÓN CON ABIRATERONA MÁS PREDNISONA/PREDNISOLONA, COMPARADO CON PLACEBO EN COMBINACIÓN CON ABIRATERONA MÁS PREDNISONA/PREDNISOLONA, EN PACIENTES ADULTOS CON CÁNCER DE PRÓSTATA RESISTENTE A CASTRACIÓN METASTÁSICO, ASINTOMÁTICOS O LEVEMENTE SINTOMÁTICOS QUE NO HAN SIDO TRATADOS PREVIAMENTE. Reference: /3474	GC06
Méndez Vidal, María José; Estudio fase 2 de eficacia y seguridad de Niraparib en hombres con cáncer de próstata metastásico resistente a castración y anomalías en la reparación de ADN. Reference: /3246	GC06
Méndez Vidal, María José; Estudio fase III aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de pazopanib como tratamiento adyuvante en sujetos con carcinoma de células renales localizado o localmente avanzado tras nefrectomía. Reference: 0194/10	GC06
Méndez Vidal, María José; ESTUDIO FASE III MULTICÉNTRICO, RANDOMIZADO, CON ATEZOLIZUMAB (ANTICUERPO ANTI PD- L1) EN COMBINACIÓN CON ENZALUTAMIDA FRENTE A ENZALUTAMIDA SOLA EN PACIENTES CON CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN TRAS FALLO DE UN INIHIBIDOR DE LA SÍNTESIS DE ANDRÓGENOS Y FALLO O NO ELEGIBLE O RECHAZO DE TRATAMIENTO CON TAXANOS. Reference: /3627	GC06
Méndez Vidal, María José; ESTUDIO FASE III, ABIERTO, MULTICENTRICO Y RANDOMIZADO PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE MPDL3280A (ANTICUERPO ANTI-PD-L1) COMPARADO CON QUIMIOTERAPIA EN PACIENTES CON CANCER UROTELIAL DE VEJIGA LOCALMENTE AVANZADO O METASTASICO DESPUES DE FALLO A QUIMIOTERAPIA BASADA EN REGIMEN DE PLATINO. Reference: 0311/14	GC06
Méndez Vidal, María José; Estudio fase III, aleatorizado y abierto de MPDL3280A (ANTICUERPO antiPD-L1) en combinacion con BEVAZUMAB comparado con SUNITINIB en pacientes con carcinoma de celulas renales avanzado no tratado. Reference: 0019/15	GC06
Méndez Vidal, María José; Estudio fase III, doble ciego, controlado con placebo, randomizado y multicentrixo de atezolizumab (anticuerpo anti-pd-l1) como tratamiento adyuvante en pacientes con carcinoma de celulas renales con alto riego de desarrollo de metastasis tras nefrectomia. Reference: /3333	GC06
Méndez Vidal, María José; Estudio multicéntrico, abierto con un solo grupo de tratamiento para evaluar la seguridad de atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinaio localmente avanzado o metastásico. Reference: /3325	GC06
Méndez Vidal, María José; Estudio observacional, prospectivo y multicéntrico de calidad de vida en relación con la fatiga y el síndrome mano-pie de los pacientes con carcinoma renal metastásico tratados con un inhibidor de la tirosina quinasa en primera línea. Reference: 3221	GC06
Méndez Vidal, María José; TRITON3: Estudio en fase III, multicéntrico, aleatorizado y abierto de rucaparib frente al tratamiento elegido por el médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado a una deficiencia en la recombinación homóloga. Reference: /4218	GC06
Moreno Vega, Alberto Luis; Estudio de fase I/II sobre la seguridad, la tolerabilidad y la eficacia de INCAGN01876 en combinación con inmunoterapias en sujetos con neoplasias malignas avanzadas o metastásicas. Reference: /3609	GC06
Ortiz Moraes, María José; Estudio abierto, aleatorizado, fase 3 comparando trifluridina/tipiracilo (S95005) en combinación con bevacizumab y capecitabina en combinación con bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candidatos a terapia intensiva (Estudio SOLSTICE). Reference: /3748	GC06
Ortiz Moraes, María José; Estudio aleatorizado, multicéntrico, de grupos paralelos y de fase III, para comparar la eficacia de arfolitixorin frente a leucovorin en combinación con 5-fluorouracilo, oxaliplatino y bevacizumab en pacientes con cáncer colorrectal avanzado. Reference: /4072	GC06
Ortiz Morales, María José; ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO Y ABIERTO, DE 3 GRUPOS: ENCORAFENIB + CETUXIMAB, CON O SIN BINIMETINIB, FRENTE A IRINOTECÁN/ CETUXIMAB O 5-FLUOROURACILO (5-FU)/ÁCIDO FOLÍNICO (FA)/IRINOTECÁN (FOLFIRI)/ CETUXIMAB EN INFUSIÓN, CON UNA EVALUACIÓN PREVIA DE LA SEGURIDAD DE ENCORAFENIB + BINIMETTINIB + CETUXIMAB, EN PACIENTES CON CÁNCER COLORRECTAL METASTÁSICO CON LA MUTANTE V600E DEL GEN BRAF. Reference: /3418	GC06

CLINICAL TRIALS	IMIBIC GROUP
Porras Quintela, Ignacio; ESTUDIO EN FASE 3, ALEATORIZADO, DOBLE CIEGO SOBRE AVELUMAB COMBINADO CON LA QUIMIORRADIOTERAPIA DE REFERENCIA (CISPLATINO MÁS RADIOTERAPIA DEFINITIVA) EN COMPARACIÓN CON LA QUIMIORRADIOTERAPIA DE REFERENCIA EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CARCINOMA EPIDERMOIDE LOCALMENTE AVANZADO DE CABEZA Y CUELLO. Reference: /3562	GC06
Porras Quintela, Ignacio; ESTUDIO EN FASE III MULTICÉNTRICO, ABIERTO, RANDOMIZADO, CON DOS BRAZOS DE TRATAMIENTO, PARA EVALUAR LA FARMACOCINÉTICA, LA EFICACIA Y LA SEGURIDAD DE LA ADMINISTRACIÓN SUBCUTÁNEA DE LA COMBINACIÓN EN DOSIS FIJAS DE PERTUZUMAB Y TRASTUZUMAB EN COMBINACIÓN CON QUIMIOTERAPIA EN ACIENTES CON CÁNCER DE MAMA PRECOZ HER2 POSITIVO. Reference: /3864	GC06
Sanchez Mauriño, Pedro; Estudio fase 3, aleatorizado, abierto, de NKTR-214 en combinación con nivolumab frente a nivolumab en pacientes con melanoma irresecable o metastásico previamente no tratado. Reference: /4033	GC06
Sanchez Mauriño, Pedro; Evaluación de la calidad de vida de pacientes con estreñimiento incluido por opioides en tratamiento con Naloxegol. Estudio de un año de seguimiento. ESTUDIO KYONAL. Reference: 3792	GC06
Serrano Blanch, Raquel; Efectividad de la dosis de 120 mg de lanreotida en pacientes con tumores neuroendocrinos pancreaticos (TNEP) localmente avanzados o metastásicos en la práctica clínica habitual. Reference: 4324	GC06
Serrano Blanch, Raquel; Estudio multicéntrico abierto para la evaluación de la frecuencia de mutaciones en genes accionables asociados al Cáncer Hereditario. Reference: 2617	GC06
Valladares Ayerbes, Manuel Jesús; Determinación del estado mutacional del RAS en biopsias líquidas de sujetos con cáncer colorrectal metastásico RAS no mutado en primera línea: estudio observervacional, prospectivo y multicéntrico en España (Estudia PERSEIDA). Reference: 3860	GC06
Agüera Morales, María Luisa; Registro nacional de rechazo humoral: Estudio epidemiológico multicéntrico observacional prospectivo para evaluar las características clínicas, serológicas e histológicas y la evolución a 5 años del rechazo humoral post-trasplante renal en España. Reference: 1762	GC07
Espinosa Hernández, Mario; A 6 year, multicentre, non-interventional, post-authorisation safety study for patients prescribed Jinarc for autosomal dominant polycystic kidney disease. Reference: 3656	GC07
Espinosa Hernández, Mario; A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN). Reference: /4416	GC07
Espinosa Hernández, Mario; A randomized, double-blind, placebo-controlled, Phase III Study of the Safety and Efficacy of OMS721 in Patients with Inmunoglobin A (IgA) Nefropathy (ARTEMIS-IGAN). Reference: /3910	GC07
Espinosa Hernández, Mario; Estudio controlado con principio activo, aleatorizado, multicéntrico, doble ciego y paralelo de los efectos de esparsentán, un receptor dual de endotelina y un bloqueador del receptor de angiotensina, sobre los resultados renales en pacientes con glomeruloesclerosis segmentaria y focal (GESF) primaria. Reference: /4147	GC07
Espinosa Hernández, Mario; Estudio de fase 2, aleatorizado, doble ciego y controlado con placebo de cemdisirán en pacientes adultos con nefropatía por IgA. Reference: /4169	GC07
Martín Malo, Alejandro; An observer-blind, multi-center, placebo-controlled, parallel group study to assess the safety and tolerability and to characterize the pharmacokinetics and the pharmacodynamics of different doses of BAY 1213790 in patients with end-stage renal disease undergoing hemodialysis. Reference: /4092	GC07
Navarro Cabello, María Dolores; Estudio de fase 2 aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de una vacuna, ASP0113, en receptores CMV-Seronegativos de trasplante de riñón procedente de donante CMV-Seropositivo. Reference: 0145/14	GC07
Navarro Cabello, María Dolores; Estudio retrospectivo, multicéntrico, para evaluar los factores que influyen en la supervivencia en pacientes con un trasplante de páncreas. Estudio EFISPAN. Reference: 2391	GC07

CLINICAL TRIALS	IMIBIC GROUP
Rodríguez Benot, Alberto Manuel; Impacto de los niveles de tacrólimos en la prevención del rechazo en pacientes de edad avanzada receptores de trasplante renal de novo: estudio observacional prospectivo en las condiciones de la práctica clínica habitual (BITÁCORA). Reference: 3976	GC07
Rodríguez Benot, Alberto Manuel; Seguimiento a largo plazo de adultos que recibieron alotrasplantes de riñón e hígado y que han participado previamente en un ensayo con Tacrolimus (Advagraf). Estudio multicéntrico no intervencional posterior a la autorización (EPA). Reference: 2612	GC07
Santamaria Olmo, Rafael; Ensayo multicéntrico internacional, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo del efecto de atrasentan sobre los resultados renales de sujetos con diabetes tipo 2 y nefropatía. SONAR: ensayo de nefropatía diabética con atrasentan. Reference: 0190/13	GC07
Santamaria Olmo, Rafael; Estudio de fase IIb, multicéntrico, aleatorizado, doble ciego y controlado con placebo de verinurad y alopurinol en pacientes con nefropatía crónica e hiperuricemia. Reference: /4323	GC07
Santamaria Olmo, Rafael; Estudio fase III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, dirigido por eventos, para evaluar la eficacia y seguridad de finerenona, asociada al tratamiento estándar, en la progresión de la enfermedad renal en pacientes con Diabetes Mellitus Tipo 2 y diagnóstico clínico de nefropatía diabética. Reference: /3335-1	GC07
Santamaria Olmo, Rafael; Estudio fase III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, dirigido por eventos, para evaluar la eficacia y seguridad de finerenona, asociada al tratamiento estándar, en la reducción de la morbilidad y mortalidad cardiovascular en pacientes con Diabetes Mellitus Tipo 2 y diagnóstico clínico de nefropatía diabética. Reference: /3334	GC07
Soriano Cabrera, Sagrario; ADAPTATION: Estudio observacional de corrección de la anemia con darbepoetin alfa con una frecuencia de adminsitración mensual en pacientes con insuficiencia renal crónica no sometidos a diálisis en la UE y Australia (Observational Study of Correction of Anaemia with Darbepoetin Alfa at Monthly Dose Frequency in EU and Australian patients with Chronic Kidney Disease not on Dialisis). Reference: 2591	GC07
Soriano Cabrera, Sagrario; Estudio de fase 3, aleatorizado, abierto y controlado con tratamiento activo para evaluar la eficacia y la seguridad de FG-4592 en el tratamiento de la anemia en pacientes con insuficiencia renal crónica no tratados con diálisis. Reference: 0239/13	GC07
Blanco Molina, Mª Angeles; XALIA-Xarelto® para la anticoagulación a largo plazo e inicial en el troboembolismo venoso (TEV). Reference: 2053	GC09
Delgado Lista, Francisco Javier; Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, para demostrar los efectos de Sotagliflozina sobre los eventos cardiovasculares y renales en pacientes con diabetes tipo 2, factores de riesgo cardiovascular y función renal moderadamente reducida. Reference: /3687	GC09
Delgado Lista, Francisco Javier; Efecto de semaglutida una vez a la semana frente a insulin aspart tres veces al día, ambas añadidas a metformina e insulina glargina optimizada (U100), en sujetos con diabetes tipo 2 Ensayo de 52 semanas, multicéntrico, multinacional, abierto, con control activo, de dos grupos paralelos y aleatorizado en sujetos con diabetes tipo 2. Reference: /3970	GC09
Delgado Lista, Francisco Javier; Estudio de las cardiopatias con semaglutida en pacientes con diabetes tipo 2 (SOUL). Reference: /4343	GC09
Delgado Lista, Francisco Javier; Pemafibrato para reducir los episodios cardiovasculares mediante la reducción de los triglicéridos en pacientes con diabetes (PROMINENT). Reference: /4108	GC09
Fernández De La Puebla Giménez, Rafael Ángel; Protocolo registro Gaucher. Reference: 2488	GC09
Fuentes Jiménez, Francisco; Ensayo aleatorizado, doble ciego y controlado con placebo para evaluar el efecto de 300 mg de inclisirán sódico administrado en inyecciones subcutáneas a sujetos con hipercolesterolemia familiar heterocigótica (HFHe) y elevado colesterol de las lipoproteínas de baja densidad (C-LDL). Reference: /3651	GC09
Fuentes Jiménez, Francisco; Ensayo aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar el efecto de SAR236553/REGN727 sobre la aparición de acontecimientos cardiovasculares en pacientes que han experimentado recientemente un síndrome coronario agudo. Reference: 0314/12	GC09

CLINICAL TRIALS	IMIBIC GROUP
Fuentes Jiménez, Francisco; Ensayo de extensión a largo plazo de los ensayos de fase III con hipolipemiantes, para evaluar el efecto del tratamiento a largo plazo con inclisirán administrador en inyecciones subcutáneas a sujetos con alto riesgo cardiovascular y LDL - C elevado. ORION-8. Reference: /4145	GC09
Fuentes Jiménez, Francisco; Estudio abierto, multicéntrico para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de AMG 145 en el C-LDL en sujetos con hipercolesterolemia familiar severa. Reference: 0032/13	GC09
Fuentes Jiménez, Francisco; Estudio abierto, multicéntrico y de un solo grupo para evaluar la seguridad, tolerabilidad y eficacia de evolocumab, como tratamiento adyuvante de la dieta y del tratamiento hipolipeminate, en la reducción del C-LDL en sujetos pediátricos de 10 a 17 años de edad con hipercolesterolemia familiar heterocigótica (HFHe) o hipercolesterolemia familiar homocigótica (HFHo). Reference: /3121	GC09
Fuentes Jiménez, Francisco; Estudio aleatorizado, doble ciego, multicentrico, controlado con placebo y de grupos paralelos para describir la eficacia, seguridad y tolerabilidad de evolocumab administrado durante 24 semanas, como tratamiento adyuvante de la dieta y del tratamiento hipolipemiante, en la reduccion del colesterol ligado a lipoproteinas de baja densidad (C-LDL) en sujetos pediatricos de 10 a 17 años de edad con hipercolesterolemia familiar heterocigota (HFHe). Reference: 0090/15	GC09
Fuentes Jiménez, Francisco; Estudio observacional multinacional para evaluar la seguridad de Repatha en el embarazo. Reference: 3565	GC09
Fuentes Jiménez, Francisco; Long-term legacy effects of LDL-C lowering with alirocumab: observational follow-up of the ODYSSEY OUTCOMES study. Reference: 3833	GC09
Gómez Delgado, Francisco Jesús; Estudio epidemiológico, multicéntrico y trasversal para caracterizar la prevalencia y distribución de los niveles de lipoproteína (a) en pacientes con enfermedad cardiovascular establecida. Reference: 4354	GC09
Gómez Delgado, Francisco Jesús; Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, con control activo y de 24 semanas de duración para evaluar el efecto de LCZ696 sobre el nivel de NTproBNP, los síntomas, la capacidad de realizar ejercicio y la seguridad en comparación con el tratamiento médico individualizado de las comorbilidades en pacientes con insuficiencia cardíaca y fracción de eyección preservada. Reference: /3861	GC09
Gómez Delgado, Francisco Jesús; EU-Wide Cross-Sectional Observational Study of Lipyd-Modifying Therapy Use in Secondary and Primary Care DA VINCI. Reference: 3637	GC09
López Jimenez, Luciano; Estudio sobre el seguimiento en la práctica clínica de las recomendaciones sobre el tratamiento con anticoagulantes orales (ACOs) en pacientes con Fibrilación Auricular (FA) de edad avanzada. Estudio ESPARTA. Reference: 2766	GC09
Lopez Miranda, Jose; Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar el impacto de evolocumab sobre los acontecimientos cardiovasculares mayores en pacientes con riesgo cardiovascular elevado sin infarto de miocardio o ictus previo (vesalius-cv). Reference: /4316	GC09
Lopez Miranda, Jose; Estudio Multinacional, Multicéntrico, de un solo Grupo y Abierto para Documentar la Seguridad, la Tolerabilidad y el Efecto de Alirocumab sobre las lipoproteínas aterogénicas en Pacientes de Alto Riesgo Cardiovascular con Hipercolesterolemia Severa no controlados adecuadamente con Tratamientos Hipolipemiantes Convencionales. Reference: 0197/15	GC09
Montero Pérez-Barquero, Manuel; Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, con control activo, para evaluar la eficacia y seguridad de LCZ696 comparado con valsartan, sobre la morbilidad y mortalidad en pacientes con insuficiencia cardiaca (Clase II-IV NYHA) con fracción de eyección preservada. Reference: 0216/13	GC09
Pérez Martínez, Pablo; Estudio aleatorizado, doble ciego, controlado con placebo, de la seguridad y la eficacia de diferentes dosis y pautas posológicas de evinacumab en pacientes con hipercolesterolemia crónica a pesar del tratamiento hipolipidemiante máximo tolerado. Reference: /3778	GC09
Pérez Martínez, Pablo; Estudio de fase III, internacional, multicéntrico, aleatorizado y abierto, para evaluar la eficacia en la reducción de cLDL y presión arterial, y la seguridad de Trinomia® versus tratamiento habitual en pacientes de muy alto riesgo cardiovascular sin evento previo: Estudio VULCANO. Reference: /3346	GC09

CLINICAL TRIALS	IMIBIC GROUP
Rodríguez Portillo, Juan Mariano; Estudio doble ciego, aleatorizado, controlado con placebo para evaluar el efecto de SNF472 en la progresión de la calcificación cardiovascular además del tratamiento de referencia en pacientes con nefropatía terminal (NT) sometidos a hemodiálisis (HD). Reference: /3294	GC09
Rodríguez Portillo, Juan Mariano; Estudio Fase 3b, aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de TRC101 en retrasar la progresión de la enfermedad crónica renal en sujetos con Acidosis Metabólica. Reference: /4030	GC09
Rodríguez Portillo, Juan Mariano; Estudio no intervencionista para investigador la seguridad, la efectividad y la adherencia de Velphoro a corto y a largo plazo en la vida real de pacientes con hiperfosfatemia sometidos a hemodiálises o a diálesis peritoneal. Reference: 3353	GC09
González Lama, Jesús; Ensayo clínico en fase III multicéntrico, aleatorizado, doble ciego, controlado por placebo, con grupos paralelos para investigar la eficacia, seguridad y tolerabilidad de Naloxona HCl LP comprimidos en pacientes con estreñimiento inducido por opioides. Reference: /4034	GC12
Hidalgo Requena, Antonio; Estudio observacional, transversal, multicéntrico para describir el perfil de exacerbaciones de los pacientes con EPOC tratados con corticoides inhalados en la práctica clínica real de atención primariaen España. Estudio OPTI; Non-Intervetional, cross-sectional, multicenter study to describe the exacerbations profile of COPD patients treated with ICS in real-life primary care population in Spain. OPTI Study. Reference: 3974/1	GC12
Martín Rioboo, Enrique; Estudio observacional de corte transversal para evaluar las caracteristicas sociodemograficas y clinicas de los pacientes diagnosticados de FANV con riego de ictus o embolia sistematica, que reciben tratamiento para el control adecuado de su coagulacion y que son atendidos en consultas de atencion primaria. Estudio SILVER-AP. Reference: 2742	GC12
Ruiz Moruno, Francisco Javier; Estudio observacional multicéntrico para establecer la prevalencia, perfil clínico y manejo terapeútico de pacientes con hidradenitis supurativa en servicios hospitalarios de Dermatología y centros de salud en España. Reference: 2883/2	GC12
Arizon Del Prado, José Mª; Estdio doble ciego, aleatorizado, controlado con placebo, multicentrico para evaluar la eficiacia de Omecamtiv y mecarbil en la mortalidad y morbilidad de sujetos con insuficiencia cardiaca cronica conf raccion de eyeccion reducida. Reference: /3327	GC15
Arizon Del Prado, José Mª; Estudio multicéntrico, aleatorizado, doble ciego, prospectivo para evaluar el efecto de sacubitril/valsartán vs. enalapril en la actividad física diaria utilizando un actígrafo de muñeca en pacientes adultos con insuficiencia cardíaca crónica. Reference: /3388	GC15
Castillo Domínguez, Juan Carlos; Estudio de fase 3, multinacional, aleatorizado y controlado con placebo de ARRY-371797 en pacientes con miocardiopatía dilatada sintomática por mutación del gen lamina A/C. Reference: /3969	GC15
Hidalgo Lesmes, Francisco José; Estudio observacional retrospectivo del uso de evolocumab en unidades españolas de cardiología (RETOSS-Cardio). Reference: 3619	GC15
López Aguilera, Jose; Estudio observacional descriptivo de conveniencia en pacientes tartados con dabigatrán para la prevención del ictus en fibrilación auricular no valvular. Reference: 3693	GC15
López Aguilera, Jose; ESTUDIO PARA VALORAR LA SATISFACCIÓN Y PREFERENCIAS DE LOS PACIENTES EN TRATAMIENTO PREVENTIVO DE EVENTOS CARDIOVASCULARES SECUNDARIOS CON UNA POLIPÍLDORA CARDIOVASCULAR. Reference: 3073	GC15
López Granados, Amador; Factores de riesgo asociados con la progresión de la insuficiencia cardiaca en pacientes con fibrilación auricular tratados con anticoagulante oral directo. Reference: 3834	GC15
López Granados, Amador; Registro global de tratamiento antitrombótico oral a largo plazo en pacientes con fibrilación auricular (Fase II/III Estados miembros de la UE/AEE). Reference: 2594	GC15
Ojeda Pineda, Soledad; Registro multicentrico de REVAscularizacion SECundaria. REGISTRO REVASEC. Reference: 3639	GC15
Pavlovic Djurovic, Djordje; Estudio en Fase III, aleatorizado, doble ciego y controlado con placebopara evaluar los efectos de dalcetrapib sobre el riesgo cardiovascular (CV) en una población definida genéticamente con síndrome coronario agudo reciente (SCA): el ensayo dal-genE. Reference: /3126	GC15
Ruiz Ortiz, Martin; Estudio observacional y transversal para evaluar las características sociodemográficas y clínicas de los pacientes tratados con rivaroxaban en la práctica clínica habitual de hematólogos, cardiólogos e internistas de todo el territorio nacional (Estudio HEROIC). Reference: 2602	GC15

CLINICAL TRIALS	IMIBIC GROUP
Álvarez Rivas, Miguel Ángel; Estudio de fase 3, aleatorizado, controlado con placebo, doble ciego del tratamiento de mantenimiento con ixazomib citrato por vía oral (MLN9708) en pacientes con mieloma múltiple después de autotrasplante de células madre. Reference: 0112/14	GC16
Arqueros Martínez, Víctor; Efficacy and safety of M281 in adults with warm autoimmune Hemolytic anemia: a multicenter, randomized, doble blind, placebo controlled study with a long-term open label extension. Reference: /4351	GC16
Fernández De La Mata, Margarita; Estudio observacional retrospectivo del tratamiento de la leucemia linfocítica crónica (LLC) con Ibrutinib en la práctica clínica habitual. Reference: 3977	GC16
Fernández De La Mata, Margarita; Evaluación retrospectiva no intervencional posterior a la autorización del uso de idelalisib en pacientes con leucemia cinfocítica crónica (LLC) en recaía/refractaria (R/R) en España. Reference: 4026	GC16
Martín Calvo, María Del Carmen; Estudio adaptativo y aleatorizo de fase 3 para comparar la eficacia y la seguridad de Defibrotide frente al mejor tratamiento de soporte en la prevención de la enfermedad venooclusiva hepática en pacientes adultos y pediátricos sometidos a un transplante hematopoyético de células madre. Reference: /3340	GC16
Molina Hurtado, José Ramón; ESTUDIO DE FASE IIIB MULTICÉNTRICO, INTERNACIONAL, ABIERTO, CON UN SOLO GRUPO DE TRATAMIENTO PARA EVALUAR LA SEGURIDAD DE OBINUTUZUMAB COMO AGENTE ÚNICO O EN COMBINACIÓN CON QUIMIOTERAPIA EN PACIENTES CON LEUCEMIA LINFÁTICA CRÓNICA RECURRENTE/REFRACTARIA O NO TRATADOS PREVIAMENTE. Reference: 0148/13	GC16
Molina Hurtado, José Ramón; Incidencia y resultados asociados al tratamiento de las infecciones por adenovirus en receptores de alotrasplante de celulas hematopoyeticas: Advance. Reference: 3390	GC16
Molina Hurtado, José Ramón; oPEN LABEL PHASE 1 STUDY TO ASSESS THE MAXIMUM TOLERATED DOSE, PHARMACOKINETICS, AND SAFETY OF iXAZOMIB ADMINITERED INTRAVENOUSLY TO PEDIATRIC PATIENTS AGED 0 TO LESS THAN 18 YEARS WITH RELAPSE RELAPSE OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA, WITH OR WITHOUT EXTREMEDULLARY DISEASSE, OR RELAPSE OR REFRACTORY LYMPHOBLASTIC LYMPHOMA. Reference: /4275	GC16
Rojas Contreras, Rafael; Ensayo de fase 3 aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia protectora y la seguridad de una vacuna terapéutica, ASP0113, en receptores seropositivos para el citomegalovirus (CMV) sometidos a alotrasplante de células hematopoyéticas (ATCH). Reference: 0123/13	GC16
Rojas Contreras, Rafael; Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, con doble simulación, con control activo para evaluar la eficacia y la seguridad de maribavir en comparación con valganciclovir para el tratamiento de la infección por citomegalovirus (CMV) en receptores de un trasplante de células madre hematopoyéticas. Reference: /3584	GC16
Rojas Contreras, Rafael; Estudio de fase III aleatorizado, abierto y multicéntrico de ruxolitinib frente a la mejor terapia disponible en pacientes con enfermedad de injerto contra huésped crónica refractaria a corticosteroides tras trasplante alogénico de células madre. Reference: /3551	GC16
Sánchez García, Joaquin; A randomized, doubled blinde, parallel-group, phase III study to compare the efficacy, safety and immunogenicity of proposed rituximab biosimilar (DRL-RI) with Mabthera in subjects with previously untreated, stage II-IV, cluster of differenciation (CD) 20-positive, low tumour burden follicular lymphoma. Reference: /4223	GC16
Sánchez García, Joaquin; Ensayo aleatorizado y doble ciego para evaluar la eficacia, la seguridad y la inmunogenicidad de abp 798 en comparación con rituximab en sujetos con linfoma no hodgkin (lnh) de células b sd20+. Reference: /3190	GC16
Sánchez García, Joaquin; Estudio de fase 1/1b de pevonedistat en combinación con azacitidina en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica o leucemia mielógenaguda con insuficiencia renal grave o insuficiencia hepática leve. Reference: /4276	GC16
Sánchez García, Joaquin; Estudio de fase 2, abierto y de un solo un grupo, del inhibidor de HDAC oral abexinostat en pacientes con linfoma folicular en recaída o refractario. Reference: /4270	GC16
Sánchez García, Joaquin; Estudio de fase 3, doble ciego y aleatorizado para comparar la eficacia y la seguridad de rituximab más lenalidomida (CC-5013) frente a rituximab más placebo en sujetos con linfoma indolente recidivante/resistente. Reference: 0202/13	GC16

CLINICAL TRIALS	IMIBIC GROUP
Sánchez García, Joaquin; Estudio multicêntrico de fase 2/3 para evaluar la seguridade y la eficácia de blinatumomab em sujetos com linfoma no Hodgkin de células B agressivo em recaída/refractario. Reference: /3269	GC16
Sánchez García, Joaquin; Estudio Observacional retrospectivo sobre el tratamiento de linfoma de células del manto con Ibrutinib en la práctica clinica habitual. Reference: 3832	GC16
Serrano López, Josefina; Estudio de fase III, doble ciego, controlado con placebo de quizartinib (AC220) administrado en combinación con quimioterapia de inducción y consolidación, y administrado como terapia de mantenimiento a sujetos de 18 a 75 años con leucemia mielógena aguda FLT3-ITD (+) de nuevo diagnóstico (QuANTUM First). Reference: /3218	GC16
Serrano López, Josefina; Estudio de la correlacióln entre la respuesta ex vivo a fármacos antineoplásicos y su eficacia en el tratamiento de la leucemia mieloide aguda. Reference: 1790	GC16
Serrano López, Josefina; Estudio fase 3, aleatoriado, doble ciego y controlado con placebo para comparar la eficacia y la seguridad de azacitidina oral más el mejor tratamiento de apoyo frente al mejor tratamiento de apoyo como terapia de mantenimiento en pacientes con leucemia mieloide aguda en remisión completa. Reference: 0293/12	GC16
Serrano López, Josefina; Estudio fase III, aleatorizado, doble ciego, de quimioterapia de inducción (daunorrubicina o idarrubicina y citarabina) y de consolidación (dosis intermedias de citarabina) más midostaurina (PKC412) o de quimioterapia más placebo en pacientes con leucemia mieloide aguda (LMA) de nuevo diagnóstico sin mutaciones en FLT-3. Reference: /3871	GC16
Serrano López, Josefina; Estudio fase III, multicéntrico, aleatorizado y abierto con la guadecitabina (SGI-110) en comparación con el tratamiento de elección en adultos con leucemia mieloide aguda tratados previamente. Reference: /3557	GC16
Serrano López, Josefina; Estudio observacionesl prospectivo sobre la supervivencia global y la calidad de vida en pacientes de mayores de 60 años diagnosticados de leucemia mieloide aguda en España, tratados según la práctica clínica habitual. Estudio SvLMA. Reference: 3658	GC16
Serrano López, Josefina; Patrones de tratamiento y resultados clínicos en vida real en pacientes unfit con Leucemia Mieloide Aguda tratados con una primera línea de tratamiento sistémico o con el mejor tratamiento de soporte. Estudio Current. Reference: 4355	GC16
Serrano López, Josefina; Phase III Randomized double-blind, placebo-controlled study investigating the efficacy of the addition of crenolaninb to salvage chemotherapy alone in subjects less than 75 years of age with Relapsed/refractory FLT3 Mutated Acute Leukemia. Reference: /4105	GC16
Quesada Gómez, José Manuel; Estudio no intervencional con Binosto 70mg en forma de comprimidos efervescentes administradosuna vez a la semana para investigar los acontecimientos gastrointestinales y los errores de medicaciones. Reference: 3071	GC17
Quesada Gómez, José Manuel; Efecto de la administración de diferentes regímenes de tratamiento de Hidroferol® Cápsulas de Gelatina Blanda (calcifediol) y colecalciferol (Dibase®) en los niveles de 25(OH)D y marcadores de remodelado óseo en mujeres postmenopáusicas con deficiencia de 25(OH)D. Influencia de factores clínicos y genéticos en la población osteoporótica y no-osteoporótica. Reference: /3653	GC17
Anton Gamero, Montserrat; Estudio en fase III multicéntrico y abierto de ALXN1210 en niños y adolescentes con síndrome hemolítico urémico atípico (SHUa). Reference: /3477	GC23
Gil Campos, Mª Mercedes; Phase 2, open label study to evaluate the efficacy and safety of KB195 in subjects with urea cycle dosrder with inadecuate control on standard of care. Reference: /4321	GC23
López Laso, Eduardo; Un registro internacional de enfermedad que recoge datos sobre manifestaciones, intervenciones y resultados en pacientes con complejo esclerosis tuberosa. Reference: 2060	GC23
Mateos González, Mª Elena; Estudio de fase II abierto global para evaluar el efecto de dabrafenib en combinación con trametinib en pacientes niños y adolescentes con Glioma de Alto Grado (HGG) recidivante o refractario con mutación BRAF V600 positiva. Reference: /3941	GC23
Pérez Navero, Juan Luis; Estudio internacional aleatorizado, controlado, doble ciego y de grupos paralelos para investigar la seguridad y la toleracia de una leche de fórmula infantil parcialmente fermentada que contiene oligosacáridos prebióticos en lactantes nacidos a término sanos. VOYAGE. Reference: 3912	GC23

CLINICAL TRIALS	IMIBIC GROUP
Martínez Martínez, Luis; Estudio epidemiológico para estimar la distribución del serotipo O del Escherichia coli patógeno extraintestinal (ExPEC) aislado en pacientes hospitalizados de todos los grupos de edad con enfermedad por ExpEC invasivo y para evaluar la definición de caso clínico y los factores de riesgo. Reference: 4038	GC24
Rivero Roman, Antonio; A Phase III, randomised, double-find, multicentre, parallelgroup, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naive adults. Reference: /3192	GC26
Rivero Roman, Antonio; Ensayo en fase 3, randomizado, controlado con tratamiento activo y doble ciego para evaluar la eficacia y seguridad del régimen combinado de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (D/C/F/TAF) administrado una vez al día frente al régimen consistente en la combinación de darunavir/cobicistat coadministrado junto con la combinación emtricitabina/tenofovir disoproxil fumarato en sujetos naive en tratamiento antirretroviral infectados por el virus de la inmunodeficiencia humana de tipo 1. Reference: 0114/15	GC26
Rivero Roman, Antonio; Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/emtricitabina/tenofovir alafenamida en comparación con abacavir/dolutegravir/lamivudina en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Reference: /3124	GC26
Rivero Roman, Antonio; Estudio en fase 3, aleatorizado y doble ciego para evaluar la seguridad y eficacia del cambio de un régimen formado por dolutegravir y ABC/3TC, o una combinación de dosis fijas (CDF) de ABC/DTG/3TC a una CDF de GS 9883/F/TAF en sujetos infectados por el VIH-1 con supresión virológica. Reference: 0369/15	GC26
Rivero Roman, Antonio; Estudio fase III aleatorizado, multicéntrico abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intremuscular de acción prolongada con cabotegravir y rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica.A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed. Reference: /3248	GC26
Rivero Roman, Antonio; Estudio Fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica. Reference: /3632	GC26
Agüera Morales, Eduardo; A 24-Month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker, and pharmacokinetic study of AZD3293 in early alzheimer disease (the amaranth study). Reference: /3069	GE01
Agüera Morales, Eduardo; A 52-WEEK OPEN-LABEL EXTENSION STUDY OF PIMAVANSERIN FOR THE TREATMENT OF AGITATION AND AGGRESSION IN SUBJECTS WITH ALZHEIMER'S DISEASE. Reference: /3386	GE01
Agüera Morales, Eduardo; A multicenter, global, retrospective, observational study to characterize real-world clinical outcomes in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapies (Tecfidera, Copaxone, Aubagio, or Gilenya) (EFFECT). Reference: 3222	GE01
Agüera Morales, Eduardo; A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjets with Early Alzheimer´s Disease. Reference: 0150/15	GE01
Agüera Morales, Eduardo; Efectos de levosimendán oral (ODM-109) en la función respiratoria de pacientes con ELA. Reference: /3827	GE01
Agüera Morales, Eduardo; Ensayo clínico de fase IIb, internacional, en doble ciego, aleatorizado y controlado con placebo, para evaluar la eficacia, la seguridad y la farmacocinética de GNbAC1 en pacientes con esclerosis múltiple recidivante remitente. Reference: /3066	GE01
Agüera Morales, Eduardo; Ensayo clínico, abierto, no aleatorizado, de grupos paralelos, multicéntrico para evaluar la eficacia de fingolimod como terapia en pacientes de novo vs. fingolimod como terapia en pacientes previamente tratados con interferones o acetato de glatirámeto, en base a la presencia de brotes, en pacientes con esclerosis múltiple remitente-recurrente. Reference: 0103/11	GE01

CLINICAL TRIALS	IMIBIC GROUP
Agüera Morales, Eduardo; Estudio abierto, aleatorizado, multicéntrico, controlado con tratamiento activo, de grupos paralelos para evaluar la seguridad, la tolerabilidad y la eficacia de BIIB017 en pacientes pediátricos de entre 10 y menos de 18 años de edad para el tratamiento de la esclerosis múltiple recidivante-remitente, con una extensión abierta opcional. Reference: /4227	GE01
Agüera Morales, Eduardo; Estudio aleatorizado, doble ciego, controlado con placebo del TEV-50717 (deutetrabenazina) para el tratamiento de la discinesia en la parálisis cerebral en niños y adolescentes. Reference: /4411	GE01
Agüera Morales, Eduardo; Estudio de 24 meses, de grupos paralelos, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de E2609 en pacientes con enfermedad de Alzheimer temprana. Reference: /3865	GE01
Agüera Morales, Eduardo; Estudio de extensión en fase III, multicéntrico, a largo plazo sobre la seguridad y eficacia de AVP-786 (bromhidrato de [d6]-dextrometorfano deuterado [d6-DM]/ sulfato de quinidina [Q]) para el tratamiento de la agitación en pacientes con demencia de tipo Alzheimer. Reference: /3991	GE01
Agüera Morales, Eduardo; Estudio de extensión, abierto, multicéntrico para evaluar la eficacia y la seguridad a largo plazo de BIIB019, Daclizumab obtenido mediante un proceso de alto rendimiento (DAC HYP), como monoterapia en sujetos con esclerosis múltiple que hayan completado el estudio 205MS301. Reference: 0031/13	GE01
Agüera Morales, Eduardo; Estudio de fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo, con diseño de grupos paralelos, para evaluar la eficacia, la seguridad y la tolerabilidad de AVP-786 (bromhidrato de deudextrometorfano [d6-DM]/sulfato de quinidina [Q]) en el tratamiento de la agitación en pacientes con demencia de tipo Alzheimer. Reference: /3721	GE01
Agüera Morales, Eduardo; Estudio de Fase III, Multicéntrico, Aleatorizado, Doble Ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de Gantenerumab en pacientes con enfermedad de alzheimer precoz (de Prodrómica a leve) y los sub-estudios Subestudio longitudinal, de PET para amiloide''. Reference: /3911	GE01
Agüera Morales, Eduardo; Estudio de retirada aleatorizado en fase II, controlado con placebo y doble ciego con reclutamiento enriquecido para evaluar la eficacia y la seguridad de BIIB074 en el tratamiento del dolor sufrido por sujetos con neuropatía de fibras pequeñas confirmada e idiopática o asociada a diabetes mellitus. Reference: /3715	GE01
Agüera Morales, Eduardo; Estudio doble ciego, de grupos paralelos, controlado con placebo, de 18 meses de duración, con una Fase de Extensión abierta, para confirmar la seguridad y eficacia de BAN2401 en sujetos con enfermedad de Alzheimer en etapa inicial. Reference: /4348	GE01
Agüera Morales, Eduardo; ESTUDIO EN FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, EN GRUPOS PARALELOS, QUE EVALÚA LA EFICACIA Y SEGURIDAD DE MTAU9937A EN PACIENTES CON ENFERMEDAD DE ALZHEIMER DE FASE PRODRÓMICA A LEVE. Reference: /3692	GE01
Agüera Morales, Eduardo; Estudio en fase II, multicéntrico, aleatorizado, doble ciego, controlado y de grupos paralelos de Aducanumab (BIIB037) en sujetos con deterioro cognitivo leve debido a la enfermedad de Alzheimer o con demencia de la enfermedad de Alzheimer leve para evaluar la seguridad de la administración de dosis continuada en sujetos asintomáticos con anomalías en las imágenes relacionadas con el amiloide. Reference: /4031	GE01
Agüera Morales, Eduardo; ESTUDIO EN FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y SEGURIDAD DE CRENEZUMAB EN PACIENTES CON ENFERMEDAD DE ALZHEIMER DE PRODRÓMICA O LEVE. Reference: /3478	GE01
Agüera Morales, Eduardo; Estudio epidemiológico retrospectivo para el análisis de la actividad clínica y radiológica de la enfermedad en pacientes con Esclerosis Múltiple Recurrente-Remitente tras la retirada de Natalisumab por práctica clínica habitual. Reference: 3012	GE01
Agüera Morales, Eduardo; ESTUDIO MULTICENTRICO NO INTERVENCIONAL PARA EVALUAR LA EFECTIVIDAD DE OCRELIZUMAB EN PACIENTES CON ESCLEROSIS MÑULTIPE RECURRENTE O PRIMARIA PROGRESIVA EN PRACTICA CLINICA HABITUAL. Reference: 4446	GE01
Agüera Morales, Eduardo; Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en sujetos con esclerosis múltiple recurrente para evaluar la eficacia y la seguridad de BIIB033 como tratamiento adicional a los tratamientos antinflamatorios modificadores de la enfermedad. Reference: /3630	GE01

CLINICAL TRIALS	IMIBIC GROUP
Agüera Morales, Eduardo; Estudio observacional, multicéntrico, multinacional para recopilar información sobre la seguridad y documentar la utilización farmacéutica de Fampyra cuando se usa en la práctica médica habitual (LIBERATE). Reference: 2882	GE01
Agüera Morales, Eduardo; Estudio observacional, no intervencionista para evaluar los cambios en la calidad de vida en pacientes con esclerosis múltiple remitente recurrente tratados con alemtuzumab (Lemtrada) en condiciones de práctica clínica habitual. Reference: 3042	GE01
Agüera Morales, Eduardo; Estudio observacional, trasversal con recogida de datos retrospectivos para valorar el impacto económico de la esclerosis múltiple secundaria progresivas (DISCOVER). Reference: 4279	GE01
Agüera Morales, Eduardo; Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con lemtrada (alemtuzumab) en pacientes con formas recidivantes de esclerosis múltiple. OBS13434. Reference: 2879	GE01
Agüera Morales, Eduardo; Estudio prospectivo Fase III, multicéntrico, randomizado, doble ciego, de dos grupos paralelos, controlado con placebo y de 96 semanas de duración, para comparar la eficacia y seguridad de masitinib a la dosis de 4.5 mg/kg/día con placebo en el tratamiento de pacientes con esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva sin recidiva. Reference: 0301/13	GE01
Agüera Morales, Eduardo; Estudio sin enmascaramiento de seguridad, tolerabilidad y eficacia a largo plazo de TEV-50717 (deutetrabenazina) para el tratamiento de la discinesia en la parálisis cerebral en niños y adolescentes (RECLAIM-DCP abierto). Reference: /4443	GE01
Agüera Morales, Eduardo; Evaluating the Long-Term Outcomes and Durability of Effect following treatment with cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV ambispective study of patiens who previously participated in the CLARITY/CLARITY-EXT and ORACLE Tr. Reference: /4342	GE01
Agüera Morales, Eduardo; Maven4 Real- World Evidence Spanish study: A non-interventional, post-authorization prospective cohort study evaluate the long-term effectiveness, safety and health outcomes of cladribine tablets fot the treatment of relapsing multiple sclerosis under routine clinical practice in Spain. Reference: 4408	GE01
Agüera Morales, Eduardo; Multicenter Follow-Up Study to Assess Log-Term Electrophysiologyc and Clinical Outcomes in Subjects Previously Enrrolled in Study 215ON201. Reference: 0321/15	GE01
Agüera Morales, Eduardo; Open-Label, Randomised, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to less than 18 years of age with relapsing-remitting multple sclerosis, with optional open-label extension. Reference: /3268	GE01
Agüera Morales, Eduardo; Plegridy (peginterferon) Real World Effectiveness and Safety Observational Program. Reference: 3163	GE01
Agüera Morales, Eduardo; Registro español de pacientes tratados con acetato de glatiramero (Copaxone®) 40mg/ml. Reference: 3007	GE01
Bahamonde Román, Carmen; Ensayo multicéntrico aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de eculizumab en pacientes con neuromielitis óptica (NMO) recidivante. Reference: 0011/14	GE01
Ochoa Sepúlveda, Juan José; Estudio observacional y prospectivo para evaluar la efectividad de inyecciones de la toxina botulínica tipo A (BoNT-A) en pacientes con espasticidad de miembros superiores y/o inferiores tras un ictus, en la fase temprana del desarrollo de la espasticidad. (ETREAT). Reference: 2569	GE01
Valverde Moyano, Roberto; Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de BIIB093 por vía intravenosa (glibenclamida) para el edema cerebral grave tras infarto hemisférico maligno. Reference: /4319	GE01
Ruano Ruiz, Juan; A phase 2B randomnized, double blind, placebo controlled, multicenter, dose ranging study to evaluate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 and PF-06700841 in subjects with active non segmental vitiligo. Reference: /4090	GE03
Ruano Ruiz, Juan; A randomized double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety to tralokinumab monotherapy in patients with moderate to sever atopic dermatitis who are candidates for systemic therapy. Reference: /3523	GE03

CLINICAL TRIALS	IMIBIC GROUP
Ruano Ruiz, Juan; Ensayo aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, de fase 3 que investiga la eficacia, la seguridad y la tolerabilidad de tralokinumab administrado en combinación con corticosteroides tópicos a pacientes adultos con dermatitis atópica grave que no están suficientemente controlados con ciclosporina A oral o para los que este fármaco está contraindicado. Reference: /4028	GE03
Ruano Ruiz, Juan; Ensayo de extensión a largo plazo, multicéntrico, abierto y de un solo brazo, para evaluar la seguridad y eficacia de tralokinumab en pacientes con dermatitis atópica que participaron previamente en ensayos clínicos con tralokinumab. Reference: /3990	GE03
Ruano Ruiz, Juan; Estudio de extension, multicéntrico, abierto para evaluar la seguridad a largo plazo de QGE031 240 mg s.c. administrado cada 4 semanas durante 52 semanas en pacientes con urticaria espontánea crónica que hayan completado el estudio CQGE031C2201. Reference: 0020/16	GE03
Ruano Ruiz, Juan; Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y comparado con placebo, para evaluar la eficacia y la seguridad de baricitinib en combinación con corticoesteroides de administración tópica en pacientes adultos con dermatitis atópica de moderada a grave - BREEZE - AD7. Reference: /3971	GE03
Ruano Ruiz, Juan; Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de apremilast (CC-10004) en pacientes pediátricos de 6 a 17 años con psoriasis en placas de moderada a grave. Reference: /4142	GE03
Ruano Ruiz, Juan; estudio de fase II b, aleatorizado, en doble ciego, controlado con placebo, de grupos paralelos y de búsqueda de dosis, para investigar los perfiles de eficacia, seguridad y farmacocinética de REGN3500 en pacientes adultos con dermatitis atópica moderada a grave. Reference: /4170	GE03
Ruano Ruiz, Juan; Estudio de fase IIa, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y multicéntrico de un anticuerpo monoclonal anti-OX40L (KY1005) en la dermatitis atópica de moderada a grave. Reference: /4064	GE03
Ruano Ruiz, Juan; Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y un fármaco activo, de interrupción y reinicio aleatorizado del tratamiento para evaluar la eficacia y seguridad de BMS-986165 en pacientes con psoriasis en placas de moderada a grave. Reference: /4091	GE03
Ruano Ruiz, Juan; ESTUDIO EN FASE III DE RETIRADA ALEATORIZADA, DOBLE CIEGO, CONTROLADO CON PLACEBO Y MULTICÉNTRICO PARA INVESTIGAR LA EFICACIA Y LA SEGURIDAD DE PF-04965842 EN PACIENTES DE 12 O MÁS AÑOS DE EDAD CON DERMATITIS ATÓPICA MODERADA O GRAVE CON LA OPCIÓN DE UN TRATAMIENTO DE RESCATE PARA AQUELLOS PACIENTES QUE PRESENTEN UN EMPEORAMIENTO DE LA ENFERMEDAD. Reference: /3942	GE03
Ruano Ruiz, Juan; Estudio en fase III multicéntrico y de extensión a largo plazo para evaluar la eficacia y la seguridad de PF-04965842, en monoterapia o en combinación con medicamentos tópicos, administrado a pacientes de 12 años o más con dermatitis atópica moderada o grave. Reference: /3996	GE03
Ruano Ruiz, Juan; Estudio fase 3, doble ciego, aleatorizado, controlado con vehículo, sobre la eficacia y seguridad del tratamiento con Ruxolitinib en crema, en adolescentes y adultos con dermatitis atópica, de 8 semanas de duración seguido de un periodo de extensión de seguridad a largo plazo. Reference: /4229	GE03
Ruano Ruiz, Juan; Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo y fármaco comparador activo, para evaluar la eficacia y la seguridad de guselkumab en el tratamiento de pacientes con psoriasis en placa de moderada a grave. Reference: 0251/14	GE03
Ruano Ruiz, Juan; Estudio multicéntrico de Fase III, aleatorizado, doble ciego para evaluar la eficacia comparativa de Guselkumab (CNTO1959) y Secukinumab en el Tratamiento de la Psoriasis en Placa de Moderada a Grave. Reference: /3438	GE03
Ruano Ruiz, Juan; Estudio multicéntrico, aleatorizado, con doble enmascaramiento y controlado con placebo, para evaluar la eficacia y seguridad de mirikizumab con secukinumab y placebo en pacientes con psoriasis en placas moderada a grave. OASIS-2. Reference: /3873	GE03
Ruano Ruiz, Juan; Estudio multicéntrico, aleatorizado, doble ciego, con control activo y placebo para investigar la eficacia y seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica espontánea (UCE) en adolescentes y adultos inadecuadamente controlada con antihistamínicos H1. Reference: /3972	GE03

CLINICAL TRIALS	IMIBIC GROUP
Ruano Ruiz, Juan; Evaluación del paciente con urticaria crónica refractaria al tratamiento con antihistamínicos a nivel mundial. Estudio observacional en urticaria crónica para recopilar datos clínicos en la práctica clínica sobre el impacto del tratamiento, diagnóstico y el manejo de la urticaria crónica en pacientes refractarios al menos a una tanda de tratamiento con antihistamínicos H1. Estudio AWARE. Reference: 2719	GE03
Ruano Ruiz, Juan; Optimise. Optimizacion del tratamiento de mantenimiento a largo plazo de la piel blanqueada en pacientes con psoriasis cronica en placas de moderada a grave: Estudio randomizado, multicentrico, abierto con evaluacion ciega, comparativo, de 52 semanas de seguimiento para evaluar la eficacia, seguridad y tolerabilidad de secukinumab 300mg s.c. Reference: 0032/15	GE03
Ruano Ruiz, Juan; Randomized, double- blind, Placebo controlled, Multicenter trial to Evaluate the efficacy and of oral BtK Inhibitor PRN1008 in Moderate to Severe Pemphigus. Reference: /4143	GE03
Ruano Ruiz, Juan; Un estudio controlado multicéntrico, aleatorizado, doble ciego, de grupos paralelos para evaluar la eficacia y seguridad de la solución cutánea en aerosol P-3074 en el tratamiento de la alopecia androgénica. Reference: /3247	GE03
Vélez Garcia-Nieto, Antonio; Estudio clínico abierto para evaluar la eficacia y la seguridad a largo plazo de dimetilfumarato en adultos con psoriasis crónica en placas moderada-grave en la práctica clínica (Estudio DIMESKIN 1). Reference: /3587	GE03
Vélez Garcia-Nieto, Antonio; Validación del cuestionario EARP para la detección de la artritis psoriásica en población española. Estudio VALS. Reference: 2702	GE03
Gimenez Gomez, Rafael; Eficacia y seguridad del bimatoprost de liberación lenta en pacientes con glaucoma de ángulo abierto o hipertensión ocular The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension. Reference: 0360/14	GE07
Gimenez Gomez, Rafael; Estudio prospectivo, con doble enmascaramiento, aleatorizado, multicéntrico, con comparador activo y grupos paralelos de 6 meses de duración para evaluar la seguridad y la eficacia hipotensora ocular de PG324 solución oftálmica en comparación con GANFORT® (bimatoprost 0,03 %/timolol 0,5 %) solución oftálmica en sujetos con presión intraocular elevada (MERCURY 3). Reference: /3447	GE07
Álvarez Kindelán, Antonio; Estudio sobre la incidencia de tromboembolismo pulmonar en pacientes intervenidos quirúrgicamente por carcinoma broncogénico. Estudio QELER. Reference: 2812	GA01
Robles Arista, Juan Carlos; Estudio observacional, prospectivo y multicéntrico en Cuidados Intensivos para evaluar la fiabilidad diagnóstica de la pcr (reacción en cadena de la polimerasa) en pacientes en tratamiento antifúngico empírico por sospecha de candidiasis invasiva. Reference: 2168	GA01
Entrenas Costa, Luis Manuel; Estudio observacional para describir la prevalencia de asma grave en centros hospitalarios españoles. Reference: 3593	GA03
Jurado Gámez, Bernabé; Estudio prospectivo, multicéntrico, aleatorizado, abierto y de 12 semanas para evaluar la eficacia y la seguridad de glicopirronio (50 microgramos 1 v/d) o de la asociación en dosis fijas de maleato de indacaterol y bromuro de glicopirronio (110/50 microgramos 1 v/d) en los síntomas y el estado de salud de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) moderada que se cambien del tratamiento estándar para la EPOC. Reference: 0044/14	GA03
Redel Montero, Javier; Ensayo clínico de fase III, prospectivo, multicéntrico, aleatorizado y controlado para demostrar la eficacia y la seguridad de Ciclosporina A Liposómica (L-CsA) solución para inhalación administrada mediante el dispositivo en investigación eFlow® de PARI más el tratamiento de referencia frente al tratamiento de referencia solo en el tratamiento del síndrome de bronquiolitis obliterante en pacientes tras un trasplante pulmonar doble. Reference: /4107	GA03
Redel Montero, Javier; Ensayo clínico de fase III, prospectivo, multicéntrico, aleatorizado y controlado para demostrar la eficacia y la seguridad de Ciclosporina A Liposómica (L-CsA) solución para inhalación administrada mediante el dispositivo en investigación eFlow® de PARI más el tratamiento de referencia frente al tratamiento de referencia solo en el tratamiento del síndrome de bronquiolitis obliterante en pacientes tras un trasplante pulmonar simple. Reference: /4106	GA03
Vaquero Barrios, José Manuel; Calidad de vida en pacientes con hipertensión y pulmonar (hap y hptec) y su percepción sobre la calidad de la atención recibida. Reference: 3788	GA03
Gálvez Moreno, Mª Ángeles; Efecto y seguridad de semaglutida 2,4 mg una vez a la semana en sujetos con sobrepeso u obesidad y diabetes tipo 2. Reference: /3863	GA04

CLINICAL TRIALS	IMIBIC GROUP
Gálvez Moreno, Mª Ángeles; Estudio adaptativo, aleatorizado, doble ciego y controlado con placebo para evaluar la mejoría sintomática y el control metabólico en adultos con hipoparatiroidismo sintomático tratados con hormona paratiroidea humana recombinante [PTHhr(1-84)]. Reference: /3688	GA04
Gálvez Moreno, Mª Ángeles; Estudio de 26 semanas aleatorizado, doble ciego, controlado, multicéntrico con grupos paralelos para evaluar la eficacia y seguridad de sotagliflozina en comparación con empagliflozina y placebo en pacientes con diabetes de tipo 2 que tienen un control glucémico insuficiente con inhibidores de la dipeptidil peptidasa 4 (iDPP4), con o sin metformina. Reference: /3690	GA04
Gálvez Moreno, Mª Ángeles; ESTUDIO EUROPEO, OBSERVACIONAL, DE PASIREOTIDA LAR EN ACROMEGALIA - ESTUDIO ACRONIS. Reference: 3420	GA04
Gálvez Moreno, Mª Ángeles; Estudio observacional, trasversal y multicentrico para valorar el grado de actividad de la enfermedad de los pacientes acromegálicos en España según la escala ACRODAT. Estudio ACRODAT. Reference: 3597	GA04
Gómez Guzmán, Elena; Estudio multicéntrico para evaluar la seguridad y tolerabilidad a largo plazo de un tratamiento en abierto con sacubitrilo/valsartán en pacientes pediátricos con insuficiencia cardíaca debida a disfunción sistólica de ventrículo izquierdo sistémico, que han completado el estudio CLCZ696B2319 (PANORAMA-HF). Reference: /4490	GA05
Gómez Guzmán, Elena; Estudio multicéntrico, abierto, aleatorizado, basado en acontecimientos, para evaluar la eficacia, la seguridad y la farmacocinética de macitentán frente al tratamiento de referencia en niños con hipertensión arterial pulmonar. Reference: /3633	GA05
Gómez Guzmán, Elena; Estudio multicéntrico, abierto, para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de LCZ696, seguido de un estudio de 52 semanas, aleatorizado, doble ciego, paralelo controlado con fármaco activo para evaluar la eficacia y seguridad de LCZ696 comparado con enalapril en pacientes pediátricos con edades desde 1 mes hasta < 18 años, con insuficiencia cardiaca debida a disfunción sistólica del ventrículo izquierdo sistémico. Reference: /3336	GA05
Ruiz González, Mª Dolores; Estudio de fase IIb aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en prematuros sanos. Reference: /3580	GA05
Ruiz González, Mª Dolores; Estudio en fase III aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en bebés sanos nacidos prematuros tardíos y a término (MELODY). Reference: /4414	GA05
García-Revillo García, José; Eficacia y seguridad en la administración intraarterial de Rexmyelocel-T en el tratamiento de la isquemia crítica de extremidades inferiores en pacientes con diabetes mellitus: ensayo controlado con placebo, doble ciego, aleatorizado, multicéntrico. Reference: /3118	GA08
Hervás Sotomayor, Daniela; Registro universal de implantación de prótesis valvular aórtica de Sorin. SURE AVR. Reference: 3655	GA09
Muñoz Carvajal, Ignacio; ESTUDIO DE FASE 3, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE QPI-1002 EN LA PREVENCIÓN DE ACONTECIMIENTOS ADVERSOS RENALES GRAVES (MAKE) EN PACIENTES CON ALTO RIESGO DE LESIÓN RENAL AGUDA (AKI) DESPUÉS DE CIRUGÍA CARDÍACA. Reference: /4032	GA09
Muñoz Carvajal, Ignacio; Estudio fundamental EV ICD (desfibrilador automático implantable extravascular, por sus siglas en inglés). Reference: 4404	GA09
Muñoz Carvajal, Ignacio; Factores preoperatorios que influyen en la presencia de complicaciones y morbilidad post-cirugía cardíaca en pacientes con disfunción ventricular severa. Estudio observacional prospectivo. Reference: 2610	GA09
Muñoz Carvajal, Ignacio; Registro multicéntrico europeo para evaluar los resultados en pacientes con cirugía de baipás coronario con injerto: Tratamiento de conductos vasculares con DuraGraf, un novedoso inhibidor del daño endotelial. Reference: 3276	GA09
Vallejo Casas, Juan Antonio; Estudio epidemiologico, retrospectivo, longitudinal para caracterizar la historia natural de los pacientes con carcinoma diferenciado de tiroides avanzado en España y Portugal. Estudio ERUDIT. Reference: 3664	GA10

CLINICAL TRIALS	IMIBIC GROUP
Galán Cabezas, Antonio; Estudio transversal de la incidencia de bloqueo neuromuscular residual en pacientes adultos en los hospitales españoles. Reference: 2546	Anesthesiology Unit
Herrador Montiel, Inmaculada; Estudio de fase IIIb, de un solo brazo, abierto y multicéntrico para evaluar la efectividad, la seguridad, la tolerabilidad, la facilidad de uso y la utilización de recursos de Zalviso en el manejo del dolor agudo postoperatorio de moderado a intenso. Reference: /3219	Anesthesiology Unit
Herrador Montiel, Inmaculada; Estudio epidemiologico para estimar la prevalencia y evaluar la severidad, el abordaje y las estructuras organizativas empleadas para el manijo del dolor agudo postoperatorio tras cirugia mayor en pacientes ingresados en España. Reference: 2934	Anesthesiology Unit
Herrador Montiel, Inmaculada; Evaluación de la calidad de vida y satisfacción del paciente con dolor irruptivo asociado a dolor crónico neuropático. Impacto económico evaluado a través de la calidad de vida. Estudio CANDI. Reference: 3188	Anesthesiology Unit
Galan Gutiérrez, Manuel; Estudio de fase 3 aleatorizado, doble ciego, controlado con placebo para evaluar upadacitinib en sujetos adolescentes y adultos con dermatitis atópica moderada o grave. Reference: /4029	Dermatology Unit
Fraga Rivas, Enrique; A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjets with Unresectable Hepatocellular Carcinoma. Reference: 0257/15	Digestive System Unit
Fraga Rivas, Enrique; Estudio abierto y multicéntrico para evaluar los resultados a largo plazo con ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) y ABT-333 con o sin ribavirina (RBV) en adultos con infección crónica por el virus de la hepatitis C (VHC) de genotipo 1(TOPAZ-I). Reference: 0249/14	Digestive System Unit
Marin Pedrosa, Sandra; ESTUDIO ABIERTO DE EXTENSIÓN Y SUPERVISIÓN DE LA SEGURIDAD DE PACIENTES CON ENFERMEDAD DE CROHN CON ACTIVIDAD DE MODERADA A GRAVE PREVIAMENTE INSCRITOS EN EL PROTOCOLO DE FASE III CON ETROLIZUMAB, GA29144. Reference: /3908	Digestive System Unit
Marin Pedrosa, Sandra; ESTUDIO MULTICÉNTRICO DE FASE III ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DEL ETROLIZUMAB COMO TRATAMIENTO DE INDUCCIÓN Y MANTENIMIENTO EN PACIENTES CON ENFERMEDAD DE CROHN ACTIVA DE MODERADA A GRAVE. Reference: /3907	Digestive System Unit
Perez Rodriguez, Esperanza; Estudio transversal para describir el curso natural de la pancreatitis crónica y su evolución en pacientes sin seguimiento (PANCR-EVOL). Reference: 2565	Digestive System Unit
Gallardo Valverde, José Mª; Estudio fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de células madre alogénicas expandidas derivadas del tejido adiposo (eASC) para el tratamiento de la enfermedad de Crohn fistulizante perianal tras un periodo de 24 semanas y un periodo de seguimiento extendido hasta las 52 semanas. Estudio ADMIRE-CD. Reference: 0067/12	General and Digestive Surgery Unit
Gallardo Valverde, José Mª; Estudio multicéntrico, aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la tolerabilidad del hidrocloruro de diltiazem al 2% en el tratamiento de la fisura anal crónica, y extensión de diseño abierto de 24 semanas. Reference: /3119	General and Digestive Surgery Unit
Lorente González, Juan; Comparación del efecto de una combinación de mioinositol: D-quiro-inositol con baja proporción en D-quiro-inositol (40:1) frente a la combinación con una mayor proporción D-quiro-inositol (3.6:1) en la calidad de los ovocitos y las tasas de embarazo en las mujeres con síndrome de ovario poliquístico. Reference: /3146	Gynecology and Obstetrics Unit
Nieto Pascual, Laura; Estudio clínico multicéntrico e internacional para evaluar la seguridad y la eficacia del producto sanitario Essure (modelo ESS505) para evitar el embarazo en mujeres que deseen una anticoncepción permanente. Reference: 2447	Gynecology and Obstetrics Unit
Ortiz Minuesa, Ana; Estudio de extensión para evaluar la seguridad y la eficacia a largo plazo de Elagolix en participantes con dolor de moderado a severo asociado a endometriosis. Reference: 0033/14	Gynecology and Obstetrics Unit
Ortiz Minuesa, Ana; Protocolo para estudio clínico, uso de ultrasonido transvaginal para confirmar la colocación de microinsertos Essure® en las mujeres: demostración de eficacia. Reference: 2003	Gynecology and Obstetrics Unit
Santamaria Ossorio, Manuel; A Multi-center, Open-label, Single-arm Trial to Evalue Efficacy, Pharmacokinetics, and Safetyand Tolerability of IGSC 20% in Subjets with Primary Immunodeficiency. Reference: /3040	Immunology Unit

CLINICAL TRIALS	IMIBIC GROUP
León López, Rafael; XePOHCAS: Ensayo prospectivo, aleatorizado, multicéntrico y de intervención en pacientes adultos con paro cardíaco fuera del hospital en el que se compara el tratamiento con cuidados intensivos tras el paro cardíaco según el tratamiento de referencia (que es la gestión de la temperatura objetivo [GTO]) con cuidados intensivos tras el paro cardíaco según el tratamiento de referencia (incluida la GTO) más xenón inhalado. Reference: /4104	Intensive Care Unit
León López, Rafael; A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa. Reference: /3992	Intensive Medicine Unit
RUBIO PÉREZ, Mª JESÚS; ESTUDIO DE FASE 3 ALEATORIZADO Y ABIERTO DE PREBROLIZUMAB (MK3475) MÁS LENVATINIB (E7080/MK-7902) FRENTE A QUIMIOTERAPIA PARA EL TRATAMIENTO DE PRIMERA LINEA DEL CARCIBNOME ENDOMETRIAL AVANZADO O RECURRENTE (LEAP-001). Reference: /4376	Medical Oncology Unit
Rubio Pérez, Mª Jesús; A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. Reference: /3191	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Ensayo clínico en fase III abierto y aleatorizado de REGN2810 en comparación con el tratamiento de quimioterapia a elección del investigador para el carcinoma cervicouterino resistente a platino recurrente o metastásico. Reference: /3993	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Ensayo fase III, internacional y aleatorizado de trabedectina mas doxorrubicina liposomal pegilada (DLP) en comparacion con carboplatino mas DLP en pacientes con cancer de ovario que presentan progresion en los 6-12 meses siguientes al ultimo tratamiento con platino. Reference: 0037/14	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Ensayo fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo, de durvalumab en combinación con quimioterapia y bevacizumab, seguido de tratamiento de mantenimiento con durvalumab, bevacizumab y olaparib, en pacientes con cáncer de ovario avanzado recién diagnosticado (DUO-O). Reference: /4068	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Ensayo fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de mantenimiento con olaparib en monoterapia en pacientes con cáncer de ovario avanzado, estadio IIIb-IV de la FIGO, con mutación de BRCA que están en respuesta completa o parcial después de quimioterapia de primera línea basada en platino. Reference: 0136/13	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Ensayo fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de mantenimiento con Olaparib en monoterapia en pacientes con cáncer de ovario con mutación de BRCA y recaída platino sensible, que están en respuesta completa o parcial después de una quimioterapia basada en platino. Reference: 0132/13	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Estudio abierto multicentrico, controlado y aleatorizado de fase III paa evaluar la eficacia y seguridad del olaparib en monoterapia frente a la quimioterapia con agente unico de leccion por le medico en el tratamiento del cancer ovarico recidivante sensible al platino en pacientes portadoras de las mutaciones germinales BRCA1/2. Reference: 0066/15	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Estudio de extensión de un único brazo, abierto y multicentrico en pacientes con tumores sólidos que reciben tratamiento con bevacizumab en cualquiera de los estudios esponsorizados por F. Hoffmann- La Roche y/o Genentech. Reference: 0177/14	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Estudio de fase 2 de prexasertib en cáncer de ovario resistente o recurrente refractario a derivados del platino. Reference: /3779	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Estudio de fase III de ADXS11-001 administrado tras la quimiorradioterapia como tratamiento adyuvante en cáncer de cuello uterino localmente avanzado de riesgo alto: AIM2CERV. Reference: /3476	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Estudio de Fase IIIb, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del retratamiento con olaparib en pacientes con cáncer epitelial de ovario tratado previamente con un PARPi y con respuesta a la repetición de la quimioterapia con platino (OReO). Reference: /3559	Medical Oncology Unit
Rubio Pérez, Mª Jesús; Estudio fase 2 aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Farletuzumab (MORAb-003) en combinación con Carboplatino más Paclitaxel o Doxorubicina Liposómica Pegilada (PLD) en pacientes con cáncer de ovario sensible al platino bajo en CA-125 A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer. Reference: 0045/15	Medical Oncology Unit

CLINICAL TRIALS	IMIBIC GROUP
Rubio Pérez, Mª Jesús; Estudio observacional retrospectivo para evaluar las estrategias de tratamiento en práctica clínica y la evolución clínica de los pacientes con cáncer de ovario avanzado en España: Estudio OVOC (Evaluación Objetiva de Cáncer de Ovario). Reference: 4001	Medical Oncology Unit
Rubio Pérez, Mª Jesús; EUTROC-PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246. Reference: /2893	Medical Oncology Unit
Rubio Pérez, Mª Jesús; OPINIÓN - Estudio en fase IIIb, abierto, de grupo único y multicéntrico de la monoterapia de mantenimiento con olaparib en pacientes con cáncer de ovario recidivante sin mutación de BRCA en línea germinal y sensible al platino que están en respuesta parcial o completa tras la quimioterapia con platino. Reference: /3717	Medical Oncology Unit
Rubio Pérez, María Jesús; FORWARD1: estudio abierto de fase III aleatorizado para evaluar la seguridad y la eficacia de mirvetuximab soravtansina (IMGN853) frente a la elección del investigador de quimioterapia en mujeres con cáncer de las trompas de Falopio, cáncer peritoneal primario o cáncer epitelial de ovario avanzado positivo para el receptor alfa de folato. Reference: /3624	Medical Oncology Unit
Osorio Ramos, Juan Pedro; Estudio para la evaluacion de la funcionalidad en pacientes recientemente diagnosticas de esquizofrenia, que han iniciado Pamito de Paliperidona trimestral. Reference: 3663	Mental Health Unit
Cáceres Redondo, Mª Teresa; Prevalencia de la enfermedad de Parkinson avanzada en pacientes tratados en los hospitales del sistema público español. Estudio PARADISE. Reference: 3904	Neurology Unit
Estévez María, José Carlos; A 12 month noninterventional, postmarketing, multicenter study to evaluate the effectivensess of Briviact (Briviaracetam) as adjunctive therapy in patients with epilepsy with partial-onset seizures in daily clinical practice. Reference: 3548	Neurology Unit
Estévez María, José Carlos; A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS. Reference: /3067	Neurology Unit
Estévez María, José Carlos; Estudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de padsevonil como tratamiento adyuvante de crisis focales en sujetos adultos con epilepsia fármacorresistente. Reference: /3946	Neurology Unit
Estévez María, José Carlos; ESTUDIO DE EXTENSIÓN ABIERTO Y MULTICÉNTRICO PARA EVALUAR LA SEGURIDAD Y EFICACIA A LARGO PLAZO DE LACOSAMIDA COMO TRATAMIENTO COMPLEMENTARIO PARA LAS CRISIS TÓNICO-CLÓNICAS GENERALIZADAS PRIMARIAS NO CONTROLADAS EN PACIENTES CON EPILEPSIA IDIOPÁTICA GENERALIZADA. Reference: /3625	Neurology Unit
Estévez María, José Carlos; Estudio de extensión abierto y multicéntrico para evaluar la seguridad y eficacia de padsevonil como tratamiento adyuvante de crisis focales en sujetos adultos con epilepsia fármacorresistente. Reference: /3995	Neurology Unit
Estévez María, José Carlos; ESTUDIO DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO, DE GRUPOS PARALELOS, MULTICÉNTRICO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LACOSAMIDA COMO TRATAMIENTO COMPLEMENTARIO PARA LAS CRISIS TÓNICO-CLÓNICAS GENERALIZADAS PRIMARIAS NO CONTROLADAS EN PACIENTES CON EPILEPSIA IDIOPÁTICA GENERALIZADA. Reference: /3626	Neurology Unit
Jurado Cobo, Carmen; Estudio observacional, prospectivo, de 24 meses de duración para describir el uso habitual a largo plazo de BOTOX para el tratamiento sintomático de adultos con migraña crónica y medir la utilización de recursos sanitarios y los resultados notificados por el paciente observados en la práctica clínica. Reference: 2347	Neurology Unit
Martínez Agredano, Paula Mª; Valoración del sueño en pacientes epilépticos y su impacto en la calidad de vida y en el deterioro cognitivo de esos pacientes. ESTUDIO SLE-EP (SLEep and EPilepsy). Reference: 4174	Neurology Unit
Sánchez López, Fernando; Estudio de extensión, multicéntrico y con dosis ciega para determinar la seguridad y la eficacia a largo plazo de dos dosis de BG00012 en monoterapia en pacientes con esclerosis múltiple recidivante-remitente. Reference: 0133/09	Neurology Unit
Sánchez López, Fernando; Estudio multicentrico observacional no intervencionista y prospectivo para evaluar la satisfaccion de las y los pacientes con el tratamiento Extavia administrado mediante un nuevo autoinyector, ExtraviProTM, en pacientes con escleosis multiple. (EXCHANGE). Reference: 2813	Neurology Unit

CLINICAL TRIALS	IMIBIC GROUP
Solivera Vela, Juan; A multicenter, doubled-blind, multidose, placebo controlled, rtandomized, parallel group, phase 2 study to evaluate the efficacy and safety of intravenous protocol BII093 for patients with brain contusion. Reference: /4403	Neurosurgery Unit
Pérez Fernández, Francisco Miguel; Estudio para evaluar el efecto de Novalac AminA en el bienestar general y la calidad de vida de lactantes y niños con alergia grave a las proteínas de la leche de vaca. Reference: 4340	Pediatrics Unit
Tejero Hernández, Mª Ángeles; Estudio en fase I, en abierto, de dósis única y no randomizado para evaluar la farmacocinética (FC) y la farmacodinámica (FD) de Edoxaban en pacientes pediátricos. Reference: /3215	Pediatrics Unit
De la Rosa Moreno, María Luisa; PROPUESTA DE ESTUDIO PARA DETERMINAR LOS BENEFICIOS POTENCIALES DERIVADOS DE LA IMPLANTACION DE LOS SISTEMAS DE SEGURIDAD POST-ACCIDENTE DENOMINADOS E-LIGHT Y E-RESCUE. Reference: 2770	Radiodiagnosis Unit
Zurera Tendero, Luis; Ensayo clínico en fase III de TheraSphere intraarterial para el tratamiento de pacientes con carcinoma hepatocelular (CHC) no resecable. A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC). Reference: 2925	Radiodiagnosis Unit

ONGOING PROJECTS, NETWORKS & FELLOWSHIPS

PROJECTS & NETWORKS	IMIBIC GROUP
SERRANO DELGADO, PILAR; Identificación de biomarcadores en pacientes alérgicos a veneno de abeja o a polen de olivo de fenotipo grave y reacción sistémica con inmunoterapia.; Funding Agen- cy: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PC-0278-2017	GC01
RUIZ LEON, MARIA BERTA; Papel del Microbioma en las Enfermedades Alérgicas Por Proteínas Transportadoras de Lípidos; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0119-2016	GC01
PERA ROJAS, ALEJANDRA; Papel De Las Células Inmunes Pro-Inflamatorias En La Estenosis De La Válvula Aórtica (Cipyeva).; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BI-OMÉDICA DE CÓRDOBA; Reference: PI-0324-2018-FIB	GC01
MORENO AGUILAR, CARMEN; Anafilaxia por picaduras de insectos. Búsqueda de biomarcadores de respuesta precoz a la Inmunoterapia con veneno de himenóptero; Funding Agency: INSTITU-TO DE SALUD CARLOS III; Reference: PI15/02170	GC01
ALONSO DIAZ, CORONA; Implicaciones de la inmunosenescencia en el diseño de protocolos de inmunoterapia antitumoral basada en células NK en modelos de melanoma y leucemia mieloide aguda; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01615	GC01
MORENO AGUILAR, CARMEN; Estudio de la discontinuación de la inmunoterapia con veneno de abeja. ¿Persiste la protección?; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/00313	GC01
MORENO AGUILAR, CARMEN; Asma, Reacciones Adversas y Alérgicas (ARADYAL); INSTITUTO DE SALUD CARLOS III; Reference: RD16/0006/0018	GC01
BÁRCENA RUIZ, JOSÉ ANTONIO; Función de las peroxirredoxinas en la homeostasis celular como antioxidantes y en señalización.; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Refer-ence: BFU2016-80006-P	GC02
GARCÍA SÁNCHEZ, MARÍA DEL VALLE; Marcadores Proteomicos de respuesta a infliximab biosim-ilares en pacientes con colitis ulcerosa; Funding Agency: INSTITUTO DE SALUD CARLOS III; Refer-ence: PI15/01352	GC02
DE LA MATA GARCÍA, MANUEL; LIBERACIÓN DE CÉLULAS TUMORALES CIRCULANTES TRAS LA ABLACIÓN LOCAL DEL HEPATOCARCINOMA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/01736	GC02
REQUEJO AGUILAR, RAQUEL; Efecto de los sistemas antioxidantes PRdx6 y DJ-1 sobre la función mitocondrial: Influencia en la supervivencia celular; Funding Agency: UNIVERSIDAD DE CORDO-BA; Reference: PP-UCO19_RRA_Submod.2.6.	GC02
DE LA TORRES CISNEROS, JULIAN CARLOS; COMBACTE-NET - Combatting Bacterial Resistance in Europe; COMISIÓN EUROPEA; Reference: IMI-2012-001	GC03
DE LA TORRES CISNEROS, JULIAN CARLOS; COMBACTE-CARE - Combatting Bacterial Resistance in Europe – Carbapenem Resistance; COMISIÓN EUROPEA; Reference: IMI-2013-001	GC03
CASTON OSORIO, JUAN JOSE; CAVICOR - Impact of the treatment with ceftazidime/avibactam vs best available therapy on mortality of patients with infections caused by carbapenem-resist-ant Enterobacteriaceae; Funding Agency: PFIZER, S.A; Reference: INSPIRE-2018-02	GC03
DE LA TORRES CISNEROS, JULIAN CARLOS; Estudio de la cinetica de la inmunidad T CD8+ frente a CMV en trasplantados renales tratados con timoglobulina; Funding Agency: FUNDACION PUB-LI- CA ANDALUZA PROGRESO Y SALUD; Reference: PI-0294-2014	GC03
DE LA TORRES CISNEROS, JULIAN CARLOS; Ensayo clínico de suspensión de la profilaxis con val-ganciclovir en trasplantados renales CMVseropositivo que mantienen la inmunidad celular CD8+ CMV-especifica tras recibir timoglobulina.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Ref- erence: PI15/00402	GC03
CANTISAN BOHORQUEZ, SARA; Impacto de la ausencia de respuesta T CD8+ CMV-específica en donantes CMV-seropositivo sobre la reactivación de CMV tras el trasplante hematopoyético en receptores CMV-seropositivo; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI15/01419	GC03
PÉREZ NADALES, ELENA; La carga bacteriana como factor de riesgo de colonización, disemi-nación a la comunidad y mortalidad por Klebsiella pneumoniae productora de carbapenemasas (Estudio Klebcom); Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01631	GC03

PROJECTS & NETWORKS	IMIBIC GROUP
DE LA TORRES CISNEROS, JULIAN CARLOS; ENSAYO CLÍNICO DE EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE PROFILAXIS DE DURACIÓN REDUCIDA SEGUIDA DE PROFILAXIS INMUNOGUIADA EN RECEPTORES DE TRANSPLANTE PULMONAR (ESTUDIO CYTOCOR); Funding Agency: IN- STITUTO DE SALUD CARLOS III; Reference: PI18/00099	GC03
FRIAS CASAS, MANUEL MARIO; Optimización del Diagnóstico Molecular de la Infección Por el Vi- rus de la Hepatitis E Mediante el Uso de Una Técnica de Pcr (Proyecto Panhenotypic).; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0477-2017	GC03
CANTISAN BOHORQUEZ, SARA; IMPLantación de la monitorización de la Inmunidad Celular frente a CItomegalovirus en la práctica clínica para mejorar el control de la infección por este virus en el Trasplante de Órgano Sólido (IMPLICI-TOS); Funding Agency: FIBICO. FUNDACION PARA LA INVES- TIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PIN-0541-2018-FIB	GC03
DE LA TORRES CISNEROS, JULIAN CARLOS; BECA 2019 PARA LA INVETIGGACIÓN DE LA SATOT: Ensayo clínico de eficacia y seguridad de la combinación de profilaxis de duración reducida seguida de profilaxis inmunoguiada en receptores de trasplante pulmonar (Estudio CYTOCOR).; SOCIE- DAD ANDALUZA DE TRASPLANTES DE ÓRGANOS Y TEJIDOS; Reference: SATOT_2019_001	GC03
DE LA TORRES CISNEROS, JULIAN CARLOS; RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: RD16/0016/0008	GC03
MUÑOZ BLANCO, EDUARDO; Identificación de nuevas funciones y substratos de la proteína quinasa dyrk2 y sus implicaciones en carcinogénesis; MINISTERIO DE ECONOMIA Y EMPRESA; Reference: SAF2016-75228-R.	GC04
MUÑOZ BLANCO, EDUARDO; ESTUDIO DEL MECANISMO DE ACCION DEL VCE-004.8, UN DERIVA- DO QUINONA DEL CANNABIDIOL. IMPLICACIONES TERAPEUTICAS EN ESCLEROSIS MULTIPLE.; MINISTERIO DE ECONOMIA Y EMPRESA; Reference: SAF2017-87701-R	GC04
CALZADO CANALE, MARCO ANTONIO; Desarrollo preclínico de nuevos triterpenos hidroxamatos; Funding Agency: MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD; Reference: RTC-2017-6109-1	GC04
COLLANTES ESTEVEZ, EDUARDO; Desarrollo y validación del uso de sensores inerciales aplicados a la metrología de pacientes con espondiloartritis axial.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: DTS18/00046	GC05
COLLANTES ESTEVEZ, EDUARDO; Can Inertial Movement Sensors (IMUs) provide a valid and reliable way of measuring Spinal Mobility in Axial Spondyloarthritis (axSpa): a Clinimetric Evaluation; Funding Agency: FOUNDATION FOR RESEARCH IN RHEUMATOLOGY; Reference: FOREUM-2015-001	GC05
COLLANTES ESTEVEZ, EDUARDO; PRECISESADS - Molecular Reclassification to Find Clinically Use- ful Biomarkers for Systemic Autoimmune Diseases; COMISIÓN EUROPEA; Reference: IMI/0002	GC05
COLLANTES ESTEVEZ, EDUARDO; 3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions; COMISIÓN EUROPEA; Reference: IMI2-2018-14-01-F2	GC05
COLLANTES ESTEVEZ, EDUARDO; Nuevos Mecanismos de Regulación Génica Post-Transcripcional Involucrados en la Patogenia de la Espondilitis Anquilosante (Ea): Micrornas y Splicing Alternativo. Nuevas Aproximaciones Terapéuticas.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Ref- erence: PI-0139-2017	GC05
AGUIRRE ZAMORANO, MARIA ANGELES; Identificacion y Caracterizacion de Nuevos Biomarcadores Como Predictores de Respuesta A Terapias Biologicas en la Artritis Reumatoide; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0285-2017	GC05
BARBARROJA PUERTO, NURIA; Estudio de los mecanismos epigeneticos involucrados en el desar- rollo de resistencia a la insulina y obesidad asociadas a la artritis reumatoide y la artritis psoriasi- ca; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/01316	GC05
LOPEZ PEDRERA, ROSARIO; Identificación de la heterogeneidad molecular asociada a la enfermedad cardiovascular, la evolución clínica y la respuesta terapeútica en patologías autoinmunes sistémicas.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/00837	GC05
COLLANTES ESTEVEZ, EDUARDO; Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER); Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: RD16/0012/0015	GC05

PROJECTS & NETWORKS	IMIBIC GROUP
ALBURQUERQUE SENDÍN, FRANCISCO; Evaluación Clinimétrica de Los Sensores Inerciales de Movimiento en la Columna Cervical de Pacientes Con Parálisis Cerebral: Validez, Fiabilidad y Patrones de Comportamiento; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI- 0324-2017	GC05
ARANDA AGUILAR, ENRIQUE; VARIACIONES GENÉTICAS ASOCIADAS A HIPERTENSIÓN Y TROMBOSIS COMO FACTORES PREDICTORES DE RESPUESTA A TERAPIA ANTIANGIOGÉNICA EN PACIENTES DE CÁNCER COLORECTAL; ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER; Reference: AECC14/002	GC06
GUIL LUNA, SILVIA; Caracterización del microambiente inmune tumoral en cáncer colorectal y de mama y determinación de biomarcadores con terapia dirigida; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: EF-0239-2018-FIB	GC06
GUIL LUNA, SILVIA; Efecto Antitumoral de la Inmunoterapia Mediante Bloqueo de Pd-1 Combinada Con Terapia Antiangiogénica en Modelos Murinos Humanizados de Cáncer Colorectal; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0150-2017	GC06
DE LA HABA RODRÍGUEZ, JUAN RAFAEL; Perfil epigenético en pacientes oncológicos con incrementos de la presión arterial secundaria a tratamiento con anti-VEGF; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI15/00516	GC06
ARANDA AGUILAR, ENRIQUE; Asociación entre inmunidad antitumoral, el sistema renina-angiotensina y la respuesta a terapia antiangiogénica en cáncer colorrectal.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01271	GC06
RODRÍGUEZ ARIZA, ANTONIO; Las relaciones entre óxido nítrico y subtipos moleculares en cáncer colorrectal: identificación de nuevas estrategias terapéuticas.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01508	GC06
DE LA HABA RODRÍGUEZ, JUAN RAFAEL; Caracterización molecular del cáncer de mama gestacional.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/00817	GC06
ARANDA AGUILAR, ENRIQUE; CIBER-ONC ONCOLOGIA TUMORES DIGESTIVOS; INSTITUTO DE SALUD CARLOS III; Reference: CB16/12/00349	GC06
MORALES ESTEVEZ, CRISTINA; ANÁLISIS DE LA COMBINACIÓN IN VITRO DE TRASTUZUMAB Y LIRILUMAB EN CÁNCER DE MAMA. IMPLICACIÓN DE LOS PROCESOS DE SPLICING ALTERNATIVO; SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA; Reference: SEOM18/01	GC06
SORIANO CABRERA, SAGRARIO; Papel de Fgf3 en la Progresión del Daño Vascular Asociado A la Uremia: Estudios Básicos y Clínicos.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0136-2016	GC07
ALJAMA GARCÍA, PEDRO; Actividad inflamatoria mediada por la interacción de CD14+CD16+ con el endotelio: Un proceso implicado en la inducción de calcificación vascular en pacientes con enfermedad renal crónica; INSTITUTO DE SALUD CARLOS III; Reference: PI15/01785	GC07
MARTÍN MALO, ALEJANDRO; Mecanismos moleculares implicados en los procesos de adhesión y migración celular: Efecto del tratamiento de enfermedad renal crónica sobre la disfunción endotelial.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/01785	GC07
MARTÍN MALO, ALEJANDRO; Análisis de la eficacia depuradora de diferentes técnicas de hemod- iálisis sobre los niveles de miRNAs circulares en pacientes con Enfermedad Renal Crónica (Ayuda a la investigación en Diálisis Baxter 2018); SOCIEDAD ESPAÑOLA DE NEFROLOGÍA; Reference: SEN18/02	GC07
GUERRERO PAVON, FATIMA; Bioingeniería Regenerativa: Modelo in vitro de recelularización de un scaffold renal con células mesenquimales.; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PI-0268-2018-FIB	GC07
CASTAÑO FUENTES, JUSTO PASTOR; Alteraciones de la maquinaria de splicing alternativo en cánc- er de páncreas: Identificación de nuevos biomarcadores diagnósticos, pronósticos y terapeúticos.; MINISTERIO DE ECONOMIA Y EMPRESA; Reference: BFU2016-80360-R.	GC08
MARTÍNEZ FUENTES, ANTONIO JESUS ; Presencia y acciones antitumorales del sistema KISS-1/KISS1-R en tumores neuroendocrinos pancreáticos: potencial como biomarcador diagnóstico y di- ana terapéutica.; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0077-2016	GC08
CASTAÑO FUENTES, JUSTO PASTOR; Estrategia spliceosómica para mejorar el diagnóstico, la clasificación y el tratamiento de los tumores neuroendocrinos pancreáticos; Funding Agency: Group Español de Tumores Neuroendocrinos (GETNE); Reference: GETNE 2019 G1909	GC08

PROJECTS & NETWORKS	IMIBIC GROUP
CORDOBA NODE: CASTAÑO FUENTES, JUSTO PASTOR. Consolidating the traslational bioinformatic Network TransBioNet (Research Networks). Funding Agency: Spanish Ministry for Science, Innovation and Universities. Reference: RED2018-102404-T.	GC08
LOPEZ MIRANDA, JOSE; EFECTO DE UNA DIETA MEDITERRANEA RICA EN ACEITE DE OLIVA VIRGEN SOBRE LA REGRESION DE DIABETES MELLITUS TIPO 2 DE RECIENTE DIAGNOSTICO: ESTUDIO CORDIOPREV-DIRECT; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: AGL2015-67896-P	GC09
LOPEZ MIRANDA, JOSE; FAME - Fatty Acid Metabolism - Interlinking Diet with Cardiometabolic Health; MINISTERIO DE ECONOMIA Y EMPRESA; Reference: ERA-HDHLBioNH2016-001	GC09
YUBERO SERRANO, ELENA M; Efectos de dos modelos de dieta cardiovasculables sobre la reducción de los niveles de productos finales de glicación avanzada y su utilidad como marcador de arteriosclerosis carotidea en pacientes con enfermedad coronaria.; SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS; Reference: FEA2018/01	GC09
LOPEZ MIRANDA, JOSE; Proyecto de Investigación Prof. Dr. Miguel Vilardell; Funding Agency: FUNDACIÓN ESPAÑOLA DE MEDICINA INTERNA; Reference: MVILARDELL_01_2018	GC09
YUBERO SERRANO, ELENA M; Efecto del Consumo de Dos Modelos de Dieta en el Desarrollo de la Nefropatía Diabetica. Estudio Cordioprev-Nediab; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PC-0283-2017	GC09
DELGADO LISTA, FRANCISCO JAVIER; POWER2DM - Predictive model-based decision support for diabetes patient empowerment; COMISIÓN EUROPEA; Reference: PHC28-2015-001	GC09
RONCERO RAMOS, IRENE; Papel de la célula alfa en el desarrollo de diabetes mellitus tipo 2 en personas de edad avanzada; FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PI-0107-2018-FIB	GC09
RANGEL ZÚÑIGA, ORIOL ALBERTO; Identificación de nuevos biomarcadores terapéuticos en la progresión del grosor de la íntima media carotidea a través de la epigenética nutricional.; INSTITUTO DE SALUD CARLOS III; Reference: PI15/00733	GC09
PÉREZ JIMÉNEZ, FRANCISCO; La Dieta Mediterránea asociada a probióticos mejora la capacidad cognitiva en pacientes con deterioro cognitivo leve modulando el eje microbiota-intestino-cerebro; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01777	GC09
ALMADEN PEÑA, YOLANDA; Influencia del Metabolismo Mineral sobre la disfunción endotelial en el Sindrome Metabólico y la Aterosclerosis. Modulación por la Dieta Mediterránea; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/01024	GC09
GARCÍA RIOS, ANTONIO; PREDIMED+DM: Efecto de una pérdida de peso con dieta mediterránea hipocalórica y promoción de la actividad física en la prevención de diabetes tipo 2 en personas con síndrome metabólico.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/01183	GC09
FUENTES JIMÉNEZ, FRANCISCO; Determinación de nuevas variables predictoras de enfermedad coronaria en pacientes asintomáticos con hipercolesterolemia familiar.; Funding Agency: INSTI- TU- TO DE SALUD CARLOS III; Reference: PI17/01320	GC09
YUBERO SERRANO, ELENA M; INFLUENCIA DE LA OBESIDAD EN LA EVOLUCIÓN DE LA NEFROPATÍA DIABÉTICA. CONSUMO DE DOS MODELOS DE DIETA CARDIOSALUDABLES COMO ES- TRATÉGICA TERAPÉUTICA EN EL DESARROLLO DE LA ENFERMEDAD; INSTITUTO DE SALUD CAR- LOS III; Reference: PI18/01822	GC09
HARO MARISCAL, CARMEN MARIA; Herramienta de Diagnóstico Precoz de Cáncer Colorrectal Ba- sada en la Microbiota Intestinal.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0156-2016	GC09
TENA SEMPERE, MANUEL; FidiPro; Funding Agency: ACADEMY OF FINLAND; Reference: FidiPro-2014-001	GC10
TENA SEMPERE, MANUEL; KISSPEPTINAS Y PUBERTAD - NUEVOS ASPECTOS FISIOLOGICOS E IMPLICACIONES FISIOPATOLOGICAS EN ALTERACIONES PUBERALES ASOCIADAS A OBESIDAD; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: BFU2017-83934-P	GC10
TENA SEMPERE, MANUEL; MicroRNAs y Salud Reproductiva: Estudios mecanísticos y traslacionales; CONSEJERÍA DE ECONOMÍA, CONOCIMIENTO, EMPRESAS Y UNIVERSIDAD; Reference: FQM1943	GC10

PROJECTS & NETWORKS	IMIBIC GROUP
SANCHEZ-GARRIDO NOGUERAS, MIGUEL ÁNGEL; Efectos Del Tratamiento Con Glp-1 Sobre La Función Gonadal Masculina En Condiciones De Diabesidad: Análisis Mecanísticos E Implicaciones Terapéuticas Para El Hipogonadismo Asociado A Enfermedad Metabólica.; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PI-0358-2018-FIB	GC10
AVENDAÑO HERRADOR, MARIA SOLEDAD; Papel fisiopatológico, pronóstico y diagnóstico de los miRNAs circulantes en el hipogonadismo asociado a la obesidad.; CONSEJERÍA DE SALUD Y FA- MILIAS; Reference: PI-0370-2016	GC10
ROA RIVAS, JUAN; Pubertad y riesgo metabólico en niños obesos: Alteraciones epigenéticas e implicaciones fisiopatológicas y diagnósticas. Estudio PUBMEP.; INSTITUTO DE SALUD CARLOS III; Reference: PI16/01243	GC10
PINEDA REYES, RAFAEL; Society for Endocrinology Early Career Grant for Rafael Pineda Reyes; Funding Agency: SOCIETY FOR ENDOCRINOLOGY; Reference: SfE-ECG-2017-001	GC10
MALAGÓN POYATO, MARIA DEL MAR; Caracterizacion de comSpeakers extracelulares e intracelulares que definen la expansion del tejido adiposo universidad de cordoba dpto; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: BFU2016-76711-R	GC11
GUZMÁN RUIZ, ROCÍO; Identificación de biomarcadores y factores predictores de respuesta a cirugía bariátrica en pacientes obesos mórbidos. Aplicación de técnicas proteómicas avanzadas al estudio del tejido adiposo.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0159-2016	GC11
MALAGÓN POYATO, MARIA DEL MAR; Red Temática de Investigación sobre plasticidad adiposa y su impacto fisiopatológico; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: BFU2015-70454-REDT	GC11
PERULA DE TORRES, CARLOS; Efectividad de Una Intervención No Farmacológica Multicomponente para Reducir el Aislamiento Social y la Soledad de Mayores Residentes en Su Domicilio.; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0079-2016	GC12
HIDALGO REQUENA, ANTONIO; Efectividad de la Intervención Educacional Frente Al Autoaprendizaje por Documentación en el Paciente Epoc; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0140-2017	GC12
SERRANO MERINO, JESÚS; Validación Al Español del Cuestionario de Berlin para la Detección de Pacientes de 40 Años O Más Con Síndrome de Apnea-Hipoapnea del Sueño en Atención Primaria: Estudios Sahs-Cb; FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0177-2018	GC12
PERULA DE TORRES, LUIS ANGEL; Evaluación de la Difusión Internacional del Código Europeo Contra el Cáncer A Través de la Telefonía Móvil. Estudio Piloto en la Población de Andalucía (España) A Través del Servicio Click Salud + (Estudio Cecc-Oms); Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0201-2019	GC12
ARIAS BLANCO, MARIA DEL CARMEN; UTILIDAD DE LA TELEDERMATOSCOPIA EN EL DIAGNOSTI- CO DE LESIONES CUTÁNEAS TUMORALES EN ATENCIÓN PRIMARIA; FUNDACION PUBLICA ANDA- LUZA PROGRESO Y SALUD; Reference: PI-0067-2016-AP	GC12
CARRERA GONZALEZ, MARIA DEL PILAR; Adaptación y Validación de la Versión Española de la Pain Assessment In Advanced dementia Scale (Painad) y Determinacion de Biomarcadores del Do- lor en Saliva en Personas Mayores Con Deterioro Cognitivo Con Incapacidad de Comunicación; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0357-2017	GC12
RICH RUÍZ, MANUEL; Eficacia del Programa de Ejercicios de Otago aplicado de forma grupal versus individual en la probabilidad de caídas de personas entre 65-80 años no institucionalizadas; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01520	GC12
ROLDÁN VILLALOBOS, ANA MARIA; PROYECTO MINDUUDD. Eficacia de Un Programa de Entre- namiento en Mindfulness y en Autocompasión de 4 Sesiones Frente Al de 8 Sesiones para Reducir el Estrés Laboral y el Burnout en Profesionales de Medicina y Enfermería Familiar y Comunitaria: Un Ensayo C; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0155-2018	GC12
RODRÍGUEZ ORTIZ, Mª ERCARNACIÓN; Caracterización de Los Cambios en Wnt Inducidos Por Magnesio y Su Repercusión en el Trastorno Mineral, Óseo y Vascular Asociado A la Enfermedad Renal Crónica.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0154-2017	GC13

PROJECTS & NETWORKS	IMIBIC GROUP
RODRÍGUEZ PORTILLO, JUAN MARIANO; Caracterización de los cambios en Wnt inducidos por Mg y esclerotina y su repercusión en el trastorno mineral, óseo y vascular asociado a la enfermedad renal crónica; INSTITUTO DE SALUD CARLOS III; Reference: PI17/01010	GC13
MUÑOZ CASTAÑEDA, JUAN RAFAEL; Estudios básicos y clínicos acerca de la disfunción vascular in- ducida por altos niveles de FGF23 en pacientes urémicos.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/00138	GC13
RODRÍGUEZ PORTILLO, JUAN MARIANO; Ensayo clínico Fase II abierto, para evaluar en pacientes con enfermedad renal crónica grado 3b-4 la eficacia del suplemento de magnesio sobre la calcificación vascular y la densidad ósea.; Funding Agency: SOCIEDAD ESPAÑOLA DE NEFROLOGÍA; Reference: SEN18/01	GC13
RODRÍGUEZ PORTILLO, JUAN MARIANO; Red de Investigacion Renal REDINREN Kidney Research Network REDINREN; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: RD16/0009/0034	GC13
MUÑOZ CASTAÑEDA, JUAN R.; NUEVA TERAPIA PARA EL TRATAMIENTO DE LA OSTEOARTROSIS DEGENERATIVA BASADA EN UNA MODIFICACIÓN DE; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: DTS16/00061	GC13
AGUILERA TEJERO, ESCOLASTICO; RESTRICCIÓN CALÓRICA, METABOLISMO MINERAL Y ENFERMEDAD RENAL; Funding Agency: Instituto de Salud Carlos IIII; Reference: PI17/00169	GC13
CORTIJO GUTIERREZ, MARINA; DESARROLLO PRE-CLINICO DE UN NUEVO MEDICAMENTO DE TERAPIA CELULAR GÉNICA CONSTITUIDO POR LINFOCITOS T ALOGÉNICOS CON EXPRESIÓN INDUCIBLE DE RECEPTOR ANTIGENICO QUIMÉRICO (CAR) ANTI CD-19 PARA EL TRATAMIENTO DE NEOPLASIAS B REFRACTARIAS; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: OH-0014-2018	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Efecto de la hipoxia sobre el potencial regener- ativo de Células Mesenquimales Adultas derivadas de tejido adiposo (ASCs). Estudio en un mode- lo experimental de Nefropatía Diabética en ratas.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI14/00087	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Desarrollo preclínico de CAR-T anti CD19 universales con subpoblaciones predetrminadas de memoria y efectores y expresión inducible del CAR.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/01610	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; DESARROLLO PRE-CLINICO DE UN NUEVO MEDICAMENTO DE TERAPIA CELULAR GÉNICA CONSTITUIDO POR LINFOCITOS T ALOGÉNICOS CON EXPRESIÓN INDUCIBLE DE RECEPTOR ANTIGENICO QUIMÉRICO (CAR) ANTI CD-19 PARA EL TRATAMIENTO DE NEOPLASIAS B REFRACTARIAS; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: SALUD-201600073092-TRA	GC14
GONZALEZ MANZANARES, RAFAEL; PROYECTO DE LA SEC PARA INVESTIGACIÓN TRASLACIONALEN CARDIOLOGÍA - "Cardiotoxicidad tardía inducida por antraciclinas en supervivientes a leucemia aguda linfoblastica en edad pediátrica; Funding Agency: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA; Reference: BECA.SEC01/19	GC15
ROMERO MORENO, MIGUEL ÁNGEL; SECURE - Comparing the effectiveness of existing healthcare interventions in the elderly; COMISIÓN EUROPEA; Reference: PHC17-2014-002	GC15
PAN ÁLVAREZ-OSSORIO, MANUEL; VALORACIÓN MEDIANTE RATIO DE PRESIÓN INSTANTÁNEA DEL COMPROMISO FUNCIONAL DEL RAMO LATERAL TRAS LA IMPLANTACIÓN DE STENT EN EL VASO PRINCIPAL EN LESIONES CORONARIAS EN BIFURCACIÓN; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/00750	GC15
MARTÍNEZ LOSADA, CARMEN; BECA FUNDACION ANDALUZA PARA EL ESTUDIO Y TRATAMIENTO DE LAS HEMOPATIAS; Funding Agency: ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTER- APIA; Reference: AAHH2016_001	GC16
MARTÍNEZ LOSADA, CARMEN; JORNADAS DE INVESTIGACIÓN EN HEMATOLOGÍA EN ANDALUCÍA; Funding Agency: ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTERAPIA; Reference: AAHH2017_001	GC16

PROJECTS & NETWORKS	IMIBIC GROUP
SERRANO LOPEZ, JUANA; ANALISIS DE EXPRESION GENICA EN PLATAFORMA NANOSTRING Y DE MUTACION MYD88-L265P CON MUESTRAS PARAFINADAS PARA EL TRATAMIENTO PERSONAL- IZADO DE LOS LINFOMAS B DIFUSO DE CELULAS GRANDES.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0364-2016	GC16
CASADO DÍAZ, ANTONIO; Efecto de la PTH(1-34) y Vitamina D3 en la movilización y activación de células precursoras endoteliales. Implicaciones en medicina regenerativa; Funding Agency: FUNDACIÓN ESPAÑOLA DE INVESTIGACIÓN ÓSEA Y DEL METABOLISMO MINERAL; Reference: FEIOMM2016_001	GC17
CASADO DÍAZ, ANTONIO; Efecto de la PTH(1-34) y Vitamina D3 en la movilización de células pre- cursoras endoteliales y su papel en medicina regenerativa aplicada a la cicatrización de úlceras cutáneas en diabéticos; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI15/01857	GC17
QUESADA GÓMEZ, JOSE MANUEL; CARACTERIZACIÓN DE EXOSOMAS DERIVADOS DE MSC Y SU EFECTO COMBINADO CON 25 HIDROXIVITAMINA D3 E INHIBIDORES DE LA DPP4 SOBRE LA CICATRIZACIÓN EN DIABÉTICOS DE ÚLCERAS CUTÁNEAS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/01659	GC17
QUESADA GÓMEZ, JOSE MANUEL; Fragilidad y Envejecimiento saludable (Ciberfes); INSTITUTO DE SALUD CARLOS III; Reference: CB16/10/00501	GC17
INTERREG-MED-1033BRICEÑO DELGADO, FRANCISCO JAVIER; VALIDACION EXTERNA DE UN MODELO DE EMPARE- JAMIENTO DONANTE-RECEPTOR EN TRASPLANTE HEPATICO BASADO EN REDES NEURONALES ARTIFICIALES.; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Refer- ence: PI-0312-2014	GC18
ARJONA SÁNCHEZ, ÁLVARO; Estudio multicéntrico, randomizado, para evaluar el efecto adyuvante de la quimioterapia intraoperatoria intraperitoneal en hipertermia (HIPEC) con Mitomicina C asociada a cirugía frente a cirugía sola en el carcinoma colorrectal localmente; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PI-0424-2018-FIB	GC18
BRICEÑO DELGADO, FRANCISCO JAVIER; VALIDACION EXTERNA DE UN MODELO DE EMPARE-JAMIENTO DONANTE-RECEPTOR EN TRASPLANTE HEPATICO BASADO EN REDES NEURONALES ARTIFICIALES.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI15/01570	GC18
ARJONA SÁNCHEZ, ÁLVARO; EuroPMP - European Network on Pseudomyxoma Peritonei; Funding Agency: COMISIÓN EUROPEA; Reference: OC-2017-1-17101	GC18
GARRIDO CASTRO, JUAN LUIS; Desarrollo y Validación del Uso de Sensores Inerciales Aplicados A la Metrología de Pacientes Con Espondiloartritis Axial.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0079-2016	GC19
MEDINA CARNICER, RAFAEL; VOLUMETRIC MEASURING SYSTEM; MINISTERIO DE ECONOMIA Y EMPRESA; Reference: RTC-2016-5661-1_01	GC19
MUÑOZ SALINAS, RAFAEL; Sistema de vision para la localizacion y mapeado fusionando marcadores, puntos caracteristicos, informacion 3d y color, y su aplicacion a la reconstruccion; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: TIN2016-75279-P	GC19
SANCHEZ RAYA, MARIA ARACELI; Aplicación Móvil E Informática para la Detección, Diagnostico Precoz E Intervención en Atención Temprana y Su Itegración en el Sistema de Gestion Clinica Alborada; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0072-2016	GC20
ANTOLÍ CABRERA, ADORACIÓN; Aplicación del seguimiento ocular a la automatización del diseño de distribución en planta mediante algoritmos evolutivos interactivos y multiusuario; Funding Agency: Universidad de Córdoba; Reference: PP19-UCO_AAC_Mod.4.1	GC20
PRIEGO CAPOTE, FELICIANO; Desarrollo de estrategias para la mejora de la detección por espectrometría de masas en análisis metabolómico orientado y global aplicado a clínica y nutrición.; MINISTERIO DE ECONOMIA Y EMPRESA; Reference: CTQ2015-68813-R	GC21
PRIEGO CAPOTE, FELICIANO; Reinforcement of Mediterranean olive oil sector competitiveness through development and application of innovative production and quality control methodologies related to olive oil health protecting properties; COMISIÓN EUROPEA; Reference: MED-1033	GC21

PROJECTS & NETWORKS	IMIBIC GROUP
ROLDÁN ARJONA, Mª TERESA; Reparacion del ADN por escision de bases: del mantenimiento del genoma a la edicion del epigenoma; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: BFU2016-80728-P	GC22
ROLDÁN ARJONA, Mª TERESA; Epigenetic Chemical Biology; Funding Agency: COMISIÓN EUROPEA; Reference: COST-2014-002	GC22
MATEOS GONZALEZ, MARIA ELENA; ChiLTERN - Children's Liver Tumour European Research Network; COMISIÓN EUROPEA; Reference: PHC-18-2015-001	GC23
GIL CAMPOS, MARIA; MEDITERRANEAN LIFESTYLE IN PEDIATRIC OBESITY PREVENTION: ME- LIPOP; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/00930	GC23
ANTON GAMERO, MONTSERRAT; Creación de Un Sistema de Apoyo A la Toma de Decisiones Clíni- cas para el Manejo de la Enfermedad Renal Crónica No Terminal en Niños Basado en la Aplicación de Minería de Datos Sobre el Registro Español Pediátrico de Enfermedad Renal Crónica Repir Ii; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0385-2016	GC23
GIL CAMPOS, MARIA MERCEDES; CIBER DE MARIA MERCEDES GIL CAMPOS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CB15/00131	GC23
ORDOÑEZ DÍAZ, MARÍA DOLORES; Proyecto Lactoprem: Ensayo Clínico Controlado Aleatorizado para la Valoración de la Eficacia de la Lactoferrina en la Prevención de la Sepsis en Recién Nacidos Prematuros. Biomonitorización de Los Mecanismos Antinflamatorios, Antioxidantes y de la Micro- bi; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0323-2016	GC23
MARTÍNEZ MARTÍNEZ, LUIS; Study of the mechanisms of resistance to Ceftazidime-Avibactam inisolates of Klebsiella pneumoniae producing KPC-3 cultured from patients under Ceftazidime-Avibactam therapy; Funding Agency: PFIZER, S.A; Reference: INSPIRE-2018-01	GC24
GRACIA AHUFINGER, IRENE; Estudio de las modificaciones epigenéticas inducidas por el Citomeg- alovirus como marcadores de riesgo y pronósticos; Funding Agency: INSTITUTO DE SALUD CAR- LOS III; Reference: PI14/01225	GC24
MARTÍNEZ MARTÍNEZ, LUIS; Importancia de la selección de mutantes estables y de variantes persistentes en la expresión de heterorresistencia a colistina en Klebsiella pneumoniae; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/02241	GC24
MARTÍNEZ MARTÍNEZ, LUIS; Heterorresistencia y persistencia en Klebsiella pneumoniae Resistente a Carbapenémicos; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI14/01911	GC24
MARTÍNEZ MARTÍNEZ, LUIS; BECA 2016 PARA LA INVESTIGACIÓN DE LA SOCIEDAD ANDALUZA DE TRASPLANTE DE ÓRGANOS Y TEJIDOS (SATOT) COMPARTIDO CON PAULA MORENO CASADO. LUIS MARTÍNEZ MARTÍNEZ.; SOCIEDAD ANDALUZA DE TRASPLANTES DE ÓRGANOS Y TEJIDOS; Reference: SATOT_2016_001	GC24
VENTURA SOTO, SEBASTIÁN; dreaMS - A telehealth tool for monitoring and treatment of Multiple Sclerosis patients; Funding Agency: COMISIÓN EUROPEA; Reference: DIATOMIC-2019-02-002	GC25
VENTURA SOTO, SEBASTIÁN; dreaMS - A telehealth tool for monitoring and treatment of Multiple Sclerosis patients; Funding Agency: COMISIÓN EUROPEA; Reference: DIATOMIC-2019-02-001	GC25
VENTURA SOTO, SEBASTIÁN; EMERging trends in Data analysis; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: TIN2017-83445-P	GC25
RIVERO JUAREZ, ANTONIO; BIOLOGIA MOLECULAR DEL VIRUS DE LA HEPATITIS E; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: EF- 0003-2018-FIB	GC26
RIVERO ROMAN, ANTONIO; EVALUACIÓN DE LA INFLUENCIA DE LA ENFERMEDAD HEPÁTICA GRASA NO ALCOHÓLICA SOBRE EVENTOS CLÍNICOS Y MORTALIDAD DE LOS PACIENTES INFECTADOS POR VIH; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI18/01270	GC26
RIVERO JUAREZ, ANTONIO; IMPACTO DE LA INFECCION AGUDA POR VIRUS DE HEPATITIS E EN PACIENTES INFECTADOS POR EL VIH; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI16/01297	GC26
RIVERO ROMAN, ANTONIO; RED ESPAÑOLA DE INVESTIGACION EN SIDA (RIS); Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: RD16/0025/0034	GC03
RIVERO ROMAN, ANTONIO; Cohorte de seguimiento de pacientes con infección crónica por el VHC coinfectados por el VIH de Andalucía; INSTITUTO DE SALUD CARLOS III; Reference: PI15/01017	GC03

PROJECTS & NETWORKS	IMIBIC GROUP
GAHETE ORTIZ, MANUEL DAVID; Implicación de nuevos factores moleculares y endocrino-metabólicos en la interacción patológica entre la obesidad y el desarrollo de hepatocarcinoma; Fund- ing Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/02287	GC27
LUQUE HUERTAS, RAUL MIGUEL; GOAT (Ghrelin-O-acil transferase): new biomarker for prostate cancer screening CAIXAIMPULSE 2017; Funding Agency: FUNDACIÓN LA CAIXA; Reference: CAIX- AIMPULSE_003	GC27
LUQUE HUERTAS, RAUL MIGUEL; Ghrelina-O-acil-Transferasa (GOAT): Nuevo biomarcador para el Screening del Cáncer de Próstata.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: DTS18/00131	GC27
LUQUE HUERTAS, RAUL MIGUEL; Ghrelina-O-acil transferasa (GOAT): nuevo biomarcador para el cáncer de próstata; FUNDACIÓN PARA LA INNOVACIÓN Y LA PROSPECTIVA EN SALUD EN ESPAÑA; Reference: FIPSE-3188-2017	GC27
LUQUE HUERTAS, RAUL MIGUEL; Oportunidades terapéuticas de la somatostatina, ghrelina y sus receptores en las patologías hipofisarias: identificación de nuevas dianas moleculares y contribución de mecanismos de splicing; Funding Agency: Consejería de Innovación, Ciencia y Empresa; Reference: CTS-1406	GC27
YUBERO SERRANO, ELENA M; NEW BIOMARKERS AND THERAPEUTIC TARGETS IN BREAST AND PROSTATE CANCER: MOLECULAR MECHANISMS IN THE PATHOLOGICAL INTERACTION BETWEEN OBESITY AND CANCER; Funding Agency: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER; Refer- ence: AECC 2018/01	GC27
AGÜERA MORALES, EDUARDO; dreaMS - A telehealth tool for monitoring and treatment of Multi- ple Sclerosis patients; Funding Agency: COMISIÓN EUROPEA; Reference: DIATOMIC-2019-02-001	GE01
CABALLERO VILLARRASO, JAVIER; DESARROLLO DE HERRAMIENTAS TRANSVERSALES PARA LA CONSTRUCCIÓN DE NUEVOS CAR-T EN TUMORES HEMATOLÓGICOS Y SÓLIDOS.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PS-2019-636	GE01
PEÑA AMARO, JOSE; Discriminación de dolor lumbar inflamatorio y mecánico según la actividad muscular y el análisis biocinemático; Funding Agency: Universidad de Córdoba; Reference: PP19-UCO_JPA_Mod.4.2	GE01
AGÜERA MORALES, EDUARDO; Red Española de Esclerosis Múltiple; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: RD16/0015/0026	GE01
AGUILAR LUQUE, MACARENA; Comparación De Las Revisiones Sistemáticas Publicada Con Su Pro- tocolo Registrado En Prospero.; FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: EF-0399-2018-FIB	GE03
GAY MIMBRERA, JESÚS; Elucidación Del Perfil Molecular Del Cuero Cabelludo De Pacientes Con Alopecia Frontal Fibrosante; FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: EF-0400-2018-FIB	GE03
RUANO RUIZ, JUAN; Ensayo clínico aleatorizado y multicéntrico para evaluar, en términos de coste-eficiencia, un modelo predictivo de respuesta a fármacos anti-TNFs en psoriasis moderada-severa; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: ICI14/00136	GE03
RUANO RUIZ, JUAN; Proyecto Éaco: Desarrollo y Validación de Un Instrumento Tecnológico en Red para el Apoyo en la Toma de Decisiones en la Práctica Clínica; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0316-2017	GE03
LUQUE SALAS, BÁRBARA; La influencia de la autoeficacia y otras variables motivacionales en la adherencia a la dieta, la calidad de vida y el bienestar de pacientes con enfermedad cardiovascular; Funding Agency: MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD; Reference: PSI2014-58609-R.	GE04
CARRASCO VALIENTE, JULIA; Patrones Asistenciales de Cáncer de Próstata en Andalucía y Evaluación de Resultados en Salud en Cáncer de Próstata; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0126-2016	GE05

PROJECTS & NETWORKS	IMIBIC GROUP
LÓPEZ BELTRÁN, ANTONIO; Desarrollo de un perfil de expresión génica con valor pronóstico y predictivo en carcinoma vesical.; INSTITUTO DE SALUD CARLOS III; Reference: PI17/01981	GE05
REQUENA TAPIA, MARÍA JOSE; ONCOCHECK - A simple blood test for prognosis and monitoring of patients undergoing cancer therapy; COMISIÓN EUROPEA; Reference: SMEInst-2017-01	GE05
MORENO GUTIERREZ, JUAN ANTONIO; Estudio de nuevos mecanismos y dianas terapéuticas implicadas en el daño renal agudo y crónico en patologías asociadas a acumulación renal de hemoglobina; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI17/00130	GE06
LOPEZ SOTO, PABLO JESUS; Cronoprevención en las Caídas Intrahospitalarias de Personas Mayores: Una Intervención Enfermera. Chronofalls; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0360-2017	GE08
López Soto, PJ. Educación para la Salud con enfoque inclusive en el área de Enfermería Comunitaria y Enfermería Sexual. Funding agency: Universidad de Córdoba. Reference: 2019-5-3005	GE08
MORENO CASADO, PAULA; Utilidad de la perfusión pulmonar ex-vivo para optimizar los injertos pulmonares subóptimos e incrementar el pool de donantes pulmonares válidos para el trasplante.; FUNDACIÓN MUTUA MADRILEÑA; Reference: FMM16_002	GA01
JURADO GÁMEZ, BERNABÉ; Descubrimiento De Biomarcadores De Diagnóstico De Cáncer De Pulmón En Muestras No Invasivas (Esputo) Utilizando Proteómica De Próxima Generación; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PI-0321-2018-FIB	GA03
HERRERA MARTÍNEZ, AURA DULCINEA; Código GETNE: GJ1902. Title: Cambios clínico-moleculares tras la cirugía bariátrica: papel de la vitamina D en la reversión de comorbilidades metabólicas asociadas a la obesidad.; Funding Agency: GROUP ESPAÑOL DE TUMORES NEUROENDOCRINO (GETNE); Reference: GETNE19_001	GA04
HERRERA MARTÍNEZ, AURA DULCINEA; Cambios clínico-moleculares tras la cirugía bariátrica: papel de la vitamina D en la reversión de comorbilidades metabólicas asociadas a la obesidad.; Funding Agency: ; Reference: FEIOMM2019_01	GA04
TOFÉ VALERA, INES Mª; D-PREM: INFLUENCIA DEL ESTATUS MATERNO-FILIAL DE VITAMINA D EN RECIÉN NACIDOS PREMATUROS < 32 SEMANAS Y < 1500 g Y MORBILIDAD RESPIRATORIA; Fund- ing Agency: ASOCIACIÓN ESPAÑOLA DE PEDIATRÍA; Reference: AEP/2017	GA05
TOFÉ VALERA, INES Mª; ALBINO - Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome; COMISIÓN EUROPEA; Reference: PHC-18-2015-002	GA05
LUQUE HUERTAS, RAUL MIGUEL; Nuevos mecanismos moleculares en la interacción patológica entre obesidad y cáncer de próstata: splicing alternativo y miRNAs como potenciales biomarcadores y dianas terapéuticas.; INSTITUTO DE SALUD CARLOS III; Reference: PI16/00264	GC27
GALLARDO GALERA, JOSÉ Mª; Prevención, detección precoz, tratamiento y rehabilitación de las patologías oculares.Prevention, Early detection, Treatment and Rehabilitation of Ocular Pathologies; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: RD16/0008/0018	GA07
GARCÍA-REVILLO GARCÍA, JOSÉ; Estudio y Desarrollo de Un Método de Medición de la Angiogénesis en Miembros Inferiores A Partir de Imágenes de Ct Perfusión.; CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0452-2017	GA08
MUÑOZ CARVAJAL, IGNACIO; STARS - Empowering Patients by Professional Stress Avoidance and Recovery Services; COMISIÓN EUROPEA; Reference: PM-12-2016-002	GA09
HERVÁS MARTÍNEZ, CÉSAR; Hybrid Algorithms combining Machine-Learning and meta-hEurisTics for ordinal classification and prediction (HAMLET); Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: TIN2017-85887-C2-1-P	GA11
GUTIERRES PEÑA, PEDRO ANTONIO; Learning Machines for Singular Problems and Applications (MAPAS); MINISTERIO DE ECONOMIA Y EMPRESA; Reference: TIN2017-90567-REDT	GA11
SARRAMEA CRESPO, FERNANDO; Eficacia para la cesación tabáquica en el enfermo con trastorno mental grave, de un programa de intervención motivacional intensiva que ofrece información individualizada de daño respiratorio; INSTITUTO DE SALUD CARLOS III; Reference: PI16/00802	GA12
HERRADOR MONTIEL, INMACULADA; RELIEF - Recovering Life wellbeing through pain self-management techniques involving ICTs; SERVICIO ANDALUZ DE SALUD; Reference: PHC-27-2015-001	ANESTHESIA UNIT

PROJECTS & NETWORKS	IMIBIC GROUP
ORTEA GARCÍA, IGNACIO; Descubrimiento De Biomarcadores De Diagnóstico De Cáncer De Pulmón En Muestras No Invasivas (Esputo) Utilizando Proteómica De Próxima Generación.; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: PI- 0321-2018-FIB	CORE FACILITIES - PROTEOMICS UNIT
alergosur17_001LEÓN LÓPEZ, RAFAEL; PREPARE - Platform foR European Preparedness Against (Re-)emerging Epidemics; Funding Agency: COMISIÓN EUROPEA; Reference: HEALTH.2013.2.3.3-1	INTENSIVE CARE UNIT
LEÓN LÓPEZ, RAFAEL; COMBACTE-MAGNET - Combatting bacterial resistance in Europe - molecules against Gram negative infections; Funding Agency: COMISIÓN EUROPEA; Reference: IMI-2014-01	INTENSIVE CARE UNIT
SOLIVERA VELA, JUAN; Diagnóstico y Pronóstico Postquirúrgico Personalizado de Gliomas Humanos Empleando Un Nuevo Abordaje Interactómico.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PI-0143-2016	NEUROSURGERY UNIT
MAYORDOMO RIERA, FERNANDO JESUS; MERLIN - hoMEcare aRm rehabiLItatioN RL; COMISIÓN EUROPEA; Reference: EITHealth-2018-01-RL	PHYSICAL MEDICINE AND REHABILITATION UNIT
JIMBER DEL RIO, MANUEL; Mejora de la Seguridad del Paciente en Base A la Introducción de Esta Perspectiva en Tecnologías de la Información Sanitarias Mediante Metodologías para Su Evalu- ación.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PIN-0483-2017	QUALITY UNIT

FELLOWSHIPS	IMIBIC GROUP
GUERRERO MISAS, MARTA; CM19/00129: Rio Hortega - Marta Guerrero Misas; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM19/00129	GC02
DE LA TORRES CISNEROS, JULIAN CARLOS; CONTRATO DE LARGA DURACION SAS 2015; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0111	GC03
PALOMARES CAÑERO, BELEN; CONTRATOS I-PFIS: Belen Palomares CAñero _ Eduardo Muñoz; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: IFI15/00022	GC04
IBAÑEZ COSTA, ALEJANDRO; CD19/00255: Sara Borrell-Alejandro Ibáñez; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD19/00255	GC05
ESCUDERO CONTRERAS, ALEJANDRO; Intensificación Alejandro Escudero Contreras; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: INT19/00094	GC05
LOPEZ PEDRERA, ROSARIO; Renovación Contrato Nicolas Monardes Rosario Lopez Pedrera; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S-C003-006	GC05
IBAÑEZ COSTA, ALEJANDRO; SFJC1600I030825XV1/Juan de la Cierva-Alejandro Ibanez Costa; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: SFJC1600I030825XV1	GC05
LÓPEZ MEDINA, CLEMENTINA; CM19/00020: Rio Hortega-Clementina Lopez; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM19/00020	GC05
BARBARROJA PUERTO, NURIA; Miguel Servet I _ NURIA BARBARROJA _ EDUARDO COLLANTES; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: MSCP15/00158	GC05
ARANDA AGUILAR, ENRIQUE; Terapia de células T en combinación con tratamientos anti-PD1 y anti-óxido nítrico para estimular la respuesta inmune frente al cáncer colorrectal pobremente inmunogénico; Funding Agency: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER; Reference: AECC19/8959	GC06
GUIL LUNA, SILVIA; JC2017/01/AYUDA ESTANCIAS JOSE CASTILLEJOS SILVIA GUIL LUNA; Funding Agency: MINISTERIO DE EDUCACIÓN Y FORMACIÓN PROFESIONAL; Reference: JC2017/01	GC06
RODRÍGUEZ ARIZA, ANTONIO; Renovación Nicolas Monardes Conv 2012: Antonio Rodriguez Ari; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: RC-0002-2016	GC06
GUIL LUNA, SILVIA; SIJC1600I029786XV0-JUAN DE LA CIERVA INCO-SILVIA GUIL LUNA; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: SIJC1600I029786XV0	GC06

FELLOWSHIPS	IMIBIC GROUP
CARMONA MUÑOZ, ANDRÉS; Ampliación Contratación Andrés Carmona PI Excelencia Convocatoria 2011; Funding Agency: CONSEJERÍA DE ECONOMÍA, CONOCIMIENTO, EMPRESAS Y UNIVERSIDAD; Reference: CTS-7352-RRHH-2017	GC07
PEDRAZA AREVALO, SERGIO; AYUDA DEL PROGRAMA DE FORMACIÓN DE PROFESORADO UNIVERSITARIO; Funding Agency: MINISTERIO DE EDUCACIÓN Y FORMACIÓN PROFESIONAL; Reference: FPU14	GC08
FUENTES FAYOS, ANTONIO CARLOS; AYUDA DEL PROGRAMA DE FORMACIÓN DE PROFESORADO UNIVERSITARIO; Funding Agency: MINISTERIO DE EDUCACIÓN Y FORMACIÓN PROFESIONAL	GC08
BLAZQUEZ ENCINAS-REY, RICARDO; AYUDA DEL PROGRAMA DE FORMACIÓN DE PROFESORADO UNIVERSITARIO; Funding Agency: MINISTERIO DE EDUCACIÓN Y FORMACIÓN PROFESIONAL	GC08
VALS DELGADO, CRISTINA; BES-2016-077476 AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACION DE DOCTORES Cristina Vals Delgado; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: BES-2016-077476	GC09
RONCERO RAMOS, IRENE; Sara Borrel-Irene Roncero Ramos; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD16/00047	GC09
DELGADO LISTA, FRANCISCO JAVIER; INTENSIFICACION - FRANCISCO JAVIER DELGADO LISTA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: INT19/00043	GC09
CAMARGO GARCÍA, ANTONIO; CONTRATOS MIGUEL SERVET TIPO I 2014; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: MSCP14/00114	GC09
ALMADEN PEÑA, YOLANDA; Renovación Nicolás Monardes Conv 2012: Yolanda Almadén; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: RC-0001-2016	GC09
LEÓN ACUÑA, ANA; Río Hortega. Ana León Acuña. CM17/00238; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM17/00238	GC09
PEREZ CARDELO, MAGDALENA; FI17/00081-PFIS-Magdalena Pérez Cardelo; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI17/00081	GC09
DE LA CRUZ ARES, SILVIA; JCF-Silvia de la Cruz-GC09 Nutrigenomica; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: SFJC700I0163V0	GC09
AVENDAÑO HERRADOR, MARIA SOLEDAD; Sara Borrell_ Maria Solvedad Avendaño_ AES2017; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD17/00251	GC10
ROA RIVAS, JUAN; PROYECTO MOOCHILA MServet Juan Roa; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CP15/00047	GC10
MUÑOZ CASTAÑEDA, JUAN RAFAEL; VINCULACIÓN SAS INVESTIGADORES 2019-2024 JUAN MUÑOZ CASTAÑEDA; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: RC-0001-2019	GC13
MUÑOZ CASTAÑEDA, JUAN RAFAEL; VINCULACION DE INVESTIGADORES_JUAN MUÑOZ; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0024	GC13
PENDON RUIZ DE MIER, MARIA VICTORIA; Rio Hortega _ MªVictoria Pendon _ AES2018_ CM18/00250; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM18/00250	GC13
JIMENEZ MORENO, ROSARIO; S0137 Convocatoria SAS Técnicos de Apoyo: Rosario Jiménez (IATA); Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0137	GC14
JIMENEZ MORENO, ROSARIO; I Renovación Técnicos de Apoyo ECAI 2015 - Rosario Jiménez Moreno; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: RF2-0001-2019	GC14
SARMADI , HAMID; CONTRATOS I-PFIS: SARMADI NASSER, HAMID; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: IFI16/00033	GC19
FERNÁNDEZ GARCÍA, MARÍA DOLORES; CONTRATOS MIGUEL SERVET I - Mª DOLORES FERNÁNDEZ GARCÍA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CP18/00067	GC24
DELGADO OSUNA, JOSÉ ANTONIO; Desarrollo de Modelos Predictivos Aplicados A Cáncer Colorrectal; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: EF-0312-2017	GC25
PEREZ PERDOMO, EDUARDO; IFI17/00015-iPFIS-Eduardo Pérez Perdomo; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: IFI17/00015	GC25

FELLOWSHIPS	IMIBIC GROUP
FRIAS CASAS, MANUEL MARIO; CONTRATOS SARA BORRELL - MARIO FRIAS CASAS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD18/00091	GC26
RIVERO JUAREZ, ANTONIO; CONTRATOS MIGUEL SERVET - ANTONIO RIVERO JUÁREZ; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CP18/00111	GC26
LEON GONZALEZ, ANTONIO JOSE; Sara Borrell ANTONIO JOSE LEON _ Raul Luque; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD16/00092	GC27
ALORS PEREZ, EMILIA MARIA ; FI17/00282-PFIS-Emilia Alors Pérez; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI17/00282	GC27
GAHETE ORTIZ, MANUEL DAVID; Miguel Servet I - Manuel David Gahete _ Justo; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: MSCP15/00156	GC27
RAYEGO MATEOS, SANDRA; SARA BORRELL_SANDRA RAYEGO MATEOS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD19/00021	GE06
GUERRERO HUE, MELANIA; FI18/00310 - Melania Guerrero Hue; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI18/00310	GE06
HERRERA MARTÍNEZ, AURA DULCINEA; Rio Hortega_ Aura Dulcinea_ AES2017; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM17/00104	GA04
POZO SALAS, ANABEL; Personal Técnico Apoyo MINECO: Animalario (Anabel Pozo); Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PTA2015-11077-I	CORE FACILITIES - ANIMAL EXPERIMENTATION UNIT
ABOLLO JIMENEZ, FERNANDO; CONTRATO TÉCNICOS BIOINFORMÁTICOS DE APOYO A LA INVESTIGACIÓ_FERNANDO ABOLLO JIMÉNEZ; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CA19/00012	CORE FACILITIES - BIOINFORMATICS AND TECHNOLOGICAL INNOVATION UNIT
SANZ MARÍN, JUAN ANTONIO; Formación de personal técnico para análisis de datos; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004673-A	CORE FACILITIES - BIOINFORMATICS AND TECHNOLOGICAL INNOVATION UNIT
GARCÍA JURADO, GEMA; Tecnicos de apoyo 2015 (GEMA GARCIA JURADO); Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PTA2015-11242-I	CORE FACILITIES - CYTOMETRY AND MICROSCOPY UNIT
PERALBO SANTAELLA, MARÍA ESTHER; Vinculación de Técnicos a Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos aprobados en la Convocatoria 2013; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0100	CORE FACILITIES - CYTOMETRY AND MICROSCOPY UNIT
Cervantes Gómez, Natalia; FORMACIÓN DE PERSONAL TÉCNICO DE APOYO EN LA UNIDAD DEGENÓMI; Funding Agency: ; Reference: PEJ2018-003153-A	CORE FACILITIES - GENOMICS UNIT
JIMENEZ ARRANZ, ÁLVARO; I Renovación Técnicos de apoyo ECAI 2015 - Álvaro Jiménez Arranz; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: RF2-009-2019	CORE FACILITIES - GENOMICS UNIT
CHICANO GALVEZ, EDUARDO; Renovación técnicos Área de Proteómica; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0016-1	CORE FACILITIES - PROTEOMICS UNIT
ORTEA GARCÍA, IGNACIO; Vinculación de Técnicos a Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos aprobados en la Convocatoria 2013.; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0067-2018	CORE FACILITIES - PROTEOMICS UNIT
MORILLA MURGA, CRISTINA; Técnico especializado MS-Imaging Unidad Proteómica IMIBIC; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004583-A	CORE FACILITIES - PROTEOMICS UNIT
LUNA ÁLVAREZ, ISMAEL; Técnico especializado LC-MS Unidad Proteómica IMIBIC; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004626-A	CORE FACILITIES - PROTEOMICS UNIT

FELLOWSHIPS	IMIBIC GROUP
FERNANDEZ FORMOSO, LUIS MARIA; CONTRATOS DE GESTIÓN EN INVESTIGACIÓN EN SALUD EN IIS 2017; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: GIS17/00037	MANAGEMENT STAFF
CRUZ MOLEÓN, SOLEDAD; TÉCNICO ÁREA SISTEMAS DE INFORMACIÓN; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004649-A	MANAGEMENT STAFF

FINANCED PROJECTS, NETWORKS & FELLOWSHIPS

PROJECTS & NETWORKS	IMIBIC GROUP
PERA ROJAS, ALEJANDRA; Aortic stenosis immunopathology (ASim); Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/00075	GC01
JURADO ROGER, AURORA; Marcha alérgica polen-alimentos en el Sur de Europa a través de Proteínas Transportadoras de Lípidos (LTPs): Búsqueda de evidencias moleculares y celulares; Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0127-2019	GC01
ESPINAZO ROMEU, MARIA LUISA; Uso de técnicas -Ómicas en el diagnóstico y manejo de enfermedades alérgicas altamente relevantes (Allergomics19); Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0162-2019	GC01
REQUEJO AGUILAR, RAQUEL; Efecto de los sistemas antioxidantes PRdx6 y DJ-1 sobre la función mitocondrial: Influencia en la supervivencia celular; Funding Agency: UNIVERSIDAD DE CORDOBA; Reference: P.P. 2019 Submod. 2.6	GC02
RODRÍGUEZ PERÁLVAREZ, MANUEL LUÍS; Uso de inteligencia artificial para eliminar disparidades de género en el acceso al trasplante hepático: Gender-equality MELD; Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0164-2019	GC02
DE LA TORRE CISNEROS, JULIAN CARLOS; BECA 2019 PARA LA INVETIGGACIÓN DE LA SATOT: Ensayo clínico de eficacia y seguridad de la combinación de profilaxis de duración reducida seguida de profilaxis inmunoguiada en receptores de trasplante pulmonar (Estudio CYTOCOR).; Funding Agency: SOCIEDAD ANDALUZA DE TRASPLANTES DE ÓRGANOS Y TEJIDOS; Reference: SATOT_2019_001	GC03
JUAN JOSÉ CASTÓN OSORIO; Ensayo clínico aleatorizado, controlado, para valorar la eficacia del trasplante de microbiota fecal para la descolonización intestinal en pacientes colonizados por Klebsiella pneumoniae tipo KPC; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/00281	GC03
CALZADO CANALE, MARCO ANTONIO; Desarrollo preclínico de nuevos triterpenos hidroxamatos; Funding Agency: MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD; Reference: RTC-2017-6109-1	GC04
COLLANTES ESTEVEZ, EDUARDO ; Implicación de la microbiota intestinal en la progresión radiográfica en pacientes con Espondiloartritis axial.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/00701	GC05
COLLANTES ESTEVEZ, EDUARDO ; 3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions; Funding Agency: COMISIÓN EUROPEA; Reference: IMI2-2018-14-01-F2	GC05
BARBARROJA PUERTO, NURIA ; IMPACT OF JAK-STAT INHIBITION ON THE METABOLIC SYNDROME AND CARDIOVASCULAR RISK ASSOCIATED WITH RHEUMATOID ARTHRITIS; Funding Agency: PFIZER, S.A; Reference: Pfizer-ISR-2019-01	GC05
MARTÍN MALO, ALEJANDRO ; Análisis de la eficacia depuradora de diferentes técnicas de hemodiálisis sobre los niveles de miRNAs circulares en pacientes con Enfermedad Renal Crónica (Ayuda a la investigación en Diálisis Baxter 2018); Funding Agency: SOCIEDAD ESPAÑOLA DE NEFROLOGÍA; Reference: SEN18/02	GC07
CASTAÑO FUENTES, JUSTO PASTOR; Estrategia spliceosómica para mejorar el diagnóstico, la clasificación y el tratamiento de los tumores neuroendocrinos pancreáticos; Funding Agency: GRUPO ESPAÑOL DE TUMORES NEUROENDOCRINOS (GETNE); Reference: GETNE 2019 G1909	GC08
CASTAÑO FUENTES, JUSTO PASTOR; Estrategia Spliceosómica para mejorar el diagnóstico, la clasificación y el tratamiento de los tumores neuroendocrinos pancreáticos; Funding Agency: FUNDACIÓN EUGENIO RODRIGUEZ PASCUAL; Reference: FERP_2019_001	GC08
CAMARGO GARCÍA, ANTONIO ; COMPOSICIÓN MICROBIANA DEL INTESTINO COMO HERRAMIENTA PREDICTIVA DEL DESARROLLO DE DIABETES MELLITUS TIPO 2; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: DTS19/00007	GC09
CAMARGO GARCÍA, ANTONIO ; Papel de la microbiota intestinal en las diferencias en el desarrollo de enfermedad cardiovascular en función del género; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/00299	GC09
ROA RIVAS, JUAN ; Implicaciones fisiopatológicas y valor diagnóstico de miRNAs candidatos involucrados en el desarrollo temprano de obesidad y enfermedad metabólica. Estudio CHILDEM; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/00257	GC10

PROJECTS & NETWORKS	IMIBIC GROUP
PÉRULA DE TORRES, LUIS ANGEL ; Evalúa GPS (Evalúa y Aplica Guías de práctica de Promoción de la Salud): evaluación de la implementación de la guía NICE NG44; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/01525	GC12
SERRANO MERINO, JESÚS; Validación Al Español del Cuestionario de Berlin para la Detección de Pacientes de 40 Años O Más Con Síndrome de Apnea-Hipoapnea del Sueño en Atención Primaria: Estudios Sahs-Cb; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0177-2018	GC12
LUIS ANGEL PÉRULA DE TORRES; Evaluación de la Difusión Internacional del Código Europeo Contra el Cáncer A Través de la Telefonía Móvil. Estudio Piloto en la Población de Andalucía (España) A Través del Servicio Click Salud + (Estudio Cecc-Oms); Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: AP-0201-2019	GC12
RODRÍGUEZ PORTILLO, JUAN MARIANO ; Ensayo clínico Fase II abierto, para evaluar en pacientes con enfermedad renal crónica grado 3b-4 la eficacia del suplemento de magnesio sobre la calcificación vascular y la densidad ósea.; Funding Agency: SOCIEDAD ESPAÑOLA DE NEFROLOGÍA; Reference: SEN18/01	GC13
GONZALEZ MANZANARES, RAFAEL; PROYECTO DE LA SEC PARA INVESTIGACIÓN TRASLACIONAL EN CARDIOLOGÍA - "Cardiotoxicidad tardía inducida por antraciclinas en supervivientes a leucemia aguda linfoblastica en edad pediátrica; Funding Agency: SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA; Reference: BECA.SEC01/19	GC15
ARJONA SÁNCHEZ, ÁLVARO ; Caracterización molecular del Pseudmixoma Peritoneal y desarrollo de biomarcadores y terapias diana en un modelo de ratón con xenoimplante humano.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/01603	GC18
PÉREZ JIMÉNEZ, ANA BELÉN; Aplicación de la secuenciación masiva para el diagnóstico de infecciones neurológicas de origen vírico no filiadas; Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0216-2019	GC24
RIVERO JUÁREZ, ANTONIO ; Trazabilidad epidemiológica y microbiológica de la infección por el virus de la Hepatitis E: Estudio TrazHE; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/00864	GC26
RISALDE MOYA, MARIA DE LOS ANGELES; Infectividad del virus de la Hepatitis E detectado en alimentos de origen porcino utilizando modelos animales y cultivos celulares. (Estudio HepEfood); Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0287-2019	GC26
FRIAS CASAS, MANUEL MARIO; Identificación de virus zoonóticos en artrópodos vectores endémicos de España; Funding Agency: CONSEJERÍA DE SALUD; Reference: EF-0327-2019	GC26
VENTURA SOTO, SEBASTIÁN; dreaMS - A telehealth tool for monitoring and treatment of Multiple Sclerosis patients; Funding Agency: COMISIÓN EUROPEA; Reference: DIATOMIC-2019-02-001	GC25
LEON GONZALEZ, ANTONIO JOSE; Papel terapéutico de compuestos bioactivos del aceite de oliva virgen extra en la asociación patológica del cáncer de próstata y la obesidad; Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0152-2019	GC27
LOPEZ CANOVAS, JUAN LUIS; Papel de la desregulación de la maquinaria de splicing y factores de splicing en carcionoma hepatocellular y su relación con la resistencia a fármacos.; Funding Agency: CONSEJERÍA DE SALUD; Reference: EF-0197-2019	GC27
CABALLERO VILLARRASO, JAVIER ; DESARROLLO DE HERRAMIENTAS TRANSVERSALES PARA LA CONSTRUCCIÓN DE NUEVOS CAR-T EN TUMORES HEMATOLÓGICOS Y SÓLIDOS.; Funding Agency: CONSEJERÍA DE SALUD Y FAMILIAS; Reference: PS-2019-636	GE01
AGÜERA MORALES, EDUARDO; dreaMS - A telehealth tool for monitoring and treatment of Multiple Sclerosis patients; Funding Agency: COMISIÓN EUROPEA; Reference: DIATOMIC-2019-02-001	GE01
GUERRERO HUE, MELANIA; Mechanism of hematuria in humanized mouse models of IgA Nephropathy; Funding Agency: CONSEJERÍA DE SALUD; Reference: EF-0145-2019	GE06
GONZALEZ ANDRADES, MIGUEL; ENSAYO CLÍNICO FASE I-II MULTICÉNTRICO PARA EVALUAR SEGURIDAD Y EFICACIA DE UN MEDICAMENTO DE TERAPIA AVANZADA BASADO EN UNA CÓRNEA ARTIFICIAL DE PÉPTIDOS SIMILARES AL COLÁGENO CON CÉLULAS EPITELIALES PARA EL TRATAMIENTO DE ENFERMEDADES CORNEALES SEVERAS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: ICI19/00006	GE07

PROJECTS & NETWORKS	IMIBIC GROUP
GONZALEZ ANDRADES, MIGUEL; GENERACIÓN Y EVALUACIÓN IN VIVO DE MATRICES BIOARTIFICIALES DESCELULARIZADAS Y GAMMA IRRADIADAS A PARTIR DE XENOINJERTOS PORCINOS PARA SU APLICACIÓN EN TERAPIAS AVANZADAS EN CÓRNEA Y CARTÍLAGO; Funding Agency: CONSEJERÍA DE SALUD; Reference: PIGE-0194-2019	GE07
JESUS LOPEZ SOTO, PABLO; Dieta como factor modulador en la cronodisrupción generada por el Daylight Saving Time (DST) en el desarrollo de enfermedades cardiovasculares.; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI19/01405	GE08
MORALES CANÉ, IGNACIO; Contaminación ambiental (luz, sonido) en las Unidades de Cuidados Intensivos y su influencia en la evolución clínica de los pacientes-CALUCI.; Funding Agency: CONSEJERÍA DE SALUD; Reference: PIGE-0462-2019	GE08
MOLINA PUERTA, MARIA JOSE ; Beca SANCYD-VEGENAT de investigación al mejor proyecto en obesidad 2016: Uso de las TIC para control del peso en pacientes con sobrespeso y obesidad.; Funding Agency: FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA; Reference: SANCYD-VEGENAT_001	GA04
HERRERA MARTÍNEZ, AURA DULCINEA; Cambios clínico-moleculares tras la cirugía bariátrica: papel de la vitamina D en la reversión de comorbilidades metabólicas asociadas a la obesidad.; Funding Agency: FUNDACIÓN ESPAÑOLA DE INVESTIGACIÓN ÓSEA Y DEL METABOLISMO MINERAL; Reference: FEIOMM19_01	GA04
HERRERA MARTÍNEZ, AURA DULCINEA; Evolución clínico-molecular de marcadores inflamatorios, apoptóticos y hormonales tras la cirugía bariátrica: cambios metabólicos, mejoría de comorbilidades, splicing, predicción de complicaciones y mecanismos subyacentes; Funding Agency: CONSEJERÍA DE SALUD; Reference: PI-0038-2019	GA04
HERRERA MARTÍNEZ, AURA DULCINEA; Cambios clínico-moleculares tras la cirugía bariátrica: papel de la vitamina D en la reversión de comorbilidades metabólicas asociadas a la obesidad.; Funding Agency: GRUPO ESPAÑOL DE TUMORES NEUROENDOCRINOS (GETNE); Reference: GETNE19_001	GA04
ROMERO CABRERA, JUAN LUIS; Estudio de la interacción de los diferentes factores exógenos (hábitos de vida y dietéticos) y endógenos (genéticos) que podrían determinar la presencia de factores de riesgo cardiovascular y el desarrollo de enfermedades cardiovasculares en diferentes po; Funding Agency: CONSEJERÍA DE SALUD; Reference: EF-0218-2019	INTERNAL MEDICINE UNIT
MAYORDOMO RIERA, FERNANDO JESUS ; MERLIN - hoMEcare aRm rehabiLItatioN; Funding Agency: COMISIÓN EUROPEA; Reference: EITHealth-2018-01	PHYSICAL MEDICINE AND REHABILITATION UNIT

FELLOWSHIPS	IMIBIC GROUP
PERA ROJAS, ALEJANDRA; Línea de investigación-Miguel Servet- Alejandra Pera; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CP19/00008	GC01
GUERRERO MISAS, MARTA; CM19/00129: Rio Hortega-Marta Guerrero Misas; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM19/00129	GC02
DE LA MATA GARCÍA, MANUEL; Refuerzo con RRHH de la actividad investigadora en las UGC del SAS ACCION A; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: A1-0064-2019	GC02
ANTONIO RIVERO ROMÁN (25%) / JULIÁN DE LA TORRE CISNEROS (25%); Refuerzo con RRHH de la actividad investigadora en las UGC del SAS ACCION A; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: A1-0007-2019	GC03
IBAÑEZ COSTA, ALEJANDRO; CD19/00255: Sara Borrell-Alejandro Ibáñez; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD19/00255	GC05
LÓPEZ MEDINA, CLEMENTINA; CM19/00020: Rio Hortega-Clementina Lopez; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CM19/00020	GC05
ESCUDERO CONTRERAS, ALEJANDRO; Intensificación Alejandro Escudero Contreras; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: INT19/00094	GC05
COLLANTES ESTÉVEZ, EDUARDO; Refuerzo con RRHH de la actividad investigadora en las UGC del SAS ACCION A; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: A1-0059-2019	GC05

FELLOWSHIPS	IMIBIC GROUP
ARANDA AGUILAR, ENRIQUE; Terapia de células T en combinación con tratamientos anti-PD1 y anti-óxido nítrico para estimular la respuesta inmune frente al cáncer colorrectal pobremente inmunogénico; Funding Agency: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER; Reference: AECC19/8959	GC06
ESPEJO CRUZ, MARIA LOLA; FI19/00357-PFIS-Maria Lola Espejo; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI19/00357	GC07
MARTÍN MALO, ALEJANDRO; Refuerzo con RRHH de la actividad investigadora en las UGC del SAS ACCION A; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: A1-0032-2019	GC07
RANGEL ZÚÑIGA, ORIOL ALBERTO; Linea de investigación MIGUEL SERVET I - ORIOL ALBERTO RANGEL ZUÑIGA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CP19/00142	GC09
CAMARGO GARCÍA, ANTONIO; CONTRATO MIGUEL SERVET II - ANTONIO CAMARGO GARCIA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CPII19/00007	GC09
FUENTES JIMÉNEZ, FRANCISCO; Refuerzo con RRHH de la actividad investigadora en las UGC del SAS ACCION A; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: A1-0003-2019	GC09
YUBERO SERRANO, ELENA M; Nicolas Monarde Elena Yubero. Medicina Interna; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: C1-0005-2019	GC09
PODADERA HERREROS, ALICIA; FI19/00144-PFIS-alicia Podadera Herreros; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI19/00144	GC09
DELGADO LISTA, FRANCISCO JAVIER; INTENSIFICACION - FRANCISCO JAVIER DELGADO LISTA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: INT19/00043	GC09
LEÓN ACUÑA, ANA; CONTRATO JUAN RODÉS 2019_ANA LEÓN ACUÑA; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: JR19/00034	GC09
YUBERO SERRANO, ELENA M; Nicolas Monarde Elena Yubero. Medicina Interna; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0262	GC09
AVENDAÑO HERRADOR, MARIA SOLEDAD; Línea de investigación- Miguel Servet- María Soledad Avendaño; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CP19/00195	GC10
ROMERO RUIZ, ANTONIO; Nicolas Monardes Antonio Romero Ruiz. Cirugia General y Digestiva; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: S0437	GC10
ROMERO RUIZ, ANTONIO; Nicolas Monardes Antonio Romero Ruiz. Cirugia General y Digestiva; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: C1-0066-2019	GC10
GARCÍA GALIANO, DAVID; CRISPR-KissCas9 - Challenging the KNDy Hypothesis Using CRISPR-Cas9 Genome Editing: Evaluation of the Role of Neurokinin B and Dynorphin in Kiss1 neurons in the Control of Fertility; Funding Agency: European Commission; Reference: MSCA-IF-2018-003.	GC10
LOPEZ BALTANAS, RODRIGO; FI19/00317-PFIS-Rodrigo Lopez Baltanas; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI19/00317	GC13
MUÑOZ CASTAÑEDA, JUAN RAFAEL; VINCULACIÓN SAS INVESTIGADORES 2019-2024 JUAN MUÑOZ CASTAÑEDA; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: RC-0001- 2019	GC13
MARTÍNEZ MARTÍNEZ, LUIS; Refuerzo con RRHH de la actividad investigadora en las UGC del SAS ACCION A; Funding Agency: SERVICIO ANDALUZ DE SALUD; Reference: A1-0025-2019	GC24
SARMENTO BORGES CABRAL, ANDRE MORAIS; CD19/00065: Sara Borrell-Andre Cabrais; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD19/00065.	GC27
RAYEGO MATEOS, SANDRA; SARA BORRELL_SANDRA RAYEGO MATEOS; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CD19/00021	GE06
GUERRERO HUE, MELANIA; FI18/00310 - Melania Guerrero Hue; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: FI18/00310	GE06
HERRERA MARTÍNEZ, AURA DULCINEA; JR19/00050- Juan Rodes- Aura Dulcinea Herrera; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: JR19/00050	GA04
ESCUDERO JABONERO, ESTEFANIA; AYUDAS PERSONAL TÉCNICO DE APOYO 2019 ESTEFANÍA ESCUDERO JABONERO; Funding Agency: AGENCIA ESTATAL DE INVESTIGACIÓN; Reference: PTA2018-014963-I	CORE FACILITIES - ANIMAL EXPERIMENTATION
ABOLLO JIMENEZ, FERNANDO; CONTRATO TÉCNICOS BIOINFORMÁTICOS DE APOYO A LA INVESTIGACIÓ_FERNANDO ABOLLO JIMÉNEZ; Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: CA19/00012	CORE FACILITIES - Bioinformatics and Technological Innovation Unit

FELLOWSHIPS	IMIBIC GROUP
CRUZ MOLEÓN, SOLEDAD; TÉCNICO ÁREA SISTEMAS DE INFORMACIÓN; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004649-A	MANAGEMENT STAFF
Cervantes Gómez, Natalia; FORMACIÓN DE PERSONAL TÉCNICO DE APOYO EN LA UNIDAD DEGENÓMI; Funding Agency: ; Reference: PEJ2018-003153-A	CORE FACILITIES - GENOMICS UNIT
MORILLA MURGA, CRISTINA; Técnico especializado MS-Imaging Unidad Proteómica IMIBIC; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004583-A	CORE FACILITIES - PROTEOMICS UNIT
LUNA ÁLVAREZ, ISMAEL; Técnico especializado LC-MS Unidad Proteómica IMIBIC; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004626-A	CORE FACILITIES - PROTEOMICS UNIT
SANZ MARÍN, JUAN ANTONIO; Formación de personal técnico para análisis de datos; Funding Agency: MINISTERIO DE ECONOMIA Y EMPRESA; Reference: PEJ2018-004673-A	CORE FACILITIES - BIOINFORMATICS AND TECHNOLOGICAL INNOVATION UNIT

AGREEMENTS WITH COMPANIES

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
MORENO AGUILAR, CARMEN; PRESTACIÓN DE SERVICIOS JORNADA MONOGRÁFICA ige; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: pss.0117	GC01
JURADO ROGER, AURORA; Gastos derivados de la asistencia a la reunión del Ensayo Clínico EC 11084 del Fondo de Investigación Sanitaria de personal del IMIBIC.; Funding Agency: THERMO FISHER DIAGNOSTICS, S.L.U. (ANTES PHADIA SPAIN SL); Reference: PSS.0201	GC01
JURADO ROGER, AURORA; Influencia de la combinaciones genotípicas de los receptores NK tipo KIR y moléculas HLA en diferentes situaciones clínico-terapéuticas.; Funding Agency: FUJIREBIO IBERIA S.L.; Reference: CCB.0137	GC01
JURADO ROGER, AURORA; Search for cut-off points for IgE determinations to Grass and Olea allergens in a clinically useful diagnostic algorithm.; Funding Agency: THERMO FISHER DIAGNOSTICS, S.L.U. (ANTES PHADIA SPAIN SL); Reference: CCB.0160	GC01
MORENO AGUILAR, CARMEN; PROYECTO SERUM POOL. Colaboración al desarrrollo de extractos alergénicos específicos utilizados en el diagnóstico y tratamiento de las enfermedades elérgicas.; Funding Agency: ALK-ABELLO S.A.; Reference: CCB.0197	GC01
GARCÍA SÁNCHEZ, MARÍA DEL VALLE; Prognosis of patients with ulcerative colitis in sustained remission after thiopurines withdrawal _ Medical writer; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: PSS.0091	GC02
DE LA MATA GARCÍA, MANUEL; PROGRAMA aHCtion: Excelencia en la ENFERMEDAD HEPÁTICA AVANZADA Y TRASPLANTE HEPÉTICO.; Funding Agency: ABBVIE SPAIN S.L.U.; Reference: PSS.0144	GC02
IGLESIAS FLORES, EVA; Banderola publicitaria en la I Semana de la EII.; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0207	GC02
IGLESIAS FLORES, EVA; II Semana de la Enfermedad Inflamatoria Intestinal. 12-16 de Noviembre de 2018 - 1 Banderola publicitaria (1.200€/banderola) - Inclusión del logo en el programa para su impresión (1.500 €) 200 copias; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0260	GC02
MONTERO ALVAREZ, JOSE LUIS; Curso Actualización en el análisis de datos científicos para la generación de evidencia. 7 y 28 marzo de 2019.; Funding Agency: ABBVIE SPAIN S.L.U.; Reference: PSS.0276	GC02
GARCÍA SÁNCHEZ, MARÍA DEL VALLE; Convenio colaboración Docencia; Funding Agency: MUTUAL MÉDICA DE CATALUÑA Y BALEARES; Reference: CCB.0132	GC02
GARCÍA SÁNCHEZ, MARÍA DEL VALLE; CONVENIO FIBICO-MERCK SHARP & DOHME DE ESPAÑA; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: CCB.0171	GC02
GARCÍA SÁNCHEZ, MARÍA DEL VALLE; CONVENIO FUNDACION LA CAIXA PROYECTO BANCO DE LECHE MATERNA EN LA UNIDAD DE PEDIATRIA DEL HOSPITAL UNIVERSITARIO REINA SOFIA DE CORDOBA; Funding Agency: FUNDACIÓN LA CAIXA; Reference: CCB.0174	GC02
DE LA TORRE CISNEROS, JULIAN CARLOS; Colaboración para las jornadas en patología infecciosa.; Funding Agency: BRAHMS IBERIA, S.L.; Reference: PSS.0045	GC03
DE LA TORRE CISNEROS, JULIAN CARLOS; Estudio de la frecuencia, fenotipo y función de los linfocitos T CD8+ CMV – específicos como factor de riesgo de replicación de CMV en pacientes transplantados de órgano sólido; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0004	GC03
DE LA TORRE CISNEROS, JULIAN CARLOS; CONVENIO ROCHE PARA PUBLICACIONES UGC INFECCIOSOS 6.000; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0076	GC03
DE LA TORRE CISNEROS, JULIAN CARLOS; CONVENIO DE COLABORACIÓN ECONOMICA ENTRE FIBICO Y Y FISEVI. 3055,36 €. 11/03/2016; Funding Agency: FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA; Reference: CCB.0114	GC03
MUÑOZ BLANCO, EDUARDO; AGREEMENT FOR THE PROVISION OF SERVICES BETWEEN THE FOUNDATION FOR THE BIOMEDICAL RESEARCH OF CÓRDOBA AND VIVACELL BIOTECHNOLOGY ESPAÑA S. L.; Funding Agency: EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (VIVACELL); Reference: PSS.0171	GC04
MUÑOZ BLANCO, EDUARDO; FIBICO-PHYTOPLANT: Desarrollo del estudio de la eficiacia del THCA en modelos murinos de obesidad y diabetes; Funding Agency: PHYTOPLANT RESEARCH S.L; Reference: PSS.0213	GC04

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
MUÑOZ BLANCO, EDUARDO; Effect of THCA on Collagen-Induced arthritis in mice-Effect of THCA in murine live stetatosis; Funding Agency: EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (VIVACELL); Reference: PSS.0273	GC04
ANTONIO CANALE, MARCO ANTONIO; Proteome profiler Antibody Arrays (for cytokine and angiogenesis related proteins) in plasma samples collected during the trial referenced above in latest cohorts after single dose administration (SAD) and multiple dose administration (MAD) of the drug pr; Funding Agency: EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (VIVACELL); Reference: PSS.0275	GC04
MUÑOZ BLANCO, EDUARDO; Biomarkers testing and selection in both murine samples and in human samples from Phase I clinical trial: Ramdomized, Double-Blind, Placebo-Controlled Study to Evaluate the safete, toilerability, Pharmacodynamics, Pharmacokinetics, and Food effect of sing; Funding Agency: EMERALD HEALTH PHARMACEUTICALS ESPAÑA; Reference: PSS.0282	GC04
COLLANTES ESTEVEZ, EDUARDO; CONTRATO SANOFI-REUMA PARA FORMACIÓN; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: PSS.0212	GC05
COLLANTES ESTEVEZ, EDUARDO; CONTRATO BIOHOPE INMUNOBIOGRAM; Funding Agency: BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL; Reference: PSS.0228	GC05
LOPEZ PEDRERA, ROSARIO; Licencia dependiente del PI18/00837; Funding Agency: MIRNAX BIOSENS S.L; Reference: PSS.0272	GC05
COLLANTES ESTEVEZ, EDUARDO; Financiación de Publicaciones de PFIZER S.L.U; Funding Agency: PFIZER, S.L.U.; Reference: CCB.0050	GC05
COLLANTES ESTEVEZ, EDUARDO; PAPEL DE LA INFLAMACION EN LAS ARTICULACIONES EN EL DESARROLLO DE RESISTENCIA A LA INSULINA Y ATEROSCLEROSIS ASOCIADAS A LA ARTRITIS REUMATOIDE; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0100	GC05
BARBARROJA PUERTO, NURIA; CONVENIO EFECTO DE LA ARTRITISEN LA FUNCIÓN HEPÁTICA Y MODULACIÓN EN RESPUESTA A FAMES. MODELO MURINO DE ARTRITIS Y ESTUDIOS IN VITRO ROCHE; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0184	GC05
COLLANTES ESTEVEZ, EDUARDO; Identificación y caracterización de nuevos biomarcadores en la artritis reumatoide.; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0248	GC05
ARANDA AGUILAR, ENRIQUE; INTERCONECTA ONCOEXPERT BIOTECNOLOGIA PARA EL DIAGNÓSTICO Y TRATAMIENTO ONCOLÓGICO; Funding Agency: INDRA SISTEMAS, S. A.; Reference: INTER.0003/1	GC06
ARANDA AGUILAR, ENRIQUE; PROYECTO VISNU; Funding Agency: GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD); Reference: PSS.0022	GC06
ARANDA AGUILAR, ENRIQUE; DETERMINACION DE GENES NRAS EN PACIENTES CON CCRm; Funding Agency: MERCK, S.L.U.; Reference: PSS.0050	GC06
ARANDA AGUILAR, ENRIQUE; Contrato para la determinación de los biomarcadores KRAS y NRAS.; Funding Agency: AMGEN SA; Reference: PSS.0053	GC06
ARANDA AGUILAR, ENRIQUE; CONTRATO PARA LA DETERMINACIÓN DEL BIOMARCADOR RAS ENTRE EL GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS Y LA FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Funding Agency: GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD); Reference: PSS.0054	GC06
ARANDA AGUILAR, ENRIQUE; CONTRATO DEL CENTRO DE EXCELENCIA ONCOBEAM; Funding Agency: SYSMEX ESPAÑA S.L.; Reference: PSS.0108	GC06
ARANDA AGUILAR, ENRIQUE; LIQUIDACIÓN CONGRESO CÁNCER DIGESTIVO; Funding Agency: TACTICS MEDICINA Y DESARROLLO, S.L.; Reference: PSS.0140	GC06
ARANDA AGUILAR, ENRIQUE; CONTRATO PRESTACIÓN ENTRE FIBICO-GRUPO TTD; Funding Agency: GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD); Reference: PSS.0147	GC06
ARANDA AGUILAR, ENRIQUE; GASTOS GESTIÓN ENSAYO CLÍNICO ELUXA; Funding Agency: BOEHRINGER INGELHEIM INTERNATIONAL GMBH; Reference: PSS.0153	GC06
GÓMEZ ESPAÑA, MARIA AUXILIADORA; CONTRATO TTD/ENSAYO AFEMA; Funding Agency: GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD); Reference: PSS.0180	GC06
ARANDA AGUILAR, ENRIQUE; Liquidación III Jornada Científica temas de Actualidad en Cáncer Digestivo; Funding Agency: TACTICS MEDICINA Y DESARROLLO, S.L.; Reference: PSS.0211	GC06

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
BARNETO ARANDA, ISIDORO; Estudio de práctica clínica en condiciones reales para evlauar la toma de decisiones en el tratamiento de seugnda línea conforme a las normas asistenciales y basado en los perfiles de foundation medicine en pacientes con CPNM localmente avanzado o metast; Funding Agency: ROCHE FARMA, S.A.; Reference: PSS.0264	GC06
DE LA HABA RODRÍGUEZ, JUAN; Analytical assays for the evaluation of AGTR1 expression in tumors as a possible predictor of response to angiogenic therapy in connection with the clinical development of bevacizumab.; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0028	GC06
SANCHEZ MAURIÑO, PEDRO; CONVENIO COLABORACIÓN PARA LA APORTACIÓN DE AYUDAS ECONÓMICAS A LA INVESTIGACIÓN (ROVI); Funding Agency: LABORATORIOS FARMACEUTICOS ROVI, SA; Reference: CCB.0069	GC06
ARANDA AGUILAR, ENRIQUE; CONVENIO COLABORACION FINANCIACIÓN INVESTIGACIÓN AREA ONCOLOGIA ROCHE; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0119	GC06
ARANDA AGUILAR, ENRIQUE; Convenio colaboración área de oncología; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0172	GC06
ALJAMA GARCÍA, PEDRO; WEBINAR ALEXION NEFROLOGIA; Funding Agency: ALEXION PHARMA SPAIN SL; Reference: PSS.0202	GC07
SANTAMARIA OLMO, RAFAEL; CONTRATO PRESTACIÓN DE SERVICIOS POR PROFESIONAL SANITARIO-EMPRESA; Funding Agency: SANIDAD Y EDICIONES S.L.; Reference: PSS.0234	GC07
SANTAMARIA OLMO, RAFAEL; Prestacion de servicios Nefrología; Funding Agency: SANIDAD Y EDICIONES S.L.; Reference: PSS.0283	GC07
ALJAMA GARCÍA, PEDRO; Convenio Sanofi/Genzyme Curso Nefrologia; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: CCB.0134	GC07
ALJAMA GARCÍA, PEDRO; CONVENIO FRESENIUS MEDICAL CARE; Funding Agency: FRESENIUS MEDICAL CARE ESPAÑA, S.A.; Reference: CCB.0147	GC07
CASTAÑO FUENTES, JUSTO PASTOR; Jornada de actulaización en tumores neuroendocrinos - 29/04/2019; Funding Agency: IPSEN PHARMA S.A.; Reference: PSS.0286	GC08
PÉREZ JIMÉNEZ, FRANCISCO; Contrato de I+D entre el Centro Tecnológico Andaluz de Diseño y la Fundación para la Investigaicón Biomédica de Córdoba para la realización de un proyecto de investigación.; Funding Agency: FUNDACION CENTRO TECNOLOGICO ANDALUZ DE DISEÑO; Reference: PSS.0001	GC09
MONTERO PÉREZ-BARQUERO, MANUEL; Apoyo al desarrollo de la Investigación Científica en Insuficiencia Cardíaca de la Unidad del Manejo Integral del Paciente con Insuficiencia Cardiaca (UMIPIC) del Hospital Universitario Reina Sofía.; Funding Agency: LABORATORIOS SERVIER, S.L.; Reference: PSS.0051	GC09
PÉREZ JIMÉNEZ, FRANCISCO; SERVICIOS DE INVESTIGACIÓN RELATIVOS AL PROYECTO INFLUENCIA DEL HIDROXITIROSOL SOBRE EL PERFIL LIPÍDICO, EL METABOLISMO DE LOS HIDRATOS DE CARBONO Y LA FUNCIÓN ENDOTELIAL EN MAYORES DE 65 AÑOS; Funding Agency: BIOMASLINIC S.L.; Reference: PSS.0070	GC09
LOPEZ MIRANDA, JOSE; CONTRATO DE PRESTACIÓN DE SERVICIOS EDICIONES MAYO SA; Funding Agency: EDICIONES MAYO SA; Reference: PSS.0233	GC09
LOPEZ MIRANDA, JOSE; Contratación Dietista ERC-Universidad de Navarra; Funding Agency: UNIVERSIDAD DE NAVARRA; Reference: PSS.0238	GC09
CAMARGO GARCÍA, ANTONIO; Convenio de Colaboración entre la Fundación para la Investigación Biomédica de Córdoba y Cooperativas Olivareras; Funding Agency: COOPERATIVA AGRICOLA NUESTRA SEÑORA DE LA SALUD; Reference: CCB.0183	GC09
RANGEL ZUÑIGA, ORIOL ALBERTO; SERVICIOS PARA LA UNIVERSIDAD DE CALDAS, COLOMBIA; Funding Agency: UNIVERSIDAD DE CALDAS; Reference: PSS.0266	GC09
TENA SEMPERE, MANUEL; analisis de Genomica del proyecto de Endometriosis; Funding Agency: UNIVERSITY OF TURKU; Reference: PSS.0249	GC10
ROMERO RUIZ, ANTONIO; Facturación asistencia a Barcelona Summit – 22nd October 2018; Funding Agency: NANOSTRING TECHNOLOGIES EUROPE LIMITED; Reference: PSS.0268	GC10
ROA RIVAS, JUAN; FIBICO-EHBE. Effect of VCE-006.1 and (+) CBD-HPE on glucose and insulin tolerance in a murine model of obesity/diabetes; Funding Agency: EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (VIVACELL); Reference: PSS.0270	GC10

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
ROA RIVAS, JUAN; Mechanism of action of VCE-004 in the PHD/HIF-1 axis and effect of VCE-004.8 on macrophage cell functions and Arginase 1 gene regulation; Funding Agency: EMERALD HEALTH BIOTECHNOLOGY ESPAÑA,S.L.U. (VIVACELL); Reference: PSS.0271	GC10
RICH RUÍZ, MANUEL; Servicio a la gestión de apoyo en la investigación en el proyecto: Eficacia del Programa de Ejercicios de Otago aplicado de forma grupal versus individual en la probabilidad de caídas de personas entre 65-80 años no institucionalizadas.; Funding Agency: UNIVERSIDAD DE CORDOBA; Reference: PSS.0164	GC12
RICH RUÍZ, MANUEL; Organización cursos para el incremento de las capacidades investigadoras de enfermería.; Funding Agency: UNIVERSIDAD DE CORDOBA; Reference: PSS.0209	GC12
PÉRULA DE TORRES, LUIS ANGEL; Prestación de servicios para el proyecto EPIRCE II. realización de la recogida de las variables de estudio en los sujetos de la cohorte mediante entrevista, la recogida y custodia de muestras biológicas de sangre y orina en el Biobanco de Córdoba hasta su; Funding Agency: FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS); Reference: PSS.0226	GC12
RODRÍGUEZ PORTILLO, JUAN MARIANO; Efecto del Paricalcitol en las células del músculo liso vascular; Funding Agency: ABBVIE SPAIN S.L.U.; Reference: PSS.0015	GC13
RODRÍGUEZ PORTILLO, JUAN MARIANO; Research Program Agreement for measuring AMG 416 activity against isolated rat PTG; Funding Agency: AMGEN INC.; Reference: PSS.0020	GC13
MUÑOZ CASTAÑEDA, JUAN RAFAEL; Preclinical Research Program Agreement for anti-PCSK9 mAb1; Funding Agency: AMGEN RESEARCH (MUNICH) GMBH; Reference: PSS.0162	GC13
MUÑOZ CASTAÑEDA, JUAN; Estudio para medir y evaluar Lactobacilo y DMG017 Dazamart; Funding Agency: DAZAMART DE INVERSIONES, SL; Reference: PSS.0208	GC13
RODRÍGUEZ PORTILLO, JUAN MARIANO; PRECLINICAL RESEARCH PROGRAM AGREEMENT AMGEN; Funding Agency: AMGEN INC.; Reference: PSS.0247	GC13
MUÑOZ CASTAÑEDA, JUAN; Research Program Agreement Amgen-GC13; Funding Agency: AMGEN INC.; Reference: PSS.0251	GC13
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Ponencias Hematología. Ponencias Hematología; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0040	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; SESIÓN CLÍNIC- Arrend Salas Formacion servicio hematología 600 euros; Funding Agency: ROCHE FARMA, S.A.; Reference: pss.0066	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; DONACION JANSEM HEMATOLOGIA; Funding Agency: JANSSEN-CILAG, S.A.; Reference: pss.0075	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; INFORME MEJORAS A IMPLEMENTAR EN LA HERRAMIENTA ORIENTA; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0088	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Publicidad Institucional; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0103	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; CONTRATO DE PRESTACIÓN DE PONENCIA BRISTOL HEMATOLOGÍA; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: PSS.0129	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; SPONSORSHIP JANSESS JORNADA PARA FAMILIARES Y PACIENTES HEMATOLÓGICOS; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0130	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; SPONSORSHIP III JORNADAS FORMACIÓN HEMATOLOGÍA. Jornadas para familiares y pacientes hematológicos. Abriendo la puerta a la esperanza.; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0169	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; BMS Contrato de ponencia: Programa de desarrollo de Spyercel en LMC/LLA+ tratamienot y manejo actual de la LMC+ el papel del sistema inmune en la LMC; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: PSS.0172	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; SPONSORSHIP JORNADA DE PACIENTES HEMATOLOGÍA; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0177	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; IV Jornadas Actualización Hematología; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0204	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; PATROCINIO FORMACION TRASPLANTE HEMATOPOYÉTICO; Funding Agency: AMGEN SA; Reference: PSS.0218	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Jornadas Trasplante Hematopoyetico Janssen; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0220	GC14

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
HERRERA ARROYO, INMACULADA CONCEPCIÓN; PATROCINIO JORNADAS PACIENTES 2018 JANSSEN; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0239	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; REUNIÓN DE ACTUALIZACIÓN EN HEMATOLOGÍA; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: PSS.0252	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Patrocinio Jornadas de formación UGC Hematología; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0257	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Patrocinio Pfizer Jornadas Hematologicas; Funding Agency: PFIZER, S.L.U.; Reference: PSS.0262	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Patocinio Takeda Jornadas Hematologicas; Funding Agency: TAKEDA FARMACEUTICA ESPAÑA,S.A.U; Reference: PSS.0263	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Patrocinio - VII Jornada actualización en hematología - 15/ Mayo/2019; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0285	GC14
HERRERA ARROYO, INMACULADA CONCEPCIÓN; Ponencia en la Reunión Científica organizada por Pfizer Sesión clínica de productos Pfizer en hematología el 26/11/2014, en particular en la reunión Datos de temsirolimus en LCM. Estudios publicados.; Funding Agency: PFIZER, S.L.U.; Reference: CCB.0078	GC14
PAN ÁLVAREZ-OSSORIO, MANUEL; Prestación para la Jornada de Actualización en Cardiología - Bristol-Myers Squibb; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: PSS.0240	GC15
ARIZON DEL PRADO, JOSÉ MARÍA; Prestación para curso de insuficiencia cardíaca y asistencia ventricular; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0244	GC15
ARIZON DEL PRADO, JOSÉ MARÍA; Prestación para la jornada de Insuficiencia Cardiaca Secera y Asistencia Ventricular - Medtronic-; Funding Agency: MEDTRONIC IBERICA, S.A; Reference: PSS.0245	GC15
PAN ÁLVAREZ-OSSORIO, MANUEL; Jornada Actualización en el manejo del Síndrome Coronario Agudo.; Funding Agency: ASTRAZENECA FARMACEUTICA ESPAÑA S.A.; Reference: CCB.0188	GC15
MOLINA HURTADO, JOSÉ RAMÓN; Publicación científica sobre GALACTOMANNAN ANTIGEN IN CHILDREN UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION AND PRIMARY ANTIFUNGAL PROPHYLAXIS WITH VORICONAZOLE.; Funding Agency: PFIZER, S.L.U.; Reference: PSS.0043	GC16
ALVAREZ RIVAS, MIGUEL ANGEL; CONTRATO COLABORACIÓN PARA LA EXCELENCIA EN EL MANEJO DEL PACIENTE CON MIELOMA MULTIPLE; Funding Agency: CELGENE S.L.U.; Reference: PSS.0104	GC16
ALVAREZ RIVAS, MIGUEL ANGEL; ACUERDO PARA APOYAR UN ENSAYO INICIADO POR UN INVESTIGADOR POMALIDOMIDA; Funding Agency: CELGENE INTERNATIONAL SARL; Reference: PSS.0120	GC16
SÁNCHEZ GARCÍA, JOAQUIN; PSS.0152 Gene expression analysis and MYD88 L265 mutation in paraffin embedded samples of diffuse large B cell lymphomas; Funding Agency: CELGENE S.L.U.; Reference: PSS.0152	GC16
SÁNCHEZ GARCÍA, JOAQUIN; Desarollo de la plataforma de diagnóstico centralizado a nivel nacional para realizar el diagnóstico molecular rápido y estandarizado por secuenciación masiva (NGS) - Fundación PETHEMA; Funding Agency: FUNDACION PETHEMA; Reference: PSS.0200	GC16
SÁNCHEZ GARCÍA, JOAQUIN; Cuenta de gestión GC-16; Funding Agency: CELGENE INTERNATIONAL SARL; Reference: pss.0237	GC16
SERRANO LÓPEZ, JOSEFINA; ACUERDO DE COLABORACIÓN PFIZER HERRAMIENTA INFORMATICA PARA LA ELABORACIÓN Y MANTENIMIENTO DE LA HERRAMIENTA PARA EL PROCESAMIENTO Y ANALISIS DE DATOS DEL ESTUIO VORICONAZOLE ANTIFUNGAL PROPHYLASIS IN PATIENTS WITH NEUTROPENIA; Funding Agency: PFIZER, S.L.U.; Reference: CCB.0068	GC16
SÁNCHEZ GARCÍA, JOAQUIN; Convenio Incyte Biosciences Iberia SL 2018; Funding Agency: INCYTE BIOSCIENCE IBERIA S.L.; Reference: CCB.0168	GC16
SÁNCHEZ GARCÍA, JOAQUIN; ANALISIS DE EXPRESION GENICA EN PLATAFORMA NANOSTRING Y DE MUTACION MYD88-L265P CON MUESTRAS PARAFINADAS PARA EL TRATAMIENTO PERSONALIZADO DE LOS LINFOMAS B DIFUSO DE CELULAS GRANDES.; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0173	GC16

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
BRICEÑO DELGADO, FRANCISCO JAVIER; Stand en Curso de Cirugía hepática avanzada, Hospital Reina Sofía. 26 de febrero de 2014, 16 de diciembre de 2014.; Funding Agency: COVIDIEN SPAIN S. L.; Reference: PSS.0041	GC18
LUQUE DE CASTRO, MARIA DOLORES; Determination of vitamin D and its 25(OH)D 1,25(OH)2D and 24,25(OH)D metabolites (potentially also the C3 epimer) in serum samples provided by the organisation.; Funding Agency: OSPEDALE SAN RAFFAELE S.R.L; Reference: PSS.0112	GC21
LUQUE DE CASTRO, MARIA DOLORES; Metabolomics profile of sweat samples by GC-QTOF (in the latter case in positive and negative ionization modes). Identificaction by public databases and the private database of the Research Group.; Funding Agency: BEIERSDORF AG; Reference: PSS.0137	GC21
LUQUE DE CASTRO, MARIA DOLORES; Determination of vitamin D and its 25(OH)D 1,25(OH)2D and 24,15(OH)2D metabolites in serum samples provided by the Organisation.; Funding Agency: OSPEDALE SAN RAFFAELE S.R.L; Reference: PSS.0146	GC21
PRIEGO CAPOTE, FELICIANO; NUTRAFAD; Funding Agency: ACER CAMPESTRES SL; Reference: ITC-20161265_01	GC21
PRIEGO CAPOTE, FELICIANO; NUTRAFAD; Funding Agency: ELAYOTECNIA SL; Reference: ITC-20161265_02	GC21
PRIEGO CAPOTE, FELICIANO; NUTRAFAD; Funding Agency: EMILIO VALLEJO, S.A.; Reference: ITC-20161265_03	GC21
ROLDÁN ARJONA, Mª TERESA; Prestación de servicios CANVAX; Funding Agency: CANVAX BIOTECH S.L.; Reference: PSS.0032	GC22
MARTÍNEZ MARTÍNEZ, LUIS; Update of antimicrobial spectrum and potency of dalbavancin and other antibiotics tested in clinical isolates of Gram-positive pathogens from southern and central Europe and Russia.; Funding Agency: IQVIA RDS SWITZERLAND SARL; Reference: CCB.0144	GC24
GRACIA AHUFINGER, IRENE; Convenio colaboración_Estudiio iCREST; Funding Agency: ASTRAZENECA FARMACEUTICA ESPAÑA S.A.; Reference: PSS.0155	GC24
VENTURA SOTO, SEBASTIÁN; Servicios GC25: Extracción de conocimiento y sistemas inteligentes en biomedicina; Funding Agency: UNIVERSIDAD DE CORDOBA; Reference: PSS.0259	GC25
RIVERO ROMAN, ANTONIO; Curso sobre hepatitis C a especialistas de los centros de Drogas y Adicciones; Funding Agency: GILEAD SCIENCES, S.L.; Reference: CCB.0121	GC26
RIVERO JUAREZ, ANTONIO; AYUDA FISEVI ANTONIO RIVERO JUAREZ; Funding Agency: FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA; Reference: PSS.0181	GC26
RIVERO JUAREZ, ANTONIO; Sesiones de investigación - Grupo de investigación en enfermedades infecciosas; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0184	GC26
RIVERO JUAREZ, ANTONIO; Colaboración Antonio Rivero - FISEVI; Funding Agency: FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA; Reference: PSS.0217	GC26
RIVERO JUAREZ, ANTONIO; Colaboración para la grabación de datos cohorte Hepavir-DAA; Funding Agency: SOCIEDAD ANDALUZA ENFERMEDADES INFECCIOSAS; Reference: PSS.0219	GC26
RIVERO JUAREZ, ANTONIO; Contrato Prestación Servicios VIRCELL-FIBICO; Funding Agency: BECTON DICKINSON S.A.U.; Reference: PSS.0253	GC26
RIVERO JUAREZ, ANTONIO; Contrato Prestación Servicios VIRCELL-FIBICO; Funding Agency: VIRCELL, S.L.; Reference: PSS.0253	GC26
RIVERO JUAREZ, ANTONIO; Colaboración Antonio Rivero - F. Cádiz; Funding Agency: FUNDACIÓN PARA LA GESTIÓN DE LA INVESTIGACIÓN BIOMÉDICA DE CÁDIZ; Reference: PSS.0287	GC26
RIVERO ROMAN, ANTONIO; PROGRAMA ACADEMIA VIH Y COINFECCION; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: CCB.0049	GC26
RIVERO ROMAN, ANTONIO; CONVENIO_ROCHE_15000€_031114 ANTONIO RIVERO; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0075	GC26
RIVERO ROMAN, ANTONIO; CONVENIO FIBICO-MERCK SHARP Y DOHME DE ESPAÑA 2016; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: CCB.0115	GC26
RIVERO ROMAN, ANTONIO; ACUERDO DE COOPERACIÓN EN EL PROGRAMA DE BECAS DE INVESTIGACIÓN CIENTÍFICA; Funding Agency: JANSSEN-CILAG, S.A.; Reference: CCB.0123	GC26

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
RIVERO ROMAN, ANTONIO; CONVENIO FIBICO-MERCK SHARP Y DOHME DE ESPAÑA 2017; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: CCB.0148	GC26
RIVERO ROMAN, ANTONIO; Convenio Janssen-Cilag, S.A.; Funding Agency: JANSSEN-CILAG, S.A.; Reference: CCB.0150	GC26
RIVERO JUAREZ, ANTONIO; Convenio Antonio Rivero Gilead 2017; Funding Agency: GILEAD SCIENCES, INC; Reference: CCB.0152	GC26
RIVERO ROMAN, ANTONIO; Convenio para Jornadas de Actualización en VIH 2018; Funding Agency: VIIV HEALTHCARE, S.L.; Reference: CCB.0166	GC26
RIVERO ROMAN, ANTONIO; CONVENIO FIBICO-MERCK SHARP Y DOHME DE ESPAÑA 2018; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: CCB.0179	GC26
RIVERO ROMAN, ANTONIO; Convenio de Colaboración en Investigación Científica y Técnica entre Fundación para la Investigación Biomédica de Córdoba y la Compañía GILEAD SCIENCIES SLU; Funding Agency: GILEAD SCIENCES, S.L.; Reference: CCB.0190	GC26
LUQUE HUERTAS, RAUL MIGUEL; Gestión de servicios de apoyo a la investigación del Grupo de Biología Celular; Funding Agency: UNIVERSIDAD DE CORDOBA; Reference: pss.0178	GC27
GOMEZ GOMEZ, ENRIQUE; Advisoty Board Select Mdx_ Enrique Gómez Urología; Funding Agency: FERRER FARMA S.A.; Reference: PSS.0261	GC27
GOMEZ GOMEZ, ENRIQUE; Colaboración Proyectos Casos Clínicos. Enfermedades del Aparato Genitourinario - Oncobesidad y metabolismo/IMIBIC/Hospital Reina Sofía/Universidad de Cordoba/IMIBIC; Funding Agency: JF MAGUIRE, S.L.; Reference: PSS.0315	GC27
TÚNEZ FIÑANA, ISAAC; Proyecto Prueba en modelos animales de inflamación de moléc; Funding Agency: MBT SL; Reference: PSS.0115	GE01
TÚNEZ FIÑANA, ISAAC; Prestación de servicios para cofinanciación proyecto Retos; Funding Agency: CANVAX BIOTECH S.L.; Reference: PSS.0135	GE01
AGÜERA MORALES, EDUARDO; ABORDAJE MULTIDISCIPLINAR PARA PACIENTES CON ESCLEROSIS MÚLTIPLE; Funding Agency: BIOGEN SPAIN S.L.U; Reference: PSS.0195	GE01
AGÜERA MORALES, EDUARDO; Subcontract to H2020 Grant Agreement Num. 690090; Funding Agency: ARTICA TELEMEDICINA SL; Reference: PSS.0229	GE01
AGÜERA MORALES, EDUARDO; Contrato de Prestación de Servicios entre FIBICO y ROCHE FARMA S.A. para el esttudio Percepción del riesgo y toma de decisiones compartidas en pacientes con esclerosis múltiple (perceptions-ms) y código de protocolo ML40361.; Funding Agency: ROCHE FARMA, S.A.; Reference: PSS.0269	GE01
AGÜERA MORALES, EDUARDO; dreaMS - A telehealth tool for monitoring and treatment of Multiple Sclerosis patients; Funding Agency: HEALIOS LLC; Reference: PSS.0319	GE01
RODRÍGUEZ CANTALEJO, FERNANDO; Evaluación Técnica del Sistema Atellica Solution Sci; Funding Agency: SIEMENS HEALTHCARE S.L.U.; Reference: CCB.0201	GE01
AGÜERA MORALES, EDUARDO; Eficacia del trasplante autólogo de células mononucleadas de médula ósea en el ictus isquémico. Ensayo Clínico Fase II, Multicéntrico, Controlado y Aleatorizado.; Funding Agency: FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA; Reference: CCB.0136	GE01
TÚNEZ FIÑANA, ISAAC; Desarrollo de modelos animales para terapias con CAR-T para enfermedades infecciosas y autoinmunes.; Funding Agency: CANVAX BIOTECH S.L.; Reference: CCB.0143	GE01
AGÜERA MORALES, EDUARDO; Convenio: Test Breve para la prevención de la demencia.; Funding Agency: FUNDACION CAJASUR; Reference: CCB.0153	GE01
AGÜERA MORALES, EDUARDO; Convenio colaboración Neurología - Abordaje multidisciplinar en pacientes con EM; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0156	GE01
AGÜERA MORALES, EDUARDO; Convenio colaboración Neurología; Funding Agency: MERCK, S.L.U.; Reference: CCB.0157	GE01
AGÜERA MORALES, EDUARDO; "Eficacia del trasplante autólogo de células mononucleadas de médula ósea en el ictus isquémico. Ensayo Clínico Fase II, Multicéntrico, Controlado y Aleatorizado"; Funding Agency: FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACIÓN EN SALUD DE SEVILLA; Reference: CCB.0243	GE01
GIRALDO POLO, ANA ISABEL; Convenio para el desarrollo del curso: Estimulación Magnética transcraneal y neuromodulación; presente y futuro en neurociencias.; Funding Agency: NEUROELECTRICS; Reference: CCB.0247	GE01

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
RUANO RUIZ, JUAN; Patrocinio del II Curso Práctico Sobre Revisiones Sistemáticas y Meta-Análisis, que se celebrará en Córdoba, desde el 4 de abril al 16 de mayo de 2018.; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: PSS.0222	GE03
RUANO RUIZ, JUAN; PROYECTO UGC DERMATOLOGÍA/IMIBIC Y JANSSEN ESPAÑA; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0227	GE03
RUANO RUIZ, JUAN; Servicios de Evaluación de Tecnologías Sanitarias.; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: PSS.0267	GE03
RUANO RUIZ, JUAN; Ajuste de fondos del curso de revisiones sistemáticas - Traspasos de Farmacia a Dermatología; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: PSS.0281	GE03
RUANO RUIZ, JUAN; CURSO PRACTICO REVISIONES SISTEMATICAS Y META-ANALISIS; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0138	GE03
RUANO RUIZ, JUAN; II Curso práctico sobre revisiones sistemáticas y meta-análisis.; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: CCB.0178	GE03
RUANO RUIZ, JUAN; DERIVA-Derm: desarrollo e implementación de una app para la gestión coordinada internivel de pacientes con patología dermatológica.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: CCB.0227	GE03
RUANO RUIZ, JUAN; III Curso Semipresencial de Revisiones Sistemáticas y Meta-análisis.; Funding Agency: NOVO NORDISK PHARMA, S.A.; Reference: CCB.0230	GE03
REQUENA TAPIA, MARÍA JOSÉ; I JORNADA PROVINCIAL EN EL DIAGN Y TRATAM DEL CANCER DE PROSTATA CORDOBA 10 ABRIL 2015; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0078	GE05
REQUENA TAPIA, MARÍA JOSÉ; PRIMERA JORNADA PROVINCIAL EN EL DIAG Y TTO DEL CA; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0079	GE05
REQUENA TAPIA, MARÍA JOSÉ; ACUERDO DE PRESTACIÓN DE SERVICIO ENTRE FIBICO Y MECWINS; Funding Agency: MECWINS S.A.; Reference: PSS.0114	GE05
REQUENA TAPIA, MARÍA JOSÉ; Sponsorship Jansse Curso Estadística Urología I; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0124	GE05
REQUENA TAPIA, MARÍA JOSÉ; Sposorship Janssen Curso Estadística Urología II; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0125	GE05
REQUENA TAPIA, MARÍA JOSÉ; CONTRATO FIBICO-FIU 4-KALLICREINAS; Funding Agency: FUNDACION PARA LA INVESTIGACION EN UROLOGIA; Reference: PSS.0126	GE05
REQUENA TAPIA, MARÍA JOSÉ; Patrocinio de la sesion clinica de la UGC de urología celebrada el 11 de noviembre de 2016 en la sinstalaciones de IMIBIC; Funding Agency: BAYER HISPANIA S.L.; Reference: PSS.0157	GE05
REQUENA TAPIA, MARÍA JOSÉ; Astellas Urología: Manejo integral del paciente con vejiga hiperactiva; Funding Agency: ASTELLAS PHARMA, S.A.; Reference: PSS.0166	GE05
REQUENA TAPIA, MARÍA JOSÉ; ACUERDO PRESTACIÓN SERVICIOS URO-MECWINS; Funding Agency: MECWINS S.A.; Reference: PSS.0214	GE05
CARRASCO VALIENTE, JULIA; Recogida y grabación de información clínica en el proyecto Patrones asistenciales de Cáncer de Próstata en Andalucía y Evaluación de Resultados en Salud en Cáncer de Próstata. Código interno 17-31246; Funding Agency: ESCUELA ANDALUZA DE SALUD PUBLICA; Reference: PSS.0248	GE05
REQUENA TAPIA, MARÍA JOSÉ; Patrocinio Janssen Curso Urologia-Radiología; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0278	GE05
REQUENA TAPIA, MARÍA JOSÉ; Colaboración GSK - Drs. Requena y Pérula - INTRODUCCIÓN A LA INFERENCIA BAYESIANA.; Funding Agency: GLAXOSMITHKLINE, S.A.; Reference: CCB.0040	GE05
REQUENA TAPIA, MARÍA JOSÉ; Convenio Urología-Life Length para la realización del estudio clínico LL-HURS-INC001; Funding Agency: LIFE LENGTH S.L.; Reference: CCB.0133	GE05
REQUENA TAPIA, MARÍA JOSÉ; Medición de las variables asociadas a los telómeros (TAVS) para su uso diagnóstico para el cáncer de próstata. PROSTAV001; Funding Agency: LIFE LENGTH S.L.; Reference: CCB.0252	GE05
GONZALEZ ANDRADES, MIGUEL; Presupuesto de gestión de datos para el ensayo clínico CMMo/MD/2013 de la Iniciativa Andaluza en Terapias Avanzadas durante el ejercicio 2019: 6.699,92 €; Funding Agency: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD; Reference: PSS.0280	GE07

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
MORENO CASADO, PAULA; APOYO A LA FORMACION CIRUGIA TORACICA; Funding Agency: MEDTRONIC IBERICA, S.A; Reference: CCB.0238	GA01
ENTRENAS COSTA, LUIS MANUEL; CONVENIO NOVARTIS - L.M. ENTRENAS NEUMOLOGÍA Diagnóstico de novo de pacientes asmáticos o no seguidos en el servicio de alergia que acuden al servicio de Urgencias con clínica de broncoespasmo.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: CCB.0060	GA03
JURADO GÁMEZ, BERNABÉ; Relación de la prueba de marcha de 6 minutos y desaturación durante la actividad física habitual en pacientes con enfermedad pulmonar obstructiva crónica.; Funding Agency: LABORATORIOS DEL DR. ESTEVE S.A.; Reference: CCB.0145	GA03
SANTOS LUNA, FRANCISCO; CURSO DE FORMACION CONTINUADA EN PATOLOGIA INTERSTICIAL: FIBROSIS PULMONAR IDIOPATICA.; Funding Agency: BOEHRINGER INGELHEIM ESPAÑA, S.A.; Reference: CCB.0162	GA03
VAQUERO BARRIOS, JOSE MANUEL; Efectividad y adherencia al tratamiento nebulizado en bronquiectasis no fibrosis quítica colonizadas por Pseudomonas aeruginosa.; Funding Agency: ZAMBON, S.A.U.; Reference: CCB.0229	GA03
GÁLVEZ MORENO, Mª ÁNGELES; Prestación de Servicios Endocrinología; Funding Agency: JYC EDICIONES MEDICAS; Reference: PSS.0163	GA04
CALAÑAS CONTINENTE, ALFONSO; Estudio de intervención sobre el estilo de vida en mujeres obesas con infertilidad que precisan técnicas de reproducción asistida.; Funding Agency: NUTRICIA SRL; Reference: CCB.0116	GA04
ALVAREZ BENITO, MARINA; Colaboracion Praxair 40 aniversario HURS; Funding Agency: NIPPON GASES ESPAÑA, S.L.U.; Reference: pss.0143	GA08
LOPEZ RUIZ, DANIEL JOSE; Charla de Fernando Delgado: VALORACION DEL USO COMBINADO DE LA TROMBECTOMIA MECANICA E HIPOTERMIA (COMO METODO NEUROPROTECTOR) EN ICTUS CAROTIDEOS GRAVES (ASPECTS ≤ 4); Funding Agency: BOSTON SCIENTIFIC IBERICA SA; Reference: pss.0210	GA08
ROLDÁN ROMERO, ELISA; Actividades relacionadas con la formación MIR.; Funding Agency: MUTUAL MÉDICA DE CATALUÑA Y BALEARES; Reference: CCB.0175	GA08
MUÑOZ CARVAJAL, IGNACIO; estudio ASIS-TC Cirugía Cardiovascular; Funding Agency: FUNDACIÓN PROFESOR NOVOA SANTOS; Reference: PSS.0165	GA09
VALLEJO CASAS, JUAN ANTONIO; Educational Grant General Electric; Funding Agency: GE HEALTHCARE EUROPE GMBH; Reference: CCB.0192	GA10
VALLEJO CASAS, JUAN; PRUEBAS DE MEDICINA NUCLEAR PROTOCOLO B9991016; Funding Agency: SYNEOS HEALTH IVH UK LIMITED; Reference: pss.0230	GA10
HERRADOR MONTIEL, INMACULADA; CONTRATO GRUNENTAL UNIDAD DEL DOLOR; Funding Agency: GRÜNENTHAL PHARMA, S.A.; Reference: PSS.0159	ANESTHESIOLOGY AND RESUSCITATION
JIMENEZ ARRANZ, ALVARO; ESTUDIO PERSEIDA; Funding Agency: AMGEN SA; Reference: PSS.0242	CORE FACILITIES - PROTEOMICS
JIMENEZ PUYA, RAFAEL; prestacion de servicio PFIZER 2500€ 151014 FLEX; Funding Agency: PFIZER, S.L.U.; Reference: PSS.0060	DERMATOLOGY AND VENEREOLOGY
DÍAZ LÓPEZ, CESAR ANTONIO; seminario y gestión de stand en curso de cirugía color rectal avanzada; Funding Agency: COVIDIEN SPAIN S. L.; Reference: PSS.0122	GENERAL AND DIGESTIVE SURGERY
NARANJO TORRES, ALVARO; Apoyo a la formación a la Unidad de Cirugia Abdominal; Funding Agency: PROTESIS HOSPITALARIAS S.A.; Reference: CCB.0235	GENERAL AND DIGESTIVE SURGERY
GÓMEZ GARCÍA, PEDRO; PONENCIA DRO GULLERMO RODRIGUEZ GARCIA: ACTUALIZACION SOBRE POST-ASH Y LUGANO 2013; Funding Agency: ROCHE FARMA, S.A.; Reference: PSS.0027	HEMATOLOGY AND HEMOTHERAPY
DEL PRADO LLERGO, JOSE RAMÓN; I Jornadas de Investigación en Psoriasis; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0073	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio curso; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0087	HOSPITAL PHARMACY

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
DEL PRADO LLERGO, JOSE RAMÓN; IV Curso practico: El técnico de farmacia en la elaboración de medicamentos estériles y Nutrición Parenteral.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0149	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Curso práctico sobre revisiones sistemáticas y meta-análisis.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0170	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; El técnico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: TEVA PHARMA, SLU; Reference: PSS.0182	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; V curso práctico para técnicos en farmacia: el técnico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0186	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; V curso práctico para técnicos en farmacia: el técnico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0187	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Curso de técnico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: PSS.0188	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; V Curso: El técinico de farmacia en la manipulación de madicamentos biopeligrosos (2 ediciones).; Funding Agency: GILEAD SCIENCES, S.L.; Reference: PSS.0189	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio curso: Actualización del uso de Medicamentos Huérfanos en las Enfermedades Raras mediadas por la actividad del Complemento y Patrocinio web del IMIBIC.; Funding Agency: ALEXION PHARMA SPAIN SL; Reference: PSS.0198	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio Web; Funding Agency: MERCK, S.L.U.; Reference: PSS.0205	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Curso práctico para técnicos en farmacia 2018; Funding Agency: BAXTER, SL; Reference: PSS.0206	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; PATROCINIO-CICLO DE SESIONES DE ACTUALIZACIÓN EN ONCOHEMATOLOGÍA.; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0224	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; "II Curso práctico sobre revisiones sistemáticas y meta-análisis" que se celebrará en Córdoba los días 04, 11, 18 y 25 de abril, 02, 09, 16, de mayo 2018.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0225	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; VI Curso práctico para técnicos en farmacia: El técinico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: PSS.0241	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; VI Curso práctico para técnicos en farmacia: El técnico de farmacia en la manipulación de medicamentos biopeligrosos. 1ª edición 4,5 junio y 2ª edición 11,12 junio 2018.; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0246	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio del VI curso practico para tecnicos en farmacia: El tecnico de farmacia en la manipulacion de medicamentos biopeligrosos.; Funding Agency: GILEAD SCIENCES, S.L.; Reference: PSS.0250	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Realización formación en trazabilidad; Funding Agency: NOVARTIS FARMACEUTICA, S.A.; Reference: PSS.0258	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio página web; Funding Agency: MERCK, S.L.U.; Reference: PSS.0265	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio III Curso revisiones sitemáticas y meta-análisis; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: PSS.0274	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio III curso práctico sobre revisiones sitemáticas y meta-análisis; Funding Agency: BRISTOL-MYERS SQUIBB, S.A.U.; Reference: PSS.0277	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMÓN; Patrocinio VII Curso práctico para técnicos en farmacia: El técnico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: GILEAD SCIENCES, S.L.; Reference: PSS.0290	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Curso el tecnico de farmacia en los servicios de farmacia hospitalaria; Funding Agency: SANOFI-AVENTIS, S.A.; Reference: CCB.0088	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Patrocinio Formación de Técnicos de Farmacia en Campanas de Flujo Laminar.; Funding Agency: TEVA PHARMA, SLU; Reference: CCB.0106	HOSPITAL PHARMACY

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
DEL PRADO LLERGO, JOSE RAMON; V Curso practico para técnicos de farmacia: EL TECNICO DE FARMACIA EN LA MANIPULACION DE MEDICAMENTOS BIOPELIGROSOS; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0139	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Patrocinio Web; Funding Agency: VIFOR PHARMA ESPAÑA, S.L.; Reference: CCB.0155	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; V curso práctico para técnicos en farmacia; Funding Agency: BOEHRINGER INGELHEIM ESPAÑA, S.A.; Reference: CCB.0163	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Patrocinio del "V Curso práctico para técnicos de farmacia: El técnico de farmacia en la manipulación de medicamentos biopeligrosos" que se celebrará en Córdoba el 6 y 7 de Noviembre y el 13 y 14 de Noviembre 2017 organizado por FIBICO mediante inserción ; Funding Agency: CELGENE S.L.U.; Reference: CCB.0165	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Convenio de colaboración proyecto: TTPharmacy: Track and Trace Pharmacy.; Funding Agency: PFIZER, S.L.U.; Reference: CCB.0167	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Track and trace pharmacy.; Funding Agency: AMGEN SA; Reference: CCB.0180	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; VI Curso practico para técnicos en farmacia: El técnico de farmacia en la manipulación de medicamentos biopeligrosos. 1ª edición: 4 y 5 de Junio 2018. 2ª edición: 11 y 12 de Junio 2018.; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: CCB.0181	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; CONVENIO DE COLABORACIÓN PARA LA FINANCIACIÓN DEL PLAN DE PUBLICACIONES DEL SERVICIO DE FARMACIA DEL HOSPITAL REINA SOFÍA; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0182	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; VI Curso Tecnicos en farmacia hospitalaria; Funding Agency: BOEHRINGER INGELHEIM ESPAÑA, S.A.; Reference: CCB.0187	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Colocación de una enara en la zona de acceso al curso denominado VI Curso práctico para técnicos en farmacia: El técnico de farmacia en la manipulación de medicamentos biopeligrosos.; Funding Agency: SHIRE PHARMACEUTICALS IBERICA, S.L.; Reference: CCB.0189	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Convenio Patrocinio página web desde 22 de septiembre (12 meses).; Funding Agency: VIFOR PHARMA ESPAÑA, S.L.; Reference: CCB.0194	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Convenio Colaboración TTpharmacy; Funding Agency: SANDOZ FARMACÉUTICA S.A.; Reference: CCB.0198	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Patrocinio Sistematic Reviews and Meta-Analyses Course 2019 IMBIC; Funding Agency: BOEHRINGER INGELHEIM ESPAÑA, S.A.; Reference: CCB.0228	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Esponsorización de la sesión presencial CAlidad metodológoca de las revisiones sistemáticas. AMSTAR y ROBIS.; Funding Agency: MERCK SHARP & DOHME DE ESPAÑA SA; Reference: CCB.0232	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; "VII CURSO PRÁCTICO PARA TÉCNICOS EN FARMACIA: EL TÉCNICO DE FARMACIA EN LA MANIPULACIÓN DE MEDICAMENTOS BIOPELIGROSOS"; Funding Agency: ROCHE FARMA, S.A.; Reference: CCB.0244	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Convenio Colaboración Farmacia; Funding Agency: SANDOZ FARMACÉUTICA S.A.; Reference: CCB.0246	HOSPITAL PHARMACY
DEL PRADO LLERGO, JOSE RAMON; Convenio de Colaboración entre FIBICO y VIFOR PHARMA ESPAÑA, S.L. Patrocinio Web.; Funding Agency: VIFOR PHARMA ESPAÑA, S.L.; Reference: CCB.0304	HOSPITAL PHARMACY
LEÓN LÓPEZ, RAFAEL; PROSPECTIVE OBSERVATIONAL STUDY OF THE RISK FACTORS FOR HOSPITAL ACQUIRED AND VENTILATOR ASSOCIATED BACTERIAL PNEUMONIA; Funding Agency: UNIVERSITY MEDICAL CENTER UTRECHT; Reference: pss.0176	INTENSIVE CARE MEDICINE
LEÓN LÓPEZ, RAFAEL; Agreement for provision of resources, UMC Utrecht and FIBICO REMAP-CAP; Funding Agency: UNIVERSITY MEDICAL CENTER UTRECHT; Reference: PSS.0243	INTENSIVE CARE MEDICINE
DE LA FUENTE MARTOS, MARIA DEL CARMEN; Enseñanza homologada SEMICYUC - Alquiler Maniqui UCI; Funding Agency: CCUAF SL; Reference: PSS.0256	INTENSIVE CARE MEDICINE
ARIAS RUIZ, MARIA JOSE; Convenio Hospira Aplicacion QuimioAyuda; Funding Agency: ICU MEDICAL PRODUCTOS FARMACÉUTICOS Y HOSPITALARIOS, S.L.; Reference: CCB.0164	MEDICAL ONCOLOGY

AGREEMENTS WITH COMPANIES	IMIBIC GROUP
GUISADO LÓPEZ, RAMÓN; Patrocinio del curso de Fomarción en Cirugía Laparoscópica para médicos Ginecólogos; Funding Agency: TAKEDA FARMACEUTICA ESPAÑA S.A.; Reference: PSS.0049	OBSTETRICS AND GYNECOLOGY
GUISADO LÓPEZ, RAMÓN; Patrocinio del curso de Fomarción en Cirugía Laparoscópica para médicos Ginecólogos, la semana del 25 de noviembre del 2015; Funding Agency: TAKEDA FARMACEUTICA ESPAÑA S.A.; Reference: PSS.0097	OBSTETRICS AND GYNECOLOGY
LORENTE GONZÁLEZ, JUAN; Convenio _12000€ _161014; Funding Agency: MERCK, S.L.U.; Reference: CCB.0081	OBSTETRICS AND GYNECOLOGY
GALLARDO GALERA, JOSÉ MARÍA; II Curso teórico-práctico del tratamiento del queratocono.; Funding Agency: BAUSCH & LOMB S.A; Reference: QUERATOCO2017	OPHTHAL-MOLOGY
IBARRA LARROSA, ENCARNACIÓN; III Curso teórico-práctico del tratamiento del queratocono.; Funding Agency: BAUSCH & LOMB S.A; Reference: QUERATOCO2018	OPHTHAL-MOLOGY
MAYORDOMO RIERA, FERNANDO JESUS; EVOLUCIÓN DE DOLOR, FUNCIONALIDAD Y EXPLORACIÓN FÍSICA DE PACIENTES CON SÍNDROME DE SENSIBILIZACIÓN CENTRAL EN ARTROSIS TRAS ARTROPLASTIA DE RODILLA.; Funding Agency: LABORATORIOS DEL DR. ESTEVE S.A.; Reference: CCB.0176	PHYSICAL MEDICINE AND REHABIL-ITATION
PALACIOS EITO, AMALIA; IDENT MARCADORES EN DISF TEJ ADIPOSO Y RESIST INSULINA; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0133	RADIATION ONCOLOGY
PALACIOS EITO, AMALIA; El anciano con Diabetes.16/06/2016 Córdoba.; Funding Agency: JANSSEN-CILAG, S.A.; Reference: PSS.0134	RADIATION ONCOLOGY
RAYA POVEDANO, JOSE LUIS; Preoperative Breast MRI in Clinical Practice: Multiple International Prospective Meta-Analysis of Individual Woman Data (the MIPA study); Funding Agency: EIBIR GEMEINNUTZIGE GMBH; Reference: PSS.0030	RADIODIAG-NOSIS

SEMINARS

JANUARY	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Fecha: 15 de enero de 2019 - 13:00h Ponente: Mª Soledad Avendaño Herrador Grupo: GC10 Regulación hormonal del balance energético, la pubertad y la reproducción. Título: "Mecanismos y consecuencias del hipogonadismo inducido por obesidad: novedoso papel de miR-103, miR-107 y miR-137 sobre kisspeptina a nivel hipotalámico"	Date: 17 de enero de 2018 Speaker: Lisardo Boscá Organisation: Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM Title: Avances en el estudio del metabolismo para mejorar la imagen biomédica. Aplicaciones a la patología aterogénica.
	Fecha: 29 de enero de 2019 - 13:00h Ponente: Jon Peñarando Sáez Grupo: GC06 Nuevas terapias en cáncer Título: "Role of endothelial nitric oxide synthase in the biology of intestinal cancer stem cells: New options in the treatment of colorectal cancer"	

FEBRUARY	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Fecha: 12 de febrero de 2019 - 13:00h Ponente: Francisco José Romero Ramírez Grupo: GC19 Aplicaciones de la visión artificial. Título: "Speeded Up Camera Pose Estimation From Squared Fiducial Markers".	Date: Juevess,17 de febrero de 2018 Speaker: Guadalupe Sabio. Organisation: Investigadora CNIC Title: Stress kinases in the modulation of metabolism and energy balance and energy balance.
		Date: Jueves, 21 de febrero de 2018 Speaker: José Javier García-Campayo Organisation: Hospital Universitario Miguel Servet perteneciente al SALUD, Servicio Aragonés de Salud. Title: Evidencias actuales sobre la eficacia del mindfulness en la salud

MARCH	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Fecha: 19 de marzo de 2019 - 13:00h Ponente: Juan Antonio Vallejo Casas Grupo: GA10 Medicina Nuclear Título: "Teragnosis"	Fecha: Miércoles, 6 de marzo de 2019 - 13:00 h. Ponente: Dawid Pieper Institución: Witten/Herdecke University. Cologne, Germany. Título: Multiple and overlapping systematic reviews – how can we make use of them?
		Fecha: Jueves, 21 de marzo de 2019 – 13:00 h. Ponente: Lina García Cañamaque Institución: Jefe de Servicio Medicina Nuclear. Hospitales de Madrid. Hospital Madrid Sanchinarro Título: Aplicaciones del PET/RM en la actualidad
		Fecha: Jueves, 28 de marzo de 2019 – 13:00 h. Ponente: Isabel Fariñas Institución: Universidad de Valencia Título: Control remoto de las células madre adultas: El nicho extendido

APRIL	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Fecha: 23 de abril de 2019 - 13:00h Ponente: Julia Sánchez Ceinos Grupo: GC11 Metabolismo y diferenciación adipocitaria. Síndrome metabólico. Título: "New contributions of preadipocytes in the development of obesity-related metabolic disease".	Fecha: Jueves, 04 de abril de 2019 – 13:00 h. Ponente: Sonia Fernández Veledo Institución: Pere Virgili Institute - Rovira i Virgili University University Hospital Joan XXIII Research Unit Título: Inmunometabolismo
		Fecha: Jueves, 11 de abril de 2019 – 13:00 h Ponente: Dr Babita Singh Institución: Computational RNA Biology Group. Research Programme on Biomedical Informatics (GRIB). Universitat Pompeu Fabra (UPF) - La Fundació Institut Mar d'Investigacions Mèdiques (IMIM) Título: MIRA (Mutation identification for RNA alternations)

MAY	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Fecha: 7 de mayo de 2019 – 13:00h Ponente: Guillermo Lasarte Aragonés Grupo: Departamento de Química Analítica de la UCO. Grupo de investigación FQM-215 del Instituto Universitario de Nanoquímica (IUNAN) Título: "Aplicaciones de los nanomateriales. Del Diagnostico al Tratamiento".	Fecha: Jueves, 02 de mayo de 2019 – 13:00 h Ponente: Jose Alberto Diaz-Ruiz Ruiz Institución: Instituto IMDEA Alimentación Título: Estrategias antienvejecimiento: from bench-to-bedside
	Fecha: 14 de mayo de 2019 - 13:00h Ponente: Nathalie Jouy Grupo: GC10 Regulación hormonal del balance energético, la pubertad y la reproducción y perteneciente al INSERM, Universidad de Lille. Título: "How to sort rare events? What about neurons?"	
	Fecha: 28 de mayo de 2019 - 13:00h Ponente: Pablo Jesús López Soto. Grupo: GA02 Cuidados enfermeros integrales. Perspectiva multidisciplinar. Título: "Chronotype, nursing activity and gender: implications in sleep and mood".	

MAY	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
		Fecha: Jueves, 23 de mayo de 2019 – 13:00 h Ponente: Isabel Gonzalez Mariscal Institución: Hospital Regional de Málaga. Título: Receptores de Cannabinoides como posibles dianas para el tratamiento de la diabetes

JUNE	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
	Fecha: 18 de junio de 2019 - 13:00h Ponente: María Asunción López Bascón. Grupo: GC21 Metabolómica. Identificación de componentes bioactivos. Título: “Metabolomics analysis predicts the occurrence of diabetes mellitus. FLEXI-MET Study.”.	Fecha: Martes, 4 de junio de 2019 – 13:00 h Ponente: Darío Acuña Castroviejo Institución: Instituto Internacional de la Melatonina, Universidad de Granada. Título: De la cronodisrupción a la disfunción mitocondrial
	-	Fecha: Jueves, 6 de junio de 2019 – 13:00 h Ponente: Laureano de la Vega Institución: Universidad de Dundee en Escocia Título: “Herramientas CRISPR, vías de respuesta a stress y cáncer”
		Fecha: Jueves, 13 de junio de 2019 – 13:00 h Ponente: Dr. Ignacio Bernabeu Morón Institución: Especialista en Endocrinología y Nutrición del Servicio Gallego de Salud / Profesor Asociado Medicina Universidad Santiago Compostela Título: Factores predictivos de la respuesta al tratamiento de la acromegalia Investigador Responsable: Raúl M. Luque Huertas
		Fecha: Jueves, 20 de junio de 2019 – 13:00 h Ponente: Anabel Rojas. Institución: Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) Título: Liver fibrosis regression mediated by the modulation of hepatic stellate cells phenotype
		Fecha: Jueves, 27 de junio de 2019 – 13:00 h Ponente: Natalia Vilor-Tejedor. Institución: CRG-Center for Genomic Regulation, BarcelonaBeta Brain Research Center (BBRC) Título: “Statistical tools for omics data analysis”

OCTOBER

WEEK	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
22		Fecha: jueves, 17 de octubre de 2019 – 18:00 h. Ponentes: José Peña. Real Academia de Medicina de Sevilla. Rafael Solana. IMIBIC. Raquel Tarazona. Universidad de Extremadura. Francisco Borrego. Biocruces. Florian Kern. Brighton and Sussex Medical School, Reino Unido. Institución: Detalladas anteriormente. Título: “Inmunosenescencia: Estado actual y perspectivas”.

NOVEMBER

WEEK	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
44		Fecha: jueves, 21 de noviembre de 2019 – 13:00 h. Ponente: Carmen Álvarez Nieto. Institución: Universidad de Jaén. Título: “La sostenibilidad ambiental en Ciencias de la Salud” / “Environmental sustainability in health sciences and biomedicine”.

DECEMBER	INTRAMURAL SEMINARS	EXTERNAL SEMINARS
		Fecha: miércoles, 4 de diciembre de 2019 – 17:30 h. Ponente: Patrizia Steca. Institución: Universidad de Milán. Título: “Promoting health through a personalized approach and the use of new technologies”.

THESIS

name	title	supervised by	
*** Manfredini, Roberto**	**ASPECTOS EPIDEMIOLOGICOS, CRONOBIOLOGICOS Y ORIENTADOS EN EL GENERO DE ENFERMEDADES MÉDICAS**	**Pablo Jesús López Soto**	**Juan Manuel Carmona Torres**
*** Heras Domínguez, Violeta**	**NOVEL REGULATORY PATHWAYS IN THE CENTRAL CONTROL OF PUBERTY: ANALYSIS OF THE ROLE OF CERAMIDE SIGNALING AND MKRN3/MIR-30B SYSTEM**	**Manuel Tena Sempere**	**Juan Manuel Castellano Rodríguez**
*** Aura Dulcínea Herrera Martínez**	**NUEVOS MARCADORES DIAGNÓSTICOS Y OPCIONES TERAPÉUTICASEN TUMORES NEUROENDOCRINOS***	**Justo P. Castaño**	**María A. Gálvez Moreno**
*** Juan Miguel Díaz Tocados**	**ESTUDIO DE LAS ALTERACIONES DEL METABOLISMO MINERAL Y DE LOS TRASTORNOS ÓSEOS ASOCIADOS A LA ENFERMEDAD RENAL CRÓNICA.**	**Juan R. Muñoz Castañeda**	**Yolanda Almadén Peña**
Jiménez Lucena, Rosa	IDENTIFICATION OF NEW BIOMARKERS TO PREDICT THE RISK OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH CARDIOVASCULAR DISEASE: CORDIOPREV-DIAB STUDY	José López Miranda	Oriol Alberto Rangel Zúñiga
Amat Serna, Tania	FACTORES PREDICTORES DE MORTALIDAD DE LA BACTERIEMIA POR ACINETOBACTER BAUMANNII SENSIBLE A COLISTINA EN PACIENTES CRÍTICOS	Julián de la Torre Cisneros,	
*** López Sejas, Nelson**	**SUBPOBLACIONES DE CÉLULAS NK: CAMBIOSCON LA INMUNOSENESCENCIA**	**Rafael Solana Lara**	
*** Portero de la Cruz, Silvia**	**ESTRÉS LABORAL, BURNOUT, SATISFACCIÓN, AFRONTAMIENTO Y SALUD GENERAL EN PERSONAL SANITARIO DE URGENCIAS**	**Manuel Vaquero Abellán**	**Javier Herruzo Cabrera**
Morales Cané, Ignacio	ASPECTOS PREVALENTES EN LA ATENCIÓN AL PACIENTE TRAUMA GRAVE EN CUIDADOS CRÍTICOS: LARGA ESTANCIA, INFECCIÓN, ADMINISTRACIÓN DE ÁCIDO TRANEXÁMICO	María Aurora Rodríguez Borrego	Pablo Jesús López Soto
Manfredini, Fabio	TERAPIA DE EJERCICIOS PARA ENFERMEDADES CRÓNICAS: DISCAPACIDAD Y RESULTADOS CLÍNICOS A LARGO PLAZO EN UNA COHORTE DE PACIENTES CON ENFERMEDAD ARTERIAL PERIFÉRICA INSCRITOS EN UN PROGRAMA DE REHABILITACIÓN ORIGINAL	Pablo Jesús López Soto	Maria Aurora Rodriguez Borrego
*** Vázquez Borrego, Mª Carmen**	**IDENTIFICACIÓN DE NUEVOS MARCADORES MOLECULARES Y/O CELULARES IMPLICADOS EN LA RESPUESTA FARMACOLÓGICA Y CONTRIBUCIÓN DE MECANISMOS DE SPLICING EN LOS TUMORES HIPOFISARIOS**	**Raúl Luque Huertas**	**Justo Pastor Castaño Fuentes**
Fabbian, Fabio	GESTION HOSPITALARIA Y COMPLICACIONES EN EL PACIENTE COMÓRBIDO	Pablo Jesús López Soto	Maria Aurora Rodriguez Borrego
*** Rodríguez Muñoz, Pedro Manuel**	**CONSUMO DE ALCOHOL Y TABACO Y SU RELACIÓN CON HÁBITOS ALIMENTICIOS, ACTIVIDAD FÍSICA Y COMPORTAMIENTO SEXUAL DE ESTUDIANTES DE LAS UNIVERSIDADES DE CÓRDOBA Y CASTILLA LA MANCHA**	**Mª Aurora Rodríguez Borrego**	**Juan Manuel Carmona Torres, Pablo Jesús López Soto**
*** Romero Martín, Sara**	**COMPARACIÓN DE LA TOMOSÍNTESIS MÁS MAMOGRAFÍA SINTETIZADA CON LA MAMOGRAFÍA CONVENCIONAL 2D EN LOS PROGRAMAS DE DETECCIÓN PRECOZ DE CÁNCER DE MAMA**	**Marina Álvarez Benito**	**Antonio Cano Sánchez**

name	title	supervised by	
*** Gómez Gómez, Enrique**	**IDENTIFICACIÓN DE NUEVOS FACTORES CLÍNICOS Y MOLECULARES PARA EL DIAGNÓSTICO Y AGRESIVIDAD DEL CÁNCER DE PRÓSTATA**	**Raúl Luque Huertas**	**Julia Carrasco Valiente**
Torres Peña, José David	INFLUENCIA DE UN MODELO DE ALIMENTACIÓN SALUDABLE SOBRE LA FUNCIÓN ENDOTELIAL EN PACIENTES DE ALTO RIESGO CARDIOVASCULAR	José López Miranda	Antonio García Ríos
*** Del Río Moreno, Mercedes**	**PAPEL DE LA ALTERACIÓN DEL PROCESO DE SPLICING EN LA APARICIÓN DE ENFERMEDADES ENDOCRINO-METABÓLICAS Y PATOLOGÍAS TUMORALES**	**Raúl Luque Huertas**	**Manuel D. Gahete Ortiz**
Rodelo Haad, Cristian Roberto	HIPERPARATIROIDISMO SECUNDARIO Y CAMBIOS DE FGF23 EN PACIENTES EN HEMODIÁLISIS	Mariano Rodríguez Portillo	Alejandro Martín Malo
Velasco Aguayo, Inmaculada	ANÁLISIS DEL PAPEL DEL SISTEMA KISS1/KISSPEPTINAS EN EL CONTROL DE LA FUNCIÓN METABÓLICA: ESTUDIOS FARMACOLÓGICOS Y DE GENÓMICA FUNCIONAL	Manuel Tena Sempere	María Jesús Vázquez Villar
*** Leiva Cepas, Fernando**	**RECONSTRUCCIÓN POR INGENIERÍA TISULAR DE PÉRDIDAS VOLUMÉTRICAS DE MÚSCULO ESQUELÉTICO.**	**José Peña Amaro**	**Rafael Villalba Montoro**
Ruiz Pino, Francisco	CARACTERIZACIÓN DEL PAPEL DEL SISTEMA NKB/NK3R EN EL CONTROL DE LA FUNCIÓN REPRODUCTORA.	Manuel Tena Sempere	Juan Manuel Castellano Rodríguez
Alexia Barroso Romero	INTERACCIÓN ENTRE LA FUNCIÓN REPRODUCTIVA Y METABÓLICA: CARACTERIZACIÓN DEL PAPEL DE FACTORES NEUROENDOCRINOS Y EL SENSOR ENERGÉTICO, PROTEÍNA QUINASA ACTIVADA POR AMP (AMPK)	Manuel Tena Sempere	Leonor Pinilla Jurado
Navas Romo, Ana María	MARCADORES INMUNOLÓGICOS PREDICTORES DE EVOLUCIÓN DEL TRASPLANTE	Rafael Solana Lara	Corona Alonso Díaz
Pendón Ruiz De Mier, Mª Victoria	RELEVANCIA CLÍNICA Y BÁSICA DE LA SOBRECARGA DE FÓSFORO SOBRE LOS RECEPTORES RENALES DE FGF23 Y LA PROGRESIÓN DE LA ENFERMEDAD RENAL CRÓNICA	Rodríguez Portillo, Juan Mariano	Juan Rafael Muñoz Castañeda
*** Corina Baba; Andrea**	**"RELACIÓN ENTRE LOS NUTRIENTES Y EL GRADO DE ENVEJECIMIENTO BIOLÓGICO**	**Pérez Martínez, Pablo**	**José López Miranda**
*** Calvo-Rubio Barrera, Miguel**	**MARCADORES DE ENVEJECIMIENTO EN RIÑÓN DE RATONES SOMETIDOS A INTERVENCIÓN GENÉTICA Y NUTRICIONAL.**	**Villalba Montoro, José Manuel**	**-**
Gómez Fernández, Antonio Rafael	BIOMONITORIZACIÓN DE MARCADORES DE ESTRÉS OXIDATIVO, INFLAMACIÓN, MICROBIOTA INTESTINAL Y DE LA EXPOSICIÓN A METALES PESADOS EN EL TRASTORNO DEL ESPECTRO AUTISTA EN LA INFANCIA	Juan Luís Pérez Navero.	Mercedes Gil Campos.

*** Thesis with International Mention**

IMIBIC
MAIMONIDES BIOMEDICAL RESEARCH INSTITUTE OF CORDOBA

Junta de Andalucía

UNIVERSIDAD DE CÓRDOBA